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1021-159 Effect of 1 Year of Pravastatin on Coronary Plaque 
Regression Assessed by intravascular Ultrasound. Results 
of the “Demonstration of Regression of Atherosclerosis by 
ULtrasonographic Assessment” (DRACULA) Pilot Trial 
Fadi Matar, Nehal Dessani, Seth Goldberg, Dawn Garret, J T. Sullebarger. Florida 
Cardiovascular Research Foundation, Tampa, FL 
Angiographic trials demonstrated 
that lipid lowering significantly / ‘cIL-~--y-- ---- ~- --- 
improves clinical endpoints yet its / dbl 1 r” 
impaCt on coronary artery disease ‘: “i- .E I:““,,, ! 
(CAD) progression and regression ,$ 
is minimal. Intravascular “ltra- 
sound (IVUS) allows for the accu- 
rate assessment of plaque mass 
and is therefore ideal in elucidat- i 
ing the mechanism of clinical ben- 
efit of lipid lowering. Method. This 
trial rs a multicenter prospective 
enrollment of 50 patients with 
angiographically proven CAD and LDL level >/= 100 mgidl presenting for angroplasty. 
IVUS with automated pull-back was performed on a non-intervened upon vessel and 
357+/-a days after treatment with Pravastatin 40 mgid. Results. 175 cross-sections (82 
soft (S), 68 fibrocalcific (FC), 25 normal), in 6 male patients (@c/-12 yrs. Baseline LDL 
148+/-14, final LDL 86+/-6 mgldl) with follow up are being reported. Plaque cross-sec- 
tional area (CSA) increased from 3.8+/-2.3 mm2 to 4.1+/-2.5 mm2 (pcO.001). Plaque 
cross-sections were classified as either with no change, progression or regression. 
Change in GSA for the S and FC plaques is graphically shown. Conclusion. 1. Plaque 
mass slightly increased despite 1 year of treatment with Pravastatin. 2. This increase 
was mainly due to an increase in fibrocalcific plaque mass with stabilization of soft 
plaques. 
1021-160 The West of Scotland Coronary Prevention Study 
(WOSCOPS): Three-Year Post-Study Follow-Up 
I. Ford, A.!? Holmes, J. Innes, A. Nears, S.M. Cobbe. Robertson Centre forEiosfatistics, 
Glasgow, United Kingdom, University of Glasgow, Glasgow, United Kingdom 
Background: WOSCOPS randomized 6595 men, 45-64 years old, and with no history of 
myocardial infarction, to receive pravastatin or placebo and followed them up for an aver- 
age of 4.8 years. At the end of the study, in addition to significant benefits on nonfatal 
events, there were 241 deaths and a 33% risk reduction in cardiovascular (CV) mortality 
(P=O.O33), a neutral effect on non-CV mortality and, overall, a 22% reduction in all-cause 
mortality (P=O.O51). 
Methods: Subjects were followed up for a further 3 years beyond the randomized double 
blind period. All deaths were identified and adjudicated in a blinded fashion. 
Results: There were 486 deaths, including within-trial events (223 CV, 259 non-CV, and 
4 unclassifiable). The overall percent proportional risk reduction (95% Cl, P value) asso- 
ciated with treatment with pravastatin was 27% [(4,44),0.022] for CV deaths, 6%[(- 
20,+26),0.64] for non-CV deaths, and 16% [(0,30),0.051] for all cause mortality. The 
Kaplan-Meier time-to-event curves for all-cause mortality are shown in the Figure. 
Conclusion: The 3.year extended follow-up of the WOSCOPS recruits confirms the effi- 
cacy and safety associated with long term treatment with pravastatin. 
1021-161 The Relationship Between On-Treatment Lipid Levels and 
Clinical Outcome: The Pravastatin Pooling Project 
I. Ford, T. Craven, C. Furberg, R. Byington, A. Tonkin, J. Simes, F. Sacks, E. Braunwald. 
University of Glasgow, Glasgow. United Kingdom, Wake Forest University, Winston- 
Salem, NC 
Background: Although the subject remains controversial, epidemiologic data suggest 
that a decreasing gain in clinical benefit is achieved from aggressively reducing low-den- 
sity lipoprotein cholesterol (LDL-6). The benefits to be gained by modifying high-density 
lipoprotein cholesterol (HDL-C) and triglycerides, in addition to LDL-C, are less clear. 
Therefore, the prospective Pravastatin Pooling Project investigators evaluated the results 
from the West of Scotland Coronary Prevention Study (WOSCOPS), the Long-term 
Intervention with Pravastatin rn lschaemic Disease (LIPID study, and the Cholesterol and 
Recurrent Events (CARE) study to examine the relationship between achieved levels of 
LDL-C, and changes in LDL-C, HDL-C and triglycerides. 
Methods: This study was designed to investigate the varration in long-term benefits 
associated with modifying LDL-C, HDL-C, and triglycerides to different extents.At 12 
months, patients rn the pravastatin-treated groups were separated into quintlies of 
achieved levels of and changes in LDL-C, HDL-C and triglycerides. Future coronary 
event rates were calculated and compared statistically after adjusting for baseline risk 
factors and lipids and other relevant on-treatment values. 
Results: No significant evidence of heterogeneity of risk was found to be associated with 
variations in percent change in LDL-C, HDL-C and log-triglycerides. In CARE, achieved 
LDL-C was not associated with the risk of a coronary event. In LIPID and WOSCOPS. 
where baseline LDL-C levels were higher, there was a positive association, primarily due 
to higher risk in subjects rn the qulntiles with highest on-treatment LDL-C (>I26 mgidl in 
LIPID and >164 mgidl in WOSCOPS). 
Conclusion: These results are consistent wrth the concept of a diminishing return, in 
terms of additional clinical benefit, wtth greater LDL-C lowering. In this study, we could 
not demonstrate additronal benefit associated with greater changes in HDL-C and triglyc- 
erides. However, the changes in HDL-C and triglycerides were modest. 
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1022-163 Increased Alpha-i Adrenergic Sensitivity in Patients With 
Renal Failure 
Ademola K. Abiose, Richard Lafayette, Heitor Moreno, Jr., Terrence F. Blaschke, Brian B. 
Hoffman. Stanford University, Palo A/Q CA, Universify of Connecticuf, Farmington., CT 
Objective: To evaluate vascular responsiveness to adrenergic sensitivity and nitric oxide 
(NO)-mediated vasodilation in patients with End-Stage Renal Disease (ESRD) on recom- 
binant human erythropoietin (rHuEP0). 
Background: ESRD is associated with altered hemodynamics regulation as a result of 
the pathophysiology and/or treatment of renal failure. Hypertension, common in ESRD, IS 
a recognized complication of rHuEP0 therapy. The mechanisms responsible for the 
development of the increase in arterial blood pressure remain poorly defined. 
Method: We determined vascular adrenergic and NO mediated responsiveness in 7 
patients with ESRD on regular hemodialysis and 13 healthy controls using the dorsal 
hand vein technique. This technique has the advantage of using very low infusion rates of 
vasoactive drugs, thus determrning only local vascular effects without confounding sys- 
temic responses. 
Results: Sensitivity to the alpha 1-adrenergic selective agonist phenylephrine (PE), 
infused over the dose range of 0.75 7917 ngimin., was significantly increased in ESAD 
patients on rH”EP0. The mean dose producing 50% venoconstriction [ED501 for PE 
was 38 ngimin in ESRD and 150 ngimin in controls, p = 0.01. In contrast, maximal veno- 
dilation [Emax] mediated by bradykinin (BK), an endothelium-dependent vasodilator, was 
not different in the 2 groups as determined by venous responsiveness to infusion of a 
maximal venodilatory dose of BK [278 ngimin]. The [Emax] was 90 + 12% in ESRD ver- 
sus 79 + 27% in controls, p = 0.30. To determine if rHuEP0 has a direct venoconstrictor 
effect, we studied venous responsiveness to local infusions of rHuEP0 in healthy con- 
trols. Increasing concentration of rHuEP0 [0.8 - 50U/min] drd not produce a direct veno- 
constriction in hand veins of normal volunteers. 
Conclusions: These results suggest that vascular responsiveness to alpha-adrenergic 
stimulation in ESRD patients on rHuEP0 IS increased whereas NO-mediated venodila- 
tion remains intact. This increase in vascular adrenergic sensitivity, which does not 
appear to be due to a direct vasoconstnctive effect of rHuEP0, may contribute to the 
increased vascular resistance and coronary artery disease commonly seen in ESRD. 
1022-164 Role of Inducible Nitric Oxide Sinthase in Chronic 
Sinoaortic Denervation 
Patricia Fiorino, Carlos A. Nascimento, Jose Xavier-Neto, Ismar N. Cestari, Eduardo M. 
Krieger, Maria C. C. Irigoyen. Heart Institute (InCor), Univ S&J Paula fvfed Sch, S8o 
Pm/o, Brazil 
The lability of arterial pressure (AP) and impairment of baroreflexes persisted, in chronic 
sinoaortic denervated rats (SAD), until AP has almost returned to normal values. 
Increased production of nitric oxide (NO) is one of the known underlying mechanisms of 
AP recovery. The aim of this paper was to evaluate the role of inducible nitric oxide 
sinthase (INOS) in the hemodynamic changes produced by chronic SAD. Two groups of 
male Wistar rats were studied: a) controls (C), b) SAD (20 days after denervatron). Intrar- 
terial catheters were implanted to obtain AP signals, which were processed by a data 
acquisitron system (CODAS, 1 kHz). AP recordings were performed during 20 minutes 
before and after aminoguanidine (AG, 25 mgikg Lv.) treatment, specific iNOS blocker. NO 
generation was estimate throgh of plasma NOx (nitrate and nitrite) determrned by Griess 
Color Reaction adapted to a 96.well microassay plate with reading at 540 nm. Immuno- 
hystochemistry analysis of renal tissue was performed using an anti-rabbit monoclonal 
antibody. Basal NOx concentration was higher in SAD (112+5 “MoliL) than in C rats 
(89+16 uMoliL) and immunohystochemical evaluation demonstrated induction of iNOS 
expression after SAD. Baseline values of AP were similar in SAD and C rats (116+4 vs 
112i: 2 mmHg, respectively). Acute administration of AG increased AP in C (+BmmHg) 
and SAD (+13 mmHg) rats and decreased NOx concentration in SAD rats (-38 uMol/L), 
but not in controls. Conclusion: Chronic sinoaortic denervation stimulated the expression 
of iNOS (AG-inhibited) and the production of NO. Suggesting that NO contribute the nor- 
malization of AP m SAD model. This result clear demonstrated the involvement of iNOS 
in the hemodynamic changes found in the SAD. 
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1022-165 Lipid Lowering Therapy Increases Heart Rate Variability in 
Subjects With Combined Hyperlipidemia 
Vojtech Melenovsky, Dan Wichterle, Jan Malik, Richard Ceska, Jaromir Hradec, Marek 
Malik. General University Hospital, Prague, Czech Republic, St. George’s Hospital 
Medical School, London, Uniied Kingdom 
Background: Reduced heart rate variability (HRV) is associated with increased cardio- 
vascular mortality and with progression of atherosclerosis. The effect of &tins and 
fibrates on HRV in subjects with combined hyperlipidemia has never been compared. 
Methods: 29 middle-aged men with combined hyperlipidemia, without other diseases or 
medication, were randomized to atorvastatin 10 mglday or micronized fenofibrate 200 
mglday. Drugs were crossed-over after 10 weeks. Recordings of EGG and non-invasive 
blood pressure (Finapres) were obtained during spontaneous (SR, 5 min) and controlled 
respiration (CR, 3 min at 0.1 Hz) before and after the therapy. Time-domain indices (mean 
RR, SDNN and RMSSD) and baroreflex sensitivity (BRS-CR) were calculated from 
records of SR and CR, respectively. Results: are shown in the table and are expressed 
as % change from baseline (” p < 0.05, ** p < 0.005). 
Baseline (*SD) Fenofibrate Atorvastatin 
mean RR 868iilOms + 3.9 % * + 5.0 % ** 
SDNN 46.2-18ms + 25.3 % *’ + 29.4 % ** 
RMSSD 27.1 + 13 ms + 31.2 % ** + 38.9 % ** 
BRS-CR 11.6 I 5.8 ms/mmHg +11.4% + 19.3 % * 
Cholesterol 7.55 + 1.2 mmol/l 12.5 % ‘* 28.0 % ” 
Triglycerides 5.4 j, 4.5 mmol/l - 49.7 % ** 32.2 % ** 
The differences between both drugs in the effect on HRV and BRS-CR did not reach sta- 
tistical significance. No significant correlation between change of serum lipid levels and 
change in cardiac autonomic indices was found. Conclusion: Both atorvastatin and fenof- 
ibrate treatment led to marked increase of time-domain indices of HRV. Results suggest 
that the lipid lowering per se, rather than the effect of particular drug class, might be the 
main operating mechanism of HRV improvement. 
1022-l 66 Peripheral Arterial Tonometry:A New Method for Detection 
and Quantification of Autonomic Nervous System 
Dysfunction 
Alan Rozanski, Ehtasham A. Qureshi, Mara Bauman, ltslk Dvir, George W. Reed, Abra- 
ham Bornstein, Ahmed Shah, George Diamond. St Luke%Roosevelt Hospital Center, 
New York, NY 
Background: Since peripheral vascular regions, such as the fingertips, are densely 
innervated by alpha-adrenergic fibers which Ton&//y regulate vascular size (to control 
body temperature), we hypothesized that measurement of this toniclty may represent a 
window into disturbances of autonomic nervous system function. Thus, using peripheral 
arterial tonometry, we evaluated variability in beat-to-beat finger pulse wave amplitude 
(PWA) and heart rate (HR) in patients (pts) subject to autonomic dysfunction. 
Method: We evaluated 30 normal volunteers (mean age 32 i 7, 78% males), 34 conges- 
tive heart failure (CHF) pts (mean age 62 + 14, 71% males), and 17 diabetic pts (mean 
age 56 i 17, 35% males). Each subject underwent 30 minutes of continuous PWA mea- 
surements at rest, followed by measurements during cold pressor stimulation achieved 
by hand immersion in a 4°C ice bath. 
Results: 
GVJUPS HR Variabtlitv PWA Variability CPS Ratio § 
Normal 0.80 i 0.15 1.18t0.12 0.36 + 0.17 
Diabetes 0.62 * 0.12 0.97 i 0.16 0.70 r 0.23 
CHF 0.59 t 0.10 0.86 * 0.17. 0.71 A 0.24 
pco.001 p<o.o01 p<o.o01 
BRatin of PWA during CPS compared to PWA at baseline 
PWA variability was moderately correlated with HR variability (r = 0.71, p<O.OOt), but not 
with age or sex. The magnitude of PWA attenuation during CPS was inversely correlated 
with both PWA variability (I = -0.73, p< 0.001) and HR variability (I = -0.52, p<O.OOl). 
Conclusions:Compared to normal subjects, PWA variability is significantly reduced in 
patients with diabetes and CHF These patients also show markedly diminished attenua- 
tion in PWA during cold pressor stimulation. These data support the use of peripheral 
arterial tonometry as a practical and convenient means of quantifying autonomic dys- 
function. 
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1023-168 Correlates of Echocardiographic Wall Motion Abnormalities 
in Hypertensive Patients With ECG Left Ventricular 
Hypertrophy. The LIFE Study 
Vittorio Palmieri, Peter M. Okin, Jonathan N. Bella, Jennifer E. Liu, Kristian Wachtell, Eva 
Gerdts, Vasilios Papademetriou, Markku S. Nieminen, Bjorn Dahlof, Richard 8. 
Devereux. Weill Medical College of Come// Universify, New York, NY 
Background: Characteristics of hypertensive patients with echocardiographic wall 
motion(WM) abnormalities are only partially described. Moreover, whether segmental 
and global WM abnormalities have differing relationships with cardiovascular disease 
(CVD) and microvascular disease remains uncertain. Methods: We studied 947 patients 
with moderate hypertension enrolled in the Los&an Intervention For Endpoint reduction 
(LIFE) study, with available echocardlographic WM score. Left ventricular (LV) hypertro- 
phy by EGG (Cornell voltage-duration product or Sokolow-Lyon criteria) was a selection 
criterion to enter LIFE. CVD, by self-report or ECG (Minnesota code), was present in 
25% of patients. Result?.: Of the study sample, 7%(n=64) had segmental and 6%(n=56) 
had global WM abnormalities. Compared to hypertensives with normal WM, those with 
WM abnormalities were slightly older (68 vs 66 years) and predominantly male (75 Ver- 
sus 57%), had higher prevalence of climcally overt CVD (41 Versus 39%), or diabetes (15 
Versus 10%. all p<O.Ol), whereas blood pressure (BP), body size and total/HDL-choles- 
terol did not differ between groups. Compared to hypertensives with normal WM, those 
with WM abnormalities had higher log urinary albuminicreatinine ratios (LUACR: 3.3 vs 
2.7 mg/g) and higher LV mass index (67 Versus 55g/m’-‘) (both p<O.Ol), but similar pro- 
portion of aortic or mitral regurgitation, aortic valve fibrocalcification or mitral annular cal- 
cification (all pb0.t). Independent correlates of abnormal vs normal WM were male 
gender, LUACR and CVD (all pcO.001). Independent logistic regression analyses dem- 
onstrated both global and segmental WM abnormalities had similar associations with 
CVD and increased LUARC; global WM abnormalities were also independently related to 
male gender. Conclusion: Among hypertensives with ECG-LV hypertrophy, both global 
and segmental WM abnormalities are similarly related to self-reported CVD and more 
severe microangiopathy. Thus, both segmental and global WM abnormalities may reflect 
coronary and microvascular disease. 
1023-169 Albuminuria Is Independently Associated With Left 
Ventricular Hypertrophy in the Hypertensive Population: the 
Strong Heart Study 
Jennifer E. Liu, Vittorio Palmieri, David C. Robbms, Mary J. Roman, Jonanthan N. Bella, 
Richard R. Fabsitr, Elisa T. Lee, Thomas K. Welty, Barbara V. Howard, Richard B. 
Devereux. The New York Hospital Cornell Medical Center, New York, NY 
Background: Albuminuria has been shown to predict cardiovascular morbidity and 
mortality in non-diabetic hypertensive patients. However, the mechanism of the associa- 
tion of albuminuria with cardiovascular events is unclear. Methods: We compared echo- 
derived- left ventricular structure and function in three groups of non-diabetic hyperten- 
sive American Indians based on albuminuria status: I = no albuminuria (~30 mg albumin/ 
g creatinine), II = mlcroalbuminuria (30-300 mg/g), Ill = macroaibuminuria (>300 mg/g). 
Results: A small step-wise increase in age was seen from Group I to Group Ill (61, 63 
and 65; p=NS) with no gender difference among the groups. A step-wise increase was 
also seen in systolic blood pressure from Group I to Group III (139, 148, 154 mm Hg, 
p<O.OOl) with no difference in the percentage of participants on anti-hypertensive treat- 
ment. Left ventricular mass and left ventricular mars indexed to height 2.7 showed a 
step-wise increase from Group I to Group Ill. Consequently, the prevalence of left ven- 
tricular hypertrophy followed a similar trend. There was no significant difference in mid- 
wall stress-corrected shortening, ejection fraction, mitral E/A ratio or mitral deceleration 
time among the three groups. On multivariate analysis, albuminuria status remained 
independently associated with LV mass after adjusting for age, gender, body ma?& 
index, systolic blood pressure and ejection fraction. Repeat analysis by combining the 
two albuminuria groups (II and Ill) revealed the same results. Conclusion: Albuminuria is 
independently associated with left ventricular hypertrophy in non-diabetic hypertensive 
American Indians, which may contribute to the increase of cardiovascular events in the 
hypertensive patients who have albuminuria. Screening for albuminuria identifies hyper- 
tensive patients with high cardiovascular risk due to established cardiac hypertrophy.(+ 
p<o.o5 is. Ill; *p<o.o5 “S. I) 
LV mass (gms) 
I (n=413) II (n=79) Ill (n=25) 
164 168 179 
LV massiht 2.7 42 + 45 49 * 
% LV hypertrophy 24% 35% 42% 
EF % 63 64 62 
Stress-corrected midwall shortening % 107 109 110 
Mitral E/A 0.84 0.84 0.82 
Mitral deceleration time (mseci 208 204 230 
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1023-170 Quantitative Assessment of Electrocardiographic Strain 
Predicts Increased Left Ventricular Mass: The Strong Heart 
Study 
Peter M. Okin, Richard 8. Devereux, Richard Ft. Fabsitz, Elisa T. Lee, James M. 
Galloway, Barbara V. Howard. !&i/l Medical C&age of Cornell University New York, NY 
Background: The strain patter” on the ECG is a marker for left ventricular hypertrophy 
(LVH) and has been associated with adverse prognosis. However, the independent rela- 
tionship of quantitative measures of ST depression (STD) in the lateral precordial leads 
vs the more qualitative strain pattern to increased LV mass remains unclear. 
Methods: Digitally-acquired ECGs and echocardiograms were examined in 1595 Amer- 
ican Indian participants in the second Strong Heart Study examination with no clinical, 
EGG, or echocardiographic evidence of coronary disease, who ware in sinus rhythm with 
no bundle branch block. The absolute magnitude of ST segment deviation above or 
below the isoelectric baseline was measured by computer to the nearest 10 pV in leads 
V5 and V6. LV mass was indexed to height2-‘, and LVH was defined by indexed LV mass 
s49.2 g/m’-’ in me” and >46.7 glmz-7 in women. 
Results: Participants were grouped according to gender-specific quartiles of the maxi- 
mal STD in lead V5 or V6 (Table). Increasing magnitude of STD was associated with 
older age, greater pulse pressure, higher serum fibrinogen levels, higher urinary albumini 
creatinine ratios, and with step-wise increases in LV mass, indexed LV mass and the 
prevalence of LVH. Using logistic regression analyses to control for clinical differences, 
increasing STD remained strongly associated with the presence of LVH (overall 
chisquare=20.1, p=O.OOOl), with step-wise increasing odds ratios (OR) for LVH corn- 
pared with the lowest quartile of STD for the Znd (OR=1.70, 95% Cl=l.lO-2.62), 3’* 
(OR=2.07, 35% Cl 1.34-3.18). and 41h quartile of’STD (OR=2.63, 95% CI=l.70-4.05). 
Conclusions: In the absence of evidence of coronary disease, increasing STD in the 
lateral precordial leads is associated with increasing LV mass and LVH. 
Variables Quartiles of Maximal ST Depression in V5 or Overall P Value 
V6 
sure overload (PO) (n=3) ware included. Based on clinical presentation and 
echocardiography, 4 (2 PO, 2 VO) had Comp LVH (NYHA I-II), whereas 5 (1 PO, 4 VO) 
had early Decomp LVH (NYHA 11-111). Coronary artery disease (CAD) was excluded by 
angiography. During valvular surgery transmural LV biopsies were taken, processed for 
LM and EM, and compared to LV biopsies from 3 donor hearts unsuitable for transplanta- 
tion. Results: In Comp LVH microscopy revealed typical (ultra-) structural aspects of 
dedifferentiation: depletion of sarcomeres, accumulation of glycogen, nuclear hetero- 
chromatin dispersion, and aberrantly shaped mitochondria. These changes resembled 
those see” in hibernating myocardium due to CAD. Extracellular matrix volume (EMV) 
was unaffected. Dedifferentiation was consistently !inked with cellular hypertrophy. In 
contrast, in early Decomp LVH LM and EM predominantly revealed degenerative alter- 
ations, such as shrunken myocytes, cytosolic vacuoles and importantly increased EMV. 
Conclusion: Comp LVH was characterized by (ultra-) structural aspects of myocyte ded- 
ifferentiation whereas degeneration was predominant in early Decomp LVH. This sug- 
gests that dedifferentiation is not exclusively see” in hibernating myocardium due to CAD 
“or is this phenotype restricted to manifest contractile dysfunction. Future studies should 
concentrate on the clinical diagnosis of Comp LVH by depicting typlcal aspects of the 
dedifferentiated myocardium. 
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Quartile Quartile 2 Quartile 3 Quartile 4 1024-173 Hemostatic Risk Factors for Coronary Disease Present in 
1 Premenopausal Women 
LV “lass (g) 145128 150*33 156+36 164+43 <O.OOl 
Indexed LV mass (g/m’.7) 38.2+7.7 39.3i8.7 40.5r9.4 44.Oi-11. ~0.001 
Elsa-Grace V. Giardina, LeRoy E. Rabbani, Nicole A. Seminario, Hong Jun Chen, Robert 
R. Sciacca. Center For Women’s Health, Columbia University, New York, NY 
0 
LVH (%) 11.6 19.1 21.5 31.2 <O.OOl 
1023-171 Lack of Association Between Genetic Polymorphism of 
CYPll B2 Gene and Hypertension in Japanese: The Suita 
Study 
Yasuyuki Tsujita, Shunroku Baba, Shinji Tamaki, Masahiko Kinoshita, Tomohiro Katsuya, 
Jitsuo Higaki, Toshio Ogihara, Toshifumi Mannami, Jun Ogata, Naoharu Iwai. Shiga 
University of Medical Science, Otsu, Japan, National Cardiovascular Center, Suita, 
Japan 
Background: Aldosterone synthase (CYP116’2) is a key enzyme in the biosynthesis of 
aldosterone. Recently, a polymorphism in the S-flanking region of the CYf 1182 gene 
[T(-344)C] has bee” reported to be associated with blood pressure and plasma aldoster- 
one levels. We investigated the association between this polymorphism and hypertension 
in a large population-based sample in Japanese. 
Methods: The study population for this study is based on a random sample selected 
from the residents of Suita, a city in a” urban area in Japan; the sample comprised 
14,200 men and women aged 30 to 73 years. The basic sampling of the population 
started in 1989 with a cohort study base. In this study we studied the subjects who visited 
National Cardiovascular Center for regular health checkups from May 1996 to February 
1998 (n=4049). The GYP1182 T(-344)C polymorphism was determined by the PCR- 
RFLP analysis. The CYP17f?Z genotype distribution was compared between normoten- 
sive (NT) group (n=2514) and hypertensive (HT) group (“=1535). Blood pressure 
adjusted for clinical covariates (age, body mass index, alcohol consumption, cigarette 
habit, the presence of ischemic heart disease, diabetes mellitus, and use of antihyperten- 
sive drugs), were analyzed according to genotype. 
Results: There were no significant differences in the frequency of the (-344)C allele 
between two groups either in me” (NT: 31.4% versus HT: 30.3%, p= 0.48) or in women 
(NT: 31.7% versus HT: 31.5%, p= 0.93). And there were no significant differences in sys- 
tolic blood pressure, diastolic blood pressure, or pulse pressuriz across the three geno- 
types either in me” or in women. 
Background: Elevated cholesterol and the hemostatic factor, plasminoge” activator 
inhibitor (PAI-l), are independent risk factors for coronary artery disease (CAD) in 
women. Both increase with age as does CAD risk, but their relationship has not been 
examined in relatively young asymptomatic, premenopausal women. 
Methods: To determine if there is variability in hemostatic factors over the menstrual 
cycle, 15 premenopausal women, mea” age 34i7 yrs, with body mass index, 25i6 Kg/ 
(m)‘, had hormones and lipids measured weekly over a normal menstrual cycle. I” addi- 
tion, PA&l, tissue plasminogen activator (tPA), “on Willebrand factor (vWF), and fibrin D- 
dimer antigens were also measured weekly by their respective ELlSAs. 
Results: During the follicular and luteal phases of the cycle, estradiol averaged 5&31 
pgiml and 87ct32 pg/ml (p<O.O5), respectively; progesterone was O&0.7 pg/ml and 7k.3 
pgiml (p<O.OOi), respectively. The hemostatic factors, PAI- and fibrin D-dimer, also var- 
ied during the cycle. 
Variables During Follicular and Luteal Phase 
Lipids Phase Hemostatic 
Follicular Luteal Variables 
Cholesterol(mg/dL)* 175&26 164~26 PAI-l(ng/ml)* 
HDL(mg/dL) 57+17 56*16 tPA (“g/ml) 
LDL(mg/dL) 99*34 92t30 vWF (mlU/ml) 
Phase 
Follicular Luteal 
42+21 32+17 
8i3 8+5 
1051+41 946i435 
8 
Triglyceride(mg/dL) 97+44 81538 fibrin D-dime? 3745224 317t192 
(mlU/ml) 
*p<O.O5 between follicular and luteal phases 
There was a correlation between age and total cholesterol (r=0.61, pcO.Ol), and also 
between age and PAI- (w0.57, p<O.OZ). Moreover, PAI- correlated with both total cho- 
lesterol (I = 0.76, p<O.OOl), and LDL (r = 0.66, pcO.01). 
Conclusions: In a population of premenopausal women, risk factors for CAD including 
age, hemostatic variables, and lipids were strongly correlated indicating that risk factors 
occur eve” in asymptomatic young women. These data may have ramifications for the 
identification and management of young women who are at risk for CAD. 
Conclusion: Our data suggest that the T(-344)C polymorphism of CYPl782 is unlikely 
to constitute major susceptibility for essential hypertension in the Japanese population 
studied. 
1024-174 Antithrombotic Effects in Humans of Escalating Doses of 
DX-9065a, a Direct Factor Xa Inhibitor. Comparative Study 
with Low Molecular Weight Heparin (Enoxaparin) 
1023-172 Does the Myocardium in Human Compensated Ventricular 
Hypertrophy Revert to a Dedifferentiated Phenotype? 
Daichi Shimbo, Julio I. Osende, Julie Chen, JayantaT. Mukherjee, Valentin Fuster, Juan 
Jose Badimon. Mount Sinai School of Medicine, New York, NY 
Dirk W. Danker, Jos G. Maessen, Marc A. Vos, Paul G. A. Voiders, Anton P. Gorgels, 
Leonard Hofstra, Jannie Ausma, Hans Duimel, Hein J. J. Wellens, Marcel Borgers. 
Department of Cardiology and Department of Cardiothoracic Surgery Academic Hospital 
Maastricht, Maastricht The Netherlands, Cardiovascular Research Institute Maastricht, 
Maastricht, The Netherlands 
Background: Compensated (Comp) left ventricular (LV) hypertrophy (LVH) is considered 
to be a reversible adaptation to hemodynamic overload. The transition to decompensated 
(Decomp) LVH is incompletely characterized and clinically difficult to diagnose. Using 
light (LM) and electron microscopy (EM) on myocardial biopsies, we charactedzed 
patients with Comp and early Decomp LVH due to valvular heart disease. Methods: Nine 
patients (5 male), 63&7 years, with LVH due to valvular heart disease (aortic regurgita- 
tion, mitral regurgitation, aortic stenosis) with predominant volume (VO) (“=I?) or pres- 
Background: Tissue Factor requires the interaction with factors Vlla and Xa to generate 
thrombin in viva New antithrombotic agents that inhibit factors Vlla and Xa are currently 
under investlgatioh. The antithrombotic properties of DX-9065a, a direct factor Xa inhibi- 
tor ware evaluated. Methods: Six healthy male volunteers were enrolled into an open- 
label, crossover study comparing three escalating doses of DX-9065a versus one dose 
of Enoxaparin. Antithrombotic effects were assessed by quantifying the changes in plate- 
let-thrombus formation before and after drug administration using the Sadimon perfusion 
chamber. Venous blood was perfused directly from the patient’s arm through the perfu- 
sion chamber. Platelet-thrombus formation was triggered by B-minute perfusions at high 
(1690/s) and low (212/s) shear rate conditions over tunica media as a model of severe 
arterial injury. The following DX-9065a doses were evaluated: 1 mg intravenous bolus + 
0.5 mg infusion over 2 hours. followed by an additional 1 mg bolus + 1.25 mg infusion, 
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and followed by a final 1 mg bolus + 2.5 mg infusion. Enoxapann was dosed subcutane- 
ously at 1 mglkg ( as in ESSENCE). Petfusion chamber experiments were performed at 
baseline and 2 hours after each DX-9065a dose or 4 hours after Enoxaoarln administra- 
tlon. Results: The results are noted in the following table. 
High Shear Rate Low Shear Rate 
Baseline 12,700 t 1,428 (100%) 4,534 + 487 (100%) 
LMWH 11,992 + 1,505 (94%) 4,488 t 268 (98%) 
DXl +0.5mg 12,687 i 1,727 (99%) 4,484 f 460 (98%) 
DXl+lZmg 10,521 f 1,842 *(al%) 4,061 A 570 (89%) 
DXl+2.5mg 8,576 i I,71 8 * (67%) 3,424 + 323’ (75%) 
Results are expressed as $/mm (mean c error) and % of baseline. ‘~~0.05 vs baseline. 
Additionally, in contrast to Enoxaparin, none of the DX-9065a doses was associated with 
a significant prolongation of aPTT and bleeding time (data not shown). Conclusion: DX- 
9065a reduces platelet-thrombus formation at high and low shear rate conditions. Our 
data indicate that specific direct inhibition of Factor Xa could serve as a novel therapeutic 
approach to prevent thromboembolic episodes. 
1024-175 Regulation of Expression of Plasminogen Activator 
Inhibitor Type-l in Human Arterial Smooth Muscle Cells by 
Protein Kinases 
Thomas K. Nordt, Susanne Baeurle, Karlheinz Peter, Burton E. Sobel, Christoph Bode. 
University of Freiburg, Freiburg, Germany: University of Vermont Coliege of Medicine, 
Burlington, VT 
Background: Increased expression of plasminogen activator inhibitor type-l (PA&l) by 
human arterial smooth muscle cells (HASMC) appears to influence atherogenesis. How- 
ever, the signal transduction involved has not yet been elucidated. Because protein 
kinases are prominent regulators of gene expression their potential contribution was 
investigated. Methods and Results: HASMC were exposed to TGF-8 and agents modu- 
lating the activity of protein kinase C (PKC). The phorbol ester PMA [up to 100 nM) 
known to enhance PKC activity increased basal PAI- expression (quantified by ELISA) 
by 40% By contrast, TGF-B-stimulated PAI- expression was not affected by PMA. 
Agents reducing PKC activity including staurosporin (up to 100 nM), H-7 (up to 100 PM), 
and Ro-31-8220 (up to 0.5 PM) induced a markedly decreased PAI- expression, both 
under basal (72%, 37%, 34%, p=O.Oll) and stimulated (90% 75%, 62%, p=O.O03) con- 
ditions. The expression of the PAI- gene (quantified by Northern blotting) was affected in 
parallel. Total protein synthesis was not changed by modulating PKC activity. H-E known 
to inhibit the activity of protein kinases A and G did not affect basal or stimulated PAI- 
expression. To examine a possible contribution of protein tyrosine kinase (PTK) HASMC 
were exposed io tyrphostin-51 known to decrease PTK activity and tyrphostin-I as a 
negative control. Tyrphostin-51 (up to 30 mM) decreased basal PAI-1 expression by 83% 
and TGF-B-stimulated PAI- expression by 76% (p=O.O04). Tyrphostin-1 (up to 30 pM) 
elicited no effect. Corresponding results were obtained with the use of the PTK inhibitor, 
genistein, and its inactive analogue, daidzein. Conclusions: Both the expression of PAI- 
1 gene and pro&In in HASMC can be decreased by inhibiting the intracellular activity of 
protein kinase C (but not of protein kinases A and G) and of protein tyrosine kinase. The 
contribution of PKC to signal transduction is supported by the fact that, in contrast to 
basal PAI- expression, stimulated PAI- expression cannot be further increased by 
PMA. Thus, pharmacologic interventions decreasmg the activity of PKC and PTK may be 
beneficial in normalizing pathophysiologically increased expression of PAI-1. 
d 
1024-176 Novel Method for Demonstrating Heightened Platelet 
Reactivity in Patients With Coronary Artery Disease 
Peter Lochow, Howard J. Mass, Tatjana van Hardenberg, Conan Li, Bruce Lages, Jeffrey 
D. Lorin, M.Johan Broekman, Steven F? Sedlis, Aaron J. Marcus. New York University, 
New York, NY, New York Veterans Administration Medical Center, New York, NY 
Purpose of Study: Detection of rapid platelet aggregation in patients with coronary 
artery disease. 
Background: Activated platelets play a major role in the pathogenesis of atherosclerosis 
and myocardial infarction. Rapid platelet aggregation may be an indicator of heightened 
reactivity of circulating platelets. We developed a novel method to measure rapid platelet 
aggregation using the Xylum Clot Signature Analyzer (CSA) and compared the Incidence 
of rapid platelet aggregation in patients with CAD and controls. 
Methods: Shear induced platelet aggregation was measured using the Xylum CSA. The 
rate of p!atelet aggregation was determined by measuring the increase in pressure over 
time (mmHg/sec) resulting from platelet mediated occlusion of micro holes punched in an 
in vitro whole blood conduit. Using this system an early peak in pressure can be detected 
which represents partial occlusion of the microholes. Platelet aggregation was expressed 
as the slope of the pressure time relationship of this early peak. Measurements were per- 
formed in 94 consecutive patients with sigmficant coronary artery disease documented 
by coronary angiography and compared to 94 healthy young control sublects. 
Results. 
N Slope f S.E.M 
Control 94 0.25 IO.02 
CAD,No Prior MI 51 0.35 i 0.03’ 
CAD, Prior Ml 43 0.59 -c 0.08” 
p=O.O15 versus Control;. p=O.O003 versus Control and p=O.O12 versus CAD, No Prior 
MI 
Conclusion: Rapid platelet aggregation can be detected in patients with CAD using the 
Xylum CSA. There was a significant increase in platelet aggregation in patients with CAD 
compared to controls. Heightened platelei reactivity was observed in patients with prior 
Ml compared to patients with no prior MI. This may have important diagnostic and/or 
therapeutic implications. 
1024-177 Flow Cytometric Characterization of Platelet Function and 
Platelet-Leukocyte Interactions Under Treatment With 
Clopidogrel in the Course of Coronary Intervention 
Christoph Altmann, Dirk Welge, Michael Haude, Judith Vonnahme, Heinrlch W&eke, 
Lothar Volbracht, Raimund Erbel. Universffy Hospital Essen, Essen, Germany 
Background: The thienopyridine clopidogrel (Clap) can effectively reduce thrombotic 
complications after percutaneous coronary Intervention (PCI). The impact on platelet 
function on a cellular level and platelet-leukocyte interactions in the course of PCI have 
not been well described. 
Methods: Platelet activation and platelet-leukocyte adhesion (PLA) were analyzed in 40 
patients receiving Ciop (300mg loading dose, 75mg/d) prior to elective PCI. surface 
expression of platelet P-selectin, GP 53, GP Ilbillla, activated GP Ilb/llla receptor (PAC- 
I), extent of PLA, and platelet aggregation upon ADP- and TRAP-stimulation were ana- 
lyzed by flow cytometry prior to and at defined time points after start of therapy with Clap. 
PCI was performed 24.72h after start of therapy. 
Results: Expression of P-selectin, GP 53, and extent of PLA were srgnificantly reduced 
by Clop with a nearly maximal inhibitton measured already 6 hrs after start of treatment 
(table). TRAP-induced platelet activation and PLA were also significantly reduced. The 
overall expression of GP llbillla was not significantly reduced, while the receptor recruit- 
ment upon stimulation and expression of PAC.1 were significanily inhibited (table). Plate- 
let aggregation was also significantly inhibited under treatment with Ciop (ADP l.OvM: 
33%, ADP 5.OpM: -2O%, p<O.OOl; TRAP 20~M: -8%, pcO.01). No significant increase of 
platelet activation, aggregation, and PLA were observed following PCI. 
Oh 6h 24h 72h 7d 
P-selectin # 1,184 i- 550 412 f 323 * 393 * 237 * 412 * 267 * 340 k 204 * 
GP53# 251 i 125 140*101 * 113t74’ 12li79* 111 *a* 
PAC.1 # 12,738 f 5,059 d 5,194 i 5,443 * 4,856 i- 
4542 2,829 * 2,993 * 3,327 * 2,836 * 
GP Ilb/llla# 61,427 * 58,437 i 56,841 f 57,856 zk 56,010 i 
8,900 8,434 7,748 7,448 8,320 
PLA (%) 13.3 f 6.7 6.9 2 5.0 * 6.6 i 4.4 * 6.1 t 4.2 * 5.7 + 4.6 * 
Mean + SD. # Antibody binding capacity and percentage of PLA after ADP-stimulation 
(5.OpM). * pcO.001 (ANOVA) 
Conclusions: Clop loading dose scheme leads to a fast inhibition of platelet activation 
as well as platelet-leukocyte interactions. A stable inhibition of platelet activation. aggre- 
gation, and PLA is maintained following PCI by intake of 75mgld. 
1024-178 Upregulated Monocytes Tissue Factor Induction by C- 
Reactive Protein Contributes to the Exacerbation Into Acute 
Coronary Syndrome From Stable Angina Pectoris 
Akihiro Nakagomi, Satoshi Aoki, Kougi Katou, Nobuhiko Fujita, Mikio Fujioka, Yoshlkl 
Kusama, Morimasa Takayama, Hiroshi Kishida, Teruo Takano. The First Deparfment of 
Internal Medinne, Nippon Medical School, Tokyo, Japan 
It has been shown that elevated plasma levels of C-Reactive Protein (CRP) predicts 
future cardiovascular events. However, the pathophysiological mechanisms underlying 
this are still unclear. CRP induces monocyte tissue factor (TF) activity (MPCA) and may 
play a prothrombotlc role at atherosclerotic plaque. Peripheral mononuclear cells 
(PBMCs) were collected from normal subjects (n-42;64+/-10 years) and patients (pts) 
with stable angina pectoris (SAP;n=38,62+/-8 years) with more ihan 90% coronary 
stenosis. PBMCs were stimulated by CRP (10 microgram/ml) obtalned from plasma of 
pts with acute coronary syndrome (ACS), LPS (lipopolysaccaride;lOpg/ml) and their 
combination. MPCA were measured by one-stage clotting assay using comparison with 
human brain powder as TF standard and expressed as mUmFIO/‘G PBMC. Basal 
(unstimulated), CRP, LPS and CRP+LPS induced MPCA in pts with SAP were signifi- 
cantly higher than those in normal controls (Basal;122+/-11 vs 73+/-4; p<O.OOl), 
(CRP;2255+/-147 “s 1754+/-181; p<O.O5). (LPS;888+/-76 “s 564+/-70; p<O.Ol), 
(CRP+LPS;3662+/-180 vs 2823+/-205; p<O.Ol), respectively. In pts with SAP, 10 pts 
developed ACS (unstable angina;8 pts, AMI; pts). CRP and CRP+LPS stimulated 
MPCA in pts with SAP that exacerbated into ACS (ACS (+), “~10) were significantly 
higher than those without events (ACS (-), n=28) (CRP;3170+/-279 vs 1928+/-125; 
piO.O05), (CRP+LPS;4693+/-272 vs 3294+/-186; p<O.OOl), respectively. There were no 
significant differences in age, sex, medication, fasting plasma glucose and lipid levels, 
number of diseased coronary vessels and left ventricular function between ACS (+) and 
ACS (-) groups. These data showed that CRP induced higher TF activity in pts with SAP 
than normal subjects and this pathaway was upregulated much more on monocytes from 
ACS(+) pts than those from ACS(-) pts. In conclusion, upregulated TF induction by CRP 
contrlbutes to the exacerbation into ACS from SAP 
1024-179 Glycoprotein Ilb/llla Inhibitor Abciximab Inhibits Collateral 
Artery Formation (Arteriogenesis) via Mac-i Blockade of 
Monocytes 
Iv0 R. Buschmann, Eva Katzer, Imo Dieter Hoefer, Niels van Royen, Jan Piek, Christoph 
Bode, Wolfgang Schaper. university clinic freiburg, freiburg, Germanl: ma planck 
institute, bad nauheim, Germany 
The invasion of monocytes into the vessel wall of preexisting collateral arterioles is an 
obligatory step in early arteriogenesis (rapid growth of collateral arteries). The inhibition 
of monocyte adhesion via monoclonal antibodies against ICAM- effectively reduces col- 
lateral artery growth (proof of concept). The platelet glycoprotein (GP) Ilb/llla inhibitors 
abciximab, eptifibatlde and tirofiban specifically inhibit the GP Ilb/ llla receptor, whereas 
only abciximab also binds with equivalent affimty to the structurally related vitronectin 
receptor alpha v/beta 3 and, more weakly, to the leukocyte Mac-l receptor resulting in 
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inhibition of monocyte adhesion and transmigra~ion We now tested the hypothesis that 
inhibition of the Mac-l receptor via abclximab, directly influences arteriogenesis. 18 New 
Zealand white rabbits were randomly assigned to receive either PBS, MCP-1(3 pg) plus 
abciximab (4 mgiweek), MCP-I(3 pg) plus monoclonal antibodies against ICAM-I(8 mg) 
or MCP-1 (3 c(g) alone locally via an osmotic mini-pump into the collateral circulation of 
the hindlimb. The right femoral artery was cannulated with a catheter, which itself was 
connected to the minipump (infusion rate 10 pL/h). After 7 days of Infusion the animals 
were again anaesthetized and a shunt between the carotid artery and the abdominal aor- 
tic artery was installed. 6 different perfusion pressures were used (30-90 mmHg) and 
each one was combined with a single bolus of different microspheres. Peripheral perfu- 
sion pressures, and total flow were measured. Collateral conductance was calculated via 
FACS Analysis: PBS=5+-2,i , MCP-1 plus abciximab=li+-32, MCP-1 plus mAb-ICAM- 
1=8+-l ,9 vs MCP alone= 33+-4,2 ml/min/100mmHg. The number of collaterals in stereo- 
scopic postmorten angiograms as well as monocyte adhesion and transmigration assays 
confirmed these data. Conclusion: The glycoprotein llbillla inhibitor abciximab is an 
effeciive inhibitors of arteriogenesis due to its blocking activity on monocyte adhesion 
and transmigration. 
-__ 
1024-180 Resistance to Activated Protein C and Factor V Leiden 
Mutation Are Risk Factors for Cardiovascular Events in 
Treated Hypertensives: A Five-Year Follow-Up Program 
Thomas K. Makris, Ankmios N. Hatrizacharias, Panagiota G. Krespi, George 
Anastasiadis, George A. Stavroulakis, Argyri Gialeraki, Emmanuel Chronakis, N~coalos 
A. Chatzizacharias, Michael K. Kyriakidis. LAlKON General Hospital, Athens, Greece 
Background: Reduced response to activated protein C (APC-R), an inherited haemo- 
static defect, and mutated factor V (FV Q506), Leiden mutation, have been identified 
recently as risk factors not only for venous but also for arterial thrombosis, as well. Aim of 
our study was to examine the possible effect of the above haemostatic defects on the fre- 
quency of cardiovascular events (CVE) in a cohort of treated controlled hypertensives 
(Hs) during a 5 year follow-up period. 
Methods: FV Q506 mutation was estimated by DNA analysis (Bertina method) in 150 
untreated Hs. Twenty two out of 150 had heterozygosity for the factor V mutation (Group 
A), while the remained 138 were negatives (Group 6). APC-R was determined using 
Coatest APC-R kit (Chromogenix). APC-R value was 1.81tO.l in Group A versus 
2.04+0.2 in Group B (p<.OOOl). The two groups were matched for age, sex, body mass 
index, the systolic and diastolic blood pressure levels, and the other predisposing cardio- 
vascular risk factors. 
Results: During the 5 year follow-up period, under treatment, 7/22 (31.8%) patients in 
Group A versus 81138 (5.8%) in Group 6 had been suffered a major cardiovascular event 
(p<.ool). 
COncluSions: These findings support the hypothesis that APC-R and FV Q506 may be 
risk factors for cardiovascular events in treated controlled hypertensive patients. 
1024-181 Thromboembolic Risk in Antiphospholipid Syndrome: A 5- 
Year Follow-Up Study 
Maurizio Turiel, Sabrina Muzzupappa, Barbara Gottardi, Stefano Casiraghi, Piercarlo 
Sarzi-Putlini, Edoardo Rossi. Internal Medicine II, L. Sacco Hospital, University of Milan, 
Milan, Italy 
Background: Thromboembolic events are frequently observed in Primary Antiphospho- 
lipid Syndrome (PAPS) patients (pts) with high (>40 U) anticardiolipin antibodies (&L-a) 
levels. Methods: we investigated thromboembolic risk in a group of 40 PAPS pts (5M and 
35F; aged 32+11yrs; 30 symptomatic, 10 asymptomatic) in B-year follow-up period. 
Results: According to aCL-a levels, we identified 2 groups (Gr): Gr I (~40 U; 58% with 
clinical manifestations (CM)), Gr Ii (z-40 U; 81% with CM). 26/40 (65%) pts (50% Gr I, 
88% Gr II) used antithrombotic therapy: aspirin, warfarin or both. Multiplane Transesoph- 
ageal Echo (TEE) showed in 63% pts mitral thickening (>3 mm), and in 14140 (35%) pts 
embolic sources (ES): Libman-Sacks vegetations (8%), mild mitral stenosis (8%) and 
spontaneous echocontrast (8%). During 5.year follow-up period aCL-a levels did not 
change significantly; lo/40 (25%) PAPS pts, all in antithrombotic therapy, showed new 
CM, as follows in the table. 10 randomized pts repeated TEE: 4 with and 6 without new 
CM. Only one pt showed a new ES. Conclusions: 1) A 5-year follow-up study confirmed 
a high thromboembolic risk in PAPS pts with aCL-a level >40 U; 2) TEE alone seems not 
able to detect thromboembolic risk factors in PAPS pts. 
Clinical results 
Death 
Thrombosis 
Autoimmune disease 
None 
Gr I (n=24) Gr II (n=16) 
3(19%) 
6 (37%) 
1 (4%) 
23 (96%) 7 (44%) 
1024-182 Aspirin Inhibits GPllb/llla, P-selectin, CD63, and CD107a 
Surface Receptor Expression on Human Platelets 
Marcus E. McKenzie, Christopher R. Bell, Eric D. Horowitz, Benjamin R. Oshrine, Victor 
L. Serebruany. Sinai Hospital, Baltimore, MD 
Background : Platelet inhibition after aspirin therapy reduce the risk for the development 
of acute coronary syndromes. However, the mechanisms by which aspirin affect platelets 
rather than prostaglandin blockade are unclear. We sought to determine an in vitro 
effects of aspirin on the surface expression of 9 platelet receptors using whole blood flow 
cytometry. Methods : Blood from 10 healthy volunteers was incubated for 30 minutes 
with 1.8 mg/L and 7.2 mg/L of phosphate buffered saline diluted acetylsalycylic asid. The 
surface expression of platelet receptors was determined using the following m~n~clonal 
antibodies: CD 41 (GP Ilbillla), CD 42b (GP lb), CD 62p (P-selectIn) (DAK0 Corporation, 
Catpenteria, CA), CD 51ICD 61 (vitronectin receptor), CD 31 (PECAM-I), CD 107-a 
(LAMP-l), CD 107b (LAMP-P), CD 63 (LIMP or LAMP3), and CD 151 (PETA-3) (PharM- 
ingen, San Diego, CA). Samples were then immediately fixed with 2% paraphormalde- 
hyde, and run on the flow cytometer within 48 hours. Results: Dose-dependent inhibition 
of GP Ilb/llla, P-selectin, CD 63, and CD 107a receptor expression was observed in the 
aspirin-treated whole blood samples. Conclusion: In addition to irreversibly inhibiting 
platelet cyclooxygenase-l, blocking thromboxane A2 synthesis, it appears that aspirin 
exhibit direct effects on selective major platelet receptors challenging the modern princi- 
ple believed to be mainly responsible for the anti-thrombotic properties of the drug. 
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1025-183 Increased Expression of VCAM mRNA in an Experimental 
Model of Lung Transplant Rejection: Diagnosis by 
Pulmonary Endoarterial Biopsy 
Melanie McGraw, Perkin Shiu, David M. Mann, Cynthia A. Behling, Jifeng Zhang, Ron G. 
Konopka, Peter G. Chiles, Craig A. Pedersen, Jolene M. Kriett. Abraham Rothman. 
University of California San Diego, San Diego, CA, Vascular Biosciences, San Diego, CA 
Background: Early detection of rejection after lung transplantation may prevent the 
development of bronchiolitis obliterans and allograft failure. The aim of this study was to 
determine if VCAM mRNA in endovascular tissue samples could be a marker of rejec- 
tion. Methods: Single left lung transplants were performed in 5 dogs. They were treated 
for 2 weeks with cyclosporine, azathioprine and prednisone, after which rejection was 
allowed to occur. Transcatheter biopsies from 2-3 mm distal branch pulmonary arteries 
were obtained in each dog from the normal and transplanted lungs at the end of immun- 
osuppresive therapy, and periodically (3-4 times) for 1-3 weeks until euthanasia. Levels of 
VCAM mRNA were quantitaled by reverse transcriptase polymerase chain reaction and 
normalized to beta-actin mRNA levels. Results: Between 3 and 5 pulmonary endoarte- 
rial biopsy samples were obtained, without significant complications, from each lung at 
each catheterization procedure. The biopsy samples were composed predominantly of 
smooth muscle cells, with a thin layer of endothelial cells. There was a significant 
increase in VCAM mRNA in the biopsies of the transplanted lung with longer rejection 
time. There was also an increase in the ratio of VCAM to beta-actin mRNA levels in the 
biopsies of the transplanted compared with native lung of each dog with increasing days 
off immunosuppressive therapy. Histologically, the biopsies in early rejection were normal 
or showed mild reactive endothelial cell changes. Later in rejection, there was transme- 
dial infiltration of lymphocytes and marked endothelial damage. Histologic rejection, 
including vasculitis in arteries accessible to biopsy, was confirmed at necropsy. Conclu- 
sion: In pulmonary endoarterial biopsy samples obtained in a canine lung transplant 
model, there is an increase in VCAM mRNA levels with increasing rejection. Changes in 
VCAM mRNA are observed earlier than histologic changes of rejection. VCAM mRNA 
quantitation by endoarterial biopsy may be useful in surveillance and early diagnosis of 
rejection in patients who undergo lung transplantation. 
1025-184 Elevation of Plasma Tissue Factor Along With Differential 
Elevation of Plasma Matrix Metalloproteinase-2 (MMP-2) in 
Deep Vein Thrombosis (DVT) & Pulmonary Embolism (PE) 
Patients 
Shaker A. Mousa, Richard Liu, Sayed Taheri. DuPont Pharmaceuticasl Co., Wilmington, 
DE, Millard Filmore Hospital, Buffalo, NY 
Recent studies suggested the involvement of pro-inflammatory mediators in plasma from 
patients with DVT & PE. &lditionally, it has been also shown that thrombin generated at 
sites of vascular injury can signal the activation of MMP-2 from pro-MMP-2 which in turn 
degrade vascular matrix proteins leading to episodes of intra-plaque hemorrhage or 
plaque disruption and thrombosis. The aim of ihe present study was to assess the 
plasma levels of various matrix metalloproteinases (MMP-2, 9, 1, and 13) in relation to 
plasma tissue factor (TF) as an initiator and amplifier of thrombin generation. Plasma 
obtained from 30 patients with diagnosed DVr, DVT I PE or DVT in congestive heart fail- 
ure patients as well as 12 healthy subjects were analyzed by specific immunoassay and 
ELISA for plasma MMPs (MMP-2, 9, 1, and 13) and TF levels. A differential elevation by 
50-100 folds in plasma levels of MMP2 (*’ P c 0.001) but not MMP-I, MMP-13 or MMP- 
9 was demonstrated in DVT & PE as compared to healthy subjects. Additionally, a signif- 
icant elevation (* P < 0.01) in plasma TF levels in DVl and PE as compared to healthy 
subjects was also shown. A significant correlation between TF and MMP-2 levels was 
demonstrated among the different DVT I PE subjects. Results suggested a differential 
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elevation of plasma MMP-2 as a potential marker of increased TF and thrombln genera- 
tion and hence a possible complication in vascular lesion stability and vascular remodel- 
ing in venous thromboembollc disorders. 
Plasma Levels of TF and MMP-2 & MMP-9 IN DVT/PE Subjects 
Plasma Biochemical Mark- Control Mean Levels +/- SD DVT / PE Mean Levels +/- 
ers SD 
TF (Pgiml) 92 +/- 36 215 +/- 43’ 
MMP-2 (ngiml) 15 +/- 8 746 +I- 184” 
MMP-9 @g/ml) 24 +I- 9 27 +/- 12 
1025-186 Increased lnterleukine 6 by Pulsative Nitric Oxide 
lnsufilation in Patients With Pulmonary Hypertension 
Achim Gutersohn, Johannes Schaar, &fan Sack. Raimuncl Erbel. Department of 
cardiologle, Essen, Germany 
Background: Pulmonary hypertension (PH) 
is characterized by either an increase in vas- 
cular tone or, and an abnormal proliferation 
of small pulmonary arteries. lnsufilation of 
nltrlc oxide (NO) has been used for diagnosti- i 30 1 
i 20 + n 
f=@ 
g ii :, I; 
n 
is supposed to mfluence the vascular tone 
c & ;; I ~I ‘GE 
and influence different cellular mechanism 
cd and therapeuticai purpose before, In this 
study we investigated whether NO-insufila- 
tion would alter interleukine 6 (116) levels. IL 6 Ii
“Sppn 
- 10 ppn- 
llke inflammation. Methods: We included 7 patients with PH (mean PAP 55 mmHG). All 
patients got pulsatile NO 5 and 1Oppm for 10 minutes during catheteriratnn. Blood was 
taken from atrium right and left (RA. LA),ventricle right and left (LA ,LV) pulmonary artery 
(PA) and aorta (AO) before and after NO insuhlation. II6 was measured according to stan- 
dard procedures. Results: II6 IS significantly (p=O,O12) elevated after 1Oppm NO insufila- 
tion in PA in comparison to baseline. There were also elevations of II6 in LA and A0 but 
not significant. Conclusion: IL6 is a mediator in different cell mechanism and plays an 
important role in the induction of lnterceliular adhesion molecule-i (ICAM-I). It is possi- 
ble that NO stimmulates II6 release directly or NO induces downregulation of an unknown 
system which results in an upregulation of 116. NO in itself is also a mediator of cell mech- 
anism therefore lt must be concluded that II 6 is upregulated by NO perhaps via facior Xa. 
1025-I 87 Tyrosine Kinase Receptor Activation, but not Hypoxia, 
Inhibits Atrial Natriuretic Peptide Clearance Receptor 
Expression in Pulmonary Arterial Smooth Muscle Cells 
Suzanne Oparil, Ju-Zhong Sun. Pamela Lucchesi, Yiu-Fai Chen. University ofAlabama 
at Birmingham, Birmingham, AL 
Background: Our previous studies have demonstrated that expresslo” of the atrial natri- 
uretic peptide (ANP).clearance receptor (NPR-C) is inhibited selectively in the lung of 
rats and mice exposed to normobaric hypoxia but not in pulmonary arterial smooth mus- 
cle cells (PASMCs) cultured under hypoxic conditions. The current study tested the 
hypothesis that growth factors FGF-1, FGF-2 and PDGF-BB that activate tyrosme kinase 
receptors and hypoxia-responsive can reduce expression of NPR-C I” PASMCs indepen- 
dent of environmental oxygen tension. Methods: Confluent and quiescent rat PASMCs 
(passages 4-8) were mcubated under hypoxic conditions (1% 02) for24 hrs, or incubated 
with FGF-1: FGF-2 or PDGF-BB (0.1-20 rig/ml for 1-24 hrs), or angiotensin II (Ail, I-100 
nM), endothelin-I (ET-I, 100 nM), ANP (100 nM), sodium nitroprusside (SNP, 0.1 mM) or 
8-bromo-cGMP (0.1 mM) for 24 hrs under normoxic (21% 02) conditions. Steady state 
NPR-C mRNA levels were assessed by Northern analysis. Results: Hypoxia, All, ET-l, 
ANP, SNP or cGMP did not change NPR-C mRNA levels under the above conditions. In 
Contrast, FGF-1, FGF-2 and PDGF-BB induced dose- and time-dependent reduction of 
NPR-C mRNA expression with onset within 1 hr of growth factors exposure. Additional 
studies of the growth factor-activated signaling pathways demonstrated that the FGF-I, 
FGF-2 or PDGF-BB induced downregulatlon of NPR-C expression were inhibited by 
mitogen-activated protein (MAP) kinase Inhibitors U1026 and PD98059. Conclusion: 
These results indicated that tyrosine kinase receptor activatton, but not G-protein cou- 
pled receptor or cGMP activation. Inhibits NPR-C gene expression in PASMCs. These 
results also suggested that FGF-1, FGF-2 or PDGF-BB may play an important role in the 
signal transduction pathway linking hypoxia to alter NPR-C expression in lung. 
1025-188 Comparison of the Effect of Combined inhibition of 
Endothelin-Converting-Enzyme/ Neutral Endopeptidase 
Activity and ETA Receptor Blockade on Hypoxia-Induced 
Pulmonary Hypertension in the Rat 
Paul F. J. Clift, Martin R. Wilkins. imperial College School of Medicine, Hammersmith 
Hosp~tai, London, United Kingdom 
Background: Neutral endopeptidase (NEP) inhibitors and endothelin A receptor (ETA) 
antagonists are effective in treating hypoxia induced pulmonary hypertension I” rats. 
Endothelin is a substrate for NEP Hence inhibition of NEP may increase endothelln lev- 
els. We investigated whether combined endothelin-converting enzyme/neutral endopeptl- 
dase (ECEINEP) inhibition was more effective than ETA antagonism and NEP inhibition 
alone. Methods: Animals were pre-treated wth an intraperitoneal infusion of the study 
agent or vehicle. Agents used were the ETA antagontst LU 135252 (20 mgikglday, n = 6 
hypoxia, n = 5 room air), the combined ECE/NEP inhibitor KC12615 (40 mgikgiday, n = 9 
hypoxia. n = 8 room air), NEP inhibitor, Candoxatrilat (5 mgikglday, n = 10 hypoxia and 
room air) and saline vehicle (n = 10 hypoxia, n = 9 mom air). Animals were housed in a 
hypoxlc chamber (FiOP 10%) or room air. After a P-week study period, pulmonary and 
systemic haemodynamic data were collected from conscious animals. Post mortem, right 
ventricular mass and pulmonary vascular remodelling was measured. Results: Mean 
pulmonary artery pressure (MPAP) rose significantly in the vehicle treated hypoxic group 
compared to room air controls (43 +I- 2 mmHg and 20 +I- 2 mmHg, P < 0.001). All 3 
treatment groups reduced significanlly MPAP compared with vehicle treated hypoxic con- 
trol: LU135252 (26 +I- 2 mmHg, P ~0.001). KC12615 (33 +/- 1 mmHg, P <O.OOl) and 
candoxatrilat (30 +/- 1 mmHg, P <O.OOl). Right ventricular mass rose m the vehicle 
treated hypoxic control compared with matched room air group (269 +I- 4 mg and 179 +I 
9 mg respectively, P ~0.001). Right ventricular weight was significantly lower in the 
hypoxic rats receiving the ETA antagonist that in the other hypoxlc groups. All 3 treat- 
ments reduced significantly pulmonary vascular remodelling. Conclusions: ETA receptor 
antagonism is more effective than NEP or combined NEPiECE Inhibition in reducing 
hypoxia-induced pulmonary hypertension and right ventricular hypertrophy in rats. 
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1026-189 The Relationship Between Left Ventricular Hypertrophy and 
Flow-Mediated Dilation of the Brachial Artery in Normal 
Coronary Angiographic Hypertensive Patients 
Ertugrul Ercan. Ceyhun Ceyhan, Cemil Gurgun, Mehdi Zoghl, Oguz Yavuzgil, Azem 
Akqllq, Cuneyt Turkoglu, Mustafa Akvn Ege Universify Medica/ School Cardiology 
Departmant, lzmir, Turkey 
High-resolution external ultrasound assessment of the brachial artery is a non-invawe 
method for determination of endothelial function. In this study we investigated if the left 
ventricular hypertrophy (LVH) exposes an additnxal negative effect on endothelium- 
dependent vasodilation in hypertensive patients (pts): Methods: Thirty-three hyperten- 
sive pts who had angiographically normal coronary arteries were dwided into two groups 
according to LVH. In group I. there was 19 pts with LVH (mean age: 56*9, male: %57). 
Group II was consisted of 14 pts without LVH (mean age: 5ltl0, male: 57%). Control 
group consist of normotensive and normal coronary arteries subjects. High-resolution 
vascular ultrasound was used to measure brachial artery responses to reactwe hypere- 
mia (with increased flow causing endothelium-dependent dilatation) and to sublingual 
nitroglycerine (causing endothellum- independent dilatation). Results: There were no sig- 
mficant difference between age and other risk factors for coronary artery disease I” all 
groups. Flow-mediated dilatation (FMD) was significantly lower in patlents with LVH than 
without LVH group. Nitrat-Induced dilatation (NID) could not be found significant rn all 
groups. In conclusion; endothelium-dependent vasodllatmn of the brachial artery is 
impaired in hypertensive patients. Left ventricular hypertrophy has an addltional negative 
effect on endothellal function of the brachial artery in patients with hypertensive normal 
coronary artwes. 
Left Ventricular Hypertrophy and Flow-mediated Vasodilation 
Control Group I Group II pl P2 P3 P4 
(n=21) (n=19) (n=14) 
Age 55?li 56*9 51+10 Ns NS NS NS 
MBP(mmHg) 89t9 124211 1191-15 <O,OOl <O,OOl Ns <O,OOl 
LVMl(grim2) 95rl6 154~12 112?14 ~0,001 <0,001 <0,05 <O,OOl 
FMD(%) 12,5+6 4,5?4 8*5 <O,OOl co,05 <0,05 <O.OOl 
NID(%) 16~5 13r5 14+3 Ns NS NS NS 
LVMI: Left Ventricular Mass Index MBP: Mean Blood Pressure Pl,for comparison of 
group I and controls; P2. for compawon of group II and controls; P3, for comparison of 
group I and group II, P4, variance analysis of three groups 
1026-190 The PARTNERS Program: Knowledge Base and Intensity of 
Peripheral Arterial Disease Detection in Community 
Practice 
Mary M. McDermott, Alan T. Hirsch, Michael H. Criqui, Judith G. Regensteiner, M. Eileen 
Walsh, Diane Treat-Jacobson, Susan Krook, Jeffrey W. Olin, Anthony J. Comerota, Emile 
R. Mohler, Ill, Mark A. Creager, William R. Hiatt. Norfhwesiern University Chicago, IL 
Objective: Available data suggest that community-based detection and treatment of 
peripheral arterial disease (PAD) is poor, possibly because of deficits in the clinician 
knowledge base regarding this common atherosclerotic condition. PARTNERS provided 
an opportunity to objectively evaluate clinician (physician and nurse) knowledge regard- 
ing PAD, community-based prevalence, disease detection, and treatment in 320 primary 
care practices in the U.S. Methods: PARTNERS was a national program of PAD detec- 
tion and professional education for clinicians in primary cam practices. The PAD knowl- 
edge base of participating clinicians was evaluated by a pre-test and then reassessed 
after their participation in PARTNERS Three general areas of knowledge were evalu- 
ated: a) PAD prevalence and diagnosis; b) association between PAD and cardiovascular 
risk; c) “ability to treat” PAD. Results: A total of 224 health-care professionals (51% MDs, 
30% RNs, and 19% other health-care profewonals) completed pre-and post-testmg. 
Increases in post-test scores occurred entirely among partlclpants who had not previ- 
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ously participated in PAD-related educational programs (75% to 80% correct, p<O.OOl). 
“Occasional” use of ABI to detect PAD increased from 33.5% to 62.6% and “frequent” 
use from 15.9% to 22.4% after the PARTNERS program. Conclusion: PAD knowledge 
and detection by health-care professionals was relatively high at baseline and increased 
modestly after the PARTNERS program. Clinician knowledge may not be the main limita- 
tion to community-based PAD detection. Additional national educational efforts within pri- 
mary care are indicated to communicate the cardiovascular risk of PAD and potential 
treatment benefits. 
Mean Scores Pre-test Post-t& D value 
iPaired t-test) 
Overall knowledge 76% 80% <O.OOl 
PAD prevalence and diagnosis 80% 84% co.oo1 
PAD and cardiovascular risk 74% 79% <O.OOl 
Ability to treat PAD 71% 72% 0.206 
1026-191 PARTNERS: A National Survey of Peripheral Arterial 
Disease (PAD) Symptoms and Treatment Intensity 
Alan T. Hirsch, William R. Hi&t, Michael H. Criqui, Mary M. McDermott, Judith G. 
Regensteiner, M. Eileen Walsh, Diane Treat-Jacobson, Susan Krook, Jeffrey W. Olin, 
Anthony J. Comerota, Emile R. Mohler, Ill, Mark A. Creager. University of Minnesota 
Medical School, Minneapolis, MN 
Background: The hallmark symptom of PAD, claudication, decreases health-related 
quality-of-life and marks a population at high risk of ischemic events. Claudication is 
manifest, however, in only a subset of PAD patients, all of whom merit medical interven- 
tions to prevent ischemic events (e.g., antiplatelet therapy) and to wnprove symptoms 
(e.g., supervised exercise, pharmacologic, and revascularization strategies). The preva- 
lence of community-based PAD, claudication symptoms, and treatment intensity has not 
been previously reported. PARTNERS was designed to: (1) identify patients with PAD 
and/or other cardiovascular diseases (CVD); (2) assess the prevalence of reported clini- 
cal and actual Rose claudication: and (3) measure use of symptom-directed treatments. 
Methods: Recruitment in 25 cities and 320 primary care practices evaluated 6979 
patients for PAD and CVD (history of angina, MI, CABG, PTCA, AAA, TIA, or stroke). 
Patients underwent an ABI measurement and were surveyed for all leg symptoms and 
PAD treatments. Results: Patients with PAD (n=1865) had a mean ABI of 0.78, com- 
pared to 1 .lO for those without PAD. Charted “claudlcation” was much more common 
than classic (questionnaire-based) Rose claudication. Pharmacotherapies and exercise 
to treat claudicatw are used less than leg bypass. Rates of treatment with symptom- 
directed therapies were low, but highest in those with CVD. All pair-wise comparisons 
were highly statistically significant (p c 0.001) except as noted below. Conclusions: PAD 
denotes a high ischemic risk in all patients, but claudication is an insensitive marker of 
true PAD prevalence. Barriers to more accurate PAD detection and global treatment 
intensity should be identified to improve PAD outcomes. 
PAD Treatment PAD+/CVD- PAD+/CVD+ PAD-/CVD+ PAD-ICVD- 
Sample size (n) 825 1040 1527 3025 
Chart History of Claudication 23% 35% 9% 4% 
History of Leg 10% 17% 0% 0% 
Revascularization 
Supervised Exercise Rx 2.5%t 7.7%$ 6.9%$ 2.5%f 
Claudication Medications* 5.1%5 5.3%§ 0.7%11 0.5%11 
‘Patients may have used more than one medication 
t $5 11 Indicate an NS pairwise comparison by the Cochran-Mantel-Haenszel statistic 
1026-192 Serum Uric Acid is Associated With Claudication Distance 
in Hypertension Complicated by Peripheral Arterial Disease 
Michel R. S. Langlois, Daniel Duprez, Joris Delanghe, Marc De Buyzere, Denis Clement. 
University Hospital, Ghent, Belgium 
Background: Serum uric acid, a risk factor in hypertension, has been proposed to reflect 
peripheral ischemia (tissue hypoxia). We hypothesized that hyperuricemia might be more 
pronounced in hypertension complicated by peripheral arterial disease (PAD) and is 
related to the patients’ functional state. Methods: Serum uric acid concentrations were 
measured in 106 patients with hypertension (age 62*14 y, 45% males) and 61 hyperten- 
sives with PAD (age 68210 y, 63% males) under comparable antihypertensive treatment. 
Biochemical risk factors (serum lipids, sensitive CRP), serum creatinine, smoking and 
diabetes status, body mass index and pulse pressure were incorporated in the analysis. 
Ankleibrachial index (ABI, 0.6OiO.12) and absolute claudication distance on a standard- 
ized graded treadmill test (ACD, 3622168 m) were measured in PAD patients. Results: 
Serum uric acid concentrations and uric acldlcreatinine ratio were higher among hyper- 
tensives with PAD (7.3i1.6 mg/dL, 6.8t0.9) than in uncomplicated hypertension (5.811.4 
mg/dL, 6.2kO.8) (P<O.Ol). Serum uric acid concentration negatively correlated with ACD 
(r-0.432, P<O.OOOl) but not with ABI. In multivariate regression analysis, serum uric 
acid (P=O.O05), serum CRP (P=O.O02), age (P=O.O3) and smoking status (P=O.O4) were 
significantly associated with ACD (r=O.682, P<O.OOOl for the model) whereas sex, serum 
lipids, serum creatinine, diabetic status, body mass index, pulse pressure and ABI did not 
reach significance. Conclusion: Hyperuricemia is more pronounced in intermittent clau- 
dicant hypertensives than in those without PAD, and is associated with impaired func- 
tional state of the oatients. 
1026-193 The Extent of Coronary Artery Calcification is Associated 
With Clinical Predicted Risk, but Does not Predict Cardiac 
Complications of Elective Vascular Surgery 
Joseph Caravalho, Jr., Mary Van Petten, Sean D. O’Donnell, Irwin M. Feuerstein, Patrick 
G. CSMalley, David L. Gillespie, James M. Gaff, Mike Brazaitis, Allen J. Taylor. Walter 
Reed Army Medical Center, Washngton, DC 
Background: EBCT is predictive of angiographic coronary artery disease, myocardial 
perfusion abnormalities, and cardiovascular events. We tested the utility of EBCT as a 
test to assess the risk of p&operative cardiac complications of elective noncardiac “as- 
cular surgery. 
Methods: 45 patients undergo’ing elective vascular surgery (CEA 58%, aortic surgery 
31%) were preoperatively evaluated using EBCT and clinical risk prediction methods. 
The EBCT results (Agatston method) were blinded to the patient and all providers until 
after hospital discharge. Based on a history of angina, myocardial infarction, congestive 
heart failure, diabetes mellitus, or advanced age, patients were divided into the followng 
clinical risk groups: low (0 risk factors; n=lO), intermediate (1 or 2 risk factors; n=28) and 
high (3 or more risk factors; n=7). 
Results: Mean patient age was 67; the mean coronary artery calcium (CAC) scora was 
883k.967. Cardiac events (clinical events or elevations in troponin T) occurred in 14 of 45 
patients (31.3%) and correlated with predicted clinical risk: low risk lo%, intermediate 
risk 32.1%, high risk 57.1% (P=.O4). CAC scores increased across strata of clinical pre- 
dicted risk: low risk 305+333; intermediate risk 893?976; high risk 1669?1058; P=.O13. 
Des& the relationshio between CAC score and clinical predicted risk. CAC scores 
were not predicted of perioperative outcome: 
Adverse Event No Adverse Event P 
CAC score-all patients (n=45) 993k857 
CAC score- intermediate risk patients 752+681 
(n=28) 
833*1022 .61 
96OillOO .61 
The CAC score did not contribute to a logistic model for adverse cardiac events. In con- 
trast, clinically-directed myocardial perfusion studies (19 patients) had a negative predic- 
tive value of 1 OO%, and a positive predictive value of 42%. 
Conclusions: Patients undergoing elective vascular surgery have extensive coronary 
arterial calcifications, the level of which is broadly related to the clinically-predicted risk of 
cardiac complications. However, because CAC is so common and severe in these 
patients, it does not aid in the prediction of perioperative cardiac events. 
1026-194 The Prognostic Value for Stroke of a Nurse-Led Screening 
Assessment of 71,527 Scottish Middle-Aged Men 
I. Ford, A.D. McMahon, J. Pell, C. Packard, P.W. Macfarlane, S.M. Cobbe, J. Shepherd. 
Robertson Centre for Biostatisbcs, Glasgow, United Kingdom, Glasgow Royal Infirmary, 
Glasgow, United Kingdom 
Background: Increasingly, guidelines on the treatment of hypertension and hypercholes- 
terolemia are driven by a patient’s absolute risk. This study evaluated the prognostic 
value for stroke of a nurse-led screening assessment program that was part of recruit- 
ment for the West of Scotland Coronary Prevention Study. 
Methods: A cohort of 71,527 men, 45-64 years old, were assessed by nurses who had 
undertaken a short training program. Variables were entered (only systolic for blood pres- 
sure) into a multivariate Cox regression analysis, with death due to stroke and death or 
hospitalization for stroke as the endpoints. Total cholesterol was measured by Reflotron. 
Results: From this cohort, 550 men (0.77%) died with stroke as the primary cause, and 
2,394 (3.3%) died or were hospitalized with stroke as the primary cause, after an average 
of 8.8 years of follow-up. Key results are summarized in the Table as multivariate hazard 
ratios for each risk factor adjusted for all others in the model. 
Conclusion: This large prospective study confirms that important prognostic information 
for fatal and nonfatal stroke can be determined from a 20.minute screening &it con- 
ducted by a nurse. Total cholesterol was not associated with the risk of a fatal stroke but 
was weakly associated with the combined outcome. 
Multivariate hazard ratios (95% Cl, P Value) 
Fatal stroke Death or hospitalization for 
stroke 
Age (5~ r) 1.68 (1.54, 1.84), <O.OOl 1.39 (1.33, 1.44), <O.OOl 
Systolic BP (20mm Hg) 1.40 (1.29, 1.51), <O.OOl 1.29 (1.24, 1.35), <O.OOl 
Height (10cm) 0.81 (0.72, 0.92), <O.OOl 0.84 (0.80, 0.89), <O.OOl 
Nonfasting total-c) (1 mmol/ 0.98 (0.91, 1.06), 0.60 1.05 (1 .Ol, 1.09), 0.006 
u 
Hx of diabetes 2.59 (1.91, 3.50), <O.OOl 2.13 (1.81, 2.49), <O.OOl 
Hx of hypertenslo” 1.53 (1.26, 1.86), ~0.001 1.66 (1.51, 1.82), <O.OOl 
Personal hx of CHD 1.34 (1.08, 1.66), <O.OOi 1.57 (1.42, 1.74). <O.OOl 
Family hx of CHD 1.16 (0.93, 1.45), 0.18 1.18 (1.07, 1.31), 0.002 
Exercise (>I hriwk vs none) 0.67 (6.52, 0.85), 0.001 0.81 (0.72, 0.90), <O.OOl 
Smoking (current vs never) 2.11 (1.66, 2.69), ~0.001 1.73 (1.56, 1.93), <O.OOl 
Body mass index was not significant in both models; model included alcohol consump- 
tion; data not shown 
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1074-159 A Novel Ultrasound Method for Evaluation of Angiogenesis 
Emile R. Mohier, III, Chandra M. Sehgal, Victor A. Ferrari. Michael S. Parmacek, Robert 
L. Wilensky, University of Pennsylvania School of A&d&e, Philadelphia, PA 
Background: Although clinical studies are underway to evaluate the effectiveness of 
angiogenesis, there are no validated, noninvasive methods to assess collateral develop- 
ment. This study was performed to validate a novel method of assessing collateral forma- 
tion I” a pig model of hindlimb ischemia. Methods: Ultrasonography (ATL 3000 machine, 
5.12mHz transducer) was performed on 10 pigs immediately after removal of right com- 
mon femoral artery, and 7, 14, 28 and 42 days after the procedure. Both the ischemic and 
the contralateral nonischemic limbs were scanned according to predefined ultrasound 
planes. A previously validated computer program was used to evaluate both the color 
Doppler (CD) and power Doppler (PD) images to generate flow Indices corresponding to 
blood velocity, area of perfusion, and blood flow. Plasma vascular endothelial growth fac- 
tor (VEGF) levels were measured at the above ultrasound time points. Angiography was 
performed at day 42. Results: Collateral development was observed in the ischemic limb 
as early as 1 week while increasing dramatlcally by 2-3 weeks. At 42 days, a collateral 
network with significantly enhanced reperfusion of the lower extremity was present in all 
ischemic limbs ior all indices (P<O.OOZ)[tablel). Areas of persistent ischemia resulting 
from inadequate collateral formation were easily quantified in all images. Collaterals 
noted on ultrasound were confirmed on angiography. Plasma VEGF levels were not ele- 
vated at any of the ultrasound time points. Conclusions: In this large, juvenile animal 
model collateral formation is initiated early after ischemic injury. This novel ultrasound 
method is useful to quantify blood flow, visualize angiogenesis and determine areas of 
persistent lower limb ischemia. Hopefully, this method will allow for improved and stan- 
dardized assessment of the angiogenic response in both animal and human studies. 
Mean @SD) for color and power Doppler images 
CD Baseline 
CD Day 42 
PD Baseline 
PD Day ff2 
Velocity index 
42.6 (17) 
94.3 (27.5) 
56.8 (27.2) 
100.2 (12 
Area Index 
22.2 (35.7) 
93 (37.3) 
31.8 (20.8) 
85.8 (34.2) 
Flow Index 
11.2 (12.2) 
86 (43.7) 
22.1 (21.4 
88 (36.4) 
1074-160 Activation of Endothelial Chloride-Channels initiate 
Collateral Artery Growth (Arteriogenesis) 
Tibor Ziegelhoeffer, Christian Friednch, Dlmltri Scholz, Armin Helisch, Shawn Wagner, 
Wolfgang Schaper. Max-Plan&lnsfitufe for Physiological & Clinical Research, Bad 
Nauheim, Germany 
Background: Arteriogenesis requires activation and proliferation of endothelial cells 
(EC). We have found EC swelling to be one of the earliest morphological hallmarks of 
arteriogenesis after experimental ligation of the femoral artery. Mlbefradil (MIB) IS a 
selective blocker of T-type Ca*+ and Ci‘ channels whrch are responsible for volume con- 
trol of EC. The goal of our study was to investigate, whether the blockade of volume-con- 
trolling EC-channels would translate into an inhlbition of arteriogenew. Methods: In 
&lb/C mice the right femoral artery was ligated and cannulated proximal to the ligailon 
with a catheter connected to an osmotic minipump filled either with MIB (10 mglkgiday) 
or solvent (PBS). Color Laser Doppler Perfusion Imaging (LDI) and hemoglobin oxygen- 
ation measurements of the feet were performed before and immediately after the surgery 
in a climatized chamber at 37’C. On the 7th postoperative day all measurements were 
repeated, both hindlimbs were subsequently Derfused at physiological pressure with 
PBS/adenosine followed by 2% formaldehyde and subsequent infusion of bismuth/ 
gelatlne contrast agent. Postmortem angiograms. electronmicroscopy for EC swelling 
and histomorphometry of collaterals were performed Results: Immediately after ligation, 
the blood flow ratio of ligated vs. non-ligated distal hindlimb was 0.054 f 0.023 in the PBS 
group and 0.053 i 0.009 in the MIB-treated animals as measured by LDI. At day 7 the 
ratio improved to 0.198 i 0.033 in the PBS group and only to 0.103 t 0.022 in the MI6 
group (p < 0.05). Collateral artery diameters increased significantly from 39 k 4.8 pm to 
77.3 f 0.9 pm #n the PBS group and from 39.5 i 3.1 urn to 61 rt 4.7 pm in the MIB group. 
This deterioration of arteriogenesls I” the MIB group was confirmed by distal hindlimb 
hemoglobin oxygenation measurements, electronmlcroscopy and postmortem angle- 
grarrls Conclusion: Mibefradil significantly decreases the recovery of hindlimb perfusion 
after femoral artery ligation in mice. This suggests that the endotheiial Cl- channels are 
involved in the initiation of arteriogenesis. 
1074-161 Myocardial Angiogenesis by Hypoxic Preconditioning Is 
Mediated by Upregulation of Rat Cytokine Induced 
Neutrophil Chemoattractant (CINC) -1: Role of Nuclear 
Factor-Kappa B 
Shoji Fukuda, Hiroaki Sasaki, Genbu Yamaura, Partha R. Ray, Li Zhu. Reni Kalfin, Dipak 
K. Das, Nilanlana Maullk. Department of Surgery; University of Connecficut Medical 
Center, Farmtngton, CT 
Background: Recent studies demonstrate that pyrrolidine dithiocarbamate (PDTC), a 
specific inhibitor of nuclear factor-kappa B (NFkB) activation, as well as antisense NFkB, 
suppressed interleukin (IL)-8 expression &inhibited in vitro tubular morphogenesis. Here 
we report the role of NFkB, cytokine induced neutrophil chemoattractanf CINC-1 (rat 
homolog of IL-8) and CXCRP (rat homolog of receptor, IL-SRB) in the induction of myo- 
cardiai angiogenesis by oxldative stress in the form of hypoxia /reoxygenation (H/R) in a 
rat model of myocardial infarction. Methods: Rats were divided Into 4 groups: nor- 
moxia+LAD occlusion (COP), H/R+LAD occlusion (HOP), PDTC+ H/R +LAD occlusion 
(PHOP), or PDTC+LAD occlusion (POP). H/R cowsted of 4hrs hypoxia (10&4%02) 
+24hrs reoxygenation, the duration of normoxia being time matched to 28hrs. Results: 
Gel-shift assay revealed significant increase in NFkB activity in the HOP group compared 
to COP or POP groups, which was effectively suppressed by PDTC in the PHOP group. 
CINC-1 in plasma samples obtamed 2,4,7 days post-op. by LV catheterization, and eval- 
uated by ELISA were significantly elevated in the HOP group (146?12, 279+16, 231r21 
pgiml, 2,4,7 days post-op.) compared to COP, while PDTC administration prior to H/R 
(PHOP) reduced the extent of such increase in CINC-1 levels (93t22, 58t5 8, 87+19 pg/ 
ml, 2,4,7 days post-op.) confirming the regulatory role of NFkB. Similarly, myocardial pro- 
tein expression of CXCR-2 as assessed by Western blotting displayed significant induc- 
tion of this receptor in HOP compared to the other groups. lmmunohistochem~cal 
analysis localtzed CXCR-2 expression to coronary endothelial cells. Capillary denstty 
measurements performed 7days post-op after anti-CD31 immunohlstochemistry demon- 
strated that prior PDTC administration in the PHOP group significantly decreased the 
proangiogenlc action of H/R in the HOP group (1614+79 vs. 1963+45 counts/mm2 
p<O.O2). Conclusion: These results strongly suggest that CINC-2AL-8 is an important 
mediator of oxidative stress induced myocardial angiogenesis and is regulated by the 
redox sensitive transcription factor NFkB. 
1074-162 Tissue and Myocardial Distribution of Endocardial vs 
Epicardial lntramyocardial Delivery of 125l-labeled Basic 
Fibroblast Growth Factor (bFGF): Is Epicardial Delivery 
Obsolete? 
Roger J. Laham, Mark J. Post, Frank W. Sellke, Michael Simons. B/DAK/Harvard 
medical School, Boston 
Background. Effective local delivery to the heart remains the major obstacle to success- 
ful therapeutic applicat(on of a number of drugs and biological agents includmg angio- 
genie growth factors. This study was designed to study and optimize the delivery 
characteristics of trans-endocardial and transepicatdial intramyocardial administration. 
Methods: Thirty-nine Yorkshire pigs were used for the study [15 for catheter optimization, 
15 to determine time course of trans-endocardial BiosenseR-guided intramyocardial 
delivery in normal and chronically ischemic animals, and 9 for trans-epicardial intramyo- 
cardial delivery). Basic fibroblast growth factor (FGF2) was used as delivery agent. 
Twenty-five mCi of 1251.FGFZ mixed with 30 mg of cold FGF2 was injected into the myo- 
cardium (trans.endocardial or trans.epicardial). Tissue and myocardial distribution was 
determined at 1 and 24 hours and 7 days by measuring 125 I-FGFZ specific activity 
indexed to the total activity administered. Results: Using 1 hour 1251.FGF2 myocardial 
deposition as a parameter for delivery efficiency, the optimal needle length in these ani- 
mals with a wail thickness of 8.9il 1 mm was 6 mm and the optimal injection volume was 
0.05 to 0.1 ml with a 50% drop off in delivery efficiency outside these parameters. Using 
these parameters for trans.endocardial delivery in ischemic animals, total 125l-FGF2 
cardiac specific activity was 18.01i3.84% at 1 hour, 11.65+5.17% at 24 hours, and 
2.32+0.87% at 7 days with most of the injected FGFQ localizing to the iargeted areas. 
Studies in non-ischemic animals prbduced similar results (18.96*8.23% at 1 hour and 
9.97t4.00% at 24 hours). For trans-epicardial delivery, total 1251.FGF2 cardiac specific 
activity was 23.14+12.67% for the 6 mm needle and 20.86111.06% for the 3 mm needle 
at 1 hour, declining to 12.32+8.50% for the 6 mm needle at 24 hr and did not differ from 
values obtained following trans-endocardial delivery. Conclusion: Optimized trans- 
endocardial intramyocardial delivery results is comparable to trans-epicardial delivery, 
both prowding markedly higher myocardial deposition and retention and lower systemic 
recirculation of than intracoronary or intravenous delivery 
1074-163 Nicotine Stimulates Tumor Angiogenesis 
Christopher Heeschen, Anjali Pathak, James J. Jang, Frances Johnson, John p. Cooke. 
Stanford University, STanford, CA 
Angiogenesis occurs during a number of physiological and pathophysiological settings. 
Tobacco-related diseases, most notably cancer and atherosclerosis, require angiogene- 
sis for sustained growth of the lesion. Here we show that nicotine, via stimulation of nico- 
tiniC receptors, enhances anglogenesis and may stimulate tumor growth in part by 
enhancing tumor vascularity. Results: Nicotine in concentrations that are observed in 
smokers stimulated proliferation of human coronary artery endothelial cells (HCAEC) by 
3-fold. This effect was completely blocked by the nicotinic receptor antagonist hexame- 
thonium. In an in vitro collagen gel assay, HCAECs did not manifest tube formation in 
response to control medium. In this setting, nicotine induced tube formation in a dose- 
dependent fashion, an effect that was antagonized by hexamethonium. To determine if 
nicotine could enhance tumor angiogenesis, an in viva Lewis lung cancer model was 
used. Seven days after Implantation of Lewis lung cancer cells, all mice exhibited similar 
tumor Size (0.21 vs. 0.23 cm2, control vs. nicotine; P=O.87). After 16 days of treatment, 
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however, excessive tumor growth in the nlcotine group required sacrifice of the animals. 
Wet weight (0.92 vs. 0.49 g, P<O.OOi) and swa (2.12 vs. 0.92 cm3, P<O.OOl) of the 
tumors in the mcotine-treated animals were significantly higher compared to the control 
group. This late increase in tumor growth for the nicotme group corresponded with 
increased vascularization of the tumor tissue (capillary index: 1 .l vs. 0.2, nicotine vs. 
control, P<O.OOl). The effect of nicotine to stimulate tumor growth may also be due in 
part to its modest effect to enhance tumor cell proliferation (35% increase compared to 
control medium; P=O.OiZ). Conclusion: These studies are consistent with previous 
obsewaiions by our group, indicating that nicotine accelerates plaque growth by increas- 
ing plaque neovascularization. Nicotine is a potent angiogenic agent and may stimulate 
tumor growth in part by enhancing their vascularization. 
1074-164 Hyperlipidemia Potentiates InVitro Angiogenesis with 
Vascular Endothelial Growth Factor 
Zhenguo Han, Damon Duquaine, Christina Addison, Sampath Parthasarathy, Jacques 
Nor, Sanjay Ralagopalan. University of Michigan, Department of lntemal Medicine, Ann 
Arbor, MI, Emory Unwersity, Atlanta, GA 
Background: Previous studies have demonstrated that oxidized lipids may inhibit endot- 
helial cell proliferation and inhibit angiogenic responses. We sought to determine the 
effects of experimental hyperlipidemia on in-vitro angiogenic responses to Vascular 
Endothelial Growth Factor (VEGF). Methods: New Zealand White rabbits were fed with 
diet containing 1% cholesterol or normal chow for a duration of 8 weeks. The rabbits 
were sacrificed at the end of this period, serum extracted in a sterile fashion, flltered, 
pooled and stored until usage. Serum cholesterol averaged 1313153 in pooled hyperlipi- 
demic serum samples and ~45 mgidl in the control samples. Serum protein concentra- 
tions were similar. Human Dermal Microvascular Endothelial Cells (HDMEC) were 
cultured on type I collagen gels in the presence of Endothelial Growth Medium (EGM- 
2MV) and VEGF,,, (50 rig/ml) supplemented with either hyperlipidemic (5%HL) or nor- 
molipidemic (5%NL) rabbit serum. Endothelial cell proliferation and capillary tube forma- 
tion was assessed over 10 days as indices of angiogenic responsiveness. Results: 
Endothelial cell proliferation were identical in the HL and NL groups. Contrary to expecta- 
tions, HL markedly increased capillary tube formation compared with NL (6ti vs. 1.2+0.5 
capillary tubes/HPF). Conclusions: Hyperllpidemic states may potent&e in-vitro angio- 
genie responses to VEGF through a selective effect on capillary iube formation. Further 
studies are needed to define the precise mechanisms mediating these apparently para- 
doxic effects of high serum lipids. 
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1075-165 We Should Target High Triglycerides for Treatment of 
Patients With Coronary Artery Disease 
Solomon Behar, Elieser Kaplinsky, Yehezekiel Kishon, Avraham Caspi, Un Goldbourt, 
Henrietta Reicher-Reiss, Avraham Shotan, Eran Graff. Neufeeld Cardiac Research 
/nstitute, Jel Hashomer. lsraei 
Background: Several landmark trials (45, CARE, LIPID) have clearly shown that statins 
reduce significantly the cardiac event rates in coronary artery disease (CAD) patlenis 
(pts) with elevated or moderate levels of total cholesterol (TC). However, a large propor- 
tion of CAD pls (225%) have nearly normal levels of TC (5200 mgidl) and the majority of 
them exhibit low HDL-C (~35 mgidl) and/or high triglyceride (TG) (>200 mgidl) levels. 
Methods: The Bezafibrate Infarction Prevention (BIP) study was conducted in Israel in 
18 cardiac departments among 3090 pts with CAD, slightly elevated TC (mean 212 mgi 
dl), relatively low HDL-C (mean 35 mgidl) and high TG (mean 148 mgidl). The aim of the 
study was to assess whether, by raising HDL-C and/or reducing TG, a reduction of car- 
diac events will ensue. Pts were randomized to receive 400 mgidl of bezafibrate or pla- 
cebo. Results: Bezafibrate increased HDL-C by 18% and lowered TG by 21%. After a 
mean follow-up of 6.2 years, primary endpoints (fatal, non-fatal acute myocardial infarc- 
tion and sudden death) were moderately reduced (9%; p=NS) in the bezafibrate group 
compared to pts in the placebo group (13.6 and 15.0% respectively). Howeverjn a sub- 
group analysis of pts with high baseline TG (2200 mg/dl; n=453), pts treated with bezafi- 
brate (n=Z34) had a primary endpoint rate of 11.5% vs. 19.1% among the group of pts 
on placebo(n=220)(40% reduction). After multivariate adjustment for age, gender, clInical 
and llpid characteristics, the relative risk for primary endpoints was 0.57 (95% Cl 0.35. 
0.93) in the subgroup of pts with high TG randomized to bezafibrate as compared with 
the group on placebo. These results were independent of HDL-C and LDL-C baseline 
levels. Conclusion: Among pts with high TG (2200 mg/dl) bezafibrate reduced the major 
cardiac event rate by 40%. This study suggests that high TG should be a target for treat- 
ment of pts with CAD. However, as these dais derive from post hoc analyses, they need 
confirmation in a prospective randomized trial. 
1075-166 Comparison of Lipid Profiles of Patients Receiving 
Gemfibrozil and Fenofibrate in a Crossover Design 
James M. Backes, Patrick M. Moriarty, Cheryl A. Gibson. Univeis@y of Kansas Medical 
Center. Kansas City, KS 
Background: The fibric acid derivatives demonstrate effectiveness in the treatment of 
hypertriglyceridemia, which is associated with an increased risk for coronary artery dis- 
ease (CAD), and pancreatitis. Although, numerous studies have established the efficacy 
of micronized fenofibrate(MF) and gemfibrozil on improving lipid profiles, there are cur- 
rently no comparative data on the lipid lowering effects of these two agents. The objective 
of this study was io evaluate the changes in lipid profiles of hypertriglyceridemic patients 
being crossed-over from gemfibrozil to MF. 
Methods: A total of 21 patients were enrolled into the study. All patients were maintained 
on gemfibrozil 600mg BID for a minimum of 3 months. Fasting lipid profiles were initially 
obtained 2 weeks prior to conversion to MF. Additional llpid profiles were obtained 3 
months after the crossover to fenofibrate 200.201mgiday. Changes in mean lipid values 
were then evaluated. Patients were excluded from the study if there were alterations in 
other lipid-lowering drug therapy and if significant changes in weight or HbAlc were 
present. 
Results: Of the 21 patients (7 Female/l4 Male), 4 had CAD, defined as a previous his- 
tory of myocardial infarction, myocardial ischemia, coronary artery bypass grafting or per- 
cutaneous transluminal coronary angioplasty. Other risk factors and descriptive statistics 
included hypertension (lo), diabetes mellitus (ll), smoking (4 current, 10 former), mean 
age 50.4 i 12.7 years, and mean body mass index 29.5 i- 2.9. Table 1 provides the 
results for the comparison of lipid values. 
Lipoprotein Gemfibrozil Micronized Fenofibrate P value 
(*SD) (*SD) 
Total Cholesterol (TC) 283.8 + 180.3 220.6 + 98.8 0.058 
Triglycerides 1211.7+ 1418.2 534.4 + 524.6 0.003 
HDL 29.6 i 10.4 36.1 & 16.3 0.031 
LDL* 84.4 + 25.8 88.8 f 11.4 0.866 
LDUHDL* 3.1 f 1.6 3.3 t 2.7 1 .oo 
TC/HDL 12.3~ 12.7 7.6 + 5.8 0.039 
*II=8 
Conclusion: The results of our study indicated that MF had a more favorable effect on 
triglycerides, HDL and TCIHDL ratio compared to gemfibrozil. MF also exhibited a nota- 
ble but not statistically significant effect in lowering TC in comparison to gemfibroril ther- 
apy. 
1075-167 Effect of Lipid Lowering Therapy With Atorvastatin Alone or 
in Association With Different Hormone Replacement 
Schemes in Female Patients With Severe 
Hypercholesterolemia 
Giuseppe M. C. Rosano, Giuseppe Mercuro, Fllippo Leonardo, Sandra Zoncu, Massimo 
Fini. San Raffaele Hospital - Roma - Josinvest Sanif& Roma, ffaiy, University of Cagliari, 
Cagliari, k/y 
Statins and hormone replacement therapy (HRT) significantly reduce plasma total (total- 
C) and LDL cholesterol (LDL-C), and raise HDL cholesterol (HDL-C). However, while 
statins are more effective in reducing total-C and LDL-C, HRT is more effective in reduc- 
ing LP(a) and in increasing HDL-C. The aim of this study was to evaluate the effect of 
therapy with Atorvastatin alone or in combination with HRT on lipid profiles in 136 post- 
menopausal women with severe hyperchoiesterolemia (plasma cholesterol 2280 mgidl). 
In a prospective, open-label, parallel trial, patients were allocated to four treatment 
groups: Atorvastatin 10 mg (A), atorvastatin 10 mg + conjugated equine estrogens 0.625 
mg and continuous combined medroxyprogesterone 2.5 mg (ACEEM), atorvastatin 10 
mg + estradiol valerate and cyproterone acetate (AEC), atorvastatin 10 mg + 100 mg 
transdermal estradiol 17.beta and norethisterone acetate (ATEN). Patients underwent 
evaluations of plasma lipids at baseline and after 2, 4 and 6 months,of therapy. Atorvasta- 
tin alone significantly reduced baselme plasma total-C, triglycerides, and LDL-C; raised 
HDL-6; but had no effect on Lp(a). The adjunct of HRT had different effects on lipid pro- 
files depending on the route of administration. No significant change between Atorvasta- 
tin only and Atorvastatin plus transdermal HRT was found in any lipoprotein parameter. 
Oral HRT significanily lowered total-C, triglycerides, LDL-C and Lp(a), and raised HDL-C 
compared to baseline and to atorvastaiin alone and atorvastatin plus transdermal HRT. 
After treatment, significanily more women achieved the NCEP goals in the Atorvastatin 
olus oral HRT comaared with the Atorvastatin alone or Atorvastatin olus transdermal 
HRT. The table below presents the % change from baseline after 6 months of therapy. 
A ACEEM AEC ATEN 
Total-C -29 -34 -35 -30 
LDL-C -36 -40 -41* -35 
HDL-C +8 +11* +io* +8 
Triglycerides -9 -12 -11 -8 
LP@) +l -37** -38” -5 
Fibrinogen -3 -2 -2 -4 
‘~~0.05, **p<O.Ol compared to A alone. In conclusion, combined therapy with oral HRT 
and Atorvastatin is more effective than Atorvastatin alone in improving lipoprotein profile 
and in achieving NCEP goals in postmenopausal women with severe hypercholester- 
olemia. 
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1075-168 Pharmacodynamic Interaction Between the New Selective 
Cholesterol Absorption Inhibitor Ezetimibe and Atorvastatin 
Teddy Kasoglou Michael Selberling, Paul Statkevich, David L Cutler, Bo Yang, LeShawn 
Anderson, Stephen E. Maxwell, Melton B. Affnme. Schering-Piough Research Institute, 
Kenilworth, NJ, Swiss Pharma Contract Ltd., Allschwil. Switzerland 
Background: Ezetimibe (SCH 58235) is a new selective cholesterol absorption inhibitor 
in clinical development which has been shown to significantly decrease LDL-cholesterol 
in patients with primary hypercholesterolemia. We evaluated a potential pharmacokinetic 
and/or pharmacodynamic interaction between ezetimibe (EZE) and atorvastatin (ATV). 
Methods: In a randomized, evaluator-blind, placebo-controlled, parallel-group study 32 
healthy hypercholesterolemics (screening LDL-C 2130 mgldi) stabilized and maintained 
on a NCEP Step I Diet were randomized to one of the following four treatments: ATV 10 
mg, EZE IO mg, ATV 10 mg plus EZE 10 mg or placebo orally, every morning for 14 days. 
Serum lipids were assessed predose (after a minimum of a 1 O-hour fast) on Day 1 (Base- 
line), Day 7 and Day 14. Results: No serious or unexpected adverse events (AEs) were 
reported. Reported AEs were generally mild, non-specific and similar among treatments. 
There were no significant increases in cllnical laboratory tests associated with any of the 
treatments. particularly those tests assessing muscie and liver function. EZE had no 
effect on the pharmacokinetics of ATV or we versa. The mean (SE) Day 14 percent (%) 
change from Baseline in serum lipids are shown in the table below. 
Treatment LDL-c Total-C HDL-C TG 
PLACEBO (n=8) -6.9 (4.6) -6.1 (3.7) -12.8 (2.2) 22.6 (21 .I) 
EZE 10 mg (n=8) -22.7 (5.2) -15.4 (4.6) -11.3 (2.6) 32.8 (15.6) 
ATV 10 mg (n=8) -40.0 (5.1) -28.4 (4.6) -0.5 (7.7) 0.5 (14.0) 
ATV + EZE (1x8) -55.7 (2.0) -38.0 (2.4) -1 .I (5.0) -8.6 (7.1) 
Conclusion: The coadmlnistration of EZE 10 mg and ATV 10 mg was safe, well toler- 
ated, and caused a significant (psO.02) reduction in LDL-C with no effect (p>O.l) on HDL- 
C or triglycerides compared to either drug alone. The coadministration of EZE 10 mg and 
low dose ATV has the potential to produce clinically slgniflcant reductions in LDL-C, com- 
parable io high doses of ATV alone, with a favorable safety profile. 
inserted Into the periphery of the pulmonary artery, and imaging data till the main pulmo- 
nary trunk were recorded by the automatic withdrawal technique. Results: In all 7 
patients who exhibited normal pulmonary arterial pressure, the intima was found to have 
a single-layer structure with visualization of neither intimal hypertrophy nor abnormal 
structures including thrombi. Among 34 patients in whom pulmonary thromboembolism 
was suspected, the acute cases were found to have fresh thrombus and smooth intima, 
whereas the chronic case?, exhibited organized thrombus and intimal hypertrophy. Four 
of six patients wth collagen diseases exhibited intimal hypertrophy. lntlmal hypertrophy, 
partly with a three-layer structure, was visualized in both patients (100%) with primary 
pulmonary hypertension. No intimal hypertrophy was observed in the patients with sec- 
ondary pulmonary hypertension associated with myocardial infarction or dilated cardi- 
omyopathy. No intimal hypertrophy was observed in patients with lung cancer or 
pulmonary arterial invasion of mediastinal tumor. In 2 of the 53 patients (2.7%), hemor- 
rhage associated with injury to the pulmonary arterial periphery occurred, but both were 
trivial and improved quickly. Conclusion: It was demonstrated that the pulmonary arterial 
intravascular ultrasonographic exammation was relatwely safe and useful for evaluation 
of the intimal condition and the presence or absence as well as the pathological state of 
thrombus, which are difficult to confirm by means of pulmonary arteriography or pulmo- 
nary blood flow scintigraphy 
1076-171 Does Aspirin Influence Prophylactic Effect of Low- 
Molecular-Weight Heparin Enoxaparin on Venous 
Thromboembolism in Medical Patients? 
Alain Leirorovlcr, F Boutltle, Nadine Weisslinger. Unite de Pharmacologic Cliniqoe, 
Faculte Laennec, Lyon, France 
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Background: the MEDENOX trial evaluated the benefit of the low-molecular-weight hep- 
arin (LMWH) enoxaparin in prophylaxis of venous thromboembollc events (VTE) in 
acutely il l medical patients. The possible interaction of LMWH and aspirin and its influ- 
ence on efficacy and safety outcomes was explored. Methods. patients randomized to 
enoxaparin 40 mg or placebo were included in this analysis. Prescription of concomitant 
aspirin was observed before and/or during the 10 days (14) treatment period in 28.5% 
and 29.2% of the LMWH and placebo groups, respectively. Patients who recwed aspirin 
were, on average, older than those who did not (75.3 vs 72.9 years old, p<O.O05) and 
were more likely to have heart failure (New York Heart Association classification Ill or IV; 
56% vs 2.6%, p ~10 + ). Results: the univariate analyses on the three main outcomes 
showed no evidence of an influence of aspirin on the effects of LMWH, i.e. similar relative 
risks of enoxaparin versus placebo and no significant interaction. Multivariate analyses 
adjusting for the major baseline characteristics coupled with interaction terms on the 
same outcome variables showed similar results. 
LMWH versus placebo -- Placebo risk; Relative risks (95%CI) 
Total (n=579) No aspirin Aspirin (n-167) Interaction p 
(n=412) value 
VTE at day 10 14.9%; 16.2%; 11.9%; 0.77 
0.37(0.21-0.64) 0.39(0.21-0.71) 0.30(0.09-1.06) 
1076-169 Enoxaparin Pharmacokinetics and Pharmacodynamics in VTE at day 90 17.1%; 18.4%; 13.7%; 0.59 
Renal Impairment 0.41(0.25-0.68) 0.44(0.25-0.77) 0.29(0.08-1.02) 
Ger-Jan Sanderink, Colette Guimart, Navin Jariwala, Umesh Shukla, Marie-Laure 
Ozoux, Bruno Boutouyrie, H W. Hutman, Maria Gutierrez, Thomas Marbury, Richard 
Preston. Aventis Pharma, Antony, France, Investigators Group, Miam~/Orlando/Fort 
Lauderdale, FL 
Background: Enoxaparin (E) is a low molecular weight heparin used for the treatment of 
various arterial and venous thrombotic diseases. The drug is in part renally cleared as 
active or inactive fragments. Patients with renal impairment (RI) are particularly at risk of 
cardiovascular events. Methods: 40 mg E was administered once daily SC for 4 days to 
4 groups of 12 age-, weight- and sex-matched volunteers: normals (creatinlne clearance 
(CrCl)>80 miim~n, mild RI (SO&RCLResults: Rate of absorption was similar across 
groups with Tmax from 3-4 hours. Amax was 10 to 35% higher in RI group?. but not 
clearly related to its severity. The median apparent elimination half-life increased with the 
level of RI (6.87, 9.94, 11.3, 15.9 h on Day 4). Exposure on Day 4 was quite well pre- 
dlcted by Day 1 pharmacokinetics in normals (+lO% accumulation), but this increased to 
29% in patients with severe RI. Log-transformed anti-Xa AUC(O-24h) at steady-state was 
20% and 21% higher in mild and moderate RI subjects than in normal volunteers (9O%CI 
tOO-145% and 100-146%). in severe RI, AUC(O-24h) was on average 65% higher 
(9O%Cl 137.199%). Apparent anti-Xa clearance was significantly linearly correlated wth 
renal function (Cl/f (L/h) = 0.0035xCrCl (ml/min)+0.589, r2=0.26 p=O.O002). aPn was not 
different across groups. Conclusion: Anti-Xa clearance decreases with degree of renal 
function. PK parameters at the tested regimen are only marginally increased in patients 
with mild or moderate renal impairment, with the exception of an increase in elimination 
half-life. Anti-Xa exposure, represented by AUC(O-24h), is significantly increased by 65% 
in patients with severe renal impairment when compared to healihy volunteers and, 
despite similar aPTT prolong&on. dose reduction in this group appears recommended. 
Any bleeding at 8.6%; 7.1%; 12.0%; 0.98 
day 10 1.46(0.95-2.26) 1.49(0.84-2.64) 1.44(0.74-2.78) 
Conclusion: in acutely il l medical patients the benefit of enoxaparin in terms of relative 
reduction of VTE appeared to be similar in patients who received aspirin and in those 
who did not. The relative excess risk of bleeding associated with enoxaparin was not 
exacerbated by the use of aspirin. 
1076-172 Enoxaparin Pharmacokinetics and Pharmacodynamics in 
Obese Subjects 
Ger-Jan Sanderink, Aim& Le Liboux, Navin Jariwala, Neasa Harding, Marie-Law 
Ozoux, Umesh Shukla, Guy Montay, Bruno Boutouyrie, Adelaida Mire. Aventis Pharma, 
Antony, France, Novum Pharmaceutical Research Services, Pittsburgh, PA 
1076-170 Evaluation of the Usefulness of Pulmonary Artery 
Intravascular Ultrasonography in Pulmonary Artery 
Diseases 
Toshiya Furuta. Fuji& He&h Unwersity, The 2nd Hospital, Nagoya, Japan 
Intravascular ultrasonography can precisely evaluate the pathological state of the vascu- 
lar wall and the degree of vascular constriction, i.e., it can give various information which 
can not be obtained by the other angiographic techniques. In the present study, we 
employed the intravascular ultrasonography for examination of 53 patients with sus- 
pected pulmonary artery diseases including pulmonary thromboembolism. Methods: As 
continuation of cardiac catheterization, an intravascular ultrasonographic catheter was 
Background: Enoxapann (E) IS a low molecular weight heparin used for the treatment of 
deep venous thrombosis at weight-adjusted doses of 1 .O mglkg q12h SC or 1.5 mglkg 
qd. Pharmacokinetics in a particular group at risk, obese patients, have not been previ- 
ously evaluated in a well-controlled study. Methods: 24 healthy obese volunteers (BMI 
30.48 kg/m2, weight 87-144 kg, 12 male, 12 female) and 24 sex-, age- and height- 
matched normal volunteers were given 1.5 mgikg E as a single 6.hr IV infusion and as 4 
repeat 1.5 mg/kg SC doses once daily. The plasma pharmacokinetics of anti-factor Xa, 
anti-factor Ila and aPm were evaluated. Results: IV infusion: anti-Xa activity showed 
generally mono-exponential elimination. Total plasma clearance of anti-Xa activity was 
0.010 Uh/kg and distribution volume 0.059 Ukg in obese. These values were -9% 
(p=O.O14) and -11% of those I” normal subjects. Because of weight-adjusted dosing, 
Amax was therefore 15% higher in obese (pcO.0001) and half-life was 9% longer 
(~~0.034). 1.5 mg/kg SC qd: absolute bioavailability was 106% (CV=7%) in both normal 
and obese subjects for anti-Xa and 85%(14%) and 75%(12%) for anti-lla. On day 4, 
Tmax was slightly longer (4 vs 3 hr), but maximum activity was not different in obese 
(1.56 vs 1.49 IUiml). AUC(O-24h) was 16% higher in obese and trough levels +44% (0.19 
vs 0.13 IU/ml) Remarkably, maximum aPTT prolongation was -28% (pcO.0001) and - 
15% (NS) in obese after 1 or 4 doses, suggesting relatively less effect on this parameter 
in obese at a given anti-Xa level. Conclusion: weight-adjusted doslng leads to only 
slightly higher anti-Xa levels in obese and mainly in the elimination phase, not at Amax. 
This is explained by slighly slower, although complete, absorption and a lower weight- 
adjusted clearance and distribution volume in these subjects. aPTT is not more 
increased in obese and no dosage adjustment appears necessary with the regimen of 
1.5 mgikg SC qd. 
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1076-173 Magnetic Resonance Imaging Indicates Remodeling of the 1077-176 The Arg389Gly Polymorphism of Human pl-Adrenergic 
Right Ventricle Early After Pulmonary Receptor Is a New Genetic Marker for Acute Myocardial 
Thromboendarterectomy Infarction 
Mario Togni, Anthony N. DeMaria, Stuart W. Jam&on, Peter F. Fedullo, Divya Bolar, 
Paul J. Friedman. University of California, Division of Cardiology, San Diego, University of 
California, Department of Radiology, San Diego 
Background: In patients with chronic thromboembolic pulmonary hypertension (CTPH) 
pulmonary thromboendarterectomy (PTE) leads to marked decreases in pulmonary 
artery pressures. Little is known about the effect of pressure relief on right ventricular 
(RV) volumes and function. Methods: Cardiac MRI was performed in 8 patients with 
CTPH 3 i 2 days (mean ? SD) before and 10 C 4 days after PTE as well as rn 8 normal 
volunteers. The RV was imaged with a series of 6-7 mm transverse slices at 10 mm Inter- 
vals from the apex through the pulmonic valve, using tine gradient echo sequences with 
breathhold. RV volumes were calculated by applying Simpson’s rule to sum the manually 
traced areas of the RV- endocardial border of each image. End- diastolic and end- sys- 
tolic RV volumes indexed to body surface area ( RVEDVi and RVESVi, respectively) and 
RV ejection fraction (RV-EF) were determined. Pulmonic artery mean pressures (PAP) in 
CTPH patients ware measured at right heart catheterization before and after PTE. 
Results: After PTE, RVEDV! and RVESVi decreased significantly (p<O.OOl and p<O.Oi, 
respectively) to values close to those measured in normals (TABLE). RV- EF did not 
change significantly. Conclusions: Marked reductions in RV volumes can be demon- 
strated after PTE surgery in CTPH patients. This may reflect early remodeling of the RV 
in response to pressure relief. Long-term follow-up studies are needed to assess racov- 
ery of RV function. 
Chikao Iwai, Hozuka Akita, Kenji Kanazawa, Nobuyuki Shiga, Masahiro Terashima, 
Yasuaki Matsuda, Eiji Takal, Yoshitomo Miyamoto, Teishi Kajiya, Takatoshi Hayashi, 
Mitsuhiro Yokoyama. The 1st Dept. of internal Medicine, Kobe University School of 
Medicine, Kobe, Japan, Dept. of Cardiology: Him@ Cardiovascular Center, Himeji, Japan 
Background: Disruption of the atherosclerotic plaque is a key event that leads to acute 
myocardial infarction (AMI). It was previously reported that augmented sympathetic activ- 
ity might play an important role as a trigger of plaque disruptron through pl-adrenergic 
receptor (Pl AR) activation. Clinical studies strongly suggest that P-blockers may reduce 
the incidence of AMI by reducing hemodynamic forces. Recently, a common polymor- 
phism has been identified at amino acid posltion 389 (Arg or Gly) of the human plAR, 
within a region important for G protein coupling and subsequent signaling. In vitro func- 
tional assays using site-directed mutagenesis revealed that adenyiyl cyclase activities of 
the Arg389 plAR were much higher than those of the Gly389 PIAR in transfected fiblo- 
blasts. Based on these observations, we hypothesized that Arg389Gly gene variant could 
be a genetic risk factor for triggering plaque disruption leading to AMI. Methods: To 
investigate the relation between Arg389Gly polymorphism in PIAR gene and AMI, we 
genotyped 354 patients with AMI and 354 age- and sex- matched control subjects by 
using polymerase chain react@ (PCR) amplification and the restriction fragment length 
polymorphism analysis. Results: The prevalence of Arg389 homozygote (CC) genotype 
was significantly more frequent in AMI patients than in control subjects (68.1% versus 
47.2%, P < 0.0001). C allele frequency of AMI was much higher than that of controls 
(0.81 vs 0.69, p< 0.0001). In logistic regression models, odds ratio of Arg389 homozy- 
gate (CC) versus Arg389Gly heterozygote (CG) + Gly389 homozygote (GG) genotypes 
between control subjects and AMI patients was 2.86. The association of Arg389Gly poly- 
morphism of pl AR with AMI was statistically significant and independent of other risk fac- 
tors. 
RVEDVi (ml/mZ) 
CTPH patients (n-8) 
pre PTE post PTE 
85 +/- 15 49 +/-IO 
Normals (n=8) 
58 +/- 5 
RVESVi (mlim2) 57 +I- 15 31 +/- 10 21 +/- 5 
RV- EF (%) 33 +/- 10 39 +I- 8 63 +/- 8 
PAP (mmHg) 41 +I- 9 29 +I- 9 
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1077-175 Genetic Susceptibility for Coronary Artery Disease: Is 
Evaluation of Multiple Genetic Polymorphisms Reasonable? 
Jan R. Ortlepp, Johannes Lauscher, Peter Hanrath, Rainer Hoffmann. Medical Clinic I 
University Hospital of Aachen, 52057 Aachen, Germany 
Background: Polymorphisms of different genes have been associated with coronary 
artery disease (CAD) before. The aim of this study was to evaluate the incremented ben- 
efit of testing multiple genetic polymorphisms to determine the individual genetic risk for 
CAD. 
Methods and Results: To achieve a balanced 
case/control study population with an identical ‘00 . 
burden of classic cardiac risk factors (age, g ;: 
sex, smoking, diabetes, hypertension. hyper- g i: ‘. 
. 
lipidemia and positive family history) an angio- g :: 
graphic controlled pair matched population 9 3o “20 . 
10 
0 with 100 control and 100 case patients from L- 
’ .’ 
.’ 
the same geographic area was evaluated. 16 
different genetic polymorphisms were analy- 
sed in the study population. Eight polymor- 
phisms (CMA A-1905G, AGTRI Al 166C, 
CYPllB2 C-344T, VDR Bsm I, PAI- 4G/5G, LPL Pvu III, LPL Hind Ill, CETP Taq I) 
showed a significant difference in the allele frequencies between case and controls. Alle- 
les with a higher prevalence in the case group were tentatively defined as risk alleles. 
The number of risk alleles per individual patient was 7.26 f 1.93 in the control and 8.47 + 
2.09 in the case group (pcO.0001). The prevalence of CAD was rising with increasing 
numbers of risk alleles per individual (Figure). There was an average odds ratio of 1.35 
(95%CI 1.16-l .56) to have CAD in a logistic regression model with each additional risk 
allele. The odds ratio was 3.29 (95%CI 1.57-6.88) to have CAD in a threshold model if 
patients had a total number of 2 9 risk alleles. 
Conclusions: The genetic predisposition for CAD is based at least in part on the sum of 
different genetic polymorphisms. Analysis of multiple genetic polymorphisms is reason- 
able to determIne the individual genetic burden for CAD. 
Conclusion: Our findings suggest that Arg389Gly polymorphism in human pl AR gene is 
associated with AMI. 
1077-177 Association of Angiotensin-Converting Enzyme and 
Angiotensin II Type 1 Receptor Gene Polymorphisms With 
Risk of Acute Myocardial Infarction in a Low Coronary Risk 
Population. Final Results of the GEMIG Study 
George Andrikopoulos, Dimitri Richter, Edward W. A. Needham, Mihalis Zairis, Elias 
Karambinos, Dimitris Man&&s, Konstantinos Paravolidakis, Paraskevi Vogiatzi, 
Stefanos Foussas, Evaggelos Papasteriadis, Christodoulos Stefanadis, John Gialafos, 
Raj Mattu, Pavlos Toutouzas. Hippokration Hospital, Athens, Greece, Warwick University 
and W&grave Hospital, Coventry, United Kingdom 
Background: The Insertion/Deletion (ID) polymorphism of the Angiotensin-Converting 
Enzyme (ACE) gene and the Al 166C single nucleotlde polymorphism of the angiotensin 
II AT1 receptor (ATRI) gene associate with increased acute myocardial infarction (AMI) in 
some studies. We investigated whether these genes determined risk of AMI in the Greek 
population. Methods: 1629 consecutive, genetically independent, AMI patients were 
recruited on admission from 9 Cardiac Departments enrolled into the GEMIG study 
(Genetic predisposition and Epidemiology of acute Myocardial Infarction in the Greek 
population), a multicentre prospective study. The control group (805 subjects) was 
derived from an epidemiological study that investiga!ed the same genetic variants in a 
representative sample of the general adult population. Subjects were genotyped for the 
ACE I/D and ATRl Al 166C polymorphisms utilising polymerase chain reaction ampiifica- 
tion: Results: 
Patients (n=1629) Controls (n=805) P 
Age (years) /Male gender (%) 621-13 179% 58+15 155% <O.OOl 
ACE genotypes (IIIIDIDD) 18.3 146.4 135.3 12.1 / 48.2 / 39.7 <O.OOl 
AT1 R genotypes (AA/AC/CC) 55.1 / 38.6 16.4 53.3 / 40.2 / 6.5 0.709 
In multivariate, backward stepwise logistic regression analysis, homozygosity for the D 
allele was inversely related to AMI (RR=0.886, 95%Cl-0.797-0.985, P=O.O26), while 
homozygosity for the C allele was not significantly associated with AMI (RR=l.137, 
95%61=0.917-1.409, P=O.241). Haplotype analysis failed to demonstrate evidence for a 
synergistic effect between the ACE and ATRl genes contributing to increased risk of 
AMI, short-term prognosis after AMI, or angiographic extent of coronary artery disease. 
In multivariate analysis the DD genotype was negatively related to hypercholesterolemia 
and the CC genotype positively related to female gender. Conclusions: Our results con- 
tradict the hypothesis that homozygosity for the D allele of the ACE gene and the C allele 
of the ATlR gene confers increased risk for AMI. Small number of participants in highly 
selected populations and inhomogeneous criteria in the selection of patients and con- 
trols, probably account for the contradictory results in the field. 
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1077-178 Lack of Association Between Polymorphisms in Four 
Candidate Genes and Myocardial infarction 
Christian Hengstenberg, Stephan R. Hotmer, Bjoern Mayer, Susanne Engel, Hannelore 
Loewel, Guenter A. J. Riegger, Heribert Schunkert. Unfvewtyof Regensburg, 
Cardioiogl: Rsgensburg, Germany 
Association studies of can&fate genes are often used to inveshgate their potential role in 
the pathogenesis of myocardial infarction (Ml). However, many positive studies lack the 
power to detect a moderate risk increase of a genetic polymorphism In this study, we 
examined the association of 4 candidate gene polymorphisms with MI and intermediate 
phenotypes tn large samples of MI patients and the general population. Methods: A total 
of 3672 individuals was examined by complete pheno- and genotyping (including a stan- 
dardized interview, blood pressure measurements, and biochemical analyses) and con- 
sisted of 1) MI patients suffering from MI prior to the age of 60 years (n=l159) and 2) 
partictpants of a population-based survey (n=2398). Polymorphisms of the G protein b3 
subunit gene (825CTT,GNB3), the ltpoproteinlipase gene (HindIll; LPL), the angiotensin 
converting enzyme (i/D; ACE), and polymorphism of the aldosterone synthase gene (- 
344T/C; CYPllBP) were genotyped. Results: The T allele of the GNB3 polymorphism 
was associated with arterial hypertension matnly in men (p<O.OOi), the H2H2 genotype 
of the LPL polymorphism was associated v&h decreased HDL- and elevated LDL-cho- 
lesterol levels (p<O 05) particularly in men. Based on effects on the lipid profile (H2H2 
genotype), we calculated that the risk of MI increases by 22% (MONICA, Framingham 
risk estimates). Given this risk increase, 2500 men with Ml and the same number of con- 
trols have to be screened to associate the H2H2 genotype with MI. Genotype frequen- 
cies of the LPL, GNBS, ACE and CYPI 182 genes were similar in the general population 
and the MI group, indicating no significant association of these polymorphisms with MI. 
Conclusion: This association study failed to show association of 4 candidate gene pofy- 
morphism with Ml. Despite considerable size of the study population (n=3672), lack of 
sufftctent power for detection of association appear to be a major reason for such failure. 
We hypothesize that on a population basis the influence of a single polymorphism in the 
pathogenesis of a complex dtsease, such as MI, may be less than expected from inter- 
mediate phenotypes or than suggested by small studies in selected populations. 
1077-179 Association of the Interleukin-18 (c3954) Polymorphism 
With Myocardial Infarction 
Katherine Stephenson, Martha Nunn, Julian Sorreli, France Di Giovine, Ken Kornmann, 
Gordon Duff, Peter 8. Berger Mayo Clinic, Rochester. MM, lnterleukin Genetics, Boston, 
MA 
Background. Interleukin-I (IL-l) plays a significant role tn the inflammatory process and 
is thought to contribute to myocardial infarction (Ml) by regulating inflammation, cellular 
adhesion, metalloproteinases and production of growth factors and various vasoactive 
substances. Polymorphisms in the IL-1 gene cluster have been associated with altered 
levels of IL-1 agonists and antagonists and coronary artery disease. Methods & 
Results. We analyzed the association between polymorphisms in the IL-1 gene cluster 
and Ml in patients (pts) ~60 years of age, including 40 cases and 200 controls derived 
from a pool of 504 pts undergoing clinically-indicated angiography for chest pain, valve 
disease, abnormal noninvasive tests, recent MI, etc. Only pts <60 years of age were ana- 
lyzed in view of many prior studies indicating that in multifactorial diseases, genetic influ- 
ences are most evident tn early onset cases. Genotyping was performed using a PCR- 
based method with Taq polymerase. Multiple logistic regrewon analysis revealed a sig- 
nificant association between male gender, a history of smoking, fibrinogen, total and HDL 
cholesterol, Lp(a) but also between allele 2 of IL-1B (+3954) (P=O.O04) and Ml even after 
adjustment for all these risk factors. There was a dose-dependent effect with an odds 
ratio (and 95%) confidence intervals) of 2.24 (95% Cl 1.29-3.9) among heterozygous pts 
and of 5.03 (95% Cl 2.89-8.73) among homozygous pts. Conclusions. These data indi- 
cate that the IL-iB (+3954) polymorphism of the IL-1 cluster is significantly associated 
with Ml. further supporting a role of genetic regulation of Inflammation I” MI. 
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1078-180 Flow Cytometry Detection of Platelet Procoagulant Activity 
and Shed Membrane Microparticles in Patients With 
Unstable Angina Treated by Percutaneous Coronary 
Angioplasty and Stent Implantation 
Catherine Vidal, Christian M. Spauiding, Frederic Schaison, Franqoise Ptcard, Josiane 
Melie, Pascal Richard, Jacques Monsegu, Faycal Belaouchi, Simon Weber, Michaela 
Fontenay-Roupie. Cochin Hospital, Rene Descartes Universi~ Paris, France 
Background: Platelet activation is known to participate to the pathogenesis of acute coro- 
nary syndromes. Aminophospholipid exposure and microparticles shedding are hall- 
marks of full platelet activation and may account for the dissemination of prothrombotic 
seats. Methods: Using flow cytometry analysis of annexin V binding to externalized 
amoniphospholipids. we followed platelet procoagulant activity (PPA) and microparticles 
(MP) in various and coronary whole blood samples from 30 patients with unstable 
angina, before and after percutaneous coronary angioplasty (PTCA) and stent implanta- 
tton. Results: Baseltne values of PPA and MP were significantly more elevated in patients 
than I” control subjects (p< 0.005). P-sefectin expression and MP shedding were higher 
in coronary than in peripheral venous blood. No increase of in vitro platelet reactivity to 
thrombin-receptor activating peptide and collagen was noticed immediatly after proce- 
dure. P-selectin expression decreased 24h and 48h after procedure. In contrast, PPA 
and MP shedding rematned as elevated as before. Interestingly, MP shedding was signif- 
icantly higher in patients with proximal lesions of leff anterior descending or circumflex 
coronary arteries than in patients with midldlstal lesions. Conclusion: These results show 
that flow cytometry is a reliable method for detectton of fully activated platelets in whole 
blood samples from patients with unstable angina. Only annexin V blnding analysis, but 
not P-selectin expression, demonstrates the persistance of platelet activation, despite the 
use of antiaggregating agents like asptrin before and aspirin and ticiopidine after PTCA 
and stenting. 
1078-181 Platelet PIA Modifies the Sensitivity of Platelets to Oxidants 
Glen E. Cooke, Yiwen Liu-Stratton, Colin Cooke, Pascal J. Goid&xnidt-Clermont. The 
Ohio Sate University Columbus, OH, Duke University, Durham, NC 
Background; Despite reports that GPllb-llla receptor polymorphism (PIA’) represents a 
risk factor for unstable coronary events, this issue remains controversial. Reacttve oxy- 
gen species (ROS) are involved in the pathophysiology of atherosclerosis and UICS. We 
sought to Investigate the role of ROS in platelets as a function of the PIA polymorphism 
MethodsL The study population consisted of 32 healthy, male volunteers (16 PIAlIl, 16 
PIAlR) who were without medication ingestion for at least ten days. Venous blood sam- 
ples were obtained in the fasting state and PRP was used for platelet aggregation, flow 
cytometry analysis for GPllb-llla activation, and measurement of oxidant species (CM- 
HeDCF-DA). Platelet agonists (epinephnne, ADP, TRAP, collagen, and pervanadate) and 
the antioxidant N-acetylcysteine were used. 
Results; The time course of aggregation induced by pervanadate was strongly PI* geno- 
type dependent. Collagen (20ugImL) induced GP Ilb-llla activation was greater in PIAIII 
platelets as compared to PIAX? platelets (530+77 vs. 345f37 AU.; p=O.O5). However, in 
the presence of NAC, collagen induced FITC-flbgn binding significantly increased in 
PIAlI2 platelets (628172 A.U.; p<O.OOl vs baseline) and only marginally increased in 
PlAlil platelets (568i54 A.U.; p=NS). NAC inhibited collagen induced platelet aggrega- 
tion in all subjects, but only at threshold concentrations 0.5, 1 and 2ug/mL), having no 
effect at higher concentrations of collagen (5,10,20ug/mL). In addition, DCF signal 
increased significantly in collagen stimulated platelets in both PIAl/l (37.1k2.9) and 
PIAlI2 (41.2il.9 AU) platelets compared to baseline (31 .lf2.3 A.U., ~~0.05; 34 3?2 
A.U., p<O.O5, respectively). 
Conclusions; There appears to be a substantial effect of PIA on the sensitivity of plate- 
lets to ROS, demonstratlng a critical role on the impact of ROS on GPllb-llla activation 
and consequent platelet aggregation. This finding could have significant impact on our 
understanding of CAD, genetics, and platelet fibrinogen receptor activation. 
1078-182 Long-Term Pravastatin Treatment Prevents Nitrate 
Tolerance. An Endothelium-Dependent Mechanism 
David Fontaine, Jeanine Fontaine, Guy Berkenboom. Physiology and Pharmacology, 
lntitute of Pharmacy lJniversit6 Libre de Bruxelles, Brussels, Belgium 
Background: Recent studies have shown that pravastatin seems to upregulate the 
endothelial NO synthase pathway (eNOS) and may, therefore, enhance NO availability, a 
direct scavenger of 02. and an inhibitor of oxidative enzymes. Methods: To assess 
whether the oxidative stress produced by an in viva exposure to nitroglycerin (NTG) is 
attenuated by pravastatin (PRA), 3 groups of normocholesterolemic rats were treated; 
group 1 (PRA/NTG) received PRA 20 mgikgid p.o.for 5 weeks and the last 3 days, a 
cotreatment with PRA plus NTG (50 mgikgid. sub-cutaneous In)ections b I d); group 2 
(NTG) received only NTG (50 mglkgid, b i d for 3 days) and group 3 served as control. 
Rings of thoracic aortas from these groups were studied in organ baths. Results: Relax 
ations to NTG (0.1 nM to 0.1 mM) were determined on phenylephrine-preconstricted 
rings and 02- production (countslminlmg) was assessed by lucigenin chemilumines- 
cence technique. 
Group(n) pD2 NC 02. 
PRA/NTG (11) 7.3*0.2 565238 528+28 
NTG (9) 5.9*0.3* 875*54* 946*51* 
control (9) 7.2+0.1 553r30 617i-76 
The protective effect on nitrate tolerance disappeared when L-NAME (an eNOS inhibitor, 
100 mg/kg/d) was coadministered with NTG in the PRA group. Moreover, before NTG 
exposure, aortic cGMP content, reflecting endothelium-derived NO availability, was sig- 
nificantly enhanced in the PRA group (Pc.05 vs control). Conclusion: PRA treatment 
protects against nitrate tolerance by counter- acting NTG-induced increase in 02. pro- 
duction. This protection seems to involve the eNOS pathway, probably an inhibition of 
oxidative enzymes by enhanced NO availability. 
1078-183 Influence of the Anatomical Location on Arterial 
Thrombosis 
Krzysztof Karnicki, Robert D. McBane, II. Erzsebet Komorowicz, David N. Fass. Whyte G. 
Owen. Mayo Clinic and Foundation, Rochester, MM 
The prevalence of atherosclerosis within an indlvldual correlates strongly among arteries. 
However, acute arterial thrombosis is common in some arteries such as coronaries and 
uncommon ln others. Variables contributing to these differences could Include arterial 
anatomy and biochemistry or hemodynamic differences. To evaluate regional differences 
in arterial thrombogenicity, we measured 111 In-platelet depositton in response to trau- 
matic injury of porcine carotid arteries, which are elastic with unidirectional flow and fem- 
oral arteries, which are muscular with triphasic bidirectional flow. In the first animal cohort 
(n=45), following 6 serial hemostat injuries applied to intact arteries in situ, carottd arter- 
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ies accumulated over 6 times as many platelets as comparably sized femoral arteries 
given the same injury. To determine the influence of known hemodynamic differences 
between these arteries, a carotid artery segment was transplanted into the femoral posi- 
tion (“x6), and a segment of the femoral artery was transplanted into the carotid position 
(n=6). The expected hemodynamic differences were confirmed by Duplex Ultrasound 
before and after transplantation. Platelet deposition (mean&EM) in the injured trans- 
planted carotid was srgnificantly lower than in injured sham carotid artery (802?216 vs. 
154Oi.323; p<O.Of) and indistinguishable from injured native femoral artery (467-c191; 
p=NS). Likewise, injury of the transplanted femoral artery yielded platelet deposition 
equivalent to that of the contralateral sham-operated carotid (600+206 vs. 270+74; 
p=NS). Platelet adhesion and accretion from whole blood on arterial cross-sections 
affixed to the floor of a high shear flow chamber revealed no differences comparing por- 
cine carotid and femoral arteries. In conclusion, regional differences in arterial hemody- 
namics can account for substantial differences in thrombosis arising from deep arterial 
injury. 
1078-184 Nitric Oxide and the Angiotensin II Receptor Blocker 
Canclesartan Are Potent Inhibitors of Tissue Factor 
Expression in Vascular Smooth Muscle Cells 
Michael T Johnstone, Alexandra Perez, Edward P. Feener. Beth lsrael Deaconess 
Medical Center, Boston, MA 
Background: Plaque disruption and thrombosis remains an important cause of acute 
cardiovascular disease. A major component of the thrombogenicity of a disrupted plaque 
is tissue factor (TF). While a variety of growth factors and hormones have been shown to 
induce TF expression in vascular smooth muscle cells (VSMC), little is known regarding 
those factors which may suppress vascular TF expression. Nitric oxide and angiotensin 
receptor blockers may attenuate the development and progression of atherosclerosis. 
Aim: We therefore evaluated the role of nitric oxide and the angiotensin receptor blocker 
Candesartan on angiotensin-mediated TF expression in VSMC. 
Results: Ang If-induced TF expression was completely blocked by &her the pretreat- 
ment of the angrotensin receptor subtype 1 (AT,) antagonist Candesartan(lmM) (p<.Ol), 
suggesting that the AT, receptor is essential for Ang II-induced TF expression. Pretreat- 
ment of rat aortic smooth muscle cells (RASMC) with the nitric oxide donor, S-nitroso-N- 
acetylpenicillamine (SNP)(iO pM/L) for 60 minutes reduced angiotensin-II (ang II) stimu- 
lated TF MRNA by 60% (pc.01). This NOeffect was mimicked by pretreatment of the cells 
with either the cyclic guanosine monophosphate analogue, 8Bromo cyclic Guanosine 
Monophosphate (6-BrcGMP) or the guanylate cyclase receptor activator C-Natriuretic 
Peptide (CNP) which attenuated ang II-stimulated TF MRNA by 55% (p< .05) and 
6O%(pc .Ol) respectively. This NO effect was attenuated by the inhibitor of soluble guany- 
late cyclase, oxadiazo-quinoxalin-I-one (ODQ)(5pM/L) by 30% (pc .05). This suggests 
that ang II-stimulated TF expression may be through a cGMP mechanism. 
Conclusion: This study suggests that ang II-induced TF expression is mediated via the 
AT, receptor and AT, blockers may suppress vascular TF expression in RASMC. NO also 
inhibits ang Ii-induced TF expression and this is mediated via a cGMP mechanrsm. This 
protective effect of NO may be diminished in endothelial dysfunction. Further research is 
needed to determine if the inhibrtory effects of these factors occur in viva. 
1078-185 Correlation Between Acute Tissue Plasminogen Activator 
Release From the Human Coronary and Peripheral 
Circulations 
David E. Newby, Fraser N. Witherow, Andrew L. McLeod, Neal G. Uren, Bernard 
Prendergast, Laura L. Flint, David J. Webb, Keith A. A. Fox, Nicholas A. Boon. Royal 
Infirmary, Edinburgh, United Kingdom, Western General Hospital, Edinburgh, United 
Kingdom 
Background Endothelial dysfunction occurs in the peripheral and coronary circulations 
of patients with coronary artery disease. The objective of the study was to establish 
whether the acute endothelial release of tissue plasminogen activator (t-PA) from the 
peripheral circulation reflects that in the coronary vascular bed. Methods After diagnostic 
coronary angiography in 8 patients, blood flow and ftbrinolytic responses to selective left 
anterior descending artery (LAD) infusion of saline, substance P (endothelium-depen- 
dent; IO-40 pmollmin) and sodium nitroprusside (endothelium-independent; 5-20 pg/mrn) 
were measured using intracoronary IVUS and Doppler, combined with arterial and coro- 
nary sinus blood sampling. These responses were repeated immediately after the coro- 
nary study, in the forearm circulation using venous occlusion plethysmography and 
brachial infusions of substance P (2-8 pmollmin) and sodium nitroprusside (1-4 pglmin). 
Results The LAD atheromatous plaque burden was 6.2 r 1.4 mm3 per mm of vessel 
(range 1.2-9.3). There was a significant release of t-PA in both the coronary (AUC 287 + 
102 ng/min; p=O.O3) and forearm (AUC 13.3 t 5.8 ng/lOO mL of tissue/min; p=O.OOl) cir- 
culations during substance P, but not sodium nitroprusside, infusion. Comparison 
between the coronary and forearm circulations demonstrated a direct correlation for the 
release of t-PA antigen (r=O.31, p=O.O8) and activity (wO.66, p=O.OOl), although there 
was no apparent correlation between blood flow responses to substance P. Conclusions 
We have found a direct correlation between the coronary and peripheral circulatory 
release of t-PA. This preliminary study suggests that the forearm vascular bed may be an 
appropriate surrogate for assessing the coronary fibrinolytic potential in patients with cor- 
onary artery disease. 
1078-186 Fibrinolytic Potentiation by Hormone Replacement Therapy 
at Conventional Dosage in Healthy Postmenopausal Women 
Is Independent of Tissue Factor Activation 
Kwang K. Koh, Dong K. Jin, Seong H. Yang, Wan Kim. Cardiology Inchon, South Korea, 
Clinical PathologL: Inchon, Sooth Korea 
Background: We have previously shown that oral conjugated estrogen (CEE) at 0.625 
mg potentiates fibrinofysrs in postmenopausal women (PMW), a process that could be 
consequence of primary estrogen-Induced coagulation activation. We measured tissue 
factor (TF) antigen (Ag), activity (Act) and plasminogen activator inhibitor (PAI)-l antigen 
levels in healthy PMW, an effect associated with proportionate increases in D-dimer com- 
patible with enhanced fibrinolysis. Methods: We administered micronized progesterone 
(MP) 200 or medroxyprogesterone acetate (MPA) 10 mg for 10 days with CEE 0.625 mg 
for 25 days during 8 weeks to 20 PMW in randomized, double-blind, crossover study. 
‘*=P~0.01;*“=P~0.001 vs. Baseline. Data= mean&D. Results: There was no associa- 
tion between %ATF Ag or Act and %APAI-1 Ag (all rc0.268, P=NS). Of note, there were 
no significant differences between CEEcMPA and CEE+MP regarding TF and PAI-1. 
Conclusion: Potentiation of fibrinolysrs is a primary effect of CEE at conventional dosage 
and likely accounts for the low risk of venous thromboemboli in healthy PMW. 
Baseline CEE+MP CEE+MPA 
223+42 194+38” 189+42** 
TF Act (“M) 
PAI- (pa/ml) 
0.854*0.258 1.455kO.584*** 1.275+0.432**’ 
33.02k12.43 22.78*8.38**’ 23.73+10.68*’ 
1078-l 87 Bone Marrow-Induced Stimulation of Endothelial and 
Smooth Muscle Cell Proliferation, Migration, Tube 
Formation, and Production of Growth Factors 
Richard Baffour, Yi Fu Zhou, Shmuel Fuchs, Jill Walker, Matie Shou, Ran Kornowski, 
Stephen E. Epstein. Cardiovascular Research Insitute, Washington Hospital Center, 
Washmgton, DC 
Background: Optimal angiogenesis and artenogenesis requires sequential expressron 
of multiple growth factors. We evaluated the effects of conditioned medium (CM) derived 
from cultured pig bone marrow cells (BMC) on pig aortic endothelial cell (PAEC) and 
smooth muscle cell (PASMC) proliferation, migration and tube formation, the secretion of 
growth factors, and the generation of endothelialismooth muscle cells from cultured 
BMCs. 
Methods: BMCs were isolated and cultured in long-term culture medium (LTCM). 
Weekly, one half of the medium was removed and replaced with fresh LTCM. At 4wks, 
CM was removed and filtered. Portions of pooled CM (N=5) with or without neutralizing 
anti-VEGF antibody were added to cultured PAEC to assess proliferation. The effects of 
CM on PAECS or PASMC migration were assessed usrng the modified Boyden chamber. 
Tube formation of PAEC and PASMC mixture (1:l ratio) was evaluated on Matrigel. The 
levels of bFGF VEGF and MCP-1 were assayed by EL&A. 
Results: bFGF VEGF and MCP-1 levels increased significantly (bFGF: 291 ng/mL vs. 0 
in control [LTCM]; VEGF: 6475 pg/mL vs. 0; MCP-1: 251 pg/mL vs. 0). CM facilitated 
migration in a dose-related manner (ANOVA p < O.OOl), induced tube-formation, and 
increased PAEC proliferation. The latter effect was attenuated by anti-VEGF antibody 
(17% by 1.5 &g/ml and 46% by 7.5 mglmi). CM had no effect on PASMC proliferatron and 
migration, but induced tube-formation. At 4 wks BMCs stained positive for Factor VIII and 
a smooth muscle actin, suggesting generation of endothelial and smooth muscle cells, 
presumably from progenitor cells. 
Conclusion: BMCs secret growth factors that are involved in angiogenesrs and arterio- 
genesis, augment endothelial cell proliferation and mrgration, and induce tube formation 
by endothelial and smooth muscle cells. These observations suggest a unique angio- 
genie and arteriogenic effect of BMCs. 
1078-188 Localisation of Vascular Endothelial Growth Factor (VEGF) 
A, B, C, and their Receptors in Human Atherosclerotic 
Arteries 
Funmi M. Belgore, Zola S. Mzimba, Gregory Y. H. Lip, Stanley H. Silverman, Andrew D. 
Blann. Haemostasis, Thrombosis and Vascular Biology Unit, Unversity Department of 
Medicine, Birmingham, Unrted Kingdom 
Background: Vascular endothelral growth factor (VEGF), an important angiogenic agent, 
has multiple isoforms (VEGF A, B, C and D) and receptors (KDR, Flt-I and 4) whose 
existence suggests that these proteins may have overlapping but distinct functions. 
These may be reflected rn their cellular distribution and role in pathology. We hypothesi- 
sised VEGF A, B and C and their receptors exhibited different tissue specificity, and that 
their expression may be altered by pathological conditions. Methods: We investigated 
the expression of the VEGF-A, B, C and receptors Flt-4, Flt-I and KDR by immunohis- 
tochemistry and Western blotting within human atherosclerotic arteries (AA) (n=30), nor- 
mal uterrne arteries (UA) and saphenous veins (SV) (n=15 each). Results: Smooth 
muscle cells (SMC) showed greatest staining of VEGF-A, B, Flt-1 and KDR in the arterial 
tissues. In the SV and UA, Fit-4 and VEGF-C were predominately localised to the endot- 
hellal lining of vasa vasorum, in contrast to the AA where SMC showed greatest staining. 
VEGF-B and KDR were not detected immunohistologically in the SV sections. However, 
VEGF-A, and Fit-1 staining in these specimens were similar to that observed in the arte- 
rial tissue. Significant differences were observed in the staning pattern of VEGF-B 
(p<O.OOl, Chr squared test), but not VEGF-A or VEGF-C between the AA, UA and SV 
sections. There.were no differences in the staining pattern of Flt-4, but Flt-1 and KDR 
showed significant variation between the three tissue types (~40.05 for both). Western 
blotting confirmed the existence of tissue variation in the expression of the VEGF pro- 
teins. Levels of tissue VEGF-B were considerably reduced in SV compared to the arterial 
tissue. VEGF-C proteins were lower than that of VEGF-B and A in all tissue specimens. 
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Conclusions: The detectlon of VEGF-A and 6 and their receptors in normal &cular tis- Willebrand factor (vWF) and vascular endothelial growth factor (VEGF) by ELISA at 
sue implies that the functions of VEGF may &end beyond endothellal cell proliferation. baseline and after 6 months treatment. Baseline levels were compared with 21 healthy 
The absence of KDR, and reduced tissue VEGF-B in SV tndicates a level of tissue spec- normotensive controls. 
ificity in the expression of VEGF and its receptors. Furthermore, we conclude that the ReSUItS: Controls High-risk Hyperten- High-risk Hyper- 
expression of VEGF-C and Fit-4 may be altered in pathological conditions, such as ath- sives at Baseline tensives after 6 
erosclerosls. months treatment 
1078-189 Effects of Statin on Nitric Oxide Bioactivity and Matrix 
Metalloproteinases-9 in Hypercholesterolemic Patients With 
Coronary Artery Disease Who Remained 
Hypercholesterolemic on Step II Diet 
Kwang K. Koh, Ji W. Son, Dong K. Jin, Jeong Y. Ahn, GI S. Park, In S. Chow, Min S. Sohn, 
Tae H. Ahn, Eak K. Shin. Cardioiogl: Inchon. South Korea, ClinicalPafhologl: Inchon, 
South Korea 
Background: Increased activity of matrix metalloproteinases-9 (MMP-9) promotes 
mechanical instability within the plaque resulting in the formation of a thrombus after 
plaque disruption. Oxidized or native LDL upregulated MMP-9 expression in monocyte- 
derived macrophages or intimal smooth muscle cells. in contrast, HDL abrogated oxi- 
dized LDL-induced MMP-9 expression. Meanwhiles, statins have been shown to inhibit 
MMP-9 production by macrophages in culture, an inhibition reverted by the addition of 
mevalonate, providing nonlipid mechanism- direct antlatherosclerotic potential. Methods: 
We administered simvastatin 20.40 mg daily during 14 weeks to 16 patients with estab- 
lished coronary artery disease who remained hypercholesterolemic on Step II diet ther- 
apy. Data= mean&D. *=P<O.O5;“*=P~O.O01 vs. Diet. Lipoproteins (mg/dl) Results: 
Compared with pre:reatment values, simvastatin significantly lowered lipoprotein levels 
and the ratio of LDL to HDL cholesterol levels and apalipoprotein B to A-l (all PcO.01). 
There were significant inverse correlations between pretreatment the ratio of apollpopro- 
tein B to A-l and the degree of change in those ratios after simvastatln (r=-0.473, 
PzO.098). Simvastatin significantly improved flow-mediated dilation (FMD) and lowered 
plasma levels of MMP-9 by 12&104% and 33*46%, respectively (P<O.OOl and P=O.O27, 
respectively) There were significant inverse correlations between pretreatment MMP-9 
levels and the degree of change in those levels after simvastatin (r-0.714, P=O.O05). 
However, there were no significant correlations between lipoprotein levels or FMD and 
MMP-9 levels on simvastatin. Conclusions; Improvement in NO bioactlvity and plaque 
stabilization followina statin may account, in part, for the cardiovascular event reduction 
and the early clinical benefit in clinical trials, independent of lipoprotein changes. 
N 21 136 
Age [years] 57.6 (5.4) 59.5 (6.6) 
Systolic BP [mmHg] 131.5 (17.2) 161.0(17.1)‘) 150.5 (16.9)‘) 
Diastolic BP [mmHgJ 85.8 (9.7) 90.8 (10.0) ‘1 85.5 (9.7) 2) 
VEGF [pgiml] 50 (18-117) 200 (140-410) ‘1 145 (95.400) 21 
vWF [lU/ml] 95 (19) 134 (38) 1) 128 (33) 2’ 
Values are expressed as mean and (SD), except VEGF as median and IQR. Statistical 
analysis: paired and unpaired T-Test as appropriate, except for VEGF, Mann-Whitney 
Test or paired Wilcoxon Test. ‘1 ~~0.05 controls vs. baseline, ‘) ~~0.05 baseline vs. 6 
months treatment. 
Conclusion: When compared to controls, high-risk hypertensives demonstrate abnormal 
angiogenesis and endothelial damage, both of which are beneficially reduced following 6 
months of antihypertensive treatment. These findings may be pathophysiologicaily 
related to hypertension and its complications and the beneficial effects of blood pressure 
lowering. 
1079-191 Is Peripheral Endothelium-Dependent Flow-Mediated 
Vasodilatation Associated With Left Ventricular Mass in 
Older Persons With Hypertension? 
Jidong Sung, Anita C. Bather, Katherine L. Turner, Jamie R. DeRegis, Paul S. Hees, 
Harry A. Silber, Edward P. Shapiro, Pamela Ouyang, Kerry J Stewart. Johns Hopkins 
School of Medicine, Baltimore, MD 
Background: Left ventricular (LV) mass is associated with increased cardiovascular risk. 
Blood pressure (BP) and body size are well-known determmants of LV mass. Recent 
studies have also shown an association of LV hypertrophy with attenuated endotheiium- 
dependent coronary flow reserve. Hypertension is associated with endothelial vasodila- 
tar dysfunction. Less is known about the association of LV mass and endotheiium-depen- 
dent flow-medtated dilatation (FMD) in peripheral arteries, ‘a non-invasive measure of 
endothelial function in mildly hypertensive elderly, Methods: Thirty-five subjects with 
untreated mild hypertension, aged 55 to 75 years, and otherwIse healthy, were examined. 
Resting BP was obtained at 4 or 5 visits at least 1 week apart and averaged. LV mass 
was determined from magnetic resonance imaging by Simpson’s method and was 
indexed by body surface area. Body composition was assessed using dual energy X-ray 
absorptiometry. FMD was measured as the percent change of brachial artery diameter 
during reactive hyperemia using ultrasound. Results: Mean + standard deviation of the 
key variables were: BP, 142.7 f 9.1 / 77.3 + 8.3 mmHg; lean body mass. 48.1 i 12.2 kg; 
LV mass index, 68.1 + 16.5 gim2; and FMD, 6.3 f 6.6%. In bivarlate analysis, LV mass 
index was correlated with lean body mass (I = 0.53), systolic BP (I = 0.44), dlastoiic BP (r 
= 0.37), and FMD (r = -0.35) (all p < 0.05). In multivariate analysis, 29% of the variance in 
LV mass index was exptained by lean body mass. An additional 12% of the variance was 
explained by FMD and additional 8% by SBP (p < 0.05). For each 1% point decrease in 
FMD, LV mass index increased by 0.94 g/me. Conclusion: In addtion to the expected 
influences of body size and BP, impairment of brachial artery FMD ES independently 
related to LV mass in elderly subjects with mild hypertension. Endothelial vasodilator dys- 
function is a known marker for atherosclerosis and may also predict cardiovascular 
events by its association with increased LV mass. 
HDL-C 
Step II Diet 
44110 
Simvastatin 
44+12 
Ape A-l 
LDL-C 
Apo S 
LDUHDL-C 
Apo BlApo A-l 
FMD (%) 
MMP-9 (ngiml) 
114+29 119+24 
153+35 81+32” 
117120 77+12** 
3.69+1.21 1.98+0.66** 
1.21+0.85 0.70+0.16** 
3.4&l .74 6.51r2.35** 
87+110 2219* 
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1079-190 Effect of Intensive Blood Pressure Treatment on Endothelial 
Damage and Vascular Endothelial Growth Factor, an Index 
of Angiogenesis in Hypertension 
Dark Felmeden, Charles 6. C. Spencer, Funmi Belgore, Andrew Blann, Gareth Beevers, 
Gregory Y. H. LIP. Unwersify Department of Medicine, City Hospital, Birmingham, United 
Kingdom 
Background: Hypertensive patients are at high risk of thrombosis and atherosclerosis, 
which can be reduced by lowering blood pressure. The complications of hypertension 
and the beneficial effects of blood pressure reduction may be related to endothelial dam- 
age and/or abnormal angiogenesis. 
Methods: We studied 136 ‘high-risk’ hypertensivea patients (untreated BP>1601100 
mmHg or treated BP>140190 mmHg). ‘High-risic’ was defined as 3 or more of the follow- 
ing risk factors: age>55, male, smoking, cholesterol >6.5 mmal/l. diabetes mellitus, family 
history of coronary artery disease, previous ischaemic stroke, peripheral vascular dis- 
ease, left ventricular hypertrophy on ECG, and Q waves or T inversion on ECG. Patients 
were randomly asslgned to treatment with atenolol + bendroflumethiazide or amlodipine 
i perindopril. Endotheliai damage and angiogenesls were assessed by measuring van 
1079-192 Improved Blood Pressure Control in Hypertensive Patients 
Treated With Statins 
Claudia Borghi, Antonio Gaddi, Ettore Ambrosioni, Ada Dormi. Deptaf Medicine- 
University of Bologna, Bologna, I&/y. Center for Atherosclerosis-University of Bologna. 
6o/ogm, My 
Objective: The aim of the present study was a prospective evaluation of the effects of 
different lipid-lowering (LL) drugs on the blood pressure (BP) profile of a population of 
patients at high risk for CV disease. 
Design and Methods: The Brislghella Heart Study is a large epidemiological survey 
aimed at the identification, follow-up and treatment of patients with high c.v. risk (total 
cholesterol > 240 mgidl + other risk factors). 1567 patients (852 M/715 F, mean age 
60tli ys) treated for 5 years with statins or other drugs (Cholestiramine, Fibrates), were 
subdivided in quartlIes of systolic BP (~130, 130-139, 140.154, >I54 mmHg) and evalu- 
ated for BP changes (Baseline-5 ys). A separate analysis has been done in patients tak- 
ing antihypertensive drugs. 
Results: Total cholesterol was evenly reduced by treatment in any quartile whereas the 
BP decrease was enhanced in hypertensive patients (Ill”, IV” quartiles). In such patients 
the concomitant use of antihypertensive drugs and statins improved BP control (* p<O 05 
vs l”,ll” quartiles; 5 pc.05 vs Other drugs. 
Conclusions: The study suggests a selective influence of LL treatment over BP control 
in patients with hypercholesterolemia and hypertension and hypothesize a synergism of 
action between antihypertensive drugs and statins. 
Treatment 1 st Quartile 2nd QuartlIe 3rd Quartile 4th Quartile 
All patients 
Statins 
%SBP %DBP %SBP %DBP %SBP %DBP %SBP %DBP 
4.2 -5.0 1.3 -1.9 -6.9 -6.4 -12.Y -9 9’ 
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Other Drugs 
Hypertensive pts 
Statins 
Other drugs 
3.8 -2.8 0.6 -3.9 -1.3 -1.2 
2.3 2.9 3.1 4.3 -10.45 -7.45 -155 -12.35 
7.6 -2.6 1.9 -8.0 0.4 -2.8 -10.7 -8.9 
1079-193 Effect of Salt Intake on Vascular Anglotensin II Receptor 
and Nitric Oxide Pathway in Cold Stress Induced 
Hypertension in Rats 
Zhiming Zhu, Shanjun Zhu, Jijin Zhu, Yongjian Yang. Hyperten&n Center. Daping 
Hospital, Chongqing, People’s Republic of China 
High salt intake and cold stress can accelerate the development and exacerbate hyper- 
tension. The purpose of the present study was to examine the effect of salt diet on vascu- 
lar angiotensin II receptor (ATI) and NO pathway in cold stress induced hypertension 
from rats. Wistar rats on low and high salt diet (8%) were exposed to cold stress ( 5+2 “C, 
4 hrs /day) for 8 weeks. Blood pressure was measured by tail-cuff weekly. Expressions of 
aortic AT1 mRNA and eNOS protein were measured by RT-PCR and Western blot, 
respectively. Hemadynamic parameters and responses of rat aortic strips to agonists and 
antagonists were observed using poiygraphy. Exposure to cold stress significantly 
caused a time-dependent increase in systolic blood pressure in rats fed low (LS) and 
high salt (HS) compared to control rats. Compared with LS rats in viva, vasacontractor 
infusion significantly enhanced MAP in HS rats ( ANG II: 147+2 mmHg vs 166+5 mmHg; 
L-NAME: 113+4 mmHg vs 122i5 mmHg ); Ach and L-arg induced a minor decrease in 
MAP in HS rats compared with LS rats. The contractions to ANG II were larger in HS rat 
rings compared with LS rats ( 2.21t0.04 vs 2.39tO.03 g, P<O.Oi). was markedly exag- 
gerated in rats fed with high salt diet. Relaxant responses to L-arg was impaired in HS 
rats compared with LS rats (22+2 vs 28+1.8 %, PcO.02). Expressions of AT1 receptor 
mRNA was significantly higher and eNOS protein lower in cold-stress exposed HS rats. 
LS rats had a lower eNOS expression and similar ATR mRNA expression compared with 
control rats. This study indicated that salt intake had a different effect on AT1 receptor 
and eNOS in rats exposed to cold stress. Although cold stress rats on LS and HS devel- 
oped a hypertension, HS mainly up-regulated AT1 mRNA expression besides impairing 
eNOS and LS inhibited NO pathway in cold stress induced hypertension(Support by 
NSFC 39725013). 
1079-194 Effects of Cyclooxygenase Inhibition on Endothelial 
Function in Hypertensive Patients Treated with 
Angiotensin-Converting Enzyme Inhibitors 
Hiroshi Yamanari, Tohru Ohe, Kazufumi Nakamura, Mikio Kakishita. Dept. of 
Cardiovascular Medicine, Okayama Univers,ty Medical School, Okayama, Japan 
Background. Cyclooxygenase inhibition restored endothelium-dependent vasodilatation 
in hypertension, but It is unknown whether cyclooxygenase inhlbition restores endothelial 
function, despite reduction of prostacyclin produced via bradykinin in hypertensive 
patients treated with angiotensin-converting enzyme (ACE) inhibitors. The purpose of 
this study was to evaluate the effects of cyclooxygenase inhibition on endothelial functlon 
in hypertensive patients treated with ACE inhibitors. Methods. Endothelium-dependent 
flow-mediated dilatation (FMD) and endothelium-independent glyceryl trinitrate-induced 
dilatation were investigated in 10 patients treated with enalapril (ACE group), 11 patients 
treated with manidipine and metoprolol (non-ACE group), and 12 normotensive control 
subjects. FMD after administration of 1000 mg of aspirin was investigated once again. 
Plasma cGMP and QrOStanOidS were also measured during reactive hyperemia before 
and after aspirin administration. Results. FMD was more impaired in the non-ACE group 
than in the ACE group (8.3 f 3.8 %, 5.7 & 1.7 %, p c 0.04). Glyceryl trinitrate-induced 
dilatation was similar in the ACE group, non-ACE group, and control subjects. FMD in the 
ACE group was reduced after administration of aspirin (5.3 * 4.2 %, p < 0.05). The per- 
cent change in FMD after administratlon of aspirin was significantly correlated with per- 
cent change in cGMP (I = 0.77, p c 0.03; y-intercept, -62.1 %, p < 0.01). Conclusions. 
Cyclooxygenase inhibition might reduce the beneficial effect on endothelium-dependent 
vasodilatation induced by ACE inhibitors. The results suggested that prostacyclin III addi- 
tion to nitric oxide play a significant role in the restoration of endothelial function in hyper- 
tensive patients treated with ACE inhibitors 
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1092-159 Percutaneous Placement of Abdominal Aortic Stent Grafts: 
Is There a Role for Intravascular Ultrasound Guidance? 
Marco T. Castagna, Neil J. Weissman, Gary S. Mintz, Michael Jaff, Nancy E. McCarthy, 
Lowell F. &tier, Augusto D. Pichard, Kenneth M. Kent, John R. Laird. Washington 
Hospital Center, Washington, DC 
Percutaneous placement of an abdominal aortic stent graft is a new approach to treat 
infra-renal abdominal aortic aneurysms (AAA). Success is dependent on accurate graft 
sizing and placement within the aorta. Helical computed tomography (CT) is commonly 
employed to assess the AAA morphology and to measure the diameters of the lnfrarenal 
aortic neck and iliac arteries. intravascular ultrasound (IVUS) may provide more precise 
assessment of vessel sizes and thus facilitate appropriate stent graft selection. Methods: 
We evaluated 76 AAA pts with high frequency IVUS (SciMedWSC 12.5 MhZ, 6F) and 
compared the IVUS assessment of lum~nal dimensions to CT. For pts who went on to 
AAA stent graft (AneuRx) placement (n=45), IVUS was used to assess the adequacy of 
graft expansion and proximal and distal stent apposition. All IVUS length measurements 
were made by withdrawing the IVUS catheter from one landmark (on the IVUS image) to 
the next and measuring the length with a ruler. Results: The CT consistently overesti- 
mated the luminal diameters and tended to underestimate the aortic lengths (table). 
CT IVUS p-value 
Ao neck diameter (mm) 25+10 22+3 0.05 
Iliac diameter (mm) 1615 14+4 0.02 
Ao length from renal to AAA (mm) 32+16 3&l 4 0.03 
Ao length from AAA to bifurcation (mm) 77i23 85i21 0.13 
Poor stent apposition not angiographically apparent was often noted at the aortic neck 
(32%) or one of the two iliac limbs (53%). No post-procedure thrombus or deep wall 
hematomas were noted, but there were 3 distal edge dissections that were detected by 
IVUS and treated with additional stents. Conclusion: IVUS measurements of the aorta 
and iliac arteries are often different than those obtamed by CT, which may impact on AAA 
stent graft procedures. IVUS also allows detailed post intervention assessment to opti- 
mize graft implantation. 
1092-160 Comparison of Surgical Repair With Balloon Angioplasty 
for Coarctation and Recoarctation: A Twenty-Three-Year 
Review 
Gordon H. Oron, Ronald J. Walhout, Jaco C. Lekkerkerker, Francois Hitchcock, Paul A. 
Hutter, Erik J. Meijboom. Wilhelmina Children’s Hospital/university Medical Canter, 
Utrecht, The Netherlands 
Background: Evaluation and comparison of the long-term results of surgical repair and 
balloon angioplasty for native and re-coarctation of the aorta. 
Methods: Surgical repair(graup A) and balloon angioplasty(group 8) for native coarcta- 
tlon of the aorta were performed in 305 pts (associated heart defects in 77%) from 1977 
to 2000. Group A consists of 273 pts (mean age 1.6&9yrs) managed surgically from 
1977 to 2000. 51% end-to-end anastomosis, 46% patch angioplasty, in 3% a combina- 
tion was performed. Group B consists of 32 pts (mean age 4.8+4.6yrs) after balloon 
angioplasty from 1990 to 2000. Pre- and postinterventional pressure gradients were ana- 
lyzed with Student’s T-test. Kaplan-Meier curves were used to compare the intervention 
free probability of both groups. 
Results: Resultant reduction in peak-to-peak systolic pressure gradient was 19 mmHg 
(SD 5,8, p<O.Ol). All-over mortality was 7,3% (n=23) in group A, 14 pts of post-operative 
complications in complex lesions, 2 of irretrievable causes. The results of end-to-end 
anastomosis and patch ang!oplasty showed no significant differenCe(Q=O,4635, log rank). 
In group B no mortality occurred. Length of follow up ranged from 1 month to 28,4 years 
(mean 11 .O, SD 7,3). In group A recoarctation occurred in 48 pts (IS%), treated in 31 by 
balloon angloplasty, in 3 by end-to-end re-anastomosis and in 14 by a patch angioplasty, 
1 developed a re-recaarctation, managed by balloon angioplasty. In group B recoarcta- 
tlon developed in 4 pts (12,5%), 2 were re-operated using an end-to-end anastomosis 
and balloon angioplasty was performed in 2. No significant statistic2 difference was 
found between the intervention free probabilities in group A and B. (p=O.4635, log rank) 
Conclusion: Balloon dilatation as primary treatment of coarctation and recoarctatlon of 
the aorta yields Comparable results to surgical management, mmediately as well as in 
long term follow up and is therefore a justifiable choice for pts over 3 months of age and a 
localized type of coarctation. 
1092-161 Acute Effects of Endovascular Photodynamic Therapy on 
Femoral Atherosclerotic Lesions in Hypercholesterolemic 
Rabbits 
J. William Phillips, TamaraE. Bogetti, Christina A. Waters, Sean E. Hesselbacher, Ross 
Heath, Robert I. Grove, Steve Rychnovsky, Jeff Walker, Ian J. Sarembock. University of 
Virginia, Charlottesville, VA. Miravant Medical Technologies, Santa Barbara, CA 
Background:Photodynamic Therapy (PDT), the combination of a photosensitizer drug 
with wavelength-specific light activation, has been proposed for inhibiting progression of 
atherosclerotic vascular disease. The aim of this study was to evaluate the acute effects 
of PDT with a new chlorin-based Qhotosensitizer. MV6401, in the atherosclerotic rabbit 
model. 
Methods: Bilateral focal femoral atherosclerosis was induced in rabbits by air desiccation 
injury and a 0.5% cholesterol diet for four weeks. In initial experiments, on day 28 after 
injury, rabbits received MV6401 (2.5kmolsikg) and were sacrificed at 1,4,12 and 24 hours 
to determine drug localization at the site of atherosclerosis (N=4 vessels per time point). 
In subsequent experiments rabbits were adlninistered MV6401 (N=14) or vehicle alone 
(N=lO) and 2-4 hours later the femoral arteries were irradiated with endovascular light via 
prototype light delivery balloon catheters (designed at Miravant) at the angiographic 
lesson site. Rabbits were sacrificed 3 days post-treatment and sections from treated and 
sham control arteries were analyzed by measuring lesion size and cell number using his- 
tomorphometric techniques. 
Results: Initial drug uptake experiments indicated that selective and maximum localiza- 
t~on of MV6401 in the lesion occurred 2-4 hours post drug adminlstration. The mean fem- 
oral artery plaque area was 0.53mm2~0.07 (n=il) for MV6401 treated vessels and 
0.66mmz co.05 (n=7) for light controls, p=O.12. Medial areas were 0.9ltO.06 and 
1 .l+O 05mm’ respectively, p=O.O2. At 3 days post-treatment, PDT with MV6401 resulted 
in a dose-dependent reduction in cell number in the treated group that was localized to 
the plaque and media. The mean cell population density (cells/mm’) for MV6401-treated 
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lesions was 1,341 and ior lrght control lesions was 4,380, (p=<O.OOOl). POSTER SESSION 
Conclusion: These results indicate that PDT with MV6401 acutely results in targeted 
reduction of the cell population in the atherosclerotic lesions of hypercholesterolemic 
rabbits. Therefore, PDT with MV6401 may have potential for ablation and/or inhibiting 
progression of atherosclerotic lesions. 
1092-162 Immediate Ambulation Following Diagnostic Angiography 
Procedures Utilizing a Femoral Closure Device (Perclose) 
1093 Atherosclerosis and Restenosis 
Monday, March 19, 2001, 9:00 a.m.-l 1 :OO a.m. 
Orange County Convention Center, Hall A4 
Presentation Hour: 9:00 a.m.-IO:00 a.m. 
Henry H. Ting. Christopher Cracker, Tamara Brevik, Robert J. Houlihan, Kevrn T Cragun, 
Farris K. Timrmi, Steven J. Melby, Krrk N. Garratt, David R. Holmes. Mayo Clinic, Division 
of Cardiovascular Diseases, Rochester, MN 
1093-165 Quantitation of Atherosclerotic Plaque Burden in the 
Carotid Arteries by MRI 
Background: After &agnostic angiography procedures, patrents routinely require 4 
hours bedrest prior to ambulation, We examined the safety and efficacy of utilizing a fem- 
oral vascular closure device (Perclose) to enable immediate ambulation. Methods: 126 
patients following diagnostic angiography and Perclose deployment were eligrble for 
immedrate ambulation. Patients were excluded for know” bleeding disorders, platelet 
count <100,000lmm3. rnternatronal “ormalrred ratio al.5, or those undergorng percuta- 
neous coronary interventions. Results: 9 (7%) patients farled to achieve immediate 
hemostasis after Perciose and required standard compression and 4 hours bedrest. 14 
(11%) patients required a” rntermedrate duratron of bedrest (mean 1.9 hours) following 
Perclose. Of these 14 patients, 8 had an ooze requiring 2-5 minutes of compression and 
6 were secondary to physician preference due to the presence of scar tissue or concom- 
itant use of anti-thrombin or anti-platelet agents. 103 (82%) patients ambulated immedi- 
ately (mean 6.2 minutes) after Perclose. All patients were observed for at least 4 hours 
post-procedure prior to discharge. All patients had follow-up at >24 hours to determine 
occurrence of late complications including bleeding requiring compressron, hematoma > 
4cm, retroperitoneal hemmorhage, or red cell transfusion. None of the 117 patients expe- 
rienced any late complications after successful Perclose deployment. Conclusion: Per- 
close use following diagnostrc procedures is safe and effective. 93% of patients had 
successful Perclose deployment. 82% ambulated immediately and 11% ambulated after 
intermediate bedrest. There may be a learning curve for device use to account for the 7% 
rate of unsuccessful Porclose deployment. 
Christof Karmonik. Christopher Eldridge, Giies W. Vick, Ill, William Insull, Joel Morris&t 
Bay/or College of Medicine, Houston, TX 
Carotid atherosclerosrs is a major cause of TIA and stroke in the western world. Interven- 
trons for the treatment of this condition include endarterectomy, angiopiasty, stenting, and 
aggressive lipid lowering therapy. Statins are now recognized not only for their cholesterol 
lowering ability, but also for their favorable pleiotropic effects on the arterial wall. Non- 
invasive assessment of these rnterventrons is highly desirable, especially for patients in 
whom serial measurements are required to monitor atherosclerotic plaque burden. We 
have used high resolution MRI and advanced image analysis to measure the plaque vol- 
ume and percent stenosis in contiguous 3mm slices of untreated common (Cl-C8) and 
internal carotids (11-15) of 19 patients either before or after endarterectomy. The mean 
plaque volume for slices C7-C4 was about 30 mm3, “sing to a maximum of about 95 
mm3 at Cl adjacent to the bifurcation. immediately above the bifurcation at II, the mea” 
volume was 50 mm3. decreasing gradually to 21 mm3 at I5 (See figure). In contrast, the 
plaque volume of the external branch was constant at 19 mm3 from El to E4. Measure- 
ments of percent area stenosis provrded complementary information. Slices 67 to C4 
showed about 18 percent stenosis, rising rapidly to 40 percent in slices C2 and Cl then 
decreasing to about 30 percent in slices I1 to 13. This study illustrates the capability of 
high resolution MRI for quantifying plaque burden and percent stenosis throughout the 
carotid arterial bed and for monitoring these parameters over time to evaluate interven- 
tion efficacy. 
1092-163 Prostaglandin El Short-Term Treatment in End-Stage 
Patients With Peripheral Arterial Disease and Coronary 
Heart Disease, Without Other Treatment Option 
Marco BUCCI, Giovanni Belcaro, Maria Rosaria Cesarone, Mariateresa De Sanctis, 
Lucrezia Incandela, Maura Griffin, Surinder Dhanjil. Michael Sabetai, Ganesh 
Ramaswami, George Geroulakos, Antonio Barsoth, Andrew N. Nicolaides. Biomedical 
Sciences, University of Cheti, Chieti. /fa/x frvme La6 St Mary’s Hospital & lmperiai 
College, London, United Kingdom 
Background: End-stage peripheral arterial diseases and coronary heart disease are 
more frequent in Western countrres as a consequence of atherosclerosis and they often 
are associated. In last years, survrval rate of patients with both coronary heart disease 
and peripheral arterial diseases is increased and there IS a greater need for their treat- 
ment. The aim of this study was to evaluate safety and clinical effectiveness of therapy 
with prostaglandrn El I” end-stage patients with peripheral arterral diseases, coronary 
heart disease and no other treatment option. Methods: For 6 months, 200 mg of prostag- 
landin El were admrnistered in 4 infusions, 2 days every month, according to the short- 
term protocol in 56 patients. During all this period, the other specific medications 
remained unchanged. Physical activity and the frequency of angina1 attacks were evalu- 
ated by the Seattle Angina Questionnaire. Myocardial perfusion and its vitality were stud- 
ied by echo B-mode. Results. No signrfrcant prostaglandin El related srde effect was 
observed. During infusion and 12 hours later there were no changes in basic cardiovas- 
cular hemodynamics, cardrac enzymes, EGG or echo; no arrhythmras were detected by 
ECG Ho!ter. CCS-Angrna class decreased from a mean value of 3.4 r 0.6 before treat- 
ment to 1.4 f 0.4 at 3 months. The increase in maximal exercise capacity was signrficant 
(48 * 11 vs 144 & 28). Both physical limitation (25 f 14 vs 44 f 9) and angina1 attacks fre- 
quency (28 f 19 vs 53 + 19) decreased according to Seattle Angina Questionnaire. 
Regarding myocardial perfusion evaluation by echo, global wash-out increased from 33 f 
8 to 46 i: 5, whereas the mea” number of ischemic segments decreased from 6.5 + 0.4 
to 3 i 0.3 at 6 months. The number of hosprtal admissions medical calls and relative 
costs decreased. Conclusions: These preliminary observations in end-stage coronary 
heart disease patients show that prostaglandin El, administered according to the short- 
term protocol, is safe, feasible and costleffectrve. ‘The treatment relieves angrna. 
increases exercise capacity and also improves myocardial perfusion. 
1093-166 Natural History of Asymptomatic Angiographic Coronary 
Artery Disease in 575 Young Men: Long-Term Study of 15 
Years 
Patrick J. Fitzsimmons, II, William T. Thompson, Sharon Barnett, William B. Kruyer. 
USAF School ofAerospace Medicine, Brooks AFB, TX 
Background: There is limited data in the medrcal literature regarding the prognosis of 
asymptomatic coronary artery disease (CAD). We determined event rates of asymptom- 
atic CAD for the development of cardiac death, nonfatal myocardial infarction (MI), and 
revascularizatio” in a 15.year study. 
Methods: We retrospectively reviewed records of 1504 consecutive asymptomatic miii- 
tary aviators who underwent a” occupational cardiac catheterization between 1971 and 
1999. All had normal left ventricular functro” and no history of prior cardiac events. Indr- 
viduals were divided into three groups based on luminal stenosis significant CAD 
(SCAD, N=323) maxrmum luminal stenosis in a single coronary artery XiO%, minimal 
CAD (MCAD, N= 252) maximum lumrnal stenosis greater than zero but ~50% and normal 
(NL, N= 929) no luminal stenosis. SCAD was further divided into two subgroups, maxr- 
mum lesion 50.70% and maximum lesion ~70%. We obtained follow-up via question- 
naires, telephone interviews, medical records, and death certificates. Events considered 
were cardiac death, nonfatal MI, and coronary revascularization. 
Results: Mean age at presentation was 45.6 (+/-5.8) for SCAD, 46.0 (+/-6.3) for MCAD, 
and 41.5 (+/-5.8) for NL. Mea” follow-up was 14.9 years for all CAD (16.0 years for 
SCAD, 13.6 years for MCAD) and 13.9 years for NL. Annual event rates for first cardrac 
event at 2, 5, 10. and 15 years were as follows: SCAD = 6.0%, 3.8%, 3.5%, and 4.6% per 
year; MCAD = 0.6% 0.4% l.l%, and 1.9% per year; and NL = O.l%, O.l%, O.Z%, and 
0.4% per year. For the SCAD subgroups, annual event rates for first event were: 50-70% 
= 1.2%, 2.5% 2.6%, and 4.6%; ~70% = 9.1%, 4.7%, 4.0% and 4.6%. During follow-up, 
angina was reported by 77/323 (23.8%) of SCAD, 26/252 (10.3%) of MCAD, and 361932 
(3.9%) of NL. 
Conclusion: Annual event rate for asymptomatic SCAD was 3.5 6.0% per year, rela- 
trvely stable over 15 years, and approached reported rates for comparable symptomatic 
SCAD populations. Although low, the annual event rate for MCAD was about five times 
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that of NL and increased progressively over 15 years. These results highlight the impor- 
tance of preventive therapy for asymptomatic CAD, including the subclinical MCAD sub- 
group. 
1093-167 Lack of Premature Coronary Calcification in Young Patients 
With Homozygous Homocystinuria 
Jean-Louis Megnien, Jerome Gariepy, Anne Hernlgou, Jean-Marie Saudubray, Gilles 
Chironi, Jaime Levenson, Alain Simon. H6pitalBoussaiq Paris, France 
Objective: Homozygous homocystinuria is well known to induce atherothrombotic com- 
plications in cerebral arteries and lower limb arteries but the injuries of coronary arteries 
seem less frequent in this disease. To explore this hypothesis, we detected non-inva- 
sively coronary calcification. Design and method&We quantified non-invasively coronary 
calcification by electron beam computed tomography in 13 homozygous homocystinuria 
patients (10 cystathionine- beta synthase deficiencies and 3 defects of remethylation). 
Four subjects had a previous history of cardiovascular disease (3 ischemlc strokes, 1 iliac 
artery thrombosis, 1 iliac venous thrombosis and 1 pulmonary embolism). None of these 
patients presented another inborn disease like homozygous hypercholesterolemia or 
secondary hypertenston. Results: The mea” age was 14 f 10 years (3 to 35) and the 
sex ratio (F/M) was 518. The mean calcium score (Agatston score) was 0 for range values 
inside [O - I]. Conclusion: This result contrasts with data from another atherosclerotic 
genetic disorder as homozygous familial hypercholesterolemia, in which coronary calcifi- 
cations were detected in children. Also absence of coronary calcium does not eliminate 
non calcified plaque. It indicates that coronary arteries are free of substantial atheroscle- 
rotic lesions in homozygous hornocystinuria in the first three decades. 
1093-168 Amiloride is a Potent Inhibitor of Smooth Muscle Cell 
Growth and Migration 
Yong Xiang Chen, Edward R. M. O’Brien. University of Ottawa Heart Institute, Ottawa, 
ON, Canada 
Background: Amiloride is a potassium sparing diuretic that effectively inhibits the Na+/ 
H+ transporter in the cell membrane and acts as a competitive inhibitor of “PA, without 
inhibiting tPA, plasmin or thrombin. Two key components of vascular lesion formation are 
smooth muscle cell (SMC) proliferation and migration. The Na+/H+ transporter is acti- 
vated by all growth factors, and uPA plays a central proteolytic role in SMC invasiveness. 
Therefore, amiloride is a good candidate drug for targeting vascular lesion formation. The 
Purpose of this study was to determine if amiloride is able to inhibit the growth and 
migration of vascular SMCs in vitro. Methods & Results: Rabbit SMCs were grown in tis- 
sue culture in the presence of serum stimulation and exposed to the amiloride derivative 
ethyl isopropyl amiloride (EIPA) in concentrations rangtng from l-80 uM. Cell number was 
manually counted and used to reflect SMC proliferation. After 24 hours, EIPA did not 
have an effect on cell number. With 48 hour exposure there was a concentration depen- 
dent decrease in cell number (e.g., 80 uM dose: 11 .l ? 5.2% of control). Cell migration 
was assessed using a scratch assay for confluent SMCs in the presence or absence of 
40 uM EIPA. The number of cells migrating into the “scratch area” was counted in 8 opti- 
cal fields (x20). Compared to controls, the number of cells that migrated after 24 and 48 
hours was reduced in the presence of EIPA (e.g., 85 + 9 vs. 56 f. 12 cells, and 177 + 17 
vs. 98 f 21 cells; respectively. PcO.001 for both time points). In Conclusion, the 
amilortde derivative EIPA is a strong inhibitor of both SMC proliferation and migration, 
and may be a useful therapeutic option for reducing vascular lesion formation after arte- 
rial injury. 
1093-169 New Therapeutic Strategy: Long-Term Administration of 
PETN Suppresses 02 l Production and Atheromatosis in 
Hypercholesterolemia 
Eberhard Bassenge, Bruno Fink. lnstrtute of Applied Physiology, University Freiburg, 
F&burg, Germany 
Background: The metabolism of pentaerythritoltetranitrate (PETN) to NO is reductive in 
contrast to the oxidative catabolism of most other nitrovasodtlators. which are associated 
with a certain coproduction of reactive oxygen species @OS). Therefore, we analyzed 
the effects of superimposed PETN given over a period of 8 weeks along with an athero- 
genie cholesterol diet (0.5%) on ROS production in hypercholesterolemic guinea pigs. 
Methods: The cholesterol diet was given without and with PETN (3 “g/kg/day). Isolated 
Langendorff hearts were prepared either before or after 8 weeks of treatment. ROS pro- 
duction was analyzed both in the perfusate and in blood samples. 
Results: ROS production both in blood samples and in p&us&es of isolated hearts of 
cholesterol treated animals increased significantly from 0.237i-0.033 pM/min by 54+6% 
to 0.364+0.024 (n = 7) uM/min and from 1.96+0.06 uM/min by 23~4% to 2.4220.042 uM/ 
min (n = 14) respectively. This excessive production was significantly lower amounting 
only to 0.294iO.012 yM/mln in ex viva blood samples of animals treated additionally with 
PETN and in perfusates amounting only to 2.29+0.044 pM/min. Likewise, concentrations 
of reduced thiols were changed from 205r9.1 to 254+18 uM after 8 weeks cholesterol 
diet, but were minimally increased when additional PETN was given daily. 
Conclusion: Excessive production of ROS during experimental hypercholesterolemia is 
effectively reduced by long term administration of PETN, which may be explained by its 
reductive metabolism in contrast to other nitrates. 
1093-170 B-mode Ultrasound imaging of Arterial Walls in FH-children, 
FH-Adults and Controls Shows the Need for Atherosclerosis 
Prevention in Individuals at High Risk for Cardiovascular 
Disease 
Eric de Groat, Albert Wiegman, Willem F. Terpstra, Marianne E. Wittekoek, Johan Gort, 
Henk D. Bakker, Jo F May, Andries J. Smit, John J. P Kastelein. Academic Medical 
Centre, Vascular Medicine, Amsterdam, The Netherlands 
Background To estimate atherosclerosis progression with age tn younger and older het- 
erozygotes for familial hypercholesterolemia (FH), and in younger and older unaffected 
subjects. Methods Carotid and femoral B-mode ultrasound intima-media thickness (IMT) 
measurements were done in FH individuals: 44 FH-children (14.8(SD2.8)years, LDL- 
C=6.1(1.8)mmol/L; 252 FH-adults (age 48.1(8.8)year.s), LDL-C=7.6(1.9)mmol/L)) and in 
controls: 44 unaffected FH-siblings (14.9(2.8)years, LDL-C=25(06)mmol/L); 26 younger 
(34.9(9.6)years, LDL-C=2.7(0.8)mmol/L) and in 43 older adults (67.4(17.6)years, LDL- 
C=3.9(l.l)mmol/L). Available IMT measurements of 6 carotid and 4 femoral arterial wall 
segments were combined on a per subject basis. Difference in IMT progression with age 
between FH and non-FH was estimated by linear regression. Results IMT was 
0.55(0.05)mm in FH and 0.53(0.03)mm in non-FH children: dlMT=0.014 mm, ~~0.15. 
IMT change in FH with age was estimated at O.OlOmm in symptomatic, O.OOSmm/yr in 
asymptomatic and 0.004mmiyr in non-FH subjects (mean differential IMTchange 0.005 
mmiyr: p<O.OOl). From our estimates in non-affected an IMT of 0.78”” is reached at the 
age of 76. This IMT was estimated to be reached at 34 years in symptomatic and at 43 
years in asymptomatic FH. Conclusions The findings indicate rapid atherosclerosis pro- 
gression in symptomatic and asymptomatic FH Individuals. Since all genetically defined 
as FH are at high cardiovascular risk, prevention of atherosclerotic disease in FH should 
start early in life. 
1093-171 BFGF Increases Atherosclerotic Plaque in the Aorta of 
Hyperlipidemic Rabbits 
Dmitri V. Baklanov, Denesh S. Rae, Anne M. Pippen, Creig F Donatucci, Brian H. Annex. 
Hospital of Saint Raphael and Yale University School of Medicine, New Haven, CT; Duke 
Urwersity MedIcal Center, Durham, NC 
Background. Angiogenic agents, such as baste fibroblast growth factor, (bFGF) are 
emerging as potentially novel therapies to treat patients with vascular disease. Although 
angiogenesis inhibition has been shown to decrease atherosclerosis in animal models, 
the effect of growth factors on plaque formation is unknown. Methods. The thoracic aor- 
tas from 35 rabbits which were fed a 1% cholesterol diet for 6 weeks, treated with boluses 
of intravenous bFGF (1 mcs/kg) or placebo 2 times/ week for 3 weeks, were harvested at 
10 (n=5 for bFGF, n=4 for controls), 21 (n=5 for bFGF, n=6 for controls), and 42 (n=5 for 
bFGF, n=lO for controls) days after the last therapy. The frozen sections from aortas 
underwent histologic analysts to determtne the extent of atherosclerotic plaque, NADPH - 
diaphorase staining to determine the presence of functional NO synthase protein; and 
immunohistochemical evaluation to examine the extent of luminal endothelial staining. All 
readings were performed in a blinded manner and analyzed using the NIH image analy- 
sis software. Single-factor Anova test was used for statistical analysis. Results. Progres- 
sion of atherosclerosis was noted both in experimental and control animals. 
Atherosclerotic plaque area measured 0.03*0.01 sq. mm in bFGF treated vs. 0.02+_0.01 
sq. mm in control group at 10 days, 0.27+0.14 sq. mm vs. 0.37t0.33 sq. mm -at 21 days, 
but was 2.92&1.17 sq. mm vs. 0.48*0.34 sq. mm at 42 days (pcO.001): NADPH dia- 
phorase activity was mom prominent in the aortas of bFGF treated group. By immunohis- 
tochemistry, there was no significant difference in the extent of luminal endothelial 
statning between the groups and mwovessels were not present in the atherosclerotic 
plaques. Conclusion. The results of our study demonstrate that repeated systemic 
administration of bFGF in hyperlipidemic rabbits is associated with an increased athero- 
sclerottc plaque at late time points. Although the mechanism for this effect is 
unclear,these results may have implications for angiogenesis studies. 
1093472 Recombinant Human Erythropoietin Stimulates 
Angiogenesis in a Novel In Vitro Assay of Human 
Myocardial Tissue 
Korff T. Krause, Mona Tawakol, Aqdreas Keck, Karl-Heinz Kuck, Kai Jaquet. St. Georg 
Hospital, Hamburg, Germany 
Erythropoietin (Epo) is a known hormone regulating proliferation and differentiation of 
erythroid cells. Recombinant human erythropoietin (rhuEpo) is applted clinically for stim- 
ulation of precursors of the erythroid lineage. Based on the hypothesis that hematopoie- 
tic and endothelial cells share a common hemangioblast progenitor and the finding that 
both cell lineages express cell surface antigens ltke CD31 and CD34, we investigated the 
angiogenic response of rhuEpo on adult human vascular tissue. Therefore we adapted a 
recently developed in vitro assay for human angiogenesis. During coronary bypass sur- 
gery obtained fragments of aortic punch biopsies, thoracic artery and cardiac auricle 
were embedded in a fibrin gel matrix and cultured for 21 days. Capillary sprouting was 
measured with an eye place graticule under an inverted phase contrast microscope every 
second day.Tube-forming endothelial cells were characterized by immunhistochemistry 
and RTPCR. We found that rhuEpo with an optimum concentration of ZU/ml stimulates 
capillary outgrowth up to threefold compared to the non-stimulated physiological out- 
growth. This effect was observed I” continuous exposure to rhuEpo only. Conclusion. 
Recombinant human erythropoietin stimulates capillary outgrowth in an in vitro assay for 
human angiogenesis using different human vascular tissues. This suggests a role of 
erythropoietin in vasoproliferative processes. rhEpo may serve as a direct angiogenic 
substance in patients with ischemic heart disease 
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1093-173 Atorvastatin Reduces the Blood Levels of Vascular 
Endothelial Growth Factor (VEGF) in Patients With Coronary 
Artery Disease 
POSTER SESSION 
Hannes F W. Alber, Jozef J. Dulak, Heike HOgel, Otmar Pachinger, Sevarin S. 
Schwarzacher, Franz F Weidinger. University of Innsbruck, Department of Cardrology, 
Innsbruck, Austria 
Background: VEGF is suggested to be involved in atherosclerotic plaque growth by 
indwng neovascularization. HMG-CoA reductase inhibitors (statins) like atorvastatin 
(Atv) are known to have atheroprotective effects beyond their lipld-lowering properties. 
The aim of this study was to determine whether these latter effects of AN are related to a 
reduction in VEGF synthesis. 
Methods: Blood was collected from 14 male hypercholesterolemic patients with angle- 
graphically confirmed coronary artery disease (CAD pts) at baseline and after 2 months 
of Atv therapy (POmg/d).To test the effect of Atv on VEGF synthesis in vitro, human coro- 
nary vascular smooth muscle cells (hSMCs) were treated with Atv (0.3, 1 and 10 
pM).The VEGF concentration was measured in EDTA plasma and in culture medium by 
ELISA. 
Results: 
Cholesterol (mg/dL) VEGF (pg/mL) p value 
Baseline 262.3 + 44 0 31.1 k22.6 < 0.001 
2 month Atv 189.9 i 42.9 19.0’13.5 < 0.05 
To verify this hypothesis tn vitro, vve observed that plasma from CAD pts collected before 
Atv therapy induced more VEGF in hSMCs compared to the plasma collected after treat- 
ment (125.3568.4 vs 27.0r53.7 % of controls; p<O.OB).The incubation of hSMCs with Atv 
(0.3,1 and 10 PM) showed no effect on the VEGF production compared to basal genera- 
tion @X.98*7.37, 68.84t9.62, 62.97i11.95v.s. 62.90?3.05pg/mL). 
Conclusion: These data suggest that Atv may lower the plasma level of VEGF in CAD 
pts, which could represent a novel non-lipid lowering effect of this and probably other 
statins and is more likely to be dependent on A!v’s metabolite(s) than on the parent drug 
itself 
1093-174 Is The Remodeling Pattern Consistent Throughout An 
Atherosclerotic Lesion? Intravascular Ultrasound Evidence 
of Heterogeneity within A Single Diseased Segment 
Atila lyisoy, Khaled M. Ziada, Mohammed Balghith, Allen Jeremias. Hiroshi Tsutsui, 
Samir R. Kapadia, Paul Schoenhagen, Mandish Rai, Steven E. Nissen. E.Murat Tuzcu. 
Cleveland Clinic foundation, Cleveland, OH 
Background: Vascular remodeling is an increase or decrease in the area of the external 
elastic membrane (EEM) during development of atherosclerosis (positive and negative 
remodeling, respectively). Most studies have reported a single value for the magnitude 
and direction of remodeling derived from analysis of the most severely narrowed site. We 
assessed whether a single value IS representative of the entire lesion. Methods: Ultra- 
sound imaging of culprit lesions was performed in 68 lesions in 65 symptomatic patients. 
An automated pullback (0.5 mmlsec) was performed from the distal to proximal reference 
sites and cross-sections measured at 1 mm intervals to determine EEM and lumen 
areas. For each slice, a theoretical (calculated) EEM area was calculated assuming grad- 
ual uniform tapering from proximal to distal reference sites. From the calculated EEM 
area, a remodeling index (RI) was computed for each site within the lesion defined as 
measured EEM area/theoretical reference EEM area. We considered negative remodel- 
ing present If RI z 0.95, positive remodeling if RI ~1.05. and neutral remodeling if RI was 
0.95 to 1.05. Results: There was significant difference in RI throughout the length of the 
lesion. The RI for the worst site(minimai lumen diameter) averaged 1 .Ol * 0.94, which 
was statistically different by paired t-test from the average RI for the entire lesion (1.06 +. 
0.18, p=O.O03). In 24/65 (37%) patients, the category of remodeling [negative vs. neutral 
vs. positive) was different comparing the most severe lesion to the segment average. 
Even within 1 to 2 millimeters of the worst site, the remodeling category shifted in some 
patients (Table). However, negative remodeling showed a more consistent pattern 
ihroughout the lesion than positive remodeling. Conclusion: Lessons have strikingly dif- 
ferent remodeling patterns along their lengths. The remodeling index of most severe part 
is not representative of the entire lesion. This finding may be related to developmental 
stage activity of the atheroma. 
The DistribUtion of Remodeling Patterns at Lesion Sites 
Negative RI Neutral RI 
2 mm distal 14 31 
1 mm distal 15 25 
Worst site 17 16 
1 mm proximal 16 21 
2 mm proximal 19 22 
Positive RI 
23 
28 
35 
31 
27 
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1094-175 Omapatrilat Potentiates the Vasorelaxant Response to 
Adrenomedullin in Resistance Arteries From Patients With 
Coronary Heart Disease 
Colin Berry, Chris Hillier, Alison Seed, John Irvine, Mark Petne, John McMurray 
University of Glasgow, Glasgow, United Kingdom 
Introduction: Adrenomedullin (ADM) is a recently described peptide with vasodilator, 
renal and other actions of potential benefit in patients with cardiovascular disease. The 
am of this study was to investigate the effect of the combined angiotensin converting 
enzyme (ACE) and neutral endopeptidase (NEP) inhibitor, omapatrilat, on the action of 
ADM in small resistance arteries from patients with coronary heart disease (CHD). Meth- 
ods: Resistance arteries (Fins), isolated from gluteal biopsies taken from CHD patients 
(n=8) with normal left ventricular ejection fractions and not on ACE inhibitor therapy, were 
mounted in a wire myograph. Following a start-up protocol, RAs were preconstricted with 
norepinephrine (lo-5M) and concentration response cwves to IO-10.10.7M ADM con- 
structed following incubation with either vehicle, TO-5M omapatrilat, lo-5M captoprll (an 
AGE inhibitor) orcaptopril and lo-5M thiorphan (a NEP inhibltor). Results: In RAs, oma- 
patrilat potentiated ADM-induced vasorelaxation compared to vehicle (‘~~0.05). Capto- 
pril with or without thiorphan showed no significant effect. Potentiation by omapatrilat was 
selectively observed at lower concentrations of ADM (Fig. 1) 
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Conclusions: We have shown, for the first time in human RA, that omapatrilat is able to 
potentiate ADM-induced vasorelaxation. The mechanism for this may involve a reduced 
breakdown of ADM. This suggests an additional, hitherto unknown effect of omapatrilat 
on human blood vessels 
1094-176 Evidence That a Novel Orally Active NEP/ECE Inhibitor 
Blocks the Vasoconstrictor Response to Big Endothelin in 
Human Resistance Arteries 
Al&on Seed, Chris Hillier, Colin Berry, Fiona Johnston, Mark Petrie, John J. V. McMurray 
University of Glasgow, Glasgow, United Kingdom 
Introduction: Plasma levels of the potent vasoconstrictor endothelin-1 (ET-I) are signifi- 
cantly increased in heart failure and correlate with prognosis. Consequently, pharmaco- 
logical manipulation of the endothelin system may be of therapeutic benefit in CHF. KC 
12615, the active metabolite of SLV306 has combined endothelin converting enzyme 
(EGE) and neutral endopeptidase (NEP) Inhibiting properties in ammal experiments. The 
aim of this study was to investigate the effect of KC12615 on ECE-dependent vasocon- 
striction to the ET-1 precursor big ET-1 in resistance arteries from patients with coronary 
heart disease (CHD). Methods: Reslstance arteries @As), isolated from gluteal biopsies 
taken from CHD patients with normal left ventricular ejection fractions were mounted in a 
wire myograph. Following a start-up protocol, concentration response curves to big ET 
were constructed following incubation with KC12615 3AA (Solvay Pharmaceuticals 
GmbH, Hannover, Germany) 10.41vl; 10.5M or IO-6M for 30 minutes. Results: Figure 1. 
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We have previously shown that NEP inhibition alone does not affect the vasoconstrictor 
response to ET-1 .KC12615 produced a concentration-dependent reduction in the vaso- 
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constriction to big ET This reached statistical significance at the highest concentration 01 
KC 12615 studied (Fig. 1. Max. response (%KCI) - vehicle: 109 i: 9 versus 10.4M KC 
12615: 32 + 8, pcO.01. Student’s t test). Conclusions: We have shown, for the first time 
in human RAs, that KCl2615, a novel compound with both ECE and NEP inhibitory prop- 
erties can significantly attenuate the contractile response to big ET. This effect is 
achieved with concentrations of KC12615 obtained in the plasma following acute and 
chronic oral dosing with SLV 306 in man. These data suggest that SLV 306 may have 
important therapeutic properties in CHD. 
1094-177 Effects of Adenosine and Alpha 1-Adrenergic Blockers on 
the No-Reflow Phenomenon 
Cuisa Gregorini, Jean Marco, Bruno Farrah, Carlo Palombo. Irene M. Bossi, Micaela 
Kozakova, Monique Bernies, Francesco Donatelli, lsabelle Marco, Adalberto Grossi. 
Jean Marco, Toulous?, France, Luisa Gragorini, Milan, ltaly 
Background: The no-reflow phenomenon may occur during mechanical coronary revas- 
cularization, despite antiplatelet (ASA & ticlopidine 250mgiBID for 3 days) and anticoagu- 
lant treatment (heparin 100 U/Kg), The no-reflow may be due to dissections, lipid 
extrusion through the stent struts, thrombus dislodgment and distal embolization. Meth- 
ads: In 16 patients undergoing coronary stenting and in whom the lack of flow persisted 
after intracoronary (ic) nitrates (ISDN 3mg) we quantified by means of angiographic TIMI 
frame count (FC) the effects of 1) 14Opgikg min adenosine intravenously, followed after 1 
minute infusion by 2) the alpha I-adrenergic blocker urapidil (10mg ic). Angiograms and 
FC were performed 1 minute after adenosine infusion and 3 minutes after urapidil ic 
injection. FC was measured in the no-reflow vessel and, in case of LAD or LCx, in non- 
culprit vessels. Results: Zero-flow was observed in the PTCI vessel in 16 patients (LAD 
n=13, LCx n=l, RCA n=2). In non-culprit vessels the FC’ resulted 68.6t28.5. In the no- 
reflow vessel adenosine infusion restored a very slow flow, FC being 145.5~488, 
whereas in nonculprit vessels FC became 50.5+10.8 (p-z 0.05). When urapidil was 
superimposed on top of adenosine, FC became 29119 and to 29tl2 in the culprit and 
non-culprit vessels, respectively (pc 0.05). The corrected FC was 14.7,l.S and 22.6k3.8, 
respectively (p< 0.05). No blood pressure changes were observed after alpha l-adrener- 
gic blockade. Conclusions: These preliminary results suggest that alpha I- adrenergic 
blockers combined with adenosine may acutely decrease coronary resistance, and 
improve flow in the culprit coronary artery. This therapeutrc approach might help in case 
of no-reflow. 
1094-178 Polymyxin B-immobilized Fiber Improves Systemic 
Hemodynamics in Patients With Severe Sepsis and Septic 
Shock via the Attenuation of Nitric Oxide., 
Yoji Kate, Yasuhiko Matsuura, Yoshiyuki Kijima, Kazuhiko Hashimura, Takenori Yasuda, 
Tetsuya Ueda, lsao Mori, Masafumt Kitakaze, Tetsuo Minamino, Tsunehiko Kuzuya, 
Masatsugu Hori. Cardiovascular Division, lshinkai Yao General Hospital, Osaka Kao, 
Japan, Department of lntemal Medicine and Therapeutics, Osaka Universify Graduate 
School of Medicine, Osaka Suita, Japan 
Background: Septic shock is a highly complex pathophysiological state. Despite aggres- 
sive treatment and increased understanding of molecular aspects of septic shock, its 
mortality is still high. It has been reported that nitric oxide plays an important role in sep- 
tic patients. Since nitric oxide causes vasorelaxation, the induction of nitric oxide syn- 
thase and the subsequent release of nitric oxide may contribute to occurrence of the 
shock condition. Recently, it has been reported that hemoperfusion using polymyxin-B 
immobilized fiber column (PMX-F) improves systemic hemodynamics in patients with 
sepsis by elimination of endotoxin. We hypothesized that PMX.F improves hemadynam- 
its of septic patients by the attenuation of activated nitric oxide pathway. Methods: 
Twentyone patients with severe sepsis were enrolled in this study. Of those patients, 11 
presented septic shock and 19 needed mechanical ventilation because of persistent 
hypoxia. Severe sepsis and septic shock were defined according to the systemic inflam- 
matory response syndrome (SIRS). Mean arterial pressure, central venous pressure and 
peripheral plasma nitrite and nitrate levels were measured at before and after PMX-F 
treatment for 4 hours. Result: Mean Mood pressure increased significantly from 81+/-l 6 
mmflg to 88+/-15 mmHg, while central venous pressure did not increase during PMX-F 
treatment. Sepsis increased the plasma nitrite and nitrate levels (20.6+/-22.4 vs 11.2+/- 
5.6 micromol/L in the healthy subject). Plasma nitrite and nitrates levels decreased signif- 
icantly from 20.6+/-22.4 micromole/L to 12.6 +I- 9.7 micromole/L. Conclusion: PMX-F 
improves systemic hemodynamics in patients with severe sepsis and septic shock, and 
enhancement of the production or release of nitric oxide may be attenuated in the benefi. 
cial effects of PMX-F treatment. 
-- 
1094-179 Hypertensive Heart Disease Is Not Associated With 
Myocardial Activation of Angiotensin II or Endothelin in the 
Dog 
Chari Y. % Hart, Donna M. Meyer, John C. Burnett, Jr., Margaret M. Redfield. Mayo 
Clinic, Rochester, MN 
Background: Myocardial activation of angiotensin II (All) and endothelin (ET) is postu- 
lated to occur in human hypertensive heart disease as studies of pressure-overload in 
the rodent indicate that local tissue actrvation of All and/or ET occurs without systemic 
activation and may contribute to the hypertrophy (LVH). fibrosrs and diastolic dysfunction 
(DD). As the local humoral response to cardiac load in the dog may more closely parallel 
that of the human, we determined if there IS myocardlal activation of All and ET in a 
canine model of hypertensive heart disease. Methods: Systemic “Page” HTN was cre. 
ated by bilateral kidney wraps with silk (HTN,n=12). Sham surgeries (SHAM) were also 
performed (n=7). Mean arterial pressure (MAP), plasma renin activity (PRA), All, ET and 
catecholamines (CCA) were measured pm-op, then weekly, ECHO was obtained pre-op 
and prior to the invasive hemodynamic study and ?issue harvest at 5 wks in SHAM and 
HTN Grpl(n=7) and at 12 wks in HTN Grp2(n=5). ‘=p<O.O5 vs SHAM. Results: Post-op, 
MAP was higher in HTN dogs at wk 1 (139r4* vs. 123+4 mmHg SHAM), at wk 5 (174+7* 
vs. 124+4 mmHg) and remained elevated at wk 12 in GrpP. Serial ECHO showed signifi- 
cant increases in LV mass without change in ejection fraction in HTN dogs. At hemody- 
namic study, end-systolic elastance was preserved indicating normal systolic function. 
Diastolic function was abnormal as Tau was increased in Grpl (50+3*ms) and Grp2 
(62+10* ms) vs. SHAM (4lt2 ms). LV end-diastolic pressure was increased in Grp2 
(lOi- .O* vs. 7+0.3 mmHg SHAM). At autopsy, LV mass index (6.4kO.2” vs. 4.9+0.3 g/kg 
SHAM) was increased in HTN dogs. The degree of myocardial fibrosis was signrficantly 
increased in Grp 2 dogs. Circulating levels of PRA, All, ET and CGA were unchanged 
from pre-op and not different from SHAM during progression of HTN. Levels of All and 
ET in LV tissue from HTN dogs were not different from SHAM. Conclusions: In this 
canine model of hypertensive heart disease associated with LVH, progressive DD and 
myocardial fibrosis, there was no myocardial or systemic activation of All or ET. These 
data suggest All and ET are not involved in early hypertensive heart disease unassoci- 
ated with systolic dysfunctron or heart failure. 
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1095-181 Hypercholesterolemia Is Undertreated in Patients With 
Coronary Artery Disease. Results of a Survey in 1997 and a 
Survey in 2000 
Frank Vermeer, Patrick Limpt, Janneke Harting, Jurn van der Wild, Anton Gorgels, Aimee 
Lousberg, Margaret Tychon, Eric Ruland, Jan van Ree. University Hospital Maastricht, 
Maastricht, The Netherlands, University Maastricht, Maastricht, The Netherlands 
Background. The efficacy of cholesterol lowering therapy in patients with coronary 
artery disease has been proven in many large randomized trials. However, in daily prac- 
tice only few patients receive optimal cholesterol lowering treatment resulting in total 
serum cholesterol levels of ~5.0 mmolll (according to the AHA guidelines). Methods. In 
the PROTECT survey performed in 1997 the prescription of cholesterol lowering agents 
was assessed in patients with established coronary artery disease who visited the out- 
patient clinic. 4041 patients from 175 cardiologists were included. The HARTSLAG 
project (performed in 2000) was a multiple risk factor intervention trial with 2400 patients 
planned. The baseline data of 800 patients with coronary artery disease are presented 
here as a survey. Results. In PROTECT total serum cholesterol was ~5.5 mmolil in 1214 
patients (30%) at the moment of inclusion and this increased to 2425 patients (60%) at a 
follow-up visit after three to six months. Mean total serum cholesterol decreased from 6.1 
mmol/l at baseline to 5.3 mmol/l at follow-up. At baseline 1826 pts (45%) were treated 
with a cholesterol lowering agent (1724 with a statin), at follow-up 3252 patients (80%) 
were treated (3158 with a statin). In HARTSLAG total serum cholesterol at baseline was 
~5.5 mmol/l in 6736 of the patients. Medtan serum cholesterol was 5.1 mmol/l. 76% of the 
patients were treated with a cholesterol lowering agent (all with a statin). Conclusions. 
1) In these surveys less than half of the patients with coronary artery disease received 
optimal cholesterol lowering treatment resulting in total cholesterol levels ~5.0 mmolil. 2) 
Participation in a survey led to improved prescription by the particrpating cardiologist. 3) 
In HARTSLAG more patients were optimally treated (48% at baseline) than in PROTECT 
(20% at baseline, 45% at follow-up), but in both surveys the majority of the patients were 
not treated with a statin or treated with a suboptimal dosage of the statin according to the 
AHA guidelines. 
1095-l 82 Secular Trends (1966-i 997) in Cholesterol Assessment and 
Management Practices in Patients With Acute Myocardial 
Infarction: A Population-Based Perspective 
Frederick A. Spencer, Jorge Yarzebski, Robert J. Goldberg, Dar&n Lessard, Joel M. 
Gore. University of Massachusetts Medical School, Worcester, MA 
Background: Elevated serum cholesterol levels are associated with an increased risk of 
acute myocardial infarction (AMI) and adverse outcomes. It is unclear what proportion of 
patients have their cholesterol measured during hospitalization for AMI and are treated 
with lipid lowering therapy. The objectives of this longitudinal study were to examine 
decade long trends in cholesterol ordering practices during hospitalization for AMI and 
use of lipid lowering therapy. Methods: Observational study of 5204 residents of the 
Worcester, MA, metropolitan area hospitalized with validated AMI and not previously on 
lipid lowering therapy in all greater Worcester hospitals (n=l3 to 16)in 7 one-year periods 
between 1986 and 1997. Results: Increases in the measurement of serum cholesterol 
levels during hospitalization for AMI were observed between 1986 (58%) and 1991 (92%) 
after which time there was a progressive decrease; only 24% of AMI patients in 1997 
underwent cholesterol testing. Of patients having their cholesterol measured, 74% had 
measurements performed during the first day of hospitalization in 1986 compared to 41% 
in 1997. Younger age, male sex, and absence of a history of cardiovascular disease were 
associated with an increased likelihood of cholesterol being measured. While the relative 
rats of lipid lowering therapy initiation increased significantly over time (<I% rn 1986; 
11% in 1997) the absolute rate remained low. In patients with an elevated cholesterol 
(z-240 mgidl), 2% were initiated on lipid lowering therapy in 1986 and 37% in 1997. Con- 
JACC February 2001 ABSTRACTS - Hypertension, Vascular Disease, and Prevention 239A 
ctusions: The present results suggest recent declrnes in the assessment of total choles- 
terol levels in patients hospitalized with AMI. In addition, measurements are increasingly 
being performed after day 1 of hospitalization (when results may be artifactually lowered). 
White the initiation of lipid towering therapy during hosprtalization for AMI has increased 
over time, particularly in patients with elevated serum cholesterol levels. considerable 
room for improvement remains. 
1095-183 Race and Sex Based Differences in the Utilization of Lipid 
Lowering Medications After Acute Myocardial Infarction 
Gregg C. Fonarow, Karol E. Watson, William J. French, NRMI 3 Investigators. UCLA 
Medical Center, Los Angeles, CA, Harbor-UCLA Medfcal Center, LOS Angeles, CA 
Background: This study armed to assess the role of race and sex on utrlization of lipid- 
lowering medication at discharge among patients hospitalized with acute myocardial inf- 
arction (AMI). 
Methods: DemographIc, procedural, and discharge medication data were collected from 
138,001 patients with AM) discharged from 1,470 U.S. hospitals participating in the 
National Registry of Myocardial infarction 3 from July 1998 to June 1999. 
Results: Lipid-towering medications were part of the discharge regimen in 31.7%. 
Women (n = 54,195) were less likely to be treated with lipid lowering medications, with 
only 26.8% being discharged on treatment as compared to 34.8% of men (odds ratio 
[OR] 0.69 95% Cl 0.67-0.70). African-Amerrcan patients (n = 9,373) were less likely to 
be treated, with 28.9% treated in contrast to 31.9% of the non-African-American patients 
(OR 0.87, 95% Cl 0.83-0.91). Treatment rates in African-American females were slightly 
higher than non-African-American females (28.2% vs. X7%), but African-American 
males were significantly less likely to be treated (29.5% vs. 35.1%, P<O.OOOi). In multi- 
vanate analysis, factors independently related to decreased lipid-lowering medication uti- 
lization included African-American race (OR 0.94, 95% Cl 0.89-0.93) and older age (age 
65-74 compared to < 55; OR 0.82, 95% Cl 0.780.86) but not female sax (OR 0.97, 0.942 
1 .OO) 
Conclusions: Racial and sex differences exist in the utilization of liprd-lowering medica- 
tions at time of hospital drscharge, but are partially explained by other confounding vari- 
ables. 
1095-184 Adherence to National Cholesterol Education Program Diet 
in Free-Living Individuals: The Women’s Health Initiative 
Judrth Hsia, William Frishman, Rebecca Rodabough, Marcra Stefanick, Barbara 
Cochrane, Milagros Rosal, Linda Snetselaar, Barbara V. Howard. George Washington 
University, Washington, DC 
Background: Although lipid-towering drug treatment is recommended only after an ade- 
quate trial of dietary therapy, adherence to the National Cholesterol Education Program 
(NCEP) Step 1 and 2 diets among free-living indrviduals is not certain. This analysis 
describes NCEP dietary adherence rn the Women’s Health Initiative Observational Study 
( WHI OS). 
Methods: The WHI OS enrolled women 50-79 years of age at 40 climes nationwide for 
collection of anthropometric and questionnaire data. Participants reported hyperlipidemia 
by responding to the question “Has a doctor told you that you have high cholesterol 
requiring pills?” Dietary mformation is from a food frequency questionnaire which has 
been validated against four-day food record and 24 hour recall. Adherence to the Step 1 
diet is defined as consuming ~30% and ~10% of calories from total and saturated fat, 
respectively, and ~300 mgiday of cholesterol. Step 2 adherence IS defined as ~30% and 
~7% of calories from total and saturated fat, respectively, and ~200 mg/day of choles- 
terol. 
Results: Of 91,627 women enrolled in the OS, 13,777 (15%) reported hyperlipidemia 
requirrng pills, and consequently should have been adhering to the NCEP Step 2 dret. Of 
these, 48% met Step 1 and 20% met Step 2 guidelines for daily dietary cholesterol, total 
and saturated fat intake. In multivanate analysis, positive determinants of NCEP Step 2 
dietary adherence included Asian, African-American or Hispanrc ethnicity, more years of 
education, residence in the Northeast, having a prior cardiovascular event, and higher 
scores on mental and physical functioning scales. Dietary non-adherence was associ- 
ated with being married, being a caregiver, residrng in the Midwest, higher body mass 
index, being a current smoker, and having self-reported diabetes. 
Conclusion: Only 20% of free-Irving women with self-reported hyperlipidemia requiring 
pills met NCEP Step 2 dretary goals, a findrng inconsistent with the characterization of 
dietary therapy as the cornerstone of lipid management. 
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1096-185 Angiotensin Ii Inhibits GP130 Signaling in Cardiac Myocytes 
by Tyrosine Phosphatase Activation 
George W. Booz, Joanna D. Smith, Kenneth M Baker. The Texas A&M Univ System 
HSC, Coil. Of Medicine, The Cardiovascular Research Institute, Temple, TX 
Activation of transcription factor STAT3 has been linked to a cytoprotective pathway in 
cardiac myocytes. Previously, we showed that angiotensin II (All) induces delayed STAT3 
activation (tyrosine phosphorylation) in cardiac myocytes by the G-protein coupled AT1 
receptor. In this study, we tested the hypothesis that delayed STAT3 tyrosine phosphory- 
latian was due to tyrosine phosphatase activation. Cell lysates were prepared from vehi- 
cle- or agonist-treated, serum-starved cells and changes in basal STAT3 phosphoryiation 
assessed by Western analysis using phosphospecific antibodies and a ten-fold greater 
amount of cell protein than previously. All rapidly induced sustained (>2h) STAT3 serine 
(S727) phosphorylation: however. tyrosine (Y705) phosphorylation was initially reduced 
following All treatment, before being increased at 90 min. Y705 phosphorylation was 
reduced 3466% by 30 min treatment with All. Endothelin-I (ET-l), which activates a G- 
protein coupled receptor, and the phorbol ester, PMA also induced time-dependent 
STAT3 Y705 dephosphorylation. Additionally, LIF-induced STAT3 Y705 phosphorylation 
at 10 min was inhibited 43, 62, and 61%, by 20 mm pretreatment wrth All, ET-l, and 
PMA, respectively. The cytokrne, LIF induces STAT3 phosphorylation via the LIF receptor 
and signaling glycoprotein, gp130. Agonist-induced Y705 dephosphorylation was not 
blocked by the protein synthesis inhibitor, cycloheximide, but was attenuated by MEKI 
inhibitor PD98059, which reduced agonist-induced 5727 phosphorylation. The latter IS 
consistent with recent reports that STAT3 senne phosphorylatron negatively modulates 
its ryrosine phosphorylation. The tyrosine phosphatase inhibitor, sodium orthovanadate 
blocked agonist-induced Y705 dephosphorylation, but drd not cause early Y705 phos- 
phorylation. Our results indicate that tyrosine phosphatase activation contributes to inhib- 
itory crosstalk between AT1 and LIF receptors, but does not explain delayed STAT3 
activation by All in cardiac myocytes. inhibition of a cytokine-activated STAT3 cytoprotec- 
tive pathway by peptide hormones that activate G-protein coupled receptors may play a 
role in the development of heart failure. 
1096-186 Localization and Regulation of NEP and ACE After AT1 
Blockade or ACE Inhibition in a Rat Model of Myocardial 
fnfarction 
Thomas Walther, Wolf E. Siems, Frank Spillmann, Heinz-Peter Schultheiss. Carsten 
Tschoepe. UKBF-FU, Ekriin, Germany 
Background: Since many cardiac peptidases are involved in myocardial disorders we 
investigated whether ACE and NEP are regulated after induction of myocardial infarction 
and may be influenced by a treatment with an ACE inhibitor or an ATl-receptor blocker. 
Methods: In a rat model of myocardial infarction, ACE and NEP distribution and regula- 
tion were determined 24h, 6 days, and 3 weeks after coronary occlusion. Beginning 48h 
after infarct Induction, additional sets of animals were treated with the ACE inhibitor 
Quinapril (lomgikgiday) or the ATl-receptor blocker lrbesartan (50mglkgiday). Animals 
have been characterized hemo-dynamically. Finally, hearts were isolated and divided in 
the RV, and Inter-ventricular S, and the infarcted and non-infarcted area of the LV. Homo- 
genates ware used to detect NEP- and ACE-specific activity. Results: Quinapril and Irbe- 
sartan treated rats showed significant improvement of the left ventricular function 6 days 
and 3 weeks after Ml compared to untreated rats. NEP activity was only changed in the 
infarcted area of MI rats. This increase was rescued by lrbesartan (70%) and less pro- 
nounced by Quinapril (20%). ACE activity was tripled in the non-infarcted areas and more 
than ten fold increased in the infarcted part of the left ventricle. lrbesartan pronounced 
this elevation after 6 days and 3 weeks. Quinapril reduced the ACE activity almost to lev- 
els of sham operated rats after 6 days whereas the actrvity was elevated to levels of Irbe- 
sartan-treated rats three weeks after Ml. Conclusion. The results indicate different 
mechanisms of NEP and ACE up-regulation influenced be mediators of the renin-angio- 
tensin system. In addition, continuous ACE-inhibitor treatment leads to an up-regulation 
of the target protein. 
1096-187 Angiotensin II and Serotonin Potentiate Endothelin-l- 
Induced Vascular Smooth Muscle Call Proliferation 
Takuya Watanabe, Rajbabu Pakala, Claude R. Benedict. Unwersityof Texas, Houstdn, 
TX 
Background: Vascular smooth muscle cell (VSMC) proliferation induced by various 
growth factors has been implicated in a wide variety of pathological processes including 
hypertension, atherosclerosis, and restenosis after angioplasty. We investigated the 
interactions among well-known potent vasoactive agents, endothelin-1 (ET-I), angio- 
tensin II (Ang II), and serotonin (5.HTJ on VSMC proliferation. 
Methods: Growth-arrested rabbit VSMCs were Incubated in serum-free medium with dif- 
ferent concentrations of ET-1 in the absence or presence of Ang II and/or 5HT. VSMC 
proliferation was examined by increases in [3H]thymidine incorporation into DNA and cell 
number. 
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Results: ET-l, Ang II, and 5.HT stimulated DNA synthesis i,n a dose-dependent manner. 
ET-1 had a maximal effect at a concentration of 0.1 KM (202%) Ang II at 1.75 uM 
(202%), and 5.HT at 50 ,uM (205%). When added together, ET-1 (0.1 mM) and Ang II (1 
PM) synergistically induced DNA synthesis (338%). When tested in combination, wan 
nonmitogenic concentration of ET-1 (0.01 nM) potentiated the 5-HT (5 FM)-induced DNA 
synthesis (395%). Coincubation of ET-1 (0.01 FM) with Ang II (1 FM) and 5-HT (5 uM) 
synergistically induced DNA syntheses (566%). These effects on DNA synthesis were 
paralleled by mcreases in cell number. TAK044 (1 uM ), an ETA/a non-selective receptor 
antagonist and BQi23 (1 mM ), an ETA selective receptor antagonist blocked the mitoge- 
nit effect of ET-1 and its interaction with Ang II and/or 5-HT. Further, TAK044 (1 mM ) or 
BQ123 (1 uM ) along with candesartan (1 FM), an AT, receptor antagonist and/or sar- 
pogrelate (IO mM), a 5-HTzA receptor antagonist completely blocked the mitogenic inter- 
actions of ET-1 with Ang Ii and/or 5-HT. 
Conclusions: Our results suggest that Ang II and 5-HT could significantly potentiate ET- 
l-induced VSMC proliferatron. lnhrbition of ETA, AT,, and 5.HTaA receptors may be effec- 
tive in the treatment of VSMC proliferative disorders assocrated with hypertension, ath- 
erosclerosis, and restenosis. 
1096-188 Reduced Pulmonary Hypertension and Right Ventricular. 
Weight in Mice Treated With the Angiotensin Receptor 
Blocker, Candesartan 
Hunter C. Champion, Trinity J. Bivalacqua, Luis Ortiz, Medal Reyes, Albert L. Hyman, 
Philip J. Kadowitz. Johns Hopkins Hospital, Baltimore, MD, Tulane Universit)! New 
Orleans, LA 
The present study was undertaken to evaluate the role of angiotensin ATI receptor acti- 
vation on bleomycin-induced pulmonary hypertensron and right heart failure in the mouse 
in viva. Pulmonary vascular measurements were made directly using a right-heart cathe- 
terization technique in the intact-chest, spontaneously breathing mouse. Bleomycin 
induced a 98% increase in pulmonary arterial pressure (PAP), a 85% increase in pulmo- 
nary vascular resistance (PVR), and a 24% increase in RV free wall weight (PcO.05) in 
C57BU6 mice. In mice treated chronically with the angiotensin ATI receptor blocker can- 
desartan, PAP, PVR, and RV free will weight were significantly lower than in control ani- 
mals (pcO.05). In addition, mice treated chronically with candesartan had significantly 
lower levels of hydroxyproline in the heart and lung when compared to control animals. 
When bleomycin was administered to mice genetically deficient in angiotensin AT1 
receptors, PAP, PVR, and RV free wall weight were significantly lower when compared to 
wild-type animals treated with bleomycin. These data suggest that mice treated with the 
angiotensin AT1 receptor blocker candesartan and AT1 knockout mice are resistant to 
the pulmonary hypertension and increase in RV weight induced by bleomycin. These 
data may suggest that angiotensin AT1 receptor activation plays a role in the pathogene- 
sis of bleomycin-induced pulmonary hypertension and right heart failure. 
1096-189 Homocysteine:lnduced Oxidative Stress Increases 
Chymase:Dependent Angiotensin Ihforming Activity in 
Mast Cell 
Kanta Fujimi, Hidenori Urata, Satomi Abe, Munehito Id&hi, Kikuo Arakawa, Keijiro 
Saku. Fukuoka University School of Medicine, Fukuoka, Japan 
Background: Hyperhomocysteinemia is an independent risk factor for atherosclerosis. 
Several reports have suggested that oxidative stress plays a key role in homocysteine- 
induced cell injury. Our previous reports have suggested strong positive association 
between hypercholesterolemia and arterial angiotensin II (All)-forming chymase expres- 
sion, which is further augmented in established atherosclerotic lesions. (Hypertension 
1999,200O) However, the detailed regulatory mechanism of chymase expression has not 
been clarified. In the present study, we tested whether homocysteine-induced oxidative 
stress increases mast cell chymase-dependent All-forming activity. Methods: Mice mas- 
tocytoma cells were cultured in DMEM supplemented with 1 % fetal bovine serum. After 
initiation of the cell culture, All-forming activity from Al in the cell homogenate gradually 
decreased, reached the baseline level at day3 and slightly increased at day4. Under 
these conditions, homocysteine and drugs were challenged at day 3 and incubated for 
further 24 hours with or without homocysteine, catalase, or superoxide dismutase, and 
for 30min in an experiment with hydrogen peroxide. All-forming activity in the cell homo- 
genate was determined at day 4. Results: Homocysteine treatment (0.1-3 mM) 
increased chymase activity in mice mast cell dose-dependently (n=9, 37.fold at 3mM 
homocysteine vs. control, p<O.OOl). This was inhibited by the addition of catalase 500 Ui 
ml (n=9, 78% less vs. homocysteine group, p<O.Ol), and completely suppressed by the 
combination of catalase and superoxide dismutase (n=8, p=O.OOl). Incubation with 
hydrogen peroxide alone (25OmicroM for 30min) caused a significant increase in chy- 
ma?e activity (n=9, 28-fold vs control, p<O,Ol), which was completely suppressed by the 
co-treatment with catalase. Conclusions: Homocysteine increased mast cell chymase 
activity through the mechanism of oxidative stress. Our result?. may suggest that the 
upregulation of chymase-dependent All production may have further accelerate local oxi- 
dative stress, since All is known to increase local free radical formation. 
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1097-190 Cardiovascular Mortality Associated With Impaired Fasting 
Glucose and the Role of Blood Pressure 
Patrick Henry, Frederique Thomas, Athanase Benetos, Louis Guize. Lariboisiere 
hospital, Paris, France, IPC, Paris, France 
Background : The association between cardiovascular (CVD) mortality and the recently 
defined impaired fasting glucose (IFG) category and its relation with blood pressure is 
unknown. Methods : We studied 124,959 consecutive subiects without any treatment for 
hypertension or diabetes who had a routine health examination with a fasting blood glu- 
cose (FBG) measurement. FBG levels were classified into 3 groups: non-diabetic (ND) = 
3.9-6 mmol/L: IFG = 6.1-6.9 mmol/L; diabetic = >6.9 mmol/L. IFG was found in 12,852 
(18%) men and 3611 (7%) women. Results : After adjustment for age, IFG was associ- 
ated with an increased risk in 8.year CVD mortality in men [0.49% vs. 0.19% for ND - RR 
(95% confidence interval) 1.44 (1.09-l .90)] but not in women 10.17% vs. 0.08% - RR 0.97 
(0.41-2.32)]. When systolic blood pressure @BP) was ~140 mmHg, CVD mortality was 
similar in IFG men compared to ND men [RR 1.05 (0.66-l .69) after adjustment for age]. 
Moderate systolic hypertension (140-159 mmHg) was associated with a major increase 
in CVD mortality in IFG men compared to ND men [RR 2.85 (1.59-5.12) vs. 1.37 (0.88. 
2.14) compared to normal SBP levels in each group]. Similar results were found for pulse 
pressure but not diastolic blood pressure. Other risk factors played only a minor role in 
determining CVD risk of IFG. Conclusion : IFG appears to be a key risk factor for CVD 
mortality only when SBP is xl40 mmHg. Moderate systolic hypertension (140-159 
mmHg) appears to be a powerful and independent predictor of CVD mortality in IFG 
men. 
1097-191 Low Body Mass Index and Cardiovascular Morbidity in 
Hypertension. 
Giuseppe Schillaci, Gianpaolo Reboldi, Paolo Verdecchia. University of Perugia, Perugia, 
Italy, Silvestrini Hospital, Perugia, J&/y 
The independent association between body mass index (BMI) and cardiovascular (CV) 
complications is controversial. In the setting of the Progetto lpertensione Umbria Monitor- 
aggio Ambulatoriale study, we followed for up to 11 years (mean 4.2) 2007 initially 
untreated hypertensive subjects (51r12 years, 53% men, office blood pressure 157198 
mmHg) without overt CV disease. Subjects were divided into sex-specific BMI quintiles 
(cut-offs: 22.8, 24.8, 26.6 and 29.3 kg/m2 in women; 24.5, 26.1, 27.8 and 30.1 kg/m2 in 
men). During follow-up there were 203 major CV morbid events and 106 all-cause deaths 
(2.4 and 1.1 per 100 patient-years, respectively). After adjustment for age, sex, diabetes, 
cholesterol, smoking, left ventricular hypertrophy and 24.hour systolic blood pressure (all 
~~0.05) in a multivariate Cox model, the 1st BMI quintile (reference) had a significantly 
greater CV morbidity compared to the 2nd (hazard ratio [HR] 0.62, 95% confidence inter- 
val [Cl] 0.40.0.97) 4th (HR 0.59, 95% Cl 0.39.0.91) and 5th quintile (HR 0.64, 95% Cl 
0.42-0.99). A U-shaped relation was found between BMI and all-cause mortality. Thus, a 
low BMI is a predictor of CV morbidity and all-cause mortality in uncomplicated subjects 
with essential hypertension. The relation persists after adjustment for several confound- 
ers including left ventricular hypertrophy, 24-h blood pressure and smoking. 
CV morbidity All-cause death 
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1097-192 Controlling Hypertension, Obesity, Insulin Resistance and 
Oxidative Stress Is More Important in Primary Prevention of 
Cerebrovascular Disease 
Junichi Taguchr, Minoru Yamakado, Minor” Ohno. Department of Cardiolodgy, Tokai 
University, Isehara, Kanagawa, Japan, Department of Cardiology University of Tokyo, 
Tokyo, Japan 
Background: Stroke is more common than coronary artery disease in Japan. For the pri- 
mary prevention of cerebrovascular disease (CVD), it is important to identify risk factors 
and to detect early atherosclerotic changes leading to CVD. The aim of the study was to 
determine risk factors that associated with asymptomatic cerebral infarction and early 
cerebrovascular atherosclerosis among healthy working generations. Methods: Sixteen 
hundred seventy subjects at working age (~65 years old) and five hundred one subjects 
older than 65, who underwent annual health check-up with brain MRI in Mitsui Memorial 
Hospital, were enrolled. To clarify specific risk factors for cerebrovascular atheroaclero- 
sis, plasma lipids, lipid peroxides (LPO), and superoxide dismutase (SOD), blood sugar, 
insulin, polymorphisms of atherosclerosis related genes including angiotensin converting 
enzyme (ACE) and carotid atherosclerosis were determined. Results: Logistic multiple 
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regression analysis identified that the significant predictors of asymptomatic mfarcbon 
(n=36) at working age were high systolic blood pressure (>150 mmHg, p=O.O003, 
RR4.9), LPO (p=O.Ol. RR3.2). hemoglobin Ale (25.9, p=O.O4, RR4.2). The same result 
was obtalned in the analysis of subgroup at higher working age (55 to 64, n=802). In con- 
trast, significant risk factor for asymptomatic infarction (n=36) in healthy seniors (> 6i) 
was male gender (p=O.OOS, RR4.7). DD genotype of ACE was a possible risk factor 
(p=O.O7, RR2.4). Risk factors for early atherosclerotic changes (hyperintensity) detected 
by brain MRI at working age were systolic blood pressure (>I50 mmHg), hemoglobin Ale 
(z&9), current smoking, triglyceride (>150 mg/dl) and HOMA index (>4, index for insulin 
resistance by hameostasis model assessment). Conclusion: The strategy for prevention 
of CVD at working population is different from that of coronary artery disease. Controlling 
hypertension and obesity, improvement in Insulin resistance and prevention of oxidative 
stress should be more important than controlling cholesterol levels 
1097-I 93 The Mechanisms in Obesity-Related Hypertension 
Kazuko Masuo, Hideki Kawaguchi, Toshio Ogihara, Michael L. Tuck. Osaka University 
Med;cal School, Suita City Osaka, Japan 
Background: Obesity and obesity hypertension is a major problem, however, the precise 
mechanism has not been clarified yet. We reported that 1) sympathetic overactivity 
underlies weight gain-induced BP elevation over 1 yr study. 2) During the treatments with 
ARB and ACE inhibltor, plasma angiotensin II level does not directly regulate BP levels, 
but sympathetic activity affected by ang II might modulate chronlcally BP levels. 3) Family 
history of obesity is closely linked to sympathetic activation. Even in lean subjects genet- 
ically predisposed to obesity, sympathetic activation is a mediating mechanism underly- 
ing subsequent development of obesity. To evaluate the precise mechanisms in weight 
loss-Induced BP reduction, we conducted the present study. It is our expectation that any 
causal contribution of weight loss (WL) to changes in sympathetic activity, ang II, insulin, 
leptin and BP would become evident. Methods: 17 lean hypertensives, 25 obese normo- 
tensives and 52 obese hypertensives were measured BMI, BP, plasma norepinephrine 
(NE), ang I/, insulin, leptin in every 2 wk during 24 wks with WL program. Results: At 
entry period, BP and plasma NE were greater in order of obese HT > lean HT > obese 
NT, although BMI and ang II were similar between obese NT and obese HT. The %reduc- 
tion in BMI was similar during the study between the 3 groups. In lean HT, plasma NE 
increased at Zwks and then decreased significantly at 4wks, but at 4 wks BMI and BP did 
not change. BP and BMI decreased significantly at 8 wks and 10 wks, respectively. Ang 
II, insulin and leptin decreased following BMI decrease (10, 10, 12 wks). In obese NT, 
NE, BP, BMI and ang II decreased at 8, IO, 12 and 16 wks, respectively. The significant 
decreases in insulin and leptin were noted later at 20 wks. In obese HT, decreases in 
every variables were noted later than obese NT and lean HT (NE at 12 wks, ang II 18 
wks, BP 16 wks, BMI 20 wks, leptin 20 wks, insulin 24 wks). Of importance, in the 3 study 
groups a decrease in plasma NE was noted prior to BP fall and weight loss. Conclusion: 
Suppression of sympathebc activation appears to play a major role in weight loss- 
induced BP fail. These results appear to add evidence that sympathetic overactivity is a 
predlctor of obesity. 
1097-194 Value of JNC VI Pressure Classification in Reflecting Global 
Cardiovascular Risk 
Jaime Levenson, Jerome Gariepy, Gilles Chirom Jean-louis Megnien, Alain Simon. 
Hopita/ Broussais, Paris, France 
Background : JNC VI and WHO-ISH blood pressure (Systolic/ Diastolic mmHg) catego- 
ries [ Optimal (0):<120/80 ; Normal (N)c130/85 ; High Normal (HN). 130-139 or 85-89; 
Mild Hypertension (MHt): 140-159 or 90-99 ; Moderate to Severe Hypertension 
(MSHt):>=IBO or 100 ; Systolic Hypertension (SHt) >=I40 and <90 ; Treated Hyperten- 
sion (THt) ] result in lowering substantially the threshold above which pressure is consid- 
ered normal and may induce overcosts of diagnosis and treatment. Objective : We 
compared between these 7 pressure categories, the Framingham risk score (%at 10 
years). and ultrasound common carotid artery far wall intima-media thickness (IMT), in a 
ger;eral population of 326 men and 462 women, 17 to 65 years, working in an insurance 
company (AXA cohort) and free from cardiovascular disease. Results : Data are shown 
in the Table, as age and sex-adjusted means (SE). 
categoric 0 N HN MHi MSM slit TM P global 
N”lTlbW 38 122 263 220 21 69 55 
RlSk % 18 (0.6) 2.1 (0.3) 3.3 (0.2) 6.3 (0.2)’ 10 9 (0.8)’ 6.0 (0 4)’ 9 0 (0.5)’ c.001 
mAT mm 0.49 (01) 0.50(.01) 051 (01) 055 (.Ol) 0.61 (.ixy 053 l.01) OS2 (.m)* <.om 
* denote p<O.Oi, for comparing N to other pressure categories Conclusion : Risk score 
and IMT of Optimal, High normal and Mild and Systolic Hypertension categories did not 
differ from Normal, except risk score higher in Mild and Systolic Hypertension as the con- 
sequence of their higher blood pressure. In contrast both risk score and IMT were notably 
higher in Moderate to Severe and Treated Hypertension than in Normal category. As the 
Framingham risk score and overall the carotid IMT both reflect the integrated effects of 
multiple risk factors over time, our findings question the relevance of JNC VI pressure 
classification as regards global cardiovascular risk assessment in the lower pressure 
range of asymptomatic population. 
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816 Unstable Plaque and Plaque Stabilization 
Monday, March 19, 2001, 9:15 a.m.-lo:30 a.m. 
Orange County Convention Center, Room 304A 
816-I 
9:15 a.m. 
Unstable Human Atherosclerotic Plaques and Thermal 
Heterogeneity: Role of the Uncoupling Protein UCP-2 
Stefan Verheye, Michiel W. M. Knaepen, Wim Martinet, Guide R. Y. De Meyer, Arnold G. 
Herman, Mark M. Kockx. Cardiovascular Transla lional Research Institute Middelheim 
Antwerp, Antwerp, Belgium, Division of Pharmacology Univewty of Antwerp, Antwerp, 
Belgium 
Background: Unstable atherosclerotic plaques are prone to rupture at the site of the thin 
fibrous cap and its increased macrophage accumulation. Recent data have shown that 
these plaques in unstable angina are associated with elevated temperature. However, the 
reason for this thermal heterogeneity is unknown. Since mitochondrial uncoupling pro- 
teins (UCP) are homologues of thermogenin (UCP-1; involved in the thermogenesis in 
brown fat tissue), we hypothesized that these proteins could explain the molecular mech- 
anism of thermal heterogeneity. Methods: Human carotid endarterectomy specimen at 
variable stages of disease were studied by laser capture microdissection followed by 
real-time quantitative RT-PCR, TUNEL and immunohistochemistry. Results: In adaptive 
intimal thickening and normal media, smooth muscle cells did not express UCP-2 but 
showed a weak expression of UCP9. However. in advanced and complicated atheroscle- 
rotic plaques, a dense infiltration of macrophages with a sub-population strongly express- 
ing UCP-2 and UCP-3, was seen. Microdissection by laser capture showed that these 
macrophages mainly expressed UCP-2 mRNA. In addition, the UCP-2 positive macroph- 
ages were associated with oxidized lipids, iNOS and nitrotyrosine. A fraction of these 
UCPP positive macrophages showed signs of caspase-independent cell death. Conclu- 
sion: Human atherosclerotic plaques are associated with an Increased and focal accu- 
mulation of UCP-2 posrtive macrophages which could explain the thermal heterogeneity. 
The increased UCP-2 expression could reflect a response to the Increased oxidative 
stress and fatty acid accumulation in plaques finally resulting in cell death by ATP deple- 
t1on 
816-2 
9:30 a.m 
Hot and Acidic Atherosclerotic Plaques Are More 
Vulnerable to Rupture 
Mohammad Madlid, Mohammed Asif, Sameh Naguib, Said Siadaty, James T Willerson. 
Ward Casscells, Morteza Naghavl. University of Texas-Houston, Houston, TX 
Background: We have discovered that human carotid endarterectomlzed plaque (CEP), 
atherosclerotic rabbit aorta, and ApoE deficient mice aorta, by virtue of inflammation, 
show marked temperature (T) heterogeneity in contrast to normal arterial wall. Recently, 
we showed that these plaques are also heterogeneous with respect to pH. Methods: 
Immediately after removal from the body, CEPs were kept in a biological media (DMEM) 
at 37C for 30 minutes. Next. in a 37C incubator with humidity > 95%, we used a glass- 
type pH microelectrode and a needle-type thermocouple electrode to measure pH and T 
of different points on 8 CEPs from 8 patients. The same procedure was performed on 11 
normal human umbilical arteries. Also, in order to study microscopic pH heterogeneity 
and features of vulnerability, 10 fresh CEPs were snap-frozen and cryo-sectioned. Next, 
multiple serial sections were prepared and pH fluorescence single and dual emission 
imaging was performed on first slide, and the following stainings were performed on the 
adjacent serial sections in each part: H&E, Movat, macrophage (CD68+), and Oil Red 0 
staimng. Reesults: 1) Areas with lower pH showed higher T (r=0.94, p<O.OOl). Areas con- 
taining large lipid core had lower pH with higher T, whereas calcified regions had lower T 
and higher pH (pcO.001). The pH in lipid-rich areas was lower than that of both calcified 
areas and normal umbilical arteries (p<O.OOi). (2) In microscopic pH imaging, foci with 
highest pH were foci of calcification, and areas with lowest pH were associated with a 
large lipid core and macrophage infiltration. Conclusion: 1) Plaque T and pH are 
inversely correlated, suggesting that hot plaques are acidic 2) plaques with a large lipid 
core, macrophage infiltration, and no calcification (vulnerable plaques) have lower pH 
than calcified and fibrotic (stable) placlues. 
816-3 
9:45 a.m. 
Inhibition of Transcription Factor NF-kB Abolishes Matrix 
Degrading Enzyme Production by Foamy Macrophages. A 
Potential Strategy to Promote Plaque Stability+ 
Alex J. Chase, Andrew C. Newby. Bristol Heart Institute, University of Bristol, Bristol. 
Umted K!ngdom 
Background: The unstable plaque is characterlsed by a high content of inflammatory 
cells which secrete the matrix degrading metalloproteinases leading to regions of weak- 
ness in the fibrous cap prone to rupture. InhIbition of matrix metalloproteinases would be 
a powerful strategy to promote plaque stability. We investigated the role of transcription 
factor NF-kB in the regulation of metalloproteinase-I and -3 and -9 secretion by foamy 
macrophages. 
Methods: Foam cells were isolated from sub-cutaneous granuloma in cholesterol-fed 
rabbits and characterised by immunocytochemistry and oil red 0 stain. Adenoviral infec- 
tion conditions were optimised using adenovirus carrying a p galactosidase reporter 
gene. Cultured foam cells were uninfected or infected with either adenovirus carrying the 
NF-KB Inhibitory subunit I-da or control virus with an empty expression cassette. Condi- 
tioned media were generated by incubating the cells in fresh serum free medium 24 
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hours after infection for a further 48 hours and analysed for metalloprotefnase content by 
western blot for metalioproteinase-I and -3 and gelatin zymography for metalloprotein- 
ase-9. 
Results: Macrophage lineage of isolated cells was confirmed by positive immunocy- 
tochemistry with a rabbit macrophage specific antibody. Oil red 0 staining demonstrated 
a heavy burden of lipid droplets confirming their foamy nature. A multiplicity of infection of 
200 virus par cells gave 100% infection efficiency as determined by tran:gene expres- 
sion via X-gal staining. Uninfected or control virus infected foam cells constitutively 
expressed metalloprotelnase-1 and -3 and -9. Over-expression of I-KB~ resulted in com- 
plebe inhibition of metalloproteinase-1 and -3 secretion. In contrast constitutive produc- 
fion of metalloproteinase 9 was not reduced. 
Conclusion: Constitutive secretion of foam cell metalloproteinases -1 and -3 is abso- 
lutely dependent on transcription factor NF-KB. Metalloproteinase -9 is NF-kB indepen- 
dent. The major substrates for metalloproteinase -1 and -3 are the structural proteins 
interstitial collagen and elastm respectively supporting the concept of NF-rB inhibition as 
a therapeutic strategy to promote plaque stability. 
816-4 
IO:00 a.m. 
Coronary Plaque inflammation in Relation to Angiographic 
Appearance of Coronary Narrowings 
Martijn Meuwissen, Allard 6. van der Wal, Jan J. Pi& Steven A. J Chamuleau, Karel T. 
Koch, Anton E. Becker. Academic Medical Center, Amsterdam, The Netherlands 
Background: Complex morphology of coronary narrowings documented by coronary 
angiography and plaque inflammation have been related to unsiable coronary syn- 
dromes. We evaluated the association between qualitative angiographic analysis of coro- 
nary lesions and plaque inflammation documented by immunohistochemistry. Methods: 
A total of 107 patients with stable and unstable angina underwent directional coronary 
atherectomy (DCA) for culprit lesions. Cryostat sections of atherosclerotic plaques were 
immunohistochemically stained with the monoclonal antibodies, alpha-a& (smooth 
muscle cells; SMC), CD-68 (macrophages; MAC) and CD-3 (T-lymphocytes; T-cells). The 
extent of atherosclerotic plaque inflammation of the coronary lesion was determined by 
MAC and T-cells, planimetrically quantified as the percentage immunopositive tissue area 
of the total tissue area (MAC) or counted per mm2 (T-cells). Two interventional cardiolo- 
gists who were blinded to the results of the immunohistochemical analysis classified cor- 
onary lesions following Ambrose’s classificzdion. The table below shows the relation 
between coronary plaque inflammation and Ambrose classification. 
Ambrose class % MAC T-cells I mm2 % SMC 
Concentric (n=15) 13+9 15r8 32+19 
Eccentric type I (n=37) 9r5 iO+6 3oi15 
Eccentric type I (n=37) 25 t13*t 18+15* 20r15 
Multiple irregularities (n=lZ) 25+16t 19513 29213 
“p=O.O05 and tp<O.OOOl compared to concentric and *p<O.O5 compared to eccentric 
type I (ANOVA). Conclusions: There is a positive association between the extent of ath- 
erosclerotic plaque inflammation and angiographlc grading of coronary Iwon complexity 
according to Ambrose. 
816-5 
1095 a.m. 
High Dose R-Apo-A-lmilano Mobilizes Tissue Cholesterol 
and Reduces Plaque-Lipid and Macrophages Within 48 
Hours: Implication for Rapid Plaque Stabilization 
Predlman K. Shah, Juliana Yano, Charles L. Bisgaier, Odette S. &yes, X. Helen Xu, M.k. 
McMurty, S. Drake, Sanjay Kaul, Kuang-Yuh Chyu, Bojan Cercek. Atherosclerosis 
Research Center. Cedars-Sinai Medicla Center, Los Angeles, CA, Esperion 
Therapeutics, Inc, Ann Arbor, 1111 
Background: We have previously documented anti-atherogenic effects of multiple doses 
of apo A-l milano phospholipid complex (A-l m) in hyperlipidemic mice. In this study we 
tested the hypothesis that a single large intravenous dose of A-lm will rapidly mobilize 
tissue cholesterol and reduce plaque lipid and macrophages in hyperiipidemic apoE null 
mice. Methods: 25 week-old apoE null mice received a single dose of A-lm (400 mglkg) 
or buffer intravenously. Serum cholesterol efflux promoting capacity (Effluxcap) was mea- 
sured before and 1 hr after treatment. Plasma total (TC) and free cholesterol (FC) levels 
were measured before and 48 hrs after treatment. Mica were sacrificed 48 hrs after treat- 
ment and plaque lipid content by oil-red-O stain and macrophage immunoreactivity ware 
measured in aortic plaques and expressed as % plaque area. Results: Pre-treatment TC 
(87&l&3 vs 761+112 mgidl, p=ns), FC (366169 vs 345155 mg/dl, p=ns) were similar 
between A-l m and buffer groups. One hr after A-l m injection, there was a 60% increase 
in Effluxcap (~~0.05, n=6). At 48 hrs there was a significant increase of FC in A-l m recip- 
ients compared to buffer group indicative mobilization of tissue cholesterol. This is asso- 
ciated with a concomi&nt significant decrease in plaque-lipid content and macrophage 
content (see table). Buffer alone did not significantly change Effluxcap at 1 hr or seruni 
TC and FC levels at 48 hrs. Conclusion: High dose r-apo A-lmilano increases Effluxcap 
within 1 hr and reduces plaque-lipid and macrophage within 48 hrs in apoE null mice sug- 
gesting a rapid plaque-stabilizing potential for r-ape-A-lmilano. 
ORAL CONTRIBUTIONS 
817 Clinical Studies of Endothelial Function 
Monday, March 19, 2001, 9:15 a.m.-l 0:30 a.m. 
Orange County Convention Center, Room 304E 
817-I 
9:15 a.m. 
Reduced Shear Stress-Induced, Nitric Oxide-Mediated, 
Dilation of the Microvasculature in Hypertensive Patients 
Oscar A. Paniagua, Melissa 6. Bryant, Julio A. Panza. National institutes of Health, 
Bethesda, MD 
Background: Patients with essential hypertension have impaired endothelium-depen- 
dent vasodilation to pharmacologic agents; however, whether this abnormality extends to 
physiologic stimuli is noi known. In this study, we tested the hypothesis that shear stress- 
induced dilation of the microvasculature is impaired in hypertensive patients due to 
reduced contribution of nitric oxide (NO). Methods: Subcutaneous arteries (internal 
diameter: 201+26 wm) were isolated from giuteal fat biopsies in 9 normotensive subjects 
(6 men; age: 46*8 years), and 12 hypertensive patients (5 men; age: 50r7 years). Arte- 
rial preparations were cannulated and perfused in chambers oxygenated at 37” C. After 
preconstriction with norepinephrine (NE, IO-7 M), shear stress was induced by stepwise 
increases in the periusate flow rate from 1 to 50 pUmin. Flow-dependent dilation was 
repeated after 30-min incubation with the NO synthase inhibitor N-nitro-L-arginine (L- 
NNA, 10-4 M). Arterial internal diameter was measured from amplified images. Data are 
expressed as percent of NE-induced contraction. Results: In arteries from normal con- 
trols, shear stress induced progressive vasodilation from 77~9% at 1 pL/min to 47i43% 
at 50 I.IL/min (p<O.OOl), which was abrogated by removing the endothelium. L-NNA slg- 
nificantly blunted the response to increases in flow (mean vasodilation before and after L- 
NNA: 73r6% vs. 94+6%, respectively; p=O.O4). Arteries from hypertensive patients had 
significant impairment of flow-mediated dilation compared to controls (mean vasodilation: 
95+2% vs. 73+6%, respectively; p=O.Ol). L-NNA did not significantly affect shear stress- 
induced dilation in hypertensive arteries (mean vasodilation before and after L-NNA: 
9&Z% vs. 89r2%, respectively; p=O.l2). Conclusion: In the normal human microvascu- 
lature, increased shear stress induces endothelial NO-dependent vasodilation. This 
mechanism is impaired in essential hypertension and may be responsible for the genesis 
and/or consequences of the vascular abnormalities characteristic of the hypertensive 
process. 
817-2 
9:30 a.m. 
Coronary Microvascular Endothelial Dysfunction is 
Associated With an increased Risk of Acute Cardiovascular 
Events During Long-Term Follow-Up 
Julian P J. H&ox, Gloria Zalos, Rita Mincemoyer, William H. Schenke, Myron A. 
Waclwiw, Khaled R. A. Nour, Abhlram Prasad, Arshed A. Quyyumi. NIH, Bethesda, MD 
Background: An association between endothelial dysfunction and impaired cardiovascu- 
lar outcome has been described in small studies where the majority of events were 
revascularization procedures. Moreover, the prognostic value of endothelial function in 
the absence of coronary atherosclerosis (CAD) is unknown. We therefore investigated 
the relationship between coronary vascular endothelial function and the occurrence of 
acute unpredictable cardiovascular events (E: cardiovascular death, myocardial infarc- 
tion, stroke and unstable angina) in patients with and without CAD. Methods: We mea- 
sured the change in coronary vascular resistance (dCVR) with intracoronary ACH 
(Ifimcgimin) and sodium nitroprusside (SNP, 20mcg/min), to test endothelium-depen- 
dent and -independent vascular function. respectively, in 300 patients undergoing cathe- 
terization (129 with CAD and 171 with normal coronary arteries [NCA]). Patients 
underwent clinical follow-up for a mean duration of 46 months (range 6-96). Results: E 
occurred in 34 patients. Vasodilation with ACH was attenuated in patients with E com- 
pared to those without E (dCVR= -29k.6 vs -42+2% respectively, p=O.Ol), whereas dCVR 
with SNP was similar in both groups (-48~4 vs -52+2%, ~~0.44). After a Cox Proportional 
Hazards multivariate analysis including risk factors for endothelial dysfunction (CAD, cho- 
lesterol, age, sax, body mass index, smoking, diabetes, hypertension) dCVR with ACH 
(RR=2.9, p=O.Ol), together with diabetes (p=O.O4), CAD (p=O.O03), body mass index 
(p=O.O003), and smoking (p=O.O3) were independent predictors of E. Furthermore, when 
the study population was divided into 3 equal groups according to dCVR with ACH, sur- 
vival by Kaplan-Meier analysis was significantly better in the tertile with the best 
response to ACH in the total population (p=O.O29), and also in the subset with NCA 
(p=O.O38). Conclusions. Coronary microvascular endothelial dysfunction is an indepen- 
dent predictor of acute cardiovascular events in patients with and without CAD. Thus the 
response to the endothelial agonist provides both functional and prognostic information 
that complements results of coronary angiography and risk factor assessment. 
Plaque-lipid Macrophaqe 
Buffer 19.7+/-6.4 n=l6 
Al-m lO.Z+/-4.3* n=l8 
‘I*’ ~~0.05 compared to buffer group 
10.4+1-3.4 n=12 
6.4+/-2.0* n=l2 
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9:45 a.m. 
Abnormal Coronary Vasomotion in Response to 
Acetylcholine Predicts Increased Cardiac Events in Women: 
Data From the NHLBI-Sponsored Women’s lschemia 
Syndrome Evaluation (WISE) Study 
Greg 0. van Merlng, Carl J Pepine, Susan P. McGonay, Dawn M. Miller, C. Noel Bairey 
Merz, Sheryl F Kelsey, Nathaniel Reichek, Steven E. &is, William J. Rogers, Barry L. 
Sharaf, George Sopko. Richard A. Kerensky. University of Florida College of Medicine, 
Gamesvi//e. FL 
Background: Endothelial function (vasodilator response wrth acetylcholine [Ach]) and 
endothelium independent microvascular function (coronary flow reserve [CFR] following 
adenosine [ado]) are linked to CAD and its risk tacror conditions in predominantly male 
populations but these relationships have not been firmly established in woman. Meth- 
ods: One hundred and sixty three women with chest pain and atherosclerosis risk factors 
referred for coronary angiography underwent coronary reactivity assessment and short 
term follow-up. Quantitative coronary angiography and intracoronary Doppler flow follow- 
ing intracoronary Ach and Ado ware used to assess vascular reactivity. Women were cat- 
egorized on the basis of angiography as no CAD (n=75). mild CAD @O-49% stenosis. 
nS0) and significant CAD (250% stenosis, n=38). Outcome defined as first recorded 
event included hospitalizabons for increased angina, myocardial infarction, stroke and 
coronary revascularization. Results: A total of 13 cardiac events in 92 women were 
recorded in follow-up (median 0.94 years, maximum 2.2 years). In multivariate analysis 
that included age, hypertension, diabetes, dyslipidemia and tobacco use, only response 
to Ach (p=O.O49), defined as percent change in vessel cross sectional area (%ACSA), 
and significant CAD (p=O.Ol) independently predicted cardiac events. For those with 
events, 1303 had constriction or no dilation with Ach (p=O 001). Of these, 4113 had none. 
2113 had mild and 7113 had severe CAD. The %ACSA with Ach varied significantly with 
CAD severity with median values: 8 16% for none, 0% for moderate and -14.79% for sig- 
nificant (p=O.Oi 1). In an artery without stenosis, volumetric CFR with Ach, but not with 
Ado varied significantly with CAD with median values. 1.59 for none, 1.65 for mild alnd 
1 .OO for significant (p=O.O37). Flow mediated vasodllation in response to Ado (%ACSA) 
was associated with CAD severity (p=O 038), but Ado associated CFR was not (~~0.25). 
Conclusions: In women, impaired response to Ach is linked to CAD. but is indepen- 
dently associated with adverse cardiovascular outcomes over short-term follow-up. No 
association between CFR with Ado and outcome was detected. 
817-4 
IO:00 a.m. 
Peripheral Arterial Tonometry: A Simplified Technique for 
Assessing Endothelium-Dependent Vasomotion 
Jeffrey T. Kuvin, Ayan Ft. Pa&l, Kathleen A. Sliney, Jacob Sheffy, Robert R Schnall, 
Natesa G. Pandian. Richard H. Karas, James E Udelson. Tufts-New England Medical 
Center, Boston. MA 
Background: impaired endothelium-dependent vasomotion (EDV) is an important 
marker of early atherosclerosis Current methods for assessrng EDV are valuable 
research tools, but are technically challenging, limiting their routine clinical use. Periph- 
eral arterial tonometry (PAT) is a novel, easily performed technique for plethysmographic 
recording of finger arterial pulsatile amplitude. We examined the correlation between bra- 
chial artery ultrasound (BAUS), a well-validated method, and PAT for the evaluation of 
EDV. 
Methods: BAUS and PAT were simultaneously performed in 119 fasting subjects (51 
women): 22 with no cardiovascular risk factors (RF) orcoronary artery disease (CAD), 75 
with RF but no CAD, and 22 with CAD (determined by SPECT myocardial perfusion 
imaging). EDV was assessed during reactive hyperemia induced by transient brachial 
artery occlusion. EDV by BAUS was expressed as par cent flow-mediated dilation (FMD); 
EDV by PAT as the hyperemic increase relative to the baseline pm-hyperemic signal. 
Endotnelium-independent vasodilation after sublingual nitroglycerin was also measured. 
Results: Subject age was 52+1 years (meaniSE, range 23.80). 40% had a history of 
hypertension, 37% had hyperlipidemia, and 8% had diabetes. The mean FMD was 
lO.liO.5% and the mean PAT score was 1.6iO.06. Regression analysis revealed a signif- 
icant relationship between BAUS and PAT for the measurement of EDV (p<O.OOl). There 
was a step-wise relationship between PAT and BAUS ranging from a FMD of 7.4?0.6% 
and a PAT score of 1.4iO.l in the lowest FMD quartile to a FMD of 12.9~1.1% and PAT 
score of 2.OiO.l in the highest quartile (p=O.O09 for trend). Subjects with abnormal EDV 
(FMD ~10%) had a PAT score of 1.4iO.07. whereas those with normal EDV (FMD 110%) 
had a PAT score of 1 720.08 (p=O.OOOB). PAT scores were higher (1.7iO.09) in subjects 
with <3 RF than those with >3 RF (1.4iO.07) (p=O.Ol). Assessment of endotheiium-inde- 
pendent vasomotion by BAUS and PAT also correlated highly (p=O.OOZ). 
Conclusion: Evaluation of EDV by PAT correlates with BAUS in subjects with and with- 
out RF and/or CAD. Because of its relatively easy application, PAT has the potential for 
widespread clinical use to non-invasively assess EDV. 
817-5 
IO:15 a.m. 
inhibition of Oxidative Iron-Catalyzed Reactions Restores 
the Matching Between Myocardial Oxygen Demand and 
Coronary Blood Flow in Type 2 Diabetic Patients With 
Normal Coronary Arteries 
Alain Nitenberg, Severme Ledoux, Paul Valens~, lsabelle Antony. H&~ita/ Louis Mot&r, 
Colombes, France, CHU Xavier B/chat, Paris, France 
Background: In type 2 diabetic patients (DTZ), endothellum-dependent dilation of epicar- 
dial coronary arteries and coronary microcirculation are impaired. This results in a mis- 
match between myocardial metabolic demand and coronary blood flow. It has been 
shown that a small dose of desferrioxamine (DFX). an iron chelator, may restore a nor- 
mai vasodilation of epicardial coronary arteries, suggesting that nitric oxide may be inac- 
tivated by increased superoxide anion production in diabetes mellitus. Methods: In order 
to assess the effects of DFX on coronary microvascular vasodilation when myocardiai 
oxygen demand is enhanced by a cold pressor test (CPT), 17 DT2 with angiographically 
normal coronary arteries and without any other coronary risk factor were studied. Coro- 
nary blood flow was measured in the left anterior descending coronary artery usrng intra- 
coronary Doppler and quantitative coronary angiography at baseline and during a CPT 
before and after intravenous administration of 50 mglmin DFX during IO minutes. 
Results: Rate-pressure product (RPP) increase during CPT was similar before and after 
DFX (+21.li8.7% vs 20.5&.9%, respectively, NS) Coronary blood flow increase was 
significantly higher after DFX (+6.3+12.9% before DFX vs 31.8~167% after DFX, 
P=O.OOOl). Moreover, when coronary resistance increased during CPT before DFX, it 
decreased after DFX (+14.8+21.9% vs -7.9tl0.9%, respectively, P=O.O02) Last, before 
DFX there was a negarive relationship between percent increases in coronary blood flow 
and RPP (rz0.546, PcO.O05), and a positive relationship between these 2 parameters 
after DFX (r=O518, P<O.O05). Conclusion: In type 2 diabetic patients, endothelium- 
dependent vasodifation of the coronary microcirculation is restored when iron-catalyzed 
oxidative reactions are inhibited by DFX, which demonstrates that production of oxygen- 
derived free radicals IS involved in endothelium-dependent impairment of metabolic coro- 
narv microcirculation vasodilation. 
ORAL CONTRIBUTIONS 
826 Treatment of Pulmonary Embolism and 
Pulmonary Hypertension 
Monday, March 19, 2001, Ii:00 a.m.-12:15 p.m. 
Orange County Convention Center, Room 304A 
826-l 
11 :oo a.m. 
A New Treatment of Pulmonary Hypertension: Simultaneus 
Pulsatile Inhalation of Nitric Oxide and lloprost 
Johannes Schaar, Olaf Oldenburg, Guido Caspari, Achim Gutersohn, S&fan Sack, 
Raimund Erbel. Department of Cardiology, Essen, Germany 
Prostacyclin improves the survival in pulmonary hypertension (PH). To overcome the 
problem of systemic side effects, vasodilators (e.g. NO) have been delivered by inhala- 
tion. To test whether simultaneous pulsatile inhalation of NO and iloprost, a prostacyciin 
analog, results in an additive vasodllator effect, 10 patients were tested with NO and ho- 
prost separately and simultaneously. Methods: Ten patients with primary and secondary 
PH were enrolled in the study. PH was verified by right heart catheterisdion. Simulta- 
neous inhalation of NO and lloprost (Ilomedine, Schering, Germany) were performed 
using especially constructed nebulizer. During inhalation hemodynamics were measured 
continuously by Swan-Ganz catheter Results: Reduction of pulmonary vascular resis- 
tance (PVR) was seen after NO and lloprost inhalations separately, further reduction 
could be measured when patients inhaled the two vasodilators simultaneously. 
Baseline NO (10 pm) lloprost NO + lloprost 
(Before NO) 
HR (beatsimin) 85 +I- 17 81 +I- 16 86 +/- 16 81 +I- 14 
CO (liter/min) 3.1 +/- 1.2 3.3 +/- 1.2 3.9 +/- 1.3 4.2 +I- I .2 
Cl (literlminim2) 2.2 +I- 0.7 2.1 +/- 0.8 2.5 +/- 0.7 2.6 +I- 0 7 
SAP mean (mmHg) 95 +/- 12 93 +/- 12 86 +I- 15 84 +/- 12 
PAP mean (mmHg) 65 +/- 11 58 ii- 10 51 ii- 10 42 +I- 14 
PCWP (mmHg) 12+/-6 14+/-7 12+/-8 14+/-g 
PVR (dyn’s’cm-5) 1355 +/- 601 1011 +/- 501 769 +/- 438 577 +/- 399 
Conclusions: Reduction of PVR was monitored using novel simultaneous pulsatile inha- 
lation of NO and aerosolized iloprost. There was an additive effect of the two substances 
resulting in an optimized reduction of pulmonary pressure. Thus, this new form of appll- 
cation could represent a new therapeutic option in the treatment of pulmonary hyperten- 
sion. 
826-2 
II:15 a.m. 
Increasing Right Ventricular Systolic Pressure (RVSP) After 
6 Months of Prostacyclin for Primary Pulmonary 
Hypertension Predicts Worse Long-Term Survival Than 
Decreasing or Unchanging RVSP 
Xing-Guo Sun, Ronaid J. Oudiz, Karlman Wasserman. Harbor-UCLA Medical Center, 
Jorrance. CA 
Background: The immediate hemodynamic response to prostacyckn (PGI2) has not 
been shown to reliably predict long-term survival in patients (pts) with primary pulmonary 
hypertension (PPH). We hypothesized that prognosis would be better revealed by the 
change in RVSP after 6 lmonths of PGl2 therapy, Methods: From 1992 to 1999, a single- 
center database of severe PPH pts treated with continuous intravenous PG12 was ana- 
lyzed. All pts had right heart catheterization at baseline. Dosage of PG12 was adjusted 
based on standard clinical indications. At 6 2+1-0.7 months of PGIZ, follow-up echocar- 
diography was performed in 61 PPH pts to serially estimate cardiac output (CO) and right 
ventricular pressure gradient (RVPG), as a surrogate for RVSP. We separated pts into 3 
different response groups: 1) an increase in RVPG?lO%; 2) no change in RVPG (~10%); 
and 3) a decrease in RVPG>IO%. Kaplan-Meier survival curves for each group were 
generated using death or transplantation as endpoints. The log-rank test was used for 
statistical analysis. Results: As shown in figure below, PPH pts on PG12 therapy for 6 
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months with a” increased RVPG (group 1, n=lO) had a worse prognosis than those with 
a” unchanged (group 2, n=13) or decreased RVPG (group 3, “=38) (pcO.05). The group 
1 survival rate was similar to that of non-PGIP, conventionally-treated PPH pts in the NIH 
registry (p>O.O5). In contrast, pts with a decreased or unchanged RVPG had better sur- 
vival rates (p<O.Oi). The changes in CO and TPVR and ihe absolute RVPG values at 
baseline and after 6 months of PGl2 (not show”) did not predict long-term survival 
(P>O.O5). 
t 
x 
-Group 3 (Decreased RVPG) 
.? --.- - 60 Group 2 (1 O%>ARVPG>-10%) 
z -------... i Grnup 1 (Increased RVPG) 
II 1 2 3 1 5 6 7 I 
Time (yearj 
Conclusions: PPH pts with increased RVPG after 6 months of PGl2 have a worse prog- 
now than those with decreased or unchanged RVPG. The PPH pts with increased 
RVPG had similar survival rate to that of non-PGl2, conventionally-treated PPH pts in the 
NIH registry. 
826-3 
Ii:30 a.m. 
Predictors of Long Term Follow-up After Thrombolytic 
Therapy in Acute Massi\ie Pulmonary Embolism 
Marie-France Seronde, Liu Pin Ming, Nicolas Meneveau, Francois Schiele, Luc 
Doutrelant, Florent Brian& Yvette Bernard, Jean-Pierre L. Bassand. University Hospifal 
Jean-Minjoz, Besancon, France 
Background: Few data on long term follow-up (FU) after thrombolytic therapy (TT) in 
massive pulmonary embolism (MPE) are available. Late evolution and prognosis after 
MPE are insufficiently documented. Methods: From January 1989 to October 1998, 260 
patients (pts) with MPE were submitled to TT Late FU results were determined using a 
composite endpoint defined as survival with no recurrent embolism or deep vein throm- 
bosis (DVT), bleeding complications or congestive heart failure. FU of pts was done by 
telephone contact with the referring physician. Multivariate analysis was carried out on 
165 pts for whom complete data was available. Statistical analysis used Cox proportional 
hazard regression to identify predictors of long term survival, using the following vari- 
ables: age, sex, body mass index, hypertension, previous thrombo-embolic disease, can- 
cer, diabetes, obstructive pulmonary disease, location of DVT, duration of anti-vitamin K 
treatment, vena cava filter; as well as right ventricular (FiV) dysfunction (dilation), systolic 
pulmonary artery pressure @PAP) (by echo) and pulmonary vascular obstruction data, 
pre- and post-TT Results: Mean FU was 5.7127 years. 22 pts died during the in-hospi- 
tal phase and were excluded from further analysis. 11 pts (4.2%) were lost for FU. The 
total number of predefined events was 118 (51.9%). 72 pts (31.7%) died during FU from : 
cancer (24/72), congestive heart failure (E/72), recurrent PE (21172) and other causes 
(19/72). Recurrent embolism was observed in 12.3% of pts; recurrent DVT in 13.6%; right 
heart failure in 20.2% and bleeding events in 4.4%. Conclusion: Independent predictors 
of event free survival are shown in the table. Long-term evolution of pts with MPE submit- 
ted to TT is dependent a” adequate pulmonary artery revascularization and may be 
detected early by non-Invasive techniques. These results justify systematic transthoracic 
echocardiography and lung scintigraphy before hospital discharge and warrant the inves- 
tigation of alternative therapy in pts with incomplete clot resolution after TT. 
sPAP 
RV dysfunction 
10 day pulmonary obstruction ~-30% 
Risk 95%CI P 
Ratlo 
3.78 [2.7;5.86] <0.0001 
2.18 [1.48;2.88] ~0.0001 
1.99 [1.25;2.7] <0.0001 
826-4 
ii:45 a.m. 
D-Dimer and Spiral CT Strategy in the Diagnosis of 
Pulmonary Embolism: a Prospective Trial 
Gerard D. Pacouret, Benedicte Delahousse, Daniel Allson, Veronique Eder, Anne 
Delhomais, Jean Maw Potier, YVIZS Gruel, Bernard Charbonnier. TROUSSEAU 
HOSPITAL, TOURS, France 
Background : D-Dimer (DD) is a valuable test to rule out the diagnosis of pulmonary 
embolism (PE), when Elisa methods are used but negative predictive value (NPV) of 1st 
generation latex methods IS not judged as optimal. Spiral CT has been prove” also, in the 
last few years, to have a both a high NPV and a high positive predictive value (PPV) on 
this field. The objective of this study was to test the value of the combination of these 2 
methods in PE diagnosis in the setting of a cardiovascular emergency room. Methods : 
during a” 18 month recruitment period, 147 consecutive out-patients (pts) with clinically 
suspected PE were screened. Exclusion criteria were : life threatening symptoms, con- 
traindication of spiral CT and/or pulmona!y angiography, curative anticoagulation > 48 H, 
PE history c 3 months. All patients were evaluated by 2 rapid DD tests (Vidas Blomerieux 
Elisa test and Llatest DD S&go, a 2nd generation latex method), Spiral CT and 2 refer- 
ence methods, duplex venous scanning and ventilation perfusion lung scan (V/Q). Pul- 
monary angiography was mandatory in patients with Intermediate or low probability V/Q 
and normal leg test. All diagnostic tests had to be performed within 48 H after admission. 
Blood samples were analyzed after the end of the recruitment period and the radiologist 
was unaware of the V/Q results. Results : 106 pts were suitable for analyzis. PE preva- 
lence was 45 % (48/l 06). Spiral CT was judged as not conclusive in 10 pts (10.4 %, PE+ 
n=2, PE- “=8). DD results were found negative (< 500 pg/L) in non PE pts in only 34,5 % 
of cases (20/58) for the Elisa method and in 43 % of cases (25158) for the latex method. 
Pulmonary angiography was performed in 15 pts. PPV and NPV of DD tests and spiral 
CT were as follows: 
% (n) PPV NPV 
DD Elisa 55.8 (48186) 100 (20120) 
DD latex 59.2 (48181) 100 (25125) 
Spiral CT 92 (46/50) 100 (46146) 
Conclusion : in the setting of a cardiovascular emergency room, a strategy of DD testing 
using either Elisa or 2nd generation latex rapid methods, followed by spiral CT in case of 
positive biological test appears highly effective to rule out the diagnosis of PE when it is 
clinically suspected. 
826-5 
Noon 
High Incidence of Silent Pulmonary Embolism in Patients 
With Atrial Fibrillation With Right Atrial Spontaneous Echo 
Contrast 
Yoshinori Yasuoaka, Johji Naito, Tare Okazaki, Noriko Sakamoto, Ryu Shutta, Junichi 
Yoshida, Katsuji Hashimoto, Wakatomi Chin, Hideo Kusuoka, Michitoshi Inoue, Yukihiro 
Koretsune. Osaka National Hospoifd, Osaka, Japan 
Background: It has been demonstrated that spontaneous echo conirast (SEC) detected 
within the cardiac chambers is connected with a” increased risk of thromboembolism. 
However, most of studies have reported the relation between left atrial SEC and embolic 
findIngs, including silent cerebral infarction. The aim of this study is io investigate the 
relation between right atria SEC and silent pulmonary embolism (PE) in humans. Meth- 
ods: Sixty patients with chronic, n~nvalvular atrial fibrillation, who had undergone transe- 
sophageal echocardiography (TEE), were divided into two groups; right atrial SEC(+) 
(“~35) and SEC(-) (n=25) groups. Paiients with a history of symptomatic PE or deep vein 
thrombosis were excluded. SEC was determined as smoke-like echoes that swirled in a 
circular pattern in the chamber by TEE. PE was diagnosed by perfusion isotope lung 
scan. Hematological parameters (fibrinogen, TAT and D-dimer) were measured in all 
patients. Results: There was no significant difference in hematological parameters 
between right atrial SEC(+) and SEC(-) groups, but the proportion of silent PE was signif- 
icantly large in right atrial SEC(t) (Chi-square, p=O.O06). Conclusion: High incidence of 
silent PE was observed in the right atrial SEC (+) group. Right atrial SEC may be a signif- 
icant parameter to predict cardiogenic PE. 
A Relation Between SEC and PE 
SEC(+) 
SEC(-) 
W+) PW1 
15 20 
2 23 
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827-i 
11:OO a.m. 
Novel Therapeutic Strategy to Maximize the Natriuretic 
Peptide System in Experimental Heart Failure: Acute 
Vasopeptidase Inhibition and Subcutaneous BNP 
Horng H. Chen, John G. Lainchbury, Margaret M. Redfield, John C. Burnett, Jr.. Mayo 
Clhc, Rochester. MN 
Background:Omapatrilat (OMA), a vasopeptidase (VP) inhibitor, is a molecule that 
inhibits both neutral endopeptidase 24.1(NEP), which degrades the natriuretic peptides 
(NP) and angiotensin-converting enzyme. Studies report that the cardiac hormone BNP 
is the most natriuretic and vasoactive of the NP, and which may reach a plateau in pro- 
duction in congestive heart failure (CHF) resulting in a relative deficiency. We have 
reported that subcutaneous (SO) administration of BNP in experimental CHF as hor- 
mone replacement therapy results in favorable cardiorenal responses. We hypothesized 
that acute VP inhibition would potentiate the cardiorenal actions of SQ BNP and com- 
bined therapy (VPI + SQ BNP) would maximize the biological actions of BNP in CHF 
Methods: We defined the cardiorenal and humoral actions of acute SQ BNP (5 microgml 
kg) alone (w5) and acute SQ BNP plus VP inhibition with OMA (1 micromol/kg iv bolus) 
(n=5), in anaesthetized dogs with CHF produced by rapid ventricular pacing for 10 days. 
Results: OMA + SQ BNP resulted in a greater increase in plasma BNP as compared to 
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SO BNP atone (56Oa 153 vs 295+ 135 pgiml ~~0.05) and prolonged the duration of the 
increase in plasma BNP from 60 to 300 minutes. This was associated in an increase in 
urinary BNP excretion, which was not observed with SQ BNP alone. The duration of the 
natriuretic response was also prolonged with OMA + SQ BNP by 200%. from 60 to 180 
minutes, which resulted in a greater increase in mean urinary sodium excretion with OMA 
+ SQ BNP as compared to SQ BNP alone (1892 20 vs 138 i 20 microEq/min P<O.O5) 
Urinary cGMP excretion was increased in both groups but the duration was greater with 
OMA + SQ BNR 120 as compared to 60 minutes with SO BNP alone. OMA + SQ BNP 
also resulted in a greater increase in cardiac output and reductions in cardiac filling pres- 
wres as compared to SC, BNP alone (PcO.001). Conclusions: This study reports for the 
first ttme that acute OMA administration potentiates the cardiorenal actions of SQ BNP in 
experimental CHF This study advances the concept that cardiac hormone replacement 
wtth SO BNP together with VP inhibition represents a novel therapeutic strategy in CHF 
to maximize the beneficial properties of the natriuretic peptide system 
827-2 
1 I:15 a.m. 
Increased Extracellular Signal-Regulated Protein Kinases 
and Apoptosis in Human Ventricular Myocardium With 
Severe Congestive Heart Failure 
Yafeng Dong, Ruxian Lin, John V. Contra, Jr., Joseph S. McLaughlin, Chiming Wei. 
University of Mary/and. Balfimore, MD. Johns Hopkins University: Baltimore, MD 
Background: Extracellular signal-regulated kinases (ERKs) belong to one subfamily of 
mitogen-activated protein kinases (MAPKs). MAPKs including ERKs are acknowledged 
to be one of the major proiein kinases regulating cell growth and apoptosts. To date, the 
expression of ERK and relationship with apoptosrs and apoptosrs-related gene expres- 
sion in human cardiomyocytes with severe congestive heart failure (CHF) remam 
unclear Methods: Human cardiac atrial and ventricular tissues were obtained from nor- 
mal subjects (n=5) and patients with end-stage CHF (n=5) during cardiac transplantation. 
ERK activity and expression was determined by Western blot analysis and immunohis- 
tochemical staining with phosphorylate-antibody. Apoptotic level tn cardiomyocytes was 
evaluated by TUNEL study and DNA fragmentation gel analysis. The apoptosis-related 
gene ~53, p21-WAF and caspase-3 were determined by IHCS. Results: In end-stage 
CHF patients, the average size oi cardiomyocytes was significantly increased compared 
with normal subjects. Western blot analysis demonstrated that the ERK activity in rnyo- 
cardium was significantly increased tn CHF patients compared with normal subjects (1.5 
fold, ~~0.03). IHCS demonstrated that positive ERK statfling nuclear was increased in 
CHF patients. TUNEL and DNA gel analysis illustrated that apoptosts level was markedly 
increased in human myocardium with end-stage CHF The ~53, ~21.WAF and caspase-3 
expression in cardiomyocytes were also significantly increased in severe CHF patients. 
Conclusion. The current study Indicates that ERK actwity is significantly increased in 
human myocardium with severe CHF compare with normal subjects. The apoptosis level 
and apoptosis-related gene expression are also markedly rncreased in CHF patients 
These data suggest that ERK may plays an important pathophysiological role in the pro- 
ce.ss of cardiac hypertrophy and apoptosis in patients with severe congestive heart fail- 
UK% 
827-3 
11:30 a.m. 
The Putative P,-Adrenoceptor-Mediated Positive Modulation 
on Cardiac L-Type Calcium Current: Normal Versus 
Congestive Heart Failure 
Zhu-Shan Zhang, Heng-Jie Cheng, Tomohiko Ukai, Hideo Tachrbana, Akihiko Igawa, 
Che-Ping Cheng. Wake Forest Universify School of Medione, Winston-Salem, NC 
Background: Evidence is accumulating for the existence of another cardtac stfmulatory 
p adrenoceptor (AR), the putative &-AR, which is distinct from pt-, pa-, and &-ARs. In 
addition to its stimulation-induced positive inoiroptc and chronotropic effects in mamma- 
lian heart, it has been shown that &-AR mediates increases in Ca2+ transients in ventric- 
ular myocytes and induces arrhythmia. Methods: To garn insight into the 
electrophysioiogical responses following stimulation of Pa-AR, we assessed the effect of 
CGP12177A (CGP), a @,-AR agonist, on cardiac L-type Ca*+ current (I& in isolated 
LV cardiomyocytes obtained from 14 normal control and 15 age-matched rats with con- 
gestive heart failure(CHF) induced by left coronary artery ligation (4 months). ICa,L was 
measured ustng whole-cell voltage clamp technique. Results: In normal myocytes, 
superfusion of CGP (10’“M) caused a 24% increase in Iqa,L (6.6-t0.3 vs. 8.2t0.4 pAipF. 
pcO.05). In CHF myocytes. CGP also increased I Ca,L by 19% (3.7i0.3 vs. 4.4eO.3 pA/pF, 
p&05), The CGP-induced increases in ICa,L were unaffected by the pretreatment of 
myocytes with nadoloi (lo’sM), a PI-and Pa-AR antagonist (Normal: 6.9kO.4 vs. 8450.4; 
CHF: 3810.4 vs. 4610.6 pA/pF, ~~0.05, respectively), but were nearly completely 
blocked by bupranolol (10-6M), a b,-AR antagonist, in I& of both normal and CHF myo- 
cytes. In addttion. the increases in ICa,L by CGP were enhanced by the pm-incubatron of 
myocytes with IBMX(I0.‘M, a phosphodiesterase inhibitor) for 30 min (Normal: 42% vs 
24%: CHF’ 34% vs. 19%. p&05, respectively). but were prevented in the presence of 
Rp-CAMP (10-4M). a PKA inhibitor, in the patch-pipette solution. Conclusion: &AR acti- 
vatton sttmulates L-type Ca2+ channel and increases ICa,L in both normal and CHF myo- 
cytes. These effects are likely to be mediated through PKA activation and coupled with 
CAMP-dependent mechanism. These observations provide addttional evidence for the 
putative &-AR positive modulation on cardiac L-type calcium current. 
11:45 a.m. 
827-4 Insulin-Like Growth Factor-l Enhanced Expression of 
Sarcoplasmic Reticulum CaS+-ATPase in Cultured 
Cardiomyocytes of Cardiomyopathic Hamsters 
Tomoko Nao, Tomoko Ohkusa, Masse Suetsugu, Jutaro Yamada, Shigeki Kobayashi, 
Masafumi Yaw, Masunori Matsuzaki. The Second Department of Internal Medicine, 
Yamaguchi University School of Meo’icine, i/be, Yamaguchi, Japan 
Cultured neonatal cardiomyocytes have proven to be useful tools in our struggle to 
understand the cellular mechamsms involved in the alterations in SR Ca2+ regulatory 
proteins during development of failing heart. Insulin-like growth factor-l (IGF-1) induced 
hypertrophy with enhanced expression of muscle specific genes in cultured cardiomyo- 
cytes. The purpose of the present study was to determine the abnormality of cardiac SR 
CaZ+-ATPase (SERCA) in UM-X 7.1 cardiomyopathic hamster (UMX) and to study the 
effects of IGF-1 on cultured cardiomyocytes. Methods: Primary cultures of neonatal 
UMX cardiomyocytes were prepared and golden hamster (G) cardiomyocytes were used 
as control. Medium supplemented with 10% fetal bovine serum for the first 72 h and then 
replaced in 0.5% serum medium for 48 h with or without 10-E M IGF-1. The relative 
expression levels of SERCA protein and mRNA were quantified by Western blot analysis 
and RT-PCR, respectively. Results: 1) At base line, there was no difference of spontane- 
ous beattng rate of cardiaomyocytes between UMX and G (120131 vs 108+25 bpm), and 
cell area was significantly larger in UMX than G (990?325 vs 816_+20lumZ, p<O.Ol). The 
treatment with IGF-1 attenuated the decrease of beating rate under tow serum condition, 
and increased cell area both in UMX and G. 2) The expression level of SERCA protein 
was significantly lower in UMX than G (0.38i-0.17 vs 1.82+0.32. p<O.Ol), as was the 
expression level of its mRNA (0.13-cO.03 vs 0.23+0 08, pcO.05). IGF-1 up-regulated the 
expression levels of SERCA protean and mRNA both in UMX and G. Conclusions: In 
UM-X7.1 hamster cardiomyocytes, the expression levels of SERCA protein and mRNA 
were down-regulated as early as neonatal stage, and the treatment with IGF-1 up-regu- 
lated the expression of SERCA The abnormality of SERCA expression may be one of 
the direct causes of heart failure in UMX. Moreover, IGF-1 might have great potential as a 
new and rational therapeutic approach to the treatment of hereditary dtseased cardiomy- 
ocytes. 
827-5 
Noon 
Hyperleptinemia in Chronic Heart Failure Relates to Growth 
Hormone Binding Protein in Male Patients With and Without 
Cardiac Cachexia 
Wolfram Doehner. Math& Rauchhaus, Karl Egerer, Claus D. Pflaum, Christian J. 
Strasburger, Constantinos H. Davos, Andrew J. S. Coats, S&fan D. Anker. C/mica/ 
Cardiology, NHLI, London, United Kingdom, Franz Volhard Klinik at MDC, Charit Berlin, 
Germany 
Background: Growth hormone binding protein (GHBP), the shed extracellular domain of 
the GH receptor, is closely related to body composition, specifically to the size of fat tis- 
sue Leptin, the adipocyte specific ob gene product, might be the signal linking adipose 
tissue and GHBP/GH-receptor expression. We have recently shown that chronic heart 
failure (CHF) is a hyperleptinemic state. We aimed to study the association between lep- 
tin and GHBP in CHF patients with and without cardiac cachexia. 
Methods: We studied 47 male CHF patients (mean age 6132 years, NYHA-class 
2.750.1, LVEF 281-2%, peak VO;! 16.8i0.9 ml/kg/min) and 21 mate healthy controls 
(Con) of similar age and total and regional fat distribution (DEXA scan). Among patients, 
19 were cachectic (cCHF) and 28 were non-cachectic (ncCHF; similar for age and LVEF). 
Results: Compared to Con, leptin levels were highest in ncCHF (9.1 ii1 .O v.s 4.83~0.7 
ngiml p=O.OOl) but nearly normal in cCHF (5.32kO.7. p>O.3). After correction for total 
body fat mass, both, ncCHF and cCHF were hyperleptinemic compared to Con (41.8e3.8 
and 37.9i3.8 L/S 24.4~2.1 ng/ml/lOOg, ANOVA p=O.OOl). There was a trend for GHBP 
levels to be increased in ncCHF and decreased in cCHF compared to Con (1019+100 “.s 
741597 vs 903*95 pmol/l, ANOVA p=O.l5). In both, patients and Con, leptin levels and 
GHBP showed a strong correlation(r=0.70 and r=O.71, respectively, both p<O.OOOl). This 
correlation held true also in CHF subgroups (ncCHF r=0.62, p<O.OOl; cCHF r=0.79, 
p<O.OOOi). In multivariate regression analysis in all CHF, leptin emerged as the strongest 
predictor of GHBP independently of age, BMI, total and regional fat mass or fat%, fasting 
insulin level, and insulin sensitvity (assessed by minimal modelling). 
Conclusion: Reduced total fat mass may account for pseudo normal leptin levels in 
cCHF. Fat mass corrected lepttn levels are elevated in both, GCHF and ncCHF In CHF 
patients with and without cachexta serum leptin levels strongly predict GHBP levels. Lep- 
tin could be the signal linktng adipose tissue and GHBP/GH receptor expression in CHF 
regardless of abnormal elevated leptin levels. 
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1126-I 59 Hypoxia Augments Endothelial Precursor Cell 
Differentiation 
Takako Akita, Toyoaki Murohara, Hisao Ikeda, Tsutomu Imarzumi. The Cardiovascular 
Research Institute, Kurume University, Kurume, Japan 
Angioblast-like endothelial precursor cells (EPCs) differentiate from CD34-positive mono- 
nuclear cells (MNCs), and have been shown to participate in neovascularization, consis- 
tent with postnatal vasculogenesis. Tissue ischemia is a potent stimulus for 
angiogenesis, and has been shown to mobriize EPCs into peripheral circulation from 
bone marrow. However, the direct effects of hypoxia on differentiation of EPCs are 
unknown. We examined whether hypoxia could enhance EPC differentiation from human 
MNCs in culture. After culturing adult peripheral blood MNCs (5,000 cellsimm2) on 
fibronectin for 7 days, spindle-shaped and attaching (AT) cells sprouted from numerous 
colonies. AT cells expressed CD31, KDR, van Wiliebrand factor and VE-cadherin, and 
incorporated Dil-labeled acetylated LDL. AT cells thus had multiple endothelial features 
and were defined as EPCs. When MNCs were cultured in a hypoxic chamber (nadir 
pO2=35 mmHg), a greater number of EPCs developed from MNCs compared with MNCs 
cultured in normoxic chamber (4Oi-3 vs. 77+1 cells/x400 field, pcO.01). A greater number 
of EPC-bearing cell clusters also developed from MNCs cultured in the hypoxic than in 
normoxic chamber (9.7+1 vs. 3.2rl 1x40 field, p<O.Oi). lmmunohistochemical examina- 
tion showed that EPCs prodbced vascular endothelial growth factor (VEGF). Since VEGF 
gene promoter has hypoxia-responsive element, we examined whether VEGF production 
by EPCs is enhanced by hypoxia. VEGF protein levels in culture media were significantly 
greater in hypoxia than in normoxia (113t6 vs. 83i8 pg/mL, p&05). Finally, neutralizing 
anti-VEGF antibody, a tyrosine kinase inhibitor, genistein, or a KDR tyrosrne kinase inhib- 
itor, SU-1498, significantly attenuated EPC differentiation from MNCs. Thus, differentia- 
tion of EPCs from human MNCs was enhanced by hypoxia in vitro, which was associated 
with enhanced release of VEGF. The secreted VEGF protein seems to play an important 
role in EPC differentiation in hypoxic condition. Hypoxia thus may play a role in not only 
mobilization of EPCs from bone marrow but also in situ differentiation of EPCs at 
ischemic foci. 
1126-l 60 The Effect of Transendocardial Delivery of Autologous Bone 
Marrow Stimulated By Granulocyte Monocyte Colony 
Stimulating Factor (GM-CSF) on lschemic Myocardial 
Perfusion and Function 
Shmuel Fuchs, Rrchard Baffour, Matie Shou, Yi Fu Zhou, Fermin 0. Tio, Martin 6. Leon, 
Stephen E. Epstein, Ran Kornowski. Cardiovascular Research Institute, Washington 
Hospital Center, Washington, DC 
Background: Transendocardial injection of autologous bone marrow (ABM) has been 
recently shown to augment collateral petfusron and function in ischemic myocardium. 
Granulocyte Monocyte Colony Stimulating Factor (GM-CSF) is a multipotent growth fac- 
tor involved in postnatal angiogenesis. We hypothesized that pre-administration of GM- 
CSF may enhance the angiogenic effect of ABM when injected into ischemic myocar- 
dium. Methods: Chronic myocardial &hernia was created in 24 pigs by placement of 
ameroid constrictors around the left circumflex artery. At 4 wks, 8 animals underwent 
transendocardial injections of freshly aspirated and filtered ABM into the ischemic zone 
using the BiosenseTM Injector (2.4 ml per animal @ 12 sites); 8 animals were similarly 
injected with ABM but were pretreated with GM-CSF injected subcutaneously @lo mgi 
kg/day for 3 days prior to ABM injection. Control animals (n=8) were injected with hep- 
arinized saline. At baseline and 4 wks after treatment, all animals underwent rest and 
pacing (0 180 blmin) echo to assess regional function, and rest and adenosine stress 
microspheres infusion to assess collateral perfusion. Four wks after ABM injection, collat- 
eral flow and function (ischemicinormal zone x 100) improved to a similar degree in ABM 
and GM-CSF stimulated (S) ABM treated pigs but not rn controls (Table). Similar 
response was observed following adenosine rnfusion and pacing. Conclusion: Injection 
of ABM augments collateral perfusion and function in ischemic myocardium, but with the 
current mode of GM-CSF administration, this effect could not be further augmented. 
Perfusion Function 
ABM 
ABM GM-CSF 
control 
baseline 4W P baseline 4W P 
841tl2 96213 0.007 61+29 85i21 0.016 
7&l 6 85*11 0.026 63+27 93k.33 0.009 
89r9 93?10 0.31 66i43 72&45 0.65 
1126-l 61 Effects of Hypoxia on VEGF and MCP-1 Secretion by 
Cultured Pig Bone Marrow Cells 
Yifu Zhou, Richard Baffour, Jill Walker, Ran Kornowski, Shmuel Fuchs, Stephen E. 
Epstein. Washington Hospital Center, CR/, Washington, D.C. 
Background We recently demonstrated that: 1) bone marrow cells (BMCs) in culture 
express VEGF and MCP-1, 2) injection of autologous BMCs cells via catheter into 
ischemic myocardium of pigs improves collateral flow and myocardial function. Because 
VEGF promoter activity is enhanced by HIF, a transcription factor activated by hypoxia 
and known to augment the expression of many genes, we determined whether exposing 
BMCs in culture to hypoxia increases VEGF expression. Methods Pig bone marrow was 
harvested and filtered sequentially using 300~ and 2001~. stainless steel mesh filters. 
BMCs were then isolated by 3 Ficolt-Hypaque gradient centrifugation and cultured at 
33°C with 5% CO2 in T-75 culture flasks. When cells became confluent at about 7 days, 
they were split 1:3 by trypsinization. After 4 wks of culture, the BMCs were either 
exposed to hypoxic conditions (placed in a chamber containing 1% oxygen) for 24 to 120 
hrs, or maintained under normal conditions. The resulting conditioned medium was col- 
lected and VEGF, MCP-1 were analyzed by ELISA. Results Exposure to hypoxia mark- 
edly increased VEGF secretion: At 24 hrs VEGF concentration increased from 106r13 
pgiml under normoxic, tol,600+196 pg/ml under hypoxic conditions (p=O.O002); after 120 
hrs it increased from 4,163162 to 6,028+167 pg/ml (p<O.OOOi). Re-oxygen&Ion after 24 
hrs of hypoxia prevented the large increase in VEGF production observed with 4 days of 
hypoxia. A separate study was performed on freshly isolated BMCs, and the same trend 
was found. Hypoxia also slowed the rate of proliferation of BMCs. MCP-1 expression was 
not increased by hypoxia, which is not surprising as its promoter is not known to have HIF 
binding sites. Conclusions Our results demonstrate that hypoxia markedly increases the 
expression of VEGF by cultured BMCs. These results suggest that ex viva exposure to 
hypoxia, by increasing expression of hypoxia-inducrble angiogenic factors, may further 
increase the collateral enhancing effects of a novel strategy we have developed to 
achieve therapeutic angiogenesis--transcatheter injection of BMCs into ischemic tissue. 
1126162 Arteriogenesis in a Rabbit Hindlimb Model can be 
Accelerated by Increased Numbers of Circulating Blood 
Monocytes 
Matthias Heil, Imo Hoefer, Niels van Royen, Ivo Buschmann, Wolfgang Schaper. Max- 
flanck-lnstifute for fhysiol. & C/in. Research, Bad Nauheim, Germany 
Background: Circulating monocytes are known to be pivotal players in early phases of 
collateral artery growth (arteriogenesis). As the growth efficiency of these vessels can be 
stimulated either by factors being chemotactic for monocytes (e.g. MCP-1) or factors pro- 
longing their survival time (GM-CSF) we sought to examine whether an increase in cir- 
culating blood monocytes may be beneficial for arteriogenesis after acute femoral artery 
occlusion. The cytostatic agent 5.fluorouracile (5-FU) is known to selectively kill cycling 
bone marrow cells leading after stopping of treatment to subsequent activation of multi- 
potential stem cells. Since the number of circulating monocytes is subsequently 
increased in a rebound we tested the effect of reactive monocytemia on arteriogenesrs. 
Methods: NZW rabbits were infused with 5-FU (20mglkg in 30 min). Monocyte counts 
were analyzed by quantitative flow cytometry. 3 days after 5-FU treatment the right femo- 
ral artery was occluded. One week after ligation development of collateral arteries was 
analyzed by postmortem angiography and bz evaluation of collateral conductance. 
Results: Monocyte concentration in peripheral blood slightly decreased 3 days after 5. 
FU treatment followed by a significant increase after 5 days (6-8 fold compared to pre-5- 
FU treatment). Postmortem angiograms from 5.FU treated rabbits revealed an increase 
in collateral artery growth compared to control animals. These data were confirmed by 
hemodynamic measurements showing a collateral conductance of 16.05 f 0.5 ml/mini 
mmHg (monocytemic rabbits) vs. 4.1 f 0.9 ml/min/mmHg (control animals). Conclusion: 
This study provides an important proof of concept for the pivotal role of monocytes in col- 
lateral artery growth after arterial occlusions. As the observed rebound effect is accom- 
panied by the release of progenitor cells into the blood we hypothesize that also 
circulating stem cells are involved in arteriogenesis providing a new potential tool for 
future therapeutical applications. 
1126-163 Stimulation of Arteriogenesis in WHHL Rabbits via 
Continuous Infusion of MCP-1 
Niels Van Royen, Imo Hoefer, Sawa Kostin, Ivo Buschmann, Keisuke Suzuki, Michiel 
Voskuil, Christoph Bode, Jan Piek, Wolfgang Schaper. Max P/an& hstitute, Bad 
Nauheim, Germany, Academic Medical Center, Amsterdam, The Netherlands 
Introduction. Monocyte Chemoattractant Protein-l (MCP-1) stimulates collateral artery 
growth (arteriogenesis) via the attraction of circulating monocytes. Stimulation of arterio- 
genesis is of potential benefit to patients with peripheral or coronary artery disease. How- 
ever, it is not known whether the arteriogenic potency of MCP-1 is preserved in a 
hyperlipidemic environment. Furthermore a potential limitation to this kind of therapy is 
the acceleration of atherosclerosis by activated monocytes. Objectives. To assess the 
potential of MCP-1 to stimulate arteriogenesis in Watanabe Heritable Hyperiipidemic 
(WHHL) rabbits and to study the long-term effect of MCP-1 on the occurrence of athero- 
sclerosis. Methods. The right femoral artery was ligated in 40 WHHL rabbits. MCP-1 
(0,14 pgikgiday, n=20) or PBS as a control (n=20) was continuously infused directly into 
the collateral circulation via the proximal stump of the femoral artery for a period of one 
week. One week after ligation post-mortem angiographies and haemodynamic measure- 
ments were performed (PBS n=lO, MCP-1 n=lO). Six months after ligation measure- 
ments were repeated in the remaining 20 rabbits. In addition, aortas, femoral arteries and 
collateral arteries were isolated and prepared for histological examinations. Results. 
MCP-1 treatment significantly Increased the number of collateral arteries one week after 
ligation of the femoral artery (12 +,1.9 vs. 25 i 2.8, peO.05). These data were confrrmed 
by haemodynamic measurements showing a fourfold increase in conductance of the col- 
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lateral clrcuiation (2.2 i 0.8 vs. 7.8 * 1.9 ml/min/lOOmmHg). SIX months after ligation 
strong iiprd depositions were observed in aortas from both the treated and the non- 
treated group (35 4 37%. vs. 41 I 34%, p=NS). No signs of atherosclerotic lesion devel- 
opment were found in either the newly developed collateral arteries or the femoral arter- 
ies Into which the MCP-1 was Infused. Conclusion. MCP-1 increases the number and 
the conductance of collateral vessels in the WHHL rabbit, one week after ligation of the 
femoral artery. The I-week infusion of MCP-1 did not increase the occurrence of athero- 
sclerosis six months after treatment. 
1127-166 Relation Between Reduced Coronary Vasodilator Capacity 
and Systemic Small Artery Hypertrophy in Hypertensive 
Patients With Chest Pain 
Carlo Palombo, Dam&no Rizroni, Enro Porteri, Michaela KozBkovB, Lorenza M. 
Muiesan, Giovanni LaCanna, Daniele Guelfi, Carmela Morizzo, Francesca Vittone, 
Enrico Agablti-Rosei. lnstitufe of Ciinicai Physiology: CNR, P~sa, /la/y, Departmenr of 
Internal Medicine, University of Brescia, Brescia, /t&y 
Background: Arterial hypertension (HBP) Is associated With the presence of structural 
alterations in small resistance arteries. A reduction in wronary flow reserve (CFR) Is 
reported in hypertensive patients without large coronary artery stenosis, but the associa- 
tion with structural alterations of microvessels is not yet documented. Aim of the study 
was to investigate the possible relationship between small resistance artery structure and 
CFR in essential HBP Methods: Eighteen hypertensive patwts With chest pain syn- 
drome and normal coronary angiograms underwent a biopsy of the subcutaneous fat 
from a gluteal region. By means of a micromyographic technique, the media thickness 
(MT), normal&d internal diameter (ID) and media to lumen ratio (M/L) of the small arter- 
ies (Internal diameter 160.280 pm) were calculated. By means of TEE-Doppler. mean 
coronary flow velocity (CFV) in LAD artery was monitored at baseline and during maxi- 
mal vasodilation induced by i.v. Adenosine (700 vg/kg/5min), and CFR and m~rwn”m cor- 
onary resistance (MCR) were calculated. Results: CFR and MCR correlated (pc.05) 
With M/L and ID (for CFR: r=-0.63 and r=+0.44, respectively; for MCR: r=+0.50 and r=- 
0.52) Patients With CFRc2.69 (ISD below the mean of normal controls) (n=8) had a 
greater M/L and smallw ID (pc.05) compared to those With CFR=2.69 (n=lO) (M/L 
O.lZiO.03 Versus O.lOi-0.02; ID: 192Lt45 Versus 251t68 pm). Patients with M/L=0.019 
(median value of controls) (n=9) had a smaller CFR compared to those with M/L<O.OlS 
(n=9) (CFR: 2.36+0.73 Versus 3.23?0.14, p<O.O5). Conclusions: the significant correla- 
tion between structural alterations in subcutaneous small arteries and impaired coronary 
vasodilator capacity suggests That hypertrophy of coronary microvessels can Be a major 
mechanism of coronary reserve impairment in hypertensive patients With chest pain and 
without coronary atherosclerosis. 
1126164 Vascular Endothelial Growth Factor Induces Monocyte 
Adhesion and Transmigration Through Endothelial Layers 
via Increased lntegrin Expression 
Matthias Hell, Matthias Claws. Svaantje Fischer, Wolfgang Schaper. Illax-P/an& 
lnstitufe for Physiol. & C/in. Research, Bad Nauheim, Germany 
Background: Monocytes play an important role in arteriogenesis (collateral vessel for- 
mation) by attaching to activated endothelwm and by invading the walls of innate collat- 
eral vessels where they produce growth factors. Previous studies demonstrated that 
beneficial effects of chemokines and growth factors On arteriogenesis rely on their mono- 
cyte-chemoattractant activity. In this study we examined the interaction between mono- 
cytes and endothelium under stimulation of the angiogenic agent vascular endothelial 
growth factor (VEGF) as monocytes express the VEGF-receptor fit-1. Methods: BZ-inte- 
grin expression on monocytes after VEGF-stimulation was quantified by flaw cytometry. 
Interaction of VEGF-stimulated monocytes on vascular endothelium was analyzed by 
adhesion and transmigration assays. Results: VEGF upregulated of LiA-1 and Mac-l 
expression on monocytes in a dose-dependent way (t&l). Monocyte adhesion to endot- 
helial cells (1643i77.6 cells/ml vs.688i45.8 in control) and transmigration through an 
endothelial monolayer was increased on VEGF-stimulated monocytes (2.68r0.077xiOE5 
cells/ml vs. 0.49?0.045 in control). Both effects were inhibited using antibodies against 
the B2-integrln and ICAM-1. Conclusion: Monocyte interactions with endothelial cells 
after exposure to VEGF in vitro are related to upregulation of.the 02.In&grins, Mac-l and 
LFA-I. These data indicate that VEGF-effects on collateral artery development might be 
secondary to monocyte recruitment. 
integrin receptor control (fluorescence “nits) VEGF (fluorescence “nits) 
UL LFA-1 730520 892249 
aM Mac-l 320&2 499i39 
I32 LFA-l/ Mac-l 1120&35 1835~98 
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1127-165 Diastolic Dysfunction in Mild Hypertension: Is the Primary 
Abnormality Slowed LV Relaxation or Augmented Atrial 
Transport Function? 
Sujood Ahmed, Jerome L. Fleg, Kerry J. Stewart, Paul S. Hees, Frances C. O’Connor, 
Edward P Shapiro. Johns Hopkins University School of Medicine, Ba/timore, MD 
Background: The pattern of diastolic dysfunction observed in hypertension has gener- 
ally been attributed to a primary slowing of LV relaxation, manifested by reduced Doppler 
E wave. The augmentation in atrial filling manlfested by an increased Doppler A wave, is 
considered compensatory and secondary. We studied whether augmented atrial trans- 
port function. rather than reduced relaxation: constitutes the primary abnormality of filling 
in the early phases of hypertension. Methods: Diastolic functrx by echo and MRI was 
measured in a group of untreated mild hypertensives (HTN, n=27), compared to age- 
matched normotensive participants in the Baltimore Longitudinal Study on Aging (NL. 
n=35). Doppler E wave height and deceleration time (DT) were measured, and relaxation 
was further evaluated using two previously vaIldated, load-insensitive methods: LV 
untwisting rate (UR) by tagged MRI, and filling wave propagation velocity (VP) by color M- 
mode echo. Atria. transport function was assessed by Doppler A wave velocity. LV cavity 
(LVID), septum (VS), posterior wall (PW) and mass were derived by echo, and ejection 
fraction (EF) by MRI in subgroup ( HTN n=24 & NL n=15 ), Results: Systolic BP was 
143i;9 in HTN and 12&19 in NL (pcO.0001). Diastolic BP was similar in the two groups. 
See table Conclusion: The earliest alteration of filling to appear in HTN is augmentation 
of atrial transport function, rather than impaired relaxation. Vigorous atrial emptying, per- 
haps due to atrial hypertrophy, may constitute the primary contributor to “diastolic dys- 
function” in HTN, with changes in early filling (E) occurring later and perhaps secondarily. 
LV structure Relaxation Atria 
Function 
LVID VS PW Mass EF E vp UR A 
Index 
HTN 4.63 1.09 1.06 107 68 77 62 -0.52 91 
NL 4.28 1.02 0.99 85 62 75 61 -0.51 77 
P 0.05 0.07 0.09 0.01 0.005 0.71 0.92 0.81 0.004 
1127-167 Right Ventricle Diastolic Dysfunction in Systemic 
Hypertension, a Common Finding 
Alicia Macelra, Joaquin Barba, Juan Cosin Sales. Elena Fernandez Jarne. Clinica 
Universitaria de Navarra. Pamplona, Spain 
Background: Systemic hypertension causes diastolic prior to systolic dysfunction of the 
left ventricle. Also, the neurohumoral alterations present in the pathogen&s of systemic 
hypertension can affect both the left and right ventricles. Previous studies have pointed 
out the possibility of right ventricular diastolic function involvement. The goal of this study 
was to assess right ventricular diastolic function in patients with systemic hypertension. 
Methods: 35 normotensive (NT) and 54 hypertensive (HT) subjects were included. All of 
them were free of any other type of cardiopathy, neumopathy or pulmonary hypertension. 
All had normal right ventricular dimensions and function. Left ventricular mass Index 
(LVMI, grim2) and left (LA) and right atrium (RA) diameters were measured. Rlght “en- 
tricular filling was studied by doppler at the level of the tricuspid valve in espiration by 
measuring E and A waves velocites (Et, At) (cm/s), their ratio (EVAt) and the decelera- 
tion time of the E wave (Edt) (ms). Statystical univariant analysis was made. Results: 
Age and sex proportion were similar for both groups. Significant differences were 
observed in LVMI, LA, RA, At and EVAt, as shown on the table below. In group NT there 
were 4 subjects (12%) with an EVAt below 1, while in group HT there were 18 (33%) 
(P&045, Cl 95% -0.39, -0.003), and notably all of them had left ventricular hypertrophy. 
In group NT only 3 patients had biyentrlcular diastolic dysfunction (8%), while in group 
HT there were 14 (25%) (PzO.05, Cl 95%=-0.33,-0.02), and these ones had the highest 
LVMI. 
Group LVMI RA At Et/At RV diastolic Biventncular 
dysfunction diastolic dys- 
function 
NT 87.9k15.6 4.4hO.3 46.6~10.5 1.3t0.3 12% (4135) 8% (3/35) 
HT 121.6143.4 4.910.5 53.7k17.7 1.1?0.2 33% (18154) 25% (14/54) 
P 0.002 0.01 0.03 0.03 0.045 0.05 
Conclusion: Systemic hypertension, overall in the presence of left ventricular hypertro- 
phy, can appear associated with diastolic dysfunction of the right ventricle in the absence 
of any right ventricular structural alteration. This can be a marker of more severe or 
advanced hypertensive cardiopathy. 
1127-I 6% Endothelin-A Receptor Antagonism Prevents Progression 
of Hypertensive Myocardial Remodeling and Impairment of 
Myocardial Function More Effectively Than ACE Inhibition in 
Stroke-Prone Spontaneously Hypertensive Bats 
Alexander Reinecke, Marc Dorenkamp, Quingui Xia, Harro Bitterling. Susanne Pew, 
Christian Storz, Net@ Welsner, Oliver Chung, Riidiger W.R. Simon and Thomas Unger. 
Clinic of Cardiology University of Kiei, Kiel, Germany, institute of Pharmacology, 
University of Kiel, Kiel, Germany 
Background: Sustained arterial hypertension in stroke-prone spontaneously hyperten- 
sive rats (SHRSP) induces myocardial remodeling including the progresslo” of myocar- 
dial fibrcws followed by impaired myocardial function. We investigated the ability of the 
ET-A receptor antagonist LU 135252 (LU) to reduce interstitial fibrosis in comparison with 
the ACE inhibitor Trandolapril (Tran) under strictly comparable hemodynamic conditions. 
Methods. Male SHRSP were treated for 10 weeks with placebo, Lu (30 mglkgld) or Tran 
(0.1 mgikgld) to reduce MAP from 185 + 6 to 157 + 7 (Lu) and from 189 + 5 to 155 + 8 
mmHg (Tran) (means + SEM). Cardiac hemodynamics and morphometric parameters 
were then determined. Myocardial fibrosis was analysed as interstitial collagen volume 
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fraction in picrosirius-red stained sections of myocardium. Results: ET-A receptor antag- 
onism reduced progression of interstitial fibrosis to a greater extent (p<O.OOi) than ACE 
inhibitlon compared to placebo treated controls. 2.62 + 0.06 (Lu) and 3.83 + 0.07 (Tran) 
% respectively vs 5.19 + 0.06 % in controls. Lu also lowered left ventricular end diastolic 
pressure mole than Tran: 6.53 + 1.43 (Lu) vs 10.99 + 1.81 mmHg (Tran) (~~0.05) vs 
12,34 + 1.91 .mmHg in controls. Conclusion: Our study demonstrates that chronic treat- 
ment with the ET-A receptor antagonist LU135252 prevents progression of hypertensive 
myocardial remodelling and subsequent impairment of myocardial function to a greater 
extent than the ACE inhIbitor Trandolapril when applied at comparably antlhypertensive 
doses. 
1127-l 69 Impaired Cardiac Function in Adult Sheep Exposed to 
Dexamethasone Early in Gestation 
Miodrag Dodic, Karen Moritz, Marelyn Wintour-Coghlan, John Morgan, Leeanne Grigg, 
James Wang. Howard Norey institute, University of Melbourne, Melbourne, Australia, 
Royal Melbourne Hospitai, Melbourne, Australia 
Background: We have shown that exposure of pregnant ewes to dexamethasone (11.5 
mg/d for 2 days) at 27 days of gestation (term 150 days), resulted in offspring with 
increased blood pressure and cardiac output (Group D). Our hypothesis was that dexam- 
ethasone Induced hypertension was associated with left ventricular hypertrophy and a 
reduced cardiac functional reserve (CO,,,,.& 
Methods: Six control animals (Group 6) and five Group D animals were instrumented 
with Swan” Ganz catheters and volume-loaded with Haemaccel until the wedge pres- 
sure (WP) was 14 mmHg (baseline). WP was maintained during incremental doses of 
dobutamine (l-12 pglkglmin), while blood pressure and cardiac output (CO) were mea- 
sured. The same protocol was repeated in each animal 5 days later under mild general 
anaeslhesia (1.5% Isoflurane), when twnsthoracic echocardography (M-mode) was 
obtained. 
Results: Mean arterial pressure in Group D was significantly higher compared with 
Group C (90 + 1 mmHg vs 80 r 1 mmHg; PiO.OOl).Group D showed a reduced COmax.O 
in response to dobutamine during both conscious (P<O.OI) and anaesthetised states 
(P<O.OS)(Table 1). The statistical significance was malntained after indexing CO against 
peripheral resistance or heart rate. Reduced COmax.o in Group D were associated with 
higher left ventricular mass index compared with Group C (2.6+0.30 g/kg of body weight 
vs 1.8+0.21 g/kg of body weight; PcO.05). 
Table 1. Baseline CO (COO), maximal CO response to dobutamine (CO,,,), cardiac 
functional reserve (CO,,,.,,) in Group C and G roup D animals when conscious or anaes- 
thetised. Results expressed as meatwsem. *P<O.O5 and **P<O.Oi 
Conscious Anaesthetised 
C(!l=6) D(n=5) C(n=6) D(n=5) 
CO&nllkglmin) 120r5 143+10* 108-ci2 11759 
CO,,,(ml/kg/min) 269i-9 232r20 263r18 209+18 
CO,,,.O(mllkg/min) 150+10 89+10*’ 156+23 91+17 
Conclusion: Brief prenatal exposure to dexamethasone led to the development of hyper- 
tension, left ventricular hypertrophy and reduced cardiac functional reserve in adult life. 
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1128-170 Apolipoprotein (a) lsoform Size Is Not the Only Determinant 
of Plasma Lipoprotein(a) Level in the Elderly: Data From the 
Prospective Study of Pravastatin in the Elderly at Risk: 
PROSPER 
Allan Gaw, Elizabeth A. Brown, John Norrie, PROSPER Executive. Glasgow Royal 
Infirmary: Glasgow, United Kingdom, University of Glasgow, Glasgow, United Kingdom 
Objectives: PROSPER is a randomized controlled trial designed to test the hypothesis 
that pravastatin will reduce vascular events in high risk elderly subjects. Subjects were 
Included with a wide range of lipid levels and no exclusions were made on the basis of 
Lp(a) levels. We present the preliminary analysis of the ape(a) phenoiyping data in the 
first 1,970 subjects in this cohort. Methods: 5804 men and women aged 70 to 82 years 
were randomized between Feb.98 and April 99. Pre-randomization, a fasting blood sam- 
ples was collected and analyzed using the Biostat immunoturbidimetric assay for Lp(a) 
and a high resolution immunoblotting system for ape(a) phenotyping. Results: In the first 
1,970 subjects assessed 26 had no detectable expressed ape(a) protein while 825 had 
only a single expressed isoform (single expressers). When the single expressers were 
examined the variability in plasma Lp(a) associated with different sized ape(a) &forms 
was not uniform across the size spectrum. In 19 subjects who had a single expressed K- 
20 isoform the plasma Lp(a) ranged between 5-145mg/dl. In contrast, in 51 subjects with 
a Single expressed K-30 isoform the range was much narrower (l-26 mgldl). Conclu- 
sions: As expected, there was a general inverse relationship between ape(a) isoform 
size and Lp(a) level. However, when groups with equivalent single expressing ape(a) iso- 
forms were studied it was clear that, while smaller isoforms were associated on average 
with higher levels, they were also associated with the greatest variability in level. As pre- 
viously reported by us another cohort the contribution of the ape(a) isoform size to the 
control of plasma Lp(a) level is therefore considerably lower than previously calculated, 
because the variability in plasma Lp(a) concentration is not uniform across the ape(a) 
size spectrum. This phenomenon has now been confirmed in an elderly cohort of both 
men and women. 
1128-171 Diagnostic implications of Circulating Oxidized Low Density 
Lipoprotein Levels as a Biochemical Risk Marker of 
Atherosclerotic Disease 
Tow Suzuki, Hiroaki Kohno, Shun-ichl Toshima, Akira Hasegawa, Masahiko Kurabayashl, 
Ryozo Nagai. University of Tokyo, Tokyo, Japan, Gunma University, Maebashi, Japan 
Background: Oxldative modification of low density lipoprotein (LDL) is an important 
underlying cause of atherosclerotic disease. However, our present understanding of the 
clinical role of oxidized LDL is limited due to the lack of a method to detect circulating 
OxLDL levels. Methods: We have developed an immunoassay of circulating OxLDL 
using specific antibodies against OxLDL (FOHlafDLH3) and apolipoprotein B. In the 
present study, we have examined ihe diagnostic implications of circulating OxLDL levels 
in an atherosclerotic patient population which includes coronary, cerebrovascular as well 
as peripheral artery atherosclerotic disease (n=556) and controls (n=128). Analysis of 
lipid profiles (comparison between groups and correlaiion of lipids with OxLDL levels) 
was done to assess diagnostic specifications (sensitivity and specificity) of OxLDL levels 
for atherosclerotic disease. Results: Patients with atherosclerotic disease showed signif- 
icantly higher OxLDL levels as compared to controls (19.6 i: 11 .l vs. 10.8 t 5.2 units/ml, 
p < 0.001). OxLDL levels did not show a significant correlation with total cholesterol, trig- 
lyceride, LDL-C, or HDL-C levels, but showed a significant correlation (r-0.77) with Lp(a) 
levels. Receiver operating characteristics curve analysis showed superior diagnostic per- 
formance of OxLDL levels as compared to other lipids for detection of atherosclerotic dis- 
ease. Conclusion: We conclude that OxLDL levels are elevated in patients with 
atherosclerotic disease and that it is superior to other lipid markers as a biochemical 
diagnostic marker of atherosclerotic disease. 
1128-172 Atorvastatin and LDL Subclass Distribution 
H. Robert Superko, Elaine Raul, Virginia Davis, Carey Aron. Berkeley HearfLab, San 
Mateo, CA 
Background: An abundance of small LDL subclasses (Illa & Illb) has been linked to 
CAD risk and arteriographic progression. Treatments including weight loss, exercise, nia- 
cin, and gemfibrozil, but not HMGCoA reductase inhibitors, have been shown to reduce 
the small LDL subclasses (Illa & Illb) proportionally more than the large LDL subclasses 
(I, Ila, and Ilb). Methods: We examined the effect of 40 mg/d atorvastatin for 8 weeks in 
42 patients with predominantly small LDL (Illa+b > 20%) in a double blind, randomized, 
controlled trial. Fasting total plasma cholesterol and triglyceride concentration were 
determined by standard enzymatic methods. HDLC concentration was determlned by 
d&ran precipitation of apoB containing particles and LDLC was calculated. LDL sub- 
class distribution, peak particle diameter, and HDLPb were determined by S3 polyacryla- 
mide gradient gel electrophoresis standardized against analytic ultracentrifugaiion. 
Results: There was no difference in BMI between groups. Compared to placebo, Atorv- 
astatin significantly reduced total and LDL cholesterol by 36.9% and 48.3% respectively 
(pcO.0001). Fasting triglycerides were reduced 39.6% (p<O.OOOi). LDL peak particle 
diameter was increased 4.8 angstrom (p=O.O4). There was no significant effect on HDLC 
or HDL2b. Change in LDL subclass distribution in the 7 LDL regions is listed in the table 
(I, Ila, Ilb = large; Illa, Illb, IVa, IVb = small). 
LDL Subclass Distribution Difference 
I Ila Ilb llla lllb IVa IVb 
Placebo -0.os5.5 2.s+7.0 -0.5~s.9 -S.l*S.i 1 .,*s.s 0.9+3 9 -0 1+3.4 
Atowastatin l.li4.4 zsi4 5 2 w.5 -5.011o.s -2.si5.0 O.li3.4 1 %%3.5 
P 0.52 0.88 0.27 0.98 0.03 0.51 0.09 
Conclusion: In patients with predomlnantiy small LDL (Illa+b > 20%) atorvastatin (40 
mg/d) reduced small LDL lllb significantly more (p=O.O3) than placebo while there was no 
significant change in the larger LDL subclasses. This may be of importance in the medi- 
cal control of the atherogenic small LDL trait. 
1128-173 Remarkably High Prevalence of Small Dense Low-Density 
Lipoprotein Particles in Japanese Men With Coronary Heart 
Disease, Irrespective of the Presence of Diabetes 
Shinji Koba, Tsutomu Hirano, Masayuki Shibata, Takeshi Kondo, Hiroshi Suzuki, Mikitaka 
Murakami, Takashi Katagiri. Showa University School of Medicine, Tokyo, Japan 
Background: Coronary heart disease (CHD) is the leading causes of diabetes-related 
morbidity and mortality. However it remains unclear which is more closely associated with 
CHD, glycemia or dyslipidemia. We examined how prevalence of small dense low-density 
lipoprotein (LDL) phenotype (pattern B), a new coronary risk factor, is in diabetic and 
non-diabetic Japanese CHD men, an ethnic group with relatively low serum cholesterol 
(C) levels and less massive obesity. Methods: Mean LDL particle diameter (LDL-PD) in 
96 diabetic and 207 non-diabetic men with angiographically documented CHD (Mean 
[SD], age=62.6 [9.8], and 62.2 [10.7], respectively), and 80 diabetic and 142 control men 
without CHD (age=61.4 [10.7] and 60.5 [10.9], respectively) was determined by gradient 
gel electrophoresis. Pattern B was defined as the diameter equal to or less than 25.5 nm 
Glycemia was evaluated by HbAlc and fasting glucose. Res.ults: CHD patients had 
lower levels of high-density lipoprotein (HDL)-C and apoprotein-Al, and higher levels of 
apoprotein-B and triglyceride (TG) regardless of the presence of diabetes, while body 
mass index, total- and LDL-C, remnant-like particle-C, and lipoprotein (a) were compara- 
ble among the 4 groups. HbAlc and plasma glucose levels of diabetics were significantly 
higher than those of control subjects while glycemic control was somewhat better among 
diabetic CHD patients than diabetic patients without CHD (HbAlc 6.9 [l.O]% vs 7.6 
JACC February 2001 ABSTRACTS - Hypertension, Vascular Disease, and Prevention 249A 
[1.4]%, pcO.005; Glucose 134.5 I50.41 vs 149.3 139.41 mgidl, respectively). LDL-PD was 
in diabetes were significantly smaller compared to those of control men (25.6 lo.61 vs 
25.9 10.41, pcO.OOOl), and was remarkably smaller in CHD patients irrespective of the 
presence of diabetes (diabetic CHD 25.3 [O.S]; non-diabetic CHD 25.4 [7.0]). Multiple 
logistic regression analysis revealed that pattern B was tndependently associated with 
incidence of CHD in both non-diabetic and diabetic cases (odds ratio [OR] 4.0, 95% con- 
fide& interval [Cl] 2.4-6.8, p=O.O069 and OR 4.0, Cl 2.1-7.6, pcO.0001). Conclusion: 
High prevalence of small dense LDL is a leading cause for CHD independent of high 
LDL-C, low HDL-C and high TG in both non-diabetic and diabetic Japanese men. 
1128-174 Effects of Extended-Release Niacin on Lipoproteins and 
Glycemic Control in Patients With Type 2 Diabetes Mellitus: 
Results of a Randomized, Double-Blind, Placebo-Controlled 
Multicenter Trial 
Scott M. Grundy, Gloria L. Vega. Mark E. McGovern. for the Diabetes Multicenter 
Research Group. University of Texas Soull?wesfern Medical Center, Dallas, TX 
Background: Paiients with type 2 diabetes have abnormal lipids primarily characterized 
by hypertriglyceridemia, low HDL-C. and small. dense LDL particles. While niacin cor- 
rects all of these abnormalities, its use may cause hyperglycemia. We thus investigated 
the effects of a once-daily extended-release niacin (ERN), N&pan, on llpids and glyce- 
mic control in’148 pailents in a 16 week, double-blind, placebo (PBO)-controlled multi- 
center trial. Methods: Patients were type 2 diabetics with fasting glucose < or = 200 mg/ 
dL and mean HbgAl c < or = 9%. Lipid entry criteria included either HDL-C c or = 40 rngi 
dL or triglycerides (TG) z or = 200 mg/dL, or, if on a statin, LDL-C > or = 130 mg/dL; if not 
on a statin, LDL-C had to be < or = 130 mg/dL. Patients were randomized to ERN lg, 
ERN 1.59, or matching PBO. At baseline, with 50% of patients on statlns, mean LDL-C 
was 105 mg/dL, HDL-C was 41 mg/dL, and TG were 264 mg/dL. investigators could 
adiust anti-diabetic drug therapy as needed. Results: Changes from baseline to Week 
16 for primary efficacy endpoints HDL-C and TG were for PBO: +4%, -5%; for ERN lg: 
+ZO%, -15%; for ERN I.59 : +24%, -29%. All differences between ERN and PBO were 
significant (p c 0.01) except for TG with EAN lg. LDL-C did not change appreciably with 
PBO or ERN lg and decreased 8% with ERN 1.5g (p < 0.05 versus PBO or ERN lg). 
Baseline and Week 16 values for primary safety endpoint, HgbAlc were for PBO: 7.12 
and 7.09; ERN lg: 7.21 and 7.33 (p = NS versus PBO): ERN 1.59: 7.21 and 7.48 (p<O.O5 
versus PBO). Over 80% of patients completed the study in all 3 groups. Global assess- 
ment of diabetes status was improved or the same ip 88% (PBO), 80% (ERN lg), and 
71% (ERN 1.59). The dose of anti-diabetic medication was increased/another drug 
added in 16% (PBO), 19% (ERN lg), and 29% (ERN 1 5g). Flushing caused 8 (5%) of 
ERN-treated patients to withdraw. Conclusions: For diabetic patients at goal for LDL-C, 
adding ERN lg increases HDL-C 20% wlthout affecting HgbAlc. Adding ERN 1.5g 
increases HDL-C 24%, decreases TG 29% and in the majority has no effect on glycemic 
control. Low doses of ERN effectively modify dyslipidemia and are well-tolerated in type 2 
diabetes. Adverse changes in glycemic control occur in only a small minority and are 
easily managed. 
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1129-175 Menopausal Status Determines the Progression of Cardiac 
Hypertrophy 
Christian GrohB, Jens Mittler, Rainer Meyer, Berndt Luederitz, Thorsten Lewalter, 
Christian Wolpert, Klaus Fink. Klaus Tiemann, Harald Becher. University of Bonn, Bonn, 
Germany 
The Imechanisms which lead to the progression of cardiac hypertrophy in postmeno- 
pausal women are poorly understood. To further elucidate the effect of menopause on 
hypertensive heart disease, female C57lBl6 mice (n=6/group) were ovariectomized or 
sham-operated. Arterial hypertension was induced by continous infusion of angiotensin II 
using osmotic minipumps for 2 weeks.ln intervals the progression of cardiac hypertrophy 
was monitored by echocardiography. Intraarterial blood pressure was analyzed and dem- 
onstrated a hypertensive profile I” angiotensin II infused animals (MAP 110 mm/hg) com- 
pared to sham controls. Thereafter vital parameters were taken. followed by an 
ultrastructural analysis. Estrogen levels were measured by standard ELISA.ln ovariecto- 
mized mice angiotenw II induced a significant increase in left ventricular mass com- 
pared to sham controls(+20 %).Western Blot analysis showed an inductlon of estrogen 
receptor (60%) and (45%) by angiotensin II in the myocardium, which was modified post- 
ovariectomy. Progesterone receptor and iNOS levels, however, remained unchanged 
compared to controls.These data suggest that the menopausal status influences the 
response to angiotensin II induced cardiac hypertrophy. Taken together these observa- 
tions offer new insight for potential treatment strategies of postmenopausal women with 
either hormone replacement therapy or AT1 receptor blockade. 
1129-176 Fish Oils Reverse CsA-Induced Na-K Pump Inhibition and 
associated Hypertension 
Mahidi Mardini, Anastasia S. Mihailidou, Helge Rasmussen. RoyalNorfh Shore Hospiial, 
Sydney Ausiralia 
Cyclospor~ne (CsA) is a potent immunosuppressive agent, however, its adverse effects, 
which include induction of hypertension, nephrotoxiccty and cardiotoxicity, limit the effi- 
cacy of CsA. Adverse effects may, at least in part, be related to a decrease in the sensi- 
tivity of the membrane Nat -K+ Pump to intracellular Nat. Since dietary fish oils have 
beneficial effects in cardiovascular disease and have been reported to alter the sodium 
sensitivity of the pump in neural tissues, we examined the effect of fish 011s on CsA 
induced inhibition of the sarcolemmal Na+-K+ Pump. We studied control rabbits and rab- 
bits given fish oil and/or cyclosporine for 7 days. At the end of the treatment period, rab- 
bits were sacrificed and single ventricular myocytes isolated, intracellularly dialyzed and 
voltage clamped with wde tipped patch pipettes. Patch pipettes filling solutions included 
10 mM Na’, a concentration near physiological intracellular levels. Na+-K+ Pump current 
(Ip, normalised for membrane capacitance), ansing from the 3:2 Nat: K+ exchange ratio 
was identified as the shift in holding current induced by pump blockade with 100 pM 
oubain. A group of rabbits were given CsA in a dose of 10 mgkg-’ d-’ SC to induce serum 
levels of CsA similar to those used in clinical practice. Mean Ip of myocytes isolated from 
the CSA treated rabbits (0.19 f 0.02 pA/pF, n=12) was significantly lower than mean Ip of 
myocytes from controls (0.33 + 0.02 pAfpF, n=9). Another group were given the CsA and 
fish oils in a dose of 1 giday by oral gavage. Co-treatment with fish 011s abolished the 
CsA induced pump inhibition (mean lp 0.32 + 0.02 pAfpF, n=5). The fish oils given to rab- 
bits not treated with CsA had no effect on Ip. We also measured blood pressure before 
and after treatment. There was no change in the pressure of rabbits given both 
cyclosporin and fish oils or in rabbits given fish oils alone. We conclude that fish oils 
abolished CsA induced inhibition of the sarcolemmal Na-K Pump and CsA induced 
hypertension. Dietary fish oils supplementation may be useful in the prevention of com- 
plicatlons of treatment with CsA. 
1129-177 Ischemia-Reperfusion Attenuates Upregulation of flk-1 in 
Myocardial Infarction 
Christian Zellner, Phuljhuri Chakraborti, Richard E. Sievers, Kanu Chatterjee, William 
Grossman, Randall J. Lee. Universify ot California, San Francisco, San Francisco. CA 
Clinical studies of therapeutic angiogenesis after admlnistration of growth factors remain 
equivocal. This suggests that functional adaptation to ischemia may involve opposing 
regulatory pathways, particulary in the setting of myocardial ischemia-reperfusion (IR). 
We hypothesized that the VEGF-receptor flk-1 plays such a regulatory role during IR. 
Methods: We studied cardiac expression of VEGF and ilk-l mFiNA in a rat model of IR 
using Northern blot hybridization. Rats underwent placement of a left coronary artery 
snare occluder and were randomized to the following groups: sham (S), 17 min ischemia, 
(ISC), 17 min ischemia and 2 h reperfusion (IR), ischemic preconditioning (PRE) followed 
17 min ischemia (PRE-ISC), and PRE followed by IR (PRE-IR). Results: lschemia 
induced time-dependent increases in expression of VEGF and flk-1. PRE with IR syner- 
gistically attenuated expression of VEGA. In contrast, upregulation of flk-i was attenuated 
by IR, but remained unchanged after PRE. Conclusions: Differential responses of flk-1 
and VEGF expression to PRE and IR suggest that flk-1 acts as a regulatory factor for 
VEGF responses to myocardial ischemia. Ischemia-reperfusion may attenuate VEGF 
rt?sponses by reducing expression of flk-1. Upregulation of flk-1 may thus represent a 
novel therapeutic target I” myocardial ischemia. 
VEGF and flk-1 mRNA expression 
Group 
S 
ISC 
IR 
PRE-ISC 
PRE-IR 
Mean&D *p<.O5 
VEGF/Actin 
1.2&0.1 
2.1*0.1* 
I.&0.1’ 
1.4vIO.l 
0.9*0.2* 
flk-l/Actin 
1.3*0.3 
3.8+0.2* 
0.9+0.0* 
3.4r0.4 
0.9cO.1’ 
1129-178 Myocardial IL-6 is Regulated by lmmunoregulatory Stimuli 
In-Vitro Superfusion Study 
Frank Muders, Andreas Jeron, Rainer H. Straub, Dietmar Elsner. Dept. Internal Medicine 
0, University Regensburg, Germany 
Background: Interieukin-6 (IL-i?) is a cytokine which is present in the myocardium and 
mediates cell proliferation, negative inotropic effects and myocardial hypertrophy In order 
to determine, whether myocardial IL-6 is modified by immunoregulatory stimuli, we stud- 
led the effects of lipopolysaccharide (LPS), isoproterenol (ISO), corticosterone (CS) and 
cycloheximide on myocardial IL-6 secretion in superfused myocardium. Methods: Slices 
of rat left ventricular myocardium were superfused in 80 1-11 chambers for 6 hours. Cell via- 
bility was documented by constant supetfusat levels of creatinine kinase, lactate dehy- 
drogenase, lactate, oxygen and potassium during the experimental protocol. LPS (1, 50, 
100 pgiml; n=6 each group). IS0 (10-8, 10.7M; n=8), CS (10.6, IO-5 M; n=6 each group) 
and cycloheximide (10 pgiml; n=6) were added to the culture medium at 2 hours; 6 
untreated slices served as controls (CTRL). IL-6 was measured in the circuiatlng super- 
fusate by ELISA. Results: Left ventricular IL-6 secretion was significantly stimulated by 
LPS (50 pg/ml: 3262 k 1684 % vs. CTRL 116 r 34 %; p < 0.05; 100 pgiml: 1066 + 861%; 
~~0.05) and IS0 lo-7M (242 i 46 %; ~~0.05) but significantly suppressed by corticoster- 
one (CS 10.6 M: 45 A 24 %, piO.05; CS 10-5: 29 + 9% p<O.OOl). Cyclohexlmide, an 
inhibitor of protein synthesis, markedly inhibited IL-6 secretion (2,4 2 0.7 %, pcO.0001 VS. 
CTRL). Conclusion: The current data Indicate an immunoregul.atory fUnCtiOn of myocar- 
dial tissue with stimulation of IL-6 secretion by LPS and isOproterenO1 as well as SUppreS- 
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sion by corticosterone. The spontaneous increase of myocardial IL-6 secretion is due to 
protein synthesis rather than release of stored IL-6 as demonstrated by the profound sup- 
pression secondary to cycloheximide. Autocrine-paracrine effects of myocardial IL-6 
might be involved in inflammatory cardiac dysfunction and can be a potential therapeutic 
goal in the treatment of cardiovascular disease. 
1129-179 Raman Spectroscopy Provides Quantitative Evaluation of 
the Effects of Anti-Atherosclerotic Drugs on Plaque 
Formation 
Sweder W. E. van de Poll, Dianne Delsing, Wouter Jukema, Arnoud van der Laarse, 
Gerwin J. Puppels. L&den University Medical Center, Leiden, The Netherlands, Erasmus 
University Rotterdam, Rotterdam, The Netherlands 
Background: Catheter based Raman spectroscopy in viva might be of value to assess 
development of atherosclerosis and evaluate the efficacy of anti-atherosclerotic drugs. 
We studied the effects of atorvastatin and amlodipine on plaque components in the aorta 
of APOE* Leiden transgenic mice in vitro, using Raman spectroscopy. Materials and 
Methods: Female APOE* mice (1~15) were randomly assigned to a group receiving 
amlodipine (AM), atorvastatin (AT) or a control group, in combination with a high choles- 
terol diet. Serum cholesterol level was tested in three week intervals. Raman spectra 
(lOOmW, 10 seconds) were obtained in 0.25x0.25 mm steps from the inner curvature of 
the longitudinally opened aortic arch (+3x6 mm) of the sacrificed mouse. For each step, 
the individual Raman spectra were modeled to calculate the dry weights of cholesterol 
and calcium salts, relative to the dehydrated weight of the artery. Results: Average cho- 
lesterol exposure (&EM) was 416r37, 316218 and 179~28 mMol”week for resp. the 
control, AM and AT group. The figure shows for each group the size of the plaque with 
210% cholesterol or calcium and their standard deviations. AM and AT showed a signifl- 
cant (~~0.05) 45% and 93% reduction in plaque size with regard to plaques with 210% 
calcium salts. AT also showed al 93% significant reduction in cholesterol rich plaque. 
There was no significant effect of AM on cholesterol deposition in the aortic arch. Similar 
reiults were observed studying plaques containing higher quantities of calcium or cho- 
lesterol. Conclusion: This study demonstrates that Raman spectroscopy allows the 
quantitative assessment of the effects of anti-atherosclerotic drugs on plaque develop- 
ment. With the possibility of performing catheter based Raman spectroscopy intravascu- 
larly in viva, this technique will be valuable for the in viva monitoring of anti- 
atherosclerotic medication. 
/ 
Cholesterol (SW%) Calcium (>W/o, 
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1130-180 Relation Between Impaired Peripheral Endothelial Function 
and Abnormal Exercise Myocardial Perfusion 
Jeffrey T. Kuvin, Ayan R. P&l, Kathleen A. Sliney, Natesa G. Pandian, James E 
Udelson, Richard H. Karas. Tufts-New England Medical Center, Boston, MA 
Background: Exercise myocardial perfusion imaging (ExMPI) is widely employed for 
detecting coronary artery disease (CAD). Endothelium-dependent vasomotion (EDV) 
correlates with the presence of CAD and has recently been shown to predict prognosis. 
We studied whether non-invasive assessment of EDV by brachial artery ultrasound 
(BAUS) predicts ExMPl positivity. 
Methods: Patients referred for clinically indicated ExMPl also underwent BAUS on the 
same day under fasting conditions. Subjects performed a symptom-limited Bruce proto- 
col (treadmill) accompanied by standard SPECT imaging. The presence of ischemia or 
infarction on nuclear images was considered a positive ExMPI, read blmded to the BAUS 
results. EDV was evaluated at least two hours after completion of exercise by high resoiu- 
tion BAUS. Flow-medlated dilation (FMD) was defined as the per cent change in arterial 
diameter during reactive hyperemia relative to the baseline after a five minute upper arm 
occlusion. Endothelium-independent vasomotion was also measured following adminis- 
tration of sublingual nitroglycerin. 
Results: 94 subjects (43 women, 51 men) with an average age of 56+1 years (range 31. 
80) were studied. 48% had hypertension, 46% had hyperlipidemia, and 10% had diabe- 
tes. Subjects with a positive ExMPl (n=23) had a lower FMD (6.3+0.7%) than those with 
a normal ExMPl (n=71) (10.5t0.6%; p=O.O004). Using the mean FMD of 10% as a cutoff 
value to separate normal from abnormal EDV, 21 of 23 positive ExMPl subjects had a 
FMD<lO% (sensitivity 91%), whereas 38 of 71 negative ExMPl subjects had a 
FMDzI 0% (specificity 54%). The negative predictive value of having a FMDzlO% was 
95%. Interestingly, among all subjects, individuals with impaired EDV had a shorter exer- 
cise time than those with FMD>lO% (456+24 vs. 544+31 seconds, respectively; p=O.O2). 
This relation held even among those subjects with normal ExMPl (444+29 vs. 547+32 
seconds; p=O.Ol). 
Conclusion: Detection of impaired EDV by BAUS has high sensitivity and an excellent 
negative predictive value. Thus, BAUS has the potential for use as a screening tool in 
patients with low prior probability of CAD or in those unable to perform exercise. 
1130-181 Expression of Cytoprotective Ferritin in Platelets Is 
Enhanced During Long-Term Glyceryl Trinitrate 
Administration 
Michael Schwemmer, Eberhard Bassenge. Institute of Applied Physiology Freiburg, 
Germany 
Background: The damaging effects of free iron-catalyzed oxidative injury are efficiently 
counteracted by the iron storage protein ferritin. Ferritin expression is tightly regulated by 
iron-regulatory proteins (IRPs) binding to iron-responsive elements (IREs). The IFiPs, in 
turn, are modulated via iron, endogenous nitric oxide (NO)-synthesis, and oxidative 
stress. We analyzed ferritin protein expression at the platelet level during tolerance to 
organic nitrates due to enhanced oxidant stress. 
Methods: Mongrel dogs were treated with 1.5pglkglmin glyceryl trinitrate (GTN) for 5 
consecutive days with subsequent additional vitamin C (55vg/kg/min) for days 6 to 8. 
Western blotting was performed on crude platelet protein extracts using a polyclonal anti- 
ferritin antibody. Quantitation of specific immunoreactivlty was achieved via densitometric 
scanning with reference to a ferritin standard derived from horse spleen. 
Results: Nonintermittent administration of chronic GTN was associated with the induc- 
tion of vascular (e.g. reduced coronary dilator responses) and cellular (e.g. increased 
platelet activity) tolerance that were completely reversed by additional vitamin C (data not 
shown). Platelet ferritin protein contents gradually increased during non-intermittent GTN 
from 1.24 (arbitrary units a.~.) at control to 2.76 a.~. (at day 5) and gradually reached 
control values during subsequent vitamin C (1.17 a.u. at day 8). Total platelet protein con- 
tents remained unchanged. 
Conclusion: Nonintermittent administration of organic nitrates is associated with devel- 
opment of tolerance due to enh&ced oxidant stress in the cardiovascular system. The 
concomitant induction of platelet ferritin expression - most probably at the post-transcrip- 
tional level - may be mediated by NO (NO, derivatives) or rather reactive oxygen species 
targeting regulatory Fe-S-clusters in IRPs. Thus, by sequestration of free iron, ferritin in 
platelets (and other vascular cells) potentially proves a cytoprotective marker counterbal- 
ancing altered NO release with enhanced oxidant stress during long-term nitrate admin- 
istration. 
1130-182 Noninvasive Measurement of Hemoglobin Saturation by 
Visible Reflectance Hyperspectral Imaging During Nitric 
Oxide Inhibition and Inhalation 
Karel J. Zuzak, Michael D. Schaeberle, MarkT. Gladwin, Richard 0. Cannon, Ill, Ira W. 
Levin. National institutes of Health, Bethesda, MD 
Background: Visible reflectance hyperspectral imaging of skin can detect small changes 
in oxyhemoglobin HbO, saturation over time and thus may be useful for noninvasive real- 
time evaluation of patients with vascular disease. In order to simulate vascular endothe- 
lial dysfunction and its treatment, HbO, saturation was measured during regional nitric 
oxide (NO) synthase inhibition, before and during NO inhalation. 
Methods: NG-monomethyl-L-arginine (L-NMMA; 8 ~molimin) was infused into the bra- 
chial arteries of 9 healthy subjects for 5 minutes in order to block synthesis of NO in the 
forearm and hand, first while breathing room air and subsequently during NO inhalation 
at 80 ppm for 1 hour. Blood flow was measured by venous occlusion plethysmography. 
The imaging data collection method integrates a liquid crystal tunable filter (LCTF) with a 
charged coupled device (CCD) detector. The data is formatted as a hyperspectral data 
cube from which analysis is performed through a multivariate least squares deconvolu- 
tion. 
Results: L-NMMA infusion resulted in a 32 + 5% (mean * SEM) reduction in flow (P < 
0.001) and a 7.80% average reduction in percent HbO, saturation (79.75 + 0.06 to 73.30 
* 0.08, P < 0.005). In 3 subjects, a time-resolved measurement showed a stepwise 
decrease in percent HbO, saturation during the infusion of L-NMMA: 78.54 + 1.49 at 1.5 
minutes, 74.70 r 1.78 at 3.0 minutes, and 72.03 f 1.86 at 4.5 minutes. While inhaling 
NO, blood flow fell by 11 c 7 % during L-NMMA infusion (P = 0.007 versus room air). The 
reduction in HbO, s&ration was only 4.24% (79.69 t 0.06 to 76.09 + 0.10, P < 0.005), 
representing a 44.19% improvement in HbO, saturation between room air and NO Inha- 
lation (6.45 * 0.08 versus 3.60 r 0.10, P < 0.005) 
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Conctusions: Reflectance hyperspectral imaging detects effects of reduced perfusion 
and restoration oi perfusion on HbOa saturation during pharmacological mampulatron of 
NO bioactivity in the forearm. Thus, this technology shows grea: promise for noninvasive 
assessment of tissue perfusion in patients with vascular dysfunctton and effects of thera- 
pies that improve perfusion. 
1130-183 The Differential Influence of Current HRT and Age on 
Vascular Function in Women: The NHLBI-Sponsored WISE 
Sttldy 
6. Delia Johnson, C. Noel Bairey Merz. Steven E. Reis. Richard Holubkov, Vera Bittner. 
Carl J. Pepine, William J. Rogers, Nathaniel Reich& Barry L. Sharaf, Richard A. 
Kerensky, Sheryl E Kelsey. George Sopko. Universify of Pittsburgh, Pit&burgh, PA 
Background: While a strong relatronship between vascular iunction and hormone 
replacement iherapy (HRT) has been reported in women, effects of HRT on peripheral 
and microvascular function have not’been compared. We evaluated effect of current HRT 
on peripheral endothelial function assessed by brachial artery flow-mediated dilation 
(Brachial FMD) and microvascular coronary flow reserve (CFR) by Doppler flow probe 
following adenosine. 
MetRods:Women (N=3lg; mean age 58210 yrs, range 27-83) enrolled in the Women’s 
lschemia Syndrome Evaluation (WISE) underwent coronary angiography, FMD (n=234) 
and brachial CFR testing (n=143) Overall, 58 (18%) had both vascular function assess- 
ments. Relationshrp of FMD and CFR with age and current HRT was assessed with mul- 
tivariate linear regression. A moderating effect of HRT on the relationship of age with 
FMD or CFR was then examined by fitting an age/HRT interaction term. 
Result?.: FMD and CFR were not signrficantly correlated (Spearman r= 10, p=.43). CFR 
decreased with age among both HRT nonusers (p= -.Ol? .Ol) and users (p= -.03 i .Ol), 
and this association was significant for women usrng HRT (p=.OZ). The stmilar slopes of 
the age/CFR regression lines for NoHRT and HRT women (p=.ll for age/HRT interac- 
tion) suggest a uniform age/CFA relationship regardless of HRT use. In contrast, while 
FMD strongly declined with age for women without HAT (p= -25 f .07, p=.OOl), this 
decline did not occur among women on HRT (p= + 11 I .lO, p= 28), and the two regres- 
sion lines were significantly different (Figure; p=.OO6). 
Controlling for baseline values or CAD did not affect these results 
Conclusions: Among women undergoing coronary angiography ior suspected rnyocar- 
dial rschemia, CFR and brachial FMD are differentially impacted by HRT. The results sug- 
gest that microvascular and peripheral function respond to drfferent regulatory 
mechanisms. 
1130-184 Association of Coagulation and Fibrinolytic Parameters 
With Brachial Artery Flow Mediated Dilation and Carotid 
Artery Intima-Media Thickness: Indicator of Patients at High 
Risk for Coronary Artery Disease 
Tomoo Furumoto, Satoshi Fujii, Naotaka Saito, raiser Mikamr, Kazushi Urasawa, Akira 
Kitabatake. Hokkaido Universify Cardiology Sapporo, Japan 
Thrombosis plays a crucial role in events of coronary artery disease (CAD). Its role at 
early stages of atherosclerosis is unclear. To determine whether thrombosis and hypofi- 
brinolysis contribute to early process of CAD 55 patients suspected of CAD were exam- 
ined morphologically by intima-media thickness (IMT) of carotid arteries, and functionally 
by flow mediated drlation (FMD) of brachial arteries. Plasma levels of tumor necrosis fac- 
tor (TNF)-alpha and interleukin (IL)-6, representative atherogenic cytokines, tissue factor 
(TF) and TF pathway inhibitor (TFPI), markers of coagulation, and activity of plasmino- 
gen activator inhibitor type-l (PA&l), marker of hypofibrinolysis, were measured (ELISA). 
Patients with CAD in one or more vessels with lesion >50% had reduced FMD compared 
with those with anglographically normal coronary arterres (9.7+/-l.l(SD)% “s 14.2+1- 
0.8,p=O.O3). IMT increased only in patients with advanced CAD in one or more vessels 
with lesionr90% (0.75+/-0.20mm “s 0.89+/-0.26, p=O.O4). There was a graded relation 
between plasma levels of TNF-alpha, IL-6, TF, TFPI, PAI- and reduction of FMD (Table). 
Thus, FMD was reduced at early stages of CAD while IMT correlated with the extent of 
CAD. Early stage of CAD is accompanied by systemic inflammation, thrombosis and 
hypofibrinolysls, which serve as an indicator of patients at high risk. 
Variables FMD<lO%, n=24 FMD 10.15%, n=16 FMD>15%, in=15 
TNF-alpha (pg/ml) 2.7+/-1.4* 1.9+/-0.4 1.5+/-0.3 
IL-6 (pgiml) 2.2+/-l .2*, *= 1.411-0.3 1.5+/-0.3 
TF (PsW 21 I+/-73 187+/-l 7 168+/-22 
TFPI (pg/ml) 80+/-l I’ 73+/-8 61+/-5 
PAI- (AU/ml) 8.1+/-2 t*, ‘* 6.4+/-1.2 6.2+/-l .1 
*<O 05 “s FMD>15%, “*p&O5 “s FMD IO-!5% 
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1131-185 Infiltration of Neutrophils in Human Coronary Unstable 
Plaques 
Takahiko Naruko, Makiko Ueda, Kazuo Haze. Akira Itoh, Masato Otsuka. Yuji Sakanoue, 
Yoshihiro Ikura, Masayuki Ogami. Osaka City Genera/ Hospifa/, Osaka, Japan. Osaka 
City University MedIcal School Osaka, Japan 
Background: Natriuretic peptides (NPs) act as a vasodilator, and neutral endopeptidase 
24.11 (NEP) plays a key role in degrading NPs. Previous in vrtro studies have reported 
that NEP is found in human neutrophrts, and human neutrophils are separated into NEP- 
positive and NEP-negative population. NEP-negative neutrophits are immature neutro- 
phils and have a greater chemotactic response than did NEP-positive neutrophils. Hence. 
NEP positivity in neutrophils may provide a better insight into the role of neutrophils in 
plaque destabilization of human coronary arteries. For this reason, we immunohis- 
tochemically studied the infiltration of neutrophils and NEP expression in neutrophils I” 
coronary atherectomy specimens obtained from patients with stable angina (SAP) and 
unstable angina pectoris (UAP). Methods: All these patients underwent atherectomy at 
primary atheroscl lesions responsible for SAP (n=25) and UAP (n=23). Frozen samples 
were studied with antibodies agatnst smooth muscle cell, macrophages (MAC), endothe- 
lial cells, NEP and neutrophils (CD1 1 b, elastase, and myeloperoxidase). The presence of 
NEP MAC, and neutrophif immunoreactivity was quanbfied, respectively, using computer- 
aided planimetry. For the identificatron of cell types which stain positive for NEP, immun- 
odouble staining was also performed. Results: Quantitative analysis demonstrated that 
neutrophil,MAC or NEP positive area in patients with UAP was siginificantly (PcO.01) 
higher than rn patients with SAP. Moreover, immunodouble statning with NEP and neutro- 
phils clearly showed that not only NEP-positive (mature) neutrophiis but also NEP-nega- 
tive (immature) neutrophils were rnfiltrated in unstable plaques obtained from culprit 
lesions in patients with UAP. Conclusions: These findings strongly suggest that neutro- 
phils play an important role in the pathogen&s of plaque dostabiltzation in human coro- 
nary arteries. Moreover, an infiltration of immature neutrophils in unstable coronary 
plaques may relate to rapidly progressive inflammation affecting atherosclerotic plaques. 
1131-186 The Acute-Phase Response of Interleukin(lL)-6 Is 
Genetically Modulated. A Prospective Study in Patients With 
Multivessel Coronary Disease Undergoing Surgical 
Revascularization 
Francesco Burzotta, Felicrta Andreotti, Licia lacoviello, August0 Di Castelnuavo, Franca 
Glreca, Nicola Luciani, Roberto Zamparelli, Rocco Schiavello. Filippo Santarelli, 
Elisabetta Lapenna, GianFederico Possati, Attilio Maseri. hslitute of Cardiology, Catholic 
UniversifL: Rome, #a/~ Deparfment of Vascular Sio/ogy and Pharmacology: Consorzio 
Mario Negti Sud, Santa Maria Imbaro, /fa/y 
Background: Plasma levels of the acute-phase cytokine, interleukin(lL)-6. can predict 
adverse events in patrents with coronary artery disease. A novel variant withrn the pro- 
moter of the IL-6 gene (-174 G/C) affects basal IL-6 levels in viva and IL-6 transcription 
rates in vitro. To date the association between this gene variant and the acute-phase 
response of IL-6 has not been investigated in any clinical setting. Methods: Elective cor- 
onary-artery-bypass-grafting was used as a clinical model of acute-phase stimulus. In 
111 consecutive patients with multivessel coronary artery disease undergoing elective 
surgical revascularization, plasma levels of IL-6 were assessed before operation, after 
24h, 48h, 72h, and at discharge. IL-6 genotyping at position -174 was performed on 
extracted DNA as previously described. Results: Baseline and surgical characteristtcs 
did not differ among genotypic groups (GG, GC and CC in 56, 35 and 9% of patients, 
respectively, in Hardy-Weinberg equilibrium). IL-6 levels showed an average 17.fold 
increase, peaking at 24h (pcO.0001). Peak IL-6 values did not differ significantly by geno- 
type, but the subsequent rate of decrease was genotype-dependent, GG homozygotes 
exhibiting higher concentrations compared to C-allele carriers (P=O.O21). GG homozy- 
gosity was also associated with srgnificantly longer intensive-care and hospital stays 
compared to C-allele carriers (2.2 “s 1.1 days, P=O.Oi, and 6.2 “s 4.5 days, P&02). 
Conclusion: Among patients undergoing surgical revascularizatron the levels of IL-6 are 
genetically modulated and such genetic background may affect clinical course. In a wider 
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sense, the -174 G/C gene variant may not only modulate the IL-6 acute-phase response 
but may contribute to disease-susceptibility and to clinical outcome in patients with coro- 
nary artery disease. 
--L.CG+CC 
1131-187 CD40 Ligand Enhances Prostaglandin E2 and Thromboxane 
A2 by Stimulating Cyclooxygenase-2 in Endothelial Cells 
Christoph D. Garlichs, Alexander Schn&sser, Tobias Geis, Saeed Eskafi, Heike Kloos, 
Margarete Goppelt-Struebe, Josef Ludwig, Werner G. Daniel. University Erlangen- 
Nuremberg, Clinic of Internal Medicine I/, Erfangen, Germany 
Human atherosclerotic lesions express cyclooxygenaseP (COX-2) indicating a potential 
inflammatory pathway. In addition, CD40L-CD40 interactions see” to play a crucial role 
in the development of atherosclerosis. We determined whether membrane-bound CD40 
ligand can (1) induce COX-2 in human endothelial cells, and (2) whether enhanced 
expression of COX-2 correlates with elevated levels of eicosanoids. Methods: Human 
endothelial cells (HUVEC) were stimulated using the CD40Ltransfected cell line P3xTB- 
A7 or P3x63 cells (wild-type control). Prostaglandin E2 (PGEP) and thromboxane A2 
(TXAP) were measured by using commercially available ELISA. COX-2 expression was 
detected by Western blot analysis. Results: Stimulation of HUVEC by mbCD40L signifi- 
cantly enhanced PGE2 production as compared to control cells (after 6 hours of coincu- 
bation: 113.3r3.0 vs. 10.&l .9 pg/mL, p<O.OOl). In addition, mbCD40L induced TXA2 
production (19.2r0.3vs. 10.3+1.4 pg/mL, ~~0.001). Western blot analysis revealed a sig- 
nificant increase in COX-2 protein after stimulation with mbCD40L as compared to con- 
trol cells or thrombin (transfectant 176% vs. wild-type control 14% vs. 1 U/ml thrombin 
100%). Conclusion: MbCD40 ligand can augment the expression of 60X-2 and causes a 
significant elevation of PGEZiTXAZ in HUVEC, thus atherogenic effects prevail. Our find- 
ing may have therapeutic implications in view of the recent availability of selective COX-2 
inhibitors, which may suppress the mbCD40L-induced increased COX-2 activity. 
1131-188 No Clear Role for the -159T/C Polymorphism of the CD14 
Monocyte Receptor in Progression of Atherosclerosis 
Willem Ft. P. Agema, Johan W. Jukema, Moniek P. M. de Maat, Joram de Kraker, Aeilko 
H. Zwinderman. John J. P. K&&in, Ton J. Rabelink. Leiden University Medical Center, 
Laiden, The Netherlands, JNO-PG Gaubius Laboratory, Leiden, The Netherlands 
Background: Coronary atherosclerosis is a disease with a clear inflammatory compo- 
nent. Therefore, genetic variations related to cytokine release by leukocytes might influ- 
ence this process. The -159TiC polymorphism in the promoter region of the CD14 
monocyte receptor gene influences the density of membrane-anchored CD14 on the 
monocyte surface. This leads to an altered ability to bind lipopolysacharides. This in turn 
results in an increased expression of E-selectin and release of inflammatory cytokines. 
These endotoxins elicit the transcription of adhesion molecules, thus possibly promoting 
atherosclerosis formation. Despite this logical cascade of physiological processes hardly 
‘any clinical information is available on the importance of this polymorphism. Therefore, 
we evaluated the association of this CD14 polymorphism with progression of coronary 
atherosclerosis. Methods: Patients were enrolled in the REGRESS trial which studied 
the impact of pravastatin therapy on coronary atherosclerosis. Angiography was per- 
formed at baseline and after 2 years and analysed by quantitative coronary angiography. 
Progression of atherosclerosis was determined by measuring changes in mean segment 
diameter (MSD) or minimum obstruction diameter (MOD). Genotyping of the -159T/C 
polymorphism was performed in 759 patients. Results: The genotype distribution was 
28% TT, 49% CT, 23% CC. The population was in Hardy-Weinberg equilibrium. Baseline 
characteristics were comparable for the genotypes. In the placebo group there was no 
difference in change in MSD, MOD or major clinical events between genotypes. Treat- 
ment with the HMG CoA reductase inhibitor pravastatin reduced progression of coronary 
atherosclerosis and adverse events equally for all genotypes. 
Endpoints per genotype in placebo group 
MSD (mm) 
MOD (mm) 
Events 
ST TC 
0.11r0.25 0.11 kO.21 
0.12+0.21 0.13*0.27 
24% 17% 
CC 
0.09+0.17 
0.10*0.22 
18% 
P-value 
NS 
NS 
NS 
Conclusion: Despite its biological effect the -159T/C polymorphism in the CD14 “ono- 
cyte receptor gene is not associated with progression of coronary atherosclerosis in this 
Dutch population nor does it influence the efficacy of pravastatin in reducing atheroscle- 
rosis. 
1131-189 Transcardiac Gradient of Plasma Matrix Metalloprotainase 
Correlates With Vascular Remodeling in Coronary Artery 
Disease: Intravascular Ultrasound Study 
Hiromitsu Yamamoto, Shire Uemura, Shinichi Fujimato, Yoshio Tomoda, Toshio 
Hashimoto, Kazuhiro Dohi. Nara Medical University, Kashihara, Japan 
Background: Matrix metalloproteinases (MMPs), that are locally overexpressed in ath- 
erosclerotic lesion, play important roles in the coronary plaque instability as well as lesion 
formation. Sirjce MMP expression is pivotal in morphological changes of vascular tissue, 
we investigated the relationship between plasma levels of MMPs and vascular remodel- 
ing in coronary artery disease. Methods: Twenty-two‘patients with stable coronary artery 
disease were enrolled in this study. Blood samplings were performed at aortic sinus (Ao) 
and coronary sinus (CS) during cardiac catheterization. Plasma levels of MMP-I, MMPP 
and MMP-9 were measured by ELISA, and transcardiac gradient of plasma MMP levels 
(dMMP; [CS] [Ao]) were calculated to estimate the quantity of their elaboration from cor- 
onary vasculature. To assess coronary arterial remodeling, the cross-sectional area 
within external elastic membrane (EEM-CSA) was measured by intravascular ultrasound 
(IVUS) at atherosclerotic lesions with “ore than 50% stenosis, as well as both proximal 
and distal reference sites. We defined a remodeling index (RI) as dividing the lesion 
EEM-CSA by the average of the proximal and distal reference site EEM-CSA, then 
patients were categorized as positive remodeling group (PR: Rl>l.O) and negative 
remodeling group (NR: RI<1 .O). Results: 1) Eight patients categorized as PR, and 14 as 
NR. 2) Transcardiac level of MMP-1 was significantly higher in group PR than group NR 
(15.9 ti- 5.9 vs. 0.2 +/- 1.9 ngiml, ~~~0.05). 3) Trasncardiac level of MMP-9 was signifi- 
cantly higher in group NR than group PR (3.9 +/- 1.9 vs. -0.8 +/- 0.8 ngiml, p<<O.O5). 4) 
Transcardiac level of MMP-2 did not correlate with coronary remodeling. Conclusions: 
Transcardiac level of MMP-1 was significantly elevated in patients with positive remodel- 
ing of coronary artery, whereas transcardiac level of MMP-9 was significantly elevated in 
patients with negative remodeling of coronary artery. It may suggest that 1) transcardiac 
levels of MMPs may represent a local elaboration of MMPs from coronary circulation. and 
2) different expression regulation of the individual members of MMPs may dominate the 
remodeling pattern in local coronary atherosclerotic lesion. 
1131-190 MMP3 (Stromelysin-1) Genetic Polymorphism Distribution 
in Patients With Aneurysmal Coronary Artery Disease 
Nicolas Lamblin, Christophe Bauters, Nicole Helbecque, Xavier Hermant, Michel 
Bertrand, Philippe Amouyel. /NSERM U508, LJLLE, France, Hepita/ Cardiologique, 
LILLE, France 
Aneurysmal coronary artery disease is characterized by abnormal dilation of a localized 
or diffuse segment of the coronary arterial tree. Approximately 1 to 5% of the patients 
with coronary atherosclerosis have coronary aneurysm(s); the pathogen&s of this pro- 
cess is unknown. Matrix metalloproteinases (MMPs) are involved in the degradation of 
extracellular matrix proteins. We investigated whether a polymorphism in the promoter 
region of MMP3 may be associated with coronary aneurysms (CA). We designed an 
angiographic case-control study : 95 patients with CA were compared with 155 control 
patients.The extent of coronary artery disease was similar in the CA group and in the 
control group. The results of the 5A/6A polymorphism analysis are shown below: 
CA (n=95) Control (n=155) P 
5A/5A 32 (34%) 31 (20%) 0.04 
5Al6A 47 (49%) 86 (56%) 
6AJ6A 16 (17%) 38 (24%) 
Allele 5A 111 (58%) 148 (48%) 0.02 
Allele 6A 79 (42%) 162 (52%) 
The 5A allele, associated with the higher transcriptionnal activity, was significantly “ore 
frequent in the CA group. This suggest that the allele 5A of MMP3 is a potential risk factor 
for CA, and that by the higher degradation of eXrracellular matrix by MMP3 may be a fac- 
tor of development of CA. 
1131-l 91 The Effect of Pravastatin on the Production of Matrix 
Metalloproteinase in Vascular Smooth Muscle Cells 
Hiroyasu Uzui, Jong-Dae Lee, Hiromasa Shimizu, Yasuhiko Mitsuke, Taketoshi 
Yamazaki, Takanori &da. Fukui Medical Universify First Department of Jnternal 
Medicine, Fukuf, Japan 
Background: It is well accepted that HMG-CoA reductase inhibitors reduce vascular 
events through stabilizing atherosclerotic plaque despite minimal effect on angiographic 
stenosis. We hypothesized that such beneficial effects are derived from their inhibitory 
effects on matrix metalloproteinase (MMP) production in atherosclerotic lesions. To test 
the hypothesis we evaluated potential effects of pravastatin (PR) on MMP production 
both in cultured rat vascular smooth muscle calls (SMC) and in patients with ischemic 
heart disease (IHD). Methods: (1) In cultured SMC, we examined the effects of PR on 
proliferation (3H-thymidine incorporation after 24h), migration, and production of MMP-2 
(gelatin zymography) stimulated by PDGF (10 ngiml). (2) We measured serum levels of 
MMP-2, tissue inhibitor of metalloproteinase (TIMP-2) and interleukin-6 (IL-6) using 
ELISA methods in 28 patients (19 male, 9 female, mean age 64) with IHD who were on 
PR therapy (mean dose 14.2 * 2.1 mglday, mean therapy period 26 + 8 months). Data 
were compared with those of patients (42 male, 16 female, mean age 62) with IHD who 
showed similar serum LDL-cholesterol level (115 t 22 mgidl) but were not on PR therapy. 
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None had evidence of acute coronary syndrome, inflammatory disease, collagen disease 
or cancer at the time of evaluation, No differences were found in the incidence of hyper- 
tension, diadetes mellitus between 2 patients’ groups. Rest&s:(i) PR (l-50 NM) did not 
affect SMC proliferation and mlgratlon, but suppressed dose-dependently the production 
of MMP-2 stimulated by PDGF(li% suppression by 10 FM of PR, 23% suppression by 
50 PM). (2) Although serum TIMP-2 levels (41 + 10 vs 37 t 8 ngidl) were not different 
between 2 patients’ groups, the serum MMP-2 (401 & 84 vs 543 + 166 ngiml, p < 0.01) 
and IL-6 (8.3 i 1.9 vs 14.9 t 2.3 pg/ml, p c 0.05) concentrations in patients on PR ther- 
apy’were significantly lower than in patients not on PR. Conclusion: Data suggested that 
PR stabilizes atherosclerotic plaques, at least in part, through its inhibitory effect on the 
production of MMP-2 in SMC, and that the reduced circulating levels of MMP-2 and IL-6 
may reflect the effect of PR on atherosclerotic plaques. 
1131-l 92 The Effect of Osteopontin on Aortas of Transgenic Mice 
Kikuo Isoda, Yasuhiro Kamezawa, Norihtro Tada, Mikoto Yoshlda, Nobutaka Hirooka, 
Fumitaka Ohsuzu. Nafional Defense Medica/ College, Jokorozawa, Japan 
Background: Osteopontin (OPN) is a noncollagenous adhesive protein found at the site 
of atherosclerotic lesion. However, the role of OPN expression is poorly understood in 
viva In the present study we examined the effect of OPN on aortas of transgenic mice. 
MethodsTo investigate the role of OPN, we generated transgenic mice overexpressing 
OPN controlled under the cytomegalovirus ‘enhancer/chicken beta-actin promoter. OPN 
expression was evaluated by Northern blot analysis, RT-PCR and immunohistochemistry. 
To assess the phenotype of aorta in transgenic mouse, histological and immunohis- 
tochemical analysts were performed. Results. We obtained 3 line of transgenic mice, the 
OPN mRNAs were detected in almost all tissues. These mice showed poor growth, 
severe hepatomegaly and splenomegaiy, and the high rate of generation of malignant 
tumor and aortlc aneurysms. Furthermore medial thickness and the amount of vascular 
smooth muscle cells (VSMCs) were increased. The VSMCs were stained immunohis- 
tochemically with SMl but were not stained with SM alpha actin, indicating the transition 
of VSMCs from the normal contractile phenotype to the synthetic phenotype and the 
mcrease of proliferative property. lmmunohistochemistry and RT-PCR revealed aortic 
wall expressed matrix metalioprote~nase (MMP)-1 and MMP-9. Conclusion: OPN plays 
an important role in regulating proilferation of VSMCs and production of SMC MMP 
1131-193 Preserved Arterial Wall Thickening After Injury in IGF-Im/m 
Mice 
Hongyan Li, Mojca Remskar, Juliana Yano, Mario Foumier, Kuang-Yuh Chyu, Prediman 
K. Shah, Bojan Cercek. Atherosclerosis Research Center, Cedars-Sinai Medica/ Center, 
Los Angeles, CA 
Background: Previous studies in hypophysectomized animals have suggested that insu- 
lin-l!ke growth factor-l (IGF-I) is a mediator of intimal thickening after arterial injury, IGF- 
lmlm mice with mutant IGF-1 allele are deficient in serum and tissue IGF-1. We evalu- 
ated the effect of IGF-1 deficiency on intimal thickening after arterial injury in IGF-im/m 
mice. Methods: Wild type (C57BLi6J) and IGF-imlm mice underwent periadventitial col- 
lar induced carotid artery injury. The IGF-1 levels in the serum and in injured and con- 
twlateral uninjured carotid arteries were determined by RIA 7 days after injury. The 
lntimal thickening in injured arteries was measured with computer-assisted morphometry 
21 days after injury. Results: IGF-lm/m mice had lower serum IGF-1 (97112 rig/ml) com- 
pared to wild type (189t24 ng/ml)(p<0.05, n=6). Carotid artery IGF-1 (pg/mg protein) and 
intimal thickening (urn sq) are shown in Table 
IGF-1 mJm wild type 
injured carotid IGF-7 ,pg/mg protein,n=4 73+/-l 2 319+/-18 
Uninjury carotid IGF-l,pg/mg Proteln,n=4 53+/-g 109+/-17 
Injured carotid intima,um sq 0.026+/-0.015 (n=6) 0.022+/-0.016 (n=lO) 
(Data are meanistd; *PcO.O5 compared to wild type uninjured carotid by T test) Conclu- 
sion: lntimal thickening after artenal wall injury is preserved in IGF-lmim mice despite 
lower carotid artery IGF-7 concentration. These data suggest that complete serum and 
vascular deficiency of IGF-1 is necessary to prevent intimal thickening after vessel injury. 
1131-I 94 Calcium-Antagonist (Amlodipine) and AtorvaStatin Synergy 
in Inhibiting Atherosclerosis in ApoE*3-Leiden Mice. The 
CASSIA Study 
Johan W. Jukema, Dianne J. M. Delslng, Arnoud van der Laarse, Hans van der Boom, 
Erik H. Offerman, Louis M. Havekes, Hans M. G. Princen. Leiden University Medica/ 
Center, Leiden, The Netherlands, JNO-PG Gaubws Laboratory, Leiden, The 
Netherlands 
Background: Calciumantagonists (CAs) have been implicated to reduce atherosclerosis. 
However, in the REGRESS trial this was only observed in combination with statins. The 
present study aimed to evaluate a potential synergistic anti-atherosclerotic effect of calci- 
urnantagonists and statins in ApoE*3-Leiden transgenic mice, which are well known to 
develop human-like atherosclerosis when fed a high cholesterol (HC) diet. Methods: 4 
groups of 15 female mice received the following diets: 1) HC (control group), 2) HC + CA 
(amlodipine (Amlo), 0,002% w/w), 3) HC + statin (atorvastatin (Ator), 0.01% w/w) 4) HC + 
Amlo + Ator. The mice had a total cholesterol level of 21.8t3.4 mM. Amlo did not have an 
effect on cholesterol levels, whereas Ator caused a 53% reduction in cholesterol levels, 
mainly confined to the VLDL, IDL and LDL fractions. After 28 weeks of treatment the 
mice were sacrificed and the atherosclerotic burden and calcium content of the aortic 
root were determlned. Results: Lesion area was 0.33+0.15 mm* (control), 0.26~0.13 
mm* (Amlo), 0.08*0.08 mm* (Ator) and 0.03+0.02 mm2 (Amlo +Ator). Ator reduced lesion 
area with 77% (p<O.OOl), Atar + Amlo with 91% (pcO.001). This 61% reduction com- 
pared to Ator alone did not reach statistical significance, However, the calcified part of the 
lesion was reduced from 0,37+0.48% to 0.78+0.22% (52%) by Ator alone with an addi- 
tional 88% reduction to 0.02+0.03% with the combination Ator+ Amlo (pcO.OOl). Conclu- 
sions: Atorvastatin reduces atherosclerotic burden in ApoE9-Leaden mice and the 
combination with Amlodipine shows an additional effect especially on calcification. 
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835-l Raloxifene Effects on Serum Triglycerides in Osteoporotic 
Postmenopausal Women: Influence of Baseline Triglyceride 
Concentration and Subject Demographics 
Kristlne D. Harper, Deborah Grady, Somnath Sarkar, David A. Cox, Elizabeth Barrett- 
Connor. Lilly Research Laboratories, Indianapolis, IN, L&SF: San Francisco, CA 
Background: Estrogen therapy mcreases serum triglyceride (TG) and occasionally 
induces hypertriglyceridemia in some postmenopausal women. The purpose of the 
present study was to characterize the effect of raloxifene (RLX). a selective estrogen 
receptor modulator, on serum TG in osteoporotlc postmenopausal women, and to deter- 
mine whether baseline hypertriglyceridemia, diabetes, or other demographic characteris- 
tics that may predispose women to hypertriglyceridemia influence this effect. Methods: 
The Multiple Outcomes of Raloxifene Evaluation (MORE) trial randomized 7705 
osteoporotic postmenopausal women to placebo (PL) or RLX (60 mgld or 120 mgld) for 3 
years. Fasting serum TG concentration was determined in a subset of 2738 women. 
Results: The median serum TG concentration decreased in all groups after 3 years, 
although significantly more so in the placebo group (PL, -3%; RLXGO. -1%; RLX120, -1%; 
P=O.O02). RLX did not increase serum TG in diabetics or in women with varying degrees 
of hypertriglyceridemia at baseline [TG >250 (N=122), >300 (N=60), or >400 mg/dL 
(N=15)]. Median serum TG increased among women in the lowest tertlle of baseline TG 
(c 79 mg/dL), but not in the middle (79-i 18 mg/dL), or upper (< 118 mg/dL) tertiles, and 
was significantly different from PL (P=O.O2) only for the RLX 120 group in the lowest ter- 
tile of baseline TG (Pi, t-4%; RLXGO, +5%; RLXlPO, +12%). Body mass index (BMI) and 
weight were the only demographic characteristics to interact significantly with treatment. 
Among women in the highest tertile of BMI, RLX increased the serum TG significantly 
compared with placebo (PL, -3%; RLX 60, +6%; RLX 120, +4%); the absolute increase 
from baseline with RLX was 4.4 mg/dL. Similar results were obtained for subgroups of 
weight. The effect of RLX on serum TG was not mfluenced by age, smoking, or alcohol 
use. Conclusions: RLX does not increase serum TG in osteoporotic postmenopausal 
women overall or in women with baseline hypertriglyceridemia or diabetes. Aside from a 
slight increase in serum TG among heavier women, the lack of effect of RLX on TG was 
not influenced by demographic characteristics. 
835-2 
2:15 p.m. 
Blood Pressure and Vascular Benefits of Hormone 
Replacement Therapy Are Enhanced in Women Who Are 
Postmenopausal For Less Than 5 Years 
Kimberly A. Brownley, Alan L. Hinderliter, Sheila G. West, Karen M. Grewen, Susan S. 
Girdler, Kathleen C. Light. Univers~fy of Norfh Carolina, Chapel Hi//, NC 
Background: Postmenopausal estrogen replacement has been related to lower cardio- 
vascular risks, including reductions in blood pressure (BP) and incidence of stroke. How- 
ever, these effects are not seen in older women with established coronary heart disease, 
Implicating age and, perhaps, menopause duration as potential moderators of estrogen’s 
cardiovascular benefits. Methods: In a 6-month placebo-controlled double-blind study, 
we investigated estrogen’s actions on hemodynamic, cardiac, and neuroendocrine 
function. Pre- vs. post-treatment BP, cardiac index (Cl), systemic vascular resistance 
index (SVRI), and plasma catecholamine responses during baseline and mental stres- 
sors were compared in 69 women (20 with mild hypertension but with no history oi heali 
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disease), who were randomized to placebo or to active hormone replacement [HRT: 
either oral conjugated estrogens alone (Premarin) or estrogens plus medroxyprogester- 
one (MPA)]. Results: Both groups on HRT showed decreases in SVRI and modest BP 
reductions which differed from the unchanged responses of those on placebo (Ps < 0.05) 
after 3 and 6 months of treatment. SVRI reductions were greater among hypertensive 
compared to notmotensive women (P < 0.05). Also, women on HRT (particularly those 
who were hypertensive and/or received MPA) showed increases in stroke volume and Cl 
at 6 months (Ps< 0.05). HRT was also related to significant decreases in echocardio- 
graphic measures of left ventricular mass index and relative wall thtckness (5% and 3%, 
respectively), and in norepinephrine (Ps 0.05). Menopause duration was a significant 
moderator of HRT effects. Compared to women who were postmenopausal more than 5 
years (n=27), women who experienced menopause less than 5 years prior to testing 
(n=i9) showed greater reductions in diastolic (-9.1 vs. -2.3 mmHg) and mean arterial BP 
(-8.7 vs. -2.5 mmHg) (Ps < 0.02) and trends toward lower SVRI and resting 
norepinephrine. Conclusion: Reductions in hemodynamic load on the heart may con- 
tribute to the reduced cardiovascular risk in relatively healthy postmenopausal women 
who use oral estrogens, and the initial postmenopausal years may present a critical win- 
dow for effective treatment. 
835-3 
2:30 p.m. 
Effects of Hormone Replacement Therapy on C-Reactive 
Protein in Healthy Postmenopausal Women: Comparison 
Between Oral and Transdermal Administration. 
Maria Grazia Modena, Leonardo Fontanesi, Annalisa IeNoci, Rosario Rossi. University of 
Modena, Modem, /taly 
Background: C-reactive protein represents an independent risk factor for cardiovascular 
desease and stroke. Previous studies have demonstrated that oral hormone replacement 
therapy (HRT) increases C-reactive protein (CRP) plasma level in postmenopausal 
women. There are no studies on the effect of transdermal estrogen on CRP concentra- 
tion in healthy postmenopausal women and on the possible different effects of various 
hormonal preparation and their routes of delwery. This study compared the effects of oral 
estrogen and transdermal estradiol on CRP serum level in healthy postmenopausal 
women. Methods: 42 healthy postmenopausal women (age 61+/-11 years) were 
enrolled in the study and were randomly assigned to receive contincus combined oral 
HRT (0.625 mgiday conjugated equine estrogen plus 2,5 mgiday medrcxyprogesterone 
acetate) or transdermal 17-b&a estradiol(50 mg/day plus 2.5 mg/day medroxyprcgester- 
one acetate) for 6 months. CRP was measured at baseline and after 6 months of treat- 
ment. All women evaluated had no prior history of cardiovascular deseases, cancer or 
inflammatory conditions. A history of hypertension, diabetes mellitus, dislipidemia, smok- 
ing habit were the exclusion criteria of the study. Results: 20 women received oral estro- 
gen and 22 transdermal estradiol. Baseline CRP concentration were similar in the two 
groups (0.22+/-0.20 mg/dl in the oral estrogen group and 0.24+/-0.19 mgidl in the trans- 
dermal estradiol group; p=ns). After 6 months of treatment, CRP concentration were sig- 
nificantly increased in the oral estrogen group (from 0.22+/-0.20 mgldl to 0.45+/-0.27 mg/ 
dl; p=O.O03) and significantly reduced in the transdermal &radio1 group (from 0.24+/- 
0.19 mgidl to 0.14+1- 0.18 mgldl; p=O.O26). Conclusion: Our observations raise the pos- 
sibility that the presumed proinflammatory effects of HRT is correlated with the estrogen 
preparation and the route of administration of the hormone. Reduction of CRP, obtained 
using transdermal estradiol, is of considerable clinical interest for the potential relevant 
impact on the atherosclerotic process. 
835-4 
2:45 p.m. 
Antianginal and Lipid Lowering Effect of Chronic Oral 
Androgen Supplementation in Elderly Male Patients with 
Coronary Heart Disease 
Giuseppe M. C. Rosano, Giuseppe Mercuro, Filippo Leonardo, Sandra Zoncu, Massimo 
Fini, Daniela Onorati. San Raffaele Roma - TOSlNVEST SANITA’, Roma, /ta/y 
Background: Low plasma testosterone levels have been suggested to be associated 
with coronary artery disease in men and acute testosterone administration has been 
shown to improve exercise-induced myocardial ischemia in men. Whether this acute 
effect is sustained in long term therapy and whethe this is associated with a more favour- 
able lipid profile is nqt known. Methods: To test the effect of chronic testosterone 
replacement upon exercise test parameteres and lipoprotein profile 87 elderly men with 
coronary artery disease (CAD) entered a placebo-controlled parallel study. Pts were ran- 
domized to receive either testosterone undecanoate (TU) or placebo for three months. 
Results: After TU supplementation, episodes of angina were reduced by 23% (p<O.O5), 
the number of patients with episodes of transient myocardial ischemia on 24 hour EC6 
monitoring was also significantly reduced by TU (66% vs 74% ~~0.05). The number of 
episodes of ST depression/ patient and the total ischemic burden were reduced after TU 
(4.3+/-1.2 vs 6.8+/-0.9, p&05; 23+/-g vs 36+/-12, ~~0.05 respectively). After oral TU 
serum total cholesterol (TC) and triglyceride (TG) levels were significantly reduced 
(238+/-18 vs 256+/-23 mg/dl, p< 0.01;196+/-32 vs 231+/-25 mg/dl, p<O.Ol respectively), 
the serum level of HDL-c were increased by 6% (p < 0.05), but the plasma levels of apo- 
lipoprotein-Al (APO-Al) and B (APO-B) remained unchanged. Conclusion: Oral test- 
osterone administration improves exercise-induced myocardial ischemia and lipoprotein 
profile in elderly men with CAD suggesting a role for testosterone replacement in men 
3:oo p.m. 
835-5 Endothelial Function and Plasma Endothelin-1 Levels 
Following Administration of Estradiol Valerate and 
Cyproterone Acetate in Menopausal Women at Risk for CAD 
Giuseppe M. C. Rosano, Filippo Leonardo, Giuseppe Mercuro, Sandra Zoncu, Massrno 
Fini. San Raffaele Roma - TOShVVEST SANITA’, Roma, f&?/x Universify of Cagliari, 
Cagliari, My 
Background: Impairment of vascular endothelial function is an initial step in the develop- 
ment of atherosclerosis. Estrogen replacement therapy in post-menopausal women 
improves endothelium-dependent, flow-mediated dilatation (FMD), while the cyclical 
adjunct of a prcgestin may reverse this effect. Methods: The purpose of this study was to 
evaluate endothelium-dependent FMD in the brachial artery and the plasma levels of 
nitrite, nitrate and endothelin-I in 14 postmenopausal women (PMW) (mean age: 64+1-6 
yrs) with 21 risk factor for CAD. After a baseline (8) evaluation, PMW entered a double- 
blinded, placebo controlled single cross-over study and were randomized to receive 
orally either estradiol valerate (EV, 2 mg) alone for 21 days or EV (2 mg) for 21 days in 
combination with cyprotercne acetate (C, 1 mg) for the last 10 days. PMW were crossed- 
over the complementary treatment 7 days after completing the 1st treatment phase. 
PMW underwent measurement of brachial artery diameter before and after reactive post- 
ischemic (5 min) hyperemia with high resolution ultrasound at B, at day 10 and 21 of each 
treatment phase. Results: No difference was noted in brachial artery diameter at B and 
at the end of each treatment phase. EV alone or in combination with C significantly 
improved FMD compared to B. No difference was noted during the treatment phases in 
the improvement in FMD between day 10 and 21. 
Effect of Estradiol and Cyproterone on Endothelial Function 
Baseline Estradiol Valerate Estradiol Valerate 
+Cyproterone ace- 
tate 
Brachial artery (mm) 4.3+/-0.8 
FMD (%) 7+1-4 
Endothelin-1 (rig/l) 1.42+/-0.3 
**=p<o.o1 
4.3+/-0.7 4.4+/-0.9 
12+1-3”* l l +/-4- 
1.21+/-0.4 1.22+/-0.5’ 
Conclusion: Hormone replacement therapy with EV and C improves endcthelial function 
and reduces plasma levels of endothelin-1 in PMW at risk of CAD. These effects may be 
relevant for cardioprotection. 
835-6 
3:15 p.m. 
Effects of Synthetic Progestin on Nitric Oxide Bioactivity 
and Markers of Inflammation in Overweight 
Postmenopausal Women 
Kwang K. Kch, Dong K. Jin, Jeong Y. Ahn, Sean-Kyu Lee, Seong H. Yang, In S. Choi, 
Eak K. Shin. Cardiology, Inchon, South Korea, Radiology, Inchon, South Korea 
Background: We have previously shown that unopposed estrogen improved nitric oxide 
(NO) bioactivity and reduced cell adhesion molecules (CAMS) in healthy postmenopausal 
women (PMW). Experimental and animal studies suggest that synthetic progestin may 
negate the favorable effects of estrogen. Nonetheless, observational studies report no 
differences in risk for clinical cardiovascular events between users of unopposed estrc- 
gen and users of estrogen combined with synthetic progestins. Obesity is “insulin resis- 
tance syndrome” Accordingly, hormone replacement therapy may not have comparable 
benefit in overweight (OW) PMW. Methods: We administered micronized progesterone 
(MP) 100 mg or medroxyprogesterone acetate (MPA) 2.5 mg with conjugated equine 
estrogen (CEE) 0.625 mg daily during 2 months to 15 OW PMW. This study was random- 
ized, double-blind, crosswer in design. *=P<0.05;“*=Pc0.001 vs. Baseline. Data= 
mean&D. Lipoproteins (mg/dl), CAMS @g/ml) Results: CEE+MP and CEE+MPA thera- 
pies significantly changed lipoprotein levels from baseline values (PcO.05 by ANOVA). 
CEE+MPA or MP significantly improved flow-mediated dilation (FMD) and further, 
reduced E-selectin (E-S) levels (PcO.001 and P=O.O23 by ANOVA, respectively). Of note, 
overall, there were no significant differences between CEE+MPA and CEE+MP However, 
there were no significant inverse correlations between the degree of change in FMD and 
the degree of change in CAMS levels after CEE+MP and CEE+MPA. Conclusions; 
Improvement in NO bicactivity and reduction of inflammatory CAMS may account, in part 
for the cardiovascular benefit of synthetic 01 natural progestagen combined with estrogen 
in OW PMW. 
FMD (%) 
E-S 
ICAM- 
VCAM-1 
Baseline CEE+MP 
4.55k1.53 ’ 7.44*1.51** 
49.6*18.5 40.9*15.9* 
2311133 188r97 
308+155 312*125 
CEE+MPA 
7.75+1.28** 
39.9r16.4 
159+92 
313t148 
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1159-159 Polycystic Ovary Syndrome Is Associated With Elevated 
Central Pulse Pressure and increased Proximal Aortic 
Stiffness 
Caren G. Solomon, Gary F. Mitcheii, Nadia 0. Skali, Rhonda Bentley-Lewis, Ellen W. 
Seely, James t? Sheehy, Scott D. Solomon, Andrea Dunaif. Brigham and Women’s 
Hospifal. Boston, MA, Cardiovascular Engineering Inc., Holltston, MA 
Background: Women with polycystic ovary syndrome, a condition characterwed by 
hyperandrogenism and chronic anovulation, are profoundly insulin resistant, and may 
have increased risk ior cardiovascular disease. Insulin resistance may be associated with 
increased conduit vessel stiffness. Methods: To determine whether conduit vessel stiff- 
ness IS increased in polycystic ovary syndrome, we evaluated central pulsatile hemody- 
namics using calibrated carotid tonometry and central aortic Doppler flow in 8 affected 
women and in 16 women with normal menstrual cycles, all with body mass index? 27 kg/ 
m2. Results: There were no significant differences between affected and control women 
in age (3Oi4 vs. 32t 6y) or body mass index (41*7 vs. 38&6 kgim2). Heart rate, mean 
arterial pressure, peripheral pulse pressure and cardiac output also did not differ 
between the groups. However, central pulse pressure was significantly higher m women 
with polycystic ovary syndrome (4959 vs. Controls 4117 mmHg, pc.05). Higher central 
pulse pressure was attributable to increased characteristic impedance of the aorta 
(188t60 vs. 145k39 dynes x sec/cm5, pc.05) and a larger forward pressure wave (42+10 
vs. 35i6 mmHg, pc.05) in the setting of similar peak aortic flow (287k.44 vs. 31 lk.56 ml/ 
set, p=NS). Conclusion: In summary, women with polycystic ovary syndrome have 
increased stiffness of the central aorta that is independent of mean arterial pressure and 
is not apparent from examination of peripheral blood pressure alone. Higher aortic stiff- 
ness may contribute to increased cardiovascular risk in affected women. 
1159-160 Unfavorable Effect of Caffeine on the Elastic Properties of 
the Aorta: Insights Into the Mechanism of Action 
Charalambos Vlachopoulos. Kozo Hirata, Mark Hicks, Michael O’Rourke. St. Vincenf’s 
Hospital Universify of Mew South Wales, Sydney Ausfralia 
Background: Studies on the effect of caffeine (the most wdely consumed active phar- 
macological substance) on the cardiovascular system have shown inconsistent results. 
Moreover, the effect of caffeine on aorlic mechanics has not been investigated. Aortic 
elastic properties are Important determinants of left ventricular function and coronary 
blood flow and have been identified as prognosticators of cardiovascular risk. 
Methods: We studied 20 healthy volunteers (50+16 yrs) in a randomized, double-blind, 
crossover fashion (250 mg of caffeine orally -equivalent to 2-3 cups of coffee- and pla- 
cebo). Carotid-femoral pulse wave velocity was measured as an index of aortic stiffness. 
Pulse wave velocity (=dUdt, where dL is the distance travelled by the pulse and di the 
time delay between the corresponding foot of pulse waves) was measured using an auto- 
mated, non-invasive device (CompliorB) that has been previously validated. To clarify 
whether any change in acrtic sliffness is due to any concomitant change in blood pres- 
sure we calculated effective vascular resistance (=[pulse wave veloc~ty]~/Mean Pressure) 
which is a pressure standardized index of aortic stiffness. 
Results: Caffeine led to an acute increase in pulse wave velocity (by 8.3.%, left fig.) 
denoting increase of aortic stiffness. This effect was prolonged (3 hours) and was accom- 
panied by an acute increase in systolic and diastolic pressure (by 10.9 and 7.3 mmHg 
respectively; P<O 001 for both). Effective vascular resistance increased with caffeine 
(right fig.) indicating contribution of a direct action of caffeine on the aorta. 
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Conclusions: Caffeine consumption leads to an acute deterioration aortic elastic proper- 
ties. A direct action of caffeine on the aorta contributes to this effect which has important 
implications on left ventricular function and coronary flow and provides a new inslght into 
the effects of caffeine on the cardiovascular system. 
1159-161 Weight Loss After Bariatric Surgery Normalizes Aortic 
Distensibility and Left Ventricular Function in Subjects With 
Morbid Obesity 
lgnatios Ikonomidis, Andreas Mazarakis, loannis Chiladakis, Periklis Davlouros, George 
Hahalis, Costas Evdoridis, Fotis Kalfarentzos, Antonis S. Manolis. University of Patras, 
Pafras, Greece 
Background.Mordid obesity has been associated with a high incidence of heart failure 
Aortic distensibility (AoD)is an important determinant of left ventricular (LV) function. We 
investigated whether: a) Increased body mass index (BMI, kgim2) is associated with 
impaired AoD and LV function b) weight loss after bariartic surgery (gastric by-pass) is 
associated with changes of AoD and LV function I” subjects with morbid obesity. Meih- 
ods: We studied 50 subjects (mean age 37+12 years) with tmorbid obesity (BM1>40 kg/ 
m2) by 2D, and Doppler Echocardiography AoD was calculated using the formula 2 x 
(pulsatlle change in aortic diameter)/[diastolic aortic diameter x (aortlc pulse pres- 
sure)].Aortic diameters were measured 3 cm above the aortic valve by 2D guided M- 
mode echocardiography and aortic pulse pressure was obtalned simultaneously by cuff 
sphygmomanometry. Forty five subjects had a follow up study 3 months after surgery. 
Results: All patients had normal systolic function before and after surgery. Aortic disten- 
sibility [normal range2.4.4.4 cmZxdyn(-1)x10(-6)] was severely impaired before surgery 
(Table). Increased BMI was related to decreased AoD (r=O.43,p<O.O1) and increased 
interventricular septum (IVS) and posterior (PW) wall thickness (IVS: wO.57, PW: r=0.58, 
pcO.01) before surgery. Decreased AoD was related to prolonged isovolumic relaxation 
time (IVRT) (r~0.43, p<O.Ol) and decelaration time (DT) (w0.40, p<O.O5). Three months 
after suroerv. BMI. LV diastolic diameter iLVDmmi. IVS imm). PW(mm). IVRT (msec) and 
”  I  
DT (msec) were all reduced, whereas AdD was it&+&d. (Table,’ pcd.01) 
surgery BMI AoD LVD IVS PW IVRT DT 
Before (1 week) 49*7 1.6+-l 5Oi4.8 11.2+1 11.2il 91+13 214+60 
After (3 months) 3819 3.4kl.i 46.7+3 9.3rI.3 9.z1.3 72*11 189r49 
P co.01 a01 <0.05 <O.Ol co.01 co.01 co.01 
Conclusion. Morbid obesity is associated wiih impaired aortic distensibility and left ven- 
tricular hyperlrophy leading to significant LV diastolic dysfunction. Weight reduction after 
bariatric surgery normalzes aortic distensibility, reduces left ventricular hypertrophy and 
thus, improves left ventricular diastolic function. 
1159-l 62 Patients With Non-Cardiac Vascular Disease and Chronic 
Angina Benefit from Enhanced External Counterpulsation 
Subash Bazaz, Elizabeth D. Kennard. Richard Holubkov, Nichole Dwyer, Lawrence 
Crawford. Cardiovascular Research Institute, UPMC, Pittsburgh, PA, University of 
Pittsburgh, Pittsburgh, PA 
Background: Enhanced external counterpulsation (EECP) is a non-invasive, non-phar- 
macological based therapy for patients wiih refractory chronic angina. EECP has been 
demonstrated to decrease angina in patients with coronary disease in randomized, pia- 
cebo-controlled trials. Patients with non-cardiac vascular disease (NCVD) are often 
excluded from EECP therapy because of presumed ineffective CounterpulsatiOn effect. 
Methods: Patients enrolled I” the International EECP Patient Registry were divided into 
those with a history of non-cardiac vascular disease (NCVD 584 patients) and those with- 
out (Non-NCVD 1499 patients). Baseline characteristics, degree of augmentation and 
clinical outcome both post-EECP and at six month follow-up were examined. 
Results: NCVD were older (68.3 yrs vs. 65.7 yrs, p<O.OOl), had higher incidence of dia- 
betes (54.8% vs. 34.9%, p<O.OOl) and congestive heart failure (35.0% vs. 24.6%, 
p<O.OOl). Cordnary artery disease was of longer duration (li.0 years vs. 10 years, 
~~0.05) and multivessel disease was more frequent (81.3% vs. 76.4% ~~0.05). NCVD 
had more frequent severe (Canadian Cardiovascular Society Classification Ill/IV) angina 
(81% for NCVD vs. 75.4% for non NCVD, pcO.01). Completion of the standard course of 
>= 35 hours of treatment was similar in the two groups (83% for NCVD vs. 84% for non- 
NCVD). Diastolic augmentarlon ratios were significantly lower in the NCVD group: at the 
end of treatment peak and area ratios achieved in patients with NCVD were 0.98 and 
1.12, and those for non-NCVD were 1.28 and 1.46 (p <O.OOl comparing both area and 
peak ratios). Despite this low level of augmentation, however, the NCVD patients had 
similar levels of angina reduction (81.4% of NCVD reduced by one CCS class vs 81.4% 
of non-NCVD, p=NS). This reduction was maintained at six months in 82.9% of NCVD vs. 
84.2% of non-NCVD, and the rate of MACE (death, MI, CABG, PCI) was also similar 
(7.9% for NCVD vs. 7.1% for non-NCVD,p=NS). 
Conclusion: Patients with non-cardiac vascular disease, despite poorer diastolic aug- 
mentation ratios, derive clinical benefit from EECP therapy m a comparable manner to 
those without NCVD, and should not be excluded from further studies involving this ther- 
apy. 
1159-l 63 Relation of Pulse Pressure to Carotid and Left Ventricular 
Geometry in Hypertension 
Pietro Sanna, Anton& Ganau, Pier Sergio Saba, *Mary J. Roman, Luciano Petretto, 
Giampaolo Sanna, *Riccardo Pini, ‘Richard 8. Devereux. Clinical Medicme, Universify of 
Sassad, Sassari, /ta& *Wei// Medical Co//ege of Cornell University, New York, NY 
Background: Pulse pressure is a risk factor for cardiovascular events. Since its impact 
on artenai and ventricular damage is not well known, we assessed relations of pulse 
pressure with carotid and left ventricular structure in hypertension. 
Methods: We studied 223 hypertensives (60% male; 55+12 years). Lefl ventricular mass 
index (g/m’) and carotid Intima-media thickness (mm) were assessed by ultrasonOgra- 
phy, We divided patients in tertiles of mean blood pressure @OS, 108-117, >I17 mmHg) 
and each tertlle in 2 subsets of pulse pressure (PP<60 and PP>60 mmHg). 
Results: (means adjusted by age and gender) 
Mea” pressure Mean pressure Mean pressure 
5108 (n. 72) 108-117 (n. 78) >117 (n. 73) 
PP<60 PP>60 PP<60 PP>60 PPCGO PP>60 
fn 41) In 311 (n 431 in 35) (n 27) , (n 46) 
49i7 67ill 52+6 71k.135 54-t6 8011 sy Pulse pressure 
Systolic pressure 135*8 147+8* 148&5§ 160+6”§ 162*7$# 182ti 9*§P 
Diastolic pressure 86*5 80r5” 96+3 89zt5” 108*8 102tIO’ 
Carotid thickness .78c.15 .8&20* .78+.17 .86&20* .79+.19 .83*.21’ 
Ventricular mass 82i13 88+15 93k.178 91+18 103t20§# 104r22§# 
‘=p<.Oi vs PPs60, same iertile; +pc 01 vs same PP group, 1st tertile: #=p<.Oi vs same 
PP group, 2nd tertlle. 
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After adjusting for mean pressure, both pulse and systolic pressure correlated positively 
and diastolic pressure negatively with carotid intima-media thickness (r=.31, .31, and 
.30; p<.Ol), not with left ventricular mass. In multivariate analyses, carotid wall thickness 
was predicted by age, gender and pulse pressure (R=.46; p<.OOl), and left ventricular 
mass by mean pressure, age and gender (R=.59; p<.OOi). 
Conclusion: In hypertension, pulsatile stress is the major hemodynamic stimulus to arte- 
rial hypertrophy. Left ventricular hypertrophy seems to be susceptible to parallel eleva- 
tions of both systolic and diastolic pressures, suggesting that the hypertrophlc stimulus of 
high systolic pressure may be offset by low diastolic pressure, possibly reflecting an 
afterload-coronary perfusion mismatch. Alternatively, these data may reflect the known 
association of elevated arterial stiffness with high resistance and low stroke volume, 
leading to ventricular concentric remodelling rather than hypertrophy. 
1159-164 Estimation of Time-Related Features of the Central 
Pressure Pulse From the Radial Artery Pressure Waveform 
Kozo Hirata, Andrew Wells, Charalambos Vlachopoulos, Michael F. O’flourke. St. 
Vincent’s Hospital, Sydney, Australia 
Background: Features of the central pressure are the wavefoot (at To), early systolic 
shoulder or peak (T,), late systolic peak or shoulder (T2) and incisura (I). From these can 
be measured time to peak aortic flow (T,-T& to peak effect of wave reflection (Tz-To), 
and left ventricular ejection duration (I-T& 
Methods: Though directly measurable from the carotid pulse, these indlces can be 
determined indirectly from the radial pulse, using applanation tonometry and a genera- 
lised transfer function to correct for pressure wave distortion in the upper limb. This 
method has the advantage of greater comfort and reproducibility plus the possibility of 
calibrating the synthesised aortic waveform from brachial pressure. Previous validation 
studies have shown correspondence between measured and synthesised aortic pres- 
sures for all indices except those dependent on identification of T,, T, or I. This may rep- 
resent a limitation of fluid-filled manometer systems. In this study, comparisons were 
made between time intervals calculated from high fidelity carotid and radial tonometric 
data, comparing T,-To, Ts-To and I-T,, between the estimated aortic pulse (generated 
from the radial), and the carotid on 255 occasions in 131 patients under a variety of con- 
ditions where waveforms were recorded sequentially, within 10 minutes under stable con- 
ditions. 
Results: In msec (with SD.). 
Estimated Central Central (Carotid) Difference 
Ejection Duration (I-T,) 331(27) 326(29) -5(19) 
TVTo llZ(11) 103(16) -9(14) 
Tz-To 230(24) 222(30) -9(24) 
Conclusion: Radial tonometric pressure tracings provide accurate timing intervals for 
hemodynamic indices in the central arterial pulse waveform. 
POSTER SESSION 
1160 Inflammation and Atherosclerosis II 
Monday, March 19, 2001, 3:00 p.m.-500 p.m. 
Orange County Convention Center, Hall A4 
Presentation Hour: 3:00 p.m.-4:OO p.m. 
1160-I 65 Selective Induction of Apoptosis in the Atherosclerotic 
Aortas of Apolipoprotein-E Deficient kite by Short-Term 
Thermal Therapy 
Tarun Tewatia, Conjun Wu, XuegingXu, Ki-soo Kil, James T. Willerson, S. Ward 
Casscells, Yang-Jian Geng. The University of Texas Health Sciences Center at Houston, 
Houston, TX, The Texas Heart Institute, Houston, TX 
Background: Apoptosis plays an important role in regulation of tissue morphogenesis 
and remodeling in both human and experimental atherosclerosis. Apolipoprotein-E 
(apoE-/-) null mice develop severe atherosclerotic lesions, closely resembling human dis- 
ease. We used this animal model of atherosclerosis to test whether thermal therapy can 
selectively induce apoptosis in arterial tissue with atherosclerosis. Methods: Aortas from 
apoE-/- (n=lO) and wild type mice (n=6) more than one year old were gently heated for 
15 min for 37% and 42°C in DMEM medium. In situ DNA end-labeling (TUNEL), DNA 
isolation and agarose gel electrophoresis, electron microscopy and immunohistochemis- 
try for cell types and caspases were performed 6 hrs after heating. Results: Thermal 
therapy by short-term gentle heating at 42’6 significantly increased numbers of TUNEL+ 
nuclei by 3540% in the intima of the aortas of apoE-/-, compared to wild type mice. Most 
of the cells with TUNEL+ nuclei were located in the atherosclerotic intima. Few or no 
TUNEL+ nuclei ware found in the media. In order to verify the occurrence of apoptosis, 
genomic DNA was isolated for electrophoresis. We detected a marked increase in inter- 
nucleosomal DNA fragmentation in apoE-/- aortas but not the wild type controls (Figure). 
Electron microscopy further confirmed the presence of apoptotic morphology of the 
nuclei. At 37% no such DNA fragmentation was found in the aortas of apoE-/- and wild 
type mice. lmmunohistochemlstry showed that the region wth majority of apoptotic cells 
was immunoreactive to antibody to Mac3, a marker for macrophages, as well as those 
against caspase-9. Conclusion Thermal therapy with short-term gentle heating selec- 
tively induced vascular cell apoptosis in the atherosclerotic aortic plaques of mice lacking 
apoE, suggesting a potential for therapeutic application in the treatment of inflammation 
in similar human atherosclerotic lesions. 
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1160-I 66 The Increased Plasma Levels of C-Reactive Protein 
Following Oral Hormone Replacement Therapy Are Not 
Related to an Increased Inflammatory Response 
Giuseppe M. C. Rosano, Otavio Gebara, Massimo Fini, Jo& Aldrighi, Fllipo Leonardo, 
Mauricio Wajngarten, Jo& A. F. &mires. San Raffaele Hospital Roma Tosinvest 
San@ &ma, ha/x University of Sao Paub, Sao Pa&, Brazil 
It has been suggested that hormone replacement therapy (HRT) in postmenopausal 
women is associated with an increased inflammatory response which may trigger acute 
cardiovascular events. This suggestion is mainly based on the finding of elevated C-reac- 
tive protein (CRP) levels following HRT. The aim of the present study was to evaluate a 
broad spectrum of vascular inflammation markers following 6 months of HRT with conju- 
gated equine estrogens (0.625 mg) and medroxyprogesterone acetate (2.5 mg) in 126 
post-menopausal women with more than 2 risk factors for CAD. Compared to baseline 
CRP levels significantly increased following HRT (0.9+0.2 mg/L vs 1.6+0.4 mg/L, 
pcO.01). This increase in CRP was not associated with a similar behaviour of all other 
vascular inflammation markers tested. Indeed soluble intracellular adhesion molecule-l 
(&CAM-l) decreased from 208+/-57 ngiml to 168+/-37 ngiml (pcO.01) following HRT, 
similarly vascular cell adhesion molecule-l (sVCAM-1) decreased from 298+/-73 ngiml 
to 258+/-47 @ml (p<O.Ol), plasma E-Selectin levels were reduced by HRT from 17.8+/- 
5.6 ngiml to 14.8+/-3.9 ngiml (p<O.Oi), and s-Thrombomodulin plasma levels decreased 
‘from 4.8+1-0.7 nglml to 4.3+/-0.9 ngiml (p<O.Ol). In conclusion, the discrepanci, between 
the increased plasma levels of CRP and the reduced plasma levels of all other markers of 
vascular inflammation suggest that the increased CRP levels seen after oral HRT may be 
related to metabolic hepatic activation and not to an acute phase response. Hormone 
replacement therapy seems to be associated with an overall decrease in vascular inflam- 
mation thereby stabilizing atherosclerothic plaque. 
1160-167 Novel Acoustic Drug-Encapsulated Liposomes for Site- 
Specific Delivery 
Susan D. Tiukinhoy, Shaoling Huang, Amer A. Khan, Robert C. MacDonald, David D. 
McPherson. Northwestern University Medical School, Chicago & Evanston, IL 
The role of infection in the development, progression, and manifestations of coronary ath- 
erosclerosis is being actively investigated. Antibiotic therapy for coronary artery disease 
is likewise being explored. A major concern however, is the non-specdic targeting of cells 
by systemic drug administration, with concomitant toxicities and decreased efficiency. 
Regional drug delivery using liposomes has advantages over other vectors, and has 
been shown to be feasible. We have developed novel acoustic liposomes that can be 
antibody-conjugated for site-specific tissue enhancement. This study aimed to develop 
our novel liposomes for local antiblotic delivery to the atherosclerotic plaque. Methods. 
Liposomes (DPPC:PE:PG:Chol at 74:8:8:10 molar ratlo) ware made using the dehydra- 
tion-rehydration method. Azithromycin was added to the lipid film before lyophllization. 
Liposomes were imaged using a 20 MHz intravascular ultrasound catheter and echoge- 
nicity assessed using computer-assisted videodensitometry. Data are reported as mean 
gray scale at 200 times dilution, and analyzed using analysis of variance. Results: Our 
liposomes retained their acoustic properties despite the addition of azithromycin. 
Echogenicity is similar to our previously reported acoustic empty liposomes (p > 0.05), 
and diffkrent from buffer (p < 0.001). Variation of antibiotic to lipid ratio did not affect 
echogenicity. The drug-liposome complex also remained echogenic up to 2 weeks in 
solution at -4 degrees C 
7 
-I 
Conclusion: We have developed a novel drug delivery agent that is acoustic, highlights 
components of the atherosclerotic plaque, and can be antibody-conjugated for directed 
antibiotic delivery. This process of drug encapsulation using our site-specific acoustic 
liposomes can be expanded to other aspects of interventions such as thrombolytics or 
lipid-modifying agents. 
1160-168 A Prospective Study of Genetic Markers of Susceptibility to 
inflammation and Severity, Progression, and Regression of 
Coronary Atherosclerosis and Response to Therapy 
Hesham Elghannam, Laura Ferlic, Antonio M Gotto Jr. Chnstie M Ballantyne, Ali J 
Marian. Baylor College of Medicine, Houston, TX 
Inflammation is involved in susceptibility to, progression of, and response to treatment of 
coronary artery disease (CAD). Elevated levels of inflammatory cytokines interleukin-6 
(IL-6) and tumor necrosis factor (TNF)-a are associated with CAD and myocardial Infarc- 
tion (Ml). IL-6 and TNF-a genes have variants that regulate their expression, and are 
potential genetic risk factors for CAD. We analyzed association of functional variants of 
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TNF-a and IL-6 with severity, progression and regression of CAD and response to ther- 
apy with fluvastatin in a large prospective study of well-characterized subjects. 371 sub- 
jects enrolled in the Lipoprotein Coronary Atherosclerosis Study (LGAS) were genotyped 
for TNF-a -308G/A and IL-6 174G/C variants by PCR and restriction mapping. Fasting 
plasma lipids and quantitative coronary angiograms were obtalned at baseline and 2.5 
years following randomization to fluvastatin or placebo. Distribution of IL-6 genotypes 
was 152 GG, 153 GC, and 62 CC, and that of TNF-a was 244 GG, 110 GC, and 17 AA. 
Baseline and flnal plasma levels of HDL, LDL, Triglycerides, and other lipoproteins, and 
conventional risk factors were not significantly different among the IL-6 or TNF-a geno- 
types. The IL-6 -174C alieie, associated with higher levels of IL-6, was weakly associated 
with a smaller baseline mean minimum lumen diameter (MLD), lesion-specific (LS) MLD 
(p=O.O43), and reduction in lipoprotein (a) with fiuvastatin (p=O.O3). The TNF-a -308A 
ail&, associated with higher production of TNF-a, was associated with previous Ml 
(p=O.O4), total coronary occlusions (p=O.O4), and systolic blood pressure (p=O.O3). The 
number of new coronary lesions, total occlusions, subjects with > 1 new lesion or total 
occlusions, or new cilnical events, and Delta MLD or LS-MLD were not significantly differ- 
ent among the genotypes. There were no genotype-treatment interactions with respect to 
plasma lipids except for Lp(a), angiographic indices, and clinical events. Thus, functional 
variants of TNF-a and IL-6 that confer susceptibility to inflammation, are weakly associ- 
ated with CAD and MI, but are not major risk factors for progression or regression of 
CAD, or its response to therapy in LCAS subjects. 
1160-169 Inflammatory Markers and Recurrent Coronary Events After 
Myocardial Infarction 
Tareq Harb, Wojciech Zareba, Arthur J. Moss, Paul M. Ridker, Victor J. Marder, Nader 
Ridai, Luc F. Miller Watelet, For THROMBO Investigators. University of Rochester, 
Rochester, NY 
Background: The prognostic value of inflammatory markers in predicting the risk of cor- 
onary events has been studied mostly in apparently healthy subjects, but only to a limited 
extent in postinfarction patients Methods: C-reactive protein (CRP) and serum amyloid 
A (SAA) as well as 6 hemostatic variables and 7 lipid factors were measured in blood 
samples 2 months after an index myocardial infarction in 957patients. Patients were fol- 
lowed up for an average of 26 month?,, with the end point being coronary death or nonfa- 
tal myocardial infarction, whichever occurred first. The association between CRP or SAA 
levels and recurrent coronary events was evaluated using Cox survivorship analyses. 
Results: Univariate analysis revealed a trend of increasing risk for recurrent coronary 
events with increasing quartile levels of CRP (p=O.Ol) and SAA (p=O.O7). After adjust- 
ment for relevant clinical covariates, neither CRP nor SAA was independently associated 
with recurrent coronary events (p=O.26 for trend by risk quartile). When CRP was dichot- 
omized into its top (Q4) and lower three (Qi-3) risk quartiles, high levels of CRP were not 
associated with recurrent coronary events (CRP hazard ratio, 1.14; 95% Cl, 0.65, 1.98; 
p=O.65) in an adjusted Cox model with three significant thrombogenic risk factors (D- 
dimer, apoA-1, and apoB). 
Contribution of Thrombogenic Factors and C-Reactive Protein to Recurrent 
Coronary Events 
Variable Hazard Ratio 95% Cl P value 
D-Dimer (Q4:Ql-3) 2.15 1.27-3.64 0.005 
Apo-B (Q4:Ql-3) 1.90 1.11-3.25 0.02 
ApoA-1 (Ql:QZ-4) 2.14 1.24-3.69 0.01 
CRP (Q4:01-Q3) 1.14 0.65-1.98 0.65 
Conclusion: In stable post-infarction patients, CRP and SAA levels are elevated among 
those at risk for recurrent coronary events. However, these inflammatory markers are not 
independent predictors of risk in analyses adjusted for other clinical covariates. 
1160-170 The Relation Between Coronary Remodelling and Plaque 
Vulnerability 
Amanda M. Varnava, Peter M. Mills, Michael J. Davies. St Georgek HospitalMedical 
School, London, United Kingdom, The London Chest Hospital, London, United Kingdom 
Background: In viva studies using intravsacular ultrasound have shown that complex 
plaque anatomy and plaque rupture are more frequent in the presence of marked out- 
ward remodelling. A large lipid core and a high macrophage count are recognised histo- 
logical markers for plaque vulnerability. The link between plaque vulnerability, in terms of 
these markers and remodelling in coronary arteries has not been explored. Methods: In 
88 subjects with IHD 108 AHA type V plaques were studied. The % remodelling was cal- 
culated and lesions with remodelling z 0% ware considered to have positive remodelling 
and those in which remodelling was c 0% were considered to have negative remodelling. 
% lipid core and macrophage count at the plaque were assessed with quantitative 
microscopy. Results: 64 of 108 (59.2%) plaque sites had undergone no or positive 
remodelling and 44 (40.7%) had negative remodelling (vessel shrinkage). Lesions with 
positive remodeliing had a larger lipid core (mean lipid core was 39.0(21.0)% vs 
22.3(23.1)%, p<.OOOi) and a higher macrophage count (mean macrophage count was 
15.6(12.3) vs 6.9(11X), ~~005) than lesions with vessel shrinkage. Conclusions: We 
have shown that coronary artery plaques with positive remodelling have a higher lipid 
content and macrophage count, both markers of plaque vulnerability. 
1160-171 Low Density Lipoprotein Reduction Is Associated With C- 
Reactive Protein Decline in Patients With Stable Coronary 
Disease: The Vascular Basis Study 
Tracy A. Timms, Scott Kinlay, Paul Ridker, Maureen Clark, M. Carolina Karam, Michael T. 
Johnstone, William D. Carlson, Alberta Ramirer, Don Lloyd-Jones, Sidney Alexander, 
Joel Rubenstein, Peter H. Stone. Brigham and Women’s Hospital Cardiovascular 
Division, Boston, MA 
Background: Elevated C-reactive protein, a marker of inflammation, is independently 
associated with an increased incidence of coronary events. It is uncertain, however, 
whether CRP is a modifiable risk factor and whether lipid-lowering can reduce CRP val- 
ues. The Vascular Basis Study is a randomized, double-blind multicenter clinical trial in 
300 patients with stable CAD investigating the effects of marked LDL reduction (atorvas- 
tatin or diet with lovastatln as needed) on coronary reactivity (brachial ultrasound) and 
ischemia (Halter, ElT). The purpose of this ancillary study is to investigate the reiation- 
ship between changes in low-density lipoproteins and changes in CRP. Methods: 
Patients have documented stable CAD, positive ETT, and >I episode of ischemia >I iTlin 
on 48-hour Halter. Plasma LDL and high sensitivity CRP (Dade Method) were deter- 
mined at 0, 1, 6, and 12 months. Changes in median values were analyzed using the Wil- 
coxon Sign rank test. Regression analysis was used to relate changes in low-density 
lipoprotein and changes in hs-CRP. Results: This preliminary analysis includes 119 
patients (99 male, 20 female; mean age 64.3 years). At b&line LDL=148+ 40 mg/dl and 
CRP=0.25* 0.54 mg/dl. Both LDL and CRP were significantly reduced during the year 
study (Table and Figure). There was a significant association between changes in LDL 
and changes in hs-CRP (r=0.34, p=O.OOl at 6 months). 
Median Changes of LDL and hs-CRP Compared to Baseline 
Plasma Param- Baseline (SD) IMonth-Base- GMonths-Base- 12Months. 
etewlime Inter- n=119 line n=119 line n=89 Baseline n=54 
val of Analysis 
LDL (mgidl) 148 (40.4) -42.5 (pc.001) -59.1 (P<.OOl) -56.8 (pc.001) 
hsCRP (mg/dl) 0.25 (0.54) -0.07 (p=.l5) -0.11 (p=.O5) -0.15 (p=.OO2) 
Conclusion: As early as 1 month after initiation of lipid-lowering, CRP appears to 
decline. Enhanced outcomes of CAD patients undergoing lipid reduction may be related 
to reduced inflammation, as indicated by CRP. 
1160-I 72 Large Lipid Core and Extensive Plaque Burden Are 
Features of Coronary Atherosclerosis in Patients With Non- 
Insulin Dependent Diabetes Mellitus 
Allen P. Burke, P J. Varghese, Eric Peterson, Gray Malcom, Andrew Farb, Renu Virmani. 
Armed Forces Institute of Pathology: Washington, DC, Louisiana State Universit): New 
Orleans, LA 
Background: Although diabetes is a well established risk factor for coronary artery dis- 
ease, the effects of insulin dependent diabetes mellitus (IDDM) and non-insulin depen- 
dent diabetes mellitus (NIDDM) on the morphology of coronary artery plaques have not 
been fully studied. Methods: We studied the histomorphometric features of 253 seg- 
ments of epicardial coronary arteries from 66 nondiabetic men and women dying with 
severe coronary artery disease and compared them to 281 segments from 66 age and 
sex-matched diabetic patients (50 with NIDDM and 16 with IDDM). In each segment, % 
lipid core and % calcified matrix were determined. Plaque burden was estimated by add- 
ing % cross sectional luminal narrowing in all segments with >50% stenosis. Diabetes 
was classified based on history of insulin treatment and postmortem evaluation of % gly- 
cohemoglobin. Total and high density lipoprotein cholesterol and thiocyanate (an index of 
cigarette smoking) were determined on post-mortem sera, and hypertension determined 
by history and histologic assessment of renal microvasculature. Results: The log mean 
% necrotic core was 1.9 f 1.8 in NIDDM, 1.7 + 1.9 in IDDM, and 1.2 + 1.9 in nondlabet- 
its. The difference between NIDDM and nondiabetics was significant at p=.OOO3. By mul- 
tivariate analysis, mean % necrotic core was associated with NIDDM independent of age 
and other risk factors (p=O.O4). The log mean % calcified matrix was 1.8 + 1.8 in NIDDM, 
1.2 f 1.8 in IDDM, and 1.5 + 1.9 in non diabetics. The difference beween NIDDM and 
nondiabetlcs was significant at p = 0.05, and between NIDDM and IDDM at p = 0.02; 
there was no significant association between calcification and IDDM or NIDDM indepen- 
dent of other risk factors. Plaque burden was significantly greater in NIDDM compared to 
both non-diabetics (p<.OOOl) and IDDM (p=O.O4), and was associated with NIDDM inde- 
pendent of other risk factors by multivariate analysis (p=O.Ol). Conclusions: The coro- 
nary artery plaques of patients with NIDDM dying with severe coronary artery disease 
demonstrate significantly greater lipid core areas than nondiabetics, and demonstrate 
greater plaque burden, independent of other risk factors. There are significant differences 
in plaque burden and calcification between NIDDM and IDDM, suggesting different 
pathogenetic mechanisms of atherogenesis between the two types of diabetes. 
1160-173 Chronic Exposure to High Glucose Conditions Regulate the 
Activation and Expression of Inflammatory Genes in Human 
Vascular Endothelial Cells 
Bobby V. Khan, Sushant R. Navalkar, Rama Natarajan, Qamar A. Khan, Sampath 
Parthasarathy. Emory University School of Medicine, Atlanta, GA, Atlanta Vascular 
Research Institute, Atlanta, GA 
Persistent hyperglycemia, or diabetes msllitus, is associated with multiple cardiovascular 
dysfunctions. However, the mechanisms associated with these abnormalities are not well 
understood. Increasing evidence indicates that mechanisms of inflammation are induced 
in a variety of cell types in response to oxidative stress. We tested the hypothesis that 
chronic exposure to high glucose functions as a signal in the atherogenic lwon to effect 
the expression of inflammatory genes. To determine the mechanisms by which hypergly- 
cemia induces endothelial dysfunction, primary human aortic endothelial cells (HAEC) 
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were grown over two passages in either normal glucose (NG, 5.5 mM glucose) or high 
glucose (HG, 22.0 mM glucose) conditions in a medium contaming 15 percent fetal 
bovine serum, endothelial growth factor, streptomycin, and penicillin. The HAEC were 
exposed or not to the cytokine TNF-alpha (100 U/ml) for thre’e hours. There was no sig- 
nificant gene expression of vascular cell adhesion molecule-l (VCAM-I), platelet derived 
growth factor-B chain (PDGF-BB), or monocyte chemotactic protein-i (MCP-1) in NG or 
HG cells not exposed to cytokine. Exposure of HAEC in NG conditions (n=5) to TNF- 
alpha did induce mRNA accumulation of VCAM-1, PDGF-BB, and MCP-1, as determined 
by Northern blot analysis. Moreover, exposure of HAEC in HG conditions (n=5) to TNF- 
alpha augmented mFiNA of VCAM-1 by 72+1-g percent (pcO.O5), PDGF-BB by 49+/-g 
percent (p&05), and MCP-1 by 63+/-l 1 percent (~~0.05) over NG conditions. Nuclear 
run-off analysis was performed and indicated an mcrease in VCAM-1, PDGF-BB, and 
MCP-1 protein in HG conditions, suggesting that increased synthesis of these genes 
occurs at the transcriptional level. These findings suggest that endothelial cells exposed 
to high glucose conditions potentiate the expression of inflammatory genes and thereby 
initiate dysfunctional endothelial changes observed in diabetes mellitus and atheroscle- 
rosis. 
1160-174 DNA Damage in Human Lymphocytes After Percutaneous 
Transluminal Coronary Angioplasty 
Maria G. Andreassi, Nicoletta Botto, Antonio Rizza, Maria G. Colombo, Cataldo Palmien, 
Sam&ha Manfredi, Serena Masetii, Aldo Clerico, Andrea Biagini. G. Pas9uinucci 
Hospital, CNR lnstifuie of C/mica/ Physiology: Massa, /t&y 
Background: although it has recognized in experimental models !hat ischemia-reperfu- 
sion can induce DNA damage, its presence in patients undergoing PTCA has not studied 
yet. The aim of this study was to investigate whether DNA damage IS produced in human 
lymphocytes of patients undergoing percutaneous transluminal coronary angioplasty 
(PTCA), an in viva model of ischemia-reperfusion injury, by evaluating micronucleus 
induction, a reliable biomarker in genotoxicity testing both in vitro and in viva Methods: 
the study involved 20 patients with ischemic heart disease who underwent elective PTCA 
(Group I); 15 patients who underwent elective coronary angiography (Group II) and 16 
healthy, age and sex-matched subjects were studied as controls (Group Ill). Venous 
blood sample were taken before and 3 days after diagnostic procedures. For each sub- 
jects, two separate cultures were performed and 1000 binucleated cells were scored for 
the evaluation of mlcronucleated binucleated cells (MNBN) and total micronuclei (MN) 
frequencies. Results ANOVA analysis showed that basal MNBN was significantly higher 
in the Group I and Group II compared with Group Ill (9.75i1.6; 9.531-1.6 vs 3.6r0.7, 
p=O.Ol and p=O.O3 respectively), without any significant difference between the frequen- 
cies in Group I and Group II, p=O.99. A high significant MNBN frequency increase was 
observed in Group I after PTCA procedure (9.75+1.6 vs 20.7&.3, p=O.O002); whereas 
any significant difference was qbserved in the Group II after coronary angiography 
(9.53+1.6 vs 11.3*1.8, o=0.285).Muitiple rearession analws showed that total inflatnn - 
time appeared to be the only determinant factor in the increase of MNBN frequency: 
MultIpIe regression coefficients 
Variable Standard coefficient Significance 
Fluoroscopy exposure rate 0.117 p=o.71 
Fluoroscopy exposure time -0.204 p=O.52 
Total inflation time 0.561 p=o.o2 
Conclusion: our results provide evidence that DNA damage in peripheral lymphocytes of 
patients with atherosclerotic heart disease is significantly enhanced in comparison to 
normal subjects and, in such patients, a further significant increase of DNA damage is 
observed after PTCA, likely as a result of oxidative stress. 
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1161-175 Cholesterol Self Management: a New Way for Better 
Cholesterol Control 
Johannes Schaar, Olaf Oldenburg, Achim Gutersohn, Raimund Erbel, Stephanie Schaar. 
Department of Cardiology Essen, Germany 
High lipid levels are a major cardiac risk factor. According to the guidelines of several 
heart associations the aim of lipid treatment is specified concerning target levels of lipids 
for secondary prevention. Currently only 20 - 30% of patients with coronary heart dis- 
ease (CHD) present with LDL levels under the recommended values. A self assessment 
of cholesterol levels may ensure a closer follow up and improve management of choles- 
terol levels. 
Methods: We enrolled 135 patients (69 male, 66 female, 52-72 y/o) with (CHD) and dys- 
lipidaemia (Chol > 160 mgidl, LDL > lOOmg/dl). Patients were randomized to a teaching 
and a teaching + self-assessment group. All patients had a standard dosage of statins 
and joined the education program done by a dietitian. In addition 66 patients were intro- 
duced to a self-assessment tool. We recommended a measurement every second week 
with documentation in an especially designed “lipid passport”. In the case of further ele- 
vated cholesterol, the patients received a personal consultation and an individual diei 
plan, but no change of medicaiion. After 6 months lipid levels were measured again in 
both groups and compared. 
Results: In both groups lipid lowering was achieved. The teaching + self-assessment 
group has a significant lower level of cholesterol and LDL as the teaching group. 
First visit 6 month 
Chol Teachmg group 251 +/- 30 170 +/- 20 p < 0.005 (teaching 
vsself assessment) 
Self assessment 244 +/- 33 155 +/- 19 
group 
LDL Teaching group 140 +I- 14 111 +/-15 p c 0.01 (teaching vsself 
assessment) 
Self assessment 135 +I- 18 99 +/- 13 
group 
Conclusion: In a copulation with CHD and statin-medication. a livid teachina proaram _. _ 
leads to significant lower lipid levels. But self-management leads to a further decrease of 
cholesterol and LDL. Based on this data we recommend an individual self-management 
of cholesterol levels to improve secondary prevention. 
1161-176 Internet Dietary Management System Is Effective in 
Lowering LDL Cholesterol, Glucose, Plasma Insulin, and 
Body Weight in Patients With Metabolic Syndrome X 
Lynne W. Scott, J. Kay Dunn, Ashok Balasubramanyam, Amy K. Ahrens, C. Michael 
Fordis, Jr., Christie M. Ballantyne. Baylor College of Medicine, Houston, TX 
Background: As the US population becomes more obese, more sedentary, and older, 
metabolic syndrome X becomes one of the most important causes of coronary heart dis- 
ease (CHD). Medical nut&on therapy, integral to treatment of dyslipidemia, elevated glu- 
cose, and overweight, is often not available or if available, is not adequately adhered to 
for achieving treatment goals. We hypothesize that the Internet could improve accesslbil- 
ity, compliance, and cost-effectiveness of dietary management. Methods: Subjects (9 
male, 14 female, 25-68 yrs) with impaired fasting glucose or frank diabetes (2110 mg/dL) 
without glucose- or lipid-lowering drugs were enrolled in a 6.week feasibility 
study. Subjects were initially screened and instructed on a hypocaloric, low-saturated fat 
(8% of calories) diet using the Internet Dietary Management System (IDMS), a pass- 
word-protected secure website. Subjects used IDMS to report food intake, weight, and 
satiety and to receive daily guidance from dietitians. Results: Mean changes in glycemic 
and lipoprotein profiles are shown below. Mean weight loss was 5.tiZ1.3 kg (pcO.001). 
IDMS was rated as very motivating (70% of subjects), very personalized (74%), and very 
convenient (91%). 
Variable N Baseline Final Mean percent p “aluet 
LDL cholesterol (mgidL) 23 
Mear! 
11 lf29.8 
change’ 
lOli20.8 -11.9 0.08 
Total cholesterol (mgidl) 23 185330.9 164SZ4.6 -11.2 co.001 
Triglyceride (mg/dL) 23 216f156.8 147?60.8 -21.5 0.05 
HDL cholesterol (mg/dL) 23 36k10.3 34510.8 -6.3 0.33 
Glucose (mg/dL) 23 146k62.9 120+36.1 -12.8 0.05 
Plasma insulin (@U/mL) 16 17+8.8 1 tf5.6 -26.0 0.01 
ApoB (mg/dL) 16 98k22.6 91?16.4 -8.1 0.09 
ApoAl (mgidi) 16 117ti3.1 98i18.6 -19 4 <O.OOl 
‘[(final-baseline)/baseline]xlOO reported as median; tPaired t-test, mean j, SD 
Conclusion: These positive changes in weight, lipoproteins, insulin, and glucose indi- 
cate that the Internet Dietary Management System is feasible for treating impaired glu- 
cose and dyslipidemia and may significantly improve CHD risk profile. This efficient, cost- 
effective technique for managing diet therapy received a favorable response from the 
subjects because of it was motivational, personalized, and convenient. 
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1162-177 African American Race Predicts Improvement in Coronary 
Microvascular Endothelial Function After L-Arginine 
Jan L. Houghton, Mikhail T. Torosoff, Patricia A. Kuhner, Steven A. Fein, Vivienne E. 
Smith Albany Medical College, Albany. NY 
Endothelium-dependent coronary vasodilator function has previously been shown to 
improve acutely after intracoronary L-arginine (L-arg) infusion in hypercholesterolemic 
patients. Systemic administration of L-arg results in transient depressnn of systemic vas- 
cular resistance in boih normotensive humans and in the salt sensitive rat model of 
hypertension. We hypothesized that African Americans (AA), a group in which Salt sensi- 
tive hypertension is highly prevalent, are more likely to show significant improvement in 
coronary microvascular function after L-arg. Twenty-six matched pairs of AA and white 
subjects underwent coronary vasodilator and endothelial function testing before and after 
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mtracoronary infusm of L-aig (3200 mcmoles). These subjects were ciinlcally referred 
for coronary angiography but had no significant CAD upon angiographic study. Pairs 
were matched for age, gender, indexed LV mass, body mass index, and LDL cholesterol. 
The study cohort consisted of 16 AA men, IO AA women, 16 white men, and 10 white 
women with a mean age of 47+1-Z yrs, mean indexed LV mass of 113 +I-7 gm/square M, 
mean BMI of 29 c/-l kg/square M. and mean LDL chol of 124 +/- 7 mgidl. Using the intra- 
coronary Doppler wire and QCA, changes in coronary blood flow (CBF) were measured 
in response to graded Infusions of acetylcholine (ACh), then after a 10 minute infusion of 
L-arg followed by the peak Infusion rate of ACh. Change in the peak response secondary 
to L-arg was compared among AA and white subjects. In addition to the matching param- 
eters, there were no significant differences in peak CBF response to intracoronary ade- 
nosine (214+1-15 vs 183+/a13%) or in the peak response to ACh before L-arg (78+1-13 vs 
89+/-14%) among AA and white subjects. However, improvement tn CBF response to 
ACh after L-arg was significantly greater among AA (50+/-14 vs 7+/-Q%, p=O.O07). We 
conclude that intracoronary infuslon of L-arg significantly enhances endothelium-depen- 
dent lnicrocirculatory relaxation in AA patients. In view of the excess prevalence of cardl- 
omyopathy in this ethnic group. pharmacologic correction of microcirculaiory dysfunction 
may ultimately prove to be clinically indicated. 
1162-178 Effect of High-Fat Meal on Coronary Flow Reserve in Young 
Healthy Men; Noninvasive Assessment by Transthoracic 
Doppler Echocardiography With a High-Frequency 
Transducer 
Takeshi Hozumi, Marc S. Eisenberg, Kenichi Sugioka, Arawnd Ft. Kokkirala, Ali ‘Fard, 
Hiroyuki Watanabe, Takashi Muro, Masakazu Teragaki, Kazuhide Takeuchi, Marco Di 
Tulio, Junichi Yoshikawa, Shunichi Homma. Coiumbia University, New York. NY; Osaka 
City Universify Graduate School of Medicine, Osaka, Japan 
Background. Previous studies analyzing brachial artery vasoactivity showed that a sin- 
gle high-fat meal reduces endotheliai function in men. However, effect of high-fat meal on 
coronary flow rawwe (CFR) has not been evaluated. Transthoracic Doppler echocardio- 
graphy (ITDE) with a high-frequency transducer enables us to assess CFR noninva- 
sively by measuring coronary flow velocity (CFV) in left anterior descending coronary 
artery (LAD) before and during drug-induced hyperemia. The purpose of this study was 
to evaluate the effect of a single high-fat meal on CFR in young healthy men using TTDE. 
Methods. The study population consisted of 14 young healthy men (mean age; 29 +/- 3 
years) in whom it was possible to record adequate diastolic CFV in LAD using TTDE with 
a high frequency transducer (5-8 MHz, Agilent SONOS 5500, 5-7 MHz, Acuson 
Sequoia). CFR was calculated as the ratio of mean diastolic CFV (MDV) at resting to 
hyperemlc condition (intravenous adenasine O.i4mgfkg/min for 2 minuets). We analyzed 
CFR before and 5 hours af?.?r taking a high-fat meal (1200 calories, 1OOg fat, 509 satu- 
rated fatty acid, 300 mg of cholesterol) using 1TDE. Results. Triglycerides levels in the 
study population significantly increased 5 hours after a high-fat meal compared with 
baseline level (from 103 +/- 220 to 220 +/- 160 mgidl, ~~0.05) although there was no sig- 
nifical?t change in total cholesterol between baseline level and after high-fat meal (165 +/ 
- 32 vs 164 +I- 35 mgidl). No difference was observed in MDV before and after taking a 
fat-meal (24.6 +I- 6.1 vs 25.7 +I- 5.7 cm/s), During hyperemia, however, MDV significantly 
decreased after high&t meal intake (93.5 +/- 14.0 vs 81.3 +I- 9.3 cm/s, pcO.01). As a 
result, there was significant decrease in CFR after high-fat meal intake (from 3.93 +/- 
0.74 to 3.27 +/- 0.59, p<O.Ol). Conclusions. TIDE reveals that CFR was reduced after a 
smgle high-fat meal in young healthy men. This result suggests that high-fat meal may 
have unfavorable effect on coronary mlcrocirculatlon. 
1162179 Long-Term Administration of Thiazolidinedione improves 
Vasomotion of Resistance Coronary Arteries in Type-2 
Diabetics 
Tatsuaki Murakami, Masateru Ohnaka. Fukui Cardkwascular Center, Fukui, Japan 
Background: Insulin resistance is thought to be highly involved in atherothrombogenic 
processes and effects of insulin sensitizer on coronary artery pathophysiology have 
marked attention, but the long-term effects remain uncertain. This study evaluated long- 
term effects of thiazolidinedione, an insulin sensitizer, upon vasomotion of resistance cor- 
onary arteries which are frequently affected by diabetes mellitus. Methods: Type-2 dia- 
betic patients (1~22) who undewent coronary angiography and flow-dynamic 
examinations were enrolled into this study of thiazolidinedione, and randomized where 
they received troglitazone ( 400 mg per day ) for more than 1 year ( group-T )s or they 
received therapy with diet or glibenclamide for more than 1 year ( group-0 ). We mea- 
sured endothelium-independent or endothelium-dependent response of resistance coro- 
nary arteries to ATP (50microgram) or acetylchaline (5Omicrogram) into the study 
(normal or minimally diseased ) left coronary artery. Reactive changes in coronary blood 
flow (coronary flow reserve ( CFR ): maximal hyperemic flow - baseline flow / baseline 
flow ) were quantified by coronary angiography and intracoronary doppler-tipped 
guldewire. Changes in CFR from the baseline through the follow-up point were compared 
between the two study groups. Results: Group-T (n=il) manifested good compliance to 
the treatment and trend for improvements in insulin resistant variables (HOMA index: 
group-T versus group-C: from 2.5&i .41 to 2.13+1.14, p=O.O21, versus, from 25521.24 
to 2.56~1.23, pzO.902). CFR to ATP mcreased in group-T but not in group-C (group-T 
versuS group-C. from 178+84% to 23O_t IlO%, ~~0.027, versus , from 195262% to 
188&8%, p=O.l02 ). CFR to acetylcholine also mcreased in group-T and decreased in 
group-c (group-T versus group-c. from 52115% to 1321t64 %, p=O.O06, versus, from 
5Oi-19% to 40+22%, p=O.O28 ). Conclusion: This study suggests that long-term thiazo- 
lidinedione use improves vasomotion of resistance coronary arteries and prevents the 
natural time-course functional impairment, which may have beneficial potentials for man- 
agement of coronary artery disease with type-2 diabetes mellitus. 
1162-i 80 Intensive Treatment of Hyperglycemia Improves Endothelial 
Dysfunction Coupled With Tumor Necrosis Factor-a in 
Patients With Non-Insulin-Dependent Diabetes Mellitus 
Satoshi Yasuda, Munetake Kanda, Yutaka Harano, Yoichi Goto, Masaaki Suzuki, 
Shunichi Miyazaki, Hiroshi Nonogi. National Cardiovascular Centei, Suita, Osaka, Japan 
Background. In patients with non-insulin-dependent diabetes mellitus (NIDDM), endot- 
helial dysfunction ContrIbutes to accelerated atherosclerosis, in which inflammatory 
cytokines such as tumor necrosis factor (TNF)-a are pathologically important. Recently, 
intensive control of blood glucose level has been recommended to decrease the preva- 
lence of cardiovascular complications. However, its underlying mechanism remains 
unclear. We hypothesized that improvement in end&h&al function and modulation of 
cytokines may play a role in the mechanism. Methods: Before and after ritensive treat- 
ment of hyperglycemia, endothelium-mediated, flow-dependent dilation (FDD: %) of the 
brachial artewes during reactive hyperemia was determined by a high-resolution ultra- 
sound method in 14 patients with NIDDM. Blood samples for glucose (mgidl), cholesterol 
(T-Chol: mgidl) and TNF-a (pgidl) analyses were also collected from the patients after 
fasting. Results: Table shows data presented as mean+/-SD (‘P<O.OOi). Intensive treat- 
ment decreased the glucose and TNF-a levels, whereas it increased the FDD. The differ- 
ence in the FDD before and after treatment correlated inversely with that of the glucose 
levels (R= -0.730, PdO.01) and that of TNF-a levels (I?= -0.711, PcO.Ol), respectively. 
The cholesterol levels did not change throughout the study. Conclusions: Intensive 
treatment of hyperglycemia effectively improves endothelial function, possibly through a 
TNF-a-mediated mechanism. This findlng may clarify the vasculoprotective effects of 
strict glycemic control in patients with NIDDM. 
Before 
After 
glucose 
1 go+/-55 
117+/-21’ 
T-Chol 
200+/-34 
172+/-28 
TNF-a FDD 
29+/-17 2.5+/-0.9 
11 c/-9” 7.2+/-3.0’ 
1162-181 Thermal Vasodiiation Therapy Improves Vascular 
Endothelial Function Impaired by Coronary Risk Factors 
Masakazu Imamura, Sadatoshi Biro, Takashi Kihara, Kunltsugu Takasaki, Stiinichi 
Mlnagoe, Yoshifumi Toyama. Chuwa Tei. First Department of Internal Medicine. 
Kagoshima University, Kagoshima, Japan, Nanpuh Hospital, Kagoshima, Japan 
Background: Exposure to heat IS widely used as a traditional type of therapy in many 
different cultures. However, precise mechanisms remain unclear. We recently found that 
repeated 60 degrees C sauna, a thermal vasodilatian therapy, improves endothelial and 
cardiac function I” patients with chronic heart failure. The purpose of this study is to 
investigate whether sauna treatment improves endothelial function impaired by coronary 
risk factors such as hyperlipldemia. hypertension, diabetes mellltus and smoking. Meth- 
ods: Ten healthy men (36*8 years old, H group) and 30 men with at least one of the car- 
onary risk factors (3827 years old, A group) were enrolled. Those in R group had a 60 
degrees C far infrared-ray dry sauna bath for 15 min and ware kept in the bed outside the 
sauna with sufficient warmth provided by blankets for 30 min once a day for 2 weeks as 
sauna therapy. To assass the endothellai function, brachial artery diameter was mea- 
sured at rest, during reactive hyperemia, again at rest, and after sublingual mtroglycerin 
(NTG) administration by using high-resolution ultrasound. The diameter change during 
reactive hyperemia was designated as percent flow-mediated dilation (%FMD, endothe- 
lium-dependent vasodilation). The diameter change after sublingual nitroglycerin admin- 
istration was designated as %NTG (endothelium-independent vasodilation). We also 
measured the plasma concentration of thiobarbituric acid reactive substances. Results: 
%FMD was significantly impaired in R group in comparison with H group (4.4+2.3 vs. 
8.2*3.0%, p<O.OOOl) and %NTG was comparable between the two groups (18.6i-4.2 vs. 
19.9&5%). Two-week sauna significantly improved %FMD in R group without any mod- 
ification of coronary risk factors (4.lk2.2 to 6.0+1.4%, pcO.001). On the other hand, 
%NTG did not change after P-week sauna (18.6i4 2 to 18.2&O%). Plasma levels of 
thiobarbiturlc acid reactive substances did not change after P-week .sauna (2.9+0.8 to 
2.8r0.6 nmollml). Conclusion: Repeated sauna therapy improves vascular endothelial 
function impalred by coronary risk factors, suggesting a preventive effect on atheroscle- 
rosis. 
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1163-I 83 Metoprolol and Carvedilol Similarly Reduce Nitrate 
Tolerance in Healthy Men 
Hans P Brunner-La Rocca, Alexandra M&r, Christoph Scharf, Ruth Schindler, Erwin 
Oechslin, Bruno Fink, Jurgen Armbrecht, Beatrix Lutiger, Eberhard Bassenge, Wolfgang 
Klowski. Cardiology: University Hospital, Zurich, Switzerland, University of Frefburg, 
Freiburg, Germany 
Background: Nitrates are frequently used for treatment of heart diseases. However, con- 
tinuous administration results in rapid development of nitrate tolerance which may be 
related to free oxygen radial production. Smce beta-blockers are often concomitantly 
used, we investigated whether a beta-blocker with antioxidative properties may prevent 
nitrate tolerance more effectively than beta-blockade alone. Methods: Arterial forearm 
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response to intraaterial infusions of nitroglycerin (NTG; 0.625, 1.25, and 2.5mg/min/ 
IOOOml forearm volume [FAV]) was measured twice using venous occlusion plethysmog- 
raphy in 30 healthy men (age 27+1 years). They were randomized in a double blinded 
fashion to carvedilol 25mg bid (n=l5) or metoprolol succinate 190mg od (n=15) for 1 
week before baseline measurements were performed. Then, nitrate patch (lOmg/24h) 
was added for another week and measurements were repeated. Arterial responses were 
compared with those of 32 healthy men (age 2&l years) who were randomized to pla- 
cebo (n=17) or nitrate (n=l5) patch wlthout beta-blockade for 1 week. Results: Intraarte- 
rial infusion of NTG caused dose dependent increase in forearm blood flow at baseline in 
all 4 groups (5.6~0.4,8.0~0.6, 10.5+0.7ml/min/100ml FAV, p<O.OOl). After 1 week of con- 
tinuous patch administration, response to intraarterial NTG was unchanged in the pla- 
cebo (changes in increase compared to baseline: -0.2+0.5, 0.2+0.5, 0.7~0.7ml/min/ 
100ml FAV, n.s.) but significantly blunted in the nitrate group (-3.3~0.6, -3.9*0.9, - 
4.5i1.0mllminll00ml FAV, p<O.OOi). Concomitant use of both carvedilol (-l.lt0.4, 
1.6kO.5, -1.8+0.7mllminil OOml FAV, pqO.05) and metoprolol (-1.3bO.6, -1.6+0.6, 
1.9~0.6ml/min/7OOml FAV, ~~0.05) was accompanied with development of nitrate t&r- 
ante. However, nitrate tolerance was significantly smaller than after nitrate patch alone 
(on average 63% less, pcO.001). Conclusions: Both carvedilol and metoprolol reduce 
development of nitrate tolerance in healthy men. Thus, activation of the sympathetic ner- 
vous system seems to play an important role in the development of nitrate tolerance 
which may exceed the impact of free oxygen radical formation. 
1163-l 84 Oral L-Arginine Improves Endothelial Dysfunction in 
Patients With Essential Hypertension 
John Lekakis, Sotirios Papathanasiou, Christos Papamichael, Nicos Zakopoulos, 
Vassilios K&is, Anna Dagre, Theodoros Papaioannou, Stamatios Stamatelopoulos. 
Dept of C/in Therapeutics, Alexandra University Hospitaf, Athens, Greece 
We assessed the efficacy of orally administered L-arginine, a nitric oxide precursor, to 
improve endothelial dysfunction present in patients (pts) with essential hypertension 
(HTN), using a prospective randomized double-blind trial design. Thirty-five pts with HTN 
underwent measurement of the endothelium-dependent, flow-mediated dilatation (FMD) 
of the brachial artery; FMD was significantly lower compared to 19 normal controls 
(2.2+3% vs 7.1*4%, pcO.001). FMD in HTN was not related to blood pressure height, left 
ventricular wall thickness and intima-media thickness of common carotid arteries (ns). 
Pts were randomized to receive orally either 6g of L-arginine (18 pts) or placebo (17 pts) 
and vasoreactivity studies were repeated 1.5hr later. Two groups were comparable 
regarding age, sex, lipid levels, diabetes, tobacco use, coronary artery disease, body 
mass index, left ventricular wall thickness, carotid intima-media thickness, clinic systolic 
and diastolic blood pressure, baseline brachial artery diameter, baseline blood flow and 
degree of reactive hyperemia (ns). L-arginine administration resulted in an improvement 
of FMD from 1.7*3.4% to 5.9&4% (p=O.O08) while placebo did not change FMD signifi- 
cantly (3.0+2.7 to 3.1&Z%, ns). L-arginine did not influence significantly nitrate-induced 
dilatation (placebo 16+6.9%, L-@nine 17.7*6.9%, ns), suggesting a lack of effect on 
smooth muscle cells. In conclusion, oral administration of L-arginine acutely improves 
endothelium-dependent dilatation of the brachial artery in patients with HTN, since 
endothelial dysfunction may be an important early step in atherosclerosis, an improve- 
ment in endothelial function might decrease the risk of cardiovascular diseases in HTN 
pts. 
1163-l 85 Effect of Sildenafil (Viagraa) on Wave Reflection: A New 
Insight Into Its Cardiovascular Effects 
Charalambos Vlachopoulos, Kozo Hirata, Michael O’Rourke. Sf. Vincent’s Hospitai 
University of New South Wales, Sydney Australia 
Background: Sildenafrl (Viagra@) is a new, effective drug for erectile dysfunction acting 
on the metabolism of nitric oxide. However, its effects on the cardiovascular system have 
not been thoroughly investigated. Wave reflection along the arterial tree is an important 
index of arterial stiffening and cardiac afterload and has been inversely associated with 
exercise capacity. 
Methods: To investigate the effect of sildenafii on arterial wave reflection we studied 27 
patientsts (age 69i9 years) with risk factors for erectile dysfunction in a randomized, dou- 
ble-blind, cross-over fashion (50 mg of sildenafil and placebo). Wave reflection was stud- 
led using a validated system (Sphygmocor@) tfxat employs (i) high-fidelity arterial 
tonometry (Millar tonometer) for the non-invasive registration of radial pulse waveform 
and (ii) appropriate computer software for pulse wave analysis. Aortic pressure waveform 
was synthesized from the radial waveform using a generalized transfer function. Aug- 
mentation index (=dP/PP %, fig.: waveform) was measured as an index of wave reflec- 
tion. Inflection point (Pi) was defined with mathematical algorithms. Lower values of 
augmentation index indicate reduced arterial stiffening and reduced cardiac load and 
vice-versa. 
Results: Sildenafil caused a decrease in aortic systolic and diastolic pressure (by 14.4 
and 9.6 mmHg respectively; P<.OOl for both). Moreover, sildenafil led to a significant 
decrease in augmentation index (by 13%) indicating dec!eased effect of wave reflection 
from the periphery (fig.: trends). 
ConclusiorwSildenafil leads to a decrease of wave reflection. This finding has impor- 
tant lmpiications for arterial stiffening and the pulsatile load of the heart and may contrib- 
ute to improved exercise capacity of the patients at intercourse. 
1163-186 Inhibition of Vascular ATP-Sensitive Potassium Channels 
Does Not Affect Exercise Induced Skeletal Muscle 
Hyperemia in the Human Forearm 
H M. 0. Farouque, R A. P. Skyrme-Jones, M J. Zhang, I T. Meredith. Monash University 
and Monash Medical Centre, Melbourne, Australia 
Background: Recent evidence suggests that endothelium-dependent vasodilators such 
as nitric oxide are important determinants of resting and exercise-induced hyperemic 
blood flow in the human forearm. Experimental evidence suggests that vascular ATP- 
sensitive (K& channels may also play a role but little is known of this in humans. 
Methods: The contribution of KATp channels in the regulation of resting forearm blood 
flow (FBF) and exercise-induced functional hyperemic blood flow (FHBF) was assessed 
using the technique of forearm venous occlusion plethysmography in 16 healthy subjects 
(mean age 22+5 years; 9 male). FHBF was induced by 2 minutes of wrist flexion-exten- 
sion exercise at 45 cycles/minute. Blood flow was measured before and after brachial 
arterial infusion of the KATZ channel inhibitor glibenclamide (GLIB) at a dose of 15wgl 
minute for 10 minutes. To document inhibition of vascular KATP channels by GLIB, the 
KATp channel opener diazoxide was co-infused (1.9, 3.8, 7.5, 15 mglminute) in 8 addi- 
tional subjects (mean age 23~6 years; 4 male). Results are expressed as mean i stan- 
dard error. 
Results: Compared to vehicle infusion (0.9% saline), GLIB did not affect resting FBF (2.1 
t 0.2 versus 2.0 i 0.2 ml/l OOml forearm/minute) or peak FHBF (20.0 r 1.3 versus 19.5 + 
1 .I ml/lOOml forearm/minute). Blood volume repaid during the 5 minutes after exercise 
was not diminished by GLIB (48.1 i; 4.8 versus 46.0 i 3.5 m11100ml). GLIB did not alter 
resting heart rate (59 f 2 versus 61 + 2 beats/minute), mean arterial blood pressure (80.6 
+ 1.8 versw 80.9 i 1.8 mmHg), plasma glucose (4.8 + 0.1 versus 4.8 * 0.1 mmolll) or 
plasma insulin levels (6.9 * 0.8 vews 7.9 * 0.7 mu/L) but resulted in attenuation of diaz- 
oxide-induced vasodilation at the highest dose (15.2 i 1.8 versus 12.9 i 1.4 ml/100ml 
forearm/minute; p<O.O5). Mean plasma GLIB concentration in the forearm venous efflu- 
ent was 465 f 134 nglml, consistent with levels achieved after prescribed oral dosing. 
Conclusion: Vascular KnTp channel inhibition with GLIB, a sulfonylurea commonly uti- 
lized in the management of type 2 diabetes, does not appear to affect resting or exercise- 
induced forearm blood flow in healthy subjects at conventionally used doses. 
1163-l 87 Reactive Hyperaemia Releases t-Pa in Uncomplicated 
Essential Hypertensive Patients 
Giulia Dell’Omo, Antonio De Giorgi, Roberta Fioriti, Ferdinand0 De Negri, France 
Carmassi, Roberto Pedrinelli, Mario Mariani. Universitti di Piss, Dipartimento Cardio 
Toracico, Pisa, My, Dip&me& di Medicina Interna, Pisa, @a/y 
Background:The importance of NO and tissue plasminogen activator (t-PA) as modula- 
tors of vasomotion and flbrinolysis respectively is well known. However, no information is 
available about the interrelationships between the two endothelial-mediated functions in 
man. Aim of the study was to evaluate t-PA release @EL) during reactive hyperemia 
(RH), a physi,clogical vasodilator stimulus operated through several mediators including 
NO and adenosine (ADE) produced in response to defective oxygen supply, in essential 
hypertensive patients (EH). To characterize further the determinants of that biological 
mechanism, additional experiments were also run by usmg intraarterial acetylcholine 
(ACH), a NO-releasing agonist, and adenosine (A), an endothelial-independent vasodila- 
tor. Methods: A total of 31 uncomplicated EH (age: 481;7yrs, 148rt7/92+10 mmHg) were 
recruited for the study. Forearm blood flow (FBF, venous plethysmography), arterial (A) 
and venous (V) t-Pa antigen concentrations (ELISA) to derive REL (V-AxFBF) were mea- 
sured before and after RH induced by a lo-min inflation of a pressure cuff at mid systo- 
diastolic values (n=13). FBF and t-PA REL were also measured at baseline and after 10 
min of intraarterial infusion of ADE (5mg/dl tissuexmin-1, n=iO) and ACH (15mgi dl tis- 
suexmin-1, n=8). Results [means+SD or medians(range)]: 1 min after cuff release, FBF 
increased from 3.2+1.6 to 18r3 ml/minxdl-1 (p<.OOl), and t-PA REL from 1.4 (-7.4/8.3) to 
49 (38/195) ngimlxmin-1 (pc.01) respectively. ADE increased FBF from 3.5+0.8 to 
17.6+4 mlidlxmin-I (p<.OOl) without changing t-PA REL (from -0.6+1 to -5.7+92 rig/ml x 
min.I, NS). Similarly, ACH increased FBF from 3.2r0.8 to 14.8k3.2 mlidlxmin-1 (p<.OOi) 
but t-PA REL did not change [from 1.6 (-6110) to -3.4 (-26128) ng/mlxmln-I] Conclu- 
sions: RH, a vasodllator response to ischemia, releases t-PA from forearm endothelial 
cells of EH, showing the existence of a physiological link between endothelial-mediated 
vasomotion and local fibrinolysis. Enhanced local t-PA REL during RH, however, cannot 
be ascribed to vasodilatation per se nor to direct effects of ADE or NO produced in 
response to ACH stimulation. 
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1164-I 89 Loss of Blood Pressure Control and Rates of Edema in 
Older Treated Hypertensive Patients Following 
Administration of the COX-2 Specific Inhibitors Celecoxib 
vs. Rofecoxib 
William B. White, Andrew Whelton, Alfonso E. Belle*, John G Fort*. Umversityof 
Connecticut School of Medicine. Farmington, C7; UCRC, Inc., and Johns Hopkins 
University School of Medicine, Baltimora, MD 
Background: Celecoxib and rofecoxtb are members of a new class of anti-inflammatory 
drugs known as cyclooxygenase-2 (COX-2) specific inhibitors. The impact of these 2 
drugs on systolic blood pressure (SBP) control and the rates of edema development in 
older (265 years) treated hypertensive patients with osteoarthritis was wwestigated in a 
randomized, prospective, double-blind trial. 
Methods: Eight hundred ten patients with hypertension recetved celecoxib 200 mg QD 
(n=4f 1) or rofecoxib 25 mg QD (n=399) for 6 weeks. Changes from baseltne in mean 
SBP and weight were determined in the overall patient population and in patients who 
developed edema. Edema was defined as any increase from baseline occurring on a 5. 
point scale of O-41. 
Results: Changes from baseline in mean SBP and body weight are shown below for the 
overall and with edema popuiatlons 
Week 1 Week 2 Week 6 
Celecoxib Rofecoxib Celecoxib Rofecoxib Celecoxib Rofecoxib 
Change in mean SBP (mm Hg) 
O”W@ll -0.3+0.6a +2.1+0.6 -0.2~0.6~ +2.6t0.7 -0.5r0.7b +2.6*0.8 
With edema +1.6*1.3 +4.7*1.2 +2.7+1.5 +5.8il.5 -1.1+1@ i-5.9*1.5 
Change in mean weight (%) 
Overall +O.i+O.ld +0.6&0.1 +0.2*0.1a +0.7io.1 +0.2*0.1b +0.8*0.1 
With edema +0.420.ia +0.8t0.2 +0.5t0.1C +1.1+0.2 +0.8i-0.2 +1.2tO 2 
a P< 0.05; b P< 0 01; ’ P< 0.005; d P< 0.001 (all comparisons versus rofecoxib) 
Conclusions: In the overali population, celecoxib was not associated with changes in 
mean SBP, whereas rofecoxib was associated with increases tn mean SBP. and the dif- 
ferences between groups were significant. Among patients in whom edema developed, 
rofecoxtb was associated with consistently greater changes in mean SBP than was cele- 
coxib; the difference was significant at week 6. In general, these data support the possi- 
bility of an association between the development of edema and a loss of BP control 
among pattents with hypertension receiving COX-2 specific inhibitors. 
‘Pharmacia Global Medical Affairs, Skokie, Illinois 
1164-190 Relationships Between Aibuminuria, Left Ventricular 
Hypertrophy, and Blood Pressure After One Year of Anti- 
Hypertensive Treatment: The LIFE Study 
Michael H. Olsen, Krishan Wachtell, Peter M. Okin, Sverre E. Kjeldsen, B~orn Dahlof, 
Knut Borch-Jensen, Richard 8. Devereux, Hans Ibsen. Glostrup University Hospital, 
G/o&up, Denmark, We!// Medical Co//ege of Cornell University, New York, NY 
Background: Recently, we found that increased urine albumin creattnine ratlo (UACR) 
as well as left ventricular (LV) hypertrophy was related to high blood pressure in patients 
wtth hypertension. it was not clear whether this reflected parallel hypertension induced 
cardiac and renal glomerular target organ damage, or a dtrect blood pressure tndepen- 
dent relattonship between LV hypertrophy and generalized endotheliaf dysfunction. 
Therefore, we re-examined after one year of anti-hypertensive treatment to evaluate the 
relative strength of the initial associations between blood pressure, UACR and LV hyper- 
trophy. Methods. In 7,207 hypertenstve patients included tn the LIFE study, we measured 
blood pressure, UACR, plasma glucose and LV hypertrophy by electrocardiography after 
two weeks of placebo treatment and again after one year of anti-hypertensive treatment 
with either an atenofoi or a losartan-based regtme. Results: After one year of treatment 
the systolic blood pressure was reduced by 24 mmHg and diastolic blood pressure by 13 
mmHg. The prevalence of LV hypertrophy was reduced from 78 to 62 % and albuminuria 
(UACR’3.5 mg/mmol) from 21 to 15%. The reduction in UACR was significantly greater in 
African Americans, Hispanics and Asians as compared to Whites (-6.3, -4.2, -10.4 vs. 0.9 
mgimol, P<O.OOl). The postfive correlation between UACR and systolic blood pressure 
was preserved after one year of treatment (wO.07, P<O.Ol) and the decrease in UACR 
was independently related to the reduction in systolic blood pressure (B=0.06, P<O.OOl) 
and in plasma glucose (B=O.O4, P<O.Ol), but not to the regresston in LV hypertrophy 
ustng either Cornell-voltage duration or Sokolow Lyon criteria as continuous variables 
(NS). Conclusions: The prevalence of cardiac and renal glomerular end organ damage 
are reduced during one year of aggressive blood pressure reduction in high-risk hyper- 
tensive patients. The reduction tn UACR was related to the reduction in blood pressure 
and plasma glucose, but not to LV hypertrophy regression, indicattng that the improve- 
ments tn cardtac and renal target organ damage are not closely related and that separate 
evaluation of both may give additional cltnical information. 
1164-191 Efficacy of Aerobic Training in the Treatment of Arterial 
Hypertension: a IO-Year Follow-Up 
Reinhard G. Ketelhut, lngomar W. Franz, Jiirgen Scholze. Universit~tsklinikum Char@ 
Berlin, Germany Klinik Wehrawald, Todtmoos, Germany 
Background: Regular conditioning has been well documented to exert a beneficial effect 
on cardiovascular risk factors, to tmprove overall cardiovascular health and to reduce the 
incidence of coronary disease. There are conflicting results concerning the effect of 
physical exercise on blood pressure (BP) in hypertensive patients and its position in anti- 
hypertensive therapy. Methods: Therefore 10 male pattents with mild arterial hyperten- 
sion (aged 43+3 years) were studied tn order to deftne the BP response to long-term 
aerobic traintng (60 min twice a week) under resting condttions, during standardized 
ergometric workload (50-100 watts), during isometric exercise, cold pressor testing and 
24-h BP monitoring. Results: After 18 months of regular training there were signiftcant 
reductions in BP at rest from 139+9/96f6 mmHg to 133+14/91*7 mmHg (peO.05) and 
from 184?10/107i6 to 170+10/96*7 mmHg during standardized ergometric workload 
(100 watts)(p<O.Ol)when compared with pre-training. The heart rate also decreased sig- 
nificantly (p<O.Ol) during exercise testing thus implying a decrease in myocardial oxygen 
consumption. During a IO-year follow-up BP con&wed to decrease to 129i7187i5 
mmHg at rest and 171+11/92+4 mmHg during ergometry after 5 years, and to 126t7/ 
8553 at rest (pcO.001) and 161i7/87?3 mmHg during ergometry (100 watts)(p<O.OOl) 
after 10 years, respectively. There were similar significant reductions in pressures during 
isometric exercise, cold pressor testing, and during 24-h BP monitoring when compared 
wtth pre-traintng. The decrease in BP was more intense in the exercise group than what 
we found using 20 mg enalapril in inactive hypertensive controls. In both groups there 
were slight but not significant increases in body weight during the observation period 
Conclusion: These results demonstrate that long-term aerobic training leads to a 
decrease in systolic and diastolic BP at rest, during exercise and stress testing and dur- 
ing 24-h-monitoring and amply a beneficial effect in the management of hypertenston that 
is comparable to that of drug therapy. 
1164-I 92 Exercise Reduces Pulse Pressure in Hypertensive 
individuals 
Alexander Butkevich. Patricia Brownstein, Robert A. Phillips. Mount Sinai Medfcal 
Center, New York, NY 
Background: Moderate exercise has been shown to reduce the risk of cardiovascular 
events. Since pulse pressure is an Important cardiovascular risk factor, we hypothesized 
that moderate exercise may exert its beneficial effects in part through reduction of pulse 
pressure 
Methods: We examined pulse pressure in 92 subjects with coronary heart disease who 
completed cardiac rehabilitation program at our institution. Blood pressure (BP), weight 
and lipid profile were assessed before enrollment and after the completion of a compre- 
hensive 2-3 months program, which included gradual exercise and counseling on control 
of cardiovascular risk factors. 
Results: There were 50 hypertensive subjects (HTN) and 42 subjects with optmxtl BP 
(cl 30/85 mmHg, NTN) in the study. The two groups were similar as to age, gender com- 
posttion and lipid profile. Baseline pulse pressure (PP) was higher in the HTN group. It 
was significantly reduced at the completion of the program tn this group. In the NTN 
group, there was a small, but statistically significant increase in pulse pressure (table). In 
multtple regresston analysts including age, sex, baseline values and changes in BP, body 
mass index and lipid profile, only baseline BP was significantly correlated with change in 
pulse pressure 
Conclusions: Moderate exercise has beneficial effects on pulse pressure in hyperten- 
sive mdividuals with coronary heart disease. This may account in part for reduction in 
cardiovascular risk observed with exercise. 
NTN HTN 
Aoe Y 64.1t13.2 65.4if0.8 
M/F 33/9 39/i 1 
BMI, kg/m2 25.8~3.7 27.9+4.2’ 
Baseline BP, mmHg 113+10/67+6 141+17477*.8* 
Baseline PP mmHg 46rlO 64~17’ 
Final PP, mmHg 49*12$ 59*14’$ 
“PcO.05 vs normotensive; SPcO.05 vs baseline 
1164-l 93 Reduction of Left Ventricular Hypertrophy (LVH) by 
Antihypertensive Therapy: Results of a Meta-Analysis of Ail 
Double-Blind Randomized Studies 
Roland E. Schmieder, Markus P. Schneider, Peter Martus, Franz H. Messerlt, Arnfried U. 
Kiingbeil. Univers;ty of Eriangen-Nlrnberg, Dept. of Medicine /V and Biostatistics, 
NUmberg. Germany, Ochsner Clinic, New Orleans, LA 
Background: To provide data on the ability of antihypertensive drugs including angio- 
tensin receptor blockers (ARB) to reduce left ventricular mass in essential hypertension, 
we analysed all double-blind, randomized, controlled trials with parallel-group design 
comparing antthypertensive drugs with respect to the effect on left ventricular ma?s in 
essential hypertension published till the end of 1999. 
Methods; The primary parameter was the reduction of left ventricular mass index (LVMI) 
by antihypertensive therapy wtth diuretics (DIU), S-blockers (BB), calcium channel block- 
ers (CEB), ACE-inhibitors (ACEI), or ARB. 
Results: 72 studies with a total of 2925 patients (age: 55 *‘9 years) were identified. They 
comprised 15 placebo (n=228) and 132 active treatment arms (n=2697),respectively. 
Overall, for active treatment LVMI was the more reduced the greater the decrease tn sys- 
tolic blood pressure (I = 0.33; p < 0.001). the longer the duration of therapy (r = 0.21; p c 
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0.02), and the higher ihe pretreatment value of LVMI (r = 0.26; p < 0.01). LVMI decreased 
by 11.8% with ACEI (95% Cl: 8.3 - 13.2%), by 10.3% with ARB (95% Cl: 5.3 - 15.2%), by 
9.4% with CEB (95% Cl: 7.2 - 11.7%), by 7.5% with DIU (95% Cl: 4.5 - 10.5%) and by 
4.7% with BB (95% Cl: 2.0 - 7.4%) (overall p < 0.01; subsequently: ACEI vs BB ~~0.05; 
CEB vs BB p < 0.09). Similar differences were found with regard to effeci on posterior 
wall thickness (overall p < 0.05). 
Conclusion; Thus, the ability to reduce LVH is different between antihypertensive drug 
classes. ARB appeared to be similar to ACEI and CEB. 
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Pravastatin Reduces Major Coronary Events in Patients 
With Low Levels of Both High-Density Lipoprotein 
Cholesterol and Low-Density Lipoprotein Cholesterol: 
Results From the LIPID Study 
David Colquhoun, Ian Marschner, John Simes, Paul Glasziou, Anthony Keech, Harvey 
White, Philip Barter, Andrew Tonkin, For the LIPID Study investigators. NHMRC Clinical 
Triais Cent% University of Sydney Sydney, Australia, CORE Research, Wesky Medical 
Centre, Brisbane, Australia 
Background: Many patients with coronary heart disease (CHD) have low levels of both 
high-density lipoproiein cholesierol (HDL-C) and low-density lipoprotein cholesterol 
(LDL-C). Gemfibrozil decreases recurrent coronary events in this group. The efficacy of 
statins in this group is unknown. We aimed to assess the efficacy of pravastatin in pre- 
venting CHD in patients with both low HDL-C and low LDL-C. 
Method: LIPID was a placebo-controlled, double-blind trial which assessed the efficacy 
of 40 mg of pravastatin over a mean of 6 years in 9,014 patients with CHD and baseline 
serum cholesterol 155-271 mg/dL. In this group, 2,463 patients fulfilled the lipid criteria of 
the VA-HIT trial: HDL 540 mg/dL, LDL ~140 mg/dL, triglycerides 5300 mg/dL. The eff- 
cacy of pravastatin in preventing major coronary events (CHD death and nonfatal myo- 
cardial infarction) was assessed and results were compared with those from gemfibrozil 
in VA-HIT 
Results: LIPID study patients satisfying the VA-HIT lipid criteria had average baseline 
lipid levels similar to those of patients in the VA-HIT study. Major baseline characteristics 
that differed included sex (LIPID, 81% vs VA-HIT, 100% male) and diabetes (LIPID 8% vs 
VA-HIT 25%). For HDL cholesterol, the two studies had identical one-year differences 
between treatment arms (6% higher in the active treatment arm), while LIPID had larger 
LDL differences (28% vs 0% lower in the active arm) and smaller triglycwde differences 
(12% vs 31% lower in the active arm). Pravastatin significantly reduced the rate of coro- 
nary events in the LIPID subqrouu (loa-rank P=O.OOl), with a relative risk reduction of 
27% (95% Cl 11 to 39), compared with 22% (95% Cl 7 to 35) in the VA-HIT study. 
Trial Coronary events: Coronary Absolute risk Relative risk 
placebo group events: drug reduction (%) reduction (%) 
(%I group (%) 
LIPID (6 years) 16.8 12.3 4.5 27 
LIPID (5 years) 
VA-HIT (5 years) 
VA-HIT (minus silent 
AMI) 
14.3 10.8 3.5 24 
21.7 17.3 4.4 22 
19.0 15.4 3.6 21 
Conclusion: This post-hoc analysis showed a risk reduction with pravastatin among 
patients with low HDL-C and LDL-C similar to that in the overall LIPID cohort and appar- 
ently similar to that of gemfibrozil in VA-HIT. 
842-2 
4:15 p.m. 
Long-Term Treatment With Pravastatin Reduces Coronary 
Heart Disease Mortality in Women With Prior Coronary 
Heart Disease and Average Cholesterol Levels 
Wendy Hague, Jennifer Johns, Peta Young, David Hunt, Robyn Bradfield, Mary Denton, 
Jan Garrett, Phil Aylward, Andrew Tonkin, John Simes, For the LIPID Investigators. 
NHMRC Clinical Trials Centre, University of Sydne)i Australia, Nationai Heart Foundation 
of Australia, Melbourne, Australia 
Background and Methods: LIPID (NEJM 1998; 339: 1349) showed highly significant 
reductions in total mortality and major cardiovascular events with 6 years of pravastatin 
treatment compared with placebo, in 9,014 patients with prior coronary heart disease 
(CHD) and average baseline total cholesterol levels (155.271 mg/dL). Treatment effects 
in the 1,516 women did noi differ significantly from ihose in men, but there were too few 
events in women to show a separate significant reduction in CHD risk. The LIPID cohort 
has now been followed up for a further 2 years and has provided a further 372 CHD 
events (CHD death and nonfaial myocardial infarction (Ml)), with 85% of patients in each 
of the original group?. taking pravastatin during the extended follow-up period. 
Results: Women originally assigned pravastatin compared with those awgned placebo 
had a significant reduction in CHD mortality of 31% (p=O.O4). Deaths from cardiovascular 
disease were reduced by 29% (~~0.04) while deaths from all causes were 12% less 
(p=O.35). The relative reduction in CHD events from treatment in women (16%) did not 
differ significantly from that in men (23%)(Test for heterogeneity p=O.17). The overall risk 
of subsequent CHD events for women was less than that for men after adjustment for 
other risk factors. 
Subgroup Placebo Pravastatin Relative Risk P-value 
Redn Percent 
~ (95% Cl) 
CHD Death 
Women 1516 9.9% 6.7% 31 (2, 52) 0.04 
Men 7698 11 6% 9.2% 23 (12, 34) <O.OOl 
CHD Death/Nonfatal Ml 
Women 17.6% 14.8% 16 (-8, 35) 0.17 
Man 20.8% 16.6% 23 (15, 31) <O.OOl 
Conclusions: LIPID provides the largest, most comprehensive database on the effects 
of cholesterol-lowering treatment in women with CHD and average cholesterol levels. 
With the extended follow-up, and with now 126 CHD deaths of women, there is now rea- 
sonable separate evidence of benefits of pravastatin treatment in reducing CHD deaths 
among women as well as among men. 
842-3 
4:30 p.m. 
Niacin Plus Simvastatin Protect Against Atherosclerosis 
Progression and Clinical Events in CAD Patients With Low 
HDLc and Diabetes Mellitus or Impaired Fasting Glucose 
Josiah S. Morse, B. Greg Brown, Xue-Qiao Zhao, Lloyd Fisher, Alan Chait, Alice Dowdy, 
Leny Serafini, Ellen Huss-Frechette, Debbie DeAngelis, Jiri Frohllich, John Albers. 
University of Washington, Seattle, WA, University of British Columbia, Vancouver, BC, 
Canada 
Background: Do niacin plus $nvastatin (NS(+)) benefit patients with fasting glucose > 
110 mgldl, CAD, and HDLc 535 mg/dl without adversely effecting glycemic control? The 
NIH-funded HDL Atherosclerosis Treatment Study (HATS) is a double-blinded, placebo- 
controlled, 3-year angiographic trial. Methods: Patients (n=160) were randomized to 
treatment (Rx) with NS(+) (daily dose 2-4 gm + lo-20 mg) or placebo (NS(-)). All 
received dietary and diabetes counseling as needed, and exercise training. The primary 
quantitailve angiographic (QCA) patient endpoint was the average change in percent 
stenosis of the 9 worst lesions in 9 standard coronary segments (A?&). The primary clin- 
ical endpolnt was the Kaplan-Meier intention-io-treat time to first event [CAD death, MI, 
stroke, or revascularization]. A subset of patients were identified by clinical history of dia- 
betes mellitus (DM) or fasting $lucose 1 lo-125 mgidl (IFG) at base-line for this analysis. 
Since the clinical, angiographic and lipid responses to NS(+) and NS(-) were quite similar 
among those with DM and IFG these two groups were combined for analysis. Results: 
By intention to treat, with 99.4% clinical follow-up and all 146 angio pairs analyzed. Of 
patients with DM or IFG, the addition or increase in dose of diabetic medications 
occurred in 41% of NS(-) and 47% of NS(+). 9% could not take niacin due high glucose 
levels (6% NS(-), 3% NS(+)). 
n Fast. HDLc TG LDLc QCA EVENT 
Glut. 
Pre-Rx/ PreFIxi Pre-Rx/ Pm-Rxi A%S % of 
Rx RX RX RX pts. 
NS(+) Non-DM 56 92197 31139 214/141 130185 -.01+ (2.9) 8%a 
DMtIFG 17 1441141 30/39 2411145 117181 +l.i’ (3.5) 11%” 
NS(-) Non-DM 56 91190 32134 2001193 124/120 2.2 (4.2) 23% 
DM+IFG 17 1361139 32134 222/235 1151115 +4.8 (6.2) 21% 
Versus NS (-): * pcO.05, c1 p<O.Ol, + p<O.OOl, n = not significant 
Conclusions: Patients with DM or IFG have a greater rate of CAD progression than non- 
DM In this Low HDLc population. Poor glycemic control was equally common over a 3- 
year period with NS(+) or NE+). The substantial benefits of niacin plus simvastatin 
appear to justify the increasingly intensive diabetic management required when niacin is 
used. 
842-4 
4:45 p.m. 
Effect of Beta-Blocker Therapy on Insulin Resistance in 
Patients With Dilated Cardiomyopathy: The Use of 
Homeostasis Model Assessment (HOMA), Insulin 
Resistance Index 
Yuji Hara, Mareomi Hamada, Yuji Shlgemats”, Tomoaki Ohtsuka, Go Hiasa, Akiyoshi 
Ogimoto, Hideyuki Saeki, Jun Suzuki, Kunio Hiwada. Ehime University, Ehime, Japan 
Background: The prognosis in patients with chronic heart failure has been improved by 
the treatment of beta-blocker. However, heart failure patients have insulin resistance and 
beta-blocker decreased insulin sensitivity. In this study, we evaluated the effect of beta- 
blocker therapy on insulin resistance in patients’ with dilated cardiomyopathy (DCM). 
Method: We studied 25 DCM patients without diabetic mellitus. Before and after the 
treatment of beta-blocker, they underwent echocardiographic examination and examined 
fasting glucose (FBS; mmolll) and insulin (mu/l). According to echocardiographic exami- 
nation, left ventricular dimension at end-d&stole (LVDd; mm) and fractional shortening 
(%FS; %) were mesured. An insulin resistance index was estimated using the homeosta- 
sis model analysis of fasting insulin-glucose interactions. An insulin resistance index (R) 
is calculated from the folIowIng equation; R=FBS x insulinI22.5. Left ventricular functional 
improvement was defined by decrease in LVDd > 5mm or/and increase in %FS > 5% 
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from baseline. As normal control, 75 control subjects measured FBS and insulin. 
Results: R in DCM was significantly larger than R in control (DCM; 3.4144.48, control; 
0.91iO.24, p<O.O5). R in DCM was not signlflcantly changed on beta-blocker therapy 
(from 3.4114.48 to 2.3522.84). Seventeen patients had left ventricular functional 
improvement (group A) and 8 patients did not have it (group B). Although R in group B 
was not changed on beta-blocker therapy, R in group A tended to be attenuated (group A: 
from 3.83t5.05 to 2.3Ok3.25, group B: from 2.53*3.05 to 2.41k1.87). Conclusion: Beta- 
blocker therapy may not deteriorate insulin resistance in patients with DCM. 
Conclusion: Although the mcidence of Ml is low in Japanese HC pts, the present study 
showed the importance of C-LT for preventing MI. The result also suggests that hyper- 
responsive pts to Simv need to be monitored very carefully. 
842-5 
5:oo p.m. 
The Effects of Simvastatin and Atorvastatin on HDL 
Subfractions 
D. Roger Illingworth, John J. P. K&&in, Leiv Ose, Evan A. Stein, Minzhi Liu, Yale B. 
Mitch& for the SimvastatinlAtorvastatin Study Group. The Oregon Health Sciences 
University, Portland, OR, Merck Research Laboratories, Rahway, NJ 
Background: HDL IS composed of a heterogenous group of particles of varying size, 
density and apoprotein (ape) content and the fraction conferring benefit in CHD remains 
uncertain. In some studies, particles in the HDLZ density range and those containing only 
apo A-l, and not apo A-II, have been shown to be inversely associated with the risk of 
CHD. In a recently completed large, double-blind, randomized, controlled study, simvas- 
tatin raised HDL-C and apo A-l more than atorvastatin and it was of interest to examine 
HDL subfractlons in this study. Methods: This was a 36-week dose-escalation study 
where approximately 800 patients received simvastatin 40 and 80 mg or atorvastatin 20 
and 40 mg for successive 6-week periods and then simvastatln 80 mg or atorvastatin 80 
mg for the final 24 weeks. Lp A-i and Lp A-]:A-II were determined by differential elec- 
troimmunoassay and HDL2 and HDL3 by preparative ultracentrifugatlon in a subset of 
230 patients. Results: The median baseline levels for HDL, apo A-l, Lp A-l Lp A-I:A-II, 
HDL2, and HDL3 were 49.5, 150.0, 49.0, 103.0, 16.0, and 35.0 mg/dL, respectively. The 
median % changes for these subfractions are shown below: 
Effects of Simvastatin Versus Atorvastatin on HDL Subfractions 
HDL-C’ 
Apo A-l’ 
Week 6 
A 20 s 40 
6.3 7.6 
3.2 4.8* 
Median % Change 
Week 12 
A40 s 80 
5.0 a.2** 
0.1 4.6** 
Week 36 
A80 S 80 
1.9 6.5” 
-4.3 1.7” 
Lp A-l 3.4 6.5 4.: 5.6* 0.0 9.7’* 
Lp A-I:A-II 0.0 2.2 -3.2 4.1”* -9.8 -3.5” 
HDL2 11.8 12.5 10.0 6.9 16.7 22.7 
HDL3 0.0 3.2 0.0 5.7** -7.0 0.0” 
*mean percent change; *p < 0.05, **p < 0.01 between treatment; S 40, S 80 = 
simvastatin 40 mg and 80 mg, respectively, A 20, A 40 = atorvastatin 20mg and 40 mg, 
respectively 
Conclusions: At higher doses, the superior HDL-C and apo A-l increases with simvasta- 
tin compared to atorvastatin are consistently reflected in larger increases or smaller 
decreases in HDL subfractions with simvastatin. 
842-6 
5:15 p.m. 
The Influence of Hypercholesterolemia on the Occurrence 
of Myocardial Infarction in 47,294 Japanese 
Hypercholesterolemic Population With No Prior Coronary 
Artery Disease: Primary Prevention in the J-LIT Study 
Masunori Matsuzaki, Toru Kita, Hiroshi Mabuchi, Yuji Matsuzawa, Noriaki Nakaya, 
Shinichi Oikawa, Yasushi Saito, Jut- Sasaki, Kazuakl Shimamoto, Hiroshige Itakura, The 
J-LIT Study Group. Yamaguchi UniversiQ Yamaguchi, Japan 
Background: The influence of hypercholesteroiemia (HC) on coronary atherogenesis is 
well known in western populations; however. this relationship has not been clearly estab- 
lished I” Japanese population. In this study, we conducted a nationwide cohort study to 
investigate the relationship between WC and the incidence of myocardial infarction (MI) in 
the ordinary clinical setting. 
Method: The study involved 6,500 general practitioners around the country, and a total of 
47,294 men (32%) and menopausal women (68%) aged < 70 yrs with total cholesterol 
(TC) level r 220 mgidl. All subjects had no prior coronary artery disease (CAD) and had 
not been treated with any cholesterol-lowerlng therapy (C-LT). C-!-T with small dose of 
simvastatin (Simv, 5mg/day) was then started in ail subjects, followed by 6-yr follow-up. 
The serum lipid level was examined once a 6 month, and the relationship between the 
lipid level and the incidence of CAD was assessed by the Cox proportional hazards 
model after adjustment for other risk factors. 
Results: C-IT significantly reduced the mean LDL-C level by 26% (from 182 f 34 to 134 
i 29 mgidl) and TC by 19% (from 270 i 34 to 220 i 30 mgidl) over the 6.yr period. One 
death and 9 cases of hospitalization (0.02%) occurred as serious adverse reaction of 
Simv (0.057/l ,000 pts-yrs). Two hundred and nine MI episodes (1.1/l ,000.yr) and 899 
deaths including non-cardiac death were observed (total observation period = 226,700 
p?-yrs). The relationship between each LDL-C level and relative risk of Ml is shown in a 
figure. A significant increase in mortality by all causes was observed in pts with LDL-C < 
70 mgidl during treattient period (p<O.OOi vs LDL-C 2 70 mgidl). 
ORAL CONTRIBUTIONS 
a43 Hypertensive Heart Disease: Flow and 
Function 
Monday, March 19, 2001, 4:00 p.m.-530 p.m. 
Orange County Convention Center, Room 304E 
4:00 p.m. 
843-I Diastolic Dysfunction and Inappropriate Left Ventricular 
Mass 
Giovanni de Simone, Maurizio Galderisi, Vittorio Palmieri, Richard B. Devereux, Marcello 
Chinali, Carmela Romano, Aldo Celentano. Dprt C/in & Experim Med, Federico II 
Universify &spit&, Naples, l&/y, l&i/i Medical College of Cornell University New York, 
NY 
Background: A deviation of left ventricular mass exceeding sex-specific value predicted 
for individual stroke work at a given body size has been previously defined as inappropri- 
ate ventricular mass. 
Methods: The relation between inappropriate ventricular mass and diastolic function 
was studied in 344 consecutive unmedicated hypertensive patients (45+10 years, 75 
obese, 161 women) and 152 normotensive subjects (32ili years, 72 obese, 100 
women), by echocardiography. Appropriateness of ventricular mass was determined as a 
percent of ratio between observed value and value predicted by gender, height”,’ and 
stroke work by a reported equation. Values of observed/predicted ventricular mass > 
123% (90’h normal percentile) ware defined inappropriate mass. Comparison with appro- 
pnate ventricular mass was carried out after controlling for differences in age, sex distri- 
bution and body mass index. 
Results: In addition to more concentric ventricular geometry and reduced systolic func- 
tion (chamber and midwall, all p<O.OOOl), in hypertensives and normotensives with inap- 
propriate ventricular mass, isovolumic relaxation time was greater and the ratio between 
peak E and peak A velocity was lower than in the presence of appropriate mass (both 
~~0.04). lsovolumic relaxation time was negatively related to midwall shortemng in 
univariate (r=-0.17) and multivariate analysis (b=-0.14, controlling for age, sex, body size, 
diastolic pressure, wall stress, ventricular diastolic dimension and relative wall thickness). 
This relation was confirmed when controlling also for ventricular mass (in g/m’-‘), but dis- 
appeared with control for inappropriateness of ventricular mass. lsovolumic relaxation 
time was also slightly prolonged in hypertensives with appropriate ventricular mass 
(p=O.O5). 
Conclusions: Values of ventricular mass exceeding individual needs to sustain hemody- 
namic load are associated with delayed ventricular relaxation, and appear to mediate the 
otherwise independent association between midwall systolic dysfunction and prolonged 
relaxation. Some degree of delayed relaxation can be even detected in the presence of 
normal systolic function and appropriate ventricular mass. 
843-2 
4:15 p.m. 
Reduced Myocardial Functional Reserve Detected by Ultra 
Low-Dose Dobutamine in Hypertensive Patients With 
Normal Left Ventricular Function at Rest 
Michaela Ko&kovB, Carlo Palombo, Simona Buralli, Armando Magagna, Carmeia 
Morizzo, Alan Fraser, Antonio Salvetti. Department of Internal Medicine, University of 
Pi%, PI%, /fag University of Wales, Cardiology Department, Cardiff, United Kingdom 
Background:LV myocardial function at rest assessed as midwall fractional shortening in 
relation to meridional end-systolic stress (MFS/ESS) is depressed in some patients with 
arterial hypertension (HBP). Furthermore, this index Is predictive of cardiovascular 
events. Whether or not the response of MFSiESS to the inotropic stimulation may identify 
early decrease of myocardial functional reserve in HBP subjects With preserved function 
at rest is unknown. Methods: Ten normotensive controls (NC; age 47~6 years, LV mass 
index 100+14g/sqm, MFSiESS 105i-15%) and 37 never treated HBP patients free of 
myocardial ischemia (age 48+7 years, LV mass index 133t29g/sqm, MFSiESS 
10&14%) underwent ultra low-dose infusion of dobutamine (Dob) (steps: 3, 6, 9, 12, 15, 
30, 60pglkgi3min) under echo monitoring. At each step BR HR, MFSiESS and total 
peripheral resistance (TPR) were assessed. Plasma catecholamines (CA) were mea- 
sured before the study. Results: Through the study, BP did Not change significantly, and 
the HR increase became significant at the second last step I” both HBP and NC. COm- 
pared to baseline, MFSiESS significantly increased m NC at a dose as low as Gpgikgi 
3min); within the HBP group, a delayed and blunted inotropic response (MFSIESS 
increase at 6pglkgi3min lower than 2SD below the meanof NC) was found in 14 subjects 
(Non-Responders: Dab-NR), while the remaining 23 (Responders:Dob-R) had an 
increase in MFSIESS withln 250 of mean value in NC. Dob-R and Dob-NR were compa 
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rable for LV mass index, basal MFS/ESS, plasma CA and for response in HR, BP, TPR to 
Dob, while relative wall thickness was higher in Dob-NR (0.41+0.5 vs 0.34+0.6, p<O.Oi). 
Changes in MFS/ESS at different steps against basal (%) Are in Table (‘: pcO.01 Versus 
NC). 
m ml w 12w 1 m 3w9 6Oclg 
NC 7+9 18t6 18+7 21+9 23r9 26110 26~12 
DOB-R 4+7 111-10 1529 17rll 19+11 18~10 1559’ 
DOB-NR -2?4* -2+3 21-4* 4i7* 7i7* 9%8* 7*10’ 
Conclusion: In patients with mild-moderate HBP, the response of MFSiESS to an “ultra- 
low” Dob identifies a subgroup With reduced myocardlal inotropic reserve despite normal 
resting function. Such a response is associated With an increased relative wall thickness, 
and may identify patients at higher risk for cardiac decompensation. 
843-3 
4:30 pm. 
Coronary Flow Reserve in Hypertensive Patients with 
Appropriate or Inappropriate Left Ventricular Mass 
Maurizio Galderisi, Pio Case, Silvana Cicala, Luigi De Simone, llaria Pietropaolo, Nunzla 
Di Palma Esposito, Aldo Celentano, Giovanni de Simone. Federico /I University Hospital, 
Nap/es, @a/J Monaldi Hospital, Naples, /ta/y 
Background: Although coronary flow reserve is often reported to be reduced rn clear-cut 
hypertensive left ventricular hypertrophy, there is no information about its relation with 
sex-specific levels of ventricular mass exceeding the need to compensate for hemody- 
namic load. 
Methods: The appropriateness of echocardiographic ventricular mass was evaluated as 
percent deviation of observed values from the ones predicted by sex, height’.’ and stroke 
work, in a case-control design. Thus, 3 hypertensives with inappropriately high ventricu- 
lar mass were compared with 9 hypertensives with appropriate mass, matched for sex, 
age, and diastolic pressure, all free of coronary heart disease. All participants underwent 
second harmonic Doppler-echocardiography (and contrast enhancement when needed) 
of left anterior descending artery at baseline and after dipyridamole (0.54 mg/Kg IV over 
4 min). Systolic and diastolic peak velocities, time-velocity integrals, and coronary 
reserve (hyperemic to basal diastolic peak velocity ratio) were measured. 
Results: 17 of 18 patients had relative wall thickness > 0.43. Patients with inappropriate 
ventricular mass (>128% of predicted, 95’h normal percentile) had higher mass and rela- 
tive wall thickness than patients with appropriate mass (all p<O.OOi). Coronary reserve 
was similar in the 5 patients with clear-cut hypertrophy (>51 g/mz7) than in the 13 
patients without (1.9+0.5 and 2.1+0.6, pas), but lower in the 9 individuals with inappro- 
priate ventricular mass (1.8t0.4), than in the 3 patients with appropriate values (2.3f0.5, 
p<O.OZ), without significant differences for systolic and diastolic pressure and heart rate. 
When analyzing only patients without ventricular hypertrophy, coronary reserve was still 
lower in the 6 patients with inappropriate ventricular ma?s (1.8kO.3) than in the 7 with 
appropriate mass (2.4+0.3, pcO.04). 
Conclusions: In arterial hypertension coronary flow reserve is significantly reduced 
when ventricular mass exceeds the sex-specific values that would be compensatory for 
individual hemodynamic workload, at a given body size, independently of the presence of 
detectable echocardiographic ventricular hypertrophy 
843-4 
4:45 p.m. 
Genetic Influences on Left Ventricular Diastolic Filling 
Parameters in American Indians: The Strong Heart Study 
Jonathan N. Bella, Richard B. Devereux, Kari North, Mary J. Roman, Jennifer E. Liu, 
Vittorio Palmieri, Thomas K. W&y, Elisa T. Lee, Richard R. Fabsitz, Barbara V. Howard, 
Jean W. MacCluer. Weill Medical Co/fege of Cornell University New York, NI: Southwest 
Foundation for Biomedical Research, San Antonio, TX 
Background: We have recently shown that abnormal left ventricular (LV) diastolic filling 
is independently associated with high mortality in middle-aged and elderly adult Ameri- 
can Indians. However, only a small proportion of the variability in LV diastolic filling can 
be explained by its clinical correlates. 
Methods: Accordingly, Doppler echocardiograms were analyzed in 1,373 American 
Indian participants in the second Strong Heart Study (SHS) examination who had one or 
more biological relatives in the study to determine whether variability in LV diastolic filling 
is influenced by genes. The total phenotypic variance due to additive genetic effects or 
heritability (t?) was calculated using variance component analysis as implemented in the 
program SOLAR. 
Results: The table shows the residual ti of Doppler indices of LV diastolic filling after 
simultaneously adjusting for age, sex and center [second column, (all p<O.OOi)] and 
additionally simultaneously adjusting for height, weight, systolic blood pressure (BP), 
diastolic BP, diabetes and heart rate [third column, (all p<O.OOl)]. 
Variable h” h2 
E velocity 0.36 0.31 
A velocity 0.27 0.27 
E/A 0.33 0.25 
Deceleration Time 0.20 0.19 
Atrial Filling Fraction 0.32 0.29 
Conclusion: After accounting for the effects of age, sex, body size, blood pressure, dia- 
betes and heart rate, a substantial proportion of the total phenotypic variability in LV dias- 
tolic filling is due to additive effects of genes. Studies that seek to identify candidate 
genes influencing LV diastolic filling are currently being undertaken in the Strong Heart 
Study. 
843-5 
5:00 p.m. 
Parallel Unfavorable Effects of Hypertension on Left 
Ventricular Diastolic Function, and Large Arteries 
Mechanics 
Constantinos Tsloufis, Christodoulos Stefanadis, loannis Kallikazaros, Christos Pitsaws. 
Kostas Toutouzas, Kostas Tzioumis, K&as Xenakis, Kostas Mavronasos, Alexandra 
Zervoudaki, Pavlos Toutouzas. HlPPOKRATlON HOSPITAL, ATHENS, Greece 
Background: Hypertension impairs left ventricular diastolic function and large artery 
elasticity but its interrelation has not been well defined. Methods: For this purpose, we 
studied by echocardiography 81 untreated, newly diagnosed patients with stage l-11 
essential hypertension (aged= 54+10 years and office blood pressure=l54~18/97~12 
mmHg). Left ventricular diastolic function was evaluated by the ratio between early and 
late flow velocity peaks (E/A) and the physical properties of large arteries was evaluated 
by calculating aortic distensibility and the augmentation index. Aortic distensibility was 
calculated as a function of changes in aortic diameter (determined by echocardiography) 
and pulse pressure (determined sphygmomanometrically ,n the brachial artery) by the 
use of the formula: Distensibility=2x(pulsatile changes in diameter)/[(diastolic diame- 
ter)x(pulse pressure)]. Augmentation index was estimated by carotid applanation tonom- 
etry. Results: In the entire study population left ventricular mass index was 92.9-+19 gri 
m2, relative wall thickness was 0.48&.06, augmentation index was 0.1 ltO.25, aortic dis- 
tensibility was 1.16?1.1 dyne-lcm210.6, and the ratio E/A was 0.84+0.24. The E/A ratio 
was negatively correlated with age (r=-0.63, p<O.O05), office systolic blood pressure(r=- 
0.27, ~~0.05 ), office pulse pressure (r=-0.24, p<O.O05), left ventricular mass index(r=- 
0.45, p<O.OOl), relative wall thickness (r=-0.34, p<O.O05) and augmentation index (r=- 
0.7, ~~0.05) and positively correlated with aortic distensibility (r=0.43, p<O.OOl). Conclu- 
sion: Apart from its well-known influence on left ventricular systolic performance, impair- 
ment of arterial elasticity is associated with parallel unfavorable modifications of the left 
ventricular diastolic function in the setting of moderate hypertension. 
843-6 
515 p.m. 
Left Ventricular Structure and Function in Untreated, 
Treated but Uncontrolled, and Controlled Hypertension: The 
Strong Heart Study 
Marilyn L. Wright, Richard B. Devereux, Mary J. Roman, Lyle Best, Filchard R. Fabsitz, 
Elisa T. Lee, Barbara V. Howard. !&i/l Come// Medical Center, New York, NY 
Background: Public health data on hypertension (HTN) report the prevalences of hyper- 
tension that is untreated (UnRx-HTN), treated but uncontrolled (UnC-HTN) and con- 
trolled (BP<140190 mm Hg)(C-HTN), but no population-based data are available on 
cardiac status in these groups. Methods: Accordingly, left ventricular (LV) structure and 
function by echocardiography were compared between 1,677 normotensive, 476 UnRx- 
HTN, 469 UnC-HTN and 561 C-HTN American Indian participants in the Strong Heart 
Study. Significant differences between groups in age, body mass index, diabetes and 
study center (but not gender) were controlled for by analysis of covariance. Results: 
After covariate adjustment, mean LV mass was highest, compared to normal BP (151 g), 
in UnRx HTN (170 g) and UnC-HTN (176 g), with intermediate values in C-HTN (163 g, 
~~0.05 vs both UnRx & UnC HTN); the prevalence of LV hypertrophy was higher in UnC- 
HTN (43%) than in UnRx-HTN or C-HTN (both=33%) or normal BP (16%, p<O.OOl). LV 
ejection fraction was lower in all 3 HTN subgroups than in normal BP (61.62% vs 64%, all 
p 0.001) as was LV midwail shortening (all 17% vs 18%, p 0.002). Stress-corrected LV 
midwall shortening, a meawre of myocardial function, was lower in C-HTN (102% of pre- 
dicted) than in other groups (104.105%). Cardiac index was elevated, compared to nor- 
mal BP (2.46 I/minlm2), in UnRx-HTN and UnC-HTN (2.57 and 2.62, both p 0.003) or C- 
HTN (2.43). Pulse pressure/stroke volume, an estimate of arterial stiffness was higher in 
UnRX-HTN and UnC-HTN (0.95 and 1 .OO mm Hgiml) than in normal BP or C-HTN (both 
=0.75 mmHg/ml, p<O.OOl). Conclusion: In a population-based sample UnRx-HTN and 
UnC HTN are associated with increased cardiac output and arterial stiffness, LV hyper- 
trophy and reduced LV ejection fraction; hypertension control normalizes hemodynamic 
parameters and reduces LV hypertrophy but may have less effect on LV function. 
ORAL CONTRIBUTIONS 
850 Infection, Inflammation, and 
Atherosclerosis 
Tuesday, March 20, 2001, 8:30 a.m.-i 0:OO a.m. 
Orange County Convention Center, Room 304A 
850-I 
8:30 a.m. 
Infection With Chlamydia pneumoniae Accelerates the 
Development of Atherosclerosis and Treatment With 
Clarithromycin Prevents It in a Murine Model 
Sumito Oguchi, Toshio Kishimoto, Tadayoshi Nosaka, Ken Nagao, Katsuo Kanmatsuse. 
Department of Cardiology, Nihon University School of Medicine, Tokyo, Japan, 
Department of Viology,Laboratory of Rickettsia&Chlamydia, National institute of 
Infectious Diseases, Tokyo, Japan 
Background: Chlamydia pneumoniae infection has been associated with atherosclerosis 
by serological studies and detection of bacterlal antigen within plaque by culture, immu- 
nohistochemistry, PCR, and electron microscopy. We sought to evaluate a possible 
causal role in an animal model. Methods and Results: Thirty-eight Apolipoprotein (apo) 
E-deficient transgenic mice, which spontaneously develop atherosclerosis, were given 
JACC February 2001 ABSTRACTS - Hypertension, Vascular Disease, and Prevention 265A 
three separate intranasai inoculations of either C.pneumon@.e (n=29) or saline (n=9) at I- 
week Intervals. Immediately after the final inoculation, infected and control mice were 
randomized and begun on a 2.week course of clarithromycin or no therapy. Three 
months after the final inoculation, mice were euthanatized and aortic atherosclerosis 
were identified with Sudan IV staining. Sections of aortas were blindly evaluated micro- 
scopically for area of aorta atherosclerosis, and quantified with computed morphometry. 
Vascular chlamydial antigen and macrophage (Mac-i antibody staining) were assessed 
by lmmunohistochemistry In comparison with uninfected control mice, Infected/untreated 
mice demonstrated a 95% increase in aortlc atherosclerosis (9.1% versus 17.7% of the 
aortic surface, P<.OOOl). In comparison with infected/untreated mice, clarithromycin 
treated mice demonstrated a 43% reduction in aortic atherosclerosis (17.7% versus 
IO.l%, P<.OOOl), whereas aortic atherosclerosis in infected/treated versus uninfected 
control mice did not differ. In the aorta, Cpneumoniae were detected within the athero- 
sclerotic lesion in infected mice. Conclusions: lntranasal C.pneumoniae infection accel- 
erates development of atherosclerosis in apo E-deficient mice. In addition, treatment with 
clarithromycin after infectious exposure prevents accelerated development of atheroscle- 
rosis. These findings strengthen the etiologic link between C.pneumoniae and athero- 
sclerosis and should stimulate additional animal and human studies, including clinical 
antibiotic trials. 
850-4 
9:15 a.m. 
Contribution of Porphyromonas Gingivalis to Accelerating 
Atheroma Formation in an ApoE (+/-) Murine Model 
ii Li, Emmanuel Messas, Robert A. Levine, Salomon Amar. &&on University Medica/ 
Centeer, Boston, MA 
850-2 
a:45 a.m. 
MCP-1 Induces Interleukin-6 in Human Vascular Smooth 
Muscle Cells Through Activation of Transcription Factors 
NF-kB and AP-1 
Christiane Viedt, Judith Vogel, Thomas Athanasiou, Katharina Yijrekcy, Jorg Kreuzer. 
Universif.& Heidelberg, Heidelberg, Germany 
Background: The role of altered inflammatory responses and subacuie infections in the 
acceleration of atherogenic plaque progression is becoming the target of intense 
research. Current epidemiological data suggest that dental infections affecting tooth-sup- 
porting tissues (periodontal diseases) could serve as a systemic port of entry for infec- 
tious agent dissemination, therefore contributing to the atherosclerosis progression. 
Methods: To dissect the molecular mechanisms mvolved in such interactions, the 
present study investigated the effect of repeated subclinical systemic infections with for- 
phyromonas gingivalis (a purported pathogen in periodontal disease) on atherogenic 
plaque formation in an ApoE(+/-) mouse model. ApoE(+/-) mice (n=7) were challenged 
systemically for IO, 12 or 15 consecutive weeks with Porphyromonas gingivalis (lo4 
CFU) twice a week. ApoE(+/-) mice (n=7) challenged with salme served as control an,- 
mals along with wild-type animals (“~7) challenged with Porphyromonas glngivalis (IO4 
CFU) at the same regimen as the ApoE (+/-) mice. All animals were fed with a high-fat 
diet. Mice were sacrificed at each time point for histology evaluation of aortic atheroma 
formation. Histomorphometric analysis at specific aortic tissue landmarks was performed 
using a computer-assisted image analysis system. 
Results: Histologically, the mean total area and extent of atherosclerotic lesions were 
two-fold greater in ApoE (+/-) challenged animals than ApoE(+/-) unchallenged animals 
or wild-type animals challenged with Porphyromonas gingivalis (~~0.05). 
Conclusions: These results provide evidence that systemic challenge with oral patho- 
gens can accelerate atherogenic plaque progression. 
Background: Monocyte chemoattractant protein-l (MCP-1) has been implicated in the 
pathogenesis of atherosclerosis through recruitment of monocytes to vascular lesions. 
Growing evidence suggests that MCP-I can act as an autocrine mediator of atherogene- 
sis, as cells in atherosclerotic lesions can both produce and respond to MCP-1. We now 
reasoned that the atherogenicity of MCP-1 may in part be mediated through inflamma- 
tory activation of smooth muscle cells (SMC). As parameters of activation we investi- 
gated the activity of extracellular signal regulated kinase (ERK) and the transcription 
factors nuclear factor kappa.6 (NF-kB) and activator protein-i (AP-I) which are involved 
in proliferation and inflammatory responses. Methods: Human SMC were stimulated with 
MCP-1 (10 ngiml). The activity of ERKiI2 were measured by Western blot analysis, NF- 
kB and AP-1 binding was ddermlned using electrophoretic mobility shift assay. Interleu- 
kin-6 (IL-t?) production was determined by ELISA. Results: Stimulation of human SMC 
with recombinant MCP-1 resulted in rapid activation of ERKlR. Furthermore, MCP-1 
activated the transcription factors NF-kB and AP-1. The inflammatory response of SMC 
to MCP-1 could be further illustarted by increased IL-6 synthesis. Both NF-kB and AP-1 
activation were involved in the induction of IL-6 by MCP-1, as demonstrated by CIS ele- 
ment double-stranded (decoy) oligonucleotides (ODN). Also pretreatment of cells with 
pertussis toxin inhibited MCP-l-dependent IL-6 release suggesting the involvement of 
Gi-proteins. Beside induction of IL-6 MCP-I significantly increased cell proliferation, 
which was inhibited by the ERKi/Z inhibitor PDO98059. Conclusions: The results indi- 
cate that MCP-1 may promote atherogenesis through NF-kB and AP-I dependent activa- 
tion of IL-6 release from human SMC. Our data support a new mechanism for the 
proatherogenic effect of MCP-1. 
850-5 
9:30 a.m. 
Cytomegalovirus Infection of ApoE Knockout Mice 
Increases IFNg Serum Levels, which Induce Expression of 
Monocyte Chemoattractant Protein-l by Endothelial Cells 
David Rott, Jianhui Zhu, Mary Susan Burnett, Yi Fu Zhou, Amy Wasserman, Stephen E. 
Epstein. The Cardiovascular Research Institute, Medstar Research Institute, 
Washington, DC 
850-3 
9:oo a.m. 
Antibodies to Human Heat Shock Protein 60 Are Associated 
With Presence and Severity of Coronary Artery Disease 
Jianhui Zhu, Arshed A. Quyyumi, David Rott, Hongsheng Wu, Julian P. J. Halcox, 
Stephen E. Epstein. Washington Hospitai Center, Weshingfon, DC, NHLBI. N/H; 
Bethesda, MD 
Background: Atherosclerosis IS an inflammatory disease in which chemokines and 
cytokines play central roles. Among the candidate inflammatory triggers is infection. We 
hypothesized that infection of apoE knockout mice with murine cytomegalovirus (MCMV) 
increases serum levels of circulating cytokines, and that such serum has the capacity to 
induce “pro-atherosclerotic” changes in vascular endothelial cells (ECs). Methods: 
ELISA was used to determine monocyte chemoattractant protein-l (MCP-1) levels of the 
supernatant of syngeneic mouse ECs mcubated with medium containing serum from 
uninfected apoE (-/-) mice or mice infected with MCMV, and to assay TNFa and IFNg 
serum levels. Blocking experiments were performed by pre-incubating serum with anti- 
mouse IFNa monoclonal antibody (mAb). Results: Serum from MCMV mfected mice 
induced MCP-1 expression by ECs. This serum contained IFNg (mean level of 116+ 40 
pg/ml), whereas IFNg was undetectable in uninfected mouse serum. TNFa was undetect- 
able in either infected or uninfected sera. Pre-incubating the infected mouse serum with 
anti-IFNB mAb significantly decreased serum-induced ECs expression of MCP-1 
(237i28 vs 104?46 pglml; PcO.01). Conclusions: MCMV infection increases IFNg 
serum levels, such serum has the capacity to induce MCP-1 in vascular ECs, and the 
serum-induced changes in MCP-1 expression are due, at least partially, to IFNg. These 
effects demonstrate a potentially important mechanism by which CMV could contribute to 
atherogenesis without directly infecting the vessel wall: infection of any tissue could, by 
increasing circulating IFNg levels and inducing EC expression of MCP-1, recruit mono- 
cytes and T-cells to the vessel wall, thereby augmenting inflammation in the vessel wall 
and exacerbating atherogenesis. 
Background: Increasing evidence suggests that autoimmunlty contributes to atherogen- 
esis, and that heat shock protein (HSP) may be one of the autoantigenic determinants. 
Because antibodles to mycobacterial HSP65 appear to be associated wth carotid artery 
thickening, we examined whether antibodies to human HSPGO are associated with the 
risk of coronary artery disease (CAD). Methods: There were 391 patients (62% men. 
mean age 57 year) being evaluated for CAD by coronary angiography. Blood samples 
from all of patients were tasted for IgG antibodies to human HSPGO by ELISA. Results: 
We found that 75% of the study subjects had anti-HSPGO IgG antibodies. The prevalence 
of CAD was increased in seropositive compared to seronegative patients (68% vs 49%, 
P=O.O009). Mean titers of HSPGO antibodies were higher in CAD patients than in non- 
CAD patients (1:153 vs. 1:i 12, P=O.O08). No association between HSPGO antibodies and 
inflammation (elevated C-reactive protem levels) or infection (seropositivity to cytomega- 
lovirus, Chlamydia pneumoniae, Helicobacter pylori, hepatitis A virus, herpes simplex 
virus type 1 and type 2) was found. Importantly, HSPGO antibodies were related to CAD 
severity. The prevalence of HSPGO antibodies was 76%, 80%, and 85% in patients wth 1, 
2, and 3 vessel disease, compared with 64% in patients without CAD (Ptrend=0.003). A 
similar association between increasing antibody titers and number of diseased vessels 
was also found (P=O.O3). Significant associations between antibodles to HSPGO and 
CAD severity persisted after adjustment for traditional risk factors by age, race, male gen- 
der, smoking, diabetes, hypertension, hyperchoiesterolemia and CRP levels. Adjusted 
OR for numbers of vessel disease was 1.86 (95%CL 1.13-3.04). Conclusion: This is the 
first study demonstrating a strong association between human HSP60 antibodies and 
both the presence and severity of CAD. These findings are compatible with the concept 
that autoimmunity plays a role in atherogenesis, and that HSP is likely one of the autoan- 
tiaenic determinants. 
850-6 
9:45 a.m. 
Respiratory Tract Infection and CAD: The Influence of 
Haemophilus lnfluenzae on Cardiovascular Events in 
Patient With CAD 
Ailaiti Maimaitiming, Stephan Blankenberg, Manfred Ossendorf, Christoph Bickel, Hans- 
Jurgen Rupprecht, Jurgen Meyer. Department of Medicine //, Johannes Gutenberg 
Universify Mainz, Mainz, Germany 
Background: Epidemiological evidence revealed an association between respiratory 
tract infection or chronic cough and myocardial infarction. Furthermore the role of 
Chlamydia pneumoniae(CP) in atherogenesis is discussed controversially. We hypothe- 
sized that also other infectious candidates of respiratory tract infection may be associated 
with CAD and investigated prospectively the influence of Haemophilus influenzae(H-in) 
on cardiovascular events in patients with documented CAD. Methods: In 1068 pts coro- 
nary angiography was performed and CAD diagnosed. Before angiography blood was 
drawn and titer of H-in determined by immunfluorescence technique (IF-test: positive 
I:100 and more). 986 (92.%) of pts had a follow-up(FU) mainly by office visit or phone 
(median 2.2 yrs, maximum 3 1 yrs). Of these 986 pts 62 died due to cardiovascular 
causes. Results: Increasing titers of H-in were associated with future cardiovascular 
mortality (p=O.O16). After controlling for age, sex, classical risk factors, number of dis- 
eased vessels. clinical history of myocardial infarction, treatment with PTCA, CABG, and 
medications, Cox regression revealed a Harzard Risk(HR) of 1.6 (Cl 1 .l-2.4; p=O.O3). 
The association of H-in with future cardiovascular death was independent of classical 
risk factors and treatment procedures. Conclusion: In patients with documented CAD 
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increasing titers of Haemophilus influenzae are associated with future cardiovascular 
mortality. The study encourages the hypothesis that several candidate infectious agents 
of respiratory tract infectlon may exist which could contribute to the acceleration of CAD. 
% Cardiovascular Death 
H-in 
l?(%) 
negative 1:100 1:320 1 :I 000 P-adjusted HR(95%CI 
) 
il(4.4) 41(6.3) 8(9.4) Z(33.3) 0.03 1.6(1.1- 
2.4) 
ORAL CONTRIBUTIONS 
851 Gene Therapy: Novel Approaches to 
Delivery and Expression 
Tuesday, March 20, 2001, 8:30 a.m.-IO:00 a.m. 
Orange County Convention Center, Room 304E 
851-1 
8:30 a.m. 
Evaluation of in Vitro and in Vivo Gene Transfer Into Cardiac 
Myocytes and Endothelial Cells Using Multiply Attenuated, 
Self-Inactivating Lentiviral Vectors 
Eleonora Simeoni, Sylvain Fleury, Robert Driscoll, Ludwig K. van Segesser, Lukas 
Kappenberger, Giuseppe Vassalli. Division of cardiology, Lausanne, Switzerland 
Naked DNA and adenovirus vectors are limited by low gene transfer efficiency and short- 
lived gene expression, respectively. Chromosomal integration, a feature of retroviral vec- 
tors, is key in achieving stable expression. Among retroviral vectors, lentiviral vectors are 
unique in that they are able to transduce nondividing cells. Recently, multiply attenuated, 
self-inactivating (SIN) lentiviral vectors have been constructed, which have a markedly 
improved safety profile compared to first-generation of vectors. We studied these novel 
vectors for cardiovascular gene transfer both in vitro and in viva Methods: Lentiviral vec- 
tors pseudotyped with the vesicular stomatitis virus (VSV)-G protein contained a IacZ 
marker gene under the control of a PGK promoter and a regulatory sequence from the 
woodchuck hepatitis virus (WHV). In vitro gene transfer was studled both in neonatal and 
in adult mouse and rat cardiac myocytes (CM), and in human umbilical cord endothelial 
cells (HUVEC). Ex viva gene transfer was studled in neonatal CM transplanted into rat 
hearts. In viva gene transfer was studied in mouse and rat hearts and carotid arteries. 
Results: Efficient in vitro gene transfer was achieved both in neonatal (-80%) and adult 
CM (-20%) and in HUVEC (-50%). Neonatal CM transduction was inhibited by n- 
butyrate, a cell cycle progression at the early Gl stage. Transduced CM were <etected 
one week after cell transplant into rat hearts. In viva gene transfer into mouse and rat CM 
and arterial EC was inefficient (~0.1% as compared to -10% with an adenoviral control 
vector). A non-attenuated lentiviral vector containing the accessory protein genes did not 
improve CM transduction in viva. Conclusions: Lentiviral vectors efficiently transduce CM 
and EC in vitro; however, in viva gene transfer into the myocardium and arterial endothe- 
lium is inefficient. The inhibitory effect of cell cycle blockers suggests that metabolically 
active ceils are more susceptible to transduction. Lentiviral vectors may be useful in ex 
viva gene therapy of cardiovascular diseases. Their unique capability of chromosomal 
integration in nondividing cells provides a potential for permanent genetlc modification of 
cardiovascular tissues. 
851-2 
8:45 a.m. 
Strong Enhancement of In Vivo Gene Transfer Into Rat 
lschemic Skeletal Muscle by Pulsed Electric Fields 
Nagendu B. Dev, Georg Widera, Jasmine Primavera, Susan Bleecher, Dietmar I? 
Rabussay. Genetronics, Inc., San Diego, CA 
Background: Viral vector mediated and electro-transfection of naked plasmid DNA in 
normal striated muscle in animals have been reported earlier. Due to the shortcomings of 
viral vectors, we sought to determine the extent to which gene expression can be 
enhanced by pulsed electric fields under ischemic conditions. Methods: Male Sprague- 
Dawley rats were subjected to bilateral hind leg ischemia by ligation of the art&a femora- 
/is and transection of nervu.s femoris. Zero to fourteen days later, the redus femoris mus- 
cle of the ipsilateral hind leg was transfected with plasmid DNA enco$ng a luciferase or 
lac-z gene, followed by random pulsing of the muscle in the right or left legs with a pre- 
determined nominal electric field strength, pulse width and number of pulses using a co- 
axial electrode. The contralateral leg was transfected identically, but not subjected to 
electric fields. All animals were sacrificed 2 days postgene transfers for evidence of 
luciferase and P-galactosidase expression in the investigated muscle. Results: The rela- 
tive luciferase activity of the homogenized muscle (electric-field treated versus sham) in 
ischemic legs (n=22) calculated for all rats was highest at a nominal electrical field 
strength of IO-iGV/mm. (an increase of 4-5 orders of magnitude) There was a precipitous 
drop in luciferase activity at 25-30V/mm and higher in all investigated animals. Regard- 
less of the duration of induced ischemia, luciferase activity remained largely unchanged. 
Beta-galactosidase expression in the muscle tissue (n=20) and lmmunohistochemistry of 
the serial sections of the muscle tissue parallels the observation of luciferase expression. 
Conclusion: Under optimized conditions, these resultsdemonstrate that the gene trans- 
fer approach, augmented by electric fields, leads to very high levels of gene expression in 
ischemic skeletal muscles of rat. Based on these findings, there are strong reasons to 
explore using this method of pulsed electric fields on cardiac muscle for the treatment of 
coronary occlusion, myocardial infarct and peripheral vascular disease for which intravas- 
cular catheter “se for gene transfer is compromised or prohibited. 
851-3 
9:00 am. 
The Murine Cytomegalovirus Immediate-Early Enhancer/ 
Promoter Is a More Potent Regulator of Transgene 
Expression Than the Human Promoter in Vascular Smooth 
Muscle Cells In Vitro 
Paul A. Kingston, Christian A. Gerdes, Anthony M. Heagerty, Pedro R. Lowenstein, Maria 
G. Castro. University of Manchester, Manchester, United Kingdom 
Background: The low activity of heterologous promoters in vascular smooth muscle 
cells (SMC) poses a substantial problem for vascular gene therapists. Powerful viral pro- 
moters that give rise to high levels of transgene expression in most tissues are poorly 
effective in SMC. The human cytomegalovirus major immediate-early enhancer/promoter 
(MIEhCMV) is amongst the most powerful promoters of transgene expression known, yet 
only a small proportion of individual copies of the promoter give rise to transgene expres- 
sion after reaching the SMC nucleus. SMC-specific promoters do not achieve signifi- 
cantly greater levels of transgene expression than MIEhCMV. We have compared the 
efficacy of MlEhCMV and the murine cytomegaiovirus major Immediate-early enhancer/ 
promoter (MIEmCMV) to promote transgene expression from recombinant adenovirus 
vectors @Ads) in human coronary and porcine aortic SMC (HCSMC & PASMC) in vitro. 
Methods: We have generated two RAds in which the expression of lacZ(E. P-galac- 
tosidase) is under the control of MlEhCMV (Ad5-LacZ) or MlEmCMV (RAd 36). HCSMC 
and PASMC were grown to 90% confluence, rendered quiescent by incubation in low- 
serum medium for 7 days, then infected with Ad5-LacZ or RAd 36 at multiplicities of Infec- 
tion (MOI) of 10, 100 and 500. SMC were incubated for 72 hours, then assayed for 
expression of P-galactosidase. Results: RAd 36 gave rise to =37-fold greater expression 
of P-galactosidase than AdS-LacZ at all MOI in PASMC (all p <O.OOl), and 4. to 7.fold 
greater expression in HCSMC (all p ~0.01). Expression of P-galactosidase was 40. to 50. 
fold greater in HCSMC than PASMC after infection with Ad5-LacZ at all MO1 (all p 
<O.OOl), but was only 3- to B-fold greater in HCSMC than PASMC after infection with RAd 
36 (all p <O.Ol). Conclusion: The MlEmCMV promoter is a substantially more powerful 
promoter of transgene expression in vascular SMC than MIEhCMV, and gives rise to less 
inter-spews variability By allowing increased transgene expression, or the use of lower 
virus doses with potentially reduced host immune responses, it represents a significant 
improvement over promoters previously employed for gene therapy in the vasculature. 
851-4 
9:15 am. 
Ultrasound Enhanced Gene Transfection Is Safe and Dose- 
dependent In Vascular Smooth Muscle Cells In Vitro 
Khalid H. Ashai, Anthony &yes-Genis, Birgit Kantor, Thomas Gerber, Robert S. 
Schwartz. Mayo Clinic, Roshester, MN 
Background: Gene delivery with naked plasmid is safe but has a poor transfection (Tfx) 
rate in vascular smooth muscle cells (SMC’s). Ultrasound (US) has only recently been 
shown to enhance Tfx in SMC, but the dose relation and safety of US is unknown. We 
hypothesized that ultrasonic energy in the presence of contrast microbubbles could 
increase Tfx in SMC’s in a safe and effective manner. Methods: Porcine SMC’s (0.8,106, 
passages 4 and 5) were suspended i.n serum-free media containing 33 pg/ml Luclferase 
(Luc), plasmid DNA and 83pL/ml Albunex@. The samples were exposed to pulsed 0.98 
MHz US (0, 0.18, 0.75, 3.0, 6.5, 11.3 and 34Wicm’ at 1Omsec pulses, 10% duty cycle) 
for 1Osec or 60 set duration. The cells were plated and Luc activity from cell lysate 
assessed in 48 hrs. Electroporation (EP) and lipofection (Lf) were used as positive con- 
trols. Cell-death and apoptosis were measured by FITC/Annexin method, after exposure 
to US. Results: Luc activity was directly proportional to US intensity (see Figure). A 
threshold effect was demonstrated at 3 W/cm*, below which Luc activity was negligible. 
Luc activity with 10 and 60sec exposures was similar. Cell toxicity was similar to negative 
control. Conclusions: Ultrasonic energy with microbubbles improves plasmid Tfx of vas- 
cular SMC in vitro, proportlonal to dose and time of exposure. US enhanced plasmid 
transfection shows little cell toxicity Translation of these results in viva may result in safe 
and efficient modes of enhancing transfection of vascular cells. 
851-5 
9:30 a.m. 
Ultrasound Enhances Therapeutic Gene Expression in 
lschemic Pig Myocardium 
Peter Schratzberger, Tengiz Tkebuchava, Rudolf Kirchmair, Charles E. Milliken, 
Ferdinand Bahlmann, Oren Tepper, Atsuhiko Kawamoto, Hideki Iwaguro, Roberto Pola, 
Robert F. Zuk, Axe1 F. Brisken, Peter R. Vale, Jeffrey M. Isner. Cardiovascular Research 
and Vascular Medicine, St. Nisabeth Medical Center, Tufts University Boston, MA, 
PharmaSonics, Inc., Sunnyvale, CA 
Background. Direct myocardial injection of naked plasmid DNA encoding for VEGF-2 via 
a minimally invasive chest wall incision has been shown to improve blood flow to 
ischemic myocardium. Studies in rabbits have demonstrated that ultrasound increases 
transfection efficiency of naked plasmid DNA in skeletal muscle in viva. Here we show in 
a porcine model of chronic myocardial ischemia (LCx ameroid constrictor) that VEGF-2 
gene transfer (GT)-induced therapeutic angiogenesis may be improved by ultrasound 
exposure (USE). Methods and Results. VEGF-2 GT was performed in 10 swine via a 
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“mini” left thoracotomy. In 5 animals, VEGF-2 was Injected directly into myocardium (4 
injections, 1 mL each, total dose 2 mg) via a 25.gauge needle; 5 animals received identi- 
cal VEGF-2 injection followed by direct USE of the injected myocardium. 6 control ani- 
mals received saline injections, 3 of which underwent adjunctive USE. Ultrasound at 1 
MHz was applied at the injections Sites for 2 mm each. USE caused no changes in heart 
rate (pm-USE = 122 + 4 beatsimin vs post-USE = 126 i 5), systolic blood pressure (BP, 
95 + 9 vs 98 i 2 mmHg), diastolic BP (59 i 1 vs 62 i 3 mmHg), or 02 saturation (100% 
vs 100%). ECG showed no arrhythmias or signs of ischemia during and after USE. GT 
improved LV ejection fraction (EF) in 3 animals (mean increase in LVEF = 4.0%) and GT 
+ USE caused a mean increase in LVEF = 7.2% (P < 0.01 vs GT) rn 4 ammats. Objactwe 
evidence of reduced rschemia was documented by LV electromechanical (NOGA) map- 
ping (mean area of ischsmia pre-GT = 6.12 cm2). 4 weeks post-GT, mean area of 
ischemia was 2.92 cm2, (P c O.Ol), and 1.12 cm2 when GT was followed by USE (P < 
0.05). Colored microspheres (15 pm diameter) demonstrated that USE after GT 
increased myocardial blood flow to ischemic myocardium after maximal vasodilatation 
significantly more than with GT alone (USE + GT = 1.69 t 0.10 mliminig; GT = 1.41 + 
0.08: P c: 0.05) Saline injections + USE did not show improvement rn any of these 
parameters Conclusion. The use of ultrasound for enhanced gene transfer of naked 
piasmid DNA IS safe and can enhance the functional outcome of VEGF GT-induced ther- 
apeutic angiogenesis in myocardium. 
851-6 
9:45 a.m. 
Successful Restoration of Blood Flow Using Contiuous 
infiltration of Naked-DNA Encoding Vascular Endothelial 
Growth Factor 
Ariei Roguin, Samy Nit&, lrit Rubinstein, Mory Resnrk, Nina S. Levy, Zard Abassi, Orit 
Lache, Aharon Hoffman, Andrew F! Levy. Raooaport Faculty of Medtcine, Technion-Israel 
lnstitue of Technology Haifa, israel 
Introduction: Vascular Endothelial Growth Factor (VEGF) is a potent angfogenic cytok- 
me that induces the development of collaterals in ischemic tissue. These cytokines are 
usually given by a single rntra-muscular injection. Several delivery systems for angio- 
genie factors use viruses. Thus treatment was recently suspected for having serious side 
effects. The purpose of this study was to evaluate the usefulness of continuous infiltration 
of naked-DNA encoding VEGF to augment collateral formation and tissue perfusion in a 
mouse unilateral ischemic hindiimb model. Methods. The left iliac artery of 657 mice 
(n=24) was ligated in two places and cut. An osmotic infusion pump containing a placebo 
or VEGF m different concentrations was implanted rntra-abdominaly and the outlet tube 
from the pump fenestrated and tunneled into the left quadriceps musck? lschemic (left)/ 
normal (right) kmb blood flow was measured using a laser Doppler blood flow meter, that 
uses a 12mW helium neon laser beam. A phoiodiode in the scanner collects the back- 
scattered light emitted by the laser. The shift rn the frequency of the Incident light is trans- 
formed into voltage variatrons, which are directly related to blood flow distributron. 
Hindlimb blood flow was monitored at day 0, 3, 7, 10, 14. 21, 28 and 35 days post sur- 
gery The tissues of the ischemic and non-ischemrc limbs were analyzed for endothelial 
cells and capillary density using CD31 and factor VIII related antigens. Results: None of 
the mice in the VEGF-treated group developed necrosis in comparison to 33% of the pla- 
cebo group. A faster restmatron of blood flow was observed in the VEGF treated mice. By 
day 7 the blood flow was almost complete for the group treated with 500 pg VEGF, while 
in the placebo group the flow returned to normal only after 21 days (p&05). Application 
of 50 ug VEGF was not sufficient to induce any beneficial effect on restoration of blood 
flow Conclusions: Our results demonstrate the rapid and successful restoration of blood 
flow using continuous infiltration of naked-DNA encoding VEGF via an osmotic pump. 
MODERATED POSTER SESSION 
7 Nonlipid Effects af Statin Therapy 
Tuesday, March 20, 2001, 300 a.m.-l 1:00 a.m. 
Orange County Convention Center, Hall A4 
9:oo a.m. 
1007-201 The Effect of Statin Therapy on Ventricular Late Potentials 
in Patients With Acute Myocardial Infarction Receiving 
Thrombolytic Therapy 
Meral Kayikcioglu, Levent H. Can, Harun Evrengul, Serdar Payzin, Hakan Kultursay. Ege 
Universlfy School of Medicine, Cardiology dept., izmir, Turkey 
Background: The value of ventricular late potentials(LP) rn risk predictron is proven as a 
predictor of sudden death and ventricular arrhythmias in AMI. Statrns are considered to 
have beneficral effects on plaque stabilization with earlier use in AMI. Aim of this study 
was to determine whether earlier statln therapy has any effect on LP which is a noninva- 
we tool for evaluation of arrhythmogenic substrate. Methods: Study population con- 
sisted of prospectively enrolled 64 patients(pts) presenting with AMI (~6 hours). Thirty of 
them began to receive statin therapy on admission irrespective of their lipid values.All pts 
received thrombolyhc therapy(TT) and were evaluated with coronary angiography at pre- 
discharge. SAECG recordings were obtained serially by using ART system prfor to TT 48 
hours after and 10 days later. LP were defined as positive if SAECG met at least 2 of 
Games criteria: filtered total QRS duration>ll4ms, root mean square voltage of the last 
40 ms of the QRS <20mV, or the duration of the terminal low (<40mV) amplrtude srgnals 
>38ms. Changes observed in SAECG recordings after TT were correlated with angio- 
graphic and clinical data with regard to statin usage. Data were evaluated with multfvari- 
ate analyses, and changes of LP were compared with McNemar test. Results: There 
were no signrficant differences between the clinical characteristics of the two randomized 
groups. There was a significant decrease in the rates of LP between the first and third 
SAECG recordings after Tr in the statin group. Pts receiving statins also had lower inci- 
dence of ventricular arrhythmias 9(30%) compared with pts not receiving them 21(62%). 
Conclusion: l.The early usage of ?&tins reduces the incidence of LP following TT in 
AMI. 2. Statin therapy also seems to be reducing the incidence of in-hospital ventricular 
arrhythmias. These possible beneficial effects of Statins might be explained through the 
prevention of new myocardial lscheamic episodes due to early plaque stabilization or reg- 
ulation of endothelial and platelet functions apart from lipid lowering. Further studies are 
needed to confirm these results. 
Groups LPi(Baseline) LP3(lOth day) 
stam (-) 16(47%) 7(21%) 
Statin (+) 10(33%) 4(13%) 
9:12 a.m. 
1007-202 Effects of Atorvastatin Treatment on Global Fibrinolytic 
Capacity, Apoptosis, and Leukocyte Activation in Patients 
With Coronary Artery Disease 
Enver Atalar, Tayfun Acyl, Kudret Aytemir, \jbrahim Haznedaroglu, Necla Qzer, Altunay 
Daver, Kenan Qviin$ Serdar Aksbyek, Syrrg Kes, Ferhan 6zmen. Hacetfepe Universih/ 
Medical School Departments of Cafdnlogy and Hematology, Ankara, Turkey 
The benefical effects of HMG-CoA reductase inhibitor treatment in coronary artery dis- 
ease (CAD) seem to be based not only their lipid lowering properties but also their favor- 
able effects on hemostasis and inflammation. Moreover, statns may affect vascular 
smooth muscle cell (VSMC) and macrophage apoptosis in the atherosclerotic plaque. 
We aimed to investigate the effects of atorvastatin on those pathobiologicai events in 
CAD patients with hyperlipidemia. Methods: Fourty-one hyperlipidemic patients (age 
5528, 26 male) with stable CAD who had not taken lipid-lowering medications were 
treated with atorvastatin lo-20 mgiday for 12 weeks to determine hemostatic-hemorheo- 
logic parameters including levels of fibrinogen, soluble Fas and sL-selectin, and Global 
Fibrinolytrc Capacity (GFC). GFC is a new technrque for evaluating the frbrinolytlc sys- 
tem. GFC assay is affected by levels of t-PA, u-PA, scu-PA, APC, Factor 7, plasminogen, 
PAI-I, and alpha-2 antipiasmin therefore, reflects the effectiveness of the entire fibrin- 
olytic system. sFas molecule, Inhibits apoptosis of many cells including leukocytes and 
(VSMC). Results: Atorvastatin treatment decreased serum low-density lipoprotein -40% 
total cholesterol -32%. and triglycerides -27%, and increased high-density lipoprotein 
+10%, at 12 weeks compared to baseline (Table). Those effects were accompanied by 
decrements in the plasma sL-selectin and sFas levels. Conclusions: These results sug- 
gest that beyond the benefical effects on plasma lipid profile, atorvastatin therapy 
increases the global fibrinolytic capacity and leads to leukocyte deactivation in hyperlipi- 
demic patients with CAD. Our findings also imply that atorvastatin treatment may lead to 
decrease VSMC and macrouhaae apoutosis in atherosclerotic plaque and therefore 
could help to understand the mechani&of plaques stabilization in.CAD. 
Before Atorvastatin After Atorvastatin P 
sFas (pg/ml) 
sL-selectin (rig/ml) 
GFC (mgr/ml) 
TK (mgidl) 
TG (mg/dl) 
LDL (mgfdl) 
HDL (mg/dl) 
656+191 
3,5+2,3 
3,5+2,3 
264t33 
i 7oAao 
179t32 
47+12 
4936*1759 0,0001 
578r153 0,001 
5,6i2,9 0,0001 
178&S 0,0001 
124+47 0,0001 
106131 0,0001 
\ 52riO 0,oooi 
9:24 a.m. 
1007-203 Do Different Statins Possess Different Antinflammatory and 
Antithrombogenic Properties? 
Steven M. Kent, Thor T. Markwood, Louis C. Coyle, Patrick J. Flaherty, Allen J. Taylor. 
Walter Reed Army Medical Center, Washington, DC 
Background: Extra-lipid effects of statins, such as anti-inflammatory and anti-thrombo- 
genie actions, may contribute to their clinical benefit. These effects, with important imp& 
cations for the concept of a statin “class effect’, may be drug-specific or may be related to 
the extent of lipid lowering. Methods: Single-center, randomized clinical trial comparing 
atorvastahn (80 mg qd; n=38) and pravastatin (40 mg qd; n=41) using serial measure- 
ments of serum ikpids, C-reactive protein, and fibrinogen. Results: The population was 
predominately male (70%) and middle-aged (mean age 63); 33% were being treated for 
secondary prevention of coronary disease. Baseline and 3.month measurements are 
shown below in the Table. 
LDL hsCRP Fibrinogen 
Baseline 3 Months Baseline 3 Months Baseline 3 Months 
Atorvastatin 15&33 81t30 .40*.34 .36+.51 376+73 396&O 
Pravastatin 157229 112r25 .42+.34 .37i.38 378+95 384285 
P NS c.001 NS NS NS NS 
The 3 month hsCRP was lower than the baseline value in 72.5% (Pc.001) of subjects, 
with a comparable proportion observed in pravastatin (77.8%; P=.OOi) and atorvastatin 
(66.7%; P=.O56) subgroups. The change in hsCRP value tended to be correlated with the 
degree of LDL lowering (r=.21, P=.O9). Conclusions: High-dose atorvastatin and prav- 
astatin have similar effects on hsCRP and fibrinogen at 3 months, despite their markedly 
different effects on LDL cholesterol. 
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1007-204 Do Statins Affect Bone Metabolism? Effects of Simvastatin 
and Atorvastatin on Biomarkers of Bone Turnover 
Evan A. Stein, Michel Farnier, Minzhi Liu, Joanne Waldstreicher, Michele Mercuri. 
Medical Research Laboratories, Highland Heights, K): Merck Research Laboratories, 
Rahway, NJ 
Background: Recently, several case control studies have reported an association 
between statin therapy and reduced risk of fractures. No data from prospective random- 
ized clinical trials designed to assess either biochemical or clinical effects of statins on 
bone metabolism are yet available. Methods: This 12.week, randomized, open-label 
study compared simvastatin 40 mg or 80 mg and atorvastatin 20 mg or 40 mg in 846 
hypercholesterolemic patients. Stored serum samples were analyzed to compare the 
effects of simvastatin and atorvastatin on 2 bone biomarkers, bon&specific alkaline 
phosphatase (BSAP), a marker of bone formation, and C-teleopeptide of type 1 collagen 
(CTx), a marker of bone resorption. Results: Simvastatin 40 and 80 mglclay, but not ator- 
vastatin 20 and 40 mglday, produced a significant (p < 0.05), dose-dependent decrease 
in BSAP. CTx showed small, not statistically significant changes with both simvastatin 
and atorvastatin. 
Effects of Simvastatin Versus Atorvastatin’ on Biochemical Markers of Bone 
Turnover 
BSAP CTx 
N Mean % A P# N Mean % A P# 
(95%CI) (95%CI) 
s40 191 -4.1 (-65-1.7) 0.001 191 -1.8 (-7.1,3.8) 0.522 
580 199 -6.3 (-8.0,-4.5) <0.001 199 -3.0 (-8.3,2.7) 0.291 
A20 199 -0.4 (-2.6,l.g) 0.739 202 0.9 (-3.8,5.6) 0.706 
A40 205 -1.4 (-3.5,0.8) 0.209 207 3.4 (-3.0,10.2) 0.305 
‘Between-group p-value for BSAP: srnvastatin versus aiorvastat~n, p < 0 00,; between-group p-value for 
CTx: simvastatin versus atorvaslafin, p = 0.115: ‘within-group p-value: 540, 580 = *imvastafin 40 mg and 
SO mg, respectdy, A20, A40 = atorvastattn 20 mg and 40 mg, respectively 
Conclusion: The present results show that treatment with simvastatin, but not atorvasta- 
tin, leads to small decreases in BSAP, and suggest that simvastatin, in addition to having 
proven cardiovascular benefits, may beneficially affect bone turnover. Further prospec- 
tlve clinical studies are needed before the clinical relevance of these findings is fully 
understood. 
9:48 a.m. 
1007-205 Cholesterol-Lowering Medication, Cholesterol Level, and 
Reproductive Hormone Levels in Women: The NHLBI- 
Sponsored WISE Study 
C. N. Bairey Merz, Marian B. Olson, B. D. Johnson, Vera Bittner, T. K. Hodgson, Sarah L. 
Berga, Glenn D. Braunstein, Sheryl F. Kelsey, George Sopko. Cedars-Sinai Medical 
Center, Los Angeles, University of Pittsburgh, Pittsburgh 
Background: Reproductive hormones (estrogen, progesterone, testosterone) are 
metabolized from a common cholesterol precursor pathway. The impact of cholesterol- 
lowering medication on blood reproductive hormone ievels is unknown. Methods: We 
evaluated 378 participants of the Women’s lschemia Syndrome E&ation (WISE) study 
who underwent coronary angiography for suspected ischemia, and were not on hormone 
therapy. Results: Baseline analysis demonstrated a mean group age of 58 (range 27-86) 
yrs, including 260 (69%) postmenopausal, 20 (5%) perimenopausal, and 98 (26%) pre- 
menopausal women. The 93 (25%) cholesterol-lowering medication users were older 
compared to the non-users (62il2 vs 56~13 yrs, p=O.OOl, respectively). After adjust- 
ment for this baseline age difference, no significant group differences in the reproductive 
hormone levels (estradiol, bioavailable estradiol, estrone, and progesterone) were 
observed despite significant lipid differences associated with cholesterol-lowering medi- 
cation use (LDL-cholesterol 107k42 vs 119+40 mg/dl, p=O.O08, respectively, compared 
to non-cholesterol-lowering medication users). Subgroup analyses in the post-, peri-, 
and premenopausal women also failed to demonstrate blood reproductive hormone level 
differences according to cholesterol-lowering medication use. When stratified by low 
blood cholesterol levels (LDL-cholesterol above vs below 70 mgidl), no blood reproduc- 
tive hormone level differences were observed in the total population. Among prameno- 
pausal women, although blood hormone levels were consistently lower in the low LDL-C 
group, this was not statistically significant, and the group mean estradiol level remained 
above 50 mg/dl (Table). 
Blood Levels LDL-C>70 mg/ LDL-Cc70 mg/ p 
dl (n=85) d(n=12) 
BioE2(pgiml) 52+38 40*26 0.32 
EWgW 91r73 69r48 0.31 
El WW 103~~60 89+55 0.46 
P0(pglml) 2.91t4.4 l.lkl.3 0.15 
BioE2=bioavailable estradiol EP=estradiol Elzestrone PO=progesterone 
Conclusions: Among women undergoing coronary angiography for suspected ischemia, 
cholesterol-lowering medication use or low LDL-C levels are not associated with signifi- 
cantly lower blood reproductive hormone levels. 
1O:OO a.m. 
1007-206 Prevalence of Depression Is Not Increased by Long-Term 
Pravastatin Therapy in Patients With Coronary Heart 
Disease 
Jeannet Weyers, David Colquhoun, Ralph Stewart, Andrew Tonkin, Adrienne Kirby, 
Harvey White, John Simes, For The LIPID Study investigators. COREResearch, Wes/Ly 
Medical Centre, Brisbane, Australia, NHMRC Clinical Trials Centre, University of Sydney 
Sydney Austmlia 
Background: It has been reported that up to 45% patients admitted to hospital with an 
acute coronary syndrome have depressive symptoms. The risk of recurrent coronary 
events is increased 2- to 4.fold in depressed patients and is independent of risk factors 
and the severity of disease. However, the prevalence of depression in stable patients with 
CHD who are on long-term statin therapy is unknown. Nor is it known whether long-term 
cholesterol reduction or long-term statin therapy increase depression rates. We aimed to 
ascertain the prevalence of depression in a cohort of LIPID Study survivors with stable 
CHD. 
Methods: The LIPID study was a placebo-controlled, double blind study that assessed 
the efficacy of pravastatin over 6 years in 9,014 patients with CHD. A cohort of 673 was 
assessed for depression using the Beck Depression Inventory (BDI-II) at the commence- 
ment of a further 2.year follow-up after the main study. 
Results: Depression (clinical or subclinical) was present in 28.75%: mild 20.35%, mod- 
erate 5.60%, severe 2.80%. Depression was slightly more common in women and was 
not related to traditional risk factors. Of those randomized to pravastatin, 27.0% were 
depressed, and of those on placebo, 30% were depressed (OR 0.83, 95% Cl 0.60-l .16, 
FO.28) 
Odds ratios for depression and on-study lipid levels 
LiDid Odds ratio 95% Cl P 
Total cholesterol 0.83 0.63-l .09 0.19 
LDL cholesterol 0.72 0.52-l .Ol 0.05 
HDL cholesterol 0.93 0.45-l .89 0.83 
Triglycerides 1.07 0.87-l .32 0.54 
Conclusion: Depression at a level that affects prognosis is common in stable CHD 
patients. Six years of pravastatin therapy was not associated with greater prevalence. No 
relationships between risk factors or on-study lipid levels and depression were observed. 
The trend seen for LDL cholesterol and depression requires further investigation. 
IO:12 a.m. 
1007-207 Statin Use and Reduction of Plasma C-Reactive Protein 
Concentration After Hospitalization for Coronary 
Angiography 
NiloufarTabatabaei, Matthew N. Alder, Joseph B. Muhlestein, Benjamin D. Home, 
Stephen K. Jones, Dale G. Renlund, Kirti Salunkhe, Jeffrey L. Anderson. LDS Hospital, 
Salt Lake City U7; University of Utah, Salt Lake City, UT 
Introduction: C-reactive protein (CRP) is a newly discovered marker of risk for coronary 
artery disease (CAD). Evidence suggests that the magnitude of risk reduction produced 
by HMG-CoA reductase inhibitors (statins) is predicted by baseline 6RP levels. Addition- 
ally, recent retrospective studies indicated that statins may actually lower plasma CRP 
concentration, though the mechanism is unknown. The objective of this study was to con- 
firm these findings by a prospective evaluation of statin use and changes in CRP in rela- 
tion to changes in LDL levels. 
Methods: Baseline blood samples and patient histories were obtained at coronary 
angiography from 371 patients who were not receiving statin therapy. After an average 
4.5 years (range= 3.5-6.3 years) repeat blood samples were obtained and recent medical 
histories recorded, including any initiation of statin use. CRP and lipid panels were mea- 
sured on baseline and follow-up blood samples. 
Results: At follow-up 198 subjects (mean age = 7Ot9 years; 75% males) reported statin 
use and 173 (average age = 70+10 years; 65% males) did not. Of those reporting statin 
use, the distribution of statin types was: 3% lovastatin, 3% fluvastatin, 7% pravastatin, 
45% atorvastatin, and 42% srnvastatin. Subjects both taking (CRP: mean&D, -0.5tl .Q 
mgidl) and not taking statins (-0.2?1.7 mgidl) experienced a CRP reduction, but the 
reduction was greater for those taking statins (~~0.02). Statin therapy reduced LDL levels 
(pcO.001) from baseline (121+_40 mgidl) to follow-up (95t29 mg/dl), but did so indepen- 
dent of changes in CRP (correlation coefficient= -0.09, p=NS). Analysis of statin dosage 
by LDL-lowering potential showed that more potent statins with higher-doses were supe- 
rior (p<O.OOl) for LDL reduction but were not different in their effect on CRP (p=O.19). 
Conclusion: In this prospective observational cohort, statin use reduced plasma CRP 
concentrations independent of changes in LDL levels. This supports recent retrospective 
data indicating that statins may play a direct role in modifying the inflammatory response 
associated with CAD. Further evaluation is required to determine if this CRP lowering 
translates directly to a reduction in cardiovascular events. 
IO:24 a.m. 
1007-208 Safety and Tolerability of Combined Niacin Plus Simvastatin 
in CAD Patients With Low HDLc With or Without Diabetes 
Xue-Qiao Zhao, B. Greg Brown, Josh S. Morse, Alice Dowdy, Debbie DeAngelis, Jiri 
Frohlich, Alan Chait, John J. Albers. University of Washington, Seattle, WA, University of 
British Columbia, Vancouver, BC, Canada 
Background: We have reported that niacin plus simvastatin (NS(+)) (mean daily dose 
2.5 g and 13 mg) halt angiographic atherosclerosis progression and reduce major clinical 
events by 70% in diabetics (DM) and non-diabetics (NDM) in comparison with placebos 
(NS(-)), over a 3.year treatment period. How safe and well-tolerated is this combination? 
Methods: 160 CAD patients (25 DM) with mean LDLc 5125 mgidl and HDL a5 [mean 
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31) mgldl were randomized to NS(+) or NS(-); the latter took 50 mg bid N to blind for 
flushing. Patients were seen monthly for 4 months and bimonthly for 32 months; side 
effects (Gl upset, nausea, anorexia, vlsion, skin, and energy problems, or muscle aches) 
were directly queried and recorded. SGOT, CPK, uric aad, and fasting glucose levels 
were regularly monitored. A safety monitor reviewed all side effects and adjtisted N and S 
dosage in bolh groups to reduce problems and to maintain patient and investigator blind- 
ing. N and/or S were reduced until side effects disappeared, then were restarted at 
reduced dosage. Results: The table compares the frequency of patrants with clinical and 
laboratory side effects and of reduced or discontinued dosage in both treatment groups. 
The regimen was repeatedly described by 52% of patients as “very easy”, 38% “fairly 
easy”, 8% “not too hard”. and 2% “very hard” to take. 
NV+) NW) P’ Red’N dose D/C 
(rl=80) (nd30) Meds 
W+) NS(-) 
SGOT 33 X UN, n(%) 3(4) l(1) NS 3(4) l(1) 0 
CPK 32 X UN. n(%) 2(3) 3(4) NS 2(3) l(l) 0 
Uric Acid 37.5 mgidl, n(%) 20(Z) 17(Z) NS 3(4) 5(6) 0 
Fast. Glu. DM, n=25 E/12(67) 4/13(31) NS 5(42) W3) 3 
3180 mgidl NOM, 1/68(i) O/67 NS l(1) 0 It 
hi35 
LDL <40 mgidl, n(%) 22(28) 0 <.OOl lS(23) 0 0 
Flu-like Symptoms, n(%) w 4(5) NS 503 l(l) 1t 
Flushing, n(%) 24(30) 18(23) NS 3(4) l(l) 2t 
UN = upper normal. *: By X’test. t: Patients quit niacin only. continued in study. Conclu- 
sions: The NS regimen is effective, safe and well-tolerated. Varying glycemic control was 
common among DM in both treatment groups. bui somewhat (p=NS) worse in those 
given NS(+). 44% of DM increased dosage or added new diabetic medication. The clini- 
cal, angiographic and lipId benefits of NS(+) appear to justify the requirement for more 
aggressive glycemic conlrcl. 
POSTER SESSION 
1191 Beyond Lipids: Inflammatory and 
Thrombotic Risk Factors for Coronary 
Artery Disease 
Tuesday, March 20, 2001, 9:00 a.m.-i I:00 a.m. 
Orange County Convention Center, Hall A4 
Presentation Hour: 9:00 a.m.-10:OO a.m. 
1191-159 Age-Related Differences in Lipid and Thrombogenic Factors 
in Postinfarction Patients 
Wojciech Zareba, Anuradha Gudavalli, Arthur J. Moss. Charles Sparks, Victor Marder, 
Emanuela Locati Heiibron, Luc F. Miller Watlet. forTHFiOMB0 Invesbgaiors. Univerisfyof 
Rochester, Rochester, NY 
Background. Llpid disorders and procoagulant siate contribute to the risk of cardiovas- 
cular events, however. ihere is limited information about age-dependency of these condi- 
tions. This study aimed lo determine the influence of age on levels of lipid and 
thrombogenic factors in patients after myocardial Infarction (Ml). Methods. Blood levels 
of cholesieroi, apolipoprotein A-l, apolipoprotein B, lipoprotein(a), triglycerides, high- 
density lipoprotein, low density lipoprotein cholesterol, insuiln, fibrinogen, “on Willebrand 
factor, factor VII and Vlla, plasminogen activator inhibitor 1, and D-dimer, were measured 
2 months after MI in 1045 patients divided into terciles by age categories: c= 53 years 
(n=358), 54-64 years (n=340) and => 64 years (n=346). Nonfatal Ml or cardiac death 
occurring during a mean 2.year follow-up were consldered as an endpoint of the study. 
Results. In comparison to older pail&s, younger patients (c 53 years) had slgnificantiy 
higher levels of triglycerides, chok?steroWHDL ratto, apoB/apoA ratio and insulin and 
lower levels of APO-A and HDL cholesterol. Also, body mass index was significantly 
higher in younger than older patient (29+-6, 28+-5, and 27+-5, respeciively; p<O.OOl). 
The elderly pabents (> 65) had significantly higher levels of fibrinogen, “on Willebrand 
factor, and D-Dimer and significantly lower PAI- levels than younger groups. During a 
mean 26-m&h follow-up recurrent cardiac events occurred with similar frequency (7%, 
8% and 8%, respectively). 
Lipid and Thrombogenic Factors by Age in Post-Ml Patients 
Parameiers Age<=53 Age 54-64 Age x64 
Triglycerides 224 (132) 199 (115) 179 (97) 
ApoA 115(24) 120 (26) 121 (26) 
HDL 37 (11) 39 (12) 41 (12) 
Insulin 21 (36) 20 (24) 17 (24) 
PAI- 33 (23) 27 (26) 25 (21) 
Fibrinogen 338 (89) 354 (87) 366 (87) 
“WF 129 (60) 151 (70) 167 (72) 
D-dim@ 348 (413) 450 (355) 773 (910) 
P value 
<O.OOi 
<0.05 
co.001 
<O.OOi 
<O.OOl 
<O.OOl 
<O.OOl 
<O.OOi 
Conclusion. Younger post-MI patients have higher incidence of metabolrc syndrome X 
(increased BMI, triglycerides, insulin, PAI-I and decreased Apo-Al and HDL cholesierol) 
while the older post-MI patients have higher Incidence of procoagulant state (increased 
“VF, fibrinogen, and D-Dimer) leading to a similar risk of recurrent cardiac events. 
1191-l 60 Inflammation Plays a More Important Role in Coronary 
Atherosclerosis in Patients With Low Cholesterol Level 
Bon Kwon Koo, Donghoon Choi, Hee Doo Kyung, Yangsoo Jang, Won-Heum Shim, 
Seung-Yun Cho. Yonsei Cardiovascular Center and Cardiovascular Research Institute, 
Seoul, South Korea 
Background: Hypercholesterolemia is a major risk factor for coronary artery disease. 
Bul in Korea, ihe prevalence of the hypercholesterolemia is much lower than western 
countries. Other risk factors may play a more important role in the pathogen&s of ath- 
eroscleros~~ in patients with low cholesterol level. Method: Sixty one stable angina 
patients without peripheral vascular disease were divided into iwo groups accordmg to 
their LDL cholesterol level, group A with LDL cholesterol <130mg/dl and group B with 
LDL cholesterol : 130mgidl. Patients with conditions that might influence C-reactwe pro- 
tein(CRP) level, previous PTCA or CABG, recent acute coronary syndrome, on lipid low- 
ering treatment and whose troponin T level was above the normal were excluded. 
Angiographic severity was evaluated by the Jenkins score. Results: 
Patients characteristics GWUP Group p vafue 
A(n=34) B(n=27) 
Age(mean+SD, years) 62i7.6 59i7.2 not significant 
Male gender(%) 67 65 not significant 
Body mass index(kgim2) 25e3.3 26zt2.3 not significant 
Diabetes mellitus(%) 21 17 not significant 
Smoking(%) 21 39 not significant 
Hypertension(%) 30 56 not significant 
Family history of premature CAOD(a) 0 0 not significant 
Jenkins score 7~3.6 7*3.4 not significant 
CRP(mean@SD, mgidi) 1.9+3.11 0.4t0.33 0.01 
There were no differences in age, gender, BMI, incidence of major risk factors and angio- 
graphic severity. CRP(log CRP) was significantly higher I” group A(p=O.Ol). Conclusion: 
In stable angina patients with low cholesterol level, inflammation plays a more important 
role in the pathogenesis of coronary atherosclerosis than the patients with high choles- 
terol level. In these patients, anti-inflammatory treatment can be more beneficial. 
1191-161 Myocardial Infarctions in Young Adults With Low Density 
Lipoprotein Cholesterol Levels Less Than or Equal to 100 
mg/dL: Clinical Profile and One-Year Outcomes 
Kwame 0. Akosah, Ross Cernlglia, Paul Haviik, Ana Schaper. Gundersen Lutheran 
Medical Center, La Crosse, WI 
Background: High lipids is considered an obligatory risk for premature coronary heart 
disease. The increased relative risk for a cardiac event in individuals with high cholesterol 
is well appreciated. However, the clinical features of young adults suffering myocardial 
infarction with low lipid levels is unknown. Our objective was io compare and contrast dif- 
ferences in clinical profiles and outcomes of young adults admitted with myocardial inf- 
arction who have optimal and abnormal cholesterol levels. 
Methods: A retrospective review was conducted on all young adults (men 5 55 years; 
women 5 65 years) admitted for myocardial infarctlon in a two year period (N=232). His- 
tory of cardiovascular risk factors and one-year outcomes were obtaIned. Patlents were 
included if a lipid profile was drawn within 24 hours of admlssion and they were not on a 
statln on admission (n = 183). 
Results: Distribution of low density lipoprotein cholesterol was as follows: <IO0 mg/dL, 
n= 53 (29%); 101-130 mg/dL, n= 71 (39%); 131-159, n= 31 (17%); a160 mg/dL, n= 26 
(14%). As many as 68% (n=124) had acceptable low density lipoprolein cholesterol Cl30 
mg/dL. Patients were categorized into groups based on low density lipoprotein choles- 
terol levels (<lo0 mg/dL = group 1; 2160 mgidL = group 2). Mean levels were 81 mg/dL 
and 188 mg/dL in group 1 and group 2, respectively. There were no differences between 
the two groups in any traditional risk factors. Patients in both groups were aggressively 
treated. Readmission rates and one-year mortality were noi different between groups. In 
group 2, 92% were placed or a statin. By one year the mean low density lipoprotein cha- 
lesterol level had decreased from 188 mg/dL to 106 mg/dL. 
Conclusions: In a population with high rates of smoking and obesity, the malority of 
young adults suffering myocardial infarction have optlmal low density lipoprotein levels 
(< 100 mg/dL). Our results show that optimal cholesterol levels do not mean freedom 
from disease. We need to develop newer risk markers to improve risk stratification in 
young adults. The best strategy for disease prevention is elimination of all preventable 
risk factors in ihe community, especially smoking and obesity. 
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POSTER SESSION subcutaneous injection of 60mgikg MCT (n=16) or saline as controls (n=6). Then, MCT- 
treated rats ware subjected to Intravenous injection of bFGF (3.2pgikg; n=7) or saline as 
placebo (n=9) via the internal Iugularvein every 2 weeks. Five weeks after MCT injection, 
the hemodynamic data were analyzed. Results. Mean pulmonary artery (PA) pressure in 
the placebo group was markedly elevated compared with the control (1723 mmHg) and 
bFGF (18+6 mmHg) groups (35+8 mmHg, p<O.Ol vs. control and bFGF groups). There 
were no significant differences in aortic pressures among the 3 groups. RV/LV+S (RV, 
right vent?cle; LV, left ventricle; S, septum) weight ratio, as an indicator of RV hypertro- 
phy, was lower in the control (28r7%) and bFGF (27+7%) 9roups than the placebo group 
(61+19%, pcO.01 vs. control and bFGF groups). The PA wall thickness and proportlon of 
muscular arteries in the bFGF group were significantly decreased as compared with 
those m the placebo group (p<O.Ol). There were no significant differences in the aortic 
blood gas analyses in the room air among the 3 groups. Myocardial endothelin-1 levels in 
RV, as an index of RV wall stress and remodeling, were lower in the control 
(43.7*12.6mg/dl) and bFGF (39.0?)6.2mgidl) groups than the placebo group 
(1550226.1 mg/dl, p<O.Oi). Conclusions. Intravenous administration of free form bFGF 
prevents the development of MCT-induced PH and RV hypertrophy in rats. 
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1192-162 Gene Transfer of the Beta-Adrenergic Receptor Kinase 
Inhibitor Into the Resistance Vasculature Enhances 
Vasorelaxation In Vivo. 
Mohamed A. Gaballa, Andrea Eckhart, Walter J. Koch, Steven Goldman. University of 
Arizona College of Medicine, Tucson, AZ, VA Medical Center, Tucson, TtJcson, AZ 
Myocardial beta-adrenergic receptor kinasel (bARK1) plays a role in desensitization of 
myocardia b-adrenergic receptors and altered left ventricular function in heart failure. 
Recent data from our laboratory has shown that in heart failure, there are elevated vascu- 
lar bARK1 levels, decreased vasorelaxation, and abnormal vascular bAR signaling. To 
define the role of bARK1 and its inhibitor, bARKct, in the vasculature, we used adenovi- 
ral-mediated gene transfer to overexpress both bARK1 and bARKct in normal rat hind- 
limb vasculature in-viva. Overexpression of the bARK1 transgene (N=6) resulted in 
decreased (PcO.05) vasorelaxation response to isoproterenol while overexpression of 
the bARKct transgene (N&) enhanced (PcO.05) vasorelaxation. The nitric oxide inhibi- 
tor, L-NAME abolished the increase in vasorelaxation with bARKct but L-NAME did not 
alter vasorelaxation in the hindiimb vasculature transfected with bARK1. Our conclusion 
is that vascular bARK1 inhibition enhances vasorelaxation in resistance vessels and this 
appears to be mediated, in part, by nitric oxide. 
1192-163 Relevance of Using Caspase-3 Detection Versus TUNEL- 
Test in Studies of Vascular Cell Apoptosis 
Randolph Hutter, Merce Roque, Berphard Sauter, John T. Fallon, Carlos Cordon-Cardo, 
Valentin Fuster, Juan Jose Badimon. Cardiovacuiar Institute. Mount Sinai School of 
Medicine, New York, NY 
Background: Research has recently focused on the study of vascular apoptosis. 
Nuclear and cytoplasmic markers of apoptosis are well described and used to detect 
apoptosis by DNA fragmentation (TUNEL) and Caspase-3 (CAS) expression. However. 
the optimal approach to detect apoptosis in the vascular wall is controversial, We com- 
pared signals for apoptosis as detected by TUNEL and CAS immunostaining with regard 
to their spatiotemporal pattern and intensity of expression after coronary arterial injury. 
Methods and Results: Using the pig model of coronary angioplasty, we performed 
TUNEC and detection of CAS in injured and control (uninjured) coronaries. In addition, 
CAS mRNA was detected by RT-PCR. Results (mean +SD) are expressed as % of posi- 
tive cells in the neointima (NI), Media (M) and Adventitia (ADV) at different time-ooints 
post injury (n=5 /point). 
Time TUNEL caspase-3 
NI M ADV NI M ADV 
Control _. 0 0 0 I+1 
6h _. 30$ 9+2 . . 6*7 14*10 
Id 26~5 23+6 -- 9+6 20+5 
7d 16k6 27111 24a7 23t4 10*7 19r3 
14d 7&i 13~6 3*3 Et+9 2+3 6210 
28 d 0 2+1 221 16elO 3*4 l&7 
In uninjured arteries, TUNEL and GAS signals were absent in the intima and M and very 
low in the ADV. Arterial injury triggered a sharp increase in medial TUNEL and CAS 
expression peaking at 1 day. However, TUNEL signals were twice as high as CAS signals 
in M. TUNEL and CAS detection in M were largely reduced at week 2 and 4. NI is not 
present until day 7. High levels of TUNEL and CAS signals in NI were detected at day 7, 
and declined at day14. However, at 4 weeks, while TUNEL kept decreasing, CAS peaked 
again in NI. ADV expression of TUNEL and CAS were high immediately post injury. At 28 
days, however, a second peak of CAS expression occurred as in NI, while TUNEL 
remained low. Of note, RT-PCR of CAS mRNA followed a similar pattern as CAS antigen 
detection. Conclusion: TUNEL seems to overestimate apoptosis early after injury as 
compared to CAS immunostaining. This could indicate a lack of discrimination by TUNEL 
between apoptosis and mechanical death (necrosis) due to arterial trauma. At later 
times, CAS proved to be more sensitive for detecting cellular apoptosis in the NI and 
ADV. In summary, our data favour the use of CAS detection as a better technique to mea- 
sure vascular cell apoptosis. 
1192-164 Intravenous Infusion of Basic Fibroblast Growth Factor 
Prevents Monocrotaline-Induced Pulmonary Hypertension 
in Rats 
Atsushi Iwakura, Masatoshi Fujita, Yasuhiko Tab&a, Akio Ikai, Tetsuhiko Yanazume, 
Masashi Komeda. Deparfmenf of Cardiovascular Surgery Kyofo University Kyofo, 
Jafm, College of Medical Technology Kyoto University, Kyoto, Japan 
Background. Basic fibroblast growth factor (bFGF) is a protective factor against endot- 
helial cell apoptosis. While pulmonary hypertension (PH) is associated with endothelial 
cell injury and smooth muscle cell proliferation, the effect of exogenous bFGF on mono- 
crotaline (MCT)-induced PH is unknown. The purpose of the present study was to evalu- 
ate whether intravenous infusion of bFGF would worsen or prevent the development of 
PH induced by MCT in rats. Methods. Twenty-two male Wistar rats received a single 
1192-165 Antisense c-iun Augments Thrombin-Induced JunB 
Expression and Induces Hypertrophy in Pulmonary Arterial 
Smooth Muscle Cells 
Lingzhi Zhang, Jifeng Zhang, Melanie P. McGraw, Abraham Rothman. University of 
California San Diego, San Diego, CA 
Background: We have previously shown that thrombin stimulates hypertrophy (increase 
in protein content&II, without an increase in cell number), while platelet-derived growth 
factor causes proliferation (increase in cell number, but no increase in protein contenii 
cell) of pulmonary arterial smooth muscle cells. Both of these agonists elicit an increase 
in c-jun and junB mRNA levels. Our aim in this study was to investigate the relationship of 
the ratio of c-Jun to JunB and pulmonary arterial smooth muscle cell growth. Methods: 
We infected cultured pulmonary arterial smooth muscle cells with adenoviruses carrying 
sense (Ad.S.c-jun) or antisense (Ad.A.c-jun) c-jun cDNA to increase or inhibit c-jun 
expression, respectively. Pulmonary arterial smooth muscle cell growth was assessed by 
cell count, determination of SH-thymidine incorporation, 3H-leucine incorporation, and 
quantitation of total cellular protein. Serum-deprived pulmonary arterial smooth muscle 
cells served as controls. Results: Thrombin, Ad.S.c-jun, and thrombin + Ad.S.c-jun 
caused increases in c-jun mRNA and protein. Ad.A.c-jun, with or without thrombin, did 
not significantly affect the low baseline levels of c-jun mRNA and protein. However, infec- 
tion of pulmonary arterial smooth muscle cells with Ad.A.ojun resulted in a small 
increase in junB mRNA and protein, while infection with Ad.A.c-jun + thrombin resulted in 
a large increase in junB mRNA and protein. Thrombin caused pulmonary arterial smooth 
muscle cell hypertrophy. Ad.S.c-jun did not augment thrombin-induced hypertrophy. 
Ad.A.c-jun in combination with thrombin caused polyploidy and more pulmonary arterial 
smooth muscle ceil hypertrophy than thrombin alone. Conclusion: These results sug- 
gest that down-regulation of c-Jun is associated with up-regulation of JunB and hypertro- 
phy. The ratio of c-Jun to JunB may be an important determinant of pulmonary arterial 
smooth muscle cell growth. 
1192-166 Heparin-Binding EGF-Like Growth Factor (HB-EGF) Plays a 
Critical Role in the EGFR Transactivation After Angiotensin 
II Stimulation in Vascular Smooth Muscle Cells 
Masanori Asakura, Masafumi Kitakaze, Seiji Takashima, Shigeki Higashiyama, Hiroshi 
Asanuma, Shoji Sanada, Yasuhiko Sakata, Hisakazu Or@, Yulin Liao, Toshihiko 
Toyofuku, Tsunehiko Kuzuya, Michihiko Tada, Masatsugu Hori. Osaka Unrversity, Osaka, 
Japan 
Angiotensin II (Ang II), which activates G-protein coupled receptor (GPCR), is believed to 
play an important role in the progression of cardiovascular remodeling and atherosclero- 
sis. In vitro, Ang II is reported to promote hypertrophy and/or hyperplasia of vascular 
smooth muscle cells (VSMC). Interestingly, recent reports showed that GPCR-stimula- 
tions transactivate epidermal growth factor receptor (EGFR) in VSMC, and that the 
EGFR twnsactivation mediated by heparin-binding EGF-like growth factor (HB-EGF) 
cleaved by metalloproteinase in Rat-l cell. Therefore, we tested the idea that HB-EGF is 
involved in EGFR transactivation after the stimulation of Ang II in cultured VSMCs. To 
investigate whether HB-EGF shedding would be involved in the EGFR transactivation by 
GPCR agonists that was revealed in VSMC, we examined the effect of the novel metallo- 
proteinase inhibitor KB-R7785. We treated VSMC with Ang II after 30-min preincubatian 
of KB-R7785 (lo-6M). KB-R7785 almost completely blocked FGFR tyrosine phosphory- 
lation after the exposure of Ang 11. Metalloproteinases can cleave various cell-surtax 
proteins including EGF family such as EGF, TGF-b, and amphiregulin. To investigate 
whether HB-EGF would mainly contribute to the transactivation of EGFR, VSMCs were 
pretreated for 30 min with the rat HB-EGF neutraiizlng antibody before the exposure to 
GPCRs. HB-EGF neutralizing antibody markedly inhibited the tyrosine phosphorylation 
of EGFR induced by Ang Il. These data suggest that HB-EGF plays a major role in EGFR 
transactivation and that the inhibition of HB-EGF shedding using metalloproteinase inhib- 
itors is effective to prevent the hypertrophy and/or hyperplasia in VSMCs. 
1192-I 67 Adeno-Associated Virus-Mediated Apo A-l Milan0 
Genetherapy for Atherosclerosis and Restenosis 
Behrooz G. Sharifi, Kai-Gen Wu, Lai Wang, Tripiathi Rajavashsith, Sanjay Kaul, 
Prediman K. Shah. Cedars-Sinai Med. Ctr., Los Angeles, CA 
Background: Experimental studies from our laboratory have documented beneficial 
effects of recombinant apo A-lmilano in atherosclerosis in apo E null mice and on neoint- 
imal thickening following arterial injury in rabbits and swine. Although our preliminary 
data using in-viva studies demonstrated successful gene transcription in-viva, the levels 
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of expression of apo A-l milano were relatively low. We optimized vector production by 
focussing on: different promoters and their configurations to increase gene transcription, 
and reporter gene constructs. Method: We used green and red fluorescence protein 
markers to monitor the activity of the CMV promoter for each marker. The exoression 
level of the Apo A-l milano protein was determined by Western blot. Results: We con- 
structed two vectors. The first contained back-to-back CMV promoters. in the other, the 
fluorescence-coding regron separated the promoters. The activity of these constructs 
was determined by flow cytometry using 293 cells. We found that the back-to-back pro- 
moter construct resulted in 6.8.fold increase in reporter gene transcription than the alter- 
nate construct. Next, we replaced one of the fluorescence proteins with the apo A- 
lmilano gene, stlli using both the back to back and the alternate configurations. The new 
vector encodes both the fluorescence protein and apo A-lmilano gene, each regulated by 
its own CMV promoter. Western blot analysis of media collected from 293 cells trans- 
fected with the newly generated constructs again revealed that the back-to-back con- 
struct is 12.fold more active than the alternate construct for expression of apo AIM 
protein. Conclusions: Back to back configuration of CMV promoter markedly increase 
gene expression. This construct will be usefuli for in viva genetherapy studies that 
requires large level of gene expression 
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1193-168 Plasma Level of Tissue Inhibitor of Matrix Metalloproteinase 
1 (TIMP-1) Reflects Functional Cardiovascular 
Abnormalities in Essential Hypertension 
Joanne Moncrieff, M M. Lindsay, Andrew D. McGavigan, Paul R. Maxwell, John M C. 
Conneil, Francis G. Dunn. Stobhill Hospital, Glasgow, United Kingdom 
Background: Sustained hypertension results in structural remodelling of the myocar- 
dium and the vasculature. This is characterised by left ventricular hypertrophy, myocar- 
dial fibrosis and reduced vascular compliance. Collagen degradation is a dynamic 
process reflecting an equilibrium between matrix metalloproteinses (MMPs), which 
degrade collagen, and naturally occurring TlMPs which inhibit MMPs’ proteolytic activity. 
Disruption of this equilibrium leads to pathological interstitial fibrosis which influences 
vascular functional properties and myocardial function. We therefore investigated the role 
of plasma markers of collagen degradation as a potential non-invasive assessment of 
myocardial fibrosis and vascular function. Methods: We enrolled patients with never 
treated hypertension All patients had 24 hr blood pressure (BP) monitoring and echocar- 
diagram to calculate LV mass index (LVMI) and measure diastolic filling indices (E:A 
ratio) as a market of fibrosis. Pulse wave velocity (PWV) was performed to assess vascu- 
lar compliance and plasma markers of collagen degradation measured (TIMP-I, MMP-2 
and MMP-9). ResuI%: 63 patientswere enrolled. Mean office BP was 161194 and mean 
24 hour BP was 136186. Mean age was 49 years (range=l7-75). Mean LVMI was ele- 
vated at 150 (+/-6.9)g/m2 and mean PWV was 8.8 (+/-l.l)m/s. Plasma level of TIMP-1 
correlated with E:A ratio (r=-0.264,p<O.O5), PWV (r=0.389,p=0.02) and plasma MMP9 
(r=-0.564,p<O.O01). Additionally, a multiple regression model was constructed and 
revealed that plasma TIMP-1 level was indeed predictive of PWV (~~0.05). This was 
independent of age, BP, LVMI and diastolic filling indices. Conclusions: In this group, 
plasma level of TIMP-1 correlated with reduced E:A ratio, a marker of myocardial fibrosis. 
It was also an independent predictor of PWV, an established assessment of vascular 
compliance This would suggest that plasma TIMP-1 is not only a non-invasive marker of 
myocardial fibrosis, but also reflects functional abnormalities in the systemic vasculature. 
1193-169 Angiotensin AT1 Receptor Antagonism and ACE Inhibition: 
Comparison of Effects on Functional and Morphological 
Parameters of Hypertensive Myocardial Remodeling in 
Stroke-Prone SHRs 
Alexander Reinecke, Marc Darenkamp, Qulngui Xia, Christian Storz, Susanne Penz, 
Harro Bitterling, Annegret Blume, Riidiger W.R. Simon and Thomas Unger. /nsfifu& of 
Pharmacology University of Kiei, Kiel, Germany, Clinic of Cardiology; University of Kiel, 
KM, Germany 
Background: Sustained arterial hypertension in stroke-prone spontaneously hyperten- 
sive rats (SHRSP) induces myocardial remodeling including the progression of myocar- 
dial fibrosis followed by impaired myocardial function. We investigated the ability of the 
AT1 receptor antagonist, irbesartan (Irb), to reduce interstitial fibrosis in comparison with 
the ACE inhibitor, fosinopril (Fos). under strictly comparable hemodynamic conditions. 
Methods: Male SHRSP were treated for 10 weeks with placebo, Irb (50 mgikgld) or Fos 
(20 mg/kg/d) to reduce MAP from 183 + 7 to 135 + 8 (irb) and from 188 + 7 to 133 + 5 
mmHg (Fos) (means + SEM). Cardiac hemodynamics and morphometric parameters 
were then determined. Myocardial fibrosis was analysed as interstitial collagen volume 
fraction in picrosirius-red stained sections of myocardium. Results: ATi receptor antago- 
nism with lib reduced progression of interstitial fibrosis to a greater extent (p<O.OOl) than 
ACE inhibition with (Fos) compared to placebo treated controls (2.26 + 0.06 (Irb) and 
2.96 + 0.10 (Fos) % respectively vs 4.38 + 0.13 % in controls). Irb also lowered left ven- 
tricular end diasto!ic pressure more than Fos: 7.28 + 1.35 (Irb) vs 8.95 + 1.15 mmHg 
(Fos) (~~0.05) vs 12,34 + 1.9l.mmHg in controls. Conclusion: Our study demonstrates 
that chronic treatment with the AT1 receptor antagonrst irbesartan prevents progression 
of hypertenwe myocardial remodelling and subsequent impairment of myocardial func- 
tion to a greater extent than the ACE inhlbitor fosinoprill when applied at equailly antlhy- 
pertensive doses. 
1193-170 Impact of Aldosterone in Early Left Ventricular Remodelling 
in Humans 
Roland E. Schmieder, Christian Delles, Markus P Schneider, Karl F. Hilgers, Arnfried U. 
Klingbeil. Dept. of Mediane /Y University of Erlangen-Ntirnberg, Niirnberg, Germany 
Objective; This study was conducted to identrfy factors contributing to changes in left 
ventricular mass (LVM) over time. 
Methods; In 120 young (age: 26 + 3 years) male, white, normotensive or mildly hyper- 
tensive subjects, we determined body mass index @MI). ambulatory 24.hour blood pres- 
sure (ABPM), LVM (2D-guided M-mode echocardiography), urinary sodium 
concentration (UNA) and serum angiotensin II and urinary aldosterone concentration 
(SAngll and UAldo; radioimmunoassay). 76 volunteers took part in a follow-up visit after 
24 + 9 months. 
Results: At follow-up, only BMI (24.5? 3.5 vs 23.7 2 2.8kg/m2; p<O.OOl) was significantly 
different from baseline acro.ss the study cohort (ABPM: 129 i- 9p7 + 7 vs 128 jl 110176 + 
7mmHg; LVM: 246 + 53 vs 241 i. 479; UNA: 199 ? 71 vs 193 t 74mmol/d; SAngll: 8.1 t 
3.6 vs 8.3 i 3.6pg/ml; UAldo: 10.1 * 3.9 vs 8.9 i 3.8pg/d; all parameters n.s.). In 42 sub- 
jects LVM increased during the follow-up perlod (group 1: mean increase: 33?26g), in 34 
subjects LVM decreased (group 2: mea” decrease:27+22g). Between the two groups, 
only the change in UAldo over time (AUAldo) was significantly different. In accordance, 
we found a significantly correlation between ALVM and AUAldo in the whole study group 
(r=0.29; p<o.o5). 
Delta BMI 
Wm*) 
Delta Delta UNa Delta SAngll Delta UAldo 
syst.ABPM (mmolld) (wfml) (WC 
WmHg) 
Group1 +0.7*1.1 -Ii6 +I t89 -0.4*4.5 +2.8&4 
Group2 +0.7t1.0 +l& +12?108 +0.0*4.7 -0.7&4.6*+ 
mean + SD, ** p<O.OOl group 1 vs group 2 
ConclusionLChanges in aldosterone concentration are the main determinant of 
changes in LVM over time. Our data underscore the impact of aldosterone in the process 
of early left ventricular remodelling. 
1193-171 Differences in Left Ventricular Geometry in Untreated or 
Treated Hypertensive Patients 
Fabrizio Pasanisi, Giovanni de Simone, Aldo Celentano, Marcello Chinali, Lucia Guida, 
Carmela Romano, Aldo L. Ferrara. Federico /I Universffy Hospiral, Naples, k/y 
Background: Presence of left ventricular hypertrophy complicates arterial hypertension 
and represents a powerful prognostic marker of adverse cardiovascular outcome. Preva- 
lence of hypertrophy is positively related to age and body mass index, as well as to 
degree and duration of hypertension. However, the magnitude of ventricular mass can be 
influenced by response to pharmacological and/or non-pharmacological treatments. 
There is no information about whether ventricular geometry is different between never- 
treated hypertensive patients and treated patients presenting at the hospital outpatient 
clinic, because of fair/poor blood pressure control, a clue with clear implications for clini- 
cal trials. 
Methods: We compared ventricular geometry in 45 never treated hypertensive patients 
(13 women, 42.4+7 years, body mass index: 26.7+2 Kg/m2, supine blood pressure: 1501 
98+15/5 mmHg) and in 45 age, sex and body size-matched patients on treatment, but fair 
control (>=135/85 mmHg) of their pressure (13 women, 42.4*7 years, 26.7-t:! kg/m’, 
149197t1715 mmHg). Treated patients were studied after 2.week drug washout. Ventricu- 
lar hypertrophy was defined as ventricular mass index >= 51 g/r+‘. 
Results: Ventricular mass index was similar in the two groups (47?9 vs 4429 g/m”, p = 
ns), but relative wall thickness was higher in never-treated than in treated patients 
(0.42+0.06 versus 0.38~0.06, p<O.O02). Prevalence of clear-cut hypertrophy was 27% in 
never-treated and 20% in treated patients (p=ns). Ventricular mass was weakly related to 
systolic pressure in the whole study population (r=0.24, p=O.O2), without difference 
between groups (increase of 1.2 versus 1.5 grim”’ per 10 mmHg in never-treated and 
treated patients respectively, p=ns). 
Conclusions: After 2.week washout, previous pharmacological treatment marginally 
influences the magnitude of ventricular mass, but might be associated with significant 
remodeling. Whether or not this difference is due to cumulative effects of treatments, 
duration of hypertension or inadequate period of wash out needs to be established, but 
might be relevant in selection of patients for clinical trials including evaluation of ventricu- 
lar hypertrophy. 
1193-172 Concentric Remodeling Is Accompanied by an Impairment 
of Aortic Mechanics, and an increased Urinary Albumin 
Excretion Rate in Untreated Essential Hypertensive 
Subjects With Normal Left Ventricular Mass 
Constantinos Tsioufis, Chrlstodoulos Stefanadis, Marina Toutouza, loannis Kallikazaros, 
Christos Pitsavos, Kostas Toutouzas, K&as Xenakis, Sofia Vaina, Eleftherios Tsiamis, 
Pavlos Toutouras. HlPPOKRAJlON HOSPITAL, ATHENS, Greece 
Background: The prognostlc contribution of left ventricular (LV) geometry in the pres- 
ence of normal LV mass in hypertensive patients has not been well defined. Methods: 
Towards this end, in 210 untreated, non-diabetic, newly diagnosed patients with stage I-II 
essential hypertension (mean age 53+8 years), LV mass index, relative wall thickness, 
aortic distensibility and urinary albumin excretion (UAE) were evaluated. Aortic distensi- 
bility was calculated as a function of changes in aortic diameter (determined by echocar- 
dioqraphv) and pulse pressure (determined sphyqmomanometrically in the brachial 
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artery) by the use of the formula: Distensibility=Zx(pulsatile changes in d)/[(diastolic 
d)x(pulse pressure)]. UAE was evaluated in three non-consecutive 24h-urine samples. 
Results: In the entire study population, office systolic and diastolic BP was 155 /99 
mmHg, LV mass index was 101 g/mP, aortic distensibility was 1.83*1 .I dyne-lcm210-6 
and UAE was 2754 mgi24h. IV mass index was positively correlated with UAE (r=0.49, 
p<O.OOl) and negatively correlated with aortic distensibility (r=-0.21, p<O.O05). LV mass 
index was within normal values (cl25 gim2) in 176 subjects. From these patients, 105 
had LV normal geometry (LV mass index=91 g/m2 and relative wall thickness=0.39) while 
71 had LV concentric remodeling (LV mass index=99 g/m2 and relative wall thick- 
ness=0.49). The group with concentric remodeling compared to the group with normal 
geometry, had signifkxintly increased age (56 vs 48 years), body surface area (1.93 vs 
1.87 m2), office systolic blood pressure (157 vs 149 mmHg) and UAE (34.5 vs 15.5mgi 
24h) and significantly decreased aortic distensibility (1.49 vs 2.17dynelcmZlO-6). Con- 
clusion: Hypertensive patients with LV concentric remodeling exhibit a reduction in aortic 
distensibility and an increase in UAE. These findings may contribute in the unfavorable 
prognosis of hypertenive subjects with concentric remodeling and normal LV mass. 
POSTER SESSION 
1194 Molecular Alterations of Hypertrophy 
Tuesday, March 20, 2001, 9:00 a.m.-l I:00 a.m. 
Orange County Convention Center, Hall A4 
Presentation Hour: 9:00 a.m.-IO:00 a.m. 
1194-174 Hiv-gp120 Enhances Cardiac Myocyte Nitric Oxide 
Production Through p38 MAP Kinase Activation 
Hong Kan, Zirong Xie, Mitchell S. Finkel. West Virginia University Morganfown, WV 
HIV infection is associated with a surprisingly high frequency of myocardial dysfunction. 
Potential mechanisms include direct effects of HIV, indirect effect?, mediated by cytokines 
or a combination. We have previously reported that interleukin-1 p (IL-I)(500 U/ml) alone 
induced nitric oxide (NO) production by neonatal rat cardiac myocytes (CM). Effects of 
the HIV-1 envelope glycoprotein, gp120 (gp120), on inducible NO synthase (iNOS) in CM 
have not been previously reported. Unlike IL-I, HIV-gp120 (1 pgiml) alone failed to 
enhance NO production in CM [0.5*0.4 vs 0.420.5 mmol/l .25xi05 cells/48hrs,gp120 vs 
control, respectively: n=12,p>0.5]. However, the addition of gp120 to IL-1 significantly 
enhanced iNOS mRNA expression [70+1.5 vs 26k2.4 optical units&l+gp120 vs IL-l, 
respectively; n=3], iNOS protein synthesis [42+1.4 vs l&O.8 optical units,IL-l+gpl20 Ye 
IL-l, respectively; n=3] and NO production (NO*-)[6.6i0.6 vs 4.1~0.8 ~mol/1.25x105 
cells/48hrs, IL-l+gplPO vs IL-l, respectively;n=12,p~O5]. HIV-gp120 enhancement of 
IL-l induced NOe- productron was blocked by SB203580 (10 pM), a selective ~38 protein 
kinase inhibitor [3.6+0.2 vs 6.6*0.6 mmol/l.25x105 cells/48hrs,IL-l+gpl20+SB203580 
vs IL-l+gpl20, respectively; n=lZ,p<0.5]. HIV-gpl20 enhanced ~38 protein kinase activ- 
ity was associated with an increase in IL-l-stimulated NF-KB activity [184+12.7 vs 
92tiO.7 optical units, IL-l+gpl20 vs IL-l, respectively;n=3]. None of these effects were 
seen with another HIV-1 protein tat. Thus, HIV-gpl20 enhancement of IL-l-induced NO 
production is associated with p38-mediated activation of NF-KB. Direct effects of HIV- 
gp120 on cardiac myocytes may provide a previously unrecognized mechanism contrib- 
uting to HIV cardiomyopathy. 
1194-175 A Novel lnhibltory Effect of Adenosine on Cardiac 
Hypertrophy 
Masanori Asakura, Masafumi Kitakaze, Seiji Takashima, Shigeki Higashiyama, Yasuhiko 
Sakata, Hiroshi Asanuma, Shoji Sanada, Hisakazu Ogita, Yulin Liao, Koichi Node, 
Toshihiko Toyofuku, Tsunehiko Kuzuya, Michihiko Tada, Masatsugu Hori. Osaka 
University, Osaka, Japan 
Although cardiac hypertrophy is an early adaptive response of the heart among a variety 
of cardiovascular diseases, prolonged cardiac hypertrophy eventually culminates in 
either chronic heart failure or sudden death. Adenosine is well known to be a cardiopro- 
tective substance, however it is unclear whether adenosine can attenuate cardiac hyper- 
trophy. To answer this question, we evaluated the effect of adenosine on cardiac 
hypertrophy in viva ad in vitro. Rats were treated with or without an antagonists of ade- 
nosine receptors, 8-sulfophenyltheophylline (8SPT) for 8 weeks. We measured body 
weight (BW) and heart weight (HW) of these rats at 8 weeks and calCulated HW/BW. 
HWiBW was 0.00019 + 0.000090 (mean + SEM) in the control group (n=6) and 0.0029 + 
0.000063 in the 8-SPT group (n=6). Cardiac hypertrophy was observed in the 8-SPT 
group compared with the control group. These in-viva data suggest that endogenous 
adenosine inhibits cardiac hypertrophy via receptor-mediated manners. We next demon- 
strated an in-vitro evidence that adenosine (lo-5 M) reduces the enhanced protein syn- 
thesis induced by phenylephrine (10-6 M) in cultured rat neonatal cardiomyocytes. We 
also showed that adenosine inhibits EGF receptor transactivation after the stimulation of 
phenylephrine receptors. Taken together, these results indicate that the elimination of the 
effects of endogenous adenosine causes cardiac hypenrophy via the EGF receptor 
transactivation. Adenosine receptor stimulation may attenuate the progression of patho- 
logical cardiac hypertrophy, and improve chronic heart failure. 
1194-176 High Ambient Pressure Produces Hypertrophy and Up- 
Regulates Cardiac Sarcoplasmic Reticulum Ca2+ 
Regulatory Proteins in Neonatal Rat Cardiomyocytes 
Tomoko Ohkusa, Masafumki Yaw, Reo Mitani, Jutaro Yamada, Tomoko Nao, Shigeki 
Kobayashi, Masunori Matsuzaki. The Second Department of Internal Medicine, 
Yamaguchi University School of Medicine, l/be, Yamaguchi, Japan 
We have demonstrated in viva that the nature of the alterations in sarcoplasmic reticulum 
(SR) function and SR Ca2+ regulatory proteins depends on the type of mechanical over- 
load imposed. Cultured neonatal rat cardiomyocytes have proven to be useful tools in 
studies of the cellular mechanisms involved in regulating SR Ca2+ regulatory proteins in 
response to mechanical factors. The purpose of the present study was to determine, in 
vitro. whether an extrinsic mechanical overload (in the form of high ambient pressure) 
would cause an up-regulation of ryanodine receptor (FiyR) and Ca2+-ATPast?, as previ- 
ously reported by us in the mildly pressure-overloaded hypertrophied rat heart. Primary 
cultures of neonatal rat cardiomyocytes were prepared and high ambient pressure was 
produced using an incubator and pressure-overloading apparatus. Cells were exposed to 
one of two conditions for 72 h: atmospheric pressure conditions (APC) or high pressure 
conditions (HPC = APC+200 mmHg). The relative expression levels of RyR and Ca2+- 
ATPase proteins and their mRNAs were quantified by Western blot analysis and RT-PCR, 
respectively. Results are as follows; 1) Cell area (pm2) was significantly greater under 
HPC than under APC (8351154 vs 564+93 at 6 h, ~~0.01) and specific genes which are 
considered as makers for hypertrophy were over-expressed; however, there was no dif- 
ference in beating rate between the two groups. 2) After 24 h exposure, the expression 
level of RyR protein was significantly higher under HPC than under APC (2.16*0.67 vs 
0.88+0.62, p<O.Ol), as was the expression level of its mRNA (0.41*0.12 vs 0.23+0.10, 
p<O.O5). 3) After 12 h exposure, the expression level of CaP+-ATPase protein was signifi- 
cantly higher under HPC than under APC (0.47~0.07 vs 0.26t0.06, p<O.Oi), as was the 
expression level of its mRNA (1.03+0.12 vs 0.74+0.01 p<O.Oi). HPC caused hypertrophy 
and up-regulated the expression of Ca2+ regulatory proteins and their genes in neonatal 
cardiomyocytes. We suggest that this in vitro pressure-overloading model should prove 
useful, as is a stretch-overloading model, for investigation of the intracellular Ca2+ regu- 
latory pathways responsible for the development of cardiac hypertrophy. 
1194-177 NKH477, a New lnotropic Reagent That Directly Stimulates 
Adenylyl Cyclase, Does Not Cause the Beta-Adrenergic 
Receptor Downregulation; Demonstration Using a Newly 
Developed Whole Cell Binding Assays 
Kousaku Iwatsubo, Yang Tao, Takeshi Onda, Yoshiyuki Toya, Takayuki Fuji&, Satoshi 
Umemura, Yoshihiro Ishikawa. Yokohama Cify University Yokohama, Japan, University of 
Medicine and Dentistry of New Jersey Newark, NJ 
Background: lnotropic reagents such as catecholamines are commonly used in the 
treatment of end stage heart failure. However, the downregulation of the beta-adrenergic 
receptor (bAR) is a major problem and the use of catecholamine may further downregu- 
late the bAR. Recently, NKH477(6-[3-(demethylaminoprapinyl] forskolin) : a direct stimu- 
lant of adenylyl cyclase, has been introduced as a new inotropic reagent. We thus 
examined the effect of NKH477 on the downregulation of bAR using the newly developed 
whole cell binding assay. Methods and Results: HEK293T cells were transiently trans- 
fected with plasmid harboring human blAR cDNA. Upon treatment wrth cold PBS, trans- 
fected 293T cells, unlike 293 or COS cells, were readily segregated and thus used for the 
whole cell binding assay with little variability in binding. We and others have found that 
the variability in radioligand binding is usually caused by the aggregation of cells. Cells 
were stimulated by either isoproterenol (lso) (100 microM) or NKH477 (100 nanoM), fol- 
lowed by the cell surface receptor binding assay using a hydrophilic antagonist [BH]CGP- 
12177. Propranolol (10 microM) was used to determine the non-specific binding, which 
was usually 20% of the total cell surface binding. The binding of [3H]CGP-12177 to the 
cell surface bAR was rapid and saturable within 15 minutes. The Bmax and Kd of overex- 
pressed bAR in 293T cells in typical binding assays were 1.6 k 0.23 fmol/mg protein and 
1 co.23 nanoM, respectively (n = 3). Iso treatment resulted in a dose- and a time-depen- 
dent loss of the number of the surface bAR; after 2 hours, 36.6 +5.7 % (n=3) of the total 
cell surface bAR were lo?. In contrast, no significant changes in the number of the cell 
surface bAR were observed when stimulated with NKH477, even after 2 hours. Intracellu- 
lar CAMP concentrations, when stimulated by either Iso (100 microM) or NKH477 (100 
nanoM), were significantly elevated in transfected cells (7.0 + 0.9 - and 8.7 + 1.8 -fold , 
respectively, n = 3) indicating that Iso and NKH477 similarly activated CAMP signal within 
the cell. Conclusion: NKH477, a new inotropic reagent, can directly stimulate adenylyl 
cyclase without causing further downregulation of the cell surface bAR. 
1194-178 Activation of K+-CI- Cotransporters Is Involved in the 
Increase in Cell Volume During Alphal-Adrenergic Agonist- 
Stimulated Hypertrophy in Cardiac Myocytes 
Tsuyoshi Kakita, Koji Hasegawa, Masatoshi Fuji&, Kazuaki Hiki, Tetsuhiko Yanazume, 
Shigetake Sasayama. Department of Cardiovascular Medicine Graduate School of 
Medicine,Kyoto University, Kyoto, Japan, College of medical Technology, Kyoto 
University Kyoto, Japan 
Myocardial cell hypertrophy is characterized by the reactivation of a fetal gene program 
and an incerease in cell volume. While cell volume change is usually associated with the 
electroneutral movement of ions across the plasma membrane to maintain cellular osmo- 
larity, nothing is known regarding the regulation of intracellular solutes during myocardial 
cell hypertrophy. The loop diuretics-sensitive K+-CI- cotransporters (KCC) have been 
implicated in the movement of solutes during cell volume change in other cell types. 
These findings raise the possibility that activation of KCC might be involved in the move- 
ment of solutes during myocardial cell hypertrophy. By isotopic flux assays in primary car- 
diac myocytes from neonatal rats, we show here that the uptake of 86Rb markedly 
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increased after exposure to the alphal-adrenergic receptor agonist phenylephnne (PE) 
in culture. The PE-stimulated increase in 86Rb uptake was dependent on extracellular 
Cl- but not Na+, and was suppressed by a loop diuretics furosemide. In addition, inhibi- 
tion of KCC activity by a therapeutic concentration of furosemide abolished the PE-stimu- 
lated increase in cell size. These results demonstrate that activation of KCC is involved in 
the illcrease in cell volume during alphal-adrenerglc agonist-stimulated hypertrophy in 
cardw myocytes. Furthermore, we examined whether the activation of KCC is involved 
I” the up-regulated expression of fetal proteins such as beta-myosin heavy chain (MHC) 
during hypertrophy. In contrast to the regulation of cell volume, transient transfection 
assay revealed that the PE-stimulated transcriptional activity of the 333bp beta-MHC pro- 
moter was not at all affected even by a high concentration of furosemide. Thus, myocar- 
dial cell regulation of volume and gene expression during hypertrophy may be mediated, 
in part, through distinct pathways. 
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1195-180 Angiotensin II Plasma Levels During Chronic ACE Inhibitor 
Therapy Are Modulated by ACE Insertion/Deletion Gene 
Polymorphism 
Ralph Wink@ Markus Nauck, Willfried Mlrz, Florian Mokler, BBrbel Klein, Rahime G6k, 
Jochen Senges, Bernhard R. Winkelmann. Herzzenfrum Ludwigshafen. Ludwigshafen, 
Germany, Universit~t Freiburg, Freiburg, Germany 
Background: A major determinant of the ACE activity (ACE A) in plasma is the insertion/ 
deletion (I/D) polymorphism of the angiotensin l-converting enzyme (ACE) gene. ACE 
Inhibitors (ACE I) decrease the cowerscon rate of angiotensin (ANG) I to ANG II. How- 
ever, the level of suppression of ANG II depends on other mechanisms as well. Objective: 
Evaluation of the influence of ACE I therapy on plasma levels of various effecters of the 
renin-angiotensin-aldasteron-system (RAAS) stratified by ACE I/D polymorphism. Pts 
and Methods: Blood was drawn and DNA extracted in 3309 consecutive, caucasians, 
enrolled in the LURIC (Ludwigshafen Risk and Cardiovascular Health) study. Pts treated 
with diuretics were excluded (w527). Results: Pts with ACE I were older (63_tlO vs. 
61~1Dyr) and sicker: CAD 84% vs. 72%, hypertension 63% vs 48%, diabetes 33% vs. 
25% left ventricular ejection fraction 57% vs 63%; (all ~~0.01) compared to those with- 
out ACE I. A stepwise increase in ACE A was observed with the number of D alleles in 
both CI~OUDS. However. D allele related ANG II conversion rate differed onlv if ACE A was 
suppressed by ACE I. “univariate for differences between ACE I/D groups. 
Parameters n ACE l/l ACE l/D ACE D/D p-value* 
Pts with ACE-inhibitor therapy 
ACE (U/l) 29715441376 241-9 31ii3 40tl6 <O.OOOi 
Anglotewn II (ngll) 29715441376 24+26 25&22 24&18 0.4 
Pts without ACE inhibitor therapy 
ACE (U/I) 360/603/402 16~11 19r14 23t19 <0.0001 
Angiotensin II @g/l) 360/603/402 23~21 28~36 32546 <0.05 
Conclusion: A stepwise increase of the ACE activity with the number of D alleles of the 
ACE I/D gene polymorphism was followed in increased ANG II conversion rate only if 
ACE activity was suppressed by ACE inhibitors. The findings suggest, that once a critical 
level of ACE A suppression has been reached the ACE activity itself is rate limiting for the 
ANG II production. 
II 95-I 81 Dose-Dependent Blockade of the Angiotensin II Type 1 
Receptor in Normal Volunteers: Incomplete and Transient 
Blockade by Losartan 50 mg 
Michael S. Berlowitz, Pierre V. Ennezat, Farhana Latif, Stacie Laura, Jiong-Ming Hu. 
Suman Tandon, Robert Moskowitz. Edmund H. Sannenblick, Thierry H. Le Jemtel. Albert 
Einstein College of Medicine, Bronx, NY 
Background: Losartan, an angiotensin II (All) type 1 receptor (AT-l) antagonist, was 
developed as a more specific alternative to ACE Inhibitors. Several large trials have been 
completed or are on going that evaluate the role of losartan in patients with hypertension, 
myocardial infarction, and CHF. In these trials, a dose of 50 mg of losartan was selected 
as the efficacious dose to examine clinical outcomes, although this dose does not neces- 
sarily suppress the activity of the Angiotensin System. The present study evaluated the 
level and duration of AT-1 receptor blockade in 50 and 150 mg of losartan, compared to 
32 mg of candesartan. Methods: Eight healthy volunteers were randomly assigned to a 
single dose of losartan 50 or 150 mg, candesartan 32 mg, or placebo. Subjects were re- 
randomized after a P-week wash out period until all four study arms were completed 
Radial artery systolic pressure response to exogenous All was measured at baseline, 
then at 2, 6, 12, and 24 hours after administration of the drug. Results: The level of AT-1 
receptor blockade achieved by losartan 50 mg was 40% at peak effect at 6 hours 
(p=O.O152 vs. placebo), 33% at 12 hours (p=NS vs. placebo), and 18% at 24 hours 
(p=NS vs. placebo). In contrast, the level of AT-I receptor blockade achieved by losartan 
150 mg was 73% at peak effect at 6 hours (p<O.OOOl vs. placebo), 65% at 12 hours 
(p=O.OOOl vs. placebo), and 62% at 24 hours (p=O.OOOi vs. placebo). The level of AT-I 
receptor blockade achieved by candesartan 32 mg was 73% at peak effect at 6 hours 
(p<O.OOOl vs. placebo), and 72% at both 12 hours (p<O.OOOl vs. placebo) and 24 hours 
(p<O.O001 vs. placebo). There was no statistical difference in the level of blockade 
between losartan 150 mg and candesartan 32 mg at all time points. Conclusion: Fifty 
mg of losartan does not achieve effective AT-1 receptor blockade. In contrast, both losar- 
tan 150 mg and candesartan 32 mg nearly completely inhibits the pressure response to 
exogenous All for the entire 24.hour period. Higher doses of losartan or alternative 
antagonists that achieve more &e&e blockade of the AT-1 receptor need to be investi- 
gated to fully assess the therapeutic efficacy of this pharmacologic intervention in clinical 
trials. 
1195-182 An ACE Inhibitor Has Better Protective Effects on 
Atherosclerosis and Coagulation Than an ARB 
Kazuko Masuo, Hideki Kawaguchi, Toshio Ogihara, Michael L. Tuck. Osaka University 
Medical School, Suita City Osaka, Japan, Sepulveda VA Medical Center, Sepulveda, CA 
Background: We reported that sympathe!ic overactivity, higher level of plasma angio- 
tensin II, hyperinsulinemia and hyperleptinemia underlies obesity-related hypertension. It 
is also well known that an ACE inhlbitor and an ARB have contrastlng effects on plasma 
angiotensin II level (ang II). The purpose of the present study was to determine whether 
an ACE inhibltor, enalapril, and an ARB, losartan, would have antiatherosclerotic and 
anticoagulative effects. Methods: Three groups of 20 obese hypertensives each were 
treated with weight loss program (WL) alone, ACE inhibitor or AAB without WL. The 3 
groups were matched in age, BMI, BP levels at entry. All subjects were men and non-dia- 
betic. At entry, month 3, 6 and 12, BMI, BP, fasting blood glucose, plasma norepinephrine 
(NE), ang II, insulin, leptin and plasminogen activator inhibitor-l (PAI-1) were measured. 
Results: The % decrease in BMI in WL group was 10% at 6 months and 13% at 12 
months, and it was greater than ACE inhibitor or ARB groups. BP fall was similar 
between ACE inhibitor group and ARB group, and it was greater in pharmacological 
groups than WL alone group. Plasma NE, insulin and leptin decreased significantly in the 
3 study groups at 6 and 12 months, however, the %decreases in these variables were 
greater in order of WL > ACE inhibitor > ARB. Plasma ang II decreased acutely and sig- 
nificantly in WL group and ACE inhibitor group, whereas ang II increased in ARB group. 
PAI- decreased significantly in WL alone group at 3 months and in ACE inhibitor group 
at 6 months, but did not change in ARB even at 12 months. Conclusion: It has been well 
documented that hyperinsulinemia contributes to atherosclerosis and that PAI- is related 
with coagulation. In the present study, WL and ACE inhlbitor have stronger ameliorative 
effects on sympathetic overactivity, hyperinsulinemia, hyperleptinemia, higher levels of 
ang II and PAI- than ARB. These results indicate that an ACE inhibitor, may have for the 
same degree of BP lowering, has better protective effects on atherosclerosis and coagu- 
lation than ARB in obese hypertensive human. Contrasting effect on plasma angiotensin 
II level appears to be related with the different mechanisms on reducing coagulation (PAI- 
1). 
1195183 Iron Supplementation Inhibits Dry Cough Associated With 
Angiotensin-Converting Enzyme Inhibitors 
Sang-Chol Lee, Seung Woo Park, June Soo Kim, Duk-Kyung Kim, Sang Hoon Lee, 
Kyung Pya Hong, Jeong-Euy Park, Jung Don Sea, Won Ro Lee. Cardiac and Vascular 
Center, Samsung Medical Center, Seoul, South Korea, Sungkyunkwan University School 
of Medicine, Seoul, South Korea 
Background: Dry cough is the most common limiting iactor of angiotensin-converting 
enzyme inhibitor (ACEI) use. Generation of nitric oxide (NO), a pro-inflammatory sub- 
stance on bronchial epithelial cells, is increased by ACEI, and this may be a possible 
mechanism for the development of ACEI-induced cough. NO is synthesized by nitric 
oxide synthase (NOS), whose activity has been reported to be suppressed by addition of 
iron in experimental studies. We tested the hypothesis that supplementation of iron may 
reduce the cough associated with ACEI use by a randomized, double-blind, placebo-con- 
trolled clinical trial. Methods: Our subjects were nineteen patients who developed ACEI- 
induced cough. After a 2-week observation period, they were randomized to either the 
iron group (a 256.mg daily dose of ferrous sulfate) or placebo group for a treatment 
period of 4 weeks. During both periods, the subjects were requested to fill out a daily 
cough diary by scoring their daily severity of cough in a scale of 0 to 4. Mean daily cough 
scores of the last week of the two periods were compared. Changes in blood cell count 
and serum iron and ferritln concentration between the two periods were also evaluated. 
Results: Our subjects included 6 men and 13 women, and their mean age was 59.9 +I- 
12.2 years. 10 subjects were randomized to the iron group and 9 subjects to the placebo 
group. Mean daily cough scores at the last week of the observation and treatment peri- 
ods were 3.06 +/- 0.70 and 1.67 +/- 1.08 for the iron group, and 2.63 +/- 0.83 and 2.39 +i 
1 .I 6 for the placebo group. respectively, showing a significant reduction in cough scores 
with iron supplementation (p<O.Oi) but not with placebo. Nine subjects showed a reduc- 
tion of over 0.5 points in mean daily cough scores and three subjects showed almost 
complete abolishment of cough in the iron group, but only one subject showed such 
reduction in cough score in the placebo group with none showing complete abolishment. 
No significant change in laboratory data was observed in either groups. Conclusion: Iron 
supplementation successfully reduces ACEI-induced cough. This effect may be related to 
the decrease of NO generation associated with Inhibition of NOS activity in bronchial epi- 
thelial cells. 
274A ABSTRACTS - Hypertension, Vascular Disease, and Prevention JACC February 2001 
1195-l 84 Lack of Adverse Long-Term Prognostic Effect of Aspirin 
Therapy in Patients Treated With Angiotensin Converting 
Enzyme Inhibitors After Myocardial Infarction. Results From 
a Nationwide French Registry of Acute Myocardial 
Infarction 
Nicolas Danchin, Laurent Vaur, Sylvie Etienne, Jean Pierre Cambou, for the French USIK 
study Group. tiopifal Europeen G. Pompidou, Paris, France, INSERM 518, Toulouse, 
France 
Background: The potential clinical affect of aspirin in patients treated with ACE inhibitors 
is debated. Methods: The aim of this study was to analyze the prognostic role of aspirin 
therapy at one year in patients receiving ACE-inhibitors from the nationwide USIK data- 
base, which prospectively included all pts admitted to a CCU for an AMI < 48 hours in 
France in November 1998. Results: Of the 2,152 patients included in the database, 955 
received ACE-inhibitors within 5 days of hospital admission. Of these, 903 (Group 1) 
received aspirin, while 52 (Group 2.) did not. Group 2 patients were older (72 +/- 11 years 
vs 67 +/- 13 years, p < 0.01) more often had a history of stroke (13.5 % vs 5 %, p = 
0.01) congestive heart failure (25 % vs 11 %, p< 0.01) peripheral arterial disease (27 % 
vs 9 %, p < 0.01) or previous myocardial infarction (38 % vs 23 %, p = 0.01). In contrast, 
there were more patients with Q-wave myocardial infarction in Group 1 (76 % vs 58 %, p 
4 0.01). One-year Kaplan-Meier survival was actually higher in Group 1 (83 %) than in 
Group 2 (74 %) (p = 0.06). Using Cox multivariate analysis, age (OR: 1.06; 95% Cl: 1.04. 
1.07), previous history of Ml (OR: 1.91; 95% Cl: 1.33-2.73) previous history df CHF (OR: 
1.80; 95% Cl: 1.15.2.81), and anterior location of Ml (OR: 2.28; 95% Cl: 1.50-3.46) were 
the only independent significant predictors of one-year survival. Aspirin use had no prog- 
nostic influence. Conclusion: Thus, in this large prospective registry, aspirin had no del- 
eterious effect in patients otherwise receiving ACE-inhibitor therapy after an episode of 
acute myocardial infarction. These data do not support the hypothesis of a strong and 
clinically relevant antagonistic action of aspirin in patients treated with ACE-inhibitors. 
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1196-185 Insulin Resistance and Premature Endothelial Dysfunction 
in Asian Indian Male Sibllngs of Women With Polycystic 
Ovary Syndrome 
Rashmi Kaushal, Nikhil Parchure, Gul Bano, Andrew Rodin, Guy S. T. J. Whitely, Stephen 
S. Nussey. St George’s Hospital Medical School, London, United Kingdom, St Helier 
Hospital, Surrey, United Kingdom 
Background: Polycystic ovary syndrome (PCO) is a common disorder of premenopausal 
women characterised by hyperandrogenism (hirsutism, acne, menstrual irregularity, and 
obesity) and insulin resistance. This condition has an autosomal dominant inheritance 
affecting 52% of Asian Indian women. Characteristics of the male phenotype apart from 
premature balding remain to be defined. We hypothesise that male siblings of women 
with PC0 share this insulin resistance which may contribute to an excess of cardiac mor- 
bidity. Aims: To investigate whether reduced insulin sensitivity occurs in male siblings of 
women with PC0 and whether this is associated with altered endothelial function. Meth- 
ods: Asian Indian male volunteers aged 16-34 were studied in two groups : 1) Brothers of 
women with confirmed PC0 (n=lS) 2) Brothers of age and body mas?. index (BMI) 
matched women with no PC0 (n=18) Short insulin tolerance tests and high- resolution 
ultrasound forearm blood flow studies (FMD) were performed. The plasma glucose dis- 
appearance rates in the 3. to 15- minute period following insulin injection of O.OSU/Kg 
(KITT) were calculated. Resulte:Table 1 
Group 1 2 
KlTr (%/min) 6.79 (SD = 1.74) 3.48 (SD = 1.13) 
FMD (mm) 10.73(SD=l.I1) 1.22 (SD = 0.16) 
Men with a Fhx of PC0 but were insulin resistant compared to men with no Fhx of PC0 
(P=O.OOZ) with evidence of endothelial dysfunction P =0.009. Conclusion: Insulin resis- 
tance and endothelial dysfunction can be documented as early as the second decade in 
the Asian Indian male siblings women with PCO. Insulin resistance is inherited by male 
siblings of women with PC0 and hence could occur in over 50% of Asian Indian men. 
This would explain the increased incidence of type 2 diabetes in this race and may be of 
significance to the high cardiac morbidity suffered by Asian Indian people. 
1196-186 Prospective Randomized Evaluation of Losartan in 
Endothelial Dysfunction of the Aged:The PREVAILED Study 
Sanjay Rajagopalan, Zhenguo Han, Mark Supiano, Robert Brook, Bertram Pitt 
University of Michigan, Ann Arbor, MI 
Background: Aging is associated with progressive deterioration in endothelial function. 
The precise mechanisms involved in this decline are not properly understood but prelimi- 
nary evidence in animal models of aging have implicated free radical dependent deple- 
tion of nitric oxide. Since angiotensin II has been implicated in oxidant stress, we 
hypothesized that selective angiotensin II receptor (ATl) blockade may represent an use- 
ful therapeutic strategy to ameliorate endothelial function in healthy aged patients. 
Methods. 18 healthy aged patients without other traditional risk factors for coronary 
artery disease were prospectively randomized in a double blind cross-over fashion to 
receive either Losartan (50 mg/day) or placebo for 6 weeks. Patients were switched to 
the opposite arm after a 2 week wash-out period. Brachial artery vasoreactivity and 
plasma levels of VCAM-1, ICAM-1, MCP-1 and E-Selectin were measured at the begin- 
ning and end of both arms. 
Results: Mean age of the patients was 75fl years LDL, HDL and triglycerides were 
12417,50+3 and 138f2 respectively. BMI was 2411. Results are summarrzed below: 
Table 1’ 
Placebo Losartan 
Baseline 6 Weeks Baseline 6 Weeks 
SBP (mm Hg) 135+3 130*3 132r4 126~3 
FM0 (%) 3.9kO.8 2.4kO.6 3.ltO.6 3.9eO.6 
NTG (%) 14.8il 14.8tl 16.421.4 14.8~1 
sVCAM-1 ngiml 612i50 788k.120 750*73 572+39* 
slCAM-1 ngiml 304*15 344*15 405i26 196?10* 
MCP-1 nglml 554?72 588t69 560156 423t35 
E-Selectin nglml 67+6 79*9 7358 5628 
All values are mea&SE. “p<O.O5 compared with baseline Losarfan byANOVA 
Conclusion: Angiotensin II blockade for a duration of 6 weeks has a favorable effect on 
inflammatory markers in the elderly but does not alter peripheral conduit endothelial func- 
tion. 
1196-l 87 Endothelial Protective Effect of Nebivolol in Salt-Induced 
Hypertension 
Francesco Cosentino, Sandra Bonetti, Rudolph Rehorik, Masato Eta, Thomas F. Liischer. 
Cardioiogy and Cardiovascular Research, University Hospital, CH-8091, Ziirich. 
Switzerland 
Background: Nebivolol is a new Beta-l-selective adrenergic receptor antagonist with at 
least acutely - a direct vasorelaxant effect that involves activation of the L-argininelN0 
pathway via a non Beta-adrenoceptor mediated mechanism. Therefore, treatment with 
Nebivolol may protect against endothelial injury in hypertension. The present study was 
designed to investigate whether chronic selective Beta-l-blockade with Nebivolol in com- 
parison to Atenolol could prevent endothelial dysfunction in salt-induced hypertension. 
Methods: Dahl salt-sensrtive rats (n=6 per group) were treated for 8 weeks with standard 
chow (Control) and chow containing 4% N&l alone (Salt) or in combinatron with Nebiv- 
0101 (10 mg/kg per day; SalttN) or Atenalol (100 mgikg per day; Salt+A). Chronic salt 
administration increased systolic blood pressure by 38+/-5 mmHg in salt treated as com- 
pared with control rats (p<O.O5). Both Nebivolol and Atenolol prevented salt-induced 
pressure rise (~~0.05 vs salt treated rats). The reactivity of isolated aortas and small 
mesenteric arteries was studied in organ chambers and arteriographs, respectively. 
Results: The impairment of endothelium-dependent relaxations to acetylcholine (lo-9 to 
IO-5 M) in salt treated rats was prevented only by Nebivolol both in large and small arter- 
ies [p<O.O5 vs control rats for maximal response (Max%) and sensitivity (pD 2) respec- 
tively]. By contrast, the reduced pD 2 to the endothelium-independent agonist sodium 
nitroprusside (IO-10 to 10-5 M) was restored by both drugs. Furthermore, the blunted 
contractile response to endothelin-1 (IO-10 to 3x10-8 M) was improved by both Nebivolol 
and Atenolol in aortas (Max% and pD 2 = 117 +/- 8 and 8.2 +/- 0.1; 58+1-3* and 7.6 +/- 
0.3’; 80+/-a and 7.8 +/-0.4; 90+/-7 and 7.9+/- 0.5 for Control, Salt, Salt+N and Salt+A, 
respectively; * p<O.O5). Conclusion: Despite the same blood pressure lowering effect, 
only Nebivolol was able to prevent endothelial dysfunction. This study demonstrates for 
the first time that the acute NO-mediated vasodilatatory action of Nebivolol is also 
present during chronic treatment and may therefore exert a vascular protective effect 
against end-organ damage in hypertension. 
1196-188 Effect of Gemfibrozil on Brachial Artery Vascular Reactivity 
in Men With Reduced HDL Cholesterol 
Eric R. Guerra, Arsalan Shin&any, Jane Gaschen, Sandra Jolly, Guy Voeller, Betty Evans, 
Marshal 6. Elam. University of Tennessee Health Sciences Center, Memphis, TN 
Background: In the VA HDL Intervention Trial (VA-HIT) treatment with gemfibrozil (GEM) 
reduced coronary heart disease (CHD) events in men with low HDL (HDL-C). Although 
this may be attributed to increasing HDL-C and lowering triglycerides, GEM may have 
other potentially beneficial effects including improvement of endothekal function. Meth- 
ods: We assessed brachial artery reactivity in 16 former VA-HIT participants who were 
being treated with GEM. Brachial artery diameter was assessed by blinded operators 
using high-resolution ultrasound at rest, during reactive hyperemia (Flow mediated dila- 
tion; FMD) and after sublingual nitroglycerin (TNG) administration in subjects while taking 
GEM (GEM-l), following two weeks of GEM withdrawal (control), and after reinstitution of 
GEM therapy for four weeks (GEM-Z). Results: Brachral artery diameter in response to 
FMD induced by reactive hyperemia was significantly greater during both GEM periods 
compared to control (9.0% vs. 11% vs. 0%; GEM-1 vs. GEM-Z vs. Control, p<O.OOOl). A 
similar result was seen when TNG was administered (13% vs. 16% vs. 2%; GEM-1 vs. 
GEM-2 vs. Control, pcO.0001). Brachiai artery FMD was associated with GEM treatment 
status (F&.703, pcO.001) and serum triglycerides (Rz.296, ~~05). FMD was not associ- 
ated with serum HDL-C (R=0.009, p=.95), with LDL-cholesterol (R=.105, p=.50), systolic 
blood pressure (R=.lZO, ~~43) or fasting glucose (R=.061, p=.69). Conclusions: In this 
high-risk male population with low HDL-C and coronary heart disease, GEM treatment 
had a favorable effect on endothelial dependent (FMD) and independent (TNG) function. 
In this study, the effect of GEM on endothelial function was independent of HDL-C and 
LDL-C levels and some changes may be attributable to reduced triglyceride levels. GEM 
may also improve endothelial function through other undefined mechanisms. 
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1196-189 Acute Endothelial Dysfunction With Systemic Adriamycin 
Infusion 
Glenn Hirsch, Michael Schmidt, Robert Brook, Melvyn Rubenfire, Anne Schott. Zhenguo 
Han, Sanjay Rajagopaian. Section of Vascular Medicine, Dwision of Cardiology 
Univerafy of Michigan, Ann Arbor, MI 
Background: Adriamycin is a commonly used chemotherapeutic agent that is believed 
to exert its effects through the generation of free radicals. We hypothesized that acute 
administraiion of adriamycin in patients undergoing chemotherapy for breast cancer is 
associated with marked alterations in endothelial function owing to the degradation of 
vessel wall nitric oxide (NO). 
Methods: 10 patients with breast cancer receiving their first dose of adriamycrn as part 
of their chemotherapy regimen were enrolled into the study. The average age of the 
patients was 52.3 -t 10 years. All studies were performed at the same time before and 30 
minutes after the administratron of an IV infusion of adriamycin. Endothelial dependent 
(reactive hyperemia) and independent ( SL NTG) function in the brachial arteries was 
determined by high resolution ultrasonography. Serum NO activity was measured by the 
Griess reaction. 
Results: The baseline brachial artery diameters before and after adriamycin did not dif- 
fer The percent flow mediated response to reactrve hyperemia decreased from 6.&l .O 
to 2.5-tl .l% (p=O.O004). Responses to NTG before and after adriamycin were 
unchanged at 16.3i3.1 and 14.33&l% respectively (p=O.36). Serum nitrite and nitrate 
concentratrons fell from 50& pre-adriamycin to 3316 mM post adriamycin infusion 
(p=0.0005). 
Conclusions: intravenous adriamycin infusion results in rapid endothelial dysfunction 
as evidenced by attenuation of reactive hyperemic responses in the brachial artery and 
reduction in serum NO activity. Vascular smooth muscle function remains Intact. These 
findings may have long term implications especially with repetrtive administration of this 
agent. 
1196-I 90 Endothelium Dysfunction of Epicardial Coronary Arteries 
Affects the Left Ventricular Function in Cardiac Hypertrophy 
Olivier Malo, Nathalie Desjardins, Yan Fen Shr, Jean-Claude Tardif, Mrchel Carrier, Louis 
P Perrault. .Moontreat Heart Insfifufe, Montreal, PQ, Canada 
Background: Left ventricular hypertrophy (LVH) secondary to aortic stenosts and hyper- 
tension is a morphological adaptive increase in myocardial mass in response to chronic 
work overload. This increase complicates myocardial protection during surgery because 
of subendocardial perfusion deficiency. A concomitant endothelial dysfunction could 
compound the situation by reducing perfusion and hampering myocardium recovery dur- 
ing repertusicn leading to ischemic injuries. These alterations could induce impairment of 
global LV function. Objective: The objective of this study was to assess the presence of 
endotheiial dysfunction in epicardial coronary arteries and its influence on the LV function 
in a porcine model of LVH. Methods: Banding was performed through a left thoracotomy 
using umbilical tapes for 24 hours and P-month period. A minimal gradient of 15 mmHg 
was created by an aortic banding 3 cm above the coronary ostia. LV function and mass 
was documented by transthoracic echocardiography before the surgery, 24 hours, 1 
week, 1 and 2 monihs after the surgery. Experiments in organ chamber was used to eval- 
uate endothefial function of the nrtric oxrde and endothelium-dependent hyperpolarizing 
pathways. Results: There was an increase in heart weight/body werght ratios 
(p&05)and a significant increase of the LV mass after 2 months, indicating a significant 
LVH. There was also a significant reduction of the LV volume, dimension and a reduction 
of LV ejection fraction. After a contraction to PGFZalpha; there was a significant decrease 
in endotheiium-dependent relaxations to serotonin (5.HT, coupled to Gi-protern) and to 
bradykinin (BK, coupled to Gq-protein), but not in the presence of BK with Nw-L-arginin 
(I-NA), and to BK with I-NA and KCI. Conclusion: Early after the development of LVH, 
NO production from coronary arteries is impaired and may affect autoregulation of the 
coronary circulation and compromise myocardial perfusion in the perioperative period 
Endotheiial dysfunction of coronary arteries may have a direct impact on LV relaxation 
Preventive and therapeutic measures should be developed to treat this endothelial dys- 
funciion to improve LV diastolic function 
1196-I 91 Vasoconstrictor Effect of the Angiotensin Converting 
Enzyme Resistant Chymase Substrate [Pro11 D-Ala121 
Angiotensin I in Human Dorsal Hand Veins: In Vivo 
Demonstration of Non ACE Conversion of Angiotensin II in 
Humans 
John E. McDonald, Neal Padmanabahn, Mark G. Petrie, Chris Hrilier, John M. C. Connell, 
John J. V. McMurray. GLASGOW UNIVERSITY GLASGOW United Kingdom, 
CALEDONIAN UNIVERSITY, GLASGOI/1! United Kingdom 
Background: [Pro1 1 D-Alai21 angiotensin I is an angiotensin converting enzyme (ACE) 
resistant substrate, specific for chymase. We have used this peptide. to determine 
whether a functionally significant non-ACE angiotensin II generating pathway exists in 
human dorsal hand veins. Methods. Using a modified Aellig technique, we studied the 
responses to angiotensin I and [Pro1 1 D-Ala121 angiotensin I in dorsal hand veins, in 
viva, in patients with ischaemic heart disease We studied the venoconstrictor response 
to both angiotensin I and [Pro1 1 D-Ala121 angiotensrn I given before and after, an oral 
dose of the ACE inhibitor, 6.25mg captoprif, or matching placebo. Placebo or captopril 
were given in a double blind randomised fashion. The mean(SEM) venoconstriction in 
response to angrotensin I infused before placebo, after placebo, before captopril and 
after captopril was 44X(10.5)%, 39.6(9.8)%, 54.5(7.5)% and 3.9(3.9)% respectively. 
Hence, the response to angiotensin I was sigmficantly reduced only after treatment with 
captopril (p=O.O02). The mean(SEM) venoconstriction in response to [Pro1 1 D-Ala121 
angiotensin I infused before placebo, after placebo, before captopril and after captopril 
was 42.0(9.1)%. 49 0(9.1)%, 47.6(10.2)% and 53.8(10 7)% respectively. Hence captopril 
had no significant effect on the response to [Pro1 1 D-Ala121 angiotensin I (p=O.6) Con- 
clusion: We have been able to confirm that [Pro1 1 D-Alai 21 angiotensin I is a chymase 
specrfic, ACE resistant, substrate in viva in humans. With thrs specrfic pharmacologic 
probe we have shown that a chymase pathway, capable of generating angiotensin II, 
exists in human veins and is functionally important. This is the first demonstration of non- 
ACE angiotensin II generating pathway in viva in humans. 
1196-192 
Pro1 1 D-Aial2 angiatemin I 
*p=a.aK! 
pkebo wpioprii piacebo captoprii 
Comparison of the Nitric Oxide Component of Flow- 
Mediated Dilatation Following Wrist Versus Upper Arm 
Occlusion 
Sagar N. Doshi, Katerina K. Naka, Moira Ashton, Nicola Payne, Christopher J. H. Jones, 
Malcolm J. Lewis, Jonathan Goodfellow. Wales Heart Research Institute, Cardift Unfted 
Kingdom 
Background: Flow-mediated dilatation (FMD) is now a wtdely accepted method to 
assess endothelial function in humans. Increased blood flow in the brachial artery is 
induced by release of an occlusive cuff. The resulting FMD is measured non-invasivefy 
and serves as a surrogate of endothelial integrity However, the technrque is not stan- 
dardized with use of different cuff occlusion positions. The usefulness of FMD rests on 
the assumption that the resulting dilatation is NO-mediated (Nitric Oxide). 
Methods: We compared the relative contributron of NO to brachial artery FMD following 
5 minutes of wrist and upper arm cuff occlusion, in 10 healthy mate subjects (34.1 years 
i- 4.56). Following an overnight fast subjects took lg Aspirin to block cycle-oxygenase. A 
27 gauge needle was inserted into the brachial artery of the non-dominant arm. After sta- 
bilization, FMD was measured using a 7.5MHz high resolution ultrasound wall tracking 
system following 5 minutes of (i) wrist occlusion (ii) upper arm occlusion at 250 mmHQ 
and then repeated with both cuff positions during infusion of the specific eNOS inhibitor 
L-NMMA at 3mgimin. 
Results: FMD following wrist occlusion was significantly less than FMD following upper 
arm occlusion (7.25% t2.49 cf. 11.61% k3.17, p=O.O02). In the presence of L-NMMA, 
FMD after wrist occlusion was abolished (7.25% *2.49 cf. -1.57% *3.0, p<O.OOl) and 
FMD after upper arm occlusion was significantly reduced (11.61% _t3.17 cf. 7.51% 
k2.34, p=O.OOZ). Examination of the time-course (see figure) suggests that FMD follow- 
ing wrist occlusion is almost exclusively NO-mediated, whereas FMD following upper arm 
occlusion is only in part NO-mediated, other potential vasodilators being lschaemic 
metabolites and EDHF. 
Conclusion: We support the recommendation of standardization of this technique and 
suggest that wrist occlusion be the preferred stimulus to test the L-argininelN0 pathway. 
-4. 
Minutes post cuff release 
1 2 3 4 5 IO 
1196-l 93 Contribution of Nicotine to Acute Endothelial Dysfunction in 
Long-Term Smokers 
Thomas Neunteufl, Sandra Heher, Karam Kostner, Goran Mitulovic, Stephan Lehr, 
Rainer W. Schmid, Gerald Maurer, Thomas Stefenelli. University of Vienna, Vienna 
Austria 
Background: Cigarette smoking causes an acute impairment of endothelium-depen- 
dent, flow-mediated dilation (FMD). The aim of this study was to determine whether nico- 
tine, a constituent of cigarette smoke, contributes to this effect. Methods: Sixteen healthy 
smokers were entered into a randomized, observer-blinded crossover study, comparing 
the effects of nicotine nasal spray (lmg nicotine) and of cigarette smoke (lmg nicotine, 
12mg tar) on vascular reactivity in the brachial artery. Using high-resolution ultrasound, 
flow-mediated dilation (FMD) and endothelium-independent, nitroglycerin-induced dila 
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tion (NMD) were assessed at baseline and 20 minutes after the administration of nicotine 
(spray or cigarette). Results: In response to similar increases in nicotine serum levels, 
FMD values declined fromlO.Zc4.4 to 6.7*4.0% after the spray (mean difference- 
3.6-t2.0%, 95%confidence interval [-2.5; -4.61, p<O.OOOl) and from 9.4+3.8 to 4.3*2.8% 
after the cigarette (- 5.ii2.6%, [-3.7; -6.51, p<O.OOOl). NMD remained similar within both 
periods. Performing a period effect Analysis of Variance (ANOVA) a significant influence 
on FMD was found for the mode of administratron (p=O.O17) and the baseline value 
(p=O.O21). The effect on FMD was more pronounced after the cigarette than after the 
spray (estimated average effect difference 1.9% FMD). Within the spray period the 
impairment of FMD was associated with an increase in oxidative stress, estimated as 
changes in thiobarbituric acid-reactive substances (r=-0.615, p=O.Oll). Conclusion: 
These results demonstrate that nicotine alone causes acute endothelial dysfunction, 
although to a lesser extent than smoking a cigarette of the same nicotine content, and 
suggest that oxidative mechanisms are at least in part responsible for this effect. 
1196-194 The Effect of the Interleukin-6 -174GK Promoter Gene 
Polymorphism on Endothelial Function 
David J. Brull, Paul Leeson, Michael Mullen, Marcello deDiviitis, Hugh E. Montgomery, 
John E. Deanfield, Steve E. Humphries. Royal Free and University College London 
Medical School, London, United Kingdom, Great Ormond Street Hospital, London, 
United Kingdom 
Background: Interleukin-6 (IL6) plays a key role rn the generation of atherosclerosis, 
through stimulation of acute phase protein synthesis. Elevated levels of CRP are associ- 
ated with endothelial dysfunction. We have examined the effect of the IL6 -174G>C 
gene promoter polymorphism on endothelial function, in a group of healthy subjects. 
Methods: 261 adults aged 20 to 28 years participated in the study. Polymerase chain 
reaction was performed for the IL6 -174GzC polymorphism. Genotypes were resolved 
using restriction endonuclease Nlalll. High-resolution ultrasound was used to measure 
brachial artery diameter at rest and after forearm cuff occlusion. Responses were repre- 
sented as absolute change in vessel diameter (in millimeters -FMDA). 
Results: Data was available for 248 subjects (131 female, 117 male). Genotype distribu- 
tion was in Hardy-Weinberg equilibrium. C-allele frequency was 0.45 (95% Cl 0.42. 
0.50). There was a trend towards greater FMDA in CC genotype overall, linear regres- 
sion coefficient 4.009 p=O.14. There was no effect of IL6 genotype in women. In men 
FMDA was greater in individuals genotype CC compared to those GC and GG, p=O.l9, 
trend for linear regression r=-0.0206, p=O.O4. By multivariate analysis, using vessel size 
and CRP as covariates there was a significant association between genotype and FMDA 
in males p=O.O38. In male non-smokers FMDA was greater for CC genotype than GG or 
GC subjects, linear regression coefficient -0.024 p=O.O7. Only in male smokers of geno- 
tvpe CC was there a sianificant reduction in FMDA ComDared to non-smokers of the 
same genotype (p=o.o48). 
Mean FMDA (SEM) cc GC GG 
Group Overall 0.114(0.011) 0.109(0.009) 0.095(0.008) 
Men 0.127(0.018) 0.113(0.016) 0.084(0.012) 
WOnlen 0.101(0.013) 0.106(0.009) 0.103(0.010) 
Male non-smokers 0.142(0.023) 0.123(0.022) 0.092(0.006) 
Male smokers 0.093(0.024) 0.096jO.019) 0.075(0.019) 
Conclusion: The IL6 -174GhC promoter polymorphism influences endothelial function 
in healthy subjects. The effects are oonfined to male volunteers. The detrimental effects 
of smoking on endothelial function are most clearly seen in individuals who were CC 
homozygotes, suggesting a genotype-specific interaction with smoking. 
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808-2 Inhibition of Arterial Thrombosis by a Peptide Analogue of 
Thrombin Receptor 
Rajbabu Pakala, Takuya Watanabe. Claude R. Benedict. University of Texas Health 
Science Center, Houston, TX 
Background: Thrombin plays a pivotal role in both fibrin rich venous and platelet rich 
arterial thrombus formation. Use of direct thrombin inhibitors to prevent thrombus forma- 
tion is accompanied by impairment of hemostasis because, apart from inhibiting platelet 
activation they also inhibit fibrin formation. Antagonist peptides to thrombin receptor 
(TRAPA) may have therapeutic value because of their specific inhibition of cellular 
actions of thrombin. In this study, we tested if AFLARAA (TRAPA) could prevent intravas- 
cular thrombus development. 
Methods: Rabbit carotid artery was instrumented with a Doppler flow probe and a nee- 
dle as an electrode. Partially occlusive thrombus was generated by applying 150mA of 
current. After 50% occlusion of the artery, current was stopped and different concentra- 
tions of AFLARAA or saline (control) were given intravenously over a period of 180 min. 
The changes in the coronary blood flow were monitored continuously. Bleeding was 
assessed by weighing the amount of blood absorbed by a preweighed sponge, placed in 
an incision that was 5cm long and 0.5 cm deep. 
Results: In control animals carotid artery was occluded in 46+14 min after stopping the 
current. However, in animals infused with AFLARAA (100 mmoles/Kg bolus followed by 
900 urn&s/Kg IV) carotid artery remained open for > 240min. As compared to control 
even at effective dose AFLARAA did not significantly increased incisional bleeding. 
Conclusion: Results of the present study suggest that TRAPAs prevent arterial throm- 
bus formation. Since thrombin plays an important role in platelet recruitment, desensitiza- 
tion of platelet thrombrn receptor may be an attractive way to prevent thrombus formation. 
808-3 
11 :oo a.m. 
The Hypercoagulable State of Type 2 Diabetes Can Be 
Reduced by Improving Metabolic Control: A Randomized 
Double Blind Study 
Julio I. Osende, Juan Jose Badimon, Valentin Fuster, Phil Rabito, Perry Herson, Azfar 
Zaman, Oswaldo Rodriguez, Eli I. Lev, Ursula Rauch, Gerard Helft, Jill P. Crandall. 
Cardiovascular Institute. Mount Sinai School of Medicine, New York, NY 
Background: We and others have reported an increased blood thrombogenicity in type 2 
diabetes mellitus patients. This blood hyperthrombogenicity has been implicated in the 
pathogen&s of the accelerated atherosclerosis and vascular complications in these 
patients. The goal of the study was to determine if the hypercoagulable state associated 
with type 2 diabetes can be reduced by a more aggressive glycemic control. We also 
compared whether the addition of troglitazone to the more conservative glycemic regi- 
men may further reduce the observed increased thrombogenicity. Methods: Type 2 dia- 
betes mellitus patients (n=40) with hemoglobin Ale t 7.5% were randomized in a double- 
blind fashion to add either placebo or troglitazone (600 mgiday) for 3 months to their drug 
regimen (insulin and/or sulfonylureas). Blood thrombogenicity was measured at baseline 
and after 3 months with the Badimon perfusion chamber, allowing every patient to served 
as his/her own control. Blood was perfused directly from the patient’s arm through the 
perfusion chamber. Platelet-thrombus formation was triggered by 5.minute perfusions at 
high (1690/s) shear rate over tunica media, as a model of severe arterial injury. Thrombo- 
genicity was assessed as the area of thrombus formed in the substrate. Results: 
Patients with improved glucose control (reduction of hemoglobin Ale 2 0.5%, n=24) 
showed a significant decrease in blood thrombogenicity (p=O.Ol). A positive correlation 
between the reduction in baseline hemoglobin Ale and the reduction of baseline blood 
thrombogenicity was observed (w0.45, p<O.Ol). Stepwise multiple regression analysis 
showed reduction of hemoglobin Ale as the only independent determinant for blood 
thrombogenicity reduction. The troglitazone group achieved a significant better glycemic 
control assessed per the number of patients with reduction of hemoglobin Ale > 0.5%. 
Conclusion: The hypercoagulable state of type 2 diabetic patients is related to the level 
of glycemic control and can be reduced as hemoglobin Al c is decreased. The effect of 
aggressive glycemic control on blood thrombogenicify may have important clinical impli- 
cations to reduce vascular thrombosis in diabetics. 
808-4 
11:15a.m. 
Pharmacogenomics: Response to Aspirin Is Dose, Agonist, 
and PLA Dependent 
Glen E. Cooke, Yiwen Lru-Stratton, David J. Frid, Raymond D. Magorien, Paul F. Bray, 
Pascal J. Goldschmidt-Clermont. The Ohio State University, Columbus, OH, Duke 
University Durham, NC 
Background: Coronary heart disease (CHD) remains the most important cause of mor- 
tality in Western society. Aspirin’s use in CHD is ubiquitous. We sought to investigate the 
role of two common dosages of aspirin in a CHD cohort by assessing platelet aggrega- 
tion induced by various agonists as a function of the PIA polymorphism. Methods: The 
study population consisted of 46 subjects (26 PIAl/l, 20 PIAIR) with established CAD. 
Subjects presented with one of two dosage regimens of aspirin (81 mg/day; 8 PlAlil, 8 
PIAlR; or 325mgide.y; 18 PIAlIl, 12 PIAl/Z). Venous blood samples were obtained in 
the fasting state and PRP was used for platelet aggregation. Platelet agonists (epineph- 
rine, ADP, and collagen) were used at varying concentrations and data analysis was per- 
formed with ANOVA and student’s t-test if significance was noted. Results: Epi induced 
platelet aggregation was significantly more inhibited in PIAl/ subjects than PlAlil sub- 
jects treated with 8lmgiday (2mM: 24.0+3.0% vs. 34.5r2.9% respectively, p<O.O5)(5mM: 
28.0+3.6% vs. 39.9*3.7% respectively, ~~0.05). With ADP induced platelet aggregation, 
platelets from PIAl/ subjects treated with Blmg/day were more inhibited than PlAlil 
subjects (0.5mM: 9.4*1.4% vs. 15.4 +2.2% respectively, p<O.O5)(lmM: 15.6+2.9% vs. 
27.4 ?4.5% respectively, pcO.05). On the contrary, in collagen induced aggregation, low- 
dose aspirin treatment (8lmg/day) was associated with significantly less inhibition in 
platelets from PIAl/ subjects as compared to PIAl/ platelets (2mM: 33.8r5.2% vs. 
14.0+1.3% respectively,’ pcO.O05)(5mM: 66.8-t5.5% vs. 32.4*5.8% respectively, 
pcO.OOl)(lOmM: 75.3r4.8% vs. 49.9+6.5% respectively, pcO.01). Conclusions: There 
appears to be a substantial effect of the PIA polymorphism on the sensitivity of platelets 
to aspirin that appears to be dosage and agonist dependent. These findings could have 
significant impact on our understanding of pharmacogenetic antithrombotic strategies in 
CAD patients as well as platelet biology. 
808-5 
II:30 a.m. 
Combined Administration of a Low Molecular Weight 
Heparin and a GP Ilb/llla Receptor Antagonist Results in 
Increased Efficacy Safety Ratio 
Adrienne L. Racanelli, Karen Schlingmann, D. Adam Lauver, Thomas Reilly. DuPont 
Pharmaceuticals, Wilmington DE, DE 
Adequate treatment of cardiovascular disease often requires concurrent administration of 
antithrombotic agents which operate through different mechanisms. Accordingly, we have 
studied the combined administration of a GPllblllla antagonist (roxifiban) with a low 
molecular weight heparin (InnohepR) to determine whether the benefits of combined 
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administration outweigh any adverse effects. Since the guinea pig represents a good 
model to study GPllb/illa receptor antagonists, a guinea pig model of arterial thrombosis 
utilizmg FeCl3 to induce thrombosis and a guinea pig cuticle bleedtng model were used 
to study the combined admrnistration of these agents. In the thrombosis model, animals 
dosed with roxifiban (0.8 mglkg i.v.) or InnohepR (150 IU/kg i.v.) produced a prolongation 
of the occlusion time by (25 +/- 3 min and 32 +I- 4 min respectively) versus a 21 +/- 2 min 
control. At these doses, InnohepR prolonged the cloning times (APTT-6x, PT-2x), while 
roxifiban had no eifect. Peak inhibition of ADP (100 uM)- induced platelet aggregatron 
was approximately 30% for InnohepR and 10% for roxifiban. Guinea pigs treated with the 
combination of these same doses produced a significant greater than additive increase in 
occlusion time (71 +i- 11 min (pc0 05) vs. control). In the bleeding model, both com- 
pounds at these doses doubled the bleeding time (195 +/- 41 set (roxifrban) and 192 +/- 
61 set (InnohepR) vs. a 112 +/- 31 set control) when administered indwidually but when 
given in combrnation, the bleeding time was 313 +/- 36 min vs control, representing an 
additive effect vs. the control group (~~0.05). Therefore, the combined administration of a 
GPllbillla receptor antagonist and low molecular weight heparin led to an increased effr- 
cacylsafety ratio. 
806-6 
1 I:45 a.m. 
Dethrombotic and Antithrombotic Effects of Glycoprotein 
Ilb/llla Inhibitor Tirofiban in an Ex Vivo Canine Stent 
Thrombosis Model 
Vladrmir Rukshin, Babak Azarbal, Vivian Tsang, Prediman K. Shah, Bojan Cercek, 
Sanjay Kaul. Sedars Sinai Medical Center, Los Angeles, CA 
Background: Platelet glycoprotein Ilb/llla inhibitor, trrofiban (tire), is known to have 
potent antrthrombotic effects. 
Objective: To investigate the effects of tiro on stent thrombosis in an ex-viva canine arte- 
riovenous shunt model of high-shear blood flow. 
Methods: Control rough-surface nitinof stents (n=284 in 7 dogs) were expanded to 2 mm 
in diameter in a tubular perfusion chamber interposed in the shunt and exposed to fiow- 
ing arterial blood at a shear rate of 2100 s-’ for 20 minutes. Animals were treated with 
intravenous tire (0.3, 3.0, and 30 mcgikglmin) alone or with heparrn (50 Uikgihr IV to 
keep AC? ,160 seconds). Effects on thrombus weight (TW), whole-blood platelet aggre- 
gation (PA), P-selectin expression, bleeding time, and ACT were quantified. Dethrom- 
botic and antithrombotrc effects were examined in stents with and without preformed 
thrombus, respectively. 
Results: see Table. Tire significantly inhibited PA by 295% at all doses and prolonged 
bleeding time (13 min at 0.3 mcg and >30 min at higher doses vs. 4 min baseline) but had 
no effect on platelet P-selectin expression, ACT, hematocrit and platelet count. Heparin 
coadministration did not produce any incremental effects at 0.3 mcglkgimin dose of tire. 
Conclusion: Tirofiban produced a dose-dependent reduction of preformed stent thrombi 
and markedly inhrbited acute de now stent thrombosis under high-shear flow. Thus, 
tirofiban may be an effective therapeutic agent for the treatment and prevention of stent 
thrombosis. 
Dethrombotic effect Antrthrombotic effect 
lnlaiwntion We-Rx TW (rq)  Pm-Rx TW (liq) Pre-Rx TW (mg) Post-Rx TW (mg) 
Tim 0.3 hep l&2 1915 19+3 &c2* 
Trro 0.3 + hep 18~3 1925 19t3 4i2*t 
Tiro 3.0 hep 21+5 16i4' 21*5 1*1* 
Tire 3.0 + hep lQt4 14+4 2154 1+1” 
Tiro 30 - hep 19+3 12f2’ 20*3 l&l’ 
Tiro 30 + hep 21t5 lli4^ 2016 1+1* 
Data are mean&D; Rx = treatment; tire = trrofiban; hep = heparin; TW= thrombus 
weight; n=15-20 stents with each intervention; PcO.05 vs. pre-Rx; TP&05 vs trro-hep at 
the same dose. ANOVA 
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IO:30 a.m. 
Ankle-Brachial Blood Pressure Index Is a Strong Predictor 
for Mortality and Cardiovascular Events: Results From the 
HOPE-Trial 
Jan 8. Ostergren, Janice Pogue, Sleight P Dagenais G, Danisa K, Yusuf S for the, 
HOPE-study investigators. Dept of Medicine Karolinska Hasp&?/. Stockholm, Sweden, 
Dept of Cardiology MeMaster University, Hamiiton, Canada 
Background: A low ankle-brachiai blood pressure index (ABI) has prwously been 
shown to be potent predictor of cardiovascular morbidity and all-cause mortality. Meth- 
ods: In the Heart Outcomes Prevention Evaluatron (HOPE) study patients at hrgh risk for 
cardiovascular events were randomised rn a 2x2 factorial design to treatment with rami- 
prii or placebo and vitamin E and placebo. ABI was measured at baseline in 8986 
patients. Manual palpation of the foot arteries or doppler ultrasound was used as the 
pulse indicator. Outcomes in relatrcn to ABI (>O.Q, 0.9-0.6 and ~0.6) were investrgated. 
Ftesufts~ 3099 patients had a subnormal ABI (~0.9). 1258 of these had an ABI of less 
than 0.6. 5887 patients had an ABI of more than 0.9. A low ABI was related to female 
gender, current smoking, hypertension, previous cardrovascutar disease, higher age and 
an increased heart rate, but the between group differences in this regard were small. A 
low ABI at baseline was a very strong predictor of cardrovascular morbidity and mortality 
during the follow-up period even when corrected for other major risk factors. This was so 
for the primary endpoint in the study and for each indrvidual component (cardiovascular 
mortality;5.3% 9.0% and 11.7% resp., myocardial infarction; 10.7%, 12.8% and 14.1% 
resp. or stroke; 3.4%, 5.1% and 6.0% resp.). Further, ABI predicted mortality from all 
causes: in those with a normal ABI it was Q.l%, in those with a moderately pathologic 
ABI 13.6% and in those with an ABI lower than 0.6 17.4% (p<O.OOOl). Development of 
heart farlure (2.6%, 3.5% and 6.0% resp.) and diabetic complications (6.1%, 7.4% and 
9.5% resp.) were also associated with the presence of a low ABI. Conclusion: ABI is a 
strong predictor for future cardio-vascular morbidity and mortality, as well as for all-cause 
mortality. The effect of ramiprri on mortality in the HOPE-study was greater in patients 
with a low ABI. The simple ankle arm blood pressure ratio allows further stratification of 
high risk and should be considered in the evaluation of such patients. 
859-2 
10:45 a.m. 
Carotid/Femoral Ultrasound Morphology Screening and 
Effects of Vitamin C on Cardiovascular Events and Vascular 
Disease Progression in Low-Risk Subjects. A lo-Year 
Follow-Up Study 
Maria Rosaria Cesarone, Marco Bucci, Mariateresa De Sanctis, Lucrezia Incandela, 
Maura Griffin, Surinder Dhanjil, Ganesh Ramaswami, George Geroulakos, Adam Carey, 
Antonio Barsotti, Giovannr V. Belcaro, Andrew N. Nicolaides. BiomedicalSciences 
Depaifment, University of Chief;, Chiefi, Ifa/% Irvine Lab. St. Mary’s Hospital & Imperial 
College, London, United Kingdom 
Background: Subclinical arteriosclerotic lesions at the carotid and femoral bifurcations 
may be related to occult coronary artery disease and to the occurrence of future cardio- 
vascular events. Aim of the study was to evaluate if B-mode ultrasound of these lesions 
may provide a sample screening method to select asymptomatic subjects at high-risk of 
events and if Vitamin C supplements may influence the outcome. Methods: 13,221 low- 
risk, asymptomatic subjects were included in a lo-year, prospective, follow-up study 
based on carotid and femoral bifurcation morphology as defined by B-mode ultrasound. 
Four classes were considered at inclusion, I = normal wall; II = wall thickening; Ill = non- 
stenosing plaques; IV = stenosing plaques). A comparable parallel group of 400 subjects 
(100 in each class) was included and treated with Vrtamin C (1 g daily) supplement for 
the duration of the study. When 10000 subjects (= 75.6% of included ones, 6055 males, 
3945 females) completed the 1 O-year follow-up. the study was concluded. Results: At IO 
year, 10 events (out of 7989 subjects) in class I; 81 events rn class II (930 subjects; incl- 
dence = 8.6%); 239 events in Ill (611 subjects: 39.28%); 381 events (470 subjects; 
81.06%) in class IV were observed. Deaths (= 61) occurred only in classes III or IV (1081 
subjects) producrng a death rate within these two classes of 5.5% (51 out of 61 = 61.5% 
in class IV). The increased event rates in classes Ill and IV were significant (p< 0.02) in 
comparison with I and II. in the Vitamin C group, 344 subjects completed the study, with a 
marked reduction in the rate of cardiovascular events, in mortality and also in progres- 
sion. Conclusions: Carotid and femoral morphology identified 2011 subjects (20.1% of 
the enrolled population) in classes II, ill, IV, includrng 98.6% of cardiovascular events and 
deaths in the following 10 years. A higher (p< 0.05) rate of progression in classes Ill and 
IV in comparison with I and II was observed. The ultrasound carotid and femoral classifi- 
cation was useful in selecting subjects at very low-risk of events (class I), at limited risk 
(class II), at moderate risk (class Ill) and at very high-risk (class IV) Vitamin C supple- 
ments can reduce the progression of vascular disease. 
859-3 
Ii:00 a.m. 
Warfarin Prevents Embolization in Patients With Thoracic 
Aortic Atheromas on TEE: Significant Early Data From the 
NYU Atheroma Group 
Gregory M. Goodkin, Paul A. Tunick, ltzhak Kronzon. NYU Atheroma Group. NYUSchool 
of Medicine, New York, NY 
Background: Our group and others have shown that aortic atheromas seen on TEE are 
responsible for a high risk of stroke and peripheral embolization in 1 year. Data on treat- 
ment to prevent emboli are avarIable for only a limited number of patients. Methods: 
Since 1988, 1182 pts had thoracic aortic atheromas, * 5mm or mobile, on TEE at our 
institution. Retrospective information regarding the occurrence of cerebral or systemic 
embolization (stroke, TIA, or peripheral) after atheroma diagnosis by TEE, as well as 
treatment with anticoagulant (warfarin) or antiplatelet drugs (aspirin. trclopidine, clopi- 
dogrel) was obtained from patient records or dwect patient contact. Treatment was deter- 
mined by referring physicians and was not randomized. Presented here are preliminary 
data from 100 randomly selected pts. Results: Of the 100 pts studied, 34 received war- 
farin and 59 received antiplatelet treatment. An embolic event occurred in 18 pts (18%) 
an average of 19.4 months after TEE (range 4 - 72 months) (stroke = 6, TIA = 8, periph- 
eral embolization = 4). Warfarin treatment was being given to only 2 (11%) of 18 pts at 
the time of their embolic event (INR > 2 in 1, < 2 in 1). Antiplatelet treatment was being 
given to 11 (61%) pts at the time of their embolic event. Of the 72 pts without emboli, 32 
(39%) were receiving watfarin and 48 (59%) antiplatelet drugs. The protective effect of 
warfarin with respect to embolic events was statistically significant (P = 0 02). No such 
protective effect was found for the antiplatelet drugs (P = 0.84). Conclusions: Although 
these data are from a preliminary sample of 100 pts, the results indicate a protective ben- 
efit of warfarin, and the lack of a protective effect of antiplatelet drugs in pts with thoracic 
aortic atheromas on TEE. Data from the entire cohort will be more definitive, and will also 
yield information regarding mortality and complicatrons. 
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859-4 
II:15 a.m. 
The PARTNERS Program: Intensity of Cardiovascular Risk 
Factor Treatment and Use of Antiplatelet Agents in Patients 
with Peripheral Arterial Disease (PAD) and Cardiovascular 
Disease (CVD) 
William R. Hiatt, Alan T. Hirsch, Michael H. Criqui, Mary M. McDermott, Judith G. 
Regensteiner, M. Eileen Walsh, Susan Krook, Anthony J. Comerota, Mark A. Creager, 
Diane Treat-Jacobson, Jeffrey W. Olin, Emile R. Mohler, III. Colorado Prevention Center, 
Denver, co , 
Background: PAD is associated with an increased risk of cardiovascular events similar 
to that of coronary disease. We hypothesized that PAD patients would have less intensive 
treatment of risk factors and less use of antiplatelet therapy than patients with other man- 
ifestations of cardiovascular disease (CVD). Methods: The PARTNERS program evalu- 
ated the prevalence of PAD in 6979 individuals seen in 320 primary care practices in the 
U.S. Patients 270 years or those between 50-69 years with a history of smoking and/or 
diabetes were eligible for evaluation. PAD was defined as an ankle-brachial index (ABI) h 
0.90, a previous diagnosis of PAD, or prior limb revascularization. CVD was defined by a 
history of angina, MI, CABG, PTCA, AAA, TIA or stroke. The overall prevalence of PAD 
alone (without other associated CVD) was 13% and CVD alone (without associated PAD) 
was 24%. The prevalence of atherosclerotic risk factors and treatment was defined by 
chart review of current diagnosis and prescribed therapies. The data in the table show 
rates of treatment for cardiovascular risk factors and use of antiplatelet agents in the PAD 
and CVD cohorts. Results: Patients with PAD alone (“=825), compared to those with 
CVD alone (n=1527), were less frequently treated wiih antiplatelet, lipid-lowering and 
blood pressure lowering agents, whereas treatment for diabetes was comparable for PAD 
and CVD. The numbers of patients identified with that risk factor are indicated for each 
therapy prescribed. Conclusion: PAD is a prevalent atherosclerotic condition in primary 
care practices, but remains under-treated in primary care settings. In order to decrease 
the morbidity and mortality of PAD, risk modification strategies, including increased use 
of antiplatelet, lipid lowering and blood pressure therapies, should be encouraged in PAD 
patients. 
Therapies Prescribed PAD Alone CVD Alone P-“dWS 
(Fisher’s exact test) 
Antiplatelet agents 48% (“=825) 74% (n=1527) <O.OOl 
Lipid-lowering agents 50% (n=519) 73% (n=849) <a.001 
Anti-hypertensive agents 86% (n=675) 95% (n=1315) <O.OOl 
Anti-diabetic agents 83% (n=311) 82% (“=572) NS 
859-5 
Ii:30 a.m. 
Dyslipidemia Is a Risk Factor for Aortic Atherosclerosis: A 
Population-Based Transesophageal Echocardiographic 
Study 
Yoram Agmon, Bijoy K. Khandheria, Irene Meissner, Tanya M. Petterso”, W. M. O’Fallon, 
David 0. Wiebers, A. J. Tajik, James B. Seward. Mayo Clinic and Mayo Foundation, 
Rochester; MN 
Background: The role of dyslipidemia as a risk factor for atherosclerosis of the thoracic 
aorta (AA) has not been determined in the general population. Methods: 386 subjects, a 
sample of the Olmsted County (Minnesota) population (median age: 66 years, range: 51. 
101; 53% men) underwent transesophageal echocardiography as part of a population- 
based study (SPARC . Stroke Prevention: Assessment of Risk in a Community). The 
presence of AA and its severity (maximal plaque thickness, mobile debris) were deter- 
mined in the population and the association between atherosclerosis risk factors (includ- 
ing plasma lipid levels) and AA was examined by multivariate analysis. Results: AA was 
detected in 267 subjects (69% of the study population). Lipid-lowering drug treatment 
was independently associated with AA (odds ratio [OR] 3.09 195% confidence interval 
1.52-6.30; P=O.O02]), adjusting for age, sex, and additional significant risk faders for AA. 
Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apolipoprotein (ape) A- 
l, and apo B levels were not associated with AA (P>O.O5), suggesting that lipid-lowering 
therapy weakens the association between measured lipid levels and AA. Thick plaques 
(4 mm or greater in maximal thickness), vary thick plaques (6 mm or greater), and mobile 
atherosclerotic debris were present in 114 (30%), 41 (1 l%), and 20 subjects (5%), 
respectively. Among the subgroup of subjects with AA, apo A-l levels were independently 
associated with thick (4 mm or greater) plaques (negative association; OR 0.85 per 10 
mg/dL 10.74.0.99; P=O.O31), HDL-cholesterol was associated with very thick (6 mm or 
greater) plaques (negative association; OR 0.69 per 10 mg/dL [0.54-0.89; P=O.O04]), and 
total cholesterol was associated with mobile debris (OR 1.13 per 10 mg/dL [l.OO-1.28; 
P=O.O5]) (all ORs adjusted for additional risk factors for AA). Conclusions: Dyslipidemia 
is associated with anatomically defined atherosclerosis (echocardiographically delin- 
eated AA) in the general population. Specifically, lower levels of HDL-cholesterol and apo 
A-l (an HDL-associated apolipoprotein) are associated with thick atherosclerotic 
plaques. 
II:45 a.m. 
859-6 Noninvasive Arterial Thrombolysis With Shock Waves 
Giovanni Belcaro, Marco Bucci, Maria Rosaria Cesarone, Lucrezia Incandela, 
Mariateresa De Sanctis, Maura Griffin, Surinder Dhanjil, Michael Sabetai, George 
Geroulakos, Ernst Marlinghaus, Andrew N. Nicolaides. Biomedical Sciences Department 
Chieti University, Chieti, k/y, St Mary’s Hospifal & Imperial College, London, United 
Kingdom 
Background: Shock waves have been mainly developed for the treatment of kidney 
stones. Vascular applications have recently been proposed and noninvasive venous 
shock waves thrombolysis has been recently achieved in selected cases using a modified 
lithotriptor (Minilith, Storz, Switzerland) coupled to a focusing ultrasound system (Kon- 
tron), which probe is inserted within ihe shock waves reflector. Methods: A group of 15 
patients (M: F = 10: 5) with acute thrombosis (echolucent thrombi) of the femoral artery 
and acute critical limb ischemia were included in a randomized study. 7 patients (M = 4; 
age 62 + 11) were treated with noninvasive venous shock waves thrombolysis and 8 
comparable patients (M = 6; age 62 r 8) were used as controls. Shock waves were used 
at the ‘“dosage” of 800 shots (conventionally defined 2-level = 0.04 mJ/mmP). The shock 
waves reflector was coupled to the skin with a silicon water cushion. No pain due to ihe 
shock waves was reported. All patients also received treatment with prostaglandins 
according to the short-term infusion protocol and were under oral anticoagulant (INR = 2 
- 3) for the follow-up period of 2 months. Results: Noninvasive venous shock waves 
thrombolysis was possible in all patients. No side effects were reported at 2 months. Two 
patients, one in each group, were treated with surgery for persisting pain and initial toe 
necrosis and therefore were considered as dropouts. In the shock waves treated patients 
(n = 6) the femoral artery had visible flow (color duplex) and thrombus breaks were visi- 
ble. In the control group (7 patients), thrombi appeared solid, without flow and the arterial 
segment was not perfused. After 2 months, limb flow, measured by strain-gauge plethys- 
mography, in the treated group was on average 94% (range 12 - 286) higher than in con- 
trols and no limb underwent amputation (2 minor amputations in the control group). 
Conclusipns: Noninvasive shock waves thrombolysis has been achieved extracorpore- 
ally in acute arterial thrombosis. Its clinical value should be assessed in a larger study 
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1225159 Expression of Calcineurin Is Increased During the 
Development of Left Ventricular Hypertrophy and Is 
Independent Phosphorylation of Phospholamban 
Ramesh C. Gupta, Sudhish Mishra, Omar Nass, Hani N. Sabbah. Henry Ford Heaith 
system, Detroit, MI 
Background: Calcineurin (CLN), also known as type-2B protein phosphatase, is impli- 
cated in the development of cardiac hypertrophy, bucits role in the regulation of phospho- 
lamban (PLB) is not known. In this study, we tested the hypothesis that CLN expression 
is increased during the development of LV hypertrophy (LVH) and is independent of 
changes in PLB phosphorylation (PLBP). 
Methods: The expression of the a-subunit of CLN (CLNa) was measured because it 
contains enzyme activity. PLBP at serine-16 (PLBP) was examined in Lewis rats (n-18) 
in which LVH was produced by the one-kidney-one clip (1KlC) method and in age- 
matched sham-operated rats (n=18). Six rats from each group were sacrificed at 1, 4, 
and 8 weeks post-operatively and the hearts removed for analysis. LV weight to body 
weight (LVWiBW) ratio was used as an index for LVH. Expression of CLNa and PLBP 
were determined in SDS-extract of LV homogenate by Western blot. The bands were 
quantified in densitometric units and calculated as percent change (%) from sham val- 
ues. 
Results: The results are shown in the table. Rats with 1 Kl C developed LVH as early as 
1 week post-operatively and the extent of LVH increased progressively thereafter. In LVH 
rats, CLNa increased at week 1 and remained elevated at 4 and 8 weeks compared to 
sham. Expression of PLBP did not change at 1 week, increased at 4 weeks, and then 
declined at 8 weeks in LVH rats compared to sham. 
Conclusions: CLN is upregulated at early stages of LVH and is independent of changes 
in PLBP This finding suggests that inhibition of CLN may be a target for regression of 
LVH. 
LVWiBW (%) CLNa (%) PLBP (%) 
Week 1 17+2 253t18 10036 
Week 4 35 i 4* 314t-Ii* 404 * 54 
Week 8 86 i 7*A 183+21*” 70+8’, 
*=p<O.O5 vs. Week 1; “=p<O.O5 vs. Week 4 
1225-160 Electrocardiographic Criteria for the Identification of Left 
Ventricular Hypertrophy in Hypertensive Patients: The LIFE 
Study 
Peter M. Okin, Richard B. Devereux, Markku S. Nieminen,‘Sverker Jern, Lasse 
Oikarinen, Matti Viitasalo, Lauri Toivonen, Steve Julius, @or” Dahlof. Weill Medical 
College of CorneM University New tirk, NY 
Background: The LIFE trial used left ventricular hypertrophy (LVH) by Cornell voltage- 
duration product and/or Sokolow-Lyon voltage criteria on a screening ECG to identify 
patients at high risk of morbid events and of having echocardiographic (echo) LVH. How- 
ever, the relative accuracy of these and other EGG LVH criteria for the detection of echo 
LVH has not been examined. 
Methods: Test accuracy of ECG LVH criteria for echo LVH was compared in 835 
patients em&d in the echo substudy of LIFE. Echo LVH was determined using LV mass 
indexed io height’.’ >49.2 gin?.’ in me” and >46.7 g/m’,7 in women. EGG LVH was 
assessed using Cornell, Sokolow-Lyon, and 12.lead sum of voltage and voltage-duration 
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criteria, and by Romhilt-Estes (RE) point score. Sensitivities of ECG LVH crfteria ware ine. CoR and CoH had lower MFS/ESS Than NG and NC (88t.15 and 89+13% vs 
compared using partitions with matched specificity of 80% to a RE point score >5 and by 104?11 and 100*7%, pc.05). Data on coronary function, LV geometry and volumes, 
comparing areas under receiver-operating characteristic (ROC) curves. indexes of myocardial oxygen demand Are in Table (* = p c ,051 Versus NC). 
Results: Because of regression to the mean, not all patients who met screening criteria 
had persistent ECG LVH by these criteria at study baseline. There were 617 patients 
with echo LVH. At matched specificity of 60%, the 36% sensitivity of Cornell product cri- 
teria was significantly greater than sensitivity of Sokolow-Lyon voltage and product, 12. 
lead voltage, and RE point score criteria, was slightly higher than the 32% sensitivity of 
12.lead product criteria, and marginally lower than the 39% sensitivity of Cornell voltage. 
However, when overall test performance was compared, independent of partition value 
selection, using ROC curve analyses, overall accuracy of the Cornell product was signifi- 
cantly greater than all of the other criteria except for Cornell voltage. (*pcO.O5, *“pcO.Ol, 
“‘*p<O.OOl vs Cornell product). 
Criteria Cornell Sokolow- 1 P-lead Cornell sokolow- IBlead Romhllt- 
Product Lyon Prod- Product VOltage Lyon Volt- Voltage Estes 
NC NG CoR CoH 
RWT 0.39+.04 0.39*.03 0.54*.09* 0.52*.04 
CFR 3.3&E 2.74t.3 2.4825 2.44*.4’ 
MCR 0.84t.2 1.25+.3’ 1.29*.3* 1.22*.3* 
Basal CFV 28+6 Z&9 33r10 3&l 0 
EDV 125+21 120r17 77*17* 124r28 
sv 85+18 86*13 62tl5’ 94+25 
HR 83~21 87218 98+10” 85~19 
PSS 13OQl 165i24* 119r36 1 Z&23 
In the overall population, basal CFV was directly related to HR (pc.05). Conclusions: in 
all HBP patients, increased MCR indicates impaired coronary vasodilator capacity due to 
microcirculatory factors. In CoR, myocardial function at midwall level and CFR are simi- 
larly reduced as in CoH. The higher impairment of CFR in CoR as compared to NG 
seems to depend on a higher basal CFV related to increased resting HR, apparently 
compensating for a lower SV in presence of a small LV cavity. 
Sensitivity (%) 36 29” 32 39. 21*** 31. 25”’ 
ROC Area 0.639 0.520”* 0.558” 0 636 0.489” 0.524” 0.538” 
Conclusions: Despite the potential for selection bias to reduce accuracy of Cornell 
product criteria, the Cornell product had the highest overall accuracy in this highly 
selected population. 
1225-192 Systolic Blood Pressure at Submaximal Exercise Predicts 
Left Ventricular Hypertrophy in Normotensive & 
Hypertensive Women 
Peter Kokkinos, Andreas Pittaras, John Colleran, Pun& Narayan, Emmanuel 
Coutoulakis, Wassim Choucair, Daniel Fernicola, Vasilios Papademetriou. Veterans 
Affairs Medical Center, Washington, DC, Georgetown University Medical Center, 
Washington, DC 
Background: Left ventricular hypertrophy (LVH) is an independent predictor of cardio- 
vascular events. An abnormal rise in peak exercise blood pressure (BP) is associated 
with increased risk for hypertension (HTN) and LVH. Systolic BP (SBP) at sub-maximal 
exercise levels may better reflect the daily hemodynamic load and therefore be a better 
predictor of HTN and LVH. Sub-maximal exercise BP may also have a wider clinical appli- 
cation than maximal exercise BP 
Methods: We assessed left ventricular structure (echo) and exercise BP(Bruce) in 
hypertensive (N=235; age=58ctlO yrs) and normotensive (N=459; age=49?13 yrs) 
women, free from heart disease, smoking, and antihypertensive medication, to determine 
associations between left ventricular structure and exercise BP. 
Results: Multiple regression analysis (stepwise) revealed that SBP at 6 minutes of exer- 
cise was the strongest predictor of left ventricular mass index (LVMI) for normotensive 
(F&0.21) and hypertensive women (R’=0.26). Since LVH was defined as LVMI>lOS gl 
m2, we regressed the change in SBP from rest to 6 minutes of exercise against LVMI for 
each group. The model revealed that a SBP of rl66 mm Hg for the normotensive and 
>160 mm Hg for hypertensive women were the minimum SBP levels to yield LVMI values 
of 110 g/m’. LVH was present in 68% of the normotensive (Odds Ratio&B; (X3.7.9.4; 
p<O.OOO) and in 72% of the hypertensive women (Odds Ratio=6.6; Cl:2.7-15.9; p=O.OOO) 
who achieved the respective exercise SBP level. Normotensive women who reached 
exercise SBP>l66 mm Hg had higher LVMI (12059 vs 97&21; p=O.OO) and exercise 
SBP (180+13 mm Hg vs 145kl4 mm Hg; p<O.OOO) than those who did not exceed that 
level. Similarly, hypertensive women who reached exercise SBP>160 mm Hg had higher 
LVMI (133t31 vs 108*23: p=O.OOO) and exercise SBP (193i16 vs 156-fE mm Hg; 
p=O.OOO) than those who did not exceed that level. 
Conclusions: 1) SBP at 6 minutes of exercise is the strongest predictor of LVH for nor- 
motensive and hypertensive women; 2)A SBP>lGO mm Hg for hypertensive and >I66 
mmHg for normotensive women at the exercise level of 27 METS may reveal a high prev- 
alence for LVH in middle-aged women. 
1225193 Relative Tachycardia Compensating for a Small Stroke 
Volume Contributes to the Coronary Reserve Reduction in 
Hypertensive Patients With Left Ventricular Concentric 
Remodeling 
Michaela Kozakova, Carlo Palombo, Carmela Morizzo, Giovanni Bigalli, Simona Buralli, 
Armendo Magagna, Antonio Salvetti. CNR Institute of Clinical Physiology, Piss, /ta/l: 
Department of Internal Medicine, University of Piss, Piss, /La/y 
Background: Coronary flow reserve (CFR) Is impaired in hypertensive patients (HBP) 
even without LV hypertrophy (LVH). LV concentric remodeling (CoR), i.e. an increase in 
LV relative wall thickness (RWT) With normal LV mass index, Is reported to Be associ- 
ated With a decrease in LV systolic function at midwall level (MFS) and an increase in 
cardiovascular risk; however, no data Are available on CFR in this subgroup. Aim of the 
study was to assess CFR and LV systolic function in HBP With CoR, and to compare 
them With data obtained in normotensive controls (NC) and in HBP With either normal LV 
geometry (NG) or concentric LVH (CoH). Methods: in fifty-eight subjects (12 NC, 11 NG, 
16 CoR and 19 CoH) without GAD, coronary flow velocity (Cn/, cm/s) in LAD artery was 
monitored by TEE-Doppler at baseline and during maximal flow response to Adenosine 
(700 pgIKgi5 min); coronary flow reserve (CFR) and minimum coronary resistance 
(MCR, mmHg”s*cm-1) ware calculated. RWT, LV volumes and stroke volume (SV, ml), 
peak and end-systolic wall stress (PSS, ESS, kPa/lOO) and MFS corrected for ESS 
(MFSESS; %) were assessed by M-mode echo. Results: HBP and NC had similar age, 
and the various HBP groups were comparable for BP and maximal CFV during adenos- 
1225-194 Myocardial PKC Epsilon, But Not PKC Beta, Activation Is 
Mechano-Sensitive and Plays a Compensatory Role in 
Ventricular Hypertrophy in Hypertensive Rats 
Koichi Inagaki, Yasuki Kihara, Wataru Hayashida, Yoshitaka Iwanaga, Asuka Yasaka, 
Shigetake Sasayama. Kyoto University Graduate School of Medicine, Kyoto, Japan 
Background: Protein kinase C (PKC) family has been implicated as a candidate of the 
second messengers in the mechano-regulation of cardiac hypertrophy. Mechanical 
stretch activates PKC in adult hearts and neonatal cardiomyocytes. However, its isoform 
specificity and activation in diseased myocardium are not yet to be revealed. We exam- 
ined isoform-specific activations of cardiac PKC by mechanical stretch in the hypertro- 
phied lefl ventricle (LV) and in failing LV obtained from Dahl salt-sensitive (DS) rats. 
Methods: In DS rats, an 8% salt diet induced systemic hypertension (237+/-18mmHg) 
and compensated concentric LV hypertrophy (LVH, n = 11) at the age of 11 weeks, which 
is, in turn, followed by LV dilatation and global hypokinesis (CHF, n = 17) at the age of 16 
to 18 weeks. As the references, DS rats fed with a 0.3% salt diet ware used, in which 
blood pressure, LVibody weight, and cardiac function were kept normal (CTL in 11 and 
18 weeks, n = 9 and 14). The hearts were isolated in the Langendorff set up, and a LV 
balloon was inflated for 15 to 30 min. to achieve an equivalent diastolic wall stress of 30 
kdyne/cmZ. Results: Western blotting showed that, among PKC alpha, betal, b&2, 
gamma, delta, epsilon, and zeta, only PKC epsilon increased by 70% in LV myocardium 
from LVH. However, in CHF this increase in PKC epsilon returned to the control level. 
whereas protein levels of PKC beta1 and beta2 increased by 37 and 22 % (p < 0.05 vs. 
CTL). By this stretch, PKCe was activated (membrane translocated) by 97% in LVH (p < 
0.05 vs. pm-stretch), which was significantly higher than that in CTL (by 23%. p = n.s. vs. 
pre-stretch, p < 0.05 vs. LVH). In contrast, this stretch-induced activation of PKCe was 
rather attenuated in CHF myocardium (by -8%, p = n.s. vs. pm-stretch). Interestingly, 
PKC beta activity was not affected by this stretch intervention either in CTL, LVH, or CHF. 
Conclusion: Thus, 1) stretch-induced myocardial PKC activation was isoform-specific; 2) 
the stretch-induced PKC epsilon activation was augmented in the hypertrophic LV myo- 
cardium, but rather reduced in the failing myocardium; 3) augmented stretch-sensitive 
PKC epsilon activity may play compensatory role in ventricular hypertrophy. 
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1226-162 Dietary Treatment of Highly Concentrated Omega-3 Fatty 
Acids Increases Tumor Necrosis Factor Alpha and Reduces 
Antioxidant Levels in Stable Heart Transplant Recipients 
Torbjorn Helm, Rolf K. Bergs Arne K. Andreassen, Thor Ueland, John Kjekshus, Svein 
Simonsen, Lars Gull&ad, Paal Aukrust. Rikshospitalet, University of OS/O, Norway 
Background: Persistent elevation of inflammatory cytokines has been suggested to play 
a pathogenic role in the development of coronary vasculopathy in heart transplant recipi- 
ents (HTx ret). Previous studies have shown immunomodulating effects of omega-3 fatty 
acids, but there has been few placebo-controlled clinical trials. We therefor investigated 
plasma levels of tumor necrosis factor-alpha (TNF), interleukin (IL-) 10 and the antioxi- 
dams, vitamin E and beta-carotene in HTx ret before and after dietary treatment of highly 
concentrated omega-3 fatty acids. Methods: Forty-five clinically stable HTx ret (age 
5&l, mean +/- SEM) were studied 6 (range l-12) years after transplantation and were 
randomized in a double blind fashion, to receive daily 3.4 g of highly concentrated 
omega-3 fatty acids or placebo for one year. Plasma levels of cytokines were measured 
by enzyme immunoassays before randomisation and at the end of the study. Results: 
With similar levels of TNF, IL-10 and TNF / IL-10 ratio at baseline, the omega-3 group 
demonstrated a significant rise in the inflammatory cytokine TNF (p=O.O2), an insignifi- 
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cant decrease in the anti-inflammatory cytokine IL-10 (p=O.O7) and a rise in TNF/IL-10 
ratio (~~0.05) after 12 months suggesting a inflammatory net effect. In contrast, no 
changes were observed in the placebo group, resulting in differences between groups 
analyzing changes in TNF (p=O.O4) and TNF/IL-10 ratio (p=O.OQ. The increase in TNF 
was to some extent dependent on an increase in serum eicosapentaenoic (EPA, r=O.58, 
pcO.02). In the omega-3 group, the increase in TNF levels was accompanied by a signifi- 
cant decrease in plasma levels vitamin E and beta-carotene, and the decrease in vitamin 
E levels was significantly correlated with the increase in TNF (r=-0.57, p<O.Ol). No 
change in antioxidant levels were seen in the placebo group. Conclusion: Dietary sup- 
plementation with highly concentrated omega-3 fatty acids may change the balance 
between inflammatory and anti-inflammatory cytokines in an inflammatory direction in 
long time survivors of heart transplantation, possibly related to pro-oxidative effects of 
these fatty acids. 
1226-163 Can the Australian Food System Cope With a Mediterranean 
Diet? 
Shawn Somerset, David Colquhoun, Pam Horsley. for the Olive Group, Griffith University. 
Gold Coast, Australia, CORE Research Group, We&y Medical Centre, Brisbane, 
Australia 
Background: Mediterranean diet (MD) describes traditional dietary patterns bordering 
the Mediterranean Sea. Pasta, coarse breads, beans, nuts, seeds, olive oil, wine, and 
seasonal fruits and vegetables predominate. MD is sustained by cultural factors and is 
ecologically sustainable. The MD may be an appropriate strategy to combat coronary 
heart disease (CHD) in non-Mediterranean countries like Australia. 
Methods: : Australian agricultural production data were used to assess current amounts 
and types of food produced in Australia. For data which are not mutinely collected by 
government authorities (eg. current olive oil production, projected olive tree plantings, 
etc.), information from relevant industry groups was obtained. The prescriptive MD 
requirements were based on those described for the Cretan diet in the Seven Countries 
study. Projected annual food requirements for individuals were calculated on the basis of 
a diet containing 7509 kJ per day (mean intake of OLIVE subjects following MD, n=Z). 
Results: There are major changes in agriculture with 4000 hectares of new olive trees 
throughout Australia and projected production being 10,000 tonnes (t). 
Requirements (t per annum) of a Cretan type MD diet in Australia 
Primary prevention Secondary Prevention Current Production 
(13.6 mil pop) (500,000 pop) 
Fats,Oils 175,ooot 6,400t 842t Olive Oil 
Meat Seafood 300,000t 11,ooot 127,OOOt fish 
1,700,OOOt beef 
Fruit 2,000,000 73,000t 442,OOOt orange 
280,OOOt apple 
220,OOOt banana 
Conclusion: Current local food production is not adequate for widespread adoption of 
Cretan type MD for primary or secondary prevention of CHD. Within a decade MD may 
be feasible for secondary prevention. But climate and geography may limit adequate pro- 
duction of these foods for adoption of the Cretan type MD for the entire population. Other 
Western Nations such as the USA may encounter similar problems with widespread 
adoption of a Cretan type MD diet. 
1226-164 Results of a Randomized Trial Comparing a High Fat Low 
Carbohydrate Diet to the NCEP Step 2 Diet: Effect on LDL 
Cholesterol Subclasses 
Y. Wady Aude, Gervasio A. Lamas, Francisco Lopez-Jimenez, Marie Almon, Melinda 
Hansen, Eric H. Lieberman, Gerard0 Rojas, Robert Superko, Arthur Agatston. Mount 
Sinai Medical Center, Miami Beach, FL 
Introduction. High fat, low carbohydrate diets have become popular with the lay public. 
We have previously reported that a high fat diet does not increase total or LDL choles- 
terol, and significantly reduces triglycerides, while encouraging weight loss. However, the 
effect of a high fat diet on atherogenic LDL subclasses has not been reported. Methods. 
The study population consisted of 45 adults with a body-mass index (BMI) >/= 27 who 
were randomly assigned to either a high fat low carbohydrate diet (study diet, n=24), or to 
the AHA Step 2 diet (n=21) for 3 months. We present the results of LDL 53 gradient gel 
electrophoresis standardized against analytic ultracentrifugation. We report changes in 
peak particle diameter of major LDL peak, and the proportion of small, dense LDL sub- 
classes (sum of lllA,lllB,lVA,lVB). Results. Patients were 45+/-10 years old. At baseline, 
LDL peak particle diameter was correlated with triglyceride (TG) (R= -0.65: pcO.OOl), 
and HDL (R= 0.51; pcO.OOl), but not total cholesterol or LDL cholesterol. The table 
shows changes between baseline and 3 months (follow up - baseline). 
Changes between baseline and three months 
TG (mg%) LDL (mg%) Peak diameter (Ang- Small LDL (?A) 
stroms) 
Study diet -EC/-1 09 p=O.O09 -4+ml p=o.4!3 4.s+,-6.3 p=o.o01 -a,+,-12.4 p=o.o24 
NCEP diet -2O+/-48 p=O.ls -e+,-1s p=o.o12 1.2+,-4.3 po.20 -,A+/-6.1 p=o.29 
At 3 months, the increase in LDL particle size was correlated with the magnitude of TG 
reduction (R=-.47; p=O.OOl). Conclusions. A high fat low carbohydrate diet leads to a 
significant increase in LDL peak particle size and a reduction in the percentage of small 
dense LDL subclasses compared to the AHA Step 2 diet. 
1226-165 Dose-Dependent Effects of Folic Acid on Plasma 
Homocysteine Levels Among 723 Individuals With Coronary 
Heart Disease: the PACIFIC Study 
Bruce Neal, Stephen MacMahon, Andrew Tonkin, Nicholas Dudman, David Hunt, Mark 
Richards, John Simes, David Wilcken, Alan Bmabic, Judy Murphy, Yvonne Cleverley, on 
behalf of the PACIFIC Study Collaborative Group. Institute for lnterna~ional Health, 
Sydney Australia 
Observational studies have demonstrated associations between plasma homocysteine 
levels and the risk of major coronary events. In addition, randomised trials have shown 
that several-fold increases in usual daily folic acid intake (0.5-5.0mg daily) reduce 
homocysteine levels. However, the effects of smaller increments in folk acid intake that 
might be achieved through fortification of foods are unknown. The PACIFIC study was a 3 
x 3 factorial, double-blind, placebo-controlled, randomised trial conducted among 723 
individuals with a history of myocardial infarction or unstable angina. The primary aims 
were to determine the effects of two doses of folic acid (2.0mg and 0.2mg folic acid) on 
plasma homocysteine levels and the effscts of two doses of omapatrilat on blood prss- 
sure and neurohormone levels. Randomised treatment was scheduled to continue for six 
months and fasting blood samples were collected at baseline and at after 6 months of fol- 
low-up. Homocysteine was measured using a fluorescence polarisation immunoassay. 
The mean age of the participants was 68 years and 82% were male. At entry, mean 
serum folic acid was POnmollL, red blood cell folata was 754nmoVL and plasma 
homocysteine was 11 mmollL. During the 6-month follow-up, adherence to both folic acid 
and placebo was 94%. Compared to placebo, 2.0mg folic acid reduced homocysteine by 
1.7mmollL (95%CI 1.3-2.2) and 0.2mg reduced homocysteine by l.Pmmol/L (0.8-1.7). 
The effect of the higher dose was greater than that of the lower dose (p=O.O06). The 
effects of both doses were significantly greater among those with higher homocysteine 
levels or lower red blood cell folate levels at entry. In conclusion, both doses of folic acid 
reduced homocysteine, but the effects of the 2.0mg dose were about one third greater 
than the 0.2mg dose. This study is the first to provide evidence of dose-dependent effects 
of folic acid on homocysteine. 
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1227-166 Beneficial Effects of Carvedilol on Angiotensin-Converting 
Enzyme and Renln Activities Escapes in Patients With 
Chronic Heart Failure 
Alain Cohen-Solal, Guillaume Jondeau, Philippe Due, Serge Witchitz, Alain Berdeaux, on 
behalf of the SYMPOXYDEX Study Group. Bicetre Hospital, Kremlin Bicetre, France, 
Beaujon Hospital, Clichy. France 
Background: Carvedilol improves survival and cardiac function in chronic heart failure 
(CHF) patients, presumably mainly by blunting the cardiac effects of catecholamines. 
However, its effects on the hormones are less well characterized. 
Methods: 50 CHF patients (LVEF < 40%) in NYHA class II (78%) and Ill (22%) were 
included in a 6 months randomized, double-blind, placebo-controlled (n=22 placebo, 
n=28 carvedilol, intention to treat analysis), multicenter study (SYMPOXYDEX trial). All 
patients were on loop diuretics and 48 on ACE-inhibitors: target dose (25 mg bid) of 
study drua was attained in 65% of the patients. Neurohormones were measured at base- 
line grid i the end of the study (table,mean *SD). 
Carvedilol Carvedilol Placebo Placebo p 
(baseline) (6 months) (baseline) (6 months) 
ACE 9.6&l 0.0 6.5i5.3 7.8k7.5 8.5+1.5 co.01 
Renin (pglml) 145*246 50+62 96*170 154+384 0.02 
Aldosterone (pg/ml) 218+132 200*152 200*112 192c113 NS 
Endothelin (pgiml) 4.3i2.6 4.2e2.7 4.3~2.3 4.3e1.9 NS 
ANP @g/ml) 349+283 293*343 270+222 260+171 NS 
Norepinephrine (pg/ml) 411+181 449+261 541r284 501+373 NS 
Epinephrine (pg/ml) 60+34 68i66 58+23 51~25 NS 
Results : ACE activity increased In the placebo group, suggesting partial ACE inhibition 
escape. Carvedilol had a profound anti-renin effect, associated with a decrease in ACE 
activity, suggesting counteraction of this escape. Plasma aldosterone was unchanged, 
suggesting that aldosterone escape remains unaltered by betablockade. Despite signifi- 
cant increases in LVEF and NYHA class, the other neurohormones were unaffected by 
carvedilol. 
Conclusions : The marked beneficial effect of carvedilol in HF may be partly related to 
more complete and sustained chronic blockade of the renin angiotensin system. 
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1227-167 Baseline and Three Month Change in Systemic Venous 
Norepinephrine as Predictors of Clinical Outcomes in the 
BEST Trial 
Michael R. Bristow, R Zeiis, R Nuzzo, J Lindenfeld, Brian D. Lowes, M J. Domanski, Eric 
J. Eichhorn, Heidi J. Krause-Steinrauf, the BEST Trial Investigators N/a. VA Cooperative 
Clinicai Trials Cente,: Palo A/fo, CA, NHLBI, Bethesda, MD 
The BEST (Beta-blocker Evaluation of Survival Trial) trial compared the third generation, 
nonselective Beta-blocker bucindolol to placebo for the primary endpoint of all-cause 
mortality. In BEST 2118 of the 2708 randomized subjects also had baseline systemic 
norepinephrine (NE) measurements performed by HPLC, and 1674 of these subjects 
had follow-up measurements after three months of treatment. Compared to placebo, 
bucindolol lowered NE by 19 % (p< ,001) at 3 months. In agreement with previous stud- 
ies, baseline NE was a strong predictor of mortality, with the low and high tertile groups 
having hazard ratios (HRs) plus 95 % confidence intervals (Cls) compared to the inter- 
mediate group of 0.56 (0.48, 0.66) and 2.66 (1.70, 4.15) respectively. For change in NE, 
which in a large heart failure clinical trial has not been previously evaluated as a predictor 
of outcome, a surprising nonlinear effect was observed. Compared to the intermediate or 
“no change” group (NE change of -758 to + 358 pgiml) both the decrease (change of > 
758 pglml) and the increase (change > + 358 pgiml) NE groups had a higher mortality 
(respective HRs (Cls) of 2.58 (1.56, 4.25) and 2.03 (1.48, 2.77). These data indicate that 
in subjects with NYHA Class Ill or IV heart failure with LVEF less than or equal to 0.35 
treated with placebo or bucindolol, marked decreases or increases in NE predict 
increased mortality. The NE lowering effect of bucindolol therefore may have negatively 
impacted clinical outcomes in BEST. 
1227-168 Beta-Aclrenergic Blockers Attenuate Exercise-Induced 
Aclrenergic Activation and Cold-Induced Impairment in 
Exercise Performance in Patients With Congestive Heart 
Failure 
Michel White, Martine Blanch@, Anique Ducharme, Normand Racine, Johanne Marquis, 
Henock St-Jacques, Jean-Claude Tardif, Lizanne Bussieres, Jean-Lucien Rouleau, 
Martin Juneau. Montreal Heart Institute, Montreal, PQ, Canada 
Background: Patients with congestive heart failure (CHF) exhibit a significant decrease 
in maximal exercise duration when exposed to a cold environment (-8°C). The purpose of 
this investigation was to study the effect of beta-blockers (BB), on submaximal exercise 
performance, and adrenergic activation at 20°C and -8°C in patients with CHF. Twenty- 
four patients with CHF, NYHA 11-111 (2.1*0.06; mean ? SEM), aged of 60.8kl.9 years, and 
with left ventricular ejection fraction of 25.2~1% were treated with carvedilol (n=l2; 35+7 
mglday), or metoprolol (n=l2; 75rll mg/day) for 6 months. Exercise performance was 
assessed using a RAMP protocol with respiratory gas exchange analysis, and submaxi- 
mal exercise duration was evaluated by an endurance protocol slightly above anaerobic 
threshold at 20°C and -8°C. Catecholamines were measured in resting state, at 4 min- 
utes within the constant load exercise protocol, and at the time of exhaustion before and 
after treatment. Data were compared with 12 aged-matched healthy subjects (NF). The 
duration of exercise for the endurance protocols and the norepinephrine levels are pre- 
sented: 
Exercise riuration (set) Norepinephrine (pglml) 
Baseline 4 ml” rnax 
20°C -8°C 20°C -8°C 20°C -8°C 2OT -8°C 
CHF press 11331% 907*79” 636154 70,*49 1202*127 2105r329’f 22911297 328ck408 
postsI I‘m*135 13131130 648189 723r73 890173P 1962***01’ 1483i2519 3o60i350f’ 
NF 13101132 1rmr139” war33 407r47 Ion+165 1319r215 2282i543 *4w*5‘En 
Mean f SEM; *‘pcO.O5 “s 20°C; ‘p=O.O6 vs 20°C; §p<O.O5 vs preBB: p<O.O5 vs CHF 
preBB. Conclusion: Moderate cold exposure impairs submaximal exercise performance 
and increases adrenergic activation in patients with CHF but not in NF. Chronic BB ther- 
apy improves submaximal exercise duration both at 20°C and -8°C. This beneficial effect 
is associated with a decrease in exercise-induced systemic adrenergic activation at 20°C 
but not at -8°C. 
1227-169 Carvedilol Increases Plasma Vascular Endothelial Growth 
Factor (VEGF) in Patients With Chronic Heart Failure 
Rudolf A. De Boer, Hans-Marc J. Siebelink, Rem? A. Tio, Dirk J. Van Veldhuisen. 
University Hospital, Thoraxcenter. Department of Cardiology, Groningen, The 
Netherlands 
Background: In coronary artery disease (CAD) and subsequent chronic heart failure 
(CHF), vascular dysfunction causes impaired myocardial function. Enhancement of 
angiogenesis, e.g. by induction of vascular endothelial growth factor (VEGF), may restore 
the diminished blood supply in the hypoxic myocardium. Recently, experimental data 
showed that by lowering heart rate (HR), angiogenesis is induced by VEGF-upregulation. 
Genetic induction of VEGF is accompanied by an increase in plasma VEGF (pVEGF). 
Therefore, we determined the effect of the beta-blocker carvedilol on pVEGF in patients 
with CHF due to CAD. Methods: We randomized 16 patients with CHF (LVEF<40%) to 
either carvedilol (dose: 6 112 to 50 mg bid), or to placebo, in a 2: 1 ratio. Blood samples 
were obtained at baseline and after 3 months on treatment, and pVEGF was determined 
with ELISA. Results: In patients on carvedilol pVEGF increased (mean+sem, pg/mL): 
22.5e4.3 to 34.5r4.2, p=O.O6. In the placebo-group, a decrease in pVEGF was observed 
in patients from 298~6.3 to 20.7k7.8 (p=NS). The difference between the carvedilol and 
placebo groups was statistically significant (p=O.O2).The levels of pVEGF were compara- 
ble to previous studies in patients with CAD. Conclusions: The use of carvedilol in CHF 
patients increases pVEGF. This finding confers an appealing concept to explain the ben- 
eficial effect of beta-blockers in CAD and CHF A lower HR may cause increased VEGF 
production by stretch of myocytes and capillaries. However, other than lowering HR 
alone, ancillary drug-factors of carwdilol, like alpha-blockade or an anti-oxidative effect, 
may also modulate VEGF production. 
1227-170 Comparison of Carvedilol and Metoprolol on Baroreceptor 
Gain in Heart Failwe 
John E. Sanderson, L&a Y. C. Yeung, Skiva K. W. Ghan, Wing Y. Ma, Richard Kay, 
Luciano Bernardi. The Chinese University of Hong Kong, Hong Kong, Hong Kong 
Background: Autonomic imbalance and depression of baroreceptor function relate to 
prognosis and risk of sudden death in chronic heart failure. Carvedilol is a non-selective 
lipophilic beta-blocker with alpha receptor antagonism which has been introduced for the 
treatment of chronic heart failure. It is not known what the effects of carvedilol therapy is 
on baroreceptor function in heart failure, and whether it is superior to metoprolol, a selec- 
tive beta-blocker. 
Methods: Baroreceptor gain was measured noninvasively by spectral analysis of RR 
and systolic blood pressure intervals (256-512) and respiratory signal recorded at rest, 
supine and standing with spontaneous and controlled respiration using the cross-spectral 
method when coherence was >0.5 (alpha-angle). Patients received either carvedilol 25 
mg BD (n=lO) or metoproloi 50 mg BD (n=14) for 12 weeks after a 4 week dose titration 
period. 
Results: Baroreceptor gain was significantly depressed in patients compared to a con- 
trol group (6.65 f 1.85; normal 11.73 + 1.32 msec/mmHg; p<O.OOOl). After treatment 
with metoprolol baroreceptor gain improved from 6.13 i 0.96 to 10.13 r 1.18 msecl 
mmHg (p=O.O29) and the effect was apparent after 4 weeks treatment. In contrast 
baroreceptor gain after treatment with carvedilol (7.18 f 2.21 to 9.34 f 2.16 mseci 
mmHg) was not significant. Heart rate reductions were similar in both groups. 
Conclusion: Thus metoprolol has a superior effect on restoring baroreceptor gain 
towards normal which may be due to a direct central effect of metoprolol which is greater 
than that of carvedilol despite both drugs being lipophilic. 
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1228-172 Endothelial Dysfunction and ADMA in PAD Patients 
Roberta K. Oka, Andrzei Szuba, Markus Steuhlinger, Om Kapoor, John Giacomini, John 
P Cooke. Stanford Universit)! Stanford, CA, University of California, Los Angeles, Los 
Angeles, CA 
Background: Peripheral arterial disease (PAD) is associated with a severe vasomotor 
dysfunction of the involved arteries. A systemic abnormality of endothelium dependent 
vasodilation has been observed in patients with coronary artery disease. This study was 
performed to determine if there is a systemic abnormality of endothelial function in 
patients with peripheral arterial disease, and to study the mechanisms of this disorder. 
Methods and Results: Flow-mediated vasodilation (FMVD) of the brachial artery was 
measured by duplex ultrasonography (Acuson 5500 with 7.5 MHz transducer) at rest, 
post-hyperemia and post-nitroglycerin administrationin 18 PAD patients (Fontaine Class 
II-Ill), ages 50.80 years (mean=73 years) and 8 historical controls. The endogenous 
inhibitor of nitric oxide synthase, asymmetric dimethylarginine (ADMA) was measured 
using high-performance liquid chromatography (HPLC). In the PAD patients, endothe- 
lium-independent vasodilation was slightly impaired (mean change=13.4%). By contrast, 
there was a substantial impairment of endothelium-dependent vasodilation in PAD 
patients (mean change=5.54%) compared to controls (mean change=l0.8%). The endot- 
helial dysfunction was associated with a significant increase in plasma levels of ADMA 
(2.05+0.5 v. 1.03+0.1). Conclusions: There is a substantial endothelial vasodilator dys- 
function in patients with PAD, that is associated with elevated levels of the endogenous 
inhibitor of the NO synthase pathway. This abnormality may contribute to the functional 
impairment in PAD, and to the progression of disease. 
1228173 Hyperhomocysteinaemia in Young Adults Is Not Associated 
With Impaired Endothelial Function 
Colm G. Hanratty, Ian S. Young, Dennis G. Johnston. Dept of Therapeutics, The Queens 
Universify of Belfast, Belfasf, United Kingdom, Dept. of Clinical Biochemistry, The 
Queens University Belfasf, Belfast, United Kingdom 
Background: Elevation of total homocysteine concentration (tHcy) is an established risk 
factor for vascular disease. In older individuals elevated tHcy is associated with endothe- 
lial dysfunction before overt evidence of vascular disease. As endothelial dysfunction is 
an early and potentially reversible marker of the atherosclerotic process we investigated 
whether mild hyperhomocysteinaemia was associated with endothelial dysfunction in 
healthy young males. Methods: We assessed endothelial function, by measuring fore- 
arm blood flow (FBF), in 17 males with mild hyperhomocysteinaemia (defined as tHcy > 
10 mmolil) and 14 controls with low tHcy (defined as < 5 mmolil). FBF was measured in 
response to intraarterial infusion of acetylcholine (endotheliai-dependent) and sodium 
nitroprusside (endothelial-independent). Responses to the vasoactive substances were 
expressed as the area under the curve of change in FBF from baseline. Data are mean 
plus 95% Cl. Results: The two groups were matched for age, body mass index, pulse 
and blood pressure. The tHcy was significantly different between the groups (12.3 110.4 
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14.21 vs. 4.9 [4.6 - 5.11, p=O.OOl). Vitamin 812 and f&ate were significantly higher in the 
control group. Basal FBF was similar in both groups. The endothelial-dependent (37.5 
[26.2 _ 38.81 vs. 35.3 [26.1 - 44.41 and -independent (26.1 [22.2 - 29.91 vs. 25.9 [21.0 - 
30.81) responses were not significantly different between groups. Conclusions: This 
study demonstrates that in healthy adults mild elevation of tHcy was not associated with 
impaired endothelial-dependent vasodilation. These data are significant as they suggests 
there may-be an age-related effect with regard to homocysteine and endothelial dysfunc- 
tion. The development of vascular disease with an elevated tHcy may require higher con- 
centrations, more prolonged exposure or the presence of concomitant risk factors. 
1228-174 Effect of Hyperuricoemia Upon Endothelial Function in 
Patients at Increased Cardiovscular Risk 
Giuseppe M. C. Rosano, Elena Cerquetani, Filippo Leonardo, Massimo Fini, Daniela 
Onorati. San Raffaele - Roma - JOSINVESJSANI7A: Roma, My 
Background: Hyperuricoemia is a frequent finding in elderly patients at cardiovascular 
risk and may be worsened by several cardioactive drugs. The vascular effect of increased 
plasma levels of uric acid are not known. Methods: Aim of the present study was to 
assess the effect of hyperuricoemia in 32 patients (25 men, 7 women, mean age 69+/-3 
yrs) with plasma uric acid levels > 7 mgldl and in age and sex matched controls with 
plasma uric acid levels 7~ mgfdl. In pts and controls endothelial function was evaluated 
by means of flow mediated dilatation (FMD) of brachial artery following ischemia. After 
baseline evaluation patients undenvent 3 month therapy with allopurinol with dose tri- 
trated to achieve plasma levels of uric acid 7c mgldl and were tested for endothelial func- 
tion again. Results: Compared to healthy controls pts with hyperuricoemia had 
significantly impaired endothelial function (FMD 4~1-3~~ YS 6+/-2%, pcO.01). Reduction in 
plasma uric acid levels resulted in a significant improvement in endothelial function (4+/- 
3% vs 7+/-2%, p<O.Ol. In pts endothelial function was inversely related to plasma levels 
of uric acid (rzO.61, ~~0.05) while its improvement pts was positively correlated with the 
degree of plasma uric acid reduction (r= 0.57, p<O.Ol). In controls allopurinol administra- 
tion was not associated with changes in endothelial function. Conclusion: Increased 
plasma levels of uric acid are associated with impaired endothelial function which is 
improved after specific treatment for its reduction. These findings suggest a role for uric 
acid in endothelial dysfunction. 
1228-175 Postprandial Elevation of Remnant Lipoprotein Levels 
Impairs Endothelial Function in Normolipidemic Healthy 
Volunteers 
Toru Kate, AkiraTanaka, Yoshiaki Maruyama, Tetsuo Kamiyama, Otsu Watanabe, Shugo 
Tanaka, Nobuo Yoshimoto. Saitama Medical Center, S&&ma Medical School, Kawagoe, 
Japan, Tokyo Medical and Dental Univers& Tokyo, Japan 
Background: Remnant lipoproteins (RLPs) have been suggested to be atherogenic. It 
remains undetermined whether postprandial plasma levels of RLPs have an association 
with impairment of endothelial function, one of the atherogenic factors. Methods and 
Results: The study subjects were 10 normolipidemic (fasting plasma levels of total cho- 
lesterol < 220 mg/dl and triglycerides < 150 mgfdl) volunteers. None of the subjects had a 
history of hypertension, diabetes mellitus, or smokers. We examined, before and 4 hours 
after an oral fat loading (490 k&/m2 body surface area), (1) plasma levels of total cho- 
lesterol triglycerides, highdensity lipoprotein cholesterol, low-density lipoprotein choles- 
terol, and RLPs; (2) flow-mediated vasoactivity in the brachial artery as percent diameter 
change 1 min after upper arm arterial occlusion for 5 min measured with 7.5-MHz ultra- 
sound. Plasma levels of total cholesterol, triglycerides, high-density lipoprotein choles- 
terol, low-density lipoprotein cholesterol were similar before and 4 hours after the fat 
load. Postprandial plasma levels of RLPs were elevated from 1.63 +/- 0.35 mg/dl to 2.45 
+/- 0.75 mg/dl (p < 0.05). Flow-mediated vasoactivity decreased from 16 +/- 5% to 10 +/- 
5% (p < 0.05). Conclusion: Postprandial elevation of RLPs levels may have an associa- 
tion with impairment of endothelial function after an oral fat loading. 
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1229-176 Reversible Endothelial Dysfunction Predicts a More 
Favorable Prognosis in Hypertensive Postmenopausal 
Women 
Maria Grazia Modena, Pietro Aveta, Luca Piccinini, Andrea Cantergiani, Rosario Rossi. 
University of Modena, Modem, /ta/y 
Background: Endothelial dysfunction is increasing recognized as an early event in the 
process of atherosclerosis. Postmenopausal women have been shown to have abnormal 
end&helium-dependent vascular function. However, flow-mediated vasodilation may 
change over time according to treatment; but to date, the prognostic value of these 
changes has been only poorly investigated. The aim of this study was to assess whether 
an improvement of flow-mediated vasodilation, as an expression of reversible endothelial 
dysfunction, could predict a more favorable outcome. Methods: 350 postmenopausal 
women with mild to moderate hypertension underwent repeat echocardiographic study of 
the brachial artery 6 months after the initial examination, while optimal control of blood 
pressure (valuesc140/90 mmHg) was achieved, and were then followed up for a mean 
period of 5.1 years (range: 4.1-5.4 years). Endothelial dependent vasodilation (EDVD) 
was evaluated by measuring the diameter of the brachial artery before and during reac- 
tive hyperemia (induced after deflation of a blood pressure cuff inflated to suprasystolic 
pressure for 5 minutes). Results: After 6 months of treatment EDVD had not changed 
(~10% respect to baseline)in 150 women (42.8%)(group I), whereas it was significantly 
improved (>lO% respect to baseline) in the remainig 250 (57.2%)(group II). Baseline 
EDVD was similar in in the two groups, and there were no intergroup differences regard- 
ing age, prevalence of cardiovascular risk factors and hormone replacement therapy use. 
During follow-up, 29 of 150 women (19.3%) experienced a cardiovascular event in group 
I vs. 13 of 250 (5.2%) in group II; pcO.0001. Ten of 150 women (6.6%) were admitted to 
the hospital for acute hert failure in group I than in group II [4 (l-6%)]; p<O.OOOl. There 
were 14 transient ischemic attack (9.3%) in group I as opposed to 7 (2.8%) in group II: 
p<O.OOOl. Moreover, fewer women experienced a frank ischemic stroke [5 cases (3.3%) 
in group I vs. 2 (0.8%) in group II; p=ns]. Conclusion: The present study demonstrated 
that a significant improvement of EDVD may be obtained by means of antihypertensive 
therapy, and clearly identifies postmenopausal women with more favorable outcome. 
1229-177 Endothelial Adhesiveness for Monocytes Is Increased by 
Nicotine 
Henry A. Chen, Christopher Heeschen, Markus Stuehlinger, Michael Weis, Philip S. 
Taao, John P. Cooke. Sfanford lJniversi& Palo Alto, CA 
Background: The cardiovascular risk factors hypertension and diabetes have both been 
shown to increase monocyte adherence to the endothelium, which is an early and critical 
event in atherosclerosis and angiogenesis. Smoking, however, another risk factor with 
strong correlation with coronary artery disease, has been poorly studied in this regard. 
Monocyte adherence to the endothelium is an early and critical event in processes such 
as fatty streak formation leading to atherogenesis and in processes of arteriogenesis and 
angiogenesis. We and others have demonstrated that many of the known risk factors 
strongly influence endothelial adhesiveness. However, the contribution of nicotine to 
monocyte adherence is not fully characterized. We hypothesize that nicotine increases 
endothelial adhesiveness for monocytes. Methods and Results: Functional mononu- 
clear leukocyte adhesion assays were performed in parallel. Endothelial cells (trans- 
formed human umbilical vein endothelial cell line ECV304 (American Type Culture 
Collection) were treated with nicotine (10.6, 10-8, lo-10 M) and then exposed to rnono- 
cytoid cells (WEHI 78124, 2X106/ml) on a rocking platform for 30 minutes. Adherent cells 
were counted by epifluorescence microscopy. Nicotine caused a dose-dependent 
increase in endothelial adhesiveness for monocytes as assessed in this functional bind- 
ing assay., as did the inflammatory cytokine, TNF-alpha (250 U/ml). In comparison to 
vehicle, nicotine(lO-6, 10-8, 1010 M) increased the number of bound cells (by 108 %, 
132 %, and 144 %, respectively.) Conclusions: These results indicate that nicotine 
increases endothelial adhesiveness for mononuclear cells. These observations may 
explain in part the effect of tobacco to accelerate atherosclerosis. 
1229-178 Obesity in Children Is Associated With Arterial Endothelial 
Dysfunction 
Kam S. Woo, Ping Chook, Rita Y. T. Sung, Chung W. Yu, Christopher W. K. Lam, Sophie 
S. F. Leung, Con Metreweli, David S. Celermajer. The Chinese Univeris& of Hong Kong, 
Hong Kong, Hong Kong, The Royal Prince Alfred Hospifal, Sydney, Australia 
Background: Obesity or abnormal fat distribution is a risk factor for arterial endothelial 
function (a marker of early atherosclerosis) in asymptomatic adults. The impact of obe- 
sity in children has not been investigated. 
Methods: To delineate the impact of obesity on development of endothelial dysfunction 
in children, 36 asymptomatic children (age 10.3+/-0.9 years, 21 males) with body mass 
index (BMI) >23 (OBESE) and 36 age and gender-matched children with BMlc23 (CON- 
TROL) were studied. Flow-mediated dilation (FMD, endothelium-dependent) and nitro- 
glycerin-induced dilation (NTG, endothelium-independent) of brachial artery were 
measured by high resolution B-mode ultrasound. 
Results: BMI, body fat (BEXA) and plasma triglyceride were significantly higher in obese 
group (pcO.OOl), but the 2 groups were well matched in blood pressures, blood choles- 
terol, glucose and vessel diameter. FMD were significantly lower in obese group 
(pcO.0001) but NTG were similar. BMI is independently predictive (p=O.38) of impaired 
FMD in multivariate analysis (partial R=0.61; model F-value=PO.l; pcO.0001). 
Conclusion: Obesity in children is associated with impaired arterial endothelial function, 
with great implication in atherosclerosis prevention. 
CONTROL OBESE p-VALUE 
BMI (%) 20.2+/-2.9 26.7+/-3.0 <0.0001 
Body Fat (%) 27.247.3 35.3+/v7.0 0.001 
Triglyceride (mmol/l) 0.99+/-0.49 1.30+/-0.53 0.01 
FMD (%) 9.7+/-3.0 6.6+/-2.3 <0.0001 
NTG (%) 19.6+/-2.8 20.6+/-5.9 0.367 
1229-179 Extracellular ATP and UTP Stimulate Release of Tissue- 
Type Plasminogen Activator From Vascular Endothelium in 
Human Forearm 
David Erlinge, Th6rdis Hrafnkelsd6ttir. Sverker Jern. Dept of Cardio/ogy, Lund, Sweden, 
Depr of C/in. Exp. Research, Gothenburg, Sweden 
Background: The extracellular nucleotides ATP and UTP are potent vasodilators stimu- 
lating the release of NO, prostacyclin, and EDHF by activation of endothelial P2Y recep- 
tors. We have previously shown that several endogenous vasodilators also have powerful 
thrombolytic capacities by stimulating the release of tissue-type Plasminogen Activator (t- 
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PA) from the vascular endotheiium. The aim of this study was to examine if ATP and UTP 
can activate fibrinolysis by stimulation of release of t-PA in viva in man. Methods: 9 
healthy controls (7 men, 2 women; mean age 27.2 years) were studied in a modified per- 
fused forearm model. ATP and UTP were injected through the brachial artery in stepwise 
infusions (10-50-100-200 nmollmin) in a randomised order (n=4). In a second series the 
UTP-infusion was given twice, were the second infusion was given after pretreatment 
with indomethacin 50 mg iv and co-infusion of L-NMMA (16 microM/min, n=5). Forearm 
blood flow was measured with plethysmography and net-release of t-PA was determined 
as AV-gradient x plasmaflow. Results: Both ATP and UTP caused vasodilatation and 
stimulated t-PA-release in the forearm with similar potency and maximum effects. UTP 
increased t-PA-release from a basal level of 8.55 (4.2) to 148.7 (45.9) ng/min and L tis- 
sue at the highest dose (ANOVA p=O.OOOZ). The UTP induced t-PA-release and vasodi- 
latation was not blocked by combined NO (I-NMMA) and cyclooxygenase 
(indomethacin) inhibition. Conclusion: ATP and UTP stimulate both vasodilatation and a 
marked increase in t-PA. The activation of the fibrinoiysis is not blocked by inhibition of 
NO- or prostaglandin-release. Since both ATP and UTP induce similar t-PA-responses it 
is unlikely that the effect is mediated by adenosin receptors, instead the results strongly 
suggests the involvement of P2Y receptors. Since extracellular nucleotides are released 
in high concentrations during ischemia and platelet aggregation they may be of impor- 
tance for the activation of the endogenous fibrinolysis. 
1229-180 Effects of Synthetic Progestin on Nitric Oxide Bioactivity 
and Cytokines in Hypertensive or Overweight 
Postmenopausal Women 
Kwang K. Koh, Dong K, Jin, Jeong Y. Ahn, Sean K. Lee, Seong H. Yang, Gi S. Park, Ji W. 
Son, In S. Choi, Eak K. Shin. Card/&m Inchon, South Korea, Radiolog)! Inchon, South 
Korea 
Background: We have previously shown that unopposed estrogen improved nitric oxide 
(NO) bioactivity in healthy postmenopausal women (PMW). NO protects NF-kB from acti- 
vation by oxidized LDL or cytokines, and thus prevent or attenuate the transcription and 
expression of monocyte chemoathactant protein (MCP-I) on the endothelial cell surface. 
Experimental and animal studies suggest that synthetic progestin may negate the favor- 
able effects of estrogen. Nonetheless, observational studies report no differences in risk 
for clinical cardiovascular events between users of unopposed estrogen and users of 
estrogen combined with synthetic progestin. Hypertension (HT) and obesity are “insulin 
resistance syndrome” Accordingly, hormone replacement therapy (HRT) may not have 
comparable benefit in HT or overweight (OW) PMW. Methods: We administered micron- 
ized progesterone (MP) 100 mg or medroxyprogesterone acetate (MPA) 2.5 mg with con- 
jugated equine estrogen (CEE) 0.625 mg daily during 2 months to 20 HT or OW PMW. 
This study was randomized, double-blind, croSSOver in design. 
*=P~0.05;~*=Pc0.01;‘**=P~0.001 vs. Baseline. Data= mean&D. Results: CEE+MP and 
CEE+MPA therapies significantly changed lipoprotein levels from baseline values PcO.05 
by ANOVA). CEE+MPA or MP significantly improved flow-mediated dilation (FMD) and 
further, reduced MCP-1 and TNF-a (PcO.001, P<O.OOl, and P=O.O04 by ANOVA, respec- 
tively). Of note, there were no significant differences between CEE+MPA and CEEcMP. 
There were significant inverse correlations between pretreatment TNF-a levels and the 
degree of change in those levels (r=-0.339, P~O.077) after CEE+MP and CEE+MPA. 
Conclusions: Improvement in NO b&activity and reduction of inflammatory cytokines 
may account, in part, for the cardiovascular benefit of synthetic or natural progestagen 
combined with estrogen in HT or OW PMW. 
HDL cholesterol 
LDL cholesterol 
LDL-C/HDL-C 
FMD (%) 
MCP-1 (pS/ml) 
TNF-a (pg/ml) 
Baseline CEE+MP CEE+MPA 
53+8 57+a* 57+9 
129c31 113+30 115+30, 
2.49+0.74 2.04+0.73*’ 2.11+0.81* 
5.04~1.69 7.52+1.41*** 7.70*1.24*** 
253*:83 218*66 200*59** 
1.52ztO.88 0.9910.41’ 0.98iO.36* 
1229-181 Thrombospondin 1 Induces Apoptosis of Human Lisette 0. Jensen, Knud E. Pedersen, Per Thayssen, Keld E. Sorensen, Steen Stander, 
Endothelial Cells Through Activation of p38 Mitogen Torben Haghfelt. Department of Cardiolosy, Odense University Hospital, Odense, 
Activated Protein Kinase Denmark, Department of Cardiology, Skejby Hospital, Skejby, Denmark 
Rieko Kuwashima, Takahiro K&no, Eiichiro Takeo, Masayuki Katsumoto, Yasushi 
Toyota, Kozo Hayashi, Hideo Matsuura, Tetsuji Shingu. Hiroshima Univ. Schoo/of 
Medicine, Hiroshima, Japan 
Background: Thrombospondin (TSP) 7 is supposed to serve as an inhibitor of angiogen- 
esis. Injury of vascular endothelial cells (EC@ is one of the key mechanisms of athero- 
sclerosis. Thus, it is possible that TSPI is associated with EC injury through apoptosis. 
We therefore investigated an effect of TSPl on apoptosis of ECs in conjunction with the 
intracellular signal transduction. Methods: HUVECs were incubated in culture media 
contining 5 “g/ml of TSPl. In p38 mitogen activated protein kinase(MAPK)-inhibition 
studies, ECs were preincubated with SB203580 before treatment with TSPl. Apoptosis 
was detected by DNA ladder formation and quantitated by modified Burton’s method. In 
situ detection of DNA fragmentation was performed by TUNEL method. Phosphorylation 
of p44/42 MAPK, p38 MAPK and AM induced by TSPl was assessed by western blotting 
using the phosphorylation-specific antibodies after immunoprecipitation. Results: TSPl 
induced apoptosis in HUVECs, which was detected by DNA fragmentation and TUNEL 
method. The apoptosis was significantly inhibited by SB203580. Activation of p38 MAPK 
was observed 5 min after incubation with TSPl and continued till 60 min, which was 
inhibited by 58203580. Phospho-Akt was increased by stimulation with TSPl and got to 
the peak activation within 10 min. No detectable changes in phospho-p44/42 MAPK were 
Background: In some hyperlipidemic patients, dietary modifications can improve lipid 
profiles. Whether this relates to improved endothelial function and if so how it compares 
with responses to statins treatment has not been investigated. 
Methods: In 18 patients with documented ischemic heart disease (previous Percutane- 
ous Coronary Intervention) and hypercholesterolemia, bmchial artery responses to reac- 
tive hyperemia (endothelium dependent flow mediated vasodiiation, FMD) and to 
nitroglycerine (NTG, endothelium independent vasodilation) were assessed at baseline, 
after 3 months on a lipid lowering diet and finally 1 and 3 months after commencing sim- 
vast&in 40 mg/day. 
Results: During the diet phase, a reduction in intake of fatty foods (Eating Pattern 
Assessments Tools, EPAT score)(20.5 vs. 17.6, p=O.O03) and an increase in the intake of 
lean foods (26.0 vs. 29.2, p=O.OOi) were seen. 
Cholesterol (mmol/l) LDL (mmolil) HDL (mmolll) FMD (“) 
Baseline 6.5+ 1.0 4.4 zl 0.9 1.27 f 0.25 3.7 SC 2.6 
3 months diet 6.4 * 0.9 4.3 + 0.8 1.38 Jo 0.30° 3.7 + 2.8 
1 month simvastatin 4.1 * 0.5’ 2.2 f 0.4’ 1.50 f 0.36” 6.2 zk 2.2s 
3 months simvastatin 4.0 t 1 .I 2.1 eo.7 1.39 f 0.28’ 5.8 zt 2.9 
‘p<o.ool; ‘^p=o.o23; np=o.o34; #p=0.036, sp=o.o03 
Triglycerides did not change during the diet only phase but fell significantly after 4 weeks 
on simvastatin (1.67 vs 1.12 * 0.51, p=O.O02). No significant change in endothelium inde- 
pendent responses or reactive hyperaemic stimulus was observed throughout the study 
observed by TSPl. Conclusion: We concluded that TSPl induces apoptosis in 
HUVECs and that activation of ~38 MAPK may in part associate with induction of apopto- 
sis by TSPl. 
1229-182 Evaluation of Srachial Arterial Vasodynamics Using Leg 
Exercise 
Alexander J. Muster, Bonnie J. Kane, Ashwin Nagaraj, David D. McPherson. 
Northwestern University Medical School, Chicago, IL 
Introduction. While endotheiiai function is known to deteriorate with aging, the onset of 
such decline is unknown. Evaluating vasodynamics in a remote limb while performing 
local exercise may permit better determination of such changes. 
Methods. To determine how aging affects vascular function, we evaluated 30 men of 
various age, fitness and health history for brachial artery reactivity using continuous 2D 
ultrasound/Doppler while subjects pedaled on a recumbent bicycle. Study groups: Eld- 
erly athletes (mean age 72 yrs.); Young athletes (mean age 27 years); Young sedentary 
(mean 27 years); Elderly sedentary (mean age 69 years); Coronary history (mean are 69 
years) [n=6 for all groups) Brachial artery flow velocity and longitudinal diameter were 
measured at baseline, exercise (onset, moderate and maximal effort) and recovery. 
Results: Central nervous system mediated vasoconstriction occurred at low flow 
velocity. Vasoconstriction during high flow velocity and vasodilatation during recovery 
was endothelium mediated. Only young and old athletes had significant vasodilatation 
during recovery. Men with cardiovascular history displayed no endothelium dependent 
vascular reactivity. In elderly sedentary men arterial vasoconstriction was maintained 
well into recovery. Arterial diameter in young sedentary men revealed no exercise induc- 
ible vasodilatation. 
I 
Conclusions. This study confirms the utility of exercise in evaluation of vascular reactiv- 
iky in an artery distant from the site of exercise. During high arterial flow velocity and 
recovery vasodynamics are regulated primarily by the endothelium. Vasoconstriction 
enhances blood volume shift to the active extremity during exercise. Arterial response to 
exercise becomes blunted in sedentary men early, and continues deteriorating with age. 
Athleticism maintains endothelial function even into later years. 
1229-183 Simvastatin but Not Diet Improves Endothelial Function 
Within Weeks 
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period. 
Conclusion: These data suggest that additional beneficial changes in food consumption 
in eduacated patients with coronary artery disease, does not have any significant impact 
on plasma lipids and vascular function, whereas simvastatin not only has beneficial 
impact on lipid levels but also improves endothelium dependent vasodilation within a few 
weeks time. 
1229-I 84 Nitric Oxide inhalation Enhances Systemic Vasodilator Tone 
During Regional inhibition of Nitric Oxide Synthesis 
Richard 0. Cannon, ill, MarkT. Gladwin, Melissa B. Bryant, Alan N. Schechter, Julio A. 
Panza. National Heart, Lung, and Blood Institute, Bethesda, MD 
Background: Regional blood flow may be regulated in part by nitric oxide (NO) trans- 
ported from the lungs by hemoglobin and thiol-proteins. Our purpose was to determine 
the contribution of blood-transported NO to regional vascular tone in humans before and 
during NO inhalation. 
Methods: Forearm blood flow (venous occlusion plethysmography) was measured in 16 
healthy subjects (8 males, 8 females; age range 21-59 years) at rest and after blockade 
of forearm NO synthesis with NG-monomethyl-L-arginine (L-NMMA) followed by forearm 
exercise stress, before and after 1 hour of NO inhalation (80 ppm). 
Results: L-NMMA 8 pmollmin into the brachial artery for 5 minutes reduced flow from 
2.6i0.2 (mean + SEM) to1.8+0.1 mUmin/dL of forearm tissue (P<O.OOl). After5 minutes 
of repetitive hand-grip exercise, flow increased to 19.9k2.2 mUmin/dL. During NO inhala- 
tion, L-NMMA reduced flow from 2.2kO.2 to 2.0+0.2 mL/min/dL. This 9% reduction in flow 
was significantly less than the 30% reduction in flow on room air (P=O.O44), and resulted 
in lower forearm vascular resistance (365~3.4 versus 48.3i3.9 units, P=O.O03). During 
subsequent hand-grip exercise with NO inhalation, flow increased to 21.0*2.0 mUmin/ 
dL. This 855% increase in flow tended to be greater than the 665% increase on room air 
(P=O.O99), and resulted in lower forearm vascular resistance (3.7r0.4 versus 5.0~0.6 
units, P<O.OOl). In the contralateral arm, which received intraarterial D5W infusion only, 
NO inhalation did not alter basal (P=O.602) or exercise- induced increase (P=O.987) in 
flow. 
Conclusions: NO transported in blood on room air has insufficient bioactivity to prevent 
vasoconstriction during regional blockade of NO synthesis. However, NO inhalation 
attenuates the reduction in forearm blood flow and enhances the vasodilator response to 
exercise stress when regional NO synthesis is impaired. These findings support the pri- 
mary importance of local endothelial NO synthesis in regulating blood flow, but suggest 
the therapeutic potential of NO inhalation in conditions associated with reduced 
endothelial NO bioactivity. 
1229-185 Coronary Endothelial Function in Patients With Coronary 
Spastic Angina: Role of Transcardiac Formation of Oxidized 
LDL 
Kazuo Minai, Tetsuya Matsumoto, Hajime Hone, Hiroshi Yokohama, Hiroyuki Takashima, 
Naoto Ohira, Tsutsui Takashi, Takayoshi Tsutamoto, Masayuki Takahashi, Masahiko 
Kinoshita. First Department of lnternaf Medicine, Shiga University of Medical Science, 
Ofsu, Jajxm 
Background: It is unclear whether the plasma status of oxidized LDL (ox-LDL) and 
endothelial function are linked to the pathogenesis of coronary spastic angina (CSA). 
Thus, we assessed coronary vasomotor responses to acetylcholine (ACh) and bradykinin 
(BK) and measured plasma levels of oxidized LDL in 10 patients with CSA and 10 control 
patients matched for age, sex and coronary risk factors. Methods and Results: The 
diameter of the left anterior descending coronary artery (LAD) and the change in coro- 
nary blood flow (CBF) were assessed by quantitative angiography and Doppler flow 
velocity measurement. Blood samples were taken from the aorta (Ao) and the coronary 
sinus (CS) and plasma levels of ox-LDL were measured by ELISA using DLHB, a mono- 
clonal antibody specific for ox-LDL (Kyowa Medex Co., Ltd.). ACh was found to induce 
vasospasm of the LAD with myocardial ischemia in all patients of the CSA group, but not 
in any patients of the control group. BK at doses of 200, 600, and 2000 nglmin caused 
similar dose-dependent increases in the LAD and the CBF in the control group and the 
CSA group. Plasma levels of ox-LDL were similar between the Ao and the CS in controls 
(Ao: 10.9 f 1.3; CS: 13.0 r 1.5 U/mL, n. s.), but the level in the CS was significantly 
higherthan that in the Ao in the CSA group (Ao:l6.9 c 2.5; CS: 24.2 i: 4.7 U/mL, ~~0.05). 
In the CSA group, as compared with the control group, plasma levels of ox-LDL were sig- 
nificantly higher in both the Ao and the CS (~~0.05 for each). Plasma levels of total cho- 
lesterol, LDL cholesterol, and triglycerides did not differ between the Ao and the CS in 
either of the two groups. Conclusions: Ox-LDL formed during transcardiac passage may 
play a role in the pathogenesis of CSA. In addition, it is suggested that ox-LDL selectively 
promotes vasoconstriction in response to ACh in coronary arteries in spasm, whereas 
vasarelaxation in response to BK is not affected. 
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1230-188 Clinical Manifestations of Marfan Syndrome in Hispanic 
Families 
Frank A. Laws, Dongchuan Guo, Shao-Qing Kuang, Dianna M. Milewicz. University of 
Texas-Houston Medical School, Houston, TX 
Marfan syndrome (MFS) is an autosomal dominant condition with pleotrophic manifesta- 
tions involving the skeletal, ocular, and cardiovascular systems. The diagnosis is prima- 
rily a clinical diagnosis based on involvement of these and other systems, referred to as 
the “Ghent criteria”. We have identified 2 Hispanic families with aortic root dilatation and 
dissection inherited in an autosomal dominant manner. The first family had 12 affected 
and 10 unaffected members available for assessment. FBNl sequencing of DNA from 
affected individuals revealed a frameshifi mutation in exon 24 (3074delT). Fibroblasts 
explanted from an affected member were metabolically labeled to study fibrillin-1 (fib-l). 
These studies revealed diminished amounts of fib-l synthesized and ~5% fib-l depos- 
ited in the extracellular matrix when compared with control cells. Assessment of the clini- 
cal features in 8 affected adults in the 3rd and 4th generation revealed that none of the 
affected individuals had major skeletal manifestation of MFS. Only 3 of the 8 meet the cri- 
teria for involvement of the skeletal system. None of the individuals have involvement of 
the ocular system. A second Hispanic family with aortic root dilatation and dissection had 
7 affected and 9 unaffected members. The cardiovascular phenotype was linked to mark- 
ers within and near FBNl. Two affected adults were examined and only one had skeletal 
system involvement. Two adults with the affected haplotype were assessed by local car- 
diologists and reported to have no skeletal features of the MFS. The family has not been 
examined for ocular manifestations. Other large Hispanic MFS families have not been 
identified. The results with these 2 families suggest that Hispanic individuals may not 
manifest skeletal features of the MFS to the same extent as Caucasians, indicating that 
the Ghent criteria for diagnosing MFS may need to be revised for this ethnic group. 
1230-187 Cytokine Expression of Lung and Small Intestinal in 
Experimental Abdominal Aortic Ischemia-Reperfusion 
Injury in Rabbits: a Semiquntitation of Reverse 
Transcription-Polymerase Chain Reaction Analysis 
Han-y H. Liu, Nicholas J. Morrissey, llkka Kantonen, Shepard Weiner, Sumit De, Morris 
DKerstein, Larry H.Hollier. Mount Sinai Medical Center, New York, NY 
Background: Although the abdominal aortic aneurysm surgery has become a relatively 
safe surgical procedure during the last decade. However, various postoperative compli- 
cations, such as acute lung injury and intestinal infarction following aortic cross clamping 
, still remains up to 30% of these surgical patients. The inflammatory cellular response is 
to a large extent mediated by cytokines. In this study, we used an ischemia-reperfusion 
animal model to test the local cytokine response following aortic occlusion. 
Methods: Animals (30 rabbits) were divided into three experiment groups. The abdomi- 
nal aorta and superior mesenteric artery was clamped 12 minutes (group 1) and 60 min- 
utes (group 2). After 150 minutes reperfusion, small intestinal and lung tissues were 
harvested, then homogenized for cytokine detection by using a semiquantitative reverse 
transcription polymerase chain reaction analysis. 
Results: 1, Lung: IL-1 level after 150 minutes reperfusion, in group 2 (60 minutes 
ischemic time), was elevated up to 62%?12, significantly higher, compared to control 
group (PcO.05) while the group 1 (12 minutes ischemic time) was 18%+8, compared to 
control group (PcO.05). 
2, Small intestinal: TNF-a and MCP-1 level after 150 minutes reperfusion, in group 2, 
were significantly increased to 44%*7 and 52%+9, compare with control group (PqO.05) 
while the group 1 was 17%*6 and 22%c5, compare with control group (PcO.05). 
Conclusion: Prolonged ischemic injury could contribute to the local vascular injury in 
both lung and small intestinal, which was associated with proinflammatory cytokine 
expression during reperfusion period. This finding suggest that manipulation of this 
response may benefit patients at risk of organ injury following aorta occlusion. 
1230-188 Endovascular Stent-Grafts Implantation for Descending 
Thoracic Aortic Dissection and Aneurysm 
Won Hewn Shim, Byoung-Kwon Lee, Young-Sup Yoon, Do-Yun Lee, Byung-Chul Chang. 
Yonsei Cardiovascular Center, Seoul, South Korea 
Background: The standard treatment for descending thoracic aortic dissection or aneu- 
rysm is either surgical or medical therapy. Irrespective of the forms of treatment, the 
associated mortality and morbidity are considerable. The object of the study was to eval- 
uate the early and long-term follow-up outcomes after stent-graft implantation at dissec- 
tion or aneurysm of descending thoracic aorta. Methods: Twenty four endovascular 
stem-grafts were implanted in 23 patients with aortic dissection(n=13) or aneu- 
rysm(n=lO). The custom-designed z-type stent-grafts composed of self expanding stain- 
less-steel with woven polytetrafluoroethylene material were used. The folded graft was 
delivered via 20.22Fr sheath and unloaded at the target site. Aortography was performed 
immediately after the procedure and follow-up computerized tomographies(CT) were per- 
formed 1 to 6 month, and annually after procedure for assessing leakage, false lumen 
thrombus formation and changes of lumen size. Results: Endovascular stent-graft 
implantation at target site was successful in 21 patients(91%). There was complete, or 
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ongoing resolution of the false lumen in 18 cases during the follow-up CT. Occlusion fail- 
ure of distal entry site was found in a patient having two entry sites due to stent migration. 
There were no procedure related major complications such as severe bleeding, aortic 
rupture, major vessel occlusion, paralysis or death. Post-procedural aortogram revealed 
partial leakage of the dye into the false lumen in one case. During the follow-up of 
29t?413 months, there have bee” no deaths or major complications including aortic rup- 
ture. Two patients died due to procedure unrelated causes at Gmonth after the procedure. 
Conclusion: Endovascular stent-graft implantation at descending thwack aortic dissec- 
tion or aneurysm is feasible, safe, and effective treatment modality for the prevention of 
aortic rupture. 
1230-189 Effect of Simvastatin in Preventing Progression of Carotid 
Artery Stenosis 
Givind Hegland, Kenneth Dickstein, Jan P. Larsen. Department of Neurology, Central 
Hospital of Rogaland, Stavanger NO-401 1, Norway 
Background: Atherosclerotic carotid artery disease is an important risk factor for stroke 
and the risk of clinical symptoms increases with the degree of stenosis. The role of 
statins in stroke prevention is not established. Subgroup analysis of data from clinical tri- 
als of statins in patients with coronary-heart disease has revealed reduction in the inci- 
dence of stroke. To further examine this hypothesis we investigated the influence of 
statins on the development of carotid stenosis over time. 
Methods: The iniluence of statins on the progression of carotid artery disease was stud- 
ied by repeated measurements of ultrasound-defined stenosis in 230 patients referred for 
examination during a period of 3.5 years Patients with internal carotid artery (ICA) steno- 
sis 40% were included in the study. A total of 318 stenotic arteries in 230 patients were 
identified. In that the indication for treatment with statins changed dramatically during the 
study period it was possible to compare the development of carotid stenosis in patients 
with and wthout treatment with statins. 
Results: 171 of the diseased arteries had “ever been treated with a lipid-lowering drug, 
whereas 147 had been exposed to simvastatin. Baseline data were comparable in the 
treatment groups, except for a slightly lower age and a higher proportion of patients with 
elevated baseline cholesterol among those treated with srmvastatin. We found that in 
untreated arteries, total mea” stenosis increased with 4.9 % (from 59.0 % to 63.9%) dur- 
ing 20 months, while the stenosis had decreased by 10% (from 59.8% to 49.8%, p<.OOl)) 
in simvastatin treated arteries. 
Conclusions: The results from this study suggest that simvastatin reverses the antici- 
pated progression of carotid artery stenosis over time. We postulate that the observed 
reversal of stenosis by simvastatin might also reduce the risk for developing stroke in 
patients with known carotid artery disease. This hypothesis deserves prospective evalua- 
tion. 
1230-190 Intravascular Ultrasound Characteristics of Restenotic 
Carotid Stenoses Following Surgical Endarterectomy 
Michael A. Peterson, Neil .I. Weissman, Gary S. Mintz, Daniel A. Canes, Michael R. Jaff, 
Olga Resales, John Ft. Laird, Jr., Lowell F Satler. Washington Hospital Center, 
Washington, DC 
Background:The in viva morphologic characteristics of restenotic carotid arteries after 
surgical carotid endarterectomy (CEA) are unknown. Methods: We used intravascular 
ultrasound (IVUS) to study 10 patients with restenosis 615 months following CEA prior to 
stent implantation. Results: The distal internal carotid was normal in all 10 patients, but 
there was severe diffuse intimal thickening of the common carotid in 4 patients. The 
stenosis was located distal to (and did not involve) the origin of the internal carotid in 5 
patients. Plaque was homogeneous, concentric, and soft; calcium was noted in only 2 
patients. There was a loss of the normal vascular architecture in all patients; in particular, 
the sonolucent media was indistinct or absent and a distinct external elastic membrane 
was not seen. Importantly, negative remodeling (lesion arterial area c distal reference) 
was present and contributed to lumen compromise in 5 patients; and there was periad- 
ventitial fibrosis in 8 patients. These findings are very different from IVUS findings in de 
nova carotid artery stenoses. De “ova stenoses are usually localized to the origin of the 
internal carotid and are typrcally calcified with positive remodeling. Conclusions: IVUS 
features of restenotic carotid lesions after surgical CEA are strikingly different from de 
“ova stenoses. These differences may explain the unfavorable outcomes after repeat 
CEA and the favorable outcomes after stent implantation. 
1230-191 Pravastatin Reduces the High Rate of Atherothrombotic 
Complications in Coronary Heart Disease Patients With 
Intermittent Claudication 
Andrew Tonkin, Adrienne Kirby, Paul Newman, David Hunt, Malcolm West, Harvey White, 
Norman Sharpe, Denis Friedlander, Bhuwan Singh, John Simes, For the LIPID Study 
investigators. National Heart Foundation of Australia, Melbourne, Australia, NHMRC 
Clinical Trials Centre, University of Sydnq Sydney Australia 
Background: Symptomatic peripheral arterial disease is associated with poor long-term 
Outcorr?es, primarily coronary heart disease (CHD) and stroke. 
Methods: The Long-Term Intervention with Pravastatin in lschaemic Disease (LIPID) 
study included, among 9,014 patients aged 31-75 years with prior acute myocardial inf- 
arction or unstable angina, 905 patients with claudication at baseline. During follow-up of 
6.0 years, 38.3% of the patients with claudication at baseline and 27.5% of those without 
claudicatio” had a CHD event, stroke, a peripheral vascular event, or associated surgery 
Results: The patients with claudtcatio” had a higher risk of cardiovascular death (13%) 
than those without claudication (8%) The number of events, by treatment group, for 
patients with claudication at baseline are show” in the table. 
Outcome Placebo group Pravastati” group Relative risk P 
n=467 lx438 reduction % 
CHD death 
” (%) ” (%) (95% Cl) 
54 (11.6) 45 (10.3) 10 (-34-39) 0.62 
Nonfatal Ml 50 (10.7) 30 (6.9) 36 (-159) 0.053 
Stroke 23 (4.9) 27 (6.2) -28 (-123-27) 0.39 
CABG or PTCA 83 (17.8) 65 (14.8) 17 (-14-40) 0.25 
Vascular surgery 24 (5.1) 14 (3.2) 39 (-18-68) 0.14 
Peripheral vascular disease 18 (3.9) 8 (1.8) 53 (-8-80) 0.08 
Any of the above 195 (41.8) 152 (34.7) 20 (l-35) 0.039 
Conclusion: Pravastati”, 40 mg daily, significantly reduced events of a” expanded end- 
point that included CHD events, stroke, and peripheral vascular events in CHD patients 
who also had claudication. 
ORAL CONTRIBUTIONS 
868 Vascular Biology and Angiogenesis: 
Clinical Studies 
Tuesday, March 20, 2001, 2:00 p.m.-3:30 p.m. 
Orange County Convention Center, Room 304A 
2:00 p.m. 
868-l Direct Myocardial Gene Transfer of VEGF165 in Patients 
With End-Stage Coronary Artery Disease: 1 P-Month Results 
of a Phase l/II Clinical Trial 
Peter Ft. Vale, James F. Symes, Darryl D. Esakof, Michael Maysky, Charles E. Milliken, 
Maria C. McDonald, Kishor Lathi, Jeffrey M. Isner, Douglas W. Losordo. St Ekabethk 
Medical Center, Boston, MA 
Background: A dose-escalating, non-randomized, open-label, phase l/II clinical trial was 
designed to investigate the safety of direct myocardial gene transfer (GT) of naked plas- 
mid DNA encoding the 165isoform of vascular endothelial growth factor (phVEGF165) 
and to determine as well if any of the three doses employed yielded evidence of bioactiv- 
iky in patients with symptomatic myocardial ischemia. Methods: Using a mini-thoracot- 
omy, phVEGFi65 (total dose of 1251.19 [n=lO], 25Opg [n=lO], and 5OOpg [n=lO]) was 
injected directly into the myocardium as sole therapy (no CABG) for 30 patients (23 
males, ages 48-74) with chronic angina who were not candidates for conventional revas- 
cularization. Results: Gene expression was documented by a transient increase in 
plasma levels of VEGF measured by ELISA assay (pre-GT=31.9r5.7pg/ml vs post- 
GT=l19.5+15.2 pgiml, pcO.0001). of30 patients, 26 (87%) experienced reduced angina 
episodes/week (56.2k4.1 vs 3.8tO.9, p<O.OOOl); reduced sublingual NTG tablets con- 
sumption/week (60.1a4.4 vs 2.8+0.8, p<O.OOOl); and improved >=2 functional classes. 
Exercise tolerance (Bruce protocol) increased significantly (289 sets vs 386 sets, 
p=O.OOZ) up to 360 days post-GT. Stress SPECTSestamibi myocardial imaging was per- 
formed in 29 patients followed to 60 days; mea” perfusion-defect scores for both stress 
(16.3kl.9 vs 13.9+1.9, p=O.O49) and rest (10.5c1.9 vs 8.3+1.5, p=O.O24) images were 
significantly decreased (improved) at day 60. LV ejection fraction (EF) was either 
unchanged (“~16) or improved (n=14, mean increase in LVEF = 5%) following GT One 
late death occurred at 5 months post-GT and one patient underwent cardiac transplanta- 
tion at 12 months post-GT Two other patients had regressed clinically at 12 months fol- 
low-up after an initial improvement. Conclusions: The doses of phVEGFf65 employed 
in this Phase l/II study of direct myocardial GT 1) appear safe, and 2) are associated with 
subjective and objective evidence of clinical bioactivity. These preliminary findings sug- 
gest that the strategy of therapeutic neovascularization merits further investigation in 
patients with myocardial ischemia. 
866-2 
2:15 p.m. 
Direct Myocardial Gene Transfer of Vascular Endothelial 
Growth Factor-2 (VEGF-2) Naked DNA via Thoracotomy 
Relieves Angina Pectoris and Increases Exercise Time: 
One-Year Follow-Up of a Completed Dose-Escalating Phase 
1 Study 
F. D. Fortuin, Jr., Peter Vale, Douglas W. Losordo, Giacomo A. DeLaria, J. J. Tyner. 
James Symes, Gary L. Schaer, John J. Lopez, Joseph Van Camp, Timothy D. Henry, 
Wayne Richenbachef, John D. Rogers, Jeffrey M. Isner, Richard A. Schatz. St. 
Nizabeth’s Medical Center, Boston, MA, Scripps Clinic, La Jo//e, CA 
Background: The angiogenic growth factors Vascular Endothelial Growth Factor-l 
(VEGF-1) and Vascular Endothelial Growth Factor-Z (VEGF-2) are 40% homologous. 
The effects of VEGF-1 gene transfer (GT) in patients with angina pectoris (AP) have 
been studied, however, the clinical impact of VEGF-2 GT has not been previously 
described. We present the one year clinical follow-up of direct myocardial GT of VEGF-2 
naked DNA via limited left anterior thoracotomy in 30 adult patients (pts) at total doses of 
0.2 mQ (n=lO), 0.8 mg (n=lO), or 2.0 mg (n=lO). Methods: All pts enrolled had Cana- 
dian Cardiovascular Society (CCS) class 3 or 4 angina, ejection fraction >25%, demon- 
strable ischemia by exercise treadmill test (ETT) with scintigraphy, and multivessel 
obstructive coronary artery disease not amendable to conventional revascularization and 
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unresponsive to medical therapy. History, physical, and Seattle Angina Questionnaire 
were obtained at baseline and up to 52 weeks (wks) after GT. ETT with scintigraphy, car- 
diac catheterization, NOGA mapping (selected patients), and echocardiography were 
performed at baseline and at 12 wks after GT. Results: Among 29 surviving pts studied 
at 12 wks post GT, CCS class decreased from 3.6 f 0.5 at baseline to 1.3 * 1 .O (pc.005). 
CCS class decreased by at least 2 in 21 of the 29 pts (72%). Weekly episodes of AP and 
nitroglycerin use decreased from 32 f 26 to 5.9 f 8.0 (p<.OO5), and from 20 + 18 to 2.4 * 
4.0 (pc.O05), respectively. Average ETT times increased from 555 + 3:20 minutes 
(mins) to 756 * 3:24 mins (pc.005). ETT times increased by r2 mins in 13 pts (46%) At 
12 months following treatment 26 pts (90%) were CCS class 2 or better. There were no 
complications or side effects (such as hypotension) directly related to GT. One pt died 
suddenly 20 hours after GT secondary to severe underlying disease. A second pt suf- 
fered a small myocardial infarction 18 hours after GT, followed by congestive heart failure 
which resolved without sequela. Conclusion: Direct myocardial GT of VEGF-2 naked 
DNA via limited thoracotomy appears to be safe, relieves AR and increases ETT in 
patients not responsive to conventional therapies, This clinical benefit is sustained at 
one year. 
868-3 
2:30 p.m. 
The Influence of an MCP-1 Polymorphism on Serum MCP-1 
Levels in Patients Undergoing Elective Percutaneous 
Coronary Intervention 
Michael F Deucher, Brad Rovin, Gregory M. Eaton, Pascal Goldschmidt-Clermont, 
Yiwen Liu-Stratton, Glen Cooke. The Ohio St&e Universit)! Columbus, OH 
Monocyte chemotactic protein-l (MCP-1) is a pro-inflammatory chemokine which is 
upregulated in many cardiac diseases including acute ischemic syndromes and conges- 
tive heart failure. A polymorphism has been discovered in the promoter region of the 
human MCP-1 gene. In this study, we sought to determine the influence of this polymor- 
phism on MCP-1 production in a cohort of patients with symptomatic coronary artery dis- 
ease requiring elective percutaneous intervention (PCI). Methods: This study 
prospectively enrolled 107 patients undergoing elective percutaneous intervention. 
Serum MCP-I levels were determined by ELISA (Quantikine kit, R&D Systems), and 
MCP-1 genotyping was performed using a previously described method. Results: The 
prevalence of the genotypes was 48% for AA, and 52% for the presence of a G allele 
(G+; AG plus GG). The ages were similar between groups: 63+1.7 years for the AA gen- 
otype and 61~1.6 years for subjects with a G allele (G+). The mean MCP-1 levels were 
59.3 * 4.5 pg/mL and 72.0 * 6.6 pg/mL (p=.12) for AA and G+, respectively. However, 
when differentiating by sex, males with the AA genotype (n=30) had lower MCP-1 levels 
(51.4 * 4.7 pg/mL) than Gc subjects, (n=29), (78.9 i8.5 pg/mL; pc.05). Conclusions: 
Patients with symptomatic coronary artery disease requiring PCI who have an AG or GG 
polymorphism in the MCP-1 promoter region produce higher levels of serum MCP-1 than 
those patients with an AA genotype. This finding is statistically significant in male patients 
and should have an impact on our understanding of inflammation, atherosclerosis, and 
genetics. 
868-4 
2:45 p.m. 
Association Between C-Reactive Protein and 
Polymorphisms in the Interleukin-I Gene Cluster and 
Coronary Artery Disease on Angiography 
Peter B. Berger, Martha Nunn, Katherine Stephenson, Gordon W. Duff, George G. Klee, 
Joseph P McConnell. Mayo Clinic, Rochester, MN, Interleukin Genetics, Boston, MA 
Background. C-reactive protein (CRP) is a marker of inflammation predictive of cardio- 
vascular events. Cytokines of the interleukin-1 (IL-l) family are central regulators of 
inflammation; polymorphisms in IL-1 genes are associated with a greater inflammatory 
response. The relationship between CRP and IL-1 polymorphisms, and between CRP 
and angiographic CAD after accounting for traditional and emerging risk factors, is 
unclear. Methods & Results, We investigated the relationship between CRP and IL-1 
polymorphisms and CAD, adjusting for other risk factors, in 504 pts undergoing clinically 
indicated angiography using both a standard sensitivity CRP method (Kamiya Biomedical 
Co’s immunoturbidimetric assay, sensitive to 0.25 mg/dl) and Kamiya’s latex particle 
enhanced immunoturbidimetric high sensitivity CRP(l) (hs-CRP) assay (sensitive to 0.02 
mg/dl), which correlates well with the Dade-Behring Nephelometric hs-CRP method (y = 
1.052x + 0.019, r2=0.9913). Genotyping was performed using a PC&based method with 
Taq polymerase. Significant disease (~50% stenosis) was present in 271 pts (54%). Age, 
gender, smoking, LDL, HDL, Lp(a), apo al, apo B and hs-CRP were all highly correlated 
with CAD on univariate analysis (p<O.OOl), but CRP using the less sensitive technique 
was not (and 68% of pts had a CRP co.25 with this method). Multiple logistic regression 
analysis revealed no association between CRP and CAD using the less sensitive assay, 
but hs-CRP concentration was significantly associated with CAD, with an odds ratio (and 
95% confidence intervals) of 1.92 (1.22, 3.00). There was also an association between 
hs-CRP concentration and a single base polymorphism in the IL-lB(+3954) gene: mean 
CRP was 0.687+1.48 mg/dl in pts with the wild-type pattern, 0.734+1.31 in heterozygous 
pts, and 1.914~3.94 in homozy’gous pts (pcO.001). Conclusions. CRP measured by a 
standard sensitivity assay is not associated with CAD on angiography. CRP assessed by 
high sensitive assays is associated with both angiographic CAD and an IL-1 polymor- 
phism associated with greater inflammatory response, supporting a role of inflammation 
in CAD. 
868-5 
3:00 p.m. 
Attenuated Endothellum-Dependent Vasodilation in 
Patients With Coronary Artery Disease: Impact of G894T 
Polymorphism of the Endothelial Nitric Oxide Synthase 
Rainer Hambrecht, Sandra Ebbs, Volker Adams, Axe1 Linke, Stephan Gielen, Gerhard 
Schuler. Universify Leipzig, Heart Center, Leipzig, Germany 
Background: In humans, a variant of the endothelial NO synthase (eNOS) gene within 
exon 7 has been identified resulting in a change of Glu298 to Asp. However, the func- 
tional consequence of the G894T polymorphism in eNOS with respect to endothelium- 
dependent vasodilation in patients (pts) with coronary artery disease (CAD) is still 
unclear. Methods: Fiveteen male pts with CAD (age: 60~2 yrs.; LV-EF 64+3%) under- 
went invasive assessment of endothelial function in the coronary (n=lO) or in the left 
internal mammaria artery for different study purposes, Changes in vascular diameter in 
response to infusion of increasing doses of acetylcholine (Ach) (0.072, 0.72, 7.2 uglmin) 
were determined by quantitative angiography. The mean peak flow velocity (APV) was 
measured by Doppler velocimetry. Genomic DNA was isolated from blood leukocytes. 
The presence of the G894T polymorphism (pm) was determined by polymerase chain 
reaction restriction length polymorphism (PCR-RFLP). Results: After infusion of Ach 
(7.2 ug/min) APV increased from baseline (saline infusion) by 58+12% (from 29.Ok4.1 to 
45.2k5.6 cm/s). Six out of 15 pts (40%) showed G894T pm (pm-postive) (5 GT heterozy- 
gotes, 1 TT homozygote). Agonist-mediated endotheliumdependent change in APV was 
significantly blunted in pm-positive pts (+30+13%: from 32.2elO.2 to 41.8+11.0 cm/set) 
as compared to pm-negative pts (+76*14%; from 27.Ok2.7 to 47.3k6.5 cmisec; ~~0.05 
versus pm-positive). However, Ach-induced changes in diameter of conduit vessels were 
comparable between pm-positive and pm-negative pts. Conclusions: These results sug- 
gest an aggravated agonist-mediated endothelium-dependent dysfunction in resistance 
vessels in patients with the G894T polymorphism in the eNOS gene. 
868-6 
3:15 p.m. 
Are the Responses to bFGF and VEGF Similar in Human 
Arteries Compared to Other Species? 
John 0. Altman, Mehrdad Rezaee, Antonio Bayes-Genis, Dieter Lubbe, Birgit Kantor, 
Paula Carlson, Thomas Quertermous, David FL Holmes, Jr., Robert S. Schwartz. Mayo 
Clinic, Rochester, MN, Stanford University, Stanford, CA 
Background: The lack of efficacy of phase II trials utilizing basic fibroblastic growth fac- 
tor (bFGF) and vascular endothelial growth factor (VEGF) was unexpected based on 
their proven benefits in animal models, This study was performed to examine the angio- 
genie response to bFGF and VEGF in organ culture of human, canine, and porcine arter- 
ies. Methods: Canine and porcine coronary and human mammary arteries were cut into 
l-mm rings, embedded in collagen, and incubated in serum free media at 37 degrees C 
for 14 days. The number and length of sprouting vessels was determined with and with- 
out addition of VEGF and bFGF, both were titrated to maximal response(O.l-20 rig/ml). 
After 2 weeks in culture the rings were fixed in formalin, embedded in paraffin, and sec- 
tions stained for van Willebrand Factor (vWF) and smooth muscle actin. Results: Under 
basal conditions new vessel counts per ring were 17, 7, and 0.1 from canine, porcine, 
and human arteries respectively. The length of newly formed vessels was greatest in dog 
(0.53 +/- 0.06 mm pcO.01) followed by the pig (0.32 +/- 0.02 mm ~~0.01) and least in the 
human (0.13 +/- 0.02). VEGF resulted in a 188% and 186% further increase in neoangio- 
genesis in the dog and pig respectively (see table). VEGF induced no new vessel growth 
in the human arteries. bFGF increased the number of sprouting vessels in the pig (186%) 
but induced no response in dogs or humans. Light microscopy demonstrated that these 
new vessels wera tubes, lined by endothelial cells (vWF positive cells), with actin positive 
perlcytes. Conclusion: This study indicates that the neoangiogenic response under 
basal conditions and in response to bFGF and VEGF is less in human arteries than por- 
cine and canine arteries. 
#Vessels/Arterial Ring 
Artery Control bFGF VEGF 
Canine 
Size(&) 
0.8 +/- 0.1’ 17+/-3’ 13 +I- 3 32 +/- 2*” 
Porcine 0.9 +/- 0.1* 7 +I- 3’ 13 +I- 3** 13 +/- 3*** 
Human 1.5 +I- 0.1 0.1 +I- 0.1 0.1 cl- 0.1 0 
* P<o.Ol vs Human **P<O.Ol vs Control *** P=O.O8 vs Control 
ORAL CONTRIBUTIONS 
889 Trials and Hypertension 
Tuesday, March 20, 2001, 2:00 p.m.-3:30 p.m. 
Orange County Convention Center, Room 304E 
2:00 p.m. 
869-i Comparison of the Effects of Ramipril on Ambulatory and 
Office Blood Pressures. A HOPE Substudy 
Per Svensson, Ulf de Faire, Peter Sleight, Salim Yusuf, Jan Ostergren. Dept of Medicine, 
Karolinska Hospital, Stockholm, Sweden. MC Master University Hamiffon, ON, Canada 
Background: In the HOPE-trial the ACE-inhibitor ramipril significantly reduced cardio- 
vascular morbidity and mortality in patients at high risk for cardiovascular events The 
benefit could only partly be attributed to the modest reduction of blood pressure (312 mm 
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Hg) However, since ramipril according to the HOPE-protocol was given o d at bedtime, 
and blood pressure (BP) was measured in the office at daytime the 24.hour reduction of 
blood pressure may be underestimated based of office BP 
Methods: 38 patients with peripheral vascular disease (PVD) included in the HOPE- 
study performed 24-hour ambulatory BP (ABP) measurement at inclusion and after one 
year. 
Results: (baseline BP and reduction at one year; m&SD; p values indicate differences 
between ramipril and placebo). 
BP at Baseline Ramipril BP reduction at Year one Ramipril 
Placebo (n=ZO) (n=l8) (n=ZO) Placebo (n=l8) 
Office SBP (mm Hg) 152 +/- 21 149+/-19ns 12+/-24 4 +I- 27 ns 
Office DBP (mm Hg) 83 +/- 7 79+/-12ns 5+/-IO 3+/-12ns 
24-h SBP (mm Hg) 148 +I- 19 153+/- 18 ns 12 +/- 15 2 +/- 10 p&03 
24-h DBP (mm Hg) 78 +I- 9 80 +/- 8 ns 5 +I- 7 1 +I- 6 pzo.03 
Day SBP (mm Hg) 153 +/- 20 159+/-19ns IO+/-15 4+/-12ns 
Day DBP (mm Hg) 83 +/- 9 84 +/- 9 ns 4 +I- 7 2 +I- 7 ns 
Night SBP (mm Hg) 136 +/- 20 142 +/- 19 ns 16+/- 16 -1 */- 11 p<o.o01 
Night DBP (mm Hg) 69 +I- 9 71 +/- 9 ns 7 +I- 7 -1 +/- 6 pcO.001 
Ramipril did not significantly reduce office or ambulatory day BP after one year. 24.hour 
BP however was clearly reduced (1014 mm Hg, p=O.O3). The reduction was more pro- 
nounced during nighttime (17/B mm Hg, pcO,OOi). 
Conclusion: ABP shows greater falls, especially at night, than office BP. However office 
BP is the correct comparator for the previous trials/epidemiology. The modest office BP 
fall seen in HOPE overall was similar to the fall in office as well as daytime ABP in this 
small substudy in PVD-patients. A different day/night variation of BP seems insufficient to 
explain the large benefits of ramipril in HOPE. 
869-2 
2:15 p.m. 
Muscle Sympathetic Nerve Activity in Hypertension: The 
Vera Trial comparing Nifedipine, Amlodipine, and Verapamil 
Christian Binggeli, Roberto Corti, Isabella Sudano, Thomas F. LOscher, Georg Nell. 
Cardio Vascular Center Cardiology University Hospifal , Zurich, Switzerland 
Background: The sympathetic nervous system (SNS) is an important regulator of the 
circulation. Its activity is increased in hypertension and heart failure and adversely affects 
prognosis. While certain drugs inhibit SNS, dihydropyridine calcium antagonists may 
stimulate the system. Phenylalkylamine calcium antagonists such as verapamil have a 
different pharmacological profile. We therefore tested the hypothesis whether amlodipine, 
nifedipine or verapamil differ in their effects on muscle sympathetic nerve activity (MSA). 
Methods: 45 patients (31 men, 12 women) with mild to moderate hypertension were ran- 
domly assigned to one drug for 8 weeks. Blood pressure, heart rate and MSA (by micro- 
neurography) were measured at baseline and after 8 weeks. Results: All calcium 
antagonists led to a similar decrease in blood pressure of 5.055.6 - 6.4k5.5 mmHg at 8 
weeks (p< 0.001 vs. baseline). There were no significant differences in MSA between 
groups. With amlodipine MSA averaged 49*12 b/min (+3.2 vs. baseline), with nifedipine 
4&l 1 b/min (+2.0 vs. baseline), and with verapamil49+8 b/min (-0.9; all n.s.). With vera- 
pamil norepinephrine decreased by 4%, but increased by about one third with amlodipine 
or nifedipine (ns.). Conclusion: In hypertension slow release forms of verapamil, nife- 
dipine and amlodipine do not change MSA and have comparable antihypertensive 
effects. Although there was a trend towards decreased MSA and plasma norepinephrine 
with verapamil, this did not reach statistical significance.lt is therefore unlikely that cal- 
cium antagonists do exert harm through activation of the sympathetic nervous system. 
869-3 
2:30 p.m. 
Delayed Left Ventricular Mass Reduction With Sustained 
Antihypertensive Treatment: The LIFE Study 
Richard B. Devereux, Vittorio Palmieri, Jennifer E. Liu, Kristian Wachtell, Kurt Boman, 
Eva Gerdts, Markku S. Nieminen, Vasilios Papademetriou, Bjorn Dahlof. Weill Come// 
Medical Center, New York NY 
Background:Studies documenting regression hypertensive lefl ventricular hypertrophy 
(LVH) by antihypertensive therapy have mostly been of short duration, leaving uncertain 
the long-term course of LV geometric response to blood pressure (BP) control. Methods: 
A total of 752 hypertensive patients with LVH by Cornell voltage-duration product or 
Sokolow-Lyon voltage criteria on a screening electrocardiogram were studied by 
echocardiogram at enrolment in the Losartan Intervention For Endpoint Reduction (LIFE) 
trial and after 12 and 24 months’ blinded therapy with losartan or atenolol based regi- 
mens. Results: Mean systolic (S)/Diastolic BP fell from 173/95 mm Hg to 150/84 after 1 
year (p<O.OOl) and148/83 mm Hg at year 2 (NS). Mean echocardiographic LV mass fell 
from 233 g at baseline to 206 g after 1 year (pcO.001, adjusted for change in SBP) and 
195 g at year 2 (pxO.001 vs year l), with parallel decrease in indexed LV mass (from 56.1 
g/m2.7 to 49.7 g/m2.7 (p<O.OOl) to 47.1 g/m2.7 (P<O.OOl vs year 1). Relative wall thick- 
ness decreased from 0.41 at baseline to 0.37 at year 1 (p<O.OOl) to 0.36 (P<O.OOl vs 
year 1). As a result there were serial decreases in prevalences of eccentric LVH (49% to 
44% and 37%[pcO.O01 vs year I]) and concentric LVH (26 % to 7% [p<O.OOl] to 
2%[pcO.O5 vs year I]) and increases in the proportion with normal LV geometry (17% to 
45% [p<O.OOl] and 57% [p<O.Ol vs year 11). Conclusions:Sustained blood pressure 
reduction in hypertensive patients with target organ damage as manifested by electrocar- 
diographic LVH results in continued decrease in echocardiographic LV mass and preva- 
lence of anatomic LVH for at least 2 years despite only small further decreases in BP 
after the first year Of blinded therapy. These data document cardiac benefit of sustained 
BP COntrol and suggest that maximum effect on LVH of an effective antihypertensive reg- 
imen may not be achieved for ai least 2 years. 
869-4 
2:45 p.m. 
Pulse Pressure as a Predictor of Cardiovascular Mortality. 
The Strong Heart Study 
Jacqueline Hollywood, Richard B. Devereux, Vittorio Palmieri, Jennifer E. Liu, Elise T 
Lee, Thomas K. Welty, Richard R. Fabsitr, Barbara V. Howard, Mary J. Roman. Weill 
Medical Co//ege of Come// University, New York, NY 
Backround: Pulse pressure (PP), a marker for large artery stiffness, is a predictor of car- 
diovascular morbidity and mortality. This study evaluates the relationship of PP to cardio- 
vascular mortality while accounting for target organ damage. Methods: 
Echocardiographic left ventricular (LV) mass and PP at baseline in 3,032 participants in 
the Strong Hearl Study, a study of cardiovascular disease in American Indians, were 
related to cardiovascular mortality over mean follow up of 3 years. Results: Participants 
with elevated PP (>65 mm Hg N=693, 23%) were older (64 versus 58 p < 0.001) without 
gender difference between groups. Elevated PP was associated with higher cardiovascu- 
lar mortality in participants; below/above 60years, with/without LV hypertrophy, withiwith- 
out hypertension, with/without diabetes and with/without coronary artery disease (CAD) 
(all p< 0.01). In a multivariate analysis, increasing PP predicted cardiovascular mortality 
(RR l.OZ/mmHg, p<O.O05) independent of age, heart rate, hypertension, CAD, diabetes, 
smoking, anti-hypertensive medications and LV mass. In a subsequant model in which 
systolic blood pressure (SBP) replaced PP, there was no relationship of SBP to cardio- 
vascular mortality (~~0.2) independent of the same set of covariates. When mean blood 
pressure (MBP) was added to the 2 previous multivariate models, higher PP (p<O.O05) as 
well as higher SBP in a separate model (p<O.Ol) were both related to cardiovascular 
mortality while higher MAP (both ~~0.05) was negatively related to cardiovascular mor- 
tality independent of covariates including LV mass. Conclusions: Elevated PP is a pre- 
dictor of increased cardiovascular mortality regardless of traditional cardiovascular risk 
factors and LV mass. The relation of SBP to cardiovascular mortality only in a multivariate 
model that includes MBP suggests a critical role of impaired coronary perfusion in the 
context of increased LV mass and afterload as a mechanism for increased cardiovascular 
mortality. 
869-5 
3:00 p.m. 
Antecedent Hypertension and Risk of Heart Failure After 
Myocardial Infarction 
A. Mark Richards, M.Gary Nicholls, Richard W. Troughton, John G. Lainchbury, 
Christopher Frampton, Eric A. Espiner, Hamid Ikram, Tim G. Yandle, John Turner. 
Christchurch School of Medicine, Christchurch, New Zealand, Christchurch Hospifal, 
Christchurch, New Zealand 
Background: Antecedent hypertension adversely affects mortality after acute myocardial 
infarction, but whether it also heightens the risk of acute or chronic heart failure post-inf- 
arction is less certain. We hypothesized that patients with hypertension would exhibit 
greater neurohumoral activation, more adverse ventricular remodelling and have a 
greater risk of clinical heart failure after myocardial infarction. Methods: Inpatient 
adverse events were documented in 1,093 consecutive patients (436 hypertensive and 
657 normotensive) with acute myocardial infarction. In 68% (282 hypertensive and 465 
normotensive) serial neurohormonal sampling and serial radionuclide ventriculography 
were performed at 1-4 days and again at 3-5 months post-infarction. Clinical outcomes 
were recorded over a mean follow-up of 2 years. Results: Plasma neurohormone con- 
centrations (the cardiac peptides and norepinephrine) were significantly higher in the 
hypertensive patients both l-4 days and 3-5 months post-infarct. Over this time, from 
similar initial values, left ventricular volumes significantly increased in hypertensives com- 
pared to normotensives. Lefi ventricular ejection fraction rose significantly in normoten- 
sive but not hypertensive patients. In addition to higher inpatient mortality (8.1% versus 
4.4%. P<O.OOZ) and post-discharge mortality (9.5% versus 5.5%, P=O.O43), hyperten- 
sives incurred more acute leff ventricular failure (33% versus 24%, P<O.OOl) as an inpa- 
tient and more later heart failure requiring readmission to hospital (12.4% versus 5.5%, 
P<O.OOi). Conclusions: A diagnosis of antecedent hypertension is associated with 
accentuated neurohumoral activation together with more adverse ventricular remodelling 
and confers greater risk of acute and chronic clinical heart failure after myocardial infarc- 
tion. These data, together with recent trial-based evidence suggest early aggressive anti- 
failure therapy should be considered in such patients. 
869-6 
3:15 p.m. 
Using the VA Electronic Medical Record to Identify and 
Follow Hypertensives: A 16 Month Report 
Ross D. Fletcher, Christopher D. McManus, Vasilios Papademetriou, Medhulika Agarwal, 
Ronald E. Jones. Department of Veterans Affairs, Washington, DC, Georgetown 
Universi% Washington, DC 
Background: The Department of Veterans Affairs (VA) has deployed a single Computer- 
ized Patient Record System (CPRS) throughout its 160-hospital network. The VA Medical 
Center in Washington DC, and several others, are now paperless, and can now query the 
vital signs component of the database for the presence of hypertension. Methods: We 
investigated using the Department of Veterans Affairs Computerized Patient Record Sys- 
tem (CPRS) to capture the total experience of hypertensive patients. For the past 16 
months, aggregate standard reports have been created, which compare percentage of 
current hypertension among each clinic and primary provider’s panel. These reports 
include names and pending appointments of each provider’s hypertensive patients, to 
facilitate intervention. Reports allow alternate criteria of elevation, such as BP >160/95, 
to track patients at special risk. Results: The following summary represents ali Washing 
ton VAMC patients with at least 3 successive elevated blood pressures. 
May 1999 
September 1999 
n % BP <140/90 
7,788 28.7 % 
9,108 33.2 % 
% BP <I 60/95 
52.1 % 
59.5 % 
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January 2000 
May 2000 
September 2000 
p < 0.0001 
10,277 34.3 % 60.6 % 
11,273 37.1 % 60.6 % 
11,960 40.2 %* 66.1 %’ 
Conclusion: The summary confirms a gradual and highly significant improvement, The 
data are presented to each outpatient care team, and to each primary care provider, for 
comparative feedback. Electronic problem lists are a common mechanism to identify 
hypertensive patients. Their limitation is shown by the fact that 49% of the patients who 
had at least 3 elevated blood pressures in the electronic record were not noted to have 
hypertension on the electronic active problem list. Thus, searching all vital signs mea- 
surements to determine elevations and return toward normal may become a new stan- 
dard for compliance in modern medical systems. 
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1258-159 HSP47 in Early Vascular Remodeling 
Alexander Jabs, Silvia Lentini, Juan J. Badimon, Valentin Fuster, Berndt Liideritz, 
Gerhard Bauriedel. Deparfmenf of Cardiology Universify of Bonn, Bonn, Germany, 
Cardiovascular Institufe, Mount Sinai Medical Center, New York, NY 
Background: Heat shock protein (HSP) 47, a collagen-specific molecular chaperone, 
has been reported to be involved in the formation and organization of atherosclerotic 
plaques. Angioplastic procedures induce remodeling processes of the vascular micro- 
and macroarchitecture. Thus, we sought to investigate the spatiotemporal pattern of 
HSP47 expression post angioplasty. 
Methods: Rat carotid arteries ware subjected to balloon overstretch injury. Animals were 
sacrificed at either Oh, 4d, 7d, 146 or 286 post injury (n=7 per time). HSP47 was detected 
in serial sections (4mm) by immunohistochemistry. Uninjured contralateral carotid arter- 
ies served as controls. 
Results: A parallel increase in adventitial (A) cell density and expression of HSP47 was 
seen from Oh to 4d (~~0.01). By day 7, HSP47 decreased in A, while neointima (N) for- 
mation started, revealing high cellularity and maximal HSP47 expression. Subsequently, 
HSP47 in N halved on day 28. While adventitial HSP47 decreased continuously, medial 
HSP47 remained constant. 
Oh 4d 7d 14d 28d 
Neointima E - 20,7,13,6 14,8&16,3 9,3*&O 
c 0 0 13,1+1,4 11,1+4,8 11,9*3,5 
Media E 5,3+5,2 5,6+3 4,6+3,6 5,7+6,4 6,1+5,3 
c 4,4*0,8 4,lr0,6 4,0*0,9 4,5+0,5 4,5+0,7 
Adventitia E 14,3+9,5 37,9*14,7 26,7$20,1 21,1~12,9 20,3*5,9 
c 1,6+0,5 9,0+3,8 6,2+2,9 2,7*0,8 2,2&0,5 
E, % expression; C, cells xlOs/mm* 
Conclusion: The spatiotemporal profile of HSP47 expression provides insight into the 
collagen-synthetic activity post angioplasty. Adventitial myofibroblasts rich in HSP47 may 
contribute to neointimal matrix formation following endovasal adhesion. Therefore, block- 
ade of HSP47 overexpression may prevent restenosis. 
1258-160 ER-fi Expression Correlates With Coronary Calcification 
and Atherosclerotic Plaque in Postmenopausal Women 
Rose C. Christian, Sean Harrington, Kris Shogren, William D. Edwards, Lorraine A. 
Fitzpatrick. Mayo C/inic, Rochester, MN 
Background: Estrogen receptor (ER)a activates target genes in vascular smooth muscle 
and endothelial cells. The role of ER-P in vascular tissue is less well established. Estro- 
gen status is associated with coronary calcification, an active regulated process and 
which is invariably associated with atherosclerosis. We studied the amount of ER-a and 
ER-P staining in the intima, media, and adventitia of coronary arteries obtained at 
autopsy from postmenopausal women on hormone replacement therapy (ERT) or not on 
hormone replacement therapy (non-ERT). Methods: Charts were reviewed for estrogen 
status and cardiovascular risk factors. Intact undecalcified proximal and distal arterial 
segments were fixed, embedded and contact microradiographs determined true calcium 
content. lmmunostaining determined expression of ER-a and ER-P in adventitia, media, 
and intima of each section. Results: Plaque area and calcium area increased with age in 
both ERT and non-ERT groups, but the amount of calcification and plaque was signifi- 
cantly greater in non-ERT women. ER-P expression was greater than E&a in all layers in 
both ERT and non-ERT women. The amount of ER-P in the intima layer was greater in 
untreated than in El?%treated women. Moveover, ER-P intima layer scores correlated 
with the extent of coronary artery calcification and atherosclerotic plaque in both ERT 
and non-ERT women. Conclusions: ER-a and ER-P are expressed in the coronary 
arteries of postmenopausal women. ER-P is present in higher amounts and correlates 
with the larger amount of calcification and plaque in non-ERT women. The increased 
expression of ER-P in the intimal layer correlates with calcification and plaque, suggest- 
ing that vascular calcification and atherosclerosis are modulated by an ER-P-mediated 
mechanism in postmenopausal women and may be negatively regulated by estrogen 
replacement therapy. 
1258-192 Macrophages and Vascular Stellate Cells in Human Carotid 
Plaques Are Prone to Apoptosis and Tissue Factor 
Expression 
Randolph Hutter, Bernhard Sauter, John T. Fallon, Valentin Fuster, Juan Jose Badimon. 
Cardiovascular Institute. Mount Sinai School of Medicine, New York, NY 
Background: Macrophages and vascular stellate cells contribute to vascular inflamma- 
tory processes. Tissue Factor (TF) has been implicated in the thrombogenicity of dis- 
rupted atherosclerotic plaques. Cells undergoing apoptosis (programmed cell death) 
have been postulated as a source for TF However, there is limited knowledge on the 
nature and origin of plaque cells exhibiting both TF and features of apoptosis. Methods 
and Results: Histological sections of human carotid atheroma obtained at surgery 
(n=12) were assessed for apoptosis-related expression of caspase-3 (CAS-3) and distri- 
bution of TF antigen by immunohistochemistry and immunofluorescence double-labeling. 
Macrophages were identified by CD-68 positive staining and vascular stellate cells by the 
co-expression of S-100 antigen and alpha-actin. TF and CAS-3 expression were highest 
in lipid-rich and myxomatous tissue (34 + 14 % and 24 + 12 %, respectively). Co-expres- 
sion of TF and CAS-3 on intimal cells in these areas was observed by immunofluores- 
cence double-labeling. Additional double-labeling studies in lipid-rich plaque areas 
showed an almost perfect colocalization of CD-68 antigen with TF and CAS-3 signals 
pointing to apoptotic macrophages as a source for TF. On the other hand, in myxomatous 
tissues TF and CAS-3 were mainly colocalized with S-100 antigen and alpha-actin posi- 
tive cells, indicating apoptotic stellate cells as another source of TF. Fibrosclerotic intimal 
tissue exhibited significantly less macrophages and stellate cells. Accordingly, expression 
of TF and CASB in this tissue was low. Conclusions: Positive CD-68 (macrophages) 
and S-100 (stellate) cells showing colocalization of TF and CAS-3 were identified in 
human carotid plaques. Macrophages coexpressing CAS-3 and TF were mostly localized 
in lipid-rich areas (vulnerable) whereas stellate cells were mainly found in myxomatous 
areas (plaque growth). Our data suggest that intimal apoptotic macrophages and stellate 
cells could serve as a source for TF. The presence of these proinflammatory cells, mac- 
rophages and stellate cells, indicate a possible role for inflammation in progression and 
thrombotic complications of carotid atherosclerosis. 
1258-193 Significance of Monocyte Chemoattractant Protein-l in 
Human Atherosclerosis: Assessment in Chronic 
Hemodialysis 
Kengo F Kusano, Yoichi Nakamura, Kazufumi Nakamura, Hitoshi Kusano, lsao Kusano, 
Tohru Ohe. Cardiovascular Medicine, Okayama Universify Medical School, Okayama, 
Japan, Fukushima Naika Clinic, Okayama, Japan 
Background: Although manocfle infiltration into the vessel wall mediated by monocyte 
chemoattractant protein-l (MCP-1) has been reported to be a key initial step in the pro- 
cess of atherosclerosis, none of the previous reports demonstrated correlation between 
MCP-1 and the severity of atherosclerosis in human vessels. We therefore investigated 
the role of MCP-1 and other factors that would affect atherosclerosis in hemodialysis 
(HD) patients. Method: A total of 52 non-diabetic HD patients (29 men and 23 women; 
age, 56+10 years; mean duration of hemodialysis, lO.Ir7.4 years) and 20 controls (age 
57+13 years) were investigated in this study. The degree of arterial sclerosis was 
expressed with the degree of intimal-medial thickness (IMT) in the carotid arteries evalu- 
ated by the ultrasound. Age, duration of hemodialysis, existence of left ventricular hyper- 
trophy (LVH), history of smoking, lipid profiles, lipoprotein (a), uric acid, fibrinogen, 
homocystein, and serum MCP-1 were measured and compared with IMT. In addition, 
expression of MCP-1 in the radial arterial tissues obtained from 18 HD patients were 
investigated immunoenzymatically. Results: The IMT of HD group was significantly 
greater than that of control group (0.89+0.20mm vs. 0.63+0.14mm; p<O.Ol). Serum 
MCP-1 of HD group was also greater than that of control group (457.3k152.8 pg/ml vs. 
246.2k96.3 pg/ml; p<O.O5). In HD group, univariate analysis revealed that the IMT corre- 
lated with age, serum MCP-I, smoking and LVH. Multiple regression analysis revealed 
that age, serum MCP-1, LVH and Apo A-l were independent factors influencing IMT. Tis- 
sue analysis revealed MCP-1 was constitutively expressed in both endothelial and 
smooth muscle cells. Semiquantitative immunostainings demonstrated that the tissue 
expression of MCP-1 was correlated with the serum MCP-1 (~~0.05). Conclusion: MCP- 
1 would be an important factor accelerating atherosclerosis in non-diabetic HD patients. 
1258-194 Internal Elastic Lamina in the Process of Plaque Disruption 
Pedro R. Moreno, K-Raman Purushothaman, Valentin Fuster. University of Kentuc& 
Lexington, K): Mount Sinai Medical Center, New York, NY 
Background: Disrupted atherosclerotic plaques exhibit a higher incidence of eccentric 
expansion, also known as positive remodeling. However, the intimal-medial biologic bar- 
rier may oppose to this process. Therefore, the mechanisms of remodeling may include 
disruption of the internal elastic lamina (DIEL). This study was designed to test the 
hypothesis that disrupted plaques will have a higher incidence of DIEL than non-dis- 
rupted plaques. Methods: Studies were performed on 193 histologic sections from 
advanced plaques taken sequentially at autopsy from 9 human aortas. Areas of DIEL per 
section were identified by trichrome staining. Plaques were classified as disrupted or 
non-disrupted according to the integrity of the fibrous cap. Plaque area, lipid area and 
cap thickness were quantified by computerized planimetry and ocular micrometry. 
Results: The incidence of DIEL was higher in disrupted than in non-disrupted plaques 
(p=O.OOl). Plaque areas and lipid areas were also larger, and cap thickness lower in dis- 
rupted than in nondisrupted plaques (pcO.001) (See Table). Areas of DIEL were charac- 
terized by macrophage infiltration, fibrosis, medial atrophy and zonal collapse of lamellar 
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unite. Multiple regression analysis identified plaque area as an independent predictor for 
DIEL disruption. Conclusion: Disrupted atherosclerotic plaques, which are character- 
ized by eccentric expansion have larger plaque areas and a higher incidence of DIEL 
when compared to non-disrupted plaques. Signs of inflammation and repair character- 
ized DIEL. These findings suggest an active role associated with DIEL in the pathophysi- 
ology of plaque expansion and remodeling of complex atherosclerotic lesions. 
Disrupted Plaques Non-Disrupted Plaques P Value 
DIEL 89% 57% 0.001 
Total Area (mm2) 12.9 15 9.3 + 5 0.0001 
Lipid Area (mme) 7.6 2 4 3.9 r 3 0.0001 
Cap Thickness (microns) 3424 227* 198 0.0001 
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1259-762 Regional Myocarclial Nitric Oxide Synthase 3 Gene Transfer 
Reduces Tissue-Specific Consequences of Anti aclenoviral 
Immune Response 
Zsolt Szelid, Peter Sinnaeve. Hilde Giilijns, Marijke Pellens, Veerle Laurysens. Natascha 
Van Pelt, Pieter Vermeersch, Anton-Jan Van Zonneveld, Erik Verbeken, Desire Collen, 
S&fan Janssens. Center for Transgene Technology and Gene Therapy: University of 
Leuven, Leuven, Belgium 
Background: The effect of preexisting anti-adenoviral immunity on local cardiovascular 
adenoviral gene therapy is unknown. Increased nitric oxide (NO) production following NO 
synthase 3 (NOS3) gene transfer in the heart may reduce the anti-adenoviral immune 
response. Methods: Adenoviral vectors (5xiO”pfu) carrying firefly luciferase (AdLuc) or 
human NOS3 gene (AdNOS3) were injected into the great cardiac vein of naive (n=12) 
pigs and pigs immunized by prior IV injection of 5x10gpfu adenoviral control vectors 
(wll). Neutralizing antibody (Nab) titers, assessed by the serum concentrations reduc- 
ing adenovirus infectivity by 50% of control values, were measured in these animals and 
in 26 consecutive CABG patients. Cardiac transgene expression levels 3’ days after 
AdLuc and AdNOS3 transfer were compared in naive and immunized pigs and rnyocar- 
dial inflammation graded according to the Society of Heart and Lung Transplantation Car- 
diac Rejection Working Formulation. Results: fmmunized pigs had high Nab titers 
(>1:2000), comparable to preexisting titers in 16126 patients. Luciferase expression 
(median light units, LUimg protein) was abrogated in the anterior wall in immunized pigs 
(7x10’ versus 1~10~ LUlmg protein in naive pigs, P=O.OOB). AdLuc transfer in immunized 
pigs triggered a grade illb-IV diffuse, moderate to severe inflammation and a significant 
rise in plasma CRP levels (l&5+3.7 versus 10.4i4.7 mg/L, PcO.05). In contrast, regional 
NOS expression measured by semi-quantitative RT-PCR using transgene specific prim- 
ers, remained detectable in immunized pigs (0.7~10” versus 1.6~10-~ fg NOS3 RNAIng 
GAPDH RNA in naive pigs, P=NS). AdNOS3 gene transfer in immunized pigs was asso- 
ciated with mild, unifocal grade lb-II myocardial inflammation and no change in plasma 
CRP levels (8.39~4.4 versw 1 lk5.2 mg/L, P=NS). Conclusion: Preexisting anti-adenovi- 
ral immunity abrogates intracardiac gene transfer efficacy and is associated with a 
~evare inflammatory response. Screening of patients considered for cardiovascular gene 
therapy is mandatory. Regional NOS3 gene transfer significantly reduced anti-adenoviral 
inflammation and may increase safety of intracardiac gene transfer. 
1259-163 Inhibition of Tissue Factor Induction by Blockade of the 
Nuclear Factor-KS Pathway in Human Macrophages and 
Endothelial Cells Using Adenoviral Gene Transfer: Nuclear 
Factor-rB as a Potential Therapeutic Target for Plaque 
Stabilization 
Claudia Monaco, Evangelos Andreakos, Marc Feldmann, Ewa Paleolog. Kennedy 
Institute of Rheumatology Division, Imperial Co//ege School of Medicine, London, United 
Kingdom 
Background: High content of tissue factor, the main initiator of the coagulation cascade 
in viva, has been detected in unstable coronary plaques. Recent studies suggest that 
nuclear factor-r6 (NFKB) is involved in the pathogenesis of atherosclerosis and acute 
coronary syndromes. We used an adenoviral gene delivery system to investigate the role 
of NFlcB and its upstream activator IxB-kinase 2 (IKK-2) in tissue factor expression in 
normal human macrophages and endothelial cells. Methods: Elutriation-enriched mono- 
cytes were obtained from peripheral blood mononuclear cells from blood donors, and cul- 
tured in the presence of macrophage-colony stimulating factor for differentiation to 
macrophage-like phenotype. Endothelial cells were isolated from human umbilical cords. 
Macrophages and endothelial cells were left uninfected or infected with adenowral vec- 
tors encoding IrBa, a natural inhibitor of NFKB nuclear translocation, or a dominant neg- 
ative form of IKK-2, or encoding Escherichia Co/if&galactosidase and having no insert as 
controls. Efficiency of infection was >95% at the multiplicity of infection of 1OO:l used. 
After infection, cells were stimulated with Lipopoiysaccharide (LPS). Tissue factor protein 
was measured by ELISA of cell lysates. Results: LPS (long/ml) stimulation of macroph- 
ages for 6 hours resulted in upregulation of tissue factor production, from 0.2+0.3 to 
5.6eO.3 ng per lo6 cells. Similarly, LPS (tpgfml) increased tissue factor expression by 
endotheliai cells from 3.8~05 ng to 16+0.5 ng per 10”cells. The increase in tissue factor 
production by both macrophages and endothelial cells was inhibited by 290% following 
IlcBa overexpression. However, in contrast, dominant negative IKK-2 overexpression 
resulted in inhibition 290% of tissue factor expression in endothelial cells, but not in mac- 
rophages. Conclusion: Differential signalling pathways that converge at the NFlcB level 
have a role in tissue factor expression in human macrophages and endothelial cells. 
Blockade of the NFKB pathway in macrophages and endothelial cells inhibits tissue factor 
induction. Hence, inhibition of NFKB pathway would be an effective therapeutic target in 
promoting plaque stabilization. 
1259-164 Role of Superoxide in the Reduced Nitric Oxide Activity 
Associated With Aging in the Pulmonary Vascular Bed of 
the Mouse: Influence of Gene Transfer of Superoxide 
Dismutase In Vivo 
Hunter C. Champion, Trinity J. Bivalacqua, Donald D. Heistad, Albert L. Hyman, Philip J. 
Kadowitz. Johns Hopkins Hospital, Baltimore, MD, Tulane Universit$ New Orleans, LA 
Nitric oxide (NO), a vasodilator involved in maintaing pulmonary vascular tone, is synthe- 
sized by the nitric oxide synthase (NOS) family of enzymes. It has been shown that NOS 
activity decreases with age. It has been proposed that this decrease in NOS activity may 
result from increased levels of superoxide. The purpose of the present study was to eval- 
uate the role of superoxide dismutase (SOD) in modulating pulmonary vascular 
responses in the aged mouse. The potential production of superoxide by membrane 
NADHiNADPH oxidase activation was investigated using iucigenin chemiluminescence 
and revealed higher superoxide levels in aged mouse lung when compared to young 
mice. This superoxide was primarily driven by membrane bound NADH/NADPH oxidase. 
In order to determine whether adenoviral-mediated overexpression of SOD could 
enhance pulmonary responses, we administered a recombinant adenovirus containing 
the SOD gene (AdCMVSOD) into the lung of the mouse. Adenoviral expression of the 
beta-galactostdase reporter gene was observed in lung tissue one day after intratracheal 
administration of AdCMVBgal. One day after administration of AdCMVSOD, transgene 
expression was confirmed by immunoblot staining of SOD protein and mRNA. Moreover, 
superoxide generation was lower in animals transfected with SOD when compared to 
animals transfected with the reporter gene. The decrease in pulmonary pressure in 
response to vagal nerve stimulation was enhanced in animals transfected with SOD and 
pulmonary vascular responses to acetylcholine was enhanced at a time when the 
response to the nitric oxide donor, DEAlNO was not altered. These data suggest that in 
viva gene-transfer of SOD can reduce superoxide levels in aged mice and selectively 
enhance vasodepressor responses to vagal nerve stimulation and acetylcholine. More- 
over, these data suggest that gene-transfer of SOD may alter vascular responses in the 
mouse in viva. 
1259-165 Prostacyclin Synthase Gene Transfer Inhibits Neointimal 
Formation in Rat Balloon Injured Arteries: The Possible 
Involvement of Cyclooxygenase-2(COX-2) 
Michiharu Yamada, Yasushi Numaguchi, Mitsunori Harada, Hideo Matsui, Kenji 
Okumura. Nagoya University School of Medicine, Nagoya, Japan 
Background: We have previously reported that prostacyclin synthase(PCS)gene trans- 
fer inhibits neointimal formation after arterial injury,but the role of each isozyme of COXs 
in this healing mechanism remains unknown. We hypothesized that overexpression of 
PCS could convert overspilt prostaglandinH2(PGH2) dominantly produced through COX- 
2 pathway into prostacyclin(PGI2) than PGE2. To evaluate this hypothesis we examined 
the effects of a selective COX-2 inhibitor on balloon-injured arteries after PCS gene 
transfer. Methods and Results: Rats were divided into four groups in conjunction with 
PCS gene transfer and COX-2 treatment(n=6 each).The PCS gene was transfected to rat 
carotid arteries by lipotransfection. COX-2 inhibitor(JTE-522: 30mg/kg/day, po) was given 
for 14days after balloon injury. PCS gene transfer prevented the increase in intimali 
medial area ratio (1.31r0.10 vs 0.51*0.12, p<O.Oi),but JTE-522 reversed this effect of 
PCS gene transfer (0.51r0.12 vs 1.29+0.07, p<O.Oi). Arterial segments transfected with 
PCS produced significantly higher levels of 6-keto-PGFialpha and decreased PGEP pro- 
duction compared with the segments of balloon injured arteries (8ketoPGFialpha: 
0.7&0.08 vs 2.53i-O.l4ng/mg tissue, p<O.Ol, PGE2: 79.556.7 vs 48.3r3.6pg/mg tissue, 
p<O.Ol), but JTE-522 inhibited PG12 production of arterial segments transfected with 
PCS (2.53+0.14 vs 1.48+0.20ng/mg tissue, pcO.01). In conclusions, COX-2 inhibitor 
reversed the benifical effects of PCS gene transfer after balloon injury. Overexpressed 
PCS exclusively converts PGH2 to PGI2 rather than to PGEP. Manipulation of prostag- 
landin metabolism distal to COX produces even more profound neointimal reduction than 
COX-2 inhibition and could be the basis for novel approaches to prevention of restenosis. 
1259-166 Prolonged L-Arginine Administration but Not Inducible 
Nitric Oxide Synthase Gene Transfer Reduces Neointima 
Formation After Stent Injury in Rats 
Pieter Vermeersch, Zengxuan Nong, Hilde Gillijns, Natasha Van Pelt, Olivier Varenne. 
Eugenio Stabile, Ivan De Scheerder, Desire Collen, Stefan Janssens. Cardiac Unit, 
University Hospital Gasthuisberg, Leaven, Belgium, Center for Transgene Technology 
and Gene Therapy: University of Leuven, Leuven, Belgium 
Background: Strategies to increase nitric oxide/cGMP signaling at sites of vascular stent 
injury may reduce neointima formation. 
Methods: The effect of L-arginine (L-Arg, 500 mg/kg/d IP for 14 days), the substrate for 
nitric oxide synthase (NOS), or local gene transfer with adenoviral vectors expressing 
inducible NOS (AdNOSP, 4x10” pfu/ml) or no transgene (AdRR5, 4x10” pfulml) on the 
response to stent injury was studied in rats. Stainless steel, 0.15 mm coil stents were 
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deployed in rat carotid arteries. Cell proliferation was measured using 5’-bromodeoxyuri- 
dine (BrdU) incorporation at different times after stenting and neointima formation was 
quantified morphometrically on plastic-embedded 5.mm sections. 
Results: Neointimal cell proliferation around stent struts started at 7 days, and pro- 
gressed to a circumferential neointima at 14 days (mean intima to media ratio, I/M 
2.3iO.2). Cell sorting of nuclear extracts from stented segments indicated l&8, 28+5, 
and 3327 % BrdU-positive vascular cells at 4, 7, and 14 days, respectively. Gene transfer 
efficacy of a reporter adenoviral construct expressing P-galactosidase was evidenced by 
histochemical staining of sections from infected stented segments. In L-Arg-treated rats, 
plasma L-Arg levels transiently increased greater than lo-fold without affecting systemic 
blood pressure. Neointimaformation 14 days after stenting was significantly smaller in L- 
Arg-treated than in uninfected stented rats (I/M 1.350.4 versus 2.3kO.2, FYO.01, n=7 
each). L-Arg-treated rats also had less neointima than AdRRS-, or AdNOSP-treated rats 
(I/M I.&O.4 versus P&0.4, n=7, and 1.8~0.8, n=8, respectively, PcO.01) while NOS2 
gene transfer had a partial effect in adenovirus-treated rats (PcO.05 versus AdRR5 only). 
Inflammatory cell infiltration was markedly less in L-Arg- and AdNOSP-treated rats than 
in AdRRB-infected rats. 
Conclusion: Supplemental L-Arg, the endogenous NO precursor, reduces neointima for- 
mation after stenting and may be a valuable strategy to target in-want stenosis. NOS2 
gene transfer reduces adenovirus-related vascular inflammation, but its efficacy to inhibit 
neointima may be partially offset by substrate limitation. 
1259-167 Adenovirus-Mediated Transfer of the Gene for a Truncated 
Transforming Growth Factor-6 Type II Receptor at the Time 
of Coronary Angioplasty Reduces Luminal Loss at 28 Days 
in a Porcine Model 
Paul A. Kingston, Sanjay Sinha, Maria G. Castro, Pedro R. Lowenstein, Anthony M. 
Heagerty. University of Manchesfer, Manchesfer, United Kingdom 
Background: Accumulation of extracellular matrix (ECM) is a major contributor to rest- 
enosis following coronary angioplasty. Transforming Growth Factor (TGF)-Pl plays a key 
role in regulation of ECM turnover and thereby represents a potential therapeutic target. 
Using an adenovirus vector (Ad5-Rlls) expressing a secreted form of the TGF-fi type II 
receptor (Rlls) that we have shown to antagonize TGF-pl in vitro, we tested the hypothe- 
sis that inhibition of TGF-j31 at the site of PTCA in a porcine model will inhibit luminal loss 
post-PTCA. Methods: Arteries were randomly allocated to receive 2 x109 infectious units 
of AdS-Rlls or Ad5-lacZ(expressing P-galactosidase) in 300~1 of vehicle, or 300~1 of vehi- 
cle only, delivered via an Infiltrator catheter to the site of angioplasty immediately post- 
PTCA. At 28 days post-PTCA the arteries were harvested and pressure fixed. Computer- 
ized morphometric analysis was carried out at the site of maximum luminal narrowing. 
Results: There was no significant difference pre-PTCA between the mean vessel diame- 
ter at the site of PTCA in each group as assessed by digital angiography. At 28 days 
post-PTCA the mean minimum luminal area in vessels receiving Ad5-Rlls was signifi- 
cantly larger than that of vessels receiving AdB-/acZor vehicle only (~~0.05 by ANOVA, 
see table). At the site of minimum luminal area, the AdB-Rlls treated vessels demon- 
strated small& mean neointimal area, smaller mean intimaimedia ratio, and larger mean 
area within the external elastic lamina than vessels receivina Ad&/acZ or vehicle onlv, 
although none of these parameters were statistically significant. 
Ad&Rlls Ad5-/acZ Vehicle p (by ANOVA) 
(n=12) (n=12) (n=ll) 
Luminal Area (mm’) 1.71 1.32 1.25 0.048 
Neointimal Area (mm*) 0.76 0.89 0.80 0.36 
I/M ratio 1.08 1.78 1.65 0.20 
EEL area (mm’) 3.26 2.89 2.73 0.079 
Conclusions: Antagonism of TGF-J31 at the site of PTCA by delivery of a recombinant 
adenovirus expressing Rlls results in reduced luminal loss 28 days post-PTCA. This is 
probably a consequence of reduced constrictive remodeling, although an effect on neoin- 
timal hyperplasia can not be excluded. Ad&Rlls represents a potential treatment for clin- 
ical restenosis and merits further investigation. 
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1260-168 Early Determinants of Left Ventricular Mass an Hypertrophy 
in Children and Adolecents: The Rio de Janeiro Study 
And& A. Brand&, Roberto Pozzan, Maria Eliane C. MagalhBes, Ayrton P. Brandlo. 
State University of Rio de Janeiro, Rio de Janeiro, Brazil 
Background: The identification of the possible determinant factors of the left ventricular 
mass (LVM) and left ventricular hypertrophy (LVH) in children and adolescents can be 
useful for primary prevention measures of cardiovascular diseases. Objective: To evalu- 
ate in youths the importance of anthropometric indexes, systolic blood pressure (SBP), 
diastolic blood pressure (DBP), and pressure pulse (PP), obtained 10 years earlier in the 
determinism of LVM and LVH in the adult age. Methods: 175 young (89 males) were 
examined at their schools in the years of 1987-88 (12.34 + 1.78 years old). There were 
obtained 3 supine BP measures, being registered the last for analysis and considered 
abnormal the 951h percentile of SBP, DBP and PP for sex and age. OVeweiQht was deter- 
mined as the percentile 2 90th for age and sex. PP was determined as the difference 
between SBP and DEP. Ten years later, (19.23 r 3.48 years old), all sample was evalu- 
ated with echoDopplercardiography according to American Society of Echocardiography. 
LVM = 1.05 X (VS + PW + LVDD)3 _ (LVDD)3, where LVDD: left ventricular diastolic diam- 
eter, VS: ventricular septum, and PW: posterior wall. It was considered LVH when LVM 
index (LVM/body surface area) was 2 125 g/m’. ResuI&: 1) It was found 9 individuals 
(5.1%) with LVH; 2) In a linear regression model, LVM showed positive and significant 
correlation with SBP @O-328), weigh (r=0.325), height (r=O.264) and PP (r=O.294) (p < 
0.001) obtained 10 years earlier; 3) In a multiple regression model controlled for weight, 
only PP maintained significant correlation with LVM (PC=O.490 p < 0.03); 4) Using logis- 
tic regression, it was observed that the presence of abnormal percentile PP was the only 
variable capable to determine the occurrence of LVH in the adult age (odds ratio = 9.725 
p c 0.03), even when school BMI was controlled. Conclusions: In youths, PP was the 
only variable capable to predict the occurrence of LVH 10 years after. 
1260-169 Depressed Plasma Levels of Extracellular Matrix 
Metalloproteinases 2 and 9 in Patients With Mild to 
Moderate Essential Hypertension 
Emanuel V. Economou, Christos R Pitsavos, Alexandra Zervoudaki, Konstantinos 
Tsioufis, Marina G. Toutouza, Konstantinos Kapetanios, Christodoulos I. Stefanadis, 
Pavlos K. Toutouzas. Depf. Cardiol., Univ. Athens, Hippokrafion Hospital, Athens, Greece 
Background: Previous studies on extracellular matrix metabolism in hypertension have 
focused on particular matrix metalloproteinases (MMPs)(e.g. MMP-1) mainly related to 
cardiac remodeling. This study was designed to quantify in a non invasive way the 
plasma concentrations of MMP-2 and MMP-9, two enzymes that share similar substrate 
specificity (collagen IV and gelatins A and B), mainly related to vascular remodeling us”- 
ally influencing peripheral resistances, in patients (pts) with mild to moderate essential 
hypertension (HP) before and after chronic treatment with the calcium antagonist amlo- 
dipine. Methods: Fourty two pts with never-treated HP were evaluated for plasma con- 
centrations of MMPP and MMP-9 (both measured by ELISA) before and after six months 
treatment with amlodipine and compared to 25 normotensive control subjects (CS). 
Results: Before treatment depressed values in HP pts over CS were observed for both 
MMP-2 (102+18 vs 124215 ng/mL, p<O.Ol) and MMP-9 (7.3+1.8 vs 15.9k3.2 ng/mL, 
p<O.O02). HP pts with total peripheral resistances (TPRs)< 1550 dynes.cm.sec-5 (16/42) 
exhibited higher values of MMP-2 and MMP-9 than HP pts with TPRs 21550 
dynes.cm.sec-5 (26142) (MMP-2 : ill+12 vs 97+10 ng/mL, p<O.O06 and MMP-9 : 
9.5*1.8 vs 5.4k1.2, pcO.001). Blood pressure and TPRs were both normalized after 
treatment (158/102 to 124/80 mmHg, p<O.OOl and 1742 to 1167 dynescmsec-5, 
pcO.001, respectively). Treated pts attained a non significant increase in MMP-2 plasma 
concentrations (105+12 nglmL) but a significant increase in MMP-9 plasma concentra- 
tions (16.4r2.3 ng/mL, pcO.01) compared to respective values before treatment. Conclu- 
sions: Plasma concentrations of MMP-2 and MMP-9, mainly related to vascular 
extracellular matrix metabolism, are depressed in HP pts. This may reflect decreased 
extracellular degradation of IV collagen and g&tines A and B which could contribute to 
increased TPRs-related vascular remodeling, since plasma concentrations of these par- 
ticular MMPs are lower in HP pts with the higher TPRs and are normalized when TPRs 
are normalized after treatment. Six months treatment with amlodipine can normalize 
MMP-9 but not MMP-P-mediated extracellular matrix metabolism. 
1260-170 Cardiovascular Effects of an Advanced Glycation End 
Product Breaker ALT-711 in Adult Spontaneously 
Hypertensive Rats 
Jasmina Varagic, Dinko Susie, Edward D. Frohlich. A/ton Ochsner Medical Foundation, 
New Orleans, LA 
Background: An increased accumulation and formation of advanced glycation end prod- 
ucts (AGES) that increase collagen CrOss-linking and thus aggravate fibrosis are associ- 
ated with adverse cardiovascular consequences of aging and hypertension. Therefore, 
this study was designed to determine the cardiovascular effects of prolonged treatment 
with a newly developed AGE cross-links breaker (ALT-711) in adult spontaneously hyper- 
tensive rats. 
Methods: Two groups of male spontaneously hypertensive rats were treated with ALT- 
711 (either 0.1 or 1 mg/kg: ALTO.1 and ALT-1 respectively) for 6 months. Untreated spon- 
taneously hypertensive rats served as controls. Left ventricular coronary blood flow 
(CBF), flow reserve (CFR), and minimal coronary vascular resistance (MCVR) were 
measured using radiomicrospheres in g-month old rats. Mean arterial pressure (MAP), 
peripheral resistance (TPRI), left ventricular (LVI), as well as aortic weight indexes (Awl) 
were also measured. There were at least 10 animals per group. 
Results: 
Control ALT-0.1 ALT-1 
MAP(mmHg) 173*6 171*6 156+6 
TPRI(U/kg) 
AWl(mg/mm/kg) 
Wmgig) 
CBF(mVmin/g) 
CFR(ml/minlg) 
MCVR(U/a) 
0.726+0.091 0.699r0.044 0.697kO.072 
3.243eO.076 3.074+0.067 2.807*0.072’ 
2.89120.043 2.862+0.051 2.706+0.054* 
5.935+0.655 4.914+0.288 4.5701tO.378 
4.379*1.237 4.688r0.611 4.12O~kO.772 
16.915e3.382 15.614*0.717 16.544+1.780 
x&EM:‘P<O.O5vsControl 
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Conclusion: The results of this study demonstrate that ALT-711 favorably affects cardro- 
vascular mass, although rt did not significantly affect either systemic or coronary hemody- 
namics in this experimental model of genetic hypertension. The presented data also 
indicate that ALT-711 may affect left ventricular function. 
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1260-171 Left Ventricular Mechanical Efficiency in Patients With and Tuesday, March 20, 2001, 3:00 p.m.-900 p.m. 
Without Increased Myocardial Mass and With Normal Pump Orange County Convention Center, Hall A4 
Function Presentation Hour: 3:00 p.m.-4:OO p.m. 
Alain Nitenberg, Alain Lo&au, lsabelle Antony. Hepita/ Lows Mourier, Coiombes, 
France, CHU Xavier-Bichat, Paris, France 
Background: Left ventricular hypertrophy (LVH) is a physiologrcal process of adaptation 
of the heart to mechanical load increase. Despite depression of left ventricular contractile 
performance, mechanical efftcrency and ventriculoarterial coupling are preserved in 
hypertensive patients with LVH. Methods: To assess the differences between patients 
with and without LVH, left ventricular contractile performance and the ventriculoarterial 
coupling were compared in 2 groups of hypertensive patients with similar body surface 
area and arterial pressures, and normal pump function (normal left ventricular end-dias- 
tolic volume and ejection fraction), 30 with LVH (Group 1) and 23 wrthout LVH (Group 2). 
Left ventricular angrography coupled with simultaneous recording of pressures with 
micromanometer were used to determine end-systolic stress-to-volume ratlo (ESSVR), 
end-systolic elastance (Ees), effective arterial elastance (Ea), external work (EW), and 
pressure-volume area (PVA). Results: Myocardial contractile performance assessed by 
Ees normalized by myocardial mass, and by ESSVR normalized by body surface area. 
were lower in Group 1 than in Group 2 (1.23+0.28 vs 1.89eO.48 mmHglmU1 OOg, and 
3.56iO.67 vs 5.13*0.56 g/cmZ/mUmZ, respectively, both p<O.OOl). Ventriculoarterial 
coupling evaluated through EaiEes ratio, and mechanical efficiency evaluated through 
EWiPVA ratio, were similar in the 2 groups (0.53iO.08 vs 0.51&0.05, and 0.78+0.03 vs 
0.80+0.02, respectively,NS). Conclusion: This study shows that ventriculoarterial cou- 
pling and mechanical efficiency are comparable in hypertensive patients with and without 
LVH. These results suggest that in hypertensive patrents, the matching between left ven- 
tricular performance and arterial load and the energy transfer are preserved through 
either left ventricular hypertrophy with moderate depression of myocardial contractile per- 
formance or enhancement of myocardial contractile performance in patients with normal 
ventricular mass. 
1261-173 Zd4522(Rosuvastatin) Compared With Diet and Maximal 
Lipid Therapy in Patients With Heterozygous Familial 
Hypercholesterolemia 
Evan A. Stein, Glenn Lamkin, Peter M. Laskarzewski, Michael D. Cressman. Metabolic 
and Atherosclerosis Research Center, Cincinnati, OH, Medical Research Laboratories, 
Highland Heights, KY 
We report the effects of the new HMG-CoA reductase inhibitor ZD4522 (rosuvastatin) in 
patients with Severe heteozygous familial hypercholesterolemia (HeFH) and baseline 
LDL-C >220mg/dL. Patients were screened (Wk.8) on usual lipid therapy (‘usual care’), 
consisting of high-dose statin, and in many patients, resin and niacin. After a 6wk wash- 
out period wrth AHA Step I Diet alone (Wk 0), they were randomized to an 18sweek, 3- 
period, 2.arm, multicenter, double-blind trial comparing ZD4522 and atorvastatin at 20, 
40 and 80mgIday (452211/0030). On completion, patients then entered an open label 
extension trial with 8Omgiday ZD4522 (4522lUOO34). While the original trial remains 
blinded, response after 8 wks (Wk 6) of open-label ZD4522 in 47 HeFH patients (22F; 
25M; age 47+14yrs) IS shown below (meaniSD;mg/dL). Compared with diet (DWkGvsO) 
or usual care (DWkGvs-6), ZD4522 offered substantial reductions in total cholesterol(TC), 
LDL-C and triglyceride(TG), including an additional 23% reduction in LDL-C over usual 
care. ZD4522 also produced significant elevations in HDL-C over diet alone. In these 
patients, 92%, 70% and 21% achieved LDL-C ~160, cl30 and <IO0 mg/dL, respectively, 
compared with 51%, 20% and 7% on usual care. ZD4522 was well tolerated; no clini- 
cally significant elevations (>3xULN) in ALT AST or CK were seen. For patients with 
HeFH, these data suggest that ZD4522 offers a significant additional benefit in all major 
lipid fractions above that of either diet or prior maximal lipid therapy. 
1260-172 Local Activation of Angiotensin System in the Atherotic 
Human Arterial Wail: Effects of Type 2 Diabetes and 
Smoking 
Lilrana Legedz, Jacques Aandon, Jean-Louis Magne, Jean-Michel Mallion, John L 
MacGregor, Giampiero Bricca. INSERM lJ331, Bran, France 
(Wk.6) W 0) Wk 6) ChgWk6vsO Chg Wk 6 “s -6 
LDL-C 173zt64 292r57 122ct35 -58%+1 1 %* -23%+29% 
Total-C 254+68 376263 199240 -47%i9%’ - 18%+2 1% 
Triglyceride 126t59 172~71 103238 -37%*19%* -9%+37% 
HDL-C 55214 50+12 56514 +15%*16% +3%*11% 
*p<O.OOO1’pcO.O5 (By Wilcoxon Rank Sum Test) 
The rencn angiotensin system (RAS) has been directly involved in the vascular remodei- 
ing associated with atheroma rn animal models and ACE inhibitors have proved highly 
efficient in preventing cardiovascular events in high risk patients. However in human, very 
lithe is known about how risk factors interact with the RAS to induce cardiovascular dam- 
age. We tested the hypothesis that risk factors activate local RAS and thus promote vas- 
cular remodeling by measuring with semi quantitative RT-PCR, the transcriptionnal 
modifications of the RAS and kallikrein-kinin system components rn human carotid ather- 
oma of hypertensive patients with or without non-insulin-dependent diabetes mellitus 
(NIDDM, n=7) and with or without tobacco smoking habits (n=7). RNA from atheroma 
plaque, fatty streaks and macroscopically intact adjacent tissue were obtained from 15 
nypertensive patients undergoing carotid endarteriectomy (mean age : 72 + 8, 12Mi3F 4 
NIDDM + smoking). RT-PCR was performed simultaneously for the 3 samples of each 
patient and normalized to 18s rRNA. cDNAs ior renin, AT2 receptor and kininogen 
mRNAs were never detected. No relationshrp was found between mRNA level and drug 
regimen. Angiotensinogen (AGT) and ACE mRNA levels were higher in diabetic patients 
versus non diabetrcs (3-fold and Z-fold respectively) when kallikrein mRNA was 
increased (3 fold) in smoking patients. Moreover, for ACE, AGT and AT1 receptors, the 
mRNA levels detected in the arterial wall, were significantly stepwise increased with the 
number of risk factors, (NIDDM and/or tobacco smoking). ACE and kallikrein were signif- 
icantly and highly increased (5 and 10.fold respectively) and AT1 mRNAs decreased (3. 
fold) in atheroma compared to intact tissue. AT1 receptor mRNA was also srgnificantly 
decreased (2.fold) in the fatty streaks versus intact tissue. This report shows that NIDDM 
and tobacco are strong activators of the local RAS in the carotid arterial wall. Further, it 
provides an explanation for the clinical benefit of ACE inhibitors in this type of high risk 
patients. Moreover. it indicates that not only RAS is activated in the atheroma but also 
that RAS and risk factors act synergistically rn the remodeling of the arterial wall. 
1261-174 ZD4522 Is Superior to Pravastatin and Simvastatin in 
Reducing Low Density Lipoprotein Cholesterol, Enabling 
More Hypercholesterolemic Patients to Achieve Target Low 
Density Lipoprotein Cholesterol Guidelines 
Rodolfo Paoletti, Maurice Fahmy, Gerhard Mahla, Jacques Mizan, Harry Southworth. 
University of Milan, Milan, /la& Southlea Surgery, Aldershot, United Kingdom 
Background: ZD4522 (rosuvastatin) is a new statin that has demonstrated potent, dose- 
dependent low-density lipoprotern cholesterol (LDL-C)-lowering effects of up to 65% in 
clinical trials. This randomized, double blind, multicenter trial (452X/0027) compared 
the effects of ZD4522 with pravastatin (PRA) and simvastatin (SIM) in primary hypercho- 
lesterolemic patients. Methods: 502 patients (218 years), with LDL-C levels 2160 mg/dL 
and ~250 mg/dL and triglyceride (TG) levels 5400 mg/dL were randomized to 12 weeks 
of treatment with ZD4522 5 mg/d (n=120): ZD4522 10 mg/d (n-115); PRA 20 mgid 
(n=137); or SIM 20 mgid (n=l30). Results: ZD4522 5 and 10 mg reduced LDL-C by42% 
and 49%, respectively, compared with 28% for PRA (pcO.001 vs. both ZD4522 doses) 
and 37% for SIM (pcO.01 vs. ZD4522 5 mg and p<O.OOi vs. ZD4522 10 mg). More 
patients achieved National Cholesterol Education Program (NCEP) target LDL-C levels 
following treatment with ZD4522 than with PRA or SIM; 87% of 204522 10 mg patients, 
71% of ZD4522 5 mg patients, 53% of PRA patients, and 64% of SIM patients. The 
apparent advantage of ZD4522 treatment was most marked in the high-risk group with 
42%, 67%, 7% and 19%, respectively, of patients achieving target LDL-C levels across 
the four treatment groups. ZD4522 5 and 10 mg were also associated wrth statistically 
significant reductions in total cholesterol (TC) and apolipoprotein (apo) B levels and sig- 
nificantly greater improvements in lipid ratios (table). Favorable reductions in TG and ele- 
vations in HDL-C were noted for all treatment groups. All treatment regimens were well 
tolerated. 
% Change in Lipid Values at 12 Weeks 
*poB LDLC HDL-C TC TG DL.C/ ICIHDL- “On-HDL- APOB, 
HDL-C c c, HDL-C Ape Al 
201522 5 42 J is -3O’.J -12 -33’* r7 -45’-’ -33’” -41’J a,‘.’ 
;1:4522 -49’2 17 -34 * -18 49’2 +5 +,,u 48’ 2 -47’ 2 ..Q.* 
,rlmg 
PRA 20 -28 il -20 -13 -21 +4 -29 -22 -271 -23 
w 
SlM2omg -37 14 46 -14 -29 4 -39 -28 45 32 
‘pcO.001 vs PRA; ‘pcO.001 vs SIM; 3p<0.01 vs SIM; 4p<0.05 vs SIM Conclusion: 
ZD4522 5 and 10 mg are superior to both pravastatin 20 mg and simvastatin 20 mg in 
reducing LDL-C levels in hypercholesteroiemic patients and resulted in more patients 
attaining target LDL-C levels. 
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1261-175 2D4.522 Is Superior to Atorvastatin in Decreasing Low 
Density Lipoprotein Cholesterol and Increasing High 
Density Lipoprotein Cholesterol in Patients With Type Ila or 
Ilb Hypercholesterolemia 
Michael H. Davidson, PatrickT. S Ma, Eva” Stein, Howard G. Hutchinson, Rohini Chitra, 
Ali Raza, Antonio Gotto, Jr.. Chicago Center for Clinical Research, Chicago, IL, Heart 
Health institute Research Clinic, Ca/gary Canada 
Background: Despite the availability of several HMG-CoA reductase inhibitors, many 
patients still fail to achieve the National Cholesterol Education Guidelines (NCEP) low- 
dBnsity lipoprotein cholesterol (LDL-C) targets after initiation of therapy. This may neces- 
sitate dose titration and additional clinic visits. ZD4522 (ZD; rosuvastatin) is a new, highly 
efficacious Statin which achieved up to 65% LDL-C lowering in clinical trials. This trial 
(45221UOO24) compared ZD with atorvastatin (ATV) and placebo to evaluate overall lipid 
modifying effects and achievement of NCEP LDL-C goals. Methods: A multicenter, ran- 
domized, double blind, placebo-controlled trial of 516 patients (216 years) with primary 
hypercholesterolemia (LDL-C 5160 and ~250 mg/dL; triglycerides (TG) SO0 mg/dL). 
Following a 6-wk dietary lead-in, patients received once-daily treatment with placebo, 
ATV 10 mg, or ZD 5 or 10 mg for 12 wks. Results: The groups were well-balanced with 
regard to age, race, gender, body mass index, and baseline lipid levels. The effects of 
treatment on the percentage change from baseline (+/-SE) for various lipid parameters at 
wk 12 are shown below (T&total cholesterol; HDL-C=high density lipoprotein choles- 
terol). 
N TC LDL-C ApoB TG HDL-C Apo Al 
Placebo 132 O(l) ‘J(1) +4(l) -l(2) +4(l) +3(1) 
ATV 10 mg 127 -25(l) -35(i) -26(i) -19(2) i-au ) +3(l) 
ZD5mg 128 -za(lpd -40(1pc -31 (ipc -17(3pns +13(p +7(lpd 
ZDlOmg 129 -3o(l)a,b -43(l)@ -33(l)a.b -19(3y +12(l)a,d +7(l)Q 
ap<O.OO1 vs placebo; bpeO.OO1 vs ATV; cpcO,O1 vs ATV; dp<0.05 vs ATV; “‘not signicant 
vs ATV NCEP target goals for LDL-C were achieved by 64% of patients in each ZD group 
compared with 73% in the ATV group. The difference was evident in all risk categories 
and more marked in the high-risk patients (target LDL-C 5 100 mgidL) where 42%, 47% 
and 19% reached goal with ZD 5 and 10 mg, and ATV 10 mg, respectively. Conclusion: 
ZD4522,5 and 10 mg, is superior to ATV 10 mg in lowering LDL-C, TC and Apo Band in 
raising HDL-C and Apo Al levels. These findings, along with a potential advantage in get- 
ting more patients achieving NCEP goals, make ZD4522 a promising new medication for 
the treatment of dysllpidemias. 
1261-176 ZD4522 Is Superior to Atorvastatin in the Treatment of 
Patients With Heterozygous Familial Hypercholesterolemia 
Eva” Stein, Kristina L. Strutt, Elinor Miller, Harry Southworth. Metabolic and 
Atherosclerosis Research Center, Cincinnati, OH, AstraZeneca, Macclesfield, United 
Kingdom 
Background: Heterozygous familial hypercholesterolemia (HeFH) is a common genetic 
disease leading to premature ischemic heart disease. ZD4522 (rosuvastatin) is a new 
statin with potent, dose-dependent LDL-C-lowering effects. The primary objective of this 
trial (45221UOO30) was to compare the efficacy of ZD4522 with that of atorvastatin in the 
reduction of LDL-C in patients with HeFH. Methods: A randomized, double blind, paral- 
lel-group, forced-titration, comparative trial conducted at 56 centers worldwide. Entry cri- 
teria included patients (216 years) with HeFH (based on clinical and/or genetic criteria), 
mean fasting LDL-C concentrations 2220 mg/dL (5.69 mmol/L ) but ~500 mg/dL (12.93 
mmolil), and fasting triglycerides (TG) 5400 mg/dL (4.52 mmol/L). Following a 6-week 
dietary run-in period, there was a weighted randomization to once-daily treatment with 
ZD4522 (n=435) or atorvastatin (n=167); initially 20 mgid, and force-titrated at 6-week 
intervals to 40 mgid and then 60 mg/d (16 weeks on treatment in total). Results: ZD4522 
reduced LDL-C, TC, and Apo B and increased HDL-C and Apo Al significantly (p<O.OOl) 
more than atorvastatin (see table). Similar statistical benefits were also observed at 2, 6 
and 12 weeks. At all time points, the LDL-C/HDL-C ratio was improved by 220% more fol- 
lowing ZD4522 than atorvastatin. Reductions in TG were similar in both treatment 
groups. 
% change from baseli”e’~2 % patients achieving 
NCEP goals’ 
APO LDL-C / High risk 
LDL-C HDL-C TC TG B Ape Al HDL-C All categories2 group3 
204522 20, -58. 
40180 mgid 
112’ -46’ -2P -50’ +d .62’ 61 24 
mlY%ta- 
tin*o1401*o -50 +3 -42 -32 -44 -2 41 46 3 
ma/d 
‘16 week data; ‘ZD4522 n=435, atorvastatin n=167; ‘ZD4522 n=134, atorvastatin n=63; 
‘p<O.OOi vs atorvastatin; nSnot significant vs atorvastatin. In addition to the effects on lip- 
ids, more patients achieved National Cholesterol Education Program (NCEP) goals with 
ZD4622 than atorvastatin. Adverse events were similar in both treatment groups. Con- 
clusion: ZD4522 was highly efficacious and reduced LDL-C and increased HDL-C sig- 
nificantly more than atorvastatin, thus enabling more patients with HeFH to attain NCEP 
LDL-C goals. ZD4522 was well tolerated. 
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1262-177 Quantitative Evaluation of the Changes in Plasma Levels of 
Cardiac Natriuretic Peptide Before and After Transcatheter 
Closure of Atrial Septal Defect 
Hiromi Muta, Masahiro Ishii, Wakako Himeno, Teiji Akagi, Hirohisa Kato. Kurume 
University Kurume, Japan 
Background: Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are 
known to useful biochemical markers that reflect hemodynamic status. ANP and BNP of 
congenital heart disease patients are higher than those of healthy children. But it is 
unclear that the effect of atrial septal defect (ASD) closure on ANP and BNP. A new tech- 
nique using the Amplatzer septal occluder device was developed for the transcatheter 
closure of ASD. This experlmental model provides a unique condition in which pulmonary 
blqod flow is actually changed without the effects of cardiopulmonary bypass. The pur- 
pose of this study was to investigate the changes of ANP, BNP in patients with ASD after 
transcatheter closure of defects before and after the procedure. Methods: ANP and BNP 
ware obtained from 14 patients with ASD before closure, just after, 24 hours after, 1 
month after, and 3 months after transcatheter ASD closure using Amplatzer septal 
occluder. ANP and BNP were measured directly with specific immunoradiometric assay 
kits. Results: Compared to control values (15.9+-4.9 pg/ml, 11.7+-4.9 pgiml), ANP 
(24.0+-9.6 pgiml) and BNP (l&6+-9.9 pgiml) levels before ASD closure were signifi- 
cantly elevated (~~0.05). ANP levels increased significantly at just after closure (33.7~. 
17.7 pgiml, pqO.05) when compared to pre-closured levels. At 24 hours post closure, the 
levels had significantly decreased (19.1+-10.5 pglml, ~~0.05) compared to the levels of 
just after closure. One month after, ANP levels ware similar to control values (p=NS). Just 
after closure, BNP levels (23.2+-14.1 pgiml) significantly elevated and continued to rise 
at 24 hours after closure (31.6+-10.6 pg/ml) when compared to pre-closure levels 
(~~0.05). Like ANP, BNP levels gradually decreased at 3 months post closure (12.1+-6.3 
pg/ml, ~~0.05). Conclusions: Plasma levels of ANP and BNP have the possibility of 
effective markers evaluating the intracardiac hemodynamic status after catheter interven- 
tion. 
1262-179 Prognostic Value of Natriuretic Peptides and Heart Rate 
Variability in Patients With Optimized Treatment After an 
Acute Myocardial Infarction 
Jari M. Tapanainen, Olli Vuolteenaho, Juhani LeppBluoto, Heikki V. Huikuri. Division of 
Cardiology, Dept of Internal Medicine, Oulu University, Oulu, Finland 
Background: Plasma levels of natriuretic peptides and indices of cardiovascular auto- 
nomic regulation, such as heart rate variability (HRV) and baroreflex sensitivity (BRS), 
predict mortality after an acute myocardial infarction (AMI). This study was designed to 
compare the predictive power of natriuretic peptides, HRV and BRS in a multiple risk fac- 
tor analysis trial (MRFAT) of AMI survivors. Methods: Plasma concentrations of atrial 
natriuretic peptide (ANP), N-terminal atrial natriuretic peptide (NT-ANP) and brain natri- 
uretic peptide (BNP), standard deviation of RR-intervals (SDNN) analyzed from 24-h 
ECG recordings, BRS using phenylephrine method and echocardiographic wall motion 
Index (WMI) were measured prior to discharge in 342 AMI survivors with the predefined 
treatment strategy of optimal medical and revascularization therapy in this single-center 
MRFAT. Results: Total mortality was 6.2 % (26/342) after the maximum follow-up of 2 
years (mean 556 * 166 days). In univariate analysis, high levels of NT-ANP and BNP, 
advanced age, reduced SDNN, BRS, WMI and functional class were associated with 
increased mortality. After adjusting for age, WMI and NYHA class, high NT-ANP and low 
SDNN remained independent predictors of mortality. Conclusions: Measurement of 
plasma levels of NT-ANP and HRV complement each other in risk stratification after an 
AMI. In patients with optimized therapy, these variables still provide important indepen- 
dent prognostic information. 
Predictors of All-cause Mortality in Cox Regression Analysis 
Univariate Analysis Multivariate Analysis 
NT-ANP p<0.0001*** p=O.O016** 
BNP p=O.O234’ NS 
SDNN p=0.0020** p=o.o056” 
BRS p=o.o344* NS 
1262-180 Dual Natriuretic Peptide Response to Volume Load in the 
Fetal Circulation 
Thomas Walther, Holger Stepan, Renaldo Faber. UK66FU, Berlin, Germany, 
ObstGynec-University Leipzig, Leipzig, Germany 
Background: Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are 
members of a family of structural related peptides that participate in integrated control of 
cardiovascular and renal function. ANP, secreted by the atrium, and BNP, mainly 
secreted by the ventricle, are circulating peptides that respond to increases in intracar- 
diac pressure. The current study was designed to investigate the response of ANP and 
BNP to cardiac short-term and long-term volume load in the human fetus. Methods: fetal 
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blood samples were collected from 18 fetuses (9 controls, 9 anemic fetuses with rhesus 
isoimmunization before and after intravascular transfusion). Fetal ANP and BNP concen- 
trations were measured and compared to maternal plasma levels. Results: Both, ANP 
and BNP, were significantly higher in fetal blood compared to the mothers. Fetuses with 
Rhesus isoimmunization showed significantly elevated ANP but not BNP concentration 
compared to the fetal controls (80.8 + 16.6 pglml vs. 31.6 * 7.7 pgiml). However, short- 
term volume load due to intravascular transfusion leads to a significant increase of the 
fetal BNP- but not ANP- plasm? level (112.9 + 14.1 pgiml vs. 64.8 j: 6.8 pg/ml). Conclu- 
sion: ANP and BNP respond differently to cardiac short and long-term volume load in the 
fetal circulation. Therefore, the fetal and adult cardiac natriuretic peptide system behave 
similarly to volume stimuli. 
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1263-182 ACE Inhibitor Augments the Release of Tissue Plasminogen 
Activator Induced by Bradykinin in the Human Coronary 
Circulation 
Karua Minai, Tetsuya Matsumoto, Hajime Horie, Naoto Ohira, Hiroyuki Takashima, 
Hiroshi Yokohama, Masayuki Takahashi, Masahiko Klnoshita. First Deparfmenf of 
hfernal Medicine, Shiga Universify of Medical Science, Otsu, Japan 
Background: Bradykinin (BK) is a potent 
stimulus for tPA secretion in endothelial 
cells. Angiotensin-converting enzyme 
?~OO * I 
g xm * 
(ACE) inhibitor favorably alters the fibrin- T 400 ka.Qw2 
olytic balance by inducing a decrease in p 300 
angiotensin II levels and an increase in BK 
& 200 1 
levels. However, the effect of BK on tPA 
g 100 * * 
‘-10: E 
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release in the human coronary circulation 
has not been studied. Methods: 56 
(I 0.2 0.6 2.0 Yi&-z- 
Bndykiain( !A &mio, 
patients whose coronary arteries appeared 
to be normal by angiography were ran- 
domly assigned to 2 groups: 25 patients treated with an ACE inhibitor (ACEI group) and 
31 patients not treated with ACEI (no-ACE1 group). Graded doses of BK (ZOO, 600, 2000 
nglmin), acetylcholine (ACh) and papaverine (12 mg) ware infused into the left coronary 
artery and coronary blood flow (CBF) was evaluated by quantitative angiography and 
Doppler flow velocity measurement. Blood samples were taken from the aorta (Ao) and 
the coronary sinus (CS) for measurement of transcardiac tPA antigen release. Results: 
BK induced similar increases in CBF in both groups. In the ACEI group, BK caused a 
dose-dependent increase in tPA antigen levels in both the Ao and the CS, whereas this 
effect was observed in the CS but not in the Ao in the no-ACE1 group. The net tPA release 
induced by BK, i.e., CBF X (1-hematocrit) X (tPA in the CS tPA in the Ao), was 
increased in both groups and the extent of increase in the ACEI group was markedly 
greater than that in the no-ACE1 group. BK did not alter plasminagen activator inhibitor-l 
(PAI-I) levels in the Ao or CS in either group. Neither ACh nor papaverine, which showed 
a vasodiiator effect equipotent to that of BK (2000 ng/min), altered tPA levels or PAI- lev- 
els in either group. Conclusion: lntraccronary infusion of BK stimulates tPA release with- 
out causing any change in PAI- levels in the human coronary circulation. In addition, this 
stimulatory effect of BK is augmented by an ACE inhibitor. 
1263-183 L-Arginine Prevents Tolerance During Continuous 
Transdermal Nitroglycerin Therapy 
John 0. Parker, Wayne H. Kaesemeyer. Queens Universifx Kingston, ON, Canada, 
Medical Cokge Of Georgia, Augusta, GA 
Continuous transdermal nitroglycerin (TGTjI) induces tolerance within 24 hours with 
complete loss of antianginal effects as assessed by treadmill walking time (TWT). Dimin- 
ished L-arginine (LA) availability has been implicated as a factor in the development of 
tolerance. This hypothesis was tested in a randomized, double blind, placebo controlled, 
CrosSOver study in 14 patients with stable angina pectoris. Each patient was a nitrate 
responder and had reproducible TWT to moderate angina during 2 consecutive teats. 
TGTN, 0.4 mglh was applied each morning and left in place for 24 hours for 2 periods of 
5 to 10 days separated by a 4 day nitrate free interval. Capsules of LA (700mg) or pla- 
cebo (PL) were given 4 times daily during the treatment periods. TWT was determined 
on the final day of each study period at Oh (24h after TGTN and 1 Oh after the study cap- 
sule), and 4h after TGTN application and study capsule. 
Results:wT (sets) mean +I- SD 
TGTN+LA TGTN+PI TGTN (LA vs PL) 
4h 314 +/- 95 288 +I- 96 Cl 1.3, 49.4 
24h 304 J- 100 274 +I- 93 Cl 2.7, 51.1* 
* = PcO.05 
Conclusion: Oral LA in a dose of 700 mg foul times daily increased TWT during contin- 
uous TGTN at 4 and 24h. The prevention of tolerance suggests that decreased LA avail- 
ability is an important mechanism for the development of nitrate tolerance. 
1263-184 Coronary Reactivity to Acetylcholine Varies With a 
Polymorphism in the Angiotensin II Type 1 Receptor Gene 
in Women: Data From the NHLBI-Sponsored Women’s 
lschemia Syndrome Evaluation (WISE) Study 
Greg 0. “on Mering, Carl J. Pepine, Susan P. McGorray, Richard A. Kerensky, Paul K. 
Humphiett, Sheryl F. Kelsey, Dennis M. McNamara, Steven E. Reis, Barry L. Sharaf, 
George Sopko, Daniel F. Pauly. University of Florida, Gainesville, FL 
Background: Coronary vasodilator dysfunction (CVD) with acetylcholine (Ach) predicts 
adverse cardiovascular outcome independent of CAD severity according to several stud- 
ies including the WISE. The renin-angiotensln system (RAS) is linked to endothelial func- 
tion and CAD. We hypothesized that the angiotensin II type 1 receptor (AT, R) gene is a 
significant variable in determining CVD. Methods: One hundred and sixty three women 
with chest pain and CAD risk factors referred for coronary angiography underwent quan- 
titative coronary angiography (QCA) and intracoronary Doppler flow following intracoro- 
nary Ach to assess CVD. This was measured as percent change in coronary cross 
sectional area (%ACSA), with positwe values indicating dilation and negative values mdi- 
eating constriction. Patients were categorized on the basis of QCA as no CAD (n=75), 
mild CAD (20-49% stenosis, n=50) and significant CAD (250% stenosis, n=38). Polymor- 
phisms at positions 573,1062 and 1166 of the AT, R gene were evaluated in 120 women. 
Results: Abnormal response to Ach (i 0% %ACSA) occurred in 52% of women with no 
CAD, 56% with mild, and 79% with significant CAD. The %ACSA with Ach varied signifi- 
cantly with CAD severity with median values: +82%(dilation) for none, 0% for mild and - 
14.8% (constriction) for significant (p=O.Oi 1). There was no association between geno- 
type and CAD severity (~~0.57). The allele frequency for a thymine (T) polymorphism at 
position 573 was 36% and for cytosine (C) was 64%. Abnormal response to Ach was 
associated with the CC genotype with a median %ACSA of -8.4% whereas the T allele 
(TT or CT genotypes) was associated with a median of 23.9% (p=O.O3). Sites 1062 and 
1166 showed no association with CVD. Conclusions: Regardless of angiographic CAD 
status, a majority of the women studied had abnormal CVD. A polymorphism at position 
573 in the AT,R gene was associated with response to Ach. These findings of interplay 
between CAD, AT,R genotype and coronary response to Ach, suggest a genetic compo- 
nent of coronary endothelial dysfunction, linking the abnormality with the RAS in women. 
1263-185 Racial Differences in Endothelium-Dependent and - 
Independent Dilation of Large Arteries 
Umberto Campia, Wassim K. Choucair, Melissa 8. Bryant, Carmine Cardillo, Julio A. 
Panza. National lnsfitutes of Health, Bethesda, MD 
Background: Compared to Caucasians, African Americans have higher prevalence of 
cardiovascular disease and its complications, which may be related to reduced nitric 
oxide-dependent and -independent vasodilation of the microvasculature. However, 
whether a similar impairment is also present at the level of the conductance arteries is 
unknown. 
Methods: To this end, we studied endothelium-dependent (post-hyperemia flow-medi- 
ated dilation) and -independent (nitroglycerin) vascular responses of the brachial artery 
by high-resolution ultrasound imaging. There were 46 black subjects (23 men and 23 
women; age 37+8 and 38*9 years, respectively) and 46 white subjects (23 men and 23 
women; age 38_tli and 3619 years, respectively) in this study. 
Results: Baseline diameter was similar in blacks and in whites (4.4kO.9 mm and 4.1i0.7 
mm, respectively). Mean reactive hyperemia after cuff deflation was similar in the 2 
groups (793+653% in black and 852?734% in white subjects, respectively; P=OS). Flow- 
mediated dilation was significantly lower in black compared to white individuals 
(4.79f3.5% vs 8.87i4.5%, respectively; P<O.OOOi). Nitroglycerin-mediated dilation was 
also significantly lower in black compared to white individuals (10.99r4.6% vs 
14.98&4%, respectively: P=O.O002). 
Conclusion: African Americans show reduced responsiveness of conductance vessela 
to both endogenous and exogenous nitric oxide compared to white Americans. These 
findings expand our understanding of racial differences in vascular function and suggest 
a mechanistic explanation for the increased incidence and severity of cardiovascular dis- 
ease observed in African Americans. 
1263-186 Effect of Vitamin E Supplementation on Coronary 
Endothelial Function 
Afsar Raza, Adrian J. Stewart, Sola Odemuyiwa, D J. Coitart, Michael M. M. Webb- 
Pepioe. Guy’s & St Thomas Hospital, London, United Kingdom 
Background: Long term effect of Vitamin E (Vit E) supplementation on coronary endot- 
helial function has not been studied in patients with known coronary artery disease. 
Methods: Twenty five patients undergoing elective stent implantation for a single coro- 
nary artery lesion ware randomized to receive either pravastatin 40mgiday (n=iP,Group 
A) or pravastatin and Vit E 800 IUiday for 2 weeks followed by 400 IU/day (n=iB,Group 
B)for a period of 6 months after the procedure. In the angiographically “normal” adjacent 
coronary artery (Group A:2 LAD, 10 Cx; Group 8: 3 LAD, 10 Cx),average peak veloc~- 
ties(APV)were measured immediately post procedure(Baseline) using an intracoronary 
(IC) Doppler wire after IC infusions of saline,Acetylcholine (ACh 2 pg and 20 pg/min for 2 
min each) and Adenosine (18 pg IC boius injection).Changes in coronary artery diameter 
were measured by quantitative coronary angiography. Coronary blood flow (CBF) was 
calculated from cross section area and APV. The same measurements were reseated at 
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6 months follow-up. All patients were already on statin therapy at baseline study. 
Results:Values shown in table are expressed as mean t SEM.Student t test was used 
for analysis. 
Comparison of % CBF in Treatment Groups 
~ 
% CBF Follow-up 33 + 23 82 I 21 195 f 27 
Serum cholesterol levels were similar in the two groups at baseline and at follow-up. 
Conclusion: Our data show a significant rise in CBF in response to high dose Acetyicho- 
line at follow-up suggesting an rmprovement in coronary endothelial function in patients 
on combination of Vit E and pravastatin as compared to pravastatin alone despite similar 
cholesterol levels. 
1263-187 Angiotensin II via AT1 Receptor Activation Upregulates 
Endoglin Expression in Human Coronary Artery Endothelial 
Cells 
Dayuan Li, Hongjiang Chen, Jawahar L. Mehta. University of Arkansas for Medical 
Sciences, Litfle Rock, AR 
, 
Background: Recent studies have shown that TGF-81 and its subtype receptor endoglin 
are key components in angiogenesis. Experimental and clinical studies have indicated 
that angiotensin II (Ang II) and its receptors play critical role in the remodeling of injured 
blood vessel and the heart. The present study was designed to explore the role of Ang II 
in the expression of endoglin and the underlying intracellular signal transduction mecha- 
nism. Methods: Cultured human coronary artery endotheliai cells (HCAEC?.) were incu- 
bated with Ang II (0.01 to 10 PM) for different times (6, 12 and 24 hours) and the 
expression of endoglin (mRNA and protein) measured. Parallel groups of cells were pre- 
treated with the AT1 receptor blocker losartan or the AT2 receptor blocker PO123319 
(each 1 NM for 30 min) to examine the specific Ang II receptor subtype that is involved in 
this process. Other groups of ceils were pretreated with a specific MAPK inhibitor 
PB98059 (10 pM for 30 min) to determine the role of MAPK as intracellular transduction 
mechanism. Results: Incubation of HCAECs with Ang II upregulated the expression of 
endoglin in a concentration- and time-dependent manner. The maximal effect of Ang II 
was observed with 1 uM concentration and at 24 hpurs. The effect of Ang II was medi- 
ated by AT1 receptor activation, since losartan, but not PD123319, completely blocked 
the effect of Ang II on endoglin expression. Furthermore, activation of MAPK elicited by 
Ang II played a critical role in this process, since MAPK inhibitor PD98059 fully inhibited 
the effect of Ang II on the expression of endoglin. Conclusions: Ang II via its AT1 recep- 
tor modulates the expression of endoglin in HCAECs. The activation of MAPK plays an 
important role in this process. This observation provides a new clue on the regulatory 
effect of Ang II on remodeling of vascular tissues by upregulation of TGF-81 receptor 
subtype endoglin. 
1263-188 Insulin Therapy improves Endothelial Insulin Resistance in 
Patients With Type 2 Diabetes and lschemic Heart Disease 
Christian Rask-Madsen, Nikolai Ihlemann, Thure Krarup, Erik Christiansen, Lars Kober. 
Christian Tarp-Pedersen. Genroffe University Hospital, Copenhagen, Denmark 
Background: Insulin therapy reduces mortality in patients with diabetes and acute myo- 
cardial infarction. To describe vascular targets of insulin therapy in similar patients, we 
studied endothelial function and insulin-stimulated endothelral function in patients with 
type 2 diabetes and stable ischemic heart disease and in lean, healthy volunteers. 
Methods: Patients (n=28) were not already on insulin therapy. Any oral hypoglycemic 
drugs were withdrawn 2 weeks before a study of endothelial function, where forearm 
blood flow was measured by venous occlusion plethysmography during a dose-response 
study of intraarterial infusion of acetylcholine (4 doses 7.5-60 pg min.‘). Subsequently, 
the dose-response study was repeated during intraarterial co-infusion of insulin 0.05 mU 
kg-’ min.‘, started 20 minutes in advance. Healthy volunteers (n=lO) were studied in the 
Same manner. Patients were assigned to an intervention group (n=28) which was re- 
studied after 8 weeks of subcutaneous insulin 3 times daily at meals and long-acting 
insulin once daily at bed-time; and to a control group (n=9) which was re-studied after 8 
weeks without antidiabetic medication. 
Results: During insulin stimulation, venous serum insulin in the infused forearm was 
raised to high physiological levels (135?18 mU I-’ in patients) with a minor increase in 
systemic venous serum insulin. Insulin stimulation increased the acetylcholine response 
by 96, 89, 75, and 66% on each acetylcholine dose in healthy volunteers (pcO.OOOl), but 
had no effect in patients (p=O.3). In the intervention group, HbAt, fell from 9.9kO.4 to 
7.51iO.2% after 8 weeks, and although the acetylcholine response did not change signifi- 
cantly (p=O.O6), insulin stimulation now increased the acetylcholins response by 42, 24, 
36, and 30% (p=O.OOB). In the control group, insulin stimulation remained without effect 
after 8 weeks (p=O.7). 
Conclusion: Insulin therapy partly restores insulin-stimulated encfothelial function in 
patients with type 2 diabetes and ischemic heart disease. Improved endothelial insulin 
resistance may be a mechanism of the clinical efficacy observed with insulin therapy in 
patients with diabetes and acute myocardial infarction. 
1263-189 Interstitial Lactate and Hypoxic Dilatation of Coronary 
Arteries 
Ole Frobert, Erich 0. Mikkeisen. Jens P Bagger, Claus H. Gravholt Dpf. ofCardiology@ 
Skejby University Hospital, Aarhus, Denmark 
Lactate is produced with anaerobic glycolysis and has been linked to vascular dilatation. 
We present a new approach to measure lactate in the rnterstitium of coronary arteries 
during hypoxia. Methods:porcine coronary arteries were mounted in a pressure myo- 
graph and the coronary wall was cannulated with microdialysis catheters (0.24 mm diam- 
eter) and perfused at a rate of 0.3 pl/min. During contraction with 1g5 M PGF, the 
arteries were exposed to hypoxia for 60 mins and then re-oxygenated. Results: the 
exchange fraction of lactate over the microdialysis membrane determined by [‘4C]lactate 
was 250%. Steady state coronary artery diameter increased by 15.5 % (SD 7.2%, n=l4) 
during hypoxia while a 4.0% decrease (i-1 .I%, n=ll) was found in normoxrc controls 
(p<O.OOl). Interstitial lactate rose from 0.41 (kO.29) to 1.30 (~0.76) mmolil during hypoxia 
(p<O.Ol) and was unchanged in controls. The degree of coronary dilatation and intersti- 
tial lactate correlated positively (Rz0.61, p&01). During normoxic dose-response exper- 
iments with L-lactate (1O-5 - 10.’ M) maximal coronary diameter increase was 21.4% 
(+11.4%, n=5) and interstitial lactate increased from 0.18 (r0.03) to 2.92 (tl.21) mmolll 
(p<O.OOi). In further experiments, lO-5 M of the pyruvate dehydrogenase activator dichlo- 
roacetate, added to the organ bath during hypoxia, abolished lactate production while the 
coronary diameter increased even more (30.4t12.0%, n=7, ~~0.01 vs. hypoxia and no 
dichiaroacetate). Conclusion: the present observations represent the first direct mea- 
surements of metabolites by microdialysis in a blood vessel wall. A statistically significant 
correlation between the degree of dilatation and interstitial lactate suggests a role for lac- 
tate in hypoxic vasodilatation. Both lactate from the blood and from production withrn the 
coronary artery wall may play a part in this process. 
1263-190 Relationship Between Noninvasively Evaluated Endothelial 
Dysfunction and Future Cardiovascular Events 
Tatsuaki Murakami, Yoshiyuki Arai. Fukui Cardiovascular Center, Fukui, Japan 
Background: Although endothelial dysfunction (ED) is thought to contribute to athero- 
thrombogenic processes, there has been little practical and noninvasive evidence for the 
relationship between evolution of atherosclerosis and ED. This study investigated 
whether noninvasively evaluated ED has prognostic impacts. Methods: Vasomotor func- 
tion was graded by noninvasively measured the reactive changes in lumen diameter of 
right brachial artery following transient occlusion for 5 minutes (FMD: flow-mediated 
endothelium-dependent vasodilation), and after sublingual administration of 
(300microgram) glyceril trinitrate (TNG; endothelium-independent vasodilation) in con- 
secutive 480 ambulatory patients with suspected coronary artery disease who underwent 
the above vasomotor function tests. The enrolled patients were categorized Into 3 groups 
according to the values.of FMD and TNG, and their new major adverse cardiovascular 
events [cardiac events; (CE): cardiac death, bypass surgery, non-fatal acute coronary 
syndrome, congestive heart failure, non-cardiac events; (VE): stroke, peripheral vascular 
disease] were prospectively followed-up for no less than 24 months. Results: For a mean 
follow-up period of 45 months with 100% follow-up (range; 24 to 68) The patients with 
severe endothelial dysfunction (FMD<4%; Group-L, 11~157) more frequently developed 
GE and VE [Group-L versus Group-M with mild endothelial dysfunction (8%>FMD=4% or 
more, n=162) plus Group-H with preserved endothefial function (FMD=8% or more, 
n=l61), ~~0.01, by Kapfan-M&r analyses]. In Group-H there were only two cardiovas- 
cular events. There was no significant association between future cardiovascular events 
and values of TNG. Cox regression analyses showed that severe endothelial dysfunction 
was significantly associated with future CE and VE (pcO.01). Conclusion: These results 
suggest noninvasive ultrasonic assessment of endothelial dysfunction can predict future 
cardiovascular events and stratify patients who are at high or low risk of cardiovascular 
morbidity. 
FMD and Future Cardiovascular Events 
CE 
VE 
Group-L Severe Group-M Mild 
dysfunction dysfunction 
33 (21%) 10 (6%) 
8 (5%) 3 (2%) 
Group-H Preserved 
function 
1 (1%) 
1 (1%) 
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876-I Nitric Oxide Attenuates Angiotensin II-Induced Activation of 
p70 S6 Kinase and Protein Synthesis in Rat Cardiomyocytes 
via Cyclic GMP-Dependent Mechanisms 
Masafumi Kitakaze, Hiroshi Asanuma, Shoji Sanada, Masanori Asakura, Hisakazu Ogita, 
Yulin Liao, Koichi Node, Seiji Takashima, Tsunehiko Kuzuya, Masatsugu Hori. Osaka 
University, Osaka, Japan 
The activation of angiotensin II (All) receptors of cardiomyocytes promote the intracellu- 
lar signaling of hypertrophy such as ERK or p70 S6 kinase. We have previously reported 
that inhibition of NO synthase causes cardiac hypertrophy in rats in viva , and that this 
effect is blunted by rapamycin that inhibits p70 S6 kinase. suggesting that endogenous 
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NO atienuatns the activation of p70 S6 kinase. Therefore, we tested whether NO-cyclic 
GMP systems attenuate the activity of p70 S6 kinase, and Inhibits protein synthesis in 
cardiomyocytes. Cardiomyocytes were isolated from adult male Wistar rats and were 
suspended in modified HEPES-Tyrode buffer solution. The cardiomyocytes were incu- 
bated with and without exposure to Ail (lx109 10-5 mol/L). Activity of p70 S6 kinase 
increased from 11.3+0.3 to 30.3+0.3 pmollmg proteinlmin 15 min after the onset of an 
exposure to All. This activation was blunted by the presence of either 1x10-6 SNP 
(i 1.3+0.3 to 15.2+0.5 pmolimg protein/min) or 1x10-6 rapamycin (11.3+0.3 to 14.2+0.6 
pmol/mg proternimin). This result tndicates that the NO donor, SNP, attenuates the actl- 
vation of p70 S6 kinase due to All exposure. Furthermore, either zaprinast (the phos- 
phodiesterase V Inhibitor) or ANR which increases cyclic GMP levels independent of NO, 
also attenuated the activation of p70 S6 kinase during All exposure. On the other hand, 
incorporation of [3H] phenylalamne was also increased during the exposure of All in car- 
diomyccytes, and this increase was blunted by either SNP or zaprinast. Thus we con- 
clude that NO attenuates the acttvation of p70 S6 kinase and attenuates the protein 
synthesis during exposure to angiotensin II. NO-related compounds may be promising for 
the treatment of cardiac hypertrophy and subsequent heart farlure. 
876-2 
4:15 p.m. 
Mechanical Stretch-Induced Activation of Paxillin in 
Cultured Neonatal Rat Cardiac Myocytes: Role of Small G 
Proteins 
Tahir Tak, Manuela Smith, Kenneth M. Baker, David E. Dostal. The fexasA&M Universio/ 
Sysfem Heaifh Science Center, Temple, TX, Scott and White Memorial Hospitai & Clinic, 
Temple, TX 
Mechanical etretcl? has been demonstrated to produce neonatal rat ventricular myocyte 
(NRVM) hypertrophy and stimulate release of autocrine factors, such as angiotensin II 
and endothelin-I. However. the mechanotransducer and proximal signairng molecules 
involved in this process remain to be identified. In this study, we tested the hypothesis 
that uniaxial stretch of NRVM would induce tyrosine phosphorylation of paxillin, an adap- 
tor molecule previously shown to couple to integrin signaling mechanisms. Experiments 
were performed in the presence of receptor antagonists for angiotensin II (1 uM 
EXP3174, 1 uM PD123319) and endotheiin (100 nM BQ-123)to prevent effects of these 
autocrine factors. lmmunoprecipitation and anti-phosphotyrosine blotting experiments 
demonshaled that mechanlcal stretch (O-60 minjinduced a time-dependent increase in 
phosphorylation of paxillin (1170 + 84.5%) which was maximal in 15 min. Medium condi- 
tioned by stretched NRVM had no effect on tyrosine phosphorylation of paxiilin in naive 
ceils, indicating that the phosphorylation effects were not mediated by secreted factors. 
lmmunoprecipitation experiments revealed that paxillin from stretched cells (15 min) 
associated with tensin and pl30Crk-associated substrate, but not focal-adhesion kinase. 
To test the hypothesis that small GTP-brnding proteins may have a role in stretch-medi- 
ated phosphorylation of paxillin, NRVM were transfected with DNA constructs for domi- 
nant-negative mutants of Cdc42. Rx-l, and RhoA. Expression of dominant negative 
Rat-I and RhoA markedly attenuated stretch-induced tyrosine phosphorylation of paxil- 
lin (-71.3 f 7.2% and -69.6 + 9.8% respectively), whereas expressed dominant-negative 
Cdc42 had no effect. In summary, results from thus study suggest that mechanical stretch 
stimulates paxillin tyrosine phosphotylation via Rat-1 and RhoA-dependent signaling 
mechanisms. Future studies remain to be performed to determine whether integrms 
serve as the mechanotransducer and whether paxillin couples to stretch-mediated 
growth responses and secretion of autocrine factors in cardiac myocytes. 
876-3 
4:30 p.m. 
Negative Modulation of Angiotensin II-Induced Jak/STAT 
Signaling in Cardiomyocytes via Stable Complex Formation 
of Protein Tyrosine Phosphatase SHP-2 With STAT3 
Jun Fukuzawa, Kenneth M. Baker, George W. Booz. The TexasA&M Univ System HSC, 
Colege of Med., The Cardiovascular Research Institute, Temple, TX 
The JaWSTAT signaling pathway has been linked to hypertrophy, as well as an antiapop- 
toticlsurvival program in cardiac myocytes. We have reported that angiotensin II (Ail) 
activates this pathway via the G-protein coupled AT1 receptor. In contrast to the activa- 
tion observed with interleukin-&type cytokines, All-shmulated JaWSTAT signaling is mod- 
est and characterized by a delayed activation of STAT3. In the present study, we 
investigated the role of the proiein tyrosine phosphatase SHP-2 in attenuating All- 
induced J&/STAT signaling in neonatal rat ventricular myocytes. Depending on the cell 
type. SHP-2 plays a critical role in switching off STAT activation by interleukin-6.type 
cytokines. STAT3 activation was assessed as tyrosine phosphorylation by W%si%rn anal- 
ysis using a phosphospecific antibody. Tyrosine phosphory!ation of SHP-2, which IS 
thought to increase its catalytic activity. was measured by blotting SHP-2 immunoprecipi- 
tates of cell lysates with an antiphosphotyrosine antibody, Treatment of serum-starved 
cardiac myocytes with 100 nM All induced sustalned (5-120 min) tyrosine phosphoryla- 
tion of SHP-2. Moreover, blotting SHP-2 immunoprecipitates with an anti-STAT3 antibody, 
revealed that All treatment resulted in stable (from 10 - 90 min) complex formation 
between STAT3 and SHP-2. In addition to delayed activation at 90 to 120 min, early (10 
mln) STAT3 activation, that was modest and transient, was observed following All treat- 
ment of cardiac myocytes. Transfection of cardiac myocytes with an antisense oligonucle- 
otide for SHP-2 significantly attenuated the decay in early All activation of STAT3 Our 
findings indicate that SHP-2 may dephosphorylate STAT3 in cardiac myocytes, thus play 
ing a negative role in regulating AT1 receptor Jak-STAT signaling. Phosphatases, like 
SHP-2, may serve as a key control mechanism for modulating and integrating the multi. 
pie signaling pathways activated by the AT1 receptor. 
876-4 _- 
4:45 pm. 
Impaired Ang II Mediated Activation of ERKVERK2 and 
SAPWJNK Pathways With Normal AT1 Receptor Binding 
and mRNA Expression in Myocytes From Failing Human 
Hearts 
Pietro A. Modesti, Simone Vanni, Brunella Bandinelli, Rite Paniccia, iacopo Bertolozzr. 
Gianluca Polidori, llaria Cecioni, Gian Gastone Neri Serneri. Clinica Medica Genera/e e 
Cardiologia, Florence, /t&y 
Background: Recent studies demonstrated that cardiac angiotensin II (Ang II) type 1 
(ATl) receptors are downregulated rn human failing ventricles but characteristics of Ang II 
receptor?. on human myocytes are to be defined. Methods: Ang II receptors and Ang II 
mediated activation of intracellular pathways were investigated on enzymatically dissoci- 
ated ventricular myocytes from 6 potential transplant donors (NF) and 17 heart failure 
(HF) patients who underwent cardiac transplantation. Ang II receptors were character- 
ized using 1251.Ang II (2,000 Ci/mmol) as radroligand and Ang II or valsartan and 
PO123319 as cold displacers. mRNA for AT1 receptor was quantified with RT-PCR using 
specific primers and GAPDH as internal control. AT1 mediated ERKlIERKZ and SAPW 
JNK achvation following Ang II stimulation (10.8M) was investigated in isolated myocytes 
using selective receptor antagonists. Results: 1251-Ang-II binding to membranes from 
homogenated failing hearts revealed a significant downregulation of both total Ang II 
receptors (2.4r0.5 vs 5.1~tO.7 fmol/mg protein, in HF and NF hearts respectively, p&01) 
and AT1 subtype (p<O.Ol) with unchanged affinity. Conversely, isolated cardiomyocytes 
showed no differences in density of both total Ang II receptor (0.58&10 vs 0.57?0.21 
fmolimg protein, ns) and AT1 subtype. Also at RT-PCR studies, AT1 mRNA levels were 
not significantly different between HF and NF isolated myocytes. However, AT1 mediated 
activation of both ERKlIERKZ and SAPKIJNK in HF myocytes was reduced by 88% and 
48% respectively, when compared to control cells (~~0.01 for both). Conclusion: In con- 
clusion AT1 receptors are not downregulated in human ventricular myocytes from failing 
hearts but show a blunted functional response to Ang II. 
ORAL CONTRIBUTIONS 
884 Lipid-Based Coronary Risk Assessment 
Wednesday, March 21, 2001, 8:30 a.m.-l 0:OO a.m. 
Orange County Convention Center, Room 304E 
830 a.m. 
884-l Identifying High-Risk Primary-Prevention Patients for Lipid- 
Lowering Therapy: A Comparison of the National 
Cholesterol Education Program Guidelines and 
Framingham Absolute Risk Assessment 
Terry A. Jacobson, Peter W. F Wilson, Godfrey G. Griffiths, Cristina Varas, Douglas 
Gause, Jenny C. Y Sung. Christie M. Ballantyne. Bay/or College ofMedicine, Houston, 
TX 
Background: Although recent clinical trial data suggest that many individuals without 
known CHD and only “average” LDL-C levels may benefit from lipid-lowering therapy, a 
large number of individuals must be treated to prevent each CHD event. Identification of 
high-risk primary-prevention patients may be improved by assessment of 1 O-year risk for 
CHD events using algorithms such as the Framingham risk equation. This study com- 
pares the current NCEP guidelines with the Framingham risk equation to identify patients 
who may require lipid-lowering therapy. Methods: National Health and Nutrition Exami- 
nation Survey III data (1988.94) were analyzed to determine which individuals (ages ZO- 
74) would be considered for drug therapy by the NCEP guidelines or the Framingham 
risk equation. Results: Using NCEP cutpoints for initiation of drug therapy in primary pre- 
ventlon, 8.0 million men and 6.2 million women would require drug therapy; by compari- 
son, 6.4 million men and 0.9 million women have IO-year absolute risk estimates X?O%. 
The overlap between the two methods is very low: only 2.4 million men and 0.6 million 
women are identified by both methods. 
In addition, 59% of individuals with 10.year risk 220% have LDL-C ~160 mgidl and may 
not receive lipid-lowering drug therapy by the current NCEP guidelines. Drug therapy 
would not even be considered by the NCEP guidelines for the 29% of individuals with 
220% risk and who have LDL-C <I30 mg/dl, and this population (2.1 million) has yet to 
be studied in any clinlcal trial of primary prevention. Conclusion: Substantially different 
populations would be targeted for treatment if the Framingham risk assessment is used 
instead of the NCEP guidelines. Of high-risk individuals (220% absolute risk) without 
known CHD, 29% have LDL-C ~130 mgidl and would not even be considered for drug 
therapy by the current guidelines. and no clinical trial evidence is available for these indi- 
viduals 
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884-2 
8:45 a.m. 
Elevated Triglyceride-Rich Remnants Are Associated With 
New Cardiovascular Events, but Not With Gemfibrozil 
Benefit, in the Veterans Affairs: HDL Intervention Trial 
Ernst J. Schaefer, Judith R. McNamara, Dorothea Collins, Marshall B. Elam, Hanna B. 
Rubins, Sander J. Robins, for the VA-HIT Study Group. New EnglandMedical Center, 
Boston, MA, Veterans Affairs Cooperative Studies Program, West Haven, CT 
Background: Low HDL cholesterol (HDLC) has repeatedly been associated with 
increased coronary heart disease (CHD) risk. High triglycerides (TG), however, which 
frequently accompany low HDLC, have not regularly been associated with CHD in multi- 
variate analyses that include HDLC. In the Veterans Affairs - High Density Lipoprotein 
Intervention Trial (VA-HIT), the use of gemfibrozil resulted in a 26% reduction in 5.yr inci- 
dence of nonfatal MI, CHD death, or stroke in 2531 men selected for having CHD, HDLC 
540 mg/dL, and LDLC 5140 mg/dL (Rubins et al NEJM 1999;341:410). In preliminary 
analyses (Robins et al Circulation 1999;100:1-238) benefit was associated with a mod- 
est but significant HDLC increase (6%) with gemfibrozil; however, in this analysis no ben- 
efit was associated with the accompanying significant TG reduction (-31%). It has long 
been thought that triglyceride-rich lipoprotein remnants predispose to CHD (ax, Type Ill 
hyperlipoproteinemia), and may be a stronger predictor than TG. 
Methods: We have applied a new immunoseparation assay for measuring remnant-like 
particle cholesterol (RLPC) in a nested case-control subset of VA-HIT (391 patients with, 
590 without, new endpoints). 
Results: Mean plasma RLPC values at baseline were 22.0 mg/dL; 3x higher than age- 
matched men without CHD (mean 6.8 mg/dL, McNamara et al. Clin Chem 
1998;44:1224), while directly measured LDLC levels were below average at 103 mg/dL. 
Gemfibrozil treatment resulted in a mean reduction in RLPC levels of 43.0% vs baseline 
(p <O.OOOl), and 30.2% vs placebo (p <O.Ol). Baseline RLPC values were significantly 
related to development of new MI, CHD, or stroke endpoints (p ~0.03). However, there 
was no significant relationship between endpoints and on-trial RLPC, and in multivariate 
analysis including baseline HDLC, RLPC failed to significantly predict events. 
Conclusion: Remnant-like particle cholesterol levels are strikingly elevated in men with 
CHD, normal to low LDLC, and low HDLC. In VA-HIT, baseline RLPC values were signif- 
icantly related to new endpoints. Moreover, RLPC values were significantly reduced by 
gemfibrozil. However, no statistically significant on-trial benefit could be ascribed to the 
RLPC reduction. 
884-3 
9:00 a.m. 
Low Density Lipoprotein Particles Are Small in Patients 
With Coronary Vasospasm 
Kunihisa Miwa, Katuhisa Ishii, Toshinori Makita, Takaharu Saito. Kansai Nectric Power 
Hospita/, Osaka, Japan 
Background. Increased lipid oxidative stress has been recently implicated in the patho- 
genesis of coronary vasospasm. The increased amount of small, dense LDL with high 
susceptibility to oxidation may be linked to the genesis of coronary vasospasm. Meth- 
ods. The relative migratory distance of the predominant densitometric peak of LDL from 
that of VLDL to that of HDL in a 3% polyacrylamide gel electrophoreis was determined as 
a measure of LDL particle size in 49 patients with coronary spastic angina (CSA), in 56 
patients with stable effort angina and a significant coronary stenosis (SEA) and also in 40 
control subjects without coronary artery disease (Control). Reeulta. A significant nega- 
tive correlation (r = -0.78, ~~0.05) between the relative migratory distance and the actu- 
ally estimated LDL particle size by nondenaturing 2 to 16 % polyacrylamide gradient gel 
electrophoresis had been confirmed in a experiment using 38 samples. The relative 
migratory distance was significantly (~~0.05) greater in CSA (0.38kO.05) than in Control 
(0.34*0.04). The incidence of detection of small, dense LDL or a relative migratory dis- 
tance above 0.36, corresponding to the peak particle diameter ~25.5 nm, was signifi- 
cantly (~~0.05) higher in CSA (57%) and also in SEA (39%) than in Control (20%). In 
SEA, a significantly higher serum level of triglyceride was noted in the subgroup with the 
small, dense LDL as compared with the subgroup without (149*58 vs. 104+34 mgidl, 
p<O.Ol). In contrast, in CSA, the serum level of triglyceride was not significantly different 
between the subgroups with and without the small, dense LDL, although significantly 
(~~0.05) lower serum levels of both HDL-cholesterol (39+14 vs. 46ilO mg/dl) and alpha- 
tocopherol (2.64kO.55 vs. 3.15+1.05 mg/g lipids) were noted in the former. In 16 patients 
of CSA, the detection of the small, dense LDL was significantly decreased after a >6- 
month angina-free period (69% to 31%). Conclusion. Patients with coronary spastic 
angina had smaller LDL particles, associated not with hypertriglyceridemia but low serum 
levels of both HDL-cholesterol and antioxidant vitamin E. Dyslipidemia with small, dense 
LDL may be related to the genesis of coronary vasospasrn. 
884-4 
9:15 a.m. 
The l405V but Not TaqlB Polymorphism in the Cholesteryl 
Ester Transfer Protein Gene Is Associated With LDL Particle 
Size 
Hideo Matsui, Kenji Okumura, Kazunori Hayashi, Hiroki Kamiya, Yoshihiro Saburi. 
Nagoya University School of Medicine, Nagoya, Japan 
Background: Cholesteryl ester transfer protein (CETP) plays a central role in the metab- 
olism of HDL cholesterol (HDL-C). l405V in exon 14 and TaqlB in intron 1 are two com- 
mon polymorphisms of the CETP gene. Interestingly, these two polymorphisms may 
have opposite effects on the risk of coronary heart disease (CHD) despite the fact that 
both cause genetic CETP deficiency. To investigate the mechanism governing this differ- 
ence, we determined the relationship between these polymorphisms and LDL particle 
size in Japanese individuals. 
Methods: LDL particle size was determined by gradient gel electrophoresis in 136 
patients undergoing routine check-ups, The presence of the two polymorphisms was 
determined using PCR-based methods. 
Results: The VV genotype for the l405V polymorphism was associated with both a lower 
plasma CETP concentration and a higher plasma HDL-C concentration. Furthermore, 
LDL particle size in subjects with the VV genotype was significantly smaller than in sub- 
jects with the II+IV genotype (26.0+0.8 vs. 26.3kO.7 nm, PcO.05). Although the 8282 
genotype for the TaqlB polymorphism was also associated with both a lower plasma 
CETP concentration and a higher plasma HDL-C concentration, it had no effect on LDL 
particle size (26.2kO.7 vs. 26.3~0.8 nm, PzO.73). A stepwise multiple regression analysis 
revealed that the VV genotype as well as plasma TG concentration, age, HbAlc concen- 
tration, and BMI were determinants of LDL particle size (total Rs=0.362), while no signifi- 
cant relationships were seen between any of the Taql B polymorphisms and LDL particle 
size. 
Conclusion: These data suggest that the 1405V polymorphism may be responsible for a 
distribution of LDL particle size. This may explain why genetic CETP deficiency caused 
by the l405V polymorphism but not that caused by the TaqlB polymorphism is associ- 
ated with an increased prevalence of CHD in spite of elevated HDL-C concentrations. 
884-5 
9:30 a.m. 
ApolipoproteinA-I (apoA-I) and Markers of Inflammation in 
Coronary Heart Disease (CHD) 
Axe1 Schlitt, H.J. Rupprecht, S. Blankenberg, C. Bickel, G. Hafner”, G. Rippin*‘, J. Meyer. 
university clinic mainz, II. medical clinic, Main.?, GermanN ‘clinic of clinical chemistry 
**institute for medical statistics, Mainz, Germany 
Background: ApolipoproteinA-I is described as a predictive marker for CHD. Little is 
known about the relation of apoA-I to the inflammatory process in atherosclerotic dis- 
eases. We investigated the association of apoA-I serum concentration with markers of 
inflammation and cell-adhesion: interleukin (IL)-6, fibrinogen, high sensitive CRP (HS- 
CRP), soluble vascular cell adhesion molecule (sVCAM)-1, soluble intercellular adhesion 
molecule (slCAM)-1 and soluble E-selectin (SE-selectin) in patients with angiographically 
documented coronary heart disease. Methods: We determined in 948 patients with CHD 
apoA-I serum concentrations (Tina-quant, Roche Diagnostics, Germany) and levels of IL- 
6, sVCAM-1, slCAM-1 (Biosource, Europe), HS-CRP (Roche Diagnostics, Germany), 
fibrinogen (derived fibrinogen, Innovin, Dade Behring, Marburg, Germany) and SE-Selec- 
tin ( Bender Medical Systems) before coronary angiography. Patients with acute rnyocar- 
dial infarction within the preceeding four weeks were excluded from analysis. Statistic 
analysis concerning the relation of apoA-I and markers of inflammation and cell-adhesion 
was performed by Kruskal Wallace test. Results: In patients with CHD apoA-I is signifi- 
cantly and inversely related to IL-6 (p < O.OOl)), fibrinogen (p c O.OOl), HS-CRP (p < 
0.001) and sVCAM-1 (p = 0.010). Soluble ICAM- (p: 0.468) and SE-selectin (p: 0.752) 
were not significantly related to apoA-I. Conclusion: ApoA-I serum concentration is 
inversely and significantly related to markers of inflammation and adhesion (IL-6, HS- 
CRP, fibrinogen, sVCAM-1) in patients with coronary heart disease. We conclude that 
apoA-I serum concentration is linked to inflammatory activity in coronary heart disease. 
ApoA-I and markers of inflammation and cell-adhesion in patients with CHD 
ApoA-quartiles Ql 
IL-6: median in pg/ml 16.9 
HS-CRP: median in mgll 8.5 
fibrinogen: median in mgidl 364 
sVCAM-1: median in ngiml 1478 
slCAM-1: median in nglml 256 
sE-selectin: median in nglml 72.0 
Q2 Q3 
13.0 10.7 
5.5 5.3 
348 323 
1417 1242 
274 250 
70.5 71 .o 
Q4 p-value 
9.8 < 0.001 
3.3 < 0.001 
314 < 0.001 
1423 0.010 
272 0.468 
71.5 0.752 
884-6 Lp(a) Is an Independent Predictor Of Coronary 
Atherosclerotic Burden 
9:45 a.m. 
David Grout, Mark Nidorf, Ross G. T. Walker, Sudheera Nair, Peter L. Thompson. Sydney 
Heart Image of Sydney Adventist Hospital, Sydney Australia, West Australian Heart 
Research Institute, Perth, Australia 
Background : The role of Lp(a) in the development of atherosclerosis remains unclear. 
We examined the predictive value of Lp(a) for coronary calcium as a surrogate marker for 
coronary atherosclerosis. 
Method : We used coronary artery calcium screening to detect coronary artery disease 
in 6617 asymptomatic people aged between 25-85 (69% male). We then used regression 
analysis to examine the predictors of the presence or absence of coronary artery calcium 
and coronary artery calcium score percentile. 
Results: The presence of coronary artery calcium and individual age/sex matched per- 
centile of coronary artery calcium score related independently to age (pcO.OOOl), sex 
(prO.OOOl), LDL (p<O.O5), smoking (pcO.OOdl), hypertension (pcO.OOOl), diabetes 
(~~0.05) and family history of coronary artery disease (p<O.Ol). When Lp(a) was added 
to the model, it was found to be a strong independent predictor of coronary artery cal- 
cium (p<O.OOOl). 
Conclusion: When examined in a broad asymptomatic population, there is a significant 
relation between Lp(a) and atherosclerotic burden, independent of established risk fac- 
tors of disease. 
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1301 Risk Factors for Atherosclerosis 
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Orange County Convention Center, Hall A4 
Presentation Hour: 9:00 a.m.-10:OO a.m. 
1301-159 A Comparison of Brachial Artery Stiffness and Pulse 
Pressure With Framingham Cardiovascular Risk 
Robert A. Vogel. University of Maryland School of Medicine, Baltimore, MD 
Background: Peripheral artery stiffness, measured directly or indirectly as pulse pres- 
sure, has been proposed as an index of cardiovascular disease risk. To test this hypothe- 
sis, we compared direct and indirect measurements of arterial stiffness with the 
Framingham risk-factor generated score. Methods: At a recent national cardiology meet- 
ing, 250 attendees (167 men, 83 women) had brachial artery stiffness (ASI) and pulse 
pressure (PP) measured with an automated blood pressure cuff (CardioVision) which 
uses computerized oscillometry to derive an index of arterial stiffness. Using the blood 
pressure measured by the device, along with on-site measurements of lipoproteins and 
glucose, we employed built-in soflware to calculate the lo-year Framingham cardiovas- 
cuiar risk. We evaluated predefined abnormal values for ASI (>60) and PP (>60 mmHg) 
alone and together for their ability to predict a Framingham risk score >lO%. which was 
found in 26 attendees (23 men, 3 women). Results: (see table) Conclusions: These 
data suggest that simple, inexpensive indexes of arterial stiffness, as measured by an 
automated blood pressure cuff in a health screening effort, are reasonably predictive of 
cardiovascular risk, as determined by the Framingham risk factor approach 
Diagnostic Accuracy of Arterial Stiffness and Pulse Pressure 
SENSITIVITY SPECIFICITY PREDICTIVE ACCURACY 
ASI 280 42% 91% 86% 
PP >60 mmHg 46% 86% 82% 
ABNORMAL ASI or PP 82% 61% 79% 
1301-160 Augmented Oxidantive Stress of Platelets in Chronic 
Smokers 
Yoshinori Takajo, Hisao Ikeda, Nobuya Haramaki, Toyoaki Murohara, Takfumi Ueno, 
Atushi Katoh, Yoritaka Ohtuka, Tsutom” Imaizumi. the third dep og internal medcine, 
kurume, Japan 
Background We investigated whether impaired platelet-derived nitric oxide (PDNO) bio- 
activity and augmented platelet aggregability in chronic smokers are related to the imbal- 
ance of the intraplatelet redox state caused by increased oxidative stress. Methods and 
Results Collagen-induced PDNO release, platelet aggregation, plasma and intraplatelet 
vitamin C and glutathione (GSH), intraplatelet cGMP, and intraplatelet productions of 
hydrogen peroxide and nitrotyrosine (a marker of the formation of peroxynitrite) were 
measured in 11 chronic smokers and age-matched 10 nonsmokers. Plasma nicotine lev- 
els were elevated in smokers, but not detectable in nonsmokers. PDNO release and 
intraplateiet cGMP levels were lower and platelet aggregation was greater in smokers 
than in nonsmokers. lntraplatelet levels of vitamin C and GSH were lower in smokers 
than in nonsmokers, suggesting the imbalance of the intraplatelet redox state in smokers. 
lntwplatelet productions of hydrogen peroxide and nitrotyrosine in smokers were greater 
than those in nonsmokers, indicating increased intraplatelet oxidative stress in smokers. 
Next, we investigated the acute effects of oral administration of vitamin C (2 g). After vita- 
min C administration, intraplatelet levels of vitamin C were increased and not different at 
2 hours between nonsmokers and smokers. Then, PDNO release and intraplatelet cGMP 
levels and platelet aggregation in smokers were restored to the levels of nonsmokers. In 
smokers, PDNO release and the consumption of GSH during platelet aggregation were 
inversely correlated, and the consumption was much less after vitamin C administration. 
Vitamin C administration decreased intraplatelet productions of hydrogen peroxide and 
nitrotyrosine in smokers. Conclusion Impaired bioactivity of PDNO may be caused by 
the imbalance of the intraplatelet redox state from increased oxidative stress in smokers. 
This notion is further suggested by the evidence that vitamin C decreased oxidative 
Stress and preserved intraplatelet GSH, resulting in the increased PDNO bioactivity and 
less platelet aggregability 
1301-l 61 Longer Duration of Westernization Is Associated With 
Subclinical Atherosclerosis in Chinese Americans 
Kam S. Woo, Shu W. Ghan, Ping Chook, Chris W. K. Lam, David S. Celermajer. The 
Chinese University of Hong Kong, Hong Kong, Hong Kong. Royal Prince Alfred Hospital, 
Sydney; Australia 
Background: Urbanized Chinese in Hong Kong, Sydney and San Francisco have more 
subclinical atherosclerosis than rural Chinese in southern China. 
Methods: To further test the gene-environment interaction model of atherogenesis, 380 
asymptpmatic Chinese living in San Francisco were studied. Flow-mediated dilation 
(FMD) of brachiai artery and intima-media thickness (IMT) of carotid artery were mea- 
sured “sing high resolution ultrasound on 47 Amerkzan-born Chinese (22 males, mean 
age 47.3+/-l 1.9 years) (group l), and were compared with 47 age and gender-matched 
Chinese immigrants having lived in America for ~19 years (group 2) and ~19 years 
(group 3) respectively. 
Results: The 3 groups were well matched for age, blood pressure, total cholesterol (TC) 
and other lipid profiles, fibrinogen, glucose and smoking status. Body weights of group 1 
and 2 were significantly greater than group 3 (pc0 04), but body mass index and waist/ 
hip ratio were similar. Brachial FMD was lower and carotid IMT was greater in both group 
1 and 2 than group 3 subjects (p<O.O4). On multivarlate analysis, duration of living in 
America (DUR-AM) is independently related to brachial FMD (Model F=3.5; p= -0.27; 
p&034) and carotid IMT (Model F=6.7; p&19; p=O.O5). 
Conclusion: Prolonged westernization and acculturization of Chinese in America are 
associated with a higher risk of subclinical atherosclerosis, supporting the gene-environ- 
ment interaction hypothesis of atherogenesis. 
Group 1 Group 2 
DUR-AM (yrs) 47.3+/-i 1.9 27.4+1-7.9 
TC (mmolil) 5.5+/-0.9 5.7+/-1 .o 
FMD (%) 7.6+/-2.4 7.8+/-2.2 
IMT (mm) 0.70+/-0.16 0.74+/-0.20 
(NS = Not significant; ‘group 3 vs group 1 or 2) 
Group 3 
13.2+/-2.5 
5.5+/-l .o 
8.9+/-2.0 
0.65+/-0.11 
p-Value 
<0.001 
NS 
<0.04 
<0.04 
1301-I 88 Nicotine in Second Hand Smoke Does Not Promote 
Atherogenesis 
Yiping Sun, Boqing Zhu, Amanda E. M. Browna, Richard E. Sievers, Janine M. Bekker, 
Kanu Chatterjee, William W. Parmley, Stanton A. Glantz. University of California San 
Francisco, San Francisco, CA 
Background: Second hand smoke (SHS) has been shown to accelerate atherogenesis 
and impair vascular function, but the role of nicotine in these processes is uncertain. 
Methods: To examine whether nicotine adversely affects atherogenesis and vascular 
function, forty-eight New Zealand rabbits receiving a 0.5% cholesterol diet were random- 
ized to 3 groups: control (cholesterol diet only, n=24), SHS exposure to nicotine-standard 
cigarettes (SHS-ST, n=12) and SHS exposure to nicotine-free cigarettes (SHS-NF, n=lZ). 
The 24 SHS rabbits were exposed to either 48 nicotine-standard ot’ nicotine-free filter cig- 
arettes per day (4 cigarettes every 30 minutes, 6 hours/day), 5 days/week for 10 weeks. 
Air carbon monoxide (CO), particulates, blood carboxyhemoglobin (COHb), nicotine, coti- 
nine, lipids and myocardial nitric oxide (NO,) levels ware determined. All rabbits were 
finally euthanized for measurement of vascular function and arterial lipid lesions. 
Results: Mean&EM 
Groups Control SHS-ST SHS-NF p values 
Cholesterol (mgidl) 3077*-I68 3694+331 3650+292 
Nitric oxide (1M) 18.7*4.9 6.6ztl.l 7.9*0.9 0.032 
Nicotine (ngiml) 0.65+0.08 54.92+12.09 2.28+0.26 <O.OOl 
Aorta (%) 39r4 54*5 53*7 0.049 
Pulmonary artery (%) 43i3 66~4 69i4 co.oo1 
Ach-relax (%) -66+15 -49i6 -4919 
Air CO, particulates and plasma COHb were significantly higher (p<O.OOl) in SHS 
exposed groups compared with control. An increased percentage of arterial lipid lesions 
was found in both SHS groups, but nicotine did not make it worse (p=O.O62-aorta and 
p<O.OOl-pulmonary artery for SHS, p=O.881 and p=O.585 for nicotine by 3-way ANOVA) 
compared with nicotine-free cigarette group. SHS exposure tended to decrease acety- 
choline-induced endothelium-dependent vasorelaxation (Ach-relax). The decreased NO, 
levels may be involved in the impaired vasodllation (r=O.931, p<O.OOl). Conclusion: 
SHS exposure increased arterial lipid lesions and damaged vascular endothelial func- 
tion, but nicotine did not significantly contribute to these adverse vascular effects of SHS. 
1301-189 Chronic Antioxidant Treatment Decreases Nuclear Factor 
kB Activation in the Coronary Circulation in Experimental 
Hypercholesterolemia 
Martin G. Rodriguez-Parcel, Lilach 0. Lerman, Darcy Richardson, Amir Lerman. Mayo 
Clinic, Rochester, MN 
Background: Oxidative stress has been implicated in the pathogenesis of coronary ath- 
erosclerosis. Nuclear factor kappa B (NFkB) is a transcriptional factor, which is involved 
in various signal transduction pathways. NFkB is activated in the coronary circulation in 
atherosclerosis and may be regulated by oxidative stress. This study tested the hypothe- 
sis that chronic antioxidant treatment would decrease NFkB activation in the coronary cir- 
culation in experimental hypercholesterolemia (HC). Methods: Pigs were euthanized 
after twelve weeks of either normal (N, n=6), 2 HC diet (n=6), or HC+antioxidant vitamin 
supplementation (vitamin E 100mglkgld + vitamin C lgld, HC+AO, n=6). To estimate oxi- 
dative status, plasma isoprostanes were measured in all groups. Coronary tissue homo- 
genates were analyzed for activated NFkB using Western blotting, and coronary artery 
immunostaining for NFkB was performed. Results: Plasma cholesterol levels were sig- 
nificantly increased in HC and HC+V compared to normals (400r58 and 4661-138 vs. 
71~6, respectively, both p&05). After twelve weeks of diet, HC animals had increased 
levels of plasma isoprostanes compared to normals (238+30 vs. 116?15, respectively, 
~~0.05) and increased activation of NFkB (Figure). Chronic antioxidant supplementation 
normalized levels of plasma isoprostanes (165+31 vs N, p=NS), while preserving both 
expression of NFkB (Figure). NFkB immunostaining was enhanced in the coronary 
endothelial layer in the HC pigs and normalized following treatment with anti-oxidants. 
Conclusion: This study demonstrates that chronic anti-oxidant treatment decreased the 
activation of NFkB in experimental hypercholesterolemia. This study also suggests that 
oxidative stress may contrlbute to the pathogenesis if atherosclerosis through the activa- 
tion of NFkB in early atherosclerosis. 
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1301-l 90 Pulsatile Flow Profiles Modulate MCP-I Expression in Ox- 
PAPC Treated Endothelial Cells 
Tzung K. Hsiai, Sung K. Cho, Susan Hama, Henry Honda, Srinivasa Reddy, Mohamad 
Navab, Judith Berliner, Linda Demer, Alan M. Fogelman, Chih M. Ho. UCLA Schoolof 
Medicine, Los Angeles, CA, UCLA School of Engineering & Applied Sciences, Los 
Angeles, CA 
Background Oxrdized PAPC, (1.Palmitoyl-Z-an-glycerol-3.phosphocholine), a compo- 
nent of minimally modified LDL, upregulates MCP-1 expression in endothelial cells (EC). 
Previous studies have examined the effects of various flow patterns on the induction of 
adhesion molecules. However, no studies have focused on whether pulsatile flow pat- 
terns can modulate MCP-1 expression in response to oxidized lipids. Methods: We 
examined the effects well-defined flow patterns on MCP-1 mRNA expression to ox-PAPC 
treated bovine aortic endotheiial cells (BAEC). By varying the rates of upstroke of pulsa- 
tile flow, we generated temporal shear stress gradients simulating arterial pressure pro- 
files. Ox- PAPC treated BAEC were exposed to three flow profiles with the same 
periodicity of 60 beats/min: (1) high shear stress temporal gradient ( 293 dynesicm2sec) 
at mean shear stress of 50 dyneslcm2, (2) low temporal gradient (71 dynesicm2sec) also 
at 50 dynes/cm2, and (3) oscillating flow (+/-26 mmHg) at 0 dyens/cm2. Results: After 4 
hours of flow exposure, pulsatile flow at both high and low temporal shear stress gradi- 
ents downregulated endothelial MCP-1 mRNA expression compared to no flow condi- 
tions. High temporal gradient flow further downregulated MCP-1 expression. In contrast, 
oscillating flow upregulated MCP-I in Ox-PAPC-treated BAEC. Conclusion: Unidirec- 
tional pulsatile flow downregulated MCP-1 mRNA expression to Ox-PAPC stimulated 
BAEC, whereas reversing oscillating flow, which is associated with vascular sites prone 
to atherosclerosis, upregulated MCP-lexpression. Despite the same mean shear stress 
and periodicity as in low shear stress temporal gradient, flow at high temporal gradient 
further downregulated MCP-1 expression to ox-PAPC-treated EC. This finding implicates 
the important role of temporal shear stress gradient in modulating one of the the earliest 
events of atherosclerosis. 
1301-191 Age-Dependent Increase in Vascular Smooth Muscle Cell 
Proliferation: Role of Mitogen-Activated Protein Kinases 
Giuseppa Gennaro, Sylvain Meloche, Edith Giasson, Franqois Gauthier, Catherine 
Menard, Sophie Elise Michaud, Alain Aivard. Cent% Hospifaier de l’Universif6 de 
Mont&a/, Monfrga!. PO, Canada 
Background: Aging is a major risk factor for atherosclerosis. It has previously been dem- 
onstrated that increased vascular smooth muscle cells (VSMCs) proliferation in old ani- 
mals contributes to the physiopathology of this disease. In the present study, we 
investigated the role of Mitogen-Activated Protein Kinases (MAPKs) in the age-depen- 
dent increase in VSMCs proliferation and neointimal formation. Methods and Results: 
VSMCs were isolated from the aorta of young (6 to 8 months) and old (3.5 to 4 years) 
New Zealand White rabbits and used at early passages (P2 or P3). Following serum 
stimulation, cell counting and MTS assay revealed a 70% increase in the proliferative 
index of old vs young VSMCs (p<O.OOOOl). ERK1/2 activities (phosphospecific Western 
blots and kinase assays) showed a significant induction by serum in both young and old 
VSMCs, with a peak activity at 30 minutes. However, there was a significant increase in 
ERK1/2 activities in old vs young VSMCs at 5 minutes (55% increase, p=O.O2) and 30 
minutes (47% increase, p=O.O03) after serum stimulation. This increased MAPK activity 
was specific for ERKl/Z, as both ~38 and JNK activities were shown to be similar in 
young and old VSMCs. Treatment with MEK inhibitor PD98059 successfully inhibited 
ERK1/2 activities and cellular proliferation, both in young and old VSMCs. These in vitro 
results ware confirmed in an in viva model of balloon injury in rabbit iliac arteries. ERKl/ 
2 activities were induced by angioplasty in both young and old rabbits, with maximal val- 
ues obtained at 30 minutes after arterial injury. However, the levels of ERKi/P activities 
achieved in arteries of old rabbits were significantly higher than in arteries of young rab- 
bits (72% increase, p=O.O002). This was associated with a significant increase in neointi- 
mal formation in old vs young rabbits at 14 days after injury. Conclusion: 1) These 
results suggest that increased MAPK activity contributes to augmented VSMC prolifera- 
tion and neointimal formation with aging. 2) MAPK inhibition could represent a novel ther- 
apeutic avenue against atherosclerosis and restenosis. 
1301-192 No Association Between Sex Hormone Levels and Coronary 
Artery Disease in Men 
Barbel Klein, Rahime Gok, Ralf Winkler, Karin Lindner, Florian Mokler, Gunnar Taubert, 
Jochen Senges, Bernhard R. Winkelmann. Herzzenfrum Ludwigshafen, Ludwigshafen, 
Germany 
Background: Hyperestrogenemia and hypotestosteronemia have been reported to be 
associated with myocardial infarction in men, therefore the aim of the study was to inves- 
tigate the role of sax hormones in men with CAD. Methods: LURIC is a prospective 
cohort study to assess classic and unknown risk factors for CAD. 2356 males scheduled 
for diagnostic or interventional coronary angiography were enrolled, and detailed history 
was obtained by standardized questionnaire. Sex hormones were determined in fasting 
blood samples in the early morning. Levels are presented as medians (25%, 75% quan- 
tiles). CAD was defined as the presence of at least one stenosis >= 20% in one major 
coronary artery. Results: sse table. Conclusions: CAD was not associated with any of 
the four sex hormones investigated, except for a minor increase in LH in young man with 
CAD. Therefore, estradiol and testosterone are not a risk factor for CAD in men. 
control CAD p-value 
LH (IUil) 
< 50 years n=334 3.3 (2.3, 4.7) 3.8 (2.4, 5.9) p<o.o5 
>= 50 years n=1917 3.6 (2.6, 5.6) 4.1 (2.8, 5.8) tlS. 
FSH (IUil) 
< 50 years n=334 
>= 50 years n=1925 
17.S-&radial @g/l) 
< 50 years n=326 
>= 50 years n=l866 
3.9 (2.9, 5.6) 4.5 (2.9, 6.1) n.s. 
5.1 (3.4, 7.7) 5.5 (3.9, 8.2) “.S. 
38 (31,47) 36 (29, 45) n.s. 
41 (32, 51) 40 (32, 49) n.s. 
testosterone @g/l) 
< 50 years n=335 
2 50 years n=l923 
5.7 (4.3, 7.1) 5.1 (4.0, 6.4) n.s. 
4.7 (3.7, 6.0) 4.7 (3.6, 5.9) n.s. 
1301-193 Non uniform Atherosclerotic Plaque Distribution Near the 
Septal Perforator: Intravascular Ultrasound Evidence for the 
Importance of Rheological Factors in Atheroma 
Development 
Mohammed A. Balghith, Mandish S. Rai, Atila lyisoy, E. Murat Tuzcu, Steven E. Nissen. 
The Cleveland Clinic Foundation, Cleveland, OH 
Background. Necropsy studies have shown asymmetrical atheroma formation in coro- 
nary artery disease, but are limited to deceased patients. Using intravascular ultrasound 
(IVUS), we examined plaque distribution in a population with less advanced disease to 
evaluate early atheroma formation. Methods. We analyzed fifty IVUS motorized pull- 
backs of the LAD in non-intervened arteries (pullback at 0.5 mm/set) in patients with lim- 
ited disease (no lesion>50%). The mid-point of the first septal perforator was identified 
and 5 serial cross sections selected (mid-point of septal, 1 and 2 mm proximal and distal) 
with a total of 250 cross-sections. In each cross-sectional slice, the vessel was divided 
into 2 halves (180” semicircles ipsilateral and contralateral to the septal). For each semi- 
circle, the external elastic membrane (EEM) and lumen area were planimetered and 
maximum and minimum intimal thicknesses determined. Atheroma area was calculated 
(EEM-lumen area). Results. A distinctive pattern of atheroma shape was evident. At 2 
mm proximal to the septal, the plaque on the septal side was much larger in area than the 
antiseptal side (3.78 r 1.8 vs 2.32 * 1.5 mm2), p < 0.0001, Moving more distally, the dif- 
ferences between the septal plaque and the antiseptal side narrowed progressively. At 
the cross-section through the septal, comparing septal to antiseptal, the mean area was 
closer (3.32 -+ 1.4 vs. 2.67 + 1.6 mm2), p < 0.001. At 2 mm distal to the septal, the differ- 
ences between the septal and antiseptal sides were the smallest (3.11 + 1.7 vs. 2.46 i 
1.3 mm2), p < 0.0007. Similar finding were noted for atheroma thickness. Thus, atheroma 
burden on the septal side gradually tapers from proximal to distal, whereas the atheroma 
area is nearly constant on the antiseptal side. Conclusion. Atherosclerosis in the LAD is 
strongly affected by the origin of the septal perforator. On the septal side, there is great- 
est plaque burden 1 and 2 mm proximal to the septal with tapering of atheroma distally. 
0~ the antiseptal side there is remarkably uniform burden from 2 mm proximal to 2 mm 
distal to the septal. These data demonstrate the importance of rheological factors in the 
genesis of atherosclerosis in the LAD. 
1301-194 Novel Method for In Vivo Calculation of Absolute Shear 
Stress at Any Location of a Stented Human Coronary Artery 
Attila Thury, Joianda J. Wentzel, Elbert H. Janssen, Rob Krams, Jan A. Oomen, Johan C. 
H. Schuurbiers, Jurgen M. R. Ligthart, Patrick W. Serruys, Cornelis J. Slager. Department 
of lnfervenfional Cardiology, Thoraxcenter, Rotterdam, The Netherlands, Laboratory of 
Hemodynamics, Thoraxcenter, Rotterdam, The Netherlands 
Background: Stem placement results in regional changes in 3D geometry, coronary flow 
and its distribution and as a consequence, in shear stress (SS). SS may play a pivotal 
role in in-stent neointimal proliferation. The normal range for SS is l-l.5 N/m*. Up to 
date, no technique is available that provides absolute SS data for the different locations 
of a (stented) human coronary artery in viva. 
Methods: We developed a method for true 3D reconstruction of coronary vessels com- 
bining angiographic and IVUS information (ANGUS). For previous SS calculations based 
on this reconstruction, an assumed flow and blood viscosity had to be entered when 
applying computational fluid dynamics (CFD). At present, blood velocity was recorded 
along the reconstructed segment at rest using a Doppler guide wire at the end of the 
intervention, and viscosity was measured using a pipe viscometer. This allowed calcula- 
tion of the absolute SS along the stented part and lo-20 mm reference segment on both 
sides. The output consists of 16 circumferential distinct values for each longitudinal posi- 
tion at l-mm intervals. 
Results: We report the average circumferential SS of the first two cases depicted against 
their longitudinal position in the vessel. Arrows indicate the edge(s) of stents. 
Case 1 (Fig. A). Proximal (3.5~28 mm) and distal (3.0~18 mm) stent in the mid-LAD. 
Good positioning on angiogram, on IVUS 1 mm gap between the stents. SS is lower at 
the proximal part of the 1st stem and normal at the junction. 
Case 2 (Fig. 8). RCA with a (35x33 mm) proximal stent. Good result on angiogram and 
IVUS. Markedly low SS distal to the stented segment was detected. 
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Conclusion: We demonstrate the feasibility of measuring absolute SS along a coronary 
vessel lumen surface in viva. Values tend to be lower than those in earlier studies. Differ- 
ent patterns of SS variations were observed along stented vessel: Angiographic follow-up 
is scheduled before March 2001 
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1302-162 -- Sildenafil Prescription-Event Monitoring Study. No 
Evidence of an Increase in Cardiovascular Outcomes 
Among 5,000 Men Prescribed Sildenafil in General Practice 
in England 
Saad A. W. Shakir, Lynda V. Wilton, Emma Heeley. Deborah Layton. Drug Safefy 
Research Unit, Southampton, Unifed Kingdom 
Objectives In randomised clinical trials, the rates of MI and IHD did not differ between 
sildenafil and placebo. There have been postmarketing spontaneous reports of Ml 
among users of sildenafil. The current study was undertaken to estimate the frequency of 
new adverse events and better quantify the rates of events such as MI and IHD among 
man receiving sildenafil. Methods An observational cohort study using Prescription Event 
Monitormg (PEM). The sildenafil cohort was identified from primary care prescriptions 
sent to the English Prescription Pricing Authority and outcome data from questionnaires 
sent to the prescribing primary care physicians who have knowledge of medical events 
diagnosed in primary or secondary care. The average length of follow-up was 4.9 
months. The study is ongoing and will include another 15,000 patients with follow-up of 
12 months. Results Questionnaires were sent for 9748 patients and 5601 (57.4%) were 
returned and were suitable for analysis, The cohort was 99.7% male with a mean age of 
57.4 years (r.ange18-90 years). The number of event reports (excluding those who were 
reported to have stopped sildenafil more than one month earlier), were angina 9 (0 fatal), 
ischaemic heart disease 10 (3 fatal), myocardial infarction 14 (6 fatal). chest pain 19 (0 
fatal). The age standardised mortality for the age group 35-74 in our cohort was 2.65 
(95% Cl 1.54, 4.24) and the age standard&ad morbidrty for Ml was 6.75 (95% Cl 4.98, 
9.15). Comparison figures for England are: standardised mortality rate for IHD of 2.6 per 
1000 patient years and the rate for all Ml morbidity is 6.0 per 1000 man-years. Conclu- 
sions Our analysis showed no evidence for an increased risk of MI or IHD in sildenafil 
patients during the first months of treatment. The rates observed were similar to those for 
the general population of men in the UK. This is the first large study of men using sildena- 
ii i in general practice outside of the clinical trial setting. PEM is a signal generation 
method for pharmacovigilance, subject to certain biases or under-reporting. Results 
should be viewed in context with other studies of the safety of sildenafil, 
1302-163 Metformin Versus Other Oral Agents: Does the Choice of 
Discharge Diabetic Medications Predict Mortality? Results 
From a Registry of 1,428 Diabetic Patients 
Farangis Lavasani, Joseph B. Muhlestein, Benjamin D. Home, Robert Ft. Pearson, Tami 
L. Bair, Sunni K. Kim, Chloe A. Allen Maycock, Kirti Salunkhe, Dale 6. Renlund. Jeffrey 
L. Anderson. LDS Hospifal, Salf Lake City UT 
Background: Diabetes Mellitus (DM) is a known risk factor for Coronary Artery Disease 
(CAD). Various oral diabetic medications that control hyperglycemia are available for the 
treatment of DM. It is not known, however, whether one oral medication is superior in pre- 
venting cardiovascular complications in diabetics with known CAD. The objective of this 
study was to evaluate the incidence of death or myocardial infarction (Ml) during long- 
term follow-up of diabetic patients with CAD based on the type of diabetic medications 
(including metformin (MF), glitazones (GL), sulfonylureas (SU), and insulin) prescribed at 
the time of initial angiographic diagnosis. 
Methods: A cohort of 1,428 patients (pts) with DM undergoing angiography at a single 
institution between 1994 and 2000 and documented to have severe (270% stenosis in a 
major coronary vessel) CAD were followed prospectively (mean, 2.5 + 1.5 years) for long- 
term clinical outcomes. Pt baseline clinical, demographic, and procedural characteristics 
were recorded and Cox regression controlled for these multiple covariates. Rates of 
death or Ml in these pts were analyzed based on the type of DM medication strategy they 
received at hosprtal discharge. 
Results: Patients averaged 65 * 11 years of age and 67% were male.The rate of mortal- 
ity among those receiving MF (death=7.9%, n=215) was lower compared to GL 
(death=i3.5%, hazard ratio [HR]=Z.l, p=O.O9, n=52), SU (death=15.7%, HRc1.7, 
p=O.O49, n=681), and insulin alone (death=28.2%, H&3.4, p<O.OOi, n&45). In multi- 
variate regression, SU (HRz1.7, p=O.O51) and insulin alone (Hfl~3.1, p<O.OOl) main- 
tained independent predictive value for increased rates of death compared to MF. The 
rate of MI was not different between treatment groups. In comparison to SU use, sole use 
of insulin indicated an increased hazard of death (HR=Z.O, p<O.OOl). 
Conclusion: In this large prospective study, treatment of diabetic CAD patients with met- 
formin was associated with improved survival when compared with suifonylureas or insu- 
lin. Choosing insulin sensitization therapy as first line treatment in this population may 
therefore be advantageous, though this requires additional validation. 
1302-l 64 Medication Dosages Following Percutaneous Transluminal 
Coronary Angioplasty: Results From the ROSETTA Registry 
Sacha R. Bhatia, Mark J. Eisenberg. McGill University Montreal, PQ, Canada 
Background: Multiple studies have examined the types of medication used among 
patients with coronary artery disease (CAD). Little is known, however, with respect to the 
dosages of medications used among patients wrth CAD. Many clinical trials have shown 
that high dosages of anti-ischemic. anti-lipid. and anti-platelet medications have effica- 
cious results on outcomes of patients with CAD.The purpose of our study was to examine 
the use and dosage of medication among patients who undergo percutaneous translumi- 
nal coronary angioplasty (PTCA).Methods:The Routine versus Selective Exercise 
Treadmill Testing after Angioplasty (ROSETTA) Registry is a prospective multi-center 
study examining the use of functional testing after PTCA. We examined medication use 
at discharge among 698 patients who were enrolled in the ROSETTA Registry at 11 clin- 
ical centers in 5 countries. We used the % Maximum Recommended Dosage (%MRD) to 
compare drugs within a class (e.g. ACE inhibitors). % MRD= dosage used/maximum rec- 
ommended dosage *lOO%.Results: Most patients were elderly men (mean age 61ilt 
years, 80% male). The proportion of patients receiving less than 100% MRD of a particu- 
lar medication was: 64% for aspirin (e.g. 325 mgid), 92% for beta blockers (e.g. 200 mg/d 
metoprolol), 86% for calcium channel blockers (e.g. 360 mgid dilatizem), 92% for ACE 
inhibitors (e.g. 40 mg/d enalapril) and 91% for anti-lipids (e.g. EOmg/d Simvastatin). Of 
patients with a previous history of MI, 94% were on aspirin, 49% were on anti-lipid medi- 
cation, 57% were on beta blockers, 38% were on calcium channel blockers and 40% 
were on ACE inhibitors. The percentage of these patients receiving less than 100% MRD 
of a particular drug were 73% for aspirin, 94% for beta blockers, 81% for calcium channel 
blockers, 64% for ACE inhibitors, and 91% for anti-lipid agents. Conclusions: Clinical 
trials have shown the efficacy of these studied medications but the doses, which showed 
beneficial results to the patient, are not being used in clinical practice. There are signifi- 
cant differences in the dosages and patterns of usage for these important medications. 
1302-165 Hyperemic Coronary Blood Flow Induced by Selective 
Adenosine A2A Receptor Stimulation: First Report in 
Patients of a Well Tolerated Novel Agent for Stress Imaging 
Morton J. Kern, John M. Hodgson, James D. Rossen, Tim A. Fischell, Richard J. Barrett, 
Saad R. Bitar, Michael D. Eisenhauer. St Louis Universify, Sf. Louis, MO, MetroHealfh 
Medical Center C/eve/and, OH 
Coronary hyperemia induced by IV adenosine for cardiac stress imaging is often associ- 
ated with unacceptable symptoms, including chest pain, flushing, dyspnea, ECG 
changes and hypotension. To test whether a selective adenosine As, receptor agonist 
(MRE0470), would produce equivalent hyperemia with fewer and/or less severe side 
effects, 25 patients who had completed coronary angiography were enrolled. Patients 
with 3.vessel CAD, asthma, COPD, unstable angina, CHF LBBB, valvular disease, or 
CABG were excluded. BP, HR, ECG and coronary blood flow velocity (CBFV, Doppler 
guidewire in a non-obstructed vessel) were measured. CBFV reserve (CBFVR), mea- 
sured with intracoronary adenosine (18-24 ug), was 3.41 * 0.99. Up to 3 MRE0470 
doses were infused (0.04, 0.08, 0.10, 0.12, 0.16, and 0.2 uglkgimin x 6 min each); or 
injected as a bolus (0.3, 0.6, or 1.2 Kg/kg) into a peripheral vein. Infused MRE0470 pro- 
duced dose-related coronary hyperemia (Table, expressed as % CBFVR). Maximal 
CBFV responses achieved with 0.16 and 0.2 ug/kg/min were approximately equal to IC 
adenosine, were generally achieved within 3 min, and perststed for the length of the infu- 
sions or slightly longer. Bolus IV doses produced near-maximal (>85% CBFVR), but 
short-duration (< 3 min), coronary hyperemia. insignificant changes in blood pressure 
and heart rate were observed in several patients. No significant ECG changes, no dysp- 
nea, and few other adverse events, were observed. Selective activation of ArrA produces 
dose-related coronary vasodilatation equivalent to IC adenosine in humans, but with 
fewer adverse symptoms or hemodynamic side effects. 
MRE0470 (mcgJkglminx6) 
0.04 0.08 0.1 0.12 0.16 0.20 
n=6 n=6 n=6 n=12 n=6 n=6 
47+/-10 64+/-17 81+//-19 82+/-22 91+/-26 93+/-38 
1302-166 Selective Serotonin Reuptake Inhibitors Affect Platelets in 
Patients Undergoing Coronary Stenting 
Victor L. Serebruany, Christopher M. O’Connor, Paul A. Gurbel. Sinai Hospital, Baltimore, 
MD, Duke University Durham, NC 
Background: Clinical depression has been identified as an independent risk factor for 
increased mortality in patients following acute coronary events. Enhanced platelet activity 
has been suggested as the mechanism responsible for this adverse association. We 
sought to determine whether therapy with selective serotonin reuptake inhibitors (SSRl’s) 
affected platelets in patients undergoing coronary stenting.Methods: One hundred twenty 
six patients were analyzed. Thirty four patients (27%) were chronic SSRI users, and 
ninety two patients were free from SSRI therapy and served as internal controls. Blood 
samples were obtained at baseline before elective coronary stem placement. Platelet 
characteristics were assessed by platelet rich plasma aggregation with 5umol ADP, 1 pg/ 
ml collagen, and 750 umol arachidonic acid: whole blood aggregation by 1 uglml col- 
lagen; shear - induced closure time: contractile force, and expression of 9 surface recep- 
tors by flow cytometry. Results: Patients receiving chronic SSRI therapy exhibited 
substantial decrease of platelet activity when compared with internal controls which was 
significant for ADP-, and collagen-induced aggregation, and the expression of GP Ilb/llla, 
P-selectin, and CD 107a receptor. Conclusion: The inhibitory effects of SSRl’s on platelet 
function observed in our study may be directly related to the association between treat- 
ment of depression and improved outcomes in patients with ischemic heart disease. 
Recognizing anti-platelet properties of SSRl’s, their combination with thienopyridines and 
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GP llbillla inhibitors should be considered with caution. Further clinical trials, well- 
designed, and carefully conducted, should elucidate the potential benefits of SSRl’s in 
multiple thrombotic conditions, including myocardial infarction, unstable angina, and 
ischemic stroke. 
1302-I 67 Type 2 but Nbt Type 1 Diabetes Is Associated With 
Myocardial Insulin Resistance Regardless of the Presence 
of Coronary Artery Disease 
David P. Dutka, Patricia lozzo, Michael Pitt, Panithaya Chareonthaitawee, Marco Di 
Terlizzi, Ele Ferranini, Paolo G. Camici. MRC Clinical Sciences Cent& London, United 
Kingdom 
Background: Insulin-mediated myocardial glucose uptake is a reliable indicator of myo- 
cardial viability. Diabetes is characterised by whole-body insulin resistance and a high 
prevalence of coronary artery disease (CAD). Whether insulin action is preserved in the 
normal (ie, non-ischaemic) myocardium of diabetic patients is still controversial, and 
therefore viability criteria in this population are not defined. 
Methods: Insulin-mediated whole body (M) and myocardial glucose uptake (MGU) was 
therefore assessed in normally contracting myocardium of patients with and without CAD 
(but no heart failure), with and without type 1 (Dl) or type 2 diabetes (DZ), and in healthy 
controls (CON). Whole body glucose uptake (pmol/min/Kg) was calculated during the 
steady state of the insulin clamp. MGU (pmollminilOOg) was measured during euglyce- 
mic insulin clamping by positron emission tomography using [18F]-fluoro-Z-deoxy-glu- 
case (FDG). Oxygen-15 labelled water was used to measure myocardial blood flow 
(MBF). 
Results: MGU was lower in patients with coronary artery disease (table, *p40.05 vs 
CON) and in those patients with type 2 diabetes ($p<O.Ol vs all other groups). In con- 
trast, the myocardium is not insulin resistant in type 1 diabetes in the absence of coro- 
nary disease. 
CAD Dl+CAD D2+CAD Di D2 CON 
No of Patients 17 3 13 3 4 12 
M Value i&7” 15+7* 15+8’ 29t5 i&7* 31*13 
No of segments 81 17 91 48 63 161 
MGU 42*16* 52cl8’ 36+14”$ ao*14* 35*17** 61ztll 
Conclusions: Type 2 (but not type 1) diabetes and CAD are independently associated 
with myocardial insulin resistance in normally contracting myocardium. Viability studies 
using FDG must be interpreted with caution in patients with type 2 diabetes until a dedi- 
cated reference range is established. 
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1305-179 Separate and Combined Effects of Hormone Replacement 
and Simvastatin 10 mg on Lipoprotein (a) and Lipoprotein 
Subfractions in Postmenopausal Women With 
Hypercholesterolemia 
Kevin C. Maki, Michael H. Davidson, Joanne Palmisano, Armando Susmano, Adrian 
Dabs, Irwin Kerber, Donald Hunninghake, Robert Knopp, Anne Goldberg, James 
McKenney, Peter Kakavas, David Waters, Neville Bittar. Chicago Center for Clinical 
Research, Chicago, IL, Merck & Co, Inc., West Point, PA 
Background: The purpose of this randomized, double-blind, four-arm, parallel group trial 
was to evaluate the separate and combined effects of simvastatin 10 mgid and hormone 
replacement therapy (HRT, 0.625 mg conjugated equine estrogens + 2.5 mg medrox- 
yprogesterone acetate) on serum lipids and lipoprotein subfractions among postmeno- 
pausal women with hypercholesterolemia. 
Methods: One-hundred-thirty-nine postmenopausal women who had LDL cholesterol 
2160 mg/dL without coronary artery disease (CAD), or LDL cholesterol >130 mg/dL with 
CAD, were enrolled at 10 clinical sites. Following a six-week period for diet stabilization 
and baseline measurements, women completed six weeks of double-blind, double- 
dummy treatment. 
Results: Mean or median baseline V&I& (BL) and percent changes from baseline (A) in 
lipoprotein subfractions (measured by nuclear magnetic resonance spectroscopy) and 
lipoprotein (a) are shown in the table below. 
Variable Placebo’ HRT* Sim 10 mg3 Sim 10 mg + HRT4 
mg/dL SL Percent BL Percent A EIL Percent A BL Percent A 
A 
LDL-C 193 22.4 l-30 .,,I,3 189 .2!Jv 197 .2*‘.2 
~D~%,II 52 -17 47 -69 63 -22 61 -6.5 
LDwnw,‘~, 139 143 142 -43 134 
.p 2 133 -16 
HDL-C 46 .+.4 48 14’,4 48 7” 48 2Y.3 
HD~-%,,II 79 9 16 4 19 -6 17 -9 
HD’--%ge 28 -72-4 30 31’ 2s 17’,4 31 431.3 
LP (a)  31 .,u 26 -13’,3 36 p.4 34 -6.2’,’ 
‘, 2’ 3, 4 pa05 vs. placebo, HRT, simvastatin 10 mg, simvasfatin 10 mg + HRT, respectively. Lp(a)  = l ipopro- 
tein (a), LDL-C = low density lipoprotem cholesterol, and HDL-C = high density lipoprotein cholesterol. 
Simvastatin 10 mg primarily reduced cholesterol carried by large and medium LDL parti- 
cles while HRT had a greater impact on small particle LDL-C. HRT lowered Lp (a), while 
simvastatin 10 mg did not. 
Conclusion: The combination of simvastatin 10 mg and HRT produced a more favorable 
lipid profile than either agent alone. 
1305-I 80 Impaired Reverse Cholesterol Transport in Asian Indians 
H. Robert Superko, Enas A. Enas, Purushotham Kotha, Naras K. Bhat, Harvey Hecht. 
Berkeley He&Lab, San M&o, CA 
Background: Individuals of Asian Indian descent have been reported to have a higher 
incidence of coronary heart disease (CHD) compared to other ethnic groups. This higher 
incidence of CHD may be due to an increased prevalence of metabolic disorders that 
contribute to CHD. The National Asian Indian Heart Disease Project (NAIHDP) is investi- 
gating the prevalence of metabolic disorders and their relation to CHD in this ethnic pop- 
ulation. HDL2b is of interest since it is the HDL region most associated with CHD 
protection and reflects “reverse cholesterol transport”. Methods: 176 male Asian Indian 
subjects, free of CAD, were evaluated and compared to 193 age matched male causca- 
Sian subjects who were asymptomatic but had Electron Beam Tomography evidence of 
coronary calcification. Plasma was analyzed for fasting triglycerides, total, LDL & HDL 
cholesterol by enzymatic techniques, 7 LDL and 5 HDL subclasses by 53 gradient gel 
electrophoresis, Lp(a) by ELISA, Apo B and homocysteine by immunoassay. Samples 
were frozen at -80 degrees for future analysis. Subjects were not being treated with lipid 
lowering agents that would affect lipoprotein subclass distribution. Results: 
HDL2b HDLC LDLC Lp(a) LDL Illa+b % 
Asian Indian 11.6~55.0 44.0+9.9 123+35 22.0&17.2 26.2&13.5 
Caucasian 17.1k9.6 45.Ok14.4 131*36 17.1115.6 29.8i11.3 
P 0.02 0.44 0.05 0.006 0.02 
In this cohort of the male NAIHDP, individuals of Asian Indian descent, compared to male 
Caucasians, HDLPb was significantly lower and Lp(a) significantly higher. The LDLC and 
small LDL Illatb was significantly higher in the Caucasian CAD population but there was 
no significant difference in triglycerides, tHcy or mean LDL peak particle diameter. Con- 
clusion: Individuals of Asian Indian descent free of clinical CAD exhibit significantly more 
impaired reverse cholesterol transport as reflected by reduced HDLPb, and significantly 
higher Lp(a) compared to Caucasian subjects with coronary calcification. This combina- 
tion of disorders may contribute to the high incidence of CHD in the Asian Indian Popula- 
tion. 
1305-181 Is Alternate Day Dosing of Atorvastatin Effective in 
Managing Patients With Hyperlipidemia? The Alternate Day 
Versus Daily Dosing of Atorvastatin Study (ADDAS) 
Mazen S. Matalka, Marcus C. Ravnan, Prakash C. Deedwania. VA Central California 
Health Care System, Fresno, CA, UCSF School of Medicine, San Francisco, CA 
Atorvastatin (ATV) has been shown to reduce both total plasma and LDL cholesterol up 
to 45% and 60%, respectively, in a dose dependent manner when given to hyperlipidemic 
patients. Due to the long-lasting active metabolites of AN, the half-life of HMG-CoA 
reductase inhibition reaches up to 20 to 30 hours, although the mean terminal elimination 
half-life (t ,,#) of ATV is about 14 hours. Thus, it is conceivable that alternate day treat- 
ment might be effective in maintaining the lipid-lowering efficacy of AN. In a double-blind, 
placebo-controlled design, we evaluated the comparative efficacy based on LDL-C 
reduction from baseline at 6 and 12 weeks of every other day (QOD) versus once daily 
(QD) ATV in patients with hyperlipidemia. Thirty-five eligible patients who met NCEP 
guidelines for drug therapy depending on their risk factors were randomly assigned to 
receive 10 mg of AN as an initial dose every day or every other day. Patients were 
assessed at 6 and 12 weeks as to whether they met the LDL-C goal and dose was dou- 
bled if the goal was not reached. LDL-C decreased by 27% and 38% in the QOD (n=15) 
and QD (n=15) groups at six weeks, respectively. At 12 weeks, the LDL-C was reduced 
by 35% and 38% in the QOD and QD groups, respectively (P=O.49). The mean dose was 
18 mg (9 mg/day) in the QOD group (n=14) and 12 mg/day in the QD group (n=lZ) at the 
end of the 12 weeks (P=O.OOl). These results suggest that QOD ATV is as effective as 
QD in reducing LDL-C and such use can potentially provide cost savings. 
Parameter QOD oroup (n=14) QD woup (n=l2) P value 
Mean LDL-C at baseline (mg/dL) 
%A TC at 12 weeks 
%A LDL-C at 12 weeks 
%A HDL-C at 12 weeks 
%A TG at 12 weeks 
_ _ 
168r26 16&27 0.87 
J 27 L31 0.3 
135 i 38 0.49 
14 J5 0.9 
&20 J23 0.8 
1305-182 Measurement of Lipoprotein Subclasses by Nuclear 
Magnetic Resonance Spectroscopy May Identify High Risk 
Individuals With Borderline Hyperlipidemia 
Roger S. Blumenthal, Diane M. Becker, Taryn F. May, Lisa R. Yanek, Raphael M. Yook, 
Lewis C. Becker. Johns Hopkins Medical Institutions, Baltimore, MD 
Background: A challenge in the primary prevention of coronary heart disease is identify- 
ing high risk asymptomatic adults with mild to moderately elevated LDL-cholesterol val- 
ues for possible treatment with lipid lowering agents. The NCEP ATP II guidelines specify 
a threshold LDL-C > 160 mgldl for initiating pharmacologic therapy in asymptomatic 
adults who have > 2 CHD risk factors and > 190 mg/dl if they have < 1 risk factor. How- 
ever, most individuals develop CHD at lower LDL-C values, and there are no guidelines 
for how to identify persons in the borderline LDL-C range who may be at particularly high 
risk. The purpose of this study was to determine the prevalence of atherogenic lipopro- 
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tein profiles in high risk asymptomatic adults with LDL-C values of 130-159 mg/dl to 
improve the identification of individuals in need of aggressive pharmacologic therapy. 
Methods: Our study population consisted of 126 asymptomatic siblings of persons with 
documented CHD < age 60. We measured LDL particle concentrations and sizes using 
nuclear magnetic resonance spectroscopy, and LDL-C levels were calculated using CDC 
standardized lipid measurement chemistry methods and the Friedewald formula. 
Results: The sample was 48% white and 44% male with a mean age of 51 +/- 8 years. 
The mean LDL-C was 143 +/- 8 mg/dl and mean triglyceride levels were 136 +/- 72 mg/ 
dl. Small dense LDL pattern B (<20.5nm) was found in 28% of the subjects and an LDL 
particle concentration > 1800 nmol/L (z 75th percentile) was found in 39% of the sub- 
jects; both atherogenic profiles were seen in 20% of these subjects and at least one of 
the profiles occurred in 47% of the subjects. Conclusion: Lipoprotein subclass determi- 
nations identified a subgroup of asymptomatic adults with borderline high LDL-C values 
and concomitant atherogenic lipoprotein profiles. This represents a high risk group of 
asymptomatic adults who would likely benefit from more aggressive lipid lowering phar- 
macotherapy than is currently proposed by the NCEP primary prevention guidelines. 
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1306-183 Identification of Pregnancy-Associated Plasma Protein A 
(PAPP-A) as a New Marker of Acute Coronary Syndromes. 
Antonio Bayes-Genis, Cheryl A. Conover, Michael Christiansen, Dieter Lubbe, Claus 
Oxvig, John D. Altman, Michael T. Overgaard, Paul C. Keelan, Birgit Kantor, David R. 
Holmes, Jr., Robert S. Schwartz. Mayo Clinic, Rochester. MN 
Background: Pregnancy-associated plasma protein-A (PAPP-A) is a metalloprotease 
originally known from serum of pregnant women and recently linked to the insulin-like 
growth factor (IGF) axis by its proteolytic activity on IGF binding protein-4. This study 
evaluated PAPP-A expression in acute coronary syndromes and assessed its relation- 
ship with the IGF axis and high sensitive C-reactive protein (hs-CRP). Methods: We 
measured serum PAPP-A levels in four patient groups (n=7 per group): acute myocardial 
infarction, unstable angina, stable angina, and non-atherosclerotic controls, and exam- 
ined PAPP-A expression in eight unstable coronary plaques from sudden cardiac death 
patients. Serum levels of hs-CRP, free IGF-I and total IGF-I were also measured. 
Results: Median PAPP-A levels were higher in unstable angina and acute myocardial inf- 
arction compareb to controls (p=O.O35 and p=O.M9, respectively). PAPP-A levels in 
acute myocardial infarction were significantly higher than in stable angina (p=O.O3), and a 
similar trend was observed for unstable angina (p=O.O5). A significant correlation was 
found between PAPP-A and hs-CRP (r=O.7;p=O.O005), and with free IGF-I 
(r=O&p=0.002). High PAPP-A expression was localized in the extracellular matrix and in 
the cytosol of alpha-actin and inflammatory cells wlthin unstable coronary plaques. Con- 
clusions: These data show that the circulating level and the vascular expression of 
PAPP-A are increased in acute coronary syndromes. PAPP-A appears related to inflam- 
mation and bioavailable IGF-I and is a candidate new marker for acute coronary 
ischemia. Future studies are required to elucidate better the role of PAPP-A and the IGF 
axis in acute coronary syndromes. 
1306-184 Striking Prognostic Significance of Elevated CRP in Renal 
Impairment Patients Undergoing PCI 
Mark A. Robbins, Derek P Chew, Deepak L. Bhatt. Abdulhay Albirini, Leslie S. Cho, 
Jakob Schneider, Stephen G. Ellis, Eric J. Topol. Cleveland Clinic Foundation, C/eve/and, 
OH 
Background: Patients with renal impairment bear a disproportionate burden of coronary 
artery disease. The negative prognostic impact of renal impairment on short and long- 
terri? OUtComes following coronary revascularisation is well established. However, within 
this high risk population, the significance of inflammation in patients undergoing PCI has 
not been clearly defined. 
Methods: As part of an ongoing registry of patients presenting for urgent or elective PCI, 
46 patients with renal impairment (creatinine >2,0mg/dL) were identified. The rate of 
death or MI (CK>2x) at 30 days was assessed and stratified by CRP levels (CRP < 
O.Smg/dL, CRP 0.3-2,0mg/dL, and >P.OmgfdL). 
Results. With a progressive increase in the level of baseline CRP, a striking increase in 
the rate of death or MI at 30 days is observed, increasing from 0% in patients with CRP < 
O.Bmg/dL, to 5.8% when baseline CRP was 0.3-2,OmgidL. When the baseline CRP 
exceeded il.OmgldL, a 31.8% event rate was seen. (~~0.045) On logistic regression anal- 
ysis, Ihe negative impact of sub-clinical inflammation was independent of ACCIAHA 
lesion characteristics. 
Conclusion: Within the population of patients with renal impairment, an elevated CRP 
forebodes a marked increase risk of death or Ml following percutaneous coronary intsr- 
vention. The presence of inflammatory marker &v&on in patients with renal failure may 
identity a subgroup in whom adjunctive anti-inflammatory therapies for PCI warrants fur- 
ther clinical investigation, 
1306-185 Free and Vascular Endothelial Growth Factor (VEGF) 
Complexed Soluble Receptor Flt-I in Patients With 
Cardiovascular Disease 
Funmi M. Belgore, Andrew D. Blann, Gregory Y. H. Lip. Haemostasq Thrombosis and 
Vascular Biology Unit, University department of Medicine, Birmingham, United Kingdom 
Background: The biological activities of vascular endothelial growth factor (VEGF), are 
mediated by two membrane spanning receptors KDR, and Fit-1. Alternative splicing of 
the Flt-I gene revealed the existence of a naturally occurring soluble form of Fit-1 (sFlt- 
1). The functional significance of this receptor is still unclear, although sFlt-1 has been 
shown to bind and inhibit VEGF mediated angiogenesis in vitro. Our arm was to deter- 
mine whether a relationship existed between plasma levels of free and complexed sFlt-1 
relative to VEGF in patients with cardiovascular disease (CVD). Methods: We recruited 
40 patients (29 men, mean age/SD 61/t 1 years) with CVD and 40 healthy controls (28 
men, 60114 years). VEGF, free and complexed sFlt-1 were measured in titrated plasma 
by ELISA using commerial reagents. Results: VEGF(pglml) was median 113 [IQR 33. 
2311 in controls and 403[158-9251 in patients with CVD (Mann-Whitney U test pc 0.05). 
sFlt-1 (rig/ml) was 8 12.221 in CVD and 21 [lo-731 in controls (Mann-Whitney U test p< 
0.05). Complexed sFlt-1 (pg/ml) was 8 [i-136] and 18 15-5751 in CVD patients and con- 
trols respestively. There was no significant difference in the levels of complexed sFlt-I 
between the two groups. Levels of VEGF were higher, whilst free sFlt-1 levels were lower 
in CVD compared to controls. Conclusion: Raised levels of VEGF were found in plasma 
from patients with CVD compared to controls. The contribution of sFlt-I complexed to 
VEGF in plasma IS minimal despite the presence of excess free plasma sFlt-1. This may 
partly be attributed to high dissociation constants or receptor dimerization. Thus, 
unbound plasma VEGF detected by ELISA may represent the majority of circulating 
VEGF and justifies the measurement of plasma VEGF as an indicator of circulating 
VEGF levels. 
1306-186 Simvastatin Lowers Plasma Levels of C-Reactive Protein in 
Hyperlipidemic Patients 
Jonathan Isaacsohn, Michael H. Davidson, Donald Hunninghake, Helmut Schrott, Evan 
A. Stein, Yale B. Mitchel, Michele Mercuri, Michael E. Stepanavage. Metabolic and 
Atherosclerosis Research Center, Cincinnati, OH, Merck Research Laboratories, 
Rahwax NJ 
Background: A number of studies have demonstrated a positive and independent rela- 
tionship between the risk of cardiovascular disease and plasma levels of the inflamma- 
tion marker, C-reactive protein (CRP). Recent evidence suggests that the benefits of 
hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors (statins) on atherosclerosis 
may involve factors beyond lipid-altering effects includmg direct anti-inflammatory proper- 
ties. Therefore it was of interest to examine the effects of simvastatin on CRP levels in 
patients with hyperlipidemia. Methods: CRP was measured in archived plasma samples 
from 2 multicenter, randomized, double-blind, placebo-controlled studies designed to 
examine the lipid-lowering efficacy of simvastatin in patients with hyperlipidemia. In the 
first study, 130 patients with mixed hyperlipidemia received daily doses of placebo, simv- 
as&tin 40 or simvastatin 80 mg for 6 weeks in a three-period, complete-block crossover 
study. In the second study, patients with hypertriglyceridemia received daily doses of pla- 
cebo, or slmvastatin 20, 40 or 80 mg for 6 weeks. CRP was measured at baseline and 
week 6 by high sensitivity immunonephelometry. Results: The effect of simvastatin on 
CRP was expressed as median % change from baseline. Pooled results from the 2 stud- 
ies are shown in the table below. Treatment with simvastatin 40 and 80 mg led to signifi- 
cant decreases in CRP levels versus placebo (~~0.05). The rise in the placebo group and 
the absence of a dose response may be due to the high variability in CRP levels 
observed. 
Effect of Simvastatin on CRP 
Treatment N Baseline CRP (mg/L) Median Median % Change in CRP 
(SD) (SD) 
Placebo 91 2.9 (4.5) 11.1 (60.5) 
20mg 42 2.5 (2.2) -4.4 (66.6) 
40 mg 85 3.2 (4.6) -23.1 (49.8)* 
80 mg 86 2.7 (4.1) -22.0 (47.3) 
’ p<O.O5; versus placebo 
Conclusion: Treatment with simvastatin 40 and 80 mg for 6 weeks significantly reduced 
CRP levels in hyperlipidemic patients. 
1306-187 Elevated Plasma Level of Asymmetric Dimethylarginine 
(ADMA) Is Associated With Atherosclerotic Disease of the 
Thoracic Aorta 
Carol P. Cardinale, Ali Fard, Marc S. Eisenberg, Melissa A. Kazanowski, Marco Ft. 
DiTullio, Shunichi Homma. Columbia University, New York, NY 
Background: Nitric oxide (NO) has several antiatherosclerotic actions. Asymmetric dim- 
ethyl&nine (ADMA) is a recently discovered endogenous inhibitor of NO synthase 
detectable in human plasma. Increased plasma ADMA levels have been found in patlents 
with hypercholesterolemia, impaired NO-mediated endothelial function, and have been 
correlated with carotid intima-medial thickness. However, no data are available on the 
potential association between plasma ADMA and atherosclerosis of the thoracic aorta, 
as detected by transesophageal echocardiography (TEE), independent of traditional risk 
factors. Methods: Seventy-eight patients undergoIng TEE were included in the study. 
Atherosclerosis risk factors including age, gender, history of cigarette smoking, diabetes 
mellitus, systolic and diastolic blood pressures as well as plasma lipids were obtained. 
Plasma levels of ADMA ware measured by high-performance liquid chromatography. 
Association between ADMA and atherosclerotic plaque thickness was assessed by linear 
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regression. Results: Plasma ADMA levels averaged 1.1 +/- 1.4 umoliL in patients with no 
or mild atherosclerosis (n&7), and 1.7 +I- 0.9 umoi/L in patients with severe atheroscle- 
rosis (plaques measuring > 4 mm in thickness: n=ll) (pcO.05). Plasma total cholesterol 
levels averaged 213 +I- 55 mg/dl and 210 +/- 79 mgidi, in the control and severe athero- 
sclerotic groups, respeotively (p=NS). In a univariate analysis, plasma ADMA level corre- 
lated significantly with plaque thickness in the thoracic aorta (r=0.34, p=O.O07). In a 
multivariate analysis, the relationship between plaque thickness in the thoracic aorta and 
ADMA remained after adjustment for other known risk factors (p<O.O5). ADMA correlated 
with atherosclerotic disease of the thoracic aorta in both the arch (r=0.33, p=O.O06) or in 
the descending aorta (rEO.28, p=O.O49). None of the risk factors studied correlated signif- 
icantly with ADMA levels. Conclusions: The results indicate an independent association 
between plasma ADMA levels and atherosclerotic disease of the thoracic aorta. This 
study supports the concept that elevated plasma ADMA may be a novel marker for the 
presence of aortic atherosclerosis. 
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The Effect of Long-Term Vitamin E and C Therapy on 
Coronary Microvascular Endothelial Function in Patients 
With Coronary Disease: A Prospective Randomized Trial 
Marco V. Wainstein, Jason Ganz, Oominik Behrendt, James C. Fang, Jason Morrow, 
Peter Ganz, Andrew Selwyn, Scott Kinlay. Brigham and Women’s Hospital, Boston, MA, 
Linus Pauling /nsfifufe, Cowallis, OR 
Background: Microvascular and epicardial endothelial function is impaired in athecoscle- 
rosis, partly by increased oxidant stress. Antioxidant vitamins can improve endothelial 
vasomotor function acutely. The long term effect on epicardial arteries has previously 
been reported. This study investigated the effect of long term supplementation of vita- 
mins C and Eon coronary microvascular endothelial function. Methods! 18 patients with 
coronary artery disease were randomized in a double blind manner to combined therapy 
with vitamin C (1000 mg) and E (800 IU) per day (n=9) or placebo (n=9) for 6 months. 
Microvascular coronary vasomotor function was assessed by the change in volumetric 
flow derived from velocity (using TIMI Frame Count) corrected for cross sectional area in 
response to acetylcholine (ACh) (lo-8 to 10-6 M) and to nitroglycerin (NTG). Results: 
Over 6 months, vitamins increased the plasma concentrations of vitamin C from 36 to 71 
pM and E from 27 to 57 pM, white vitamin concentrations were unchanged in the placebo 
group (C: 42 to 47 pM and E: 26 to 23 pM, p<O.Ol vitamin vs placebo). Vitamins reduced 
plasma indices of oxidant stress (mean change in FP-isoprostanes: vitamin: -40 pglml, 
placebo: -12 pglml; p=O.O3 vitamin vs placebo). At baseline, resting flow (vitamin 21114 
(mean&D) mllmin, placebo 21i12 mlimin, p=O.74) and flow responses to ACh (vitamin 
16+36 % , placebo 24+128 %, p=O.89) were similar among the groups. Over 6 months, 
vitamin therapy did not improve resting flow (vitamin: 3.9*8 %, placebo -4.6ili %, 
p=O.48), flow responses to ACh (vitamin: 2193 %, placebo -9k77 %, pzO.96) and flow 
responses to NTG (vitamin: -33*57 %, placebo: -58*195 %, p=O.O7). Conclusion: In a 
randomized study, 6 months therapy with antioxidant vitamins E and C increased plasma 
levels and reduced lipid peroxidation, but did not improve coronary microvascular endot- 
helial function. This study suggests that high dose antioxidant vitamins does not correct 
the microvascular dysfunction characteristic of human atherosclerosis. 
890-2 
IO:45 a.m. 
Arterial Stiffness Change During Flow-Mediated Dilation 
May Be Indicated by Change in Bluntness of the Blood Flow 
Velocity Profile: Assessment by Phase-Contrast Magnetic 
Resonance Angiography 
Harry A. Silber, Pamela Ouyang, David A. Bluemke, Joao A. C. Lima. Johns Hopkins 
Medical Institutions, Baltimore, MD 
Background: Blood flow velocity profile is blunter in a distensible artery than a rigid 
tube. We sought to develop an indicator of peripheral arterial stiffness change based on 
this property. Arterial stiffness is directly related to vascular smooth muscle tone, which 
is altered during flow-mediated dilation (FMD). Therefore, using phase-contrast magnetic 
resonance angiography (PCMRA), we investigated whether profile bluntness varies with 
endothelial-dependent, flow-mediated dilation in the brachial artery. 
Methods: In 15 healthy subjects, ages 25 to 46, without cardiovascular risk factors, the 
brachial arterial cross-section was imaged using PCMRA. Images were acquired at 
baseline, during peak reactive hyperemia (immediately after release of a 5-minute arte- 
rial occlusion), and during FMD (at 1 minute after occlusion release). The central blood 
flow velocity (V,) and the spatially averaged velocity (V6A) of the arterial cross-section 
were obtained. As a measure of velocity profile bluntness, the ratio of Vo to VsA was 
calculated. Thus, a lower VJvs, indicates a blunter profile. 
Results: V,NsA was inversely proportional to baseline diameter (pc.001, r =.77). How- 
ever, VflsA did not change from baseline (1.69iO.16) to peak reactive hyperemia 
(1.69ztO.21, p&7) even though vessel diameter increased significantly (from 4.21t0.56 
mm to 4.62a0.55 mm, p<.OOl). VcNsA did decrease during FMD (to 1.57M.15, p=.Ol) 
as diameter further increased (to 4.78+0.71 mm, pc.001). 
Conclusions: 1) PCMRA can be used to calculate bluntness of the blood flow velocity 
profile in the brachial artery. 2) Velocity profile did not change bluntness during peak 
hyperemia despite an increase in diameter, but did become blunter with endothelial- 
dependent FMD. 3) Therefore, after accounting for arterial diameter, a blunter profile 
may indicate decreased arterial stiffness. 
890-3 
II:00 a.m. 
Two ecNOS Polymorphisms Are Associated With Previous 
Myocardial Infarction but Not With Increased Progression of 
Coronary Atherosclerosis 
Willem R. P. Agema, Johan W. Jukema, Moniek P. M. de Maat, Joram de Kraker, Aeilko 
H. Zwinderman, John J. P Kastelein, Ton J. Rabelink. Leiden University Medical Center, 
Leiden, The Netherlands, TNO-PG Gaubius Laboratory, Leiden, The Netherlands 
Background: Nitric oxide (NO) plays a central role in endothelium-dependent dilatation 
of coronary arteries. Endothelial constitutive nitric oxide synthase (ecNOS) is the key 
enzyme in determining basal vascular wall NO production. The E/D298 (894GfT) poly- 
morphism of the gene coding for ecNOS has been associated with an increased risk for 
myocardial infarction (MI). The -786TIC polymorphism has been linked to coronary 
spasm in Orientals, thus implicating endothelial dysfunction. We investigated the impact 
of these two ecNOS polymorphisms on progression of atherosclerosis and clinical events 
such as Ml. Methods: Patients were enrolled in the REGRESS trial which studied the 
impact of pravastatin therapy on coronary atherosclerosis. Angiography was performed 
at baseline and after 2 years. Progression of atherosclerosis was determined using quan- 
titative coronary angiography measuring changes in mean segment diameter (MSD) or 
minimum obstruction diameter (MOD). Genotyping E/D298 and -786T/C was successful 
in 755 and 709 subjects respectively. Results: The rare allele was present in 32.5% (Ei 
D298) and 38% (-786T/C). There was linkage desequilibrium (delta 0.40, pcO.005). The 
population was in Hardy-Weinberg equilibrium. In both 894G1T and -786TiC polymor- 
phisms TT genotypes more often had a history of MI than GG or CC genotypes with het- 
erozygotes having an intermediate risk: 51% vs 47% vs 32%, p=O.O09 and 51% vs 48% 
vs 36%, ~~0.05, respectively. Combined genotype analysis suggested that DDiCC haplo- 
types have the lowest risk of Ml (OR: 0.33, pcO.01). However, there was no difference in 
change in MSD or MOD or major clinical events between genotypes in the placebo or the 
pravastatin group. Conclusions: This study confirms the association between the 
ecNOS polymorphisms and Ml but not with progression of coronary atherosclerosis giv- 
ing rise to the hypothesis that during acute coronary syndromes (ACS) a preserved 
endothelial function is of paramount importance in preventing the occurrence of definite 
MI. Thus, Ml is probably more related to endothelial dysfunction than to coronary steno- 
sis per se. This may have important implications for identification of patients at increased 
risk for ACS. 
890-4 
II:15 a.m. 
Association Between Polymorphisms in the Chemokine 
Receptor CXBCRl and Coronary Vascular Endothelial 
Dysfunction and Atherosclerosis 
Julian P J. Halcox, David H. McDermott, Maya N. Merrell, Neal Epstein, Philip M. Murphy, 
Arshed A. Quyyumi. N/H, Bethesda, MD 
Background: Fractalkine is a chemokine expressed by endothelial cells that influences 
adhesion and migration of leukocytes via its receptor CX3CRl. Two polymorphisms have 
been identified in the CXBCRl gene that may affect leukocyte-endothelial cell interaction. 
We hypothesized that these polymorphisms influence risk of developing atherosclerosis 
by modulating coronary vascular endothelial function. Methods: Genotyping of CX3CRl- 
V2491, and -T28OM polymorphisms was undertaken in 339 Caucasian patients with 
angiographically documented atherosclerosis (CAD, n=222), or normal coronary arteries 
(NCA, n=l17). In 203 of these patients intra-coronary acetylcholine (ACH, 15mcg/min), 
and sodium nitroprusside (NTP, 20mcglmin) were administered to test endothelium- 
dependent, and -independent coronary vascular function, respectively. Change in coroo- 
nary vascular resistance (dCVR) was measured as an index of microvascular dilation 
using a Doppler flow wire. Results: An association was observed between genotype 1 
(homozygous for the reference allele 249V and -28OT) and presence of CAD (60.4 vs 
49.6% in the CAD and NCA populations respectively, p=O.O6). Genotype 1 was also 
associated with greater severity of CAD (p=O.O18). that was independent of other risk 
factors for CAD and endothelial dysfunction by multivariate analysis (age, sex, body 
mass index, smoking, diabetes, cholesterol, and hypertension). dCVR with ACH adminis- 
tration was reduced in genotype 1 patients compared to those with other genotypes (- 
36+3 vs -46+3% respectively, p=O.O18), whereas dCVR with NTP was similar in both 
groups (-53*2 vs -55+2%, p=O.46). The association between genotype 1 and dCVR with 
ACH was independent of CAD and its risk factors by multivariate analysis (p=O.O12). Fur- 
thermore, when the population was divided into two equal groups based on response to 
ACH, the observed frequency of genotype 1 was greater in the group with worse endot- 
helial function (64.7 vs 46.5%, p=O.Oll). Conclusions: Homozygosity for the reference 
allele predisposes patients to endothelial dysfunction and CAD, consistent with reduced 
pathological interaction between the vascular endothelium and leukocytes with CX3CRl 
mutations. 
890-5 
Ii:30 a.m. 
Age-Dependent Impairment of Reendothelialization After 
Arterial Injury: Role of VEGF. 
Frangois Gauthier, Giuseppa Gennaro, Catherine Menard, Sophie Elise Michaud, Aiain 
Rivard. Centre Hospitalier de IVniversit6 de Montr&l, Mont&l, PQ, Canada 
Background: Aging is a major risk factor for atherosclerosis. However, the precise 
mechanisms responsible for this association remain to be determined. In the present 
study, we investigated the hypothesis that arterial reendothelialization after injury iS 
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impaired as a function of aging. Methods and results: Endothelium denudation was per- 
formed by balloon injury of the iliac arteries in young (6-8 months old, n=lZ) vs old (3.5-4 
years old, n=lZ) New-Zealand white rabbits. Planimetric analysis after Evans Blue stain- 
ing at 28 days after injury showed a significant decrease in reendothelialization in old vs 
young rabbits (54.4&g% vs 89.5+3.9%, p<O.Oi). Because Vascular Endothelial Growth 
Factor (VEGF) is a potent end&h&al mitogen and that it has been shown to be induced 
following angioplasty we studied the effect of aging on VEGF expression in vitro and in 
viva. Vascular smooth muscle cells (VSMCs) were isolated from the aorta of young or old 
rabbits and used at early passages (P2 or P3). After serum stimulation, Western blot 
analysis showed a significant reduction in VEGF expression in old vs young VSMCs. 
Similar analysis performed on iliac arteries isolated at different time points after angio- 
plasty demonstrated a significant reduction in the expression of VEGF up to 7 days after 
arterial inJury in old vs young rabbits. To confirm the central role of VEGF in the age- 
dependent impairment of reendothelialization, an adenoviral vector encoding for 
VEGF165 (adeno-VEGF) or BGal (adeno-BGal, used as control) was locally delivered 
via a channel balloon at the time of iliac artery angioplasty in old animals (n=S). At 28 
days after balloon injury, reendothelialization was significantly improved (73.1&Z% vs 
54.4?2.9%, ~~0.01) in adeno-VEGF vs adeno-BGal treated arteries. Conclusions: 1) 
Aging impairs reendothelialization after arterial injury. 2) This impaired endothelial growth 
in old animals is at least partly due to a reduced induction of VEGF expression following 
balloon injury that can be rescued by local delivery of adeno-VEGF. 
8904 
1 I:45 a.m. 
Selective Aidosterone Receptor Blockade improves 
Endothelial Function in Diet Induced Atherosclerosis 
Sanjay Rajagopaian, Damon Duquaine, Zhenguo Han, Catherine Venturini, Bertram Pitt, 
Clint Webb. University of Mtchtgan, Ann Arbor, MI 
Background: Aidosterone has been implicated in the effects of angiotensin II in the vas- 
culature. Since the renin-angiotensin-aidosterone system has been implicated in endot- 
hellal dysfunction that occurs with experimental atherosclerosis, we hypothesized that 
usage of a selective aldosterone receptor blocker would improve nitric oxide bio-avaiiabil- 
ity in this condition. 
Methods: New Zealand white rabbits were randomized to four treatment groups. 32 Rab- 
bits were placed on normal (NC) or 1% cholesterol chow (HC) for a duration of 8 weeks. 
After the first 2 weeks 16 rabbits were randomized to receive either saline (S) or 
eplerenone (E, 50 mgikg twice daily) by gavage feeding for an additional 6 weeks. Aab- 
bits were euthanized at the end of 8 weeks and the aortas extracted for isometric tension 
studies and estimation of superoxide (0,)generation in vessel segments by lucigenin 
chemlluminescence (250 pM). Vessels were preconstricted with phenylephnne (3 x 10.‘) 
to approximately 50% of peak constriction and dose responses to acetylcholine (Ach) 
and nitroglycerin (NTG) tested. 
Results: The peak relaxations to Ach, NTG,ED,, (M) values and 0;counts (per mg of 
dry weight) are depicted below: 
Groups %Ach ED,,, Ach % NTG EDGo NTG 07. counts 
NC-S 97e -- 2.5 x 1 O-8 104ti -” 7.1 x10-y 1478+352 
NC-E 97*3 3.2 x 10-s 107i2 5.7 x lF9 1110+373 
HC-S 61i4if 1.2x 10°C 104*3 1.3x 10-a 3445+863# 
HC-E 82+6+ 6.8 x 1 O-e# 11224 1.0x10-* 1400~504” 
*= ~~0.01 vs. HC-S, # = p<O.O5 “s. NC-S and NC-E 
Conclusion: Aldosterone receptor antagonism improves endothelial function and 
reduces 02’ generation in diet induced atherosclerosis. These data provide preliminary 
evidence that this may represent an additional therapeutic strategy in atherosclerosis. 
ORAL CONTRIBUTIONS 
895 Coronary Disease Risk Factors 
Wednesday, March 21, 2001, IO:30 a.m.-Noon 
Orange County Convention Center, Room 230D 
895-l 
10:30 a.m. 
Lack of Association Between Homocysteine and Coronary 
Artery Disease on Angiography in the Era of Fortification of 
Flour With Folate 
Peter B. Berger. Martha Nunn, Katherine Stephenson, Joseph P. McConnell, George G. 
Klee. Mayo Clinic, Rochester, MN, lnterleukin Genetics, Boston, MA 
Background. Homocysteine is associated with coronary disease (CAD). However, the 
strength of the association after accounting for traditional and emerging risk factors, par- 
ticularly since the fortification of flour with folate was mandated in the USA (which has 
reduced hyperhomocysteinemia by >50%), is unclear. Methods & Results. We analyzed 
the association between tradrtionai and emerging risk factors and CAD in 504 patients 
(pts) undergoing clinically-indicated angiography July 1998 and January 1999 for chest 
pain, valve disease, abnormal noninvasive tests, etc. Pts with diabetes and ~50 pack 
years of smoking were excluded. Significant CAD (>50% stenosis in >1 artery, blinded to 
risk factors) was present in 271 pts (54%). Mean homocysteine was 9.36k3.07; hyperho- 
mocysteinemia (>I3 mg/dL) was present in 7.9% of pts. Mean homocysteine was 
9.29k3.02 mg/dL in pts with no disease (no stenoses or stenoses <lo%), 9.09k2.47 in 
pts with mild disease (stenoses 10% to 50%). 9.12&39 in pts with 1 vessel disease 
(VD) (250% stenosis in 1 coronary artery), 9.28+3.19 in pts with 2 VD, and lO.l-c3.89 
mg/dL in pts with 3VD (p=O.O793). Age, gender, smoking, LDL, HDL, Lp(a), apo al, and 
apo 6 ware all highly correlated with CAD on univariate analysis (pcO.001); quartile of 
homocysteine was not (p=O.207), nor was the frequency of hyperhomocysteinemia (7.0% 
in pts with GAD vs 9.0% in pts without CAD, p=O.l404). Multivariate analysis revealed no 
independent association between quartile (Q) of homocysteine and odds ratio (OR) for 
CAD (Ql OR= 1, Q2 OR=l.l (0.95, 1.29), Q3 OR=l.22 (1.50, 1.43), Q4 OR= 1.35 (1.16, 
1.58), p=O.2077. Conclusions. Among 504 pts undergoing clinically indicated coronary 
angiography, we found no association between homocysteine and CAD on angiography. 
Whether the lack of association is due to the homocysteine-lowering effect of fortifying 
flour with folate in recent years, or inclusion of many traditional and emerging risk factors 
in multivariate analysis that have often not been included in prior analyses of homocys- 
teine and CAD, is unknown. 
895-2 
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Modest Efficacy of Folic Acid and the Lack of an Additional 
Effect of Vitamin 612 in Hyperhomocystinaemic Patients 
With Coronary Artery Disease 
Jo Griffiths, Manohara Senaratne. University OfAlberta, Grey Nuns Hospital, Edmonton, 
AB, Canada 
Background: Elevated plasma homocysteine levels (PH) is believed to be a risk factor 
for coronary artery disease. Folic acid (FA) and vitamin B-12 (B12) have been suggested 
as agents effective in the treatment of elevated PH. This study explored the effect of FA 
on elevated PH, initially with 1 mgiday for four weeks followed by Bmgiday (if necessary), 
and the additional effect of 812 0.5mglday in those not responding to 5mg of FA. 
Method: There were 114 patients (males=89, females=25:age: mean 64.9*0.9yr SEM) 
with coronary artery disease and elevated PH levels (>iZumolA), 70% current/former 
smokers, 32% history of acute myocardial infarction, 46% family history of coronary 
artery disease, 54% hypertensive, 20.2% diabetics, 2% on phenytoin, 5% chronic renal 
failure, 2% with psoriasis, none on theophylline or methotrexate, and none with leuke- 
mia. 
Results: FA 1 mg/day produced a significant decrease in PH( baseline PH 17.5kO.9 
umolil versus 15.1il.l umolll: p<O.OOi).The addition of FA 5 mglday did not produce a 
significant further decrease in PH (PH 20.3k2.5 umolil versus 20.0r2.9 umoli 
I;p=0,629).Addition of vitamin 812 to FA 5mg/day did not produce a significant decrease 
in PH (PH 24.2*6.1 umol/l versus 18.9+4.7 umol/l;p=0.095). Patients with a PH level of 
>20umolll had no significant response to FA lmg/day(29.0*3.2 versus 25.0+4.6umol/l, 
p=O.106, n=18) whereas the patients with a PH level i 2Oumol/l had a significant 
decrease (14.7+0.2 versus 12.7~0.5umol/l, p=O.O03, n=73). 
Conclusion: FA lmg/day caused a significant decrease in PH although the magnitude 
of the change appears small and mostly restricted to those with a baseline PH of 
c2Oumolll. FA 5mg/day and/or 812 doesn’t result in any further improvement Thus. if a 
trial is done to determine the effect of reduction of PH on future coronary events, other 
drugs such as betaine may need to be considered to achieve a meaningful reduction in 
PH. Treatment with FA empirically, as has been suggested by some, is unlikely to prove 
beneficial. 
895-3 
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Plasma Levels of Asymmetric Dimethylarginine Are Not 
Increased in Patients With Coronary Artery Disease and 
Hyperhomocysteinemia 
Torfi F. Jonasson, Thomas Hedner, Bjijrn H&berg, Hans ahlin. Dept. of Cardiology 
University Hospital, Lund, Sweden, Dept. of Clinical Pharmacology University Hospital of 
Sahlgren, Gothenburg, Sweden 
Background: Elevated plasma homocysteine (P-tHcy), an independent risk factor for 
cardiovascular disease (CAD), appears to be related to endothelial dysfunction and 
impaired nitric oxide (NO) production. We aimed to investigate whether, (1) high plasma 
levels of P-tHcy are associated with high plasma levels of asymmetric dimethylarginine 
(ADMA), an endogenous competitive inhibitor of NO synthase, (2) it reduction of P-Hey 
levels by vitamin B treatment lowers plasma concentration of ADMA. Methods: 94 
patients with CAD were investigated. 60 patients with P-Hey >14.5 pmol/L were random- 
ized to open therapy with folic acid 5 mg, pyridoxine 6 mg and cyancobalamin 1 mg once 
daily for 3 months (n=30) or to no treatment (n=30). Blood samples were obtained from 
both groups before randomization and three months later. Samples were also obtained 
from 30 patients with P-tHcy < 12 pmol/L once only. Plasma levels of ADMA were mea- 
sured using high-performance liquid chromatography with multigradient elution. Results: 
Vitamin therapy reduced P-tHcy from 21.6113.6 pmol/L to lO.O_c3.1 pmol/L (P~O.0001). 
Plasma levels of ADMA in patients with elevated homocysteine were not significantly 
higher (0.6&0.19 pmol/L) than in patients with low homocysteine (0.62+0.11 pmol/L), 
(P=O.O8). The ADMA level of the active treatment group was 0.65 * 0.13 pmoVL before, 
and 0.64 * 0.12 PmoliL (P=O.45) after 3 months. The ADMA level was correlated with 
plasma cystatin-C (p<O,OOl), a marker for glomerular filtration, but not to P-tHcy and not 
to serum creatinin. Hyperhomocysteinemia was associated with increased levels of cys- 
tatin G compared to low P-tHcy levels (p~D,OOOl). Conclusion: A non-significant trend to 
increased plasma levels of ADMA in patients with CAD and hyperhomocysteinemia may 
be explained by concomitant subtle renal dysfunction. Substantial reduction of P-tHcy 
dose not affects ADMA levels. 
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risk factors. The incidence of major CVE between the three groups at the end of the fol- 
The Ginl92Arg Polymorphism of the Paraoxonase Gene low-up period was 8/40 (20%), versus 4/60 (6.7%), versus 3/50 (6%), respectively (A-B 
(PONI) Is a Genetic Risk Factor for Coronary Artery Disease Pc.05, A-C Pc.05, B-C P=NS). 
Yiwen Liu-Stratton, Gregory M. Eaton, James P Bacon, Raymond D. Magorien, Pascal J. 
Conclusions: Our results indicate an increased frequency of homozygosity of MTHFR 
Goldschmidt-Clermont, Glen E. Cooke. The Ohio State Universify, Columbus, OH, Duke 
gene mutation (C677T) among hypertensives, that may reflect an increased incidence of 
University, Durham, NC 
cardiovascular events in this subgroup of hypertensive patients. 
Background: Coronary artery disease (CAD) remains the most important cause of mor- 
tality and genetic factors likely play an important role. Paraoxonase, an HDL-bound 
enzyme, has been considered to contribute the antiatherogenic properties of HDL by pro- 
tecting LDL against lipid peroxidation. However, levels of paraoxonase activity vary 
among individuals and a polymorphism of the paraoxonase gene (PONl) at amino acid 
position 192 has been shown to be related to paraoxonase activity. The polymorphism 
may in part account for this variability in the activity of paraoxonase. Studies in various 
populations have shown inconsistent conclusions in the significance of PONI as a risk 
factor for CAD. Methods: The study population consisted of 668 subjects (456 males and 
212 females; 68% and 32%, respectively) who presented consecutively for percutaneous 
transluminal coronary angioplasty treatment of symptomatic coronary artery disease. 
352 healthy individuals without history of myocardial infarction or CAD served as control 
subjects. PONI Glnl92Arg genotyping was determined using PCR and restriction diges- 
tion. Chi Square analysis and ANOVA ware used for statistical analysis. Results: When 
compared with healthy controls, the prevalence of the B allele in CAD patients was signif- 
icantly greater (0.33 vs. 0.26, respectively, P=O.OOl). The prevalence of the PONl geno- 
types in the study population was 46% (n=309) for AA, 41% (n=274) for AB, and 13% 
(n=85) for BB and in control subjects was 57% (n=200) for AA, 35% (n=124) for AB, and 
6% (n=28) for BB, (P=O.O03). No significant gender and age differences were observed. 
Conclusions: This is the largest study of the Glnl92Arg paraoxonase gene polymor- 
phism’s influence on the prevalence of coronary artery disease. The polymorphism of the 
paraoxonase gene appears to be a genetic risk factor for coronary artery disease and 
this finding should have significant impact on our understanding of CAD, genetics, and 
lipid peroxidation. 
11:30 a.m. 
895-5 Platelet GPllla PLA Polymorphism and Incident 
Cardiovascular Disease: The Framingham Heart Study 
DaLi Feng, Martin G. Larson, Klaus Lindpalntner, Christopher J. O’Donnell, Murray 
Mittleman, lzabella Lipinska, Ralph B. D’Agostino, Daniel Levy, Geoffrey H. Tofler. Beth 
Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 
Background: The platelet glycoprotein llbillla (GPllbillla) plays a pivotal role in platelet 
aggregation and acute coronary syndromes. Recent data suggeststhat PIA genotype of 
GPllla PIA polymorphism may be a genetic risk for cardiovascular disease (CVD), 
although the association remains controversial. Most early studies were case-control in 
design, had a small sample size, and potential for selection bias. We therefore prospec- 
tively investigated whether the PIA genotype was a genetic risk factor for CVD in the 
Framingham Heart Study. Methods and Results: 3218 subjects provided baseline blood 
specimens for DNA analysis and were followed prospectively for 7 years. Genotyping 
was performed by PCR based analysis. The allele frequencies for PlAl and PIA were 
84.8% and 15.2% respectively. During follow up, 762 subjects had a first or recurrent 
CVD event (cardiac death, myocardial infarction, angina, stroke, congestive heart failure, 
or intermittent claudication). The cumulate incidence of any CVD event was 2241891 
(25%) among PIA positive subjects, and 55812327 (24%) among PlAl homozygous 
subjects. Compared with PI,41 homozygous subjects, the relative risk for CVD for PIA 
positive subjects was 0.96 (95% Cl 0.83 to 1.15, p=O.76) after adjusting for sex, age and 
prevalent CVD at baseline examination in a proportional hazards regression model. The 
results did not change upon further adjustment for body mass index, blood pressure, anti- 
hypertensive treatment, alcohol intake, total Serum cholesterol, menopausal status, and 
estrogen replacement therapy. Conclusion: In the Framingham Heart Study population, 
PIA genotype did not predict first or recurrent CVD events. Our prospective data do not 
support the hypothesis that GPllla PIA genotype is a genetic risk factor for CVD. 
ii:45 a.m. 
895-6 A Mutation in the Methylenetetrahydrofolate Reductase 
Gene Is Associated With Increased Risk of Cardiovascular 
Events in Hypertensive Patients 
Thomas K. Malt&, Antonios N. Hatzizacharias, Panagiota G. Krespi, George 
Anastasiadis, George A. Stavroulakis, Argyri Gialeraki, Emmanuel Chronakis, Nicolaos 
A. Chatzizacharias, Michael K. Kyriakidis. LAlKON General Hospital, Athens, Greece 
Background: Moderate elevations of total plasma homocysteine (tHCV) have been 
‘associated with an increased risk of vascular disease. A relatively common, C677T, 
mutation in the methylenetetrahydrofolate reductase gene (MTHFR) has been proposed 
as a risk factor for vascular disease through its effect on HCV metabolism. Aim of our 
study was to examine the frequency of this mutation in hypertensives (Hs) and to test the 
hypothesis that the homozygous variant genotype is associated with increased risk of 
cardiovascular events (CVE). 
Methods: Blood was withdrawn from 150 Greek male untreated well nourished Hs and 
from 100 Greek male healthy volunteers (control group). MTHFR gene mutation was 
determined (PCR method) in the whole population. All Hs were followed up to 7 years 
after the initiation of therapy, in order to record major CVE. 
Re+ts: Homozygosity was present in 26.6% of Hs (40/150) versus 15% (15/100) 
among subjects (p<.O5). Among 150 hypertensives, homozygosity (+/+) was present in 
40 (Group A), heterozygosity (t/-) in 60 (Group B), and wild type (-i-) in 50 (Group C). 
The three groups are matched for age, BMI and the other predisposing cardiovascular 
